user_id,prompt id,pmid_id,selection,annotation,outcome,comparator,intervention,invalid prompt,prompt reason
edin,82,2875419,Significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).", Weight Gain , detemir , glargine ,0,
edin,17,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", cervical Bishop's score , placebo , antibiotic therapy ,0,
edin,75,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001) and through 24 weeks follow-up (Weeks 9?24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6?7.5; p < .0001).", continuous abstienence at 24 week follow up , placebo , varenicline ,0,
edin,64,1764008,No significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant., duration of labor stages , epidural analgesia , Meperidine analgesia ,0,
edin,79,2875419,No significant difference,"The proportions of patients achieving A1C <7% were also similar (44.1 and 47.8%, respectively, P = 0.254), but significantly fewer glargine- than detemir-treated patients reached A1C <6.5% (16.5 and 22.7%, respectively, P = 0.017).",  number of patients with A1C <7%  ,  glargine  ,  detemir  ,0,
edin,13,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", neonatal outcomes , antibiotic therapy and tocolysis , tocolysis ,0,
edin,88,2944158,No significant difference,"IV therapy duration did not differ between groups (P = 0.22),", therapy duration , staff inclination replacement , routine replacement ,0,
edin,42,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 50mg of Golimumab and methotrexate ,0,
edin,51,524504,Significantly decreased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05) and fewer additional doses were required (7.5% vs. 22%, p < 0.05).", administration of oxytocin augmentation , dinoprostone , misoprostol ,0,
edin,43,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group. At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,48,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 12 hours , dinoprostone , misoprostol ,0,
edin,77,3281242,Cannot tell based on the abstract,, time to make first quit attempt , placebo , varenicline ,0,
edin,77,3281242,Significantly increased,"Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074), with a median of 17 versus 24 days, respectively (Figure 2).", time to make first quit attempt , placebo , varenicline ,0,
edin,53,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05) but with the disadvantage of higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05).", abnormal fetal heart rate , misoprostol , dinoprostone ,0,
edin,60,524504,No significant difference,Hyperbilirubinemia 2	9 (11.3%)	5 (6.0%)	NS,  Hyperbilirubinemia  ,  misoprostol  ,  dinoprostone  ,0,
edin,70,1764008,No significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).,  nausea and vomiting  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,40,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group,", ACR20  , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
edin,62,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", rates of vacuum-assisted delivery rate , epidural analgesia , Meperidine analgesia ,0,
edin,95,2944158,Significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).,The maximum IVD dwell time was 1,023 hours (43 days) in the clinical replacement group, and this cannula was still working well on removal for completion of therapy.",  IVD dwell times  ,  routine replacement  ,  staff inclination replacement  ,0,
edin,39,2674549,Significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., physical function , methotrexate , golimumab and methotrexate ,0,
edin,55,524504,Cannot tell based on the abstract,,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
edin,55,524504,No significant difference,Uterine Hyperstimulation	2 (2.5%)	1 (1.2%)	NS,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
edin,3,3298351,Cannot tell based on the abstract,, venous ulcer healing , no treatment , compression therapy ,0,
edin,3,3298351,Significantly increased,The changes of ulceration area were statistically significant regardless of the type of compression therapy., venous ulcer healing , no treatment , compression therapy ,0,
edin,15,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.", gestational age , placebo , antibiotic therapy ,0,
edin,26,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
edin,26,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
edin,30,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,30,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,46,2674549,Cannot tell based on the abstract,, serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,46,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group, 55.1% (p?=?0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group.,During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.", serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,93,2944158,No significant difference,"There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).",  infiltration  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,81,2875419,No significant difference,Hypoglycemia risk was similar., Hypoglycemia , glargine , detemir ,0,
edin,34,3233526,Significantly increased,"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).", ferritin levels at week 28 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,27,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,27,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
edin,90,2944158,Significantly increased,"This review included six trials (n = 3,455) and reported no clinically important or statistically significant difference in catheter-related bloodstream infection or phlebitis between IVDs that were routinely resited (at 48-96 hours) or resited on clinical indication, yet there were significantly lower costs in the group resited on clinical indication",  cost per patient  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,18,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.", white blood cell count , placebo , antibiotic therapy ,0,
edin,23,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , daily single iron tablets , weekly supplements of two iron tablets ,0,
edin,16,2366143,No significant difference,"Clinical characteristics including gestational age at enrollment, frequency of contractions, cervical Bishop's score, and white blood cell count on admission were similar in the 2 groups.",  frequency of contractions  ,  placebo  ,  antibiotic therapy  ,0,
edin,56,524504,Cannot tell based on the abstract,,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
edin,56,524504,No significant difference,Meconium stained AF	15 (18.8%)	7 (9.6%)	NS,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
edin,54,524504,Significantly increased,"However, uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group as did abnormal heart rate tracing (22.5% vs.12%, p > 0.05) (Table 1).",  uterine tachysystole  ,  dinoprostone  ,  misoprostol  ,0,
edin,67,1764008,No significant difference,Active phase of first Stage of labor (h)	2.49 ± 1.40	2.40 ± 1.55	NS,  pain levels during first stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,37,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", ferritin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,85,2944158,No significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).", IVD comlication rates , staff inclination replacement , routine replacement ,0,
edin,76,3281242,Cannot tell based on the abstract,,  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
edin,76,3281242,No significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).",  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
edin,41,2674549,No significant difference,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", Median HAQ-DI score , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
edin,89,2944158,Significantly increased,"The overall number of IVDs per patient was significantly less (P = 0.004) for those replaced on clinical indication (mean 1.5, SD 0.8, median 1, quartiles 1 and 2) than for those routinely replaced (mean 1.8, SD 1.1, median 1, quartiles 1 and 2)",  frequency of replacements  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,49,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 24 hours , dinoprostone , misoprostol ,0,
edin,58,524504,No significant difference,"More neonates in the misoprostol group had first minute Apgar scores lower than 7 (12.6% vs. 6.1%, p > 0.05), or needed neonatal resuscitation (11.4% vs. 9.9%, p > 0.05) but none of the babies had birth asphyxia,Neonatal resuscitation	9 (11.3%)	9 (10.8%)	NS",  Neonatal resuscitation  ,  misoprostol  ,  dinoprostone  ,0,
edin,96,2858204,Significantly increased,"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up in 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).,n the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009)",  frequency of healed index ucler after 1 year  ,  placebo  ,  HBOT   ,0,
edin,80,2875419,Significantly increased,"Improvements in A1C were ?1.46 ± 1.09% for glargine and ?1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).", number of patients with A1C <6.5% , glargine , detemir ,0,
edin,91,2944158,No significant difference,"Resite on clinical indication would allow one in two patients to have a single cannula per course of IV treatment, as opposed to one in five patients managed with routine resite; overall complication rates appear similar.", IVD complications per person , staff inclination replacement , routine replacement ,0,
edin,44,2674549,Cannot tell based on the abstract,, serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,44,2674549,No significant difference,"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients", serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
edin,22,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
edin,92,2944158,No significant difference,There were no local infections or IVD-related bloodstream infections in either group., phlebitis , staff inclination replacement , routine replacement ,0,
edin,65,1764008,No significant difference,"Oxytocin augmentation After initiation of Analgesia	197(100)	192(96)	NS,Administration of epidural analgesia with 1% lidocaine do not prolong the active-first or second stages of labor significantly, and do not increase the incidence of oxytocin augmentation",  oxytocin augmentation  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,4,3298351,No significant difference,"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , two-layer bandage , four-layer bandage ,0,
edin,74,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9?12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7?9.4; p < .0001)", continuous abstienence at week 12 , placebo , varenicline ,0,
edin,97,2858204,No significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively (n.s.).",  hypoglycemia occuring after treatment  ,  placebo  ,  HBOT   ,0,
edin,86,2944158,No significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).", time until first complication , staff inclination replacement , routine replacement ,0,
edin,71,1764008,No significant difference,"The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",  obstetric outcome  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,20,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , daily single iron tablets , weekly supplements of two iron tablets ,0,
edin,83,2875419,Significantly decreased,"Insulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day (P < 0.001),Moreover, trial data suggest that, although insulin doses are indeed higher in patients using detemir twice- versus once-daily, once-daily detemir doses are still higher than once-daily NPH and glargine doses (3,10,11). At present there is no clear explanation for the increased dose requirements for detemir",  frequency of insulin doses  ,  detemir  ,  glargine  ,0,
edin,2,3298351,No significant difference,"In all patients, independently of the type of compression therapy, a few significant statistical changes of ulceration area in time were observed (Student?s t test for matched pairs, p < 0.05). The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system ? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings ? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , compression stocking , four-layer bandage ,0,
edin,66,1764008,Cannot tell based on the abstract,,  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,66,1764008,No significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 ± 1.2 vs. intravenous meperidine, 9 ± 1.3; P = 0.09).",  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,29,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  daily single iron tablets  ,0,
edin,29,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  daily single iron tablets  ,0,
edin,45,2674549,Cannot tell based on the abstract,, serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
edin,45,2674549,No significant difference,"During the placebo-controlled portion of the study (to week 16), serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.


Conclusion:", serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
edin,73,1764008,No significant difference,"As shown in table 4, infant outcome showed no evidence that the type of analgesia had any adverse effects on neonatal Apgar scores.",  neonatal outcome  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,10,3298351,Cannot tell based on the abstract,,  higher percentage of healed area  ,  Compression stocking  ,  layer compression  ,0,
edin,10,3298351,No significant difference,"Table I
Comparable characteristics of patients treated with Maxis compression stockings and ProGuide two-layer and Profore four-layer compression systems,Ulceration area [cm2] (x ± SD)	4.7 ±4.18	5.3 ±3.93	6.0 ±3.98	p > 0.05,In the group of patients who used Maxis compression stockings complete healing was achieved in 8 (53.3%) ulcerations, in the groups of patients treated with layer compression systems, complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system. The differences were statistically significant (p > 0.05).",  higher percentage of healed area  ,  Compression stocking  ,  layer compression  ,0,
edin,31,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
edin,9,3298351,Significantly increased,"However, greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week.",  faster healing dynamics  ,  Compression stocking  ,  layer compression  ,0,
edin,63,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", c-section , epidural analgesia , Meperidine analgesia ,0,
edin,38,2674549,Significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., symptoms of RA , methotrexate , golimumab and methotrexate ,0,
edin,84,2875419,Cannot tell based on the abstract,,  drop-out rate  ,  glargine  ,  detemir  ,0,
edin,84,2875419,Significantly decreased,"Detemir-treated patients had less weight gain and more often achieved A1C <6.5%, but the drop-out rate and daily insulin doses were lower in the glargine group.",  drop-out rate  ,  glargine  ,  detemir  ,0,
edin,94,2944158,No significant difference,"Occlusion, n (%)	5 (3%)	4 (2%)	RR 0.77 (0.21, 2.80), p = 0.75,There was no statistically significant difference in group outcomes for any phlebitis (P = 0.34), infiltration (P = 0.57), occlusion (P = 0.75), or accidental removal (P = 0.43).",  occlusion  ,  staff inclination replacement  ,  routine replacement  ,0,
edin,87,2944158,No significant difference,There were no local infections or IVD-related bloodstream infections in either group., infections , staff inclination replacement , routine replacement ,0,
edin,7,3298351,No significant difference,"Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05,The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.",  CEAP scores  ,  compression stocking  ,  two-layer bandage  ,0,
edin,5,3298351,No significant difference,"The statistical analysis showed homogeneity of study groups in terms of age, sex, initial ulceration area and the initial value of CEAP; C-6 score.,Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05",  CEAP scores  ,  two-layer bandage  ,  four-layer bandage  ,0,
edin,33,3233526,Significantly increased,"There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks.,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).", ferritin levels at week 28 , weekly supplements of two iron tablets , daily single iron tablets ,0,
edin,28,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,28,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,19,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
edin,12,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", birth weight , antibiotic therapy and tocolysis , tocolysis ,0,
edin,24,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , twice weekly single iron tablet , daily single iron tablets ,0,
edin,35,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", ferritin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
edin,11,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", interval to delivery , antibiotic therapy and tocolysis , tocolysis ,0,
edin,72,1764008,No significant difference,"Women in both groups were similar in both obstetric and demographic characteristics,The higher intensity of the motor block of lidocaine was not associated with any harm in terms of obstetric outcome, duration of the second stage of labor, obstetric intervention or neonatal outcome.",  obstetric intervention  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
edin,36,3233526,No significant difference,"Group B, on the other hand, achieved significantly lower ferritin levels compared with Group A and Group C at 38 weeks,,Group A consuming two iron supplementation tablets once weekly (100 mg iron per week, n = 70), Group B consuming one tablet twice weekly (100 mg iron per week, n = 70) and Group C, consuming one tablet daily (50 mg iron per day, n = 70).",  ferritin levels at week 38  ,  daily single iron tablets  ,  weekly supplements of two iron tablets  ,0,
edin,59,524504,No significant difference,The mean cord pH and the base deficit were comparable in the two groups.,  Core blood pH  ,  misoprostol  ,  dinoprostone  ,0,
edin,57,524504,Cannot tell based on the abstract,,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
edin,57,524504,No significant difference,Perinatal death	0	1(1.2%)	NS,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
edin,61,524504,No significant difference,Birth trauma 3	0	2 (2.5%)	NS,  Birth trauma  ,  misoprostol  ,  dinoprostone  ,0,
edin,98,2858204,Significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).",  downsizing of ucler area 2 weeks after treatment  ,  placebo  ,  HBOT   ,0,
edin,32,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
edin,69,1764008,Significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001).,  hypotension  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,14,2366143,Significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group., infection , placebo , antibiotic therapy ,0,
edin,21,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , twice weekly single iron tablet , daily single iron tablets ,0,
edin,8,3298351,Cannot tell based on the abstract,,  venous ulcer healing  ,  Profore compression  ,  ProGuide system  ,0,
edin,8,3298351,No significant difference,"greater dynamics of healing was observed in patients treated with the four-layer Profore system ? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week. The value of the same parameter in patients treated with the two-layer ProGuide compression system was 0.55 cm2/per week and of those treated with compression stockings 0.44 cm2/per week. Although the changes of ulceration area in each analysed group were statistically significant (p < 0.001), inter-group differences were not found (H = 4.45, p > 0.05).",  venous ulcer healing  ,  Profore compression  ,  ProGuide system  ,0,
edin,52,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol (7.5% vs. 13.3%, p > 0.05)", Caesarean section rate , misoprostol , dinoprostone ,0,
edin,78,2875419,No significant difference,"Improvements in A1C were ?1.46 ± 1.09% for glargine and ?1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254) but more detemir-treated patients reaching A1C <6.5% (P = 0.017).", improved A1C , glargine , detemir ,0,
edin,50,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05), there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05)", spontaneous rupture of membranes , dinoprostone , misoprostol ,0,
edin,68,1764008,Cannot tell based on the abstract,,  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,68,1764008,Significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor.",  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
edin,6,3298351,No significant difference,Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05,  CEAP scores  ,  compression stocking  ,  four-layer bandage  ,0,
edin,25,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,25,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
edin,47,524504,Significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).", induction-delivery interval , dinoprostone , misoprostol ,0,
edin,191,2517154,Cannot tell based on the abstract,,  Dysmenorrhea scores  ,  Placebo  ,  Infliximab  ,0,
edin,191,2517154,Significantly increased,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01), and higher dysmenorrhea scores (P < 0.001 for physician assessment, for patient VAS scales and for patient diary).",  Dysmenorrhea scores  ,  Placebo  ,  Infliximab  ,0,
edin,159,2708184,Cannot tell based on the abstract,,  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,159,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,128,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,128,2871176,Invalid Prompt,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,1, I don't have required information in abstract and I can't open the rest of article. I keep getting 404 page not found error 
edin,114,2871176,Cannot tell based on the abstract,,  Patients reaching HbA1c goals less than 7.0%   ,  Liraglutide (1.2 mg) plus glimepiride  ,  Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,114,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).",  Patients reaching HbA1c goals less than 7.0%   ,  Liraglutide (1.2 mg) plus glimepiride  ,  Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,211,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,211,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.,Forty patients undergoing coronary bypass surgery (n = 32) or aortic valve replacement (n = 8) were enrolled in this prospective, randomized, double-blind study. Two groups were formed. In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,179,2864284,Cannot tell based on the abstract,,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,179,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,132,2871176,Cannot tell based on the abstract,,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,132,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02).,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,134,2871176,Cannot tell based on the abstract,,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
edin,134,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02).,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
edin,103,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,143,2871176,Cannot tell based on the abstract,,  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,143,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).",  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,188,2517154,Cannot tell based on the abstract,,  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,0,
edin,188,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates. Routine pathology (FC) also showed no obvious differences between the two groups.",  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,0,
edin,163,2708184,Cannot tell based on the abstract,,  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,163,2708184,No significant difference,"<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,189,2517154,Cannot tell based on the abstract,,  Pain estimates after surgery  ,  Placebo  ,  Infliximab  ,0,
edin,189,2517154,No significant difference,"After surgery, all pain estimates decreased to less than 10% of the baseline in both groups (Figs 1 and 2), and no differences were found between the placebo and the infliximab group (two-way analysis of variance).",  Pain estimates after surgery  ,  Placebo  ,  Infliximab  ,0,
edin,176,2864284,Cannot tell based on the abstract,,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,176,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,178,2864284,Cannot tell based on the abstract,,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,178,2864284,No significant difference,<td></td><td></td><td></td><td></td>,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,147,2871176,Cannot tell based on the abstract,,  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
edin,147,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002).,  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
edin,197,3187863,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25?1.69) and SU (37.9%; RR 1.45, 95% CI 1.22?1.73) (Table 2).",  Pain relief: Acupuncture  ,  Normal unit & Special unit  ,  Midwife-led unit  ,0,
edin,192,1852268,No significant difference,"In this study, ertapenem was as effective as piperacillin?tazobactam for the treatment of acute pelvic infection, was generally well tolerated, and had an overall safety profile similar to that of piperacillin?tazobactam.,The most common single pathogen was Escherichia coli . At the primary efficacy endpoint 2?4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin?tazobactam were cured (95% confidence interval for the difference, adjusting for strata, ?4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillin?tazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,204,4106715,Cannot tell based on the abstract,,  Prolonged abstinence from smoking rates to 12 months  ,  placebo  ,  high Ab group  ,0,
edin,204,4106715,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32?11.20).",  Prolonged abstinence from smoking rates to 12 months  ,  placebo  ,  high Ab group  ,0,
edin,164,2708184,Cannot tell based on the abstract,,  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
edin,164,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
edin,121,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,121,2871176,Invalid Prompt,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,1, I get 404 not found error when I want to see the whole article 
edin,160,2708184,Cannot tell based on the abstract,,  Late Life Function and Disability Instrument  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,160,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Late Life Function and Disability Instrument  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
edin,201,2688140,No significant difference,"The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups."," The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS ", table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,130,2871176,Cannot tell based on the abstract,,  Weight gain  ,  Liraglutide plus glimepiride  ,  Rosiglitazone plus glimepiride  ,0,
edin,130,2871176,Significantly decreased,"Although weight effects were modest, liraglutide produced more favourable weight effects compared with rosiglitazone, which produced substantial weight gain.",  Weight gain  ,  Liraglutide plus glimepiride  ,  Rosiglitazone plus glimepiride  ,0,
edin,135,2871176,Cannot tell based on the abstract,,  HOMA-B  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,135,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).",  HOMA-B  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,208,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found.,n group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20)."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,169,2864284,Cannot tell based on the abstract,,  Parasite clearance at day 2  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,169,2864284,Significantly increased,<td></td><td></td><td></td><td></td>,  Parasite clearance at day 2  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
edin,137,2871176,Cannot tell based on the abstract,,  HOMA-B  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,137,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).",  HOMA-B  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
edin,209,2206488,Cannot tell based on the abstract,, Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,209,2206488,Significantly increased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,n group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass. Group B served as a control with identical amounts of gelatin infusion (n = 20).", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,120,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,120,2871176,Invalid Prompt,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,1, I got 404 Not Found error
edin,100,2871176,Cannot tell based on the abstract,,  HbA1c level at 26 weeks  ,  Rosiglitazone plus glimepiride  ,  Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,100,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).",  HbA1c level at 26 weeks  ,  Rosiglitazone plus glimepiride  ,  Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,154,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,154,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,205,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,205,4106715,No significant difference,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32?11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,156,2708184,Cannot tell based on the abstract,, Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,156,2708184,No significant difference,"<td colspan=""8""><hr></td>", Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,198,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Postpartum haemorrhage , Normal unit & Special unit , Midwife-led unit ,0,
edin,112,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,112,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,212,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,177,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Cure rate at day 28 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,155,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,155,2708184,No significant difference,"<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
edin,184,2517154,Cannot tell based on the abstract,, Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
edin,184,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
edin,117,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,117,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,119,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,119,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,166,3001156,Cannot tell based on the abstract,, Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,166,3001156,Significantly increased,"Increases were observed in self-referral of sick newborns for care, compliance after referral by the CHWs, and care-seeking from qualified providers and from the Kumudini Hospital, and decreases were observed in care-seeking from unqualified providers in the intervention arm.", Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,123,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,199,3187863,No significant difference,"Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth. An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively."," Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth ", Normal unit & Special unit , Midwife-led unit ,0,
edin,207,4106715,Significantly increased,"3?AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14?6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,99,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,99,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,206,4106715,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19?52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19?52) with high Ab levels ,0,
edin,172,2864284,Cannot tell based on the abstract,, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,172,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,107,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,107,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,195,3187863,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59?0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56?0.86) (Table 2).", Oxytocin infusion for augmentation of labour , Normal unit & Special unit , Midwife-led unit ,0,
edin,182,2517154,Cannot tell based on the abstract,, Nodules diameters , Placebo , Infliximab ,0,
edin,182,2517154,No significant difference,No effect of treatment was found upon the mean diameters of the nodules as measured by TVU., Nodules diameters , Placebo , Infliximab ,0,
edin,202,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
edin,202,4106715,Significantly increased,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53?12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
edin,168,2864284,Cannot tell based on the abstract,, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,168,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,190,2517154,Cannot tell based on the abstract,, Pain killers intake , Placebo , Infliximab ,0,
edin,190,2517154,Significantly increased,"The strong and significant placebo effect and the absence of an infliximab effect were consistently found for all pain estimations in this study, i.e. the five scorings by the clinician and the calculated total scores (i.e. dysmenorrhea, deep dyspareunia, chronic pain, pelvic tenderness, the sum of the 3 BB pain scores and the total BB score) and the pain recorded in the dairy by the patients (i.e. the 3 BB scores, the visual analog scales, the pain killer intake and both calculated total scores, i.e. with or without taking pain killer intake into account).", Pain killers intake , Placebo , Infliximab ,0,
edin,194,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65?0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59?0.89) (Table 2).", Labour dystocia , Normal unit & Special unit , Midwife-led unit ,0,
edin,186,2517154,Cannot tell based on the abstract,, Surgery duration , Placebo , Infliximab ,0,
edin,186,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Surgery duration , Placebo , Infliximab ,0,
edin,136,2871176,Cannot tell based on the abstract,, HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,136,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).", HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,116,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,116,2871176,Significantly decreased,"By week 2, subjects treated with liraglutide had rapid and larger decreases in FPG vs. comparator treatment. At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001), while only liraglutide 1.2 or 1.8 mg produced greater reductions than rosiglitazone. FPG treatment differences to placebo were 1.7 mmol/l for liraglutide 0.6 mg and 2.6 mmol/l for both liraglutide 1.2 and 1.8 mg.", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,173,2864284,Cannot tell based on the abstract,, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,173,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,167,3001156,Cannot tell based on the abstract,, Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,167,3001156,No significant difference,"At the time of the baseline household survey in January 2003, there was no significant difference between the intervention arm and the comparison arm of the study in the proportion of sick newborns who were taken outside the home for care from any qualified provider (including Kumudini Hospital), to the Kumudini Hospital specifically, or to an unqualified provider, most commonly an unlicensed ?village doctor?.", Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,139,2871176,Cannot tell based on the abstract,, HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,139,2871176,No significant difference,"There were no significant differences between treatments for HOMA-IR.

Table 2", HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,213,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6r (ng/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,110,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,110,2871176,Significantly increased,"The percentage of subjects reaching ADA [2] and International Diabetes Federation (IDF)/American Association of Clinical Endocrinologists (AACE) [11,12] treatment HbA1c goals with liraglutide was dose dependent (Fig. 4). At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo (Fig. 4). The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,144,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,144,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,165,3001156,Cannot tell based on the abstract,, Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,165,3001156,No significant difference,Figure 2 demonstrates that there was a highly significant (p<0.00001) increase in the proportion of families that sought care from qualified providers for sick newborns in the intervention arm (Fig. 2 and Rows 5 and 7 of Table 2) and a non-significant increase in the comparison arm (Rows 5 and 8)., Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
edin,109,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
edin,109,2871176,Significantly decreased,"Rosiglitazone also was superior to placebo (P < 0.0001).,he greatest decreases occurred with liraglutide 1.2 and 1.8 mg (Fig. 3a?c). After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d). Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.", HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
edin,106,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,106,2871176,Significantly decreased,"Estimated treatment differences and 95% CIs to placebo were: liraglutide 1.8 mg: ?1.4% (1.6, ?1.1); liraglutide 1.2 mg: ?1.3% (1.5, ?1.1); liraglutide 0.6 mg: ?0.8% (?1.1, ?0.6); rosiglitazone: ?0.7% (?0.9, ?0.4). All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,149,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,149,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01)., Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,104,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,180,2864284,Cannot tell based on the abstract,, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,180,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,111,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,111,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).

FIGURE 4", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,187,2517154,Cannot tell based on the abstract,, Bleeding during surgery , Placebo , Infliximab ,0,
edin,187,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Bleeding during surgery , Placebo , Infliximab ,0,
edin,157,2708184,Cannot tell based on the abstract,, Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
edin,157,2708184,No significant difference,"<td colspan=""8""><hr></td>", Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
edin,122,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,122,2871176,Significantly increased,"The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%).,The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).", ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,126,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,126,2871176,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,158,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,158,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,125,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,183,2517154,Cannot tell based on the abstract,, Endometrial thickness , Placebo , Infliximab ,0,
edin,183,2517154,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3?18) and 7.8 (1.9?11) mm and for the placebo group 7.7 (1.8?23) and 8.2 (3?15) mm, respectively.", Endometrial thickness , Placebo , Infliximab ,0,
edin,175,2864284,Cannot tell based on the abstract,, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,175,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,133,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,133,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,171,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Superiority of treatment given by survival curves , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,146,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,146,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7?1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,127,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,127,2871176,Significantly increased,"he percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,174,2864284,Cannot tell based on the abstract,, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,174,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,118,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,118,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,185,2517154,Cannot tell based on the abstract,, Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
edin,185,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
edin,142,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,142,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,162,2708184,Cannot tell based on the abstract,, Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,162,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,129,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,129,2871176,No significant difference,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,131,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,131,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,140,2871176,Cannot tell based on the abstract,, HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,140,2871176,No significant difference,There were no significant differences between treatments for HOMA-IR., HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,203,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,203,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53?12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,170,2864284,Cannot tell based on the abstract,, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,170,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
edin,150,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,150,2871176,No significant difference,"Main adverse events for all treatments were minor hypoglycaemia (< 10%), nausea (< 11%), vomiting (< 5%) and diarrhoea (< 8%).", Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,124,2871176,Cannot tell based on the abstract,, Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,124,2871176,Significantly decreased,reatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5?2.4 mmol/l; P < 0.0001) and greater with liraglutide 1.2 mg (0.64 mmol/l; P = 0.043) and 1.8 mg (0.87 mmol/l;P = 0.0022) compared with rosiglitazone., Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,113,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,113,2871176,Significantly increased,"he estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,145,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,145,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7?1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,161,2708184,Cannot tell based on the abstract,, Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,161,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
edin,102,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,102,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,101,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,101,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,108,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,108,2871176,No significant difference,"All liraglutide doses were superior to placebo (P < 0.0001), while the two higher liraglutide doses were superior to rosiglitazone (P < 0.0001). Liraglutide 0.6 mg was non-inferior to rosiglitazone.", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
edin,181,2517154,Cannot tell based on the abstract,, Severity of pain , Placebo , Infliximab ,0,
edin,181,2517154,No significant difference,"Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001). However, no effect of infliximab was observed for any of the outcome measures.", Severity of pain , Placebo , Infliximab ,0,
edin,141,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,141,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6?2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9?2.3 mmHg).", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
edin,153,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,153,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
edin,210,2206488,Cannot tell based on the abstract,, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,210,2206488,Significantly decreased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,196,3187863,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11?1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16?2.13).", Pain relief: Epidural anesthesia , Normal unit & Special unit , Midwife-led unit ,0,
edin,115,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,115,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,193,3187863,No significant difference,There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit & Special unit , Special unit ,0,
edin,200,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,200,2688140,No significant difference,"The overall mortality at 28 days was 37%. Mortality at 28 days was 33% in the control group and 40% in the decremental PEEP titration group (Table 2). Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,138,2871176,Cannot tell based on the abstract,, HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,138,2871176,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051).", HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
edin,148,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,148,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002), Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,152,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,152,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.", Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
edin,151,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,151,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048), occurring in the setting of lower mean HbA1c values.", Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,105,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,105,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%) (Fig. 3d).", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
edin,400,2690844,Cannot tell based on the abstract,, Complications after surgery , Midline incision , Transverse incision ,0,
edin,400,2690844,No significant difference,Postoperative complications (Table 4) were seen in 16 out of 75 patients (21%) from the midline incision group and in 15% from the transverse incision group (11 patients) (P = 0.30), Complications after surgery , Midline incision , Transverse incision ,0,
edin,442,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,442,2600646,Significantly decreased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,376,3580134,Significantly increased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score (table IV). Table III", Awakening-free nights percentage improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,472,2847809,Cannot tell based on the abstract,, Complications and mortality , Placebo , Clopidogrel ,0,
edin,472,2847809,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Death events</td><td align=""center"" colspan=""1"" rowspan=""1"">4 (4.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.47</td>", Complications and mortality , Placebo , Clopidogrel ,0,
edin,344,3580134,Significantly increased,Time to first COPD exacerbation was significantly prolonged with both budesonide/formoterol dosages compared with placebo (p ? 0.004) and with budesonide/formoterol 320/9 ?g compared with formoterol (p = 0.026) [figure 6]., Time to first COPD exacerbation , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,474,2847809,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03)., The primary arteriovenous fistula failures at two months , Placebo , Clopidogrel ,0,
edin,315,3580134,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023) [figure 3b].", 1-hour post-dose FEV1 improvements , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,279,2375236,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.", Information recall , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,480,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,324,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Mean FEV1 at 12 hours at end of treatment , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,406,2690844,Cannot tell based on the abstract,, Scar width , Midline incision , Transverse incision ,0,
edin,406,2690844,Significantly decreased,The mean width of the scar after the healing of the midline incisions was found to be 8.3 ± 1.4 mm. The mean width of the scar after the healing of the transverse incisions was measured to be 3.3 ± 1.2 mm. This observed difference is significant (P < 0.0001)., Scar width , Midline incision , Transverse incision ,0,
edin,481,2899760,Significantly increased,"Fusion rate in the SR group was 92%, and in the TM group 69% (P < 0.05).", Fusion rate , anterior cervical decompression and fusion (ACDF) with Trabecular Metal? (TM) , raditional Smith?Robinson (SR) procedure with autograft  ,0,
edin,224,1475568,Cannot tell based on the abstract,, Minnesota living with heart failure (MLHF) questionnaire baseline scores , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,224,1475568,Significantly decreased,"The control group did have statistically significantly higher baseline MLHF scores representing worse symptoms at baseline.,Patients enrolled in the control group received a general heart failure education pamphlet written at approximately the 7th grade level, and continued with usual care from their primary physician.", Minnesota living with heart failure (MLHF) questionnaire baseline scores , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,374,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].,Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score (table IV). Table III", Sleep score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,319,3580134,Significantly increased,Morning and evening PEF improved significantly for all active treatments compared with placebo (p ? 0.012), Peak expiratory flow in the morning and evening  , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,440,2600646,Cannot tell based on the abstract,, mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,440,2600646,No significant difference,"<td colspan=""8""><hr></td>", mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,268,2691927,Significantly decreased,Differences regarding postoperative dosage of opiates and the visual analog scale (VAS) for pain scoring system were in favor of the laparoscopic procedure., Need for opiates , Conventional open approach , Laparoscopic surgery ,0,
edin,286,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Quit attempt of 1 week or longer reported at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,309,2817867,Significantly increased,Sixty percent of patients suffered local recurrences after RFA compared to 7% after hepatic resection., Local recurrence rate through the study , Hepatic resection , Radiofrequency ablation ,0,
edin,241,3090298,Cannot tell based on the abstract,, Higher-order aberrations during the study , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,241,3090298,No significant difference,"Total root-mean square (RMS) HOAs, coma, trefoil, and spherical aberrations are compared in Figure 2. There were no significant differences between groups in any HOAs throughout the study (P ? 0.101), with all P values at 6 months ?0.63.", Higher-order aberrations during the study , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,216,1475568,Cannot tell based on the abstract,, Heart failure-related quality of life at the end of treatment , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,216,1475568,No significant difference,"In unadjusted analysis, the control group, on average, improved 5 points on the MLHF and the intervention group improved by 1 point. The difference was not statistically significant (3.5 points, 95% CI 11, -4, p = 0.36). After adjusting for baseline differences between the groups, the difference was 2 points (95% CI 9, -5, p = 0.59) suggesting no effect on heart failure-related quality of life.", Heart failure-related quality of life at the end of treatment , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,307,2817867,Cannot tell based on the abstract,, Overall survival rate at 5 years , Hepatic resection , Radiofrequency ablation ,0,
edin,307,2817867,Significantly decreased,"The 5-year overall survival after resection alone was 43% (95% CI = 26 to 58%), while the 5-year survival after RFA alone was 23% (95% CI = 11 to 39%), as shown in Figure 1. This difference was statistically significant (P = .02).", Overall survival rate at 5 years , Hepatic resection , Radiofrequency ablation ,0,
edin,432,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,432,3187863,Significantly increased,"There were statistically significant differences in augmentation (midwife-led unit versus normal unit RR 0.73, 95% CI 0.59?0.89; midwife-led unit versus special unit RR 0.69, 95% CI 0.56?0.86), in epidural analgesia (midwife-led unit versus normal unit RR 0.68, 95% CI 0.52?0.90; midwife-led unit versus special unit RR 0.64, 95% CI 0.47?0.86) and in acupuncture (midwife-led unit versus normal unit RR 1.45, 95% CI 1.25?1.69; midwife-led unit versus special unit RR 1.45, 95% CI 1.22?1.73).", Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,302,2817867,Cannot tell based on the abstract,, Blood loss during surgery , Hepatic resection , Radiofrequency ablation ,0,
edin,302,2817867,Significantly decreased,Operative blood loss (median 1400?mL (range 100 to 9000) versus 150?mL (range 50 to 2300); P < .0005) and transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA., Blood loss during surgery , Hepatic resection , Radiofrequency ablation ,0,
edin,326,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Baseline-adjusted average 12-hour FEV1 at end of treatment , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,443,1468428,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66),", Puerperal and neonatal infection rates  , no enema , 1 litre saline enema ,0,
edin,341,3580134,Significantly increased,"Improvements from baseline to the average over the randomized treatment period in 1-hour post-dose IC were significantly greater with both budesonide/formoterol dosages compared with placebo (p < 0.001) and formoterol (p ? 0.018) [figure 5b].,Both dosages of budesonide/formoterol resulted in a 350 mL (?25%) improvement from baseline to the average over the randomized treatment period in 1-hour post-dose IC, and formoterol resulted in a 210 mL (17%) improvement in 1-hour post-dose IC. Fig. 5", 1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,403,2690844,Cannot tell based on the abstract,, Infection of the surgical site , Midline incision , Transverse incision ,0,
edin,403,2690844,No significant difference,"Surgical site infections were diagnosed in 7 and 3 patients, respectively (P = 0.33).Table 4", Infection of the surgical site , Midline incision , Transverse incision ,0,
edin,347,3580134,Significantly decreased,"In addition, significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 ?g and 160/9 ?g versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ? 0.004) [see figure S2 in the supplementary material].", Amount of exacerbations per patient-treatment year , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,231,3090298,Cannot tell based on the abstract,, Uncorrected distance visual acuity at 1 month , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,231,3090298,Significantly decreased,"Statistically significant differences were found between PRK and thin-flap LASIK in UDVA at 1 month postoperatively, with thin-flap LASIK eyes showing more improvement in UDVA.", Uncorrected distance visual acuity at 1 month , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,389,2690844,Cannot tell based on the abstract,, Smaller incision  , Midline incision , Transverse incision ,0,
edin,389,2690844,Significantly increased,"The length of the incisions was 140 ± 24 mm and 164 ± 28 mm for the transverse and the midline incisions, respectively. The difference in scar length was found to be significant (P < 0.0001).", Smaller incision  , Midline incision , Transverse incision ,0,
edin,482,2899760,No significant difference,There was no statistically significant difference in clinical outcomes between fusion techniques or between patients who appeared radiologically fused or non-fused., clinical outcomes , anterior cervical decompression and fusion (ACDF) with Trabecular Metal? (TM) , raditional Smith?Robinson (SR) procedure with autograft  ,0,
edin,367,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Overall use of daily rescue medication improvement , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,402,2690844,Cannot tell based on the abstract,, Urinary retention , Midline incision , Transverse incision ,0,
edin,402,2690844,No significant difference,"Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).", Urinary retention , Midline incision , Transverse incision ,0,
edin,283,2361806,No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).", Overall survival , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
edin,397,2690844,Cannot tell based on the abstract,, Procedure performed directly by the staff surgeon , Midline incision , Transverse incision ,0,
edin,397,2690844,No significant difference,Staff surgeons performed 17% (13/75 patients) of all procedures performed through a midline incision. The remainder of the procedures through a midline incision was carried out under staff surgeon supervision. Staff surgeons performed 14% of all procedures in the transverse incisions study group (10/74 patients) and supervised the remainder. No statistically significant difference was found between the two randomised groups (P = 0.65)., Procedure performed directly by the staff surgeon , Midline incision , Transverse incision ,0,
edin,233,3090298,Cannot tell based on the abstract,, Corrected distance visual acuity at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,233,3090298,No significant difference,Visual acuities were not statistically different between the groups at 3 or 6 months., Corrected distance visual acuity at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
edin,254,1831737,Cannot tell based on the abstract,, Patients infected with T. vaginalis , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,254,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Patients infected with T. vaginalis , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,282,2361806,No significant difference,"For ILF and ELF, respectively, median progression-free survival was 4.5 vs 2.3 months, time to treatment failure was 3.6 vs 2.2 months (P=0.4542), and overall survival was 10.8 vs 8.3 months (P=0.2818).", Time to treatment failure , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
edin,447,2607225,Cannot tell based on the abstract,, cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,447,2607225,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046) from 3 to 24 months.", cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,385,2721929,Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).", Urgency score improvement , Bladder training only (BT) , Bladder training plus tolterodine (Co) ,0,
edin,467,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", negative correlation between CSF protein and duration of mechanical ventilation , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,305,2817867,Cannot tell based on the abstract,, Hospital stay , Hepatic resection , Radiofrequency ablation ,0,
edin,305,2817867,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.", Hospital stay , Hepatic resection , Radiofrequency ablation ,0,
edin,273,2691927,Cannot tell based on the abstract,, Time to nasogastric decompression , Conventional open approach , Laparoscopic surgery ,0,
edin,273,2691927,No significant difference,"Nasogastric decompression could be stopped after 2?3 days in both groups (Table 4).Table 4,<td align=""left"">Median duration of nasogastric decompression (days) + IQR</td><td align=""char"" char=""("">2.0 (3.0)</td><td align=""char"" char=""("">3.0 (1.3)</td><td align=""char"" char=""."">0.334</td>", Time to nasogastric decompression , Conventional open approach , Laparoscopic surgery ,0,
edin,456,3446002,Cannot tell based on the abstract,, side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,456,3446002,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed., side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,269,2691927,Cannot tell based on the abstract,, Hospital permanence , Conventional open approach , Laparoscopic surgery ,0,
edin,269,2691927,No significant difference,"Time to discharge was similar for the two groups, with a median difference of 1.5 days (Table 4),<td align=""left"">Median hospital stay (days) + IQR</td><td align=""char"" char=""("">6.5 (9.3)</td><td align=""char"" char=""("">8.0 (7.3)</td><td align=""char"" char=""."">0.235</td>", Hospital permanence , Conventional open approach , Laparoscopic surgery ,0,
edin,463,1876597,No significant difference,Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs., Adverse Events , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
edin,238,3090298,Cannot tell based on the abstract,, Contrast sensitivity at 3 months seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,238,3090298,No significant difference,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013), although it did not reach a statistically significant difference at 3 months (P = 0.101).", Contrast sensitivity at 3 months seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,265,2691927,Significantly decreased,"The VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.", Visual analog scale pain score at day 3 , Conventional open approach , Laparoscopic surgery ,0,
edin,395,2690844,Cannot tell based on the abstract,, Average patient's weight , Midline incision , Transverse incision ,0,
edin,395,2690844,No significant difference,"Furthermore, no differences were found in the body mass and average length between the two groups (Table 1).", Average patient's weight , Midline incision , Transverse incision ,0,
edin,264,2691927,Significantly decreased,"he VAS score on postoperative days 1, 3, and 7 was significant lower (P < 0.05) in the laparoscopic group.", Visual analog scale pain score at day 1 , Conventional open approach , Laparoscopic surgery ,0,
edin,278,2375236,Significantly decreased,"Provision of the question prompt sheet prolonged consultations and increased patient anxiety; however, when oncologists specifically addressed the prompt sheet, anxiety levels were significantly reduced, consultation duration was decreased and recall was significantly improved.", Anxiety , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,370,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Cough score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,479,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,261,1831737,Cannot tell based on the abstract,, Programme meeting attendance , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,261,1831737,Significantly increased,"In the general population sample interviewed in the follow-up survey, 1,779 (35%) and 647 (13%) of 5,098 respondents reported attending an HIV/AIDS meeting and a programme meeting, respectively (Table 5). More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33?1.56], p < 0.001) and a programme meeting (20% versus 5%, 4.27 [95% CI 3.52?5.17], p < 0.001),", Programme meeting attendance , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,387,2721929,Cannot tell based on the abstract,, Urgency score improvement , Tolterodine only (To) , Bladder training plus tolterodine (Co) ,0,
edin,387,2721929,No significant difference,"No difference was observed between the To and Co groups.,When we compared these changes among the three groups, we found that patients in the Co group showed greater improvements in frequency and urgency scores than did patients in the BT group (p<0.05 each), and that urgency scores in the To and Co groups showed significantly greater improvement than in the BT group (p=0.017 and p=0.021, respectively).", Urgency score improvement , Tolterodine only (To) , Bladder training plus tolterodine (Co) ,0,
edin,276,2375236,Cannot tell based on the abstract,, Prognosis information given , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,276,2375236,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients., Prognosis information given , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,237,3090298,Cannot tell based on the abstract,, Contrast sensitivity at 1 month seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,237,3090298,Significantly decreased,"The thin-flap LASIK group showed no change in contrast sensitivity postoperatively (P > 0.131), while patients in the PRK group had a slight decrease in contrast sensitivity at 1 month seen at 3 and 12 cpd (P = 0.004) and (P = 0.025), respectively", Contrast sensitivity at 1 month seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
edin,298,1871574,Cannot tell based on the abstract,, Smoking cessation at 6 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,298,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Smoking cessation at 6 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,428,3187863,Cannot tell based on the abstract,, Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,428,3187863,No significant difference,There was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,292,1871574,Cannot tell based on the abstract,, Baseline cotinine level , Usual care , Smoking cessation advice and NRT offered ,0,
edin,292,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>,<td></td><td colspan=""5""><hr></td>", Baseline cotinine level , Usual care , Smoking cessation advice and NRT offered ,0,
edin,423,1187893,Significantly increased,"<td colspan=""7""><hr></td>", Knee injury and Osteoarthritis Outcome Score quality of life subscale at 6 months , No exercise , Exercise ,0,
edin,323,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002) [table II]., Mean FEV1 at 12 hours on the day of randomization , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,295,1871574,Cannot tell based on the abstract,, Smoking reduction at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,295,1871574,Significantly increased,"<td></td><td colspan=""5""><hr></td>", Smoking reduction at 3 months , Usual care , Smoking cessation advice and NRT offered ,0,
edin,316,3580134,Significantly increased,"lthough improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023) [figure 3b].", 1-hour post-dose FEV1 improvements , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,217,1475568,Cannot tell based on the abstract,, Baseline hypertension , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,217,1475568,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men.,Regardless of these differences, none were statistically significant.", Baseline hypertension , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,258,1831737,Cannot tell based on the abstract,, Intake of STI treatment , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,258,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Intake of STI treatment , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,448,2607225,Cannot tell based on the abstract,, Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,448,2607225,Significantly decreased,"Appetite loss decreased from 3 to 6 months (mean=5.1?3.7, s.d.=14.2?11.1), worsened at 12 months (mean=5.8, s.d.=16.0) and decreased again at 24 months (mean=4.1, s.d.=12.7) in GR patients, whereas it improved from 3 to 6 and 12 months (mean=8.1, 4.0, 2.4; s.d.=17.7, 12.6, 10.8) and worsened at 24 months (mean=2.8, s.d.=10.7) in non-GR patients (F=4.1, d.f.=3/963, P=0.007).", Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,441,2600646,Cannot tell based on the abstract,, Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,441,2600646,No significant difference,"<td colspan=""8""><hr></td>", Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,377,3580134,Significantly decreased,The geometric mean values of 24-hour urinary cortisol at 6 months and end of treatment were lower in both budesonide/formoterol dosage groups compared with formoterol and placebo (see table SV in the supplementary material). Significant differences in 24-hour urinary cortisol were observed between the budesonide/formoterol 320/9 ?g and placebo groups (p = 0.035) at month 6 and between the budesonide/formoterol 320/9 ?g and formoterol groups (p = 0.044) at end of treatment., 24-hour urinary cortisol at 6 months , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,218,1475568,Cannot tell based on the abstract,, Baseline diabetes , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,218,1475568,No significant difference,"At baseline, most characteristics were similar between the two groups (Table 1). However, the control group had more participants with hypertension, fewer with diabetes, and fewer men. Of heart failure related characteristics, the control group had more participants with systolic dysfunction, and taking ?-blockers. The intervention group had more participants taking ACE inhibitors or ARBs, and digoxin. Regardless of these differences, none were statistically significant.", Baseline diabetes , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,255,1831737,Cannot tell based on the abstract,, Secondary school education , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,255,1831737,No significant difference,"T. vaginalis infection, secondary school education, and spatial mobility were more common in the control communities, whilst history of genital discharge and uptake of STI treatment and VCT services offered in the survey were low overall but more frequent in the intervention communities (Table 1). However, the differences in each case were small and were unlikely to be clinically meaningful.", Secondary school education , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,393,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day three after surgery , Midline incision , Transverse incision ,0,
edin,289,1871574,Cannot tell based on the abstract,, Baseline smoking habits , Usual care , Smoking cessation advice and NRT offered ,0,
edin,289,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Baseline smoking habits , Usual care , Smoking cessation advice and NRT offered ,0,
edin,473,2847809,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008)., First hemodialysis success , Placebo , Clopidogrel ,0,
edin,228,1475568,Cannot tell based on the abstract,, Baseline life-quality score , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,228,1475568,No significant difference,"Among these patients, there was no difference in quality of life score in unadjusted and adjusted analyses (difference = -1.6; 95% CI -15, 12); p = 0.81).", Baseline life-quality score , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,275,2375236,Significantly increased,Patients provided with a question prompt sheet asked more questions about prognosis compared with controls and oncologists gave significantly more prognostic information to these patients., Prognosis enquiry , Patients who didn't receive a question prompt sheet , Patients who received a question prompt sheet ,0,
edin,401,2690844,Cannot tell based on the abstract,, Cardiac complications , Midline incision , Transverse incision ,0,
edin,401,2690844,No significant difference,"Briefly, one patient in each group developed cardiac complications; 8 and 6 patients developed urinary retention after the midline and transverse incisions, respectively (P = 0.59).", Cardiac complications , Midline incision , Transverse incision ,0,
edin,310,3580134,Significantly increased,Time to discontinuation was significantly (p ? 0.004) prolonged in both budesonide/formoterol groups versus placebo., Time to discontinuation , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,355,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Breathlessness Cough and Sputum Scale improvement , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
edin,287,1871574,Cannot tell based on the abstract,, Gender , Usual care , Smoking cessation advice and NRT offered ,0,
edin,287,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Gender , Usual care , Smoking cessation advice and NRT offered ,0,
edin,427,1187893,Cannot tell based on the abstract,, Functional performance improvement , No exercise , Exercise ,0,
edin,427,1187893,No significant difference,"<td colspan=""7""><hr></td>", Functional performance improvement , No exercise , Exercise ,0,
edin,290,1871574,Cannot tell based on the abstract,, Baseline nicotine dependence variables , Usual care , Smoking cessation advice and NRT offered ,0,
edin,290,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Baseline nicotine dependence variables , Usual care , Smoking cessation advice and NRT offered ,0,
edin,391,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day one after surgery , Midline incision , Transverse incision ,0,
edin,384,2721929,Significantly increased,"Mean urgency score decreased by 44.8%, 62.2% and 60.2% in the BT, To, and Co groups, respectively, and the improvement was significantly greater in the To and Co groups than in the BT group (p<0.05 for each).", Urgency score improvement , Bladder training only (BT) , Tolterodine only (To) ,0,
edin,259,1831737,No significant difference,No evidence was found for reduced incidence of self-reported STI symptoms or high-risk sexual behaviour in the intervention communities., Self-reported STI symptoms , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
edin,407,2690844,Cannot tell based on the abstract,, Better cosmetic appearance of the incision as subjectively assessed by patients , Midline incision , Transverse incision ,0,
edin,407,2690844,Significantly increased,Transverse incisions were found to be significantly shorter than midline incisions and associated with more pleasing appearance., Better cosmetic appearance of the incision as subjectively assessed by patients , Midline incision , Transverse incision ,0,
edin,226,1475568,Cannot tell based on the abstract,, Knowledge about heart failure , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,226,1475568,Significantly increased,"Heart failure related knowledge improved more in the intervention group than in the control group. Mean difference in score improvement was 12 percentage points (95% CI 6, 18; p < 0.001).", Knowledge about heart failure , Standard information about self-care , Follow-up and thorough education on self-care ,0,
edin,368,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Dyspnoea score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
edin,611,5577662,Cannot tell based on the abstract,, percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
edin,611,5577662,Significantly decreased,"<td colspan=""5"">Week 8</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
edin,571,5602855,No significant difference,The EQ-5D-3L summary index is shown in Fig.Â 2. No significant change could be observed in the anxiety/depression dimension of the EQ-5D-3L system either in those with good (pÂ =Â 0.26) or inadequate (pÂ =Â 0.71) motivation/capability during the three years of follow-up., Quality of life , inadequate motivation/capability , good motivation/capability ,0,
edin,578,4577567,Significantly decreased,"Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001) and contact time (4.58%; p<0.001); inversely, a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found.,In RWF the effect of the training showed a decrease in stride length (1.18%; p<0.0001) and contact time (<1%; p<0.0001) with respect to baseline conditions and an increased stride frequency and internal work of 1.19% (p<0.0001).", internal work , free stride frequency , stride frequency manipulation ,0,
edin,495,2253708,No significant difference,"<th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th>", 7-day point prevalence abstinence , Practitioner-delivered brief advice , Tailored letters ,0,
edin,619,4139977,No significant difference,Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910)., Improvement in bowel habit ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,608,5577662,Significantly increased,"<td colspan=""5"">Week 8</td>,<td colspan=""5"">Week 8</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,595,4819709,Significantly increased,"UGFS was superior to EVLA in terms of return to fullâ??time work (hazard ratio 1Â·43, 95 per cent c.i. 1Â·11 to 1Â·85),", Full return to normal work/employment , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,593,4819709,No significant difference,The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were â??having a bath or showerâ?? and â??wearing clothes that show the legsâ??., Wearing clothes that show the legs , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,551,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,617,5062234,Significantly decreased,"The visual analog scale scores at rest and on coughing were significantly higher in the local infiltration group in the immediate postoperative period (P = 0.034 and P = 0.007, respectively).", The visual analog scale scores at rest and on coughing , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
edin,544,2666722,Cannot tell based on the abstract,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,0,
edin,544,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1, I was not able to find any connection in text between health care workers with IgG against Severe acute respiratory syndrome and the risk of SARS infection. 
edin,556,4785315,Significantly decreased,"The prespecified comparison for women with two or more social risk factors showed a statistically significant reduction in mean EPDS (MD â??0.79 (95% CI â??1.56 to â??0.02) p=0.05), although no significant differences were seen in the mean EPDS (mean difference (MD) â??0.59 (95% CI â??1.24 to 0.06)) for all the women recruited.", Postnatal depression (Edinburgh Postnatal Depression Scale17 EPDS) , standard maternity care ," additional lay support (in this instance Pregnancy Outreach Workers, POWs) ",0,
edin,519,1261533,Significantly decreased,"The mean (SD) decrease in haematocrit value at day seven from baseline was greater in the group receiving MAS3 than in the ALN group: 9.3% (SD,11.5%; 95% CI, 7.7% to 10.9%) compared with 6.7% (SD, 11.4%; 95% CI, 5.1 to 8.3%) respectively (P = 0.023).", Decrease in haematocrit level at day 7 , Mefloquine-artesunate , Artemether-lumefantrine ,0,
edin,620,4139977,No significant difference,"With regard to QOL, an improvement was observed in the probiotic (P = 0.008), but not in the placebo group (P = 0.175); though, there was no significant difference between the two groups in this regard (P = 0.372), Table 2.", quality-of-life  ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,583,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Bending the legs without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">3Â·0</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·6</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·38 (1Â·14, 1Â·67)</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â?? 2 ).", Bending the legs without discomfort , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,599,4819709,Significantly decreased,"Return to â??walking short distances without discomfortâ??, â??walking long distancesâ??, â??looking after childrenâ?? and â??full return to normal work/employmentâ?? took longer for the EVLA group than the UGFS group."," walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment ", Ultrasoundâ??guided foam sclerotherapy , Endovenous laser ablation ,0,
edin,582,3800940,Cannot tell based on the abstract,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,0,
edin,582,3800940,Invalid Prompt,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,1, Required info can't be found in abstract and there are no other sections for this article. 
edin,560,2888205,Significantly decreased,"<th></th><th colspan=""6""><hr></th>", pain , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
edin,485,2806484,No significant difference,"184 (24%) patients having home and 145 (27%) facility care either had virological failure, were lost to follow-up, or withdrew from the trial (adjusted rate ratio [RR] 0Â·88, 95% CI 0Â·70â??1Â·10).", Virological failure , Facility-based HIV-care strategy , Home-based HIV-care strategy ,0,
edin,500,2956883,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0Â·19 for interaction), or between consistent (HR 0Â·97, 95% CI 0Â·87â??1Â·35, p=0Â·87) and inconsistent (1Â·17, 0Â·42â??1Â·72, p=0Â·42) gel users (p=0Â·47 for interaction).", Gel efficacy in consistent gel users , Placebo gel , 0Â·5% PRO2000 gel ,0,
edin,561,2888205,No significant difference,"<th></th><th colspan=""6""><hr></th>", six-minute walk test , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
edin,534,3198285,Significantly decreased,The LGI group achieved a modestly lower GI than the HF group (mean Â± SEM 47 Â± 1 vs. 53 Â± 1; P < 0.001)., lowâ??glycemic index , high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
edin,502,2956883,No significant difference,No deaths or serious adverse events were regarded as related to study gels., Adverse events , Placebo gel , PRO2000 gels ,0,
edin,589,4819709,No significant difference,The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were â??having a bath or showerâ?? and â??wearing clothes that show the legsâ??., Having a bath or shower , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,601,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , glucose 5% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,510,1964758,Significantly increased,"<td colspan=""4""><hr></td>", 8-year survivorship in patients with osteoarthritis , BioModularÂ® shoulder prosthesis , Initial Nottingham TSR design prosthesis ,0,
edin,615,5062234,No significant difference,The 24 h morphine requirement (mean Â± standard deviation) was 34.57 Â± 14.64 mg in TAP group and 32.76 Â± 14.34 mg in local infiltration group (P = 0.688)., The 24 h morphine requirement , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
edin,602,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , normal saline 0.9% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,512,2829413,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 Â± 11.38 vs. - 30.07 Â± 10.46%, p < 0.001), LDL-C (48.04 Â± 14.45 vs. 39.52 Â± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 Â± 13.15 vs. - 35.52 Â± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 Â± 18.85 vs. - 32.57 Â± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.", Levels of LDL cholesterol after 6 weeks of treatment , Atorvastatin , Rosuvastatin ,0,
edin,610,5577662,Significantly increased,"<td colspan=""5"">Week 8</td>", global assessment of improvement ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,572,5602855,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up., Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,522,1261533,Significantly increased,"Of 452 patients, 119 (26.3%) had P. vivax parasitaemia detected during follow up. There were significantly fewer cases of vivax malaria in the MAS3 group (29 of 227) than in the ALN group (90 of 225) (P < 0.001).", P. vivax parasitaemia diagnosed during follow up , Mefloquine-artesunate , Artemether-lumefantrine ,0,
edin,531,2364680,No significant difference,Fifteen of 380 women (3.9%) developed a wound problem; six had scalpel and nine had electrosurgical subcutaneous incisions (P = 0.4)., wound problem , opening subcutaneous tissues with scalpel , opening subcutaneous tissues with electrocautery ,0,
edin,491,2363351,No significant difference,"Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached).", Overall survival at 3 years , Cisplatin and Cyclophosphamide ," Cisplatin and Cyclophosphamide, plus subcutaneous IFN-Î³  ",0,
edin,536,3198285,No significant difference,"Table 4
Pregnancy outcomes by diet group,<td align=""left"" colspan=""1"" rowspan=""1"" scope=""row"">Emergency caesarean (%)</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">20.5</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">11.6</td><td align=""center"" colspan=""1"" rowspan=""1"">0.263</td>"," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
edin,501,2956883,No significant difference,"Gel efficacy against HIV-1 transmission did not differ between centres (p=0Â·19 for interaction), or between consistent (HR 0Â·97, 95% CI 0Â·87â??1Â·35, p=0Â·87) and inconsistent (1Â·17, 0Â·42â??1Â·72, p=0Â·42) gel users (p=0Â·47 for interaction).", Gel efficacy in inconsistent gel users , Placebo gel , 0Â·5% PRO2000 gel ,0,
edin,498,2364533,No significant difference,"When the results were examined without regard to study site, erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4) or preterm delivery (13% vs. 15%, P = 0.7).", Preterm delivery , Placebo , Erythromycin ,0,
edin,487,2806484,Significantly decreased,"Table 6 shows mean yearly health services cost per patient calculated during 4 years, (including capital and recurrent expenses, and those of the starting phase and subsequent years). A large proportion of the costs were for drugs and staff salaries. The main cause of excess expenditure for the facility-based group was the increased number of contacts with health staffâ??especially with nurses and medical officers. These costs outweighed those of transport for field officers in the home-based group. Patient costs (transport of patient and companion, lunches, child care, and time lost from work) were much higher for the facility-based than for the home-based group (table 6).", Costs for the health service , Facility-based HIV-care strategy , Home-based HIV-care strategy ,0,
edin,609,5577662,Significantly increased,Mean change in nodular consistency and hardness were significantly improved with CCH versus placebo at Weeks 4 and 8 (PÂ â?¤Â 0.0139 for all)., Mean change in nodular consistency and hardness ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) "," receive a dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ",0,
edin,591,4819709,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Doing housework</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">2Â·1</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·5</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">2Â·10 (1Â·72, 2Â·56)</td>,Table 2
Behavioural recovery: ultrasoundâ??guided foam sclerotherapy versus surgery", Doing housework , surgery , Ultrasoundâ??guided foam sclerotherapy ,0,
edin,539,2722000,Significantly decreased,"The actuarial rebleeding rate in the prophylactic group was significantly lower than that in the ondemand group (33.9% vs. 62.1%, p=0.004).", rebleeding , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,543,2650992,No significant difference,"Overall, the fibrin glue and control groups were similar in terms of drainage duration, overall drain output, and incidence of seroma.", The mean drainage duration , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,573,5602855,Cannot tell based on the abstract,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,573,5602855,No significant difference,"At the four monthsâ?? follow-up, 112 (80.6%) subjects with good motivation/capability and 26 (39.4%) with inadequate motivation/capability continued self-assessment of pulse daily.,Irregular pulse findings were not significantly associated with the composite outcome variable (pÂ =Â 0.06), stroke/TIA (pÂ =Â 0.48), pacemaker implantation (pÂ =Â 0.10) or death (pÂ =Â 1.00).,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up.", Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,533,3221331,Cannot tell based on the abstract,, did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
edin,533,3221331,No significant difference,"In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all, but the majority of respondents in both groups made multiple quit attempts.", did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
edin,314,3580134,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 Î¼g compared with formoterol (primary comparison; p = 0.008) and for both budesonide/formoterol dosages compared with placebo (p < 0.001) [figure 3a]., Pre-dose FEV1 improvement , Placebo , Budesonide/formoterol pMDI 320/9 Î¼g ,0,
edin,604,5062194,No significant difference,There were no between-group differences regarding the neonatal outcome., neonatal outcome ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
edin,741,3446002,Cannot tell based on the abstract,, Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,741,3446002,Significantly decreased,The results show that TSB was significantly decreased after 24 and 48 hours in clofibrate group (P<0.001), Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,922,3015551,No significant difference,"Outpatient recovery was the same, unless pelvic pain required overnight observation (ligation, 4 patients; coagulation, 2 patients).", Outpatient recovery , undergo a tubal resection after bipolar coagulation with Kleppinger forceps , undergo a tubal resection after Pomeroy ligation ,0,
edin,966,5372931,Cannot tell based on the abstract,, 14 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,966,5372931,Significantly increased,"The linear dose response for each plasma metabolite was assessed and of the 60 identified metabolites, 14 (poly)phenol metabolites displayed a linear dose-response curve (r2 â¥ 0.89) in plasma (Figure 1) with slopes significantly different from zero (p < 0.05): caffeic acid 4-O-Ã-d-glucuronide and quercetin-3-O-Ã-d-glucuronide displayed r2 > 0.98, while ferulic acid 4-O-Ã-d-glucuronide, 2,5-dihydroxybenzoic acid, 2,4-dihydroxybenzoic acid, ferulic acid, caffeic acid 3-O-Ã-d-glucuronide, sinapic acid, ferulic acid 4-O-sulfate, 3-hydroxybenzoic acid and syringic acid exhibited r2 > 0.90.,The time to reach Cmax (Tmax) varied depending on the metabolite and depending on the amount of (poly)phenols in the juice (Supplementary Figure S1). The level of TP in cranberry juice seemed to impact the Tmax of individual metabolites, for example the Tmax for 3-(4-hydroxyphenyl) propionic acid varied between 7.2 h (409 mg TP juice) and 13.8 h (787 mg TP juice).", 14 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,869,5332972,Significantly increased,"The findings of the Fugl-Meyer assessment, Stroke Impairment Assessment Set, Timed Up & Go test, and 10-m walk test significantly improved after the intervention.", TUG: Timed âUp &amp; Goâ? test; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,881,5539984,Cannot tell based on the abstract,, Primary outcome effect , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,881,5539984,No significant difference,"Mixed-models for EPAS total score (see Table 3) indicated a significant effect of time (bÂ =Â 0.07, pÂ <Â 0.001), but no significant group by time interaction effect (bÂ =Â 0.02; pÂ =Â 0.258). This means with regard to the parameterisation of the mixed effects model that there was a significant change of overall empowerment in the control group, but NWpG-IC treatment had no additional effect on improvement of overall empowerment during the 18Â month study period.", Primary outcome effect , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,635,4106715,Cannot tell based on the abstract,, Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19â52) with high Ab levels ,0,
edin,635,4106715,Significantly increased,"Statistically significant differences were observed in reduction of daily cigarette consumption and cotinine between non-abstainers (weeks 19â52) with high Ab levels and non-abstainers in the placebo group (p=0.0015 and 0.019, respectively; see Figures 4A and 4C.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19â52) with high Ab levels ,0,
edin,829,4819709,Cannot tell based on the abstract,, Walking long distances (&gt;?20 min) , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,829,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Walking long distances (&gt;â20 min)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·5</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">8Â·0</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·76 (1Â·45, 2Â·14)</td>,Table 2
Behavioural recovery: ultrasoundâ?guided foam sclerotherapy versus surgery,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ),The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ", Walking long distances (&gt;?20 min) , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,676,3387601,Cannot tell based on the abstract,, side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,676,3387601,No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients., side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,699,3187863,Cannot tell based on the abstract,, Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,699,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65â0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59â0.89) (Table 2).", Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,948,4693888,Cannot tell based on the abstract,, CKMB AUC and Troponin-T AUC , Custodiol , Custodiol-N ,0,
edin,948,4693888,No significant difference,"CKMB AUC (878 Â± 549 vs. 778 Â± 439 h*U/l, non-inferiority p < 0.001) and Troponin-T AUC (12990 Â± 8347 vs. 13498 Â± 6513 h*pg/ml, non-inferiority p < 0.001) was similar in both groups.", CKMB AUC and Troponin-T AUC , Custodiol , Custodiol-N ,0,
edin,688,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,919,3616124,Cannot tell based on the abstract,, preeclampsia risk , Haptoglobinâs (Hp) 2-2 phenotypes ," Haptoglobinâs (Hp)  1-1, 2-1,  ",0,
edin,919,3616124,No significant difference,"Hp phenotype was not significantly associated with the risk of the primary outcome, preeclampsia, severe preeclampsia, or early onset preeclampsia in white/other, Hispanic or black women (Table 2).", preeclampsia risk , Haptoglobinâs (Hp) 2-2 phenotypes ," Haptoglobinâs (Hp)  1-1, 2-1,  ",0,
edin,778,2722000,Cannot tell based on the abstract,, The incidence of bacterial infection , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,778,2722000,Significantly decreased,"The incidence of bacterial infection was significantly lower in patient receiving antibiotic prophylaxis (2/62, 3.2% vs. 9/58, 15.5%, p=0.026).", The incidence of bacterial infection , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,833,4819709,Significantly increased,"UGFS was superior to EVLA in terms of return to fullâ?time work (hazard ratio 1Â·43, 95 per cent c.i. 1Â·11 to 1Â·85), looking after children (1Â·45, 1Â·04 to 2Â·02) and walks of short (1Â·48, 1Â·19 to 1Â·84) and longer (1Â·32, 1Â·05 to 1Â·66) duration.", Looking after children , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,943,5551012,Significantly decreased,"However, antibiotic use less than 24Â h to delivery was associated with a decrease in mean APGAR score.", mean Apgar , no antibiotics , antibiotics in less than 24 h to parturition ,0,
edin,812,5602855,No significant difference,Quality of life and number of outpatient clinic visits remained unchanged during follow-up., Quality of life , inadequate motivation/capability , good motivation/capability ,0,
edin,897,1198254,Significantly increased,ME-3 was well tolerated and a significant increase in total faecal lactobacilli yet no predominance of ME-3 was detected in all study groups., total fecal counts of lactobacilli , goat milk , L. fermentum ME-3 fermented goat milk ,0,
edin,871,5209819,Cannot tell based on the abstract,, Pre-treatment testing performed within the ADDO ," Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. "," After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. ",0,
edin,871,5209819,No significant difference,Pre-treatment testing performed within the ADDO increased from 0 to 65% of suspected malaria patients who visited a shop (95% CI 60.8â69.6%) with no difference between intervention districts., Pre-treatment testing performed within the ADDO ," Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. "," After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. ",0,
edin,825,4819709,Cannot tell based on the abstract,, Lifting heavy objects without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,825,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Lifting heavy objects without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·8</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">9Â·8</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·97 (1Â·59, 2Â·44)</td>,Table 2
Behavioural recovery: ultrasoundâ?guided foam sclerotherapy versus surgery,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Lifting heavy objects without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,647,1201146,Cannot tell based on the abstract,, Dry skin at the application site , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,647,1201146,Significantly increased,"<td colspan=""3""><hr></td>", Dry skin at the application site , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,814,5602855,Cannot tell based on the abstract,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,0,
edin,814,5602855,Invalid Prompt,, Self-detected pulse irregularity and outcome events , inadequate motivation/capability , good motivation/capability ,1," There is Self-detected pulse irregularity and outcome events section of the article. However, motivation/capability is not mentioned in it or I was not able to find it. "
edin,941,3039191,Cannot tell based on the abstract,, the result of frequency doubling technique (FDT) perimetry. , clear IOL was used as a control. ," IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL) ",0,
edin,941,3039191,No significant difference,"The results of FDT perimetry testing are shown in Figs. 1, 2, and 3. There were no statistically significant differences for MD and PSD between the clear IOL and Hoya YA60BBR IOL groups (MD: clear IOL, -5.09 Â± 4.72 Db; Hoya YA60BBR IOL, -3.68 Â± 3.83 dB; p = 0.21 / PSD: clear IOL, 4.26 Â± 2.45 dB; Hoya YA60BBR IOL, 3.81 Â± 1.99; p = 0.27, Mann-Whitney U-test).", the result of frequency doubling technique (FDT) perimetry. , clear IOL was used as a control. ," IOLs were selected randomly among two types of yellow IOLs (Acrysof SN60WF IOL, Hoya YA60BBR IOL) ",0,
edin,937,4918678,Significantly increased,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Reading , nothing , soundfield amplification devices in the classroom ,0,
edin,793,2830179,Significantly decreased,"<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>", pain during movement , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,880,4088715,Cannot tell based on the abstract,," tidal volume (TV), end-tidal carbon dioxide (EtCO2) and Rapid Shallow Breathing Index (RSBI) ", standard group , CPAP + standard of care (nCPAP group) ,0,
edin,880,4088715,Significantly increased,"Subjects in the nCPAP group had a greater improvement for various parameters compared with the standard group including TV (0.8 l, 0.3 l), EtCO2 (30 mmHg, 38 mmHg) and RSBI (39, 150), respectively."," tidal volume (TV), end-tidal carbon dioxide (EtCO2) and Rapid Shallow Breathing Index (RSBI) ", standard group , CPAP + standard of care (nCPAP group) ,0,
edin,846,5062194,Significantly increased,"Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group.,Preeclamptic parturients premedicated with midazolam (0.035 mg/kg) before spinal anesthesia have lower anxiety and higher postoperative satisfaction levels, with no adverse effects on the newborns.", postoperative satisfaction ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
edin,907,5816054,Cannot tell based on the abstract,, The duration of nebulization , 0.9% saline , furosemide ,0,
edin,907,5816054,No significant difference,"The duration of nebulization was not significantly different across treatments: 0.9% saline, 35.7 Â± 1.0 min; 40 mg furosemide, 36.4 Â± 1.2 min; and 120 mg furosemide, 39.2 Â± 1.1 min (p = 0.075).", The duration of nebulization , 0.9% saline , furosemide ,0,
edin,956,3330821,Cannot tell based on the abstract,, The overall satisfaction score , Employee Assistance Program , trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP) ,0,
edin,956,3330821,Significantly increased,The overall satisfaction score for the services was 3.57 (3.31 to 3.81) for the EAP alone group and 4.42 (4.17 to 4.67) for the tCBT +EAP group (p<0.001)., The overall satisfaction score , Employee Assistance Program , trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP) ,0,
edin,884,5514258,Significantly increased,"Patients in the high-risk group had greater survival (hazard ratio [HR], 0.76; P = .002; 95% confidence interval [CI], 0.64-0.91) if they received adjuvant radiation therapy.", survival , major salivary gland cancer in high risk group without adjuvant radiation therapy , major salivary gland cancer in high risk group plus adjuvant radiation therapy ,0,
edin,677,2430614,Significantly decreased,"In a per-protocol analysis, the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, pâ=â0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, pâ=â0.005).", the parasitological and clinical failure rate at day 28 post treatment , artemether-lumefantrine (AL) and  and Artesunate+chlorproguanil-dapsone (AS+CD) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,673,3387601,No significant difference,"hose in the PE group had a tendency for a shorter Pediatric Intensive Care Unit (PICU) stay (p = 0.094).,In children with GBS requiring MV, PE is superior to IVIG regarding the duration of MV but not PICU stay or the short term neurological outcome.", Pediatric Intensive Care Unit (PICU) stay , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,942,5551012,No significant difference,"Intrapartum antibiotic exposure did not significantly affect the birthweight, incidence of congenital birth defect and mean Apgar scores."," birthweight, incidence of congenital birth defect and mean Apgar scores ", no antibiotics , antibiotics ,0,
edin,638,2206488,Cannot tell based on the abstract,, Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,638,2206488,Significantly increased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,868,5332972,Cannot tell based on the abstract,, FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,868,5332972,Significantly increased,"**Significant difference p<0.01. SD: standard deviation; FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; TUG: Timed âUp & Goâ? test; 10MWT: 10-m walk test; CGS: comfortable gait speed; FGS: fast gait speed,The findings of the Fugl-Meyer assessment, Stroke Impairment Assessment Set, Timed Up & Go test, and 10-m walk test significantly improved after the intervention.", FMA-LE: the Fugl-Meyer Assessment of the lower extremity; SIAS: Stroke Impairment Assessment Set; , before repetitive facilitative exercises  and orthotic treatment. , after 4 weeks of repetitive facilitative exercises  and orthotic treatment. ,0,
edin,650,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,650,2600646,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,824,4819709,Cannot tell based on the abstract,, Bending the legs without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,824,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Bending the legs without discomfort</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">3Â·0</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·6</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·38 (1Â·14, 1Â·67)</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Bending the legs without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
edin,859,4139977,No significant difference,"After treatment, there was a decrease in abdominal pain and distension severity in both probiotic and the placebo groups (P<0.001), but there was no difference between the two groups in this regard (P>0.05).", decrease in abdominal pain and distension severity ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
edin,683,2447617,Significantly increased,The modified Functional Independence Measure scores in the progesterone group were higher than those in the placebo group at both 3-month and 6-month follow-up (P < 0.05 and P < 0.01)., The modified Functional Independence Measure scores , placebo , progesterone ,0,
edin,770,2361948,Cannot tell based on the abstract,, 6- and 12-month survival probabilities , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A) ,0,
edin,770,2361948,Significantly decreased,"In all, 6- and 12-month survival probabilities were 57% (95% CI: 42â72%) and 27% (95% CI: 14â40%) for patients receiving 16âGy/2 fr, and 30% (95% CI: 18â42%) and 11% (95% CI: 3â20%) for patients receiving 20âGy/5 fr, respectively. This difference remained significant after correction for disease extent (P=0.022) and performance status (P=0.007).", 6- and 12-month survival probabilities , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A) ,0,
edin,959,2656477,Significantly increased,<td></td><td></td><td></td><td></td><td></td><td></td>, self-efficacy related to social pressure and restraint in overweight and obese endometrial cancer survivors. , usual care , lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification ,0,
edin,717,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,811,5256321,Cannot tell based on the abstract,," he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I)  "," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,811,5256321,Significantly increased,"Table 3 shows that the experimental group showed significant improvements in all testsâBBS (p=0.001), TUG (p=0.001), forward FRT (p=0.001), affected lateral FRT (p=0.001), and unaffected lateral FRT (p=0.002)âwhen the values before and after training were compared in each group"," he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I)  "," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,935,4264479,No significant difference,All participants developed blood-stage infection confirmed by quantitative polymerase chain reaction (qPCR)., blood-stage infection , minimally exposed volunteers for both antigens , definitely exposed volunteers for both antigens  ,0,
edin,730,1468428,Invalid Prompt,, You must have prompts generated from different sections. , 2 , 1 ,1, There is no question formed and no provided answers. 
edin,885,5514258,No significant difference,"In contrast, patients in the intermediate- (HR, 1.01; P = .904; 95% CI, 0.85-1.20) and low-risk groups (HR, 0.85; PÂ =Â .427; 95% CI, 0.57-1.26) did not experience a survival benefit with adjuvant radiation therapy.", survival , major salivary gland cancer in low/intermediate risk group without adjuvant radiation therapy , major salivary gland cancer in low/intermediate risk group plus adjuvant radiation therapy ,0,
edin,939,4918678,Cannot tell based on the abstract,, Silent reading , nothing , soundfield amplification devices in the classroom ,0,
edin,939,4918678,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">âEG</td><td align=""center"" colspan=""1"" rowspan=""1"">131.8</td><td align=""center"" colspan=""1"" rowspan=""1"">59.9</td><td align=""center"" colspan=""1"" rowspan=""1"">112.9</td><td align=""center"" colspan=""1"" rowspan=""1"">52.8</td><td align=""center"" colspan=""1"" rowspan=""1"">1.31 (9)</td><td align=""center"" colspan=""1"" rowspan=""1"">.221</td>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Silent reading , nothing , soundfield amplification devices in the classroom ,0,
edin,658,2720945,Cannot tell based on the abstract,, Side effects , placebo , cineole ,0,
edin,658,2720945,No significant difference,"All patients receiving the study medication (including those with FEV1/VC > 0.7) were included in the safety examination. During treatment side effects were seen in 22 patients whereas in 17 cases adverse events were not related to the study medication. In the placebo group 11 adverse events were estimated not being related to the study medication whereas 2 cases were interpreted as being related to the study medication (heartburn). During treatment with cineole 9 cases of adverse events were reported whereas 6 adverse events were reported not being related to the study medication. In 3 patients (nausea, diarrhoea, heartburn) the adverse events were estimated being related to the study medication. The difference between the two treatment groups was neither clinically relevant nor statistically significant.", Side effects , placebo , cineole ,0,
edin,938,4918678,Cannot tell based on the abstract,, Arithmetic , nothing , soundfield amplification devices in the classroom ,0,
edin,938,4918678,No significant difference,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Arithmetic , nothing , soundfield amplification devices in the classroom ,0,
edin,680,2847809,Cannot tell based on the abstract,, Complications and mortality , Placebo , Clopidogrel ,0,
edin,680,2847809,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Death events</td><td align=""center"" colspan=""1"" rowspan=""1"">4 (4.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">2 (2.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.47</td>", Complications and mortality , Placebo , Clopidogrel ,0,
edin,809,5256321,Cannot tell based on the abstract,, The 10mWT (10-m walking test ) ," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,809,5256321,Significantly increased,"The 10mWT improved significantly (p=0.001) in the experimental group (using the Spine Balance 3D system) but not in the control group, and core muscle strength, which we checked using Spine Balance 3D system evaluation program, improved more in the experimental group as well.", The 10mWT (10-m walking test ) ," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
edin,783,2650992,Significantly decreased,"However, subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006) and overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.", overall drain output , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,675,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", negative correlation between CSF protein and duration of mechanical ventilation , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,712,4106715,Significantly increased,"3âAmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,622,3187863,Cannot tell based on the abstract,, Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,622,3187863,No significant difference,here was no significant difference between the three groups concerning the number of episiotomies or the incidence of sphincter injuries (Table 2)., Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp; Special unit , Special unit ,0,
edin,911,2774638,Cannot tell based on the abstract,, obtained calcium from dairy  , black women , white women ,0,
edin,911,2774638,Significantly increased,"White women obtained more calcium (630 [423] mg) from dairy than did black women (424 [373] mg, P < .004).", obtained calcium from dairy  , black women , white women ,0,
edin,777,3198285,Cannot tell based on the abstract,," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâglycemic index diet (target glycemic index [GI] ~50) ,0,
edin,777,3198285,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"" scope=""row"">Emergency caesarean (%)</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">20.5</td><td align=""center"" colspan=""1"" rowspan=""1"">44</td><td align=""center"" colspan=""1"" rowspan=""1"">11.6</td><td align=""center"" colspan=""1"" rowspan=""1"">0.263</td>"," Birth weight (kg), Birth weight centile, Small for gestational age, Macrosomia, Infant head circumference, Infant length (cm), Ponderal index (kg/m3), Maternal weight gain (kg), Insulin treatment, Emergency caesarean ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâglycemic index diet (target glycemic index [GI] ~50) ,0,
edin,691,2899760,Cannot tell based on the abstract,, Radiological fusion , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ¢ (TM) , raditional SmithâRobinson (SR) procedure with autograft  ,0,
edin,691,2899760,Significantly increased,"he fusion rate shown by the radiological analysis is presented in TableÂ 4. All patients in group III (clearly non-fused) showed at least 4Â° of mobility (the limit for the group set by the classification was 3.0Â°). There was no statistically significant difference in the fusion rate between smokers (92%) and non-smokers (74%) (PÂ =Â 0.2). Smokers operated on with TM showed an 87% fusion rate. Kappa analysis showed 0.63 and 0.66 for the intra-observer correlation, and 0.58 for inter-observer correlation.TableÂ 4,Radiological fusion

Fusion group	TM	SR
No.	Percentage	No.	Percentage
I (clearly fused)	18	46	35	89
IIA (probably fused)	9	23	1	3
IIB (probably non-fused)	5	13	0	0
III (clearly non-fused)	7	18	3	8
Fusion rate (IÂ +Â IIA)		69		92,his study of uninstrumented single-level ACDF showed a lower fusion rate with Trabecular Metal than with the SmithâRobinson technique with autograft after single-level anterior cervical fusion without plating.", Radiological fusion , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ¢ (TM) , raditional SmithâRobinson (SR) procedure with autograft  ,0,
edin,909,2774638,Significantly increased,"The CFFFQ estimated greater total daily calcium intake than did the 24-hour recall (mean [SD], 1,021 [624] mg/d vs 800 [433] mg/d, P < .001).", Estimation of total daily calcium intake , 24-hour recall , calcium-focused food frequency questionnaire (CFFFQ) ,0,
edin,887,5801479,Significantly decreased,"Results of RT-PCR indicated that after the 12-week intervention, compared to the placebo, vitamin D supplementation downregulated gene expression of interleukin (IL)-1Î² (P = 0.02), tumor necrosis factor alpha (TNF-Î±) (P = 0.02) and interferon gamma (IFN-Î³) (P = 0.03) in PBMCs of diabetic HD patients."," gene expression of interleukin (IL), tumor necrosis factor alpha (TNF-?), interferon gamma (IFN-?)  ", placebo (n = 30) every 2 weeks for 12 weeks ," vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks ",0,
edin,781,2722000,Cannot tell based on the abstract,, Total mortality and 30-day mortality , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,781,2722000,No significant difference,Total mortality and 30-day mortality were not different between the two groups (Table 7)., Total mortality and 30-day mortality , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
edin,672,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", Period of mechanical ventilation  , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
edin,703,3187863,No significant difference,"here were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Postpartum haemorrhage , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,719,1201146,Significantly increased,"<td colspan=""3""><hr></td>"," Pain, physical function, PGA, stiffness  ", vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,841,4819709,Cannot tell based on the abstract,," Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (&gt;?15 min) without discomfort, Walking short distances (&lt;?20 min) without discomfort, Walking long distances (&gt;?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise,  ", surgery , Endovenous laser ablation ,0,
edin,841,4819709,Significantly increased,"Participants randomized to EVLA recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 3). Return to âhaving a bath or showerâ was quicker after surgery than after EVLA. There was no difference in time to return to the participation behaviour of âwearing clothes that show the legsâ.,<td align=""left"" colspan=""1"" id=""bjs10081-ent-0450"" rowspan=""1"" valign=""top"">Participation items</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0451"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0452"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0453"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0454"" rowspan=""1"" valign=""top""></td>"," Bending the legs without discomfort, Lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (&gt;?15 min) without discomfort, Walking short distances (&lt;?20 min) without discomfort, Walking long distances (&gt;?20 min), Driving a car, Doing housework, Looking after children, Partial return to normal work/employment, Full return to normal work/employment, Going out socially, Sporting activity or exercise,  ", surgery , Endovenous laser ablation ,0,
edin,726,2600646,Cannot tell based on the abstract,, Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,726,2600646,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Gametocyte dynamics , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,784,2650992,Significantly decreased,"However, subgroup analysis showed that fibrin glue use resulted in a shorter drainage duration (3.5 vs. 4.7 days; p=0.0006) and overall drain output (196 vs. 278 mL; p=0.0255) in patients undergoing level II or III axillary dissection.", The mean drainage duration , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
edin,877,2974815,No significant difference,There was no difference in the percentage of patients with controlled blood pressure in the âphone callsâ? group and âno phone callsâ? group or in the âtraditionalâ? and âcurrentâ? groups., The percentage of patients with controlled blood pressure (&lt;140/90 mmHg) , âno phone callsâ? group , phone callsâ? group ,0,
edin,646,1201146,Cannot tell based on the abstract,, good or very good PGA response and OMERACT-OARSI responder , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,646,1201146,Significantly increased,"<td colspan=""3""><hr></td>", good or very good PGA response and OMERACT-OARSI responder , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,740,3446002,Cannot tell based on the abstract,, side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,740,3446002,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed., side effects , control group , single dose of 50 mg/kg clofibrate ,0,
edin,727,1468428,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66), and median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24).", Puerperal and neonatal infection rates  , no enema , 1 litre saline enema ,0,
edin,906,4320624,Cannot tell based on the abstract,," Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â2 ", placebo , Abediterol ,0,
edin,906,4320624,Significantly increased,"Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â24 was significantly higher for all doses of abediterol versus placebo (pâ<â0.0001 for all, TableÂ 2), with dose-related effects observed."," Change from baseline in normalized FEV1 AUC0â6, FEV1 AUC0â12, and FEV1 AUC0â2 ", placebo , Abediterol ,0,
edin,918,3616124,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Hispanic</td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>", preeclampsia risk  in Hispanic Hp 2-2 women. , placebo from 9-16 weeks gestation until delivery. , daily doses of 400 IU of vitamin E and 1000 mg of vitamin C from 9-16 weeks gestation until delivery. ,0,
edin,864,4078386,No significant difference,"We didnât find any significant differences in the mean of HCV-RNA numbers between statin and placebo groups in 12th week of treatment, in the end of treatment and 6 months after treatment (P > 0.05).", mean of HCV-RNA numbers 6 months after treatment  , placebo , 20 mg atorvastatin nightly for 3 months ,0,
edin,720,1201146,Cannot tell based on the abstract,, Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,720,1201146,Significantly decreased,"<td colspan=""3""><hr></td>", Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,823,3800940,Cannot tell based on the abstract,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,0,
edin,823,3800940,Invalid Prompt,," Indralupta is a unique, idiopathic, non-cictricial, non-inflammatory alopecia, presents as discoid areas of hair loss. ", Godugdha sodhit Langali moola with honey for external application , Gomutra sodhit Langali moola with honey for external application ,1, There is no question in this prompt. It contains only a statement 
edin,696,2858204,Cannot tell based on the abstract,," In the per-protocol analysis, complete healing of the index ulcer ", placebo , hyperbaric oxygen therapy ,0,
edin,696,2858204,Significantly increased,"In the per-protocol analysis, complete healing of the index ulcer occurred in 23/38 (61%) in the HBOT group and 10/37 (27%) in the placebo group (P = 0.009) (Fig. 2)."," In the per-protocol analysis, complete healing of the index ulcer ", placebo , hyperbaric oxygen therapy ,0,
edin,632,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,632,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53â12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
edin,873,5729252,Cannot tell based on the abstract,, hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF) , no treatment , bosentan ,0,
edin,873,5729252,Significantly increased,"At the time of survival time analysis, hospital-free survival was 358.87âÂ±â68.65Â days (meanâÂ±âSE) (median, 331Â days) in the untreated group, which was significantly different from that in the drug-treated group (603.44âÂ±â50.074Â days) as assessed by proportional hazard analysis (hazard ratio of the drug-treated group to the untreated group, 0.19, Pâ=â0.017; log-rank test, Pâ=â0.019; and Wilcoxon test, Pâ=â0.014).", hospital-free survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF) , no treatment , bosentan ,0,
edin,928,4192987,Cannot tell based on the abstract,, Median 17-hydroxy progesterone and testosterone levels , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm. , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm ,0,
edin,928,4192987,No significant difference,The difference in median was not statistically significant for serum 17-hydroxyprogesterone and testosterone levels [Tables 2 and 3]., Median 17-hydroxy progesterone and testosterone levels , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was replaced by equivalent dose of prednisolone suspension which was administered at 10.00 pm. , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm ,0,
edin,639,2206488,Cannot tell based on the abstract,, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,639,2206488,Significantly decreased,"Higher figures of the cardiac index (p = 0.010) along with reduced systemic vascular resistance (p = 0.005) were noted in group A.,In group A (n = 20), dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass.", systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,645,1201146,Cannot tell based on the abstract,, 50% reduction in pain , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,645,1201146,Significantly increased,"<td colspan=""3""><hr></td>", 50% reduction in pain , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,747,1876597,No significant difference,Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs., Adverse Events , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
edin,890,5519461,No significant difference,"The eradication rates of the EAC and RAC regimens were 79.8% (95% confidential interval: 71.7-89.0%) and 74.7% (66.0-83.4%), respectively, in a per protocol (PP) analysis (p=0.488). The eradication rates of the EAC and RAC regimens were not significantly different between patients with the homo EM genotype (p=0.999) or hetero IM or PM genotypes (p=0.286).", H. pylori eradication ," amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week. "," amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week. ",0,
edin,736,2720945,Cannot tell based on the abstract,," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,736,2720945,Significantly increased,"<td align=""left""><bold>Summarized parameter</bold><break><bold>(directional test)</bold></break></td><td></td><td></td><td align=""center"">0.0120</td>,As primary outcome measure the sum of exacerbations for frequency, duration and severity at all 6 following visits as composite endpoint (equally weighted) were calculated according to the Wei-Lachin Test procedure for multiple criteria and showed a statistically significant difference for the primary outcome measure between both treatment groups (p = 0.0120) Table 3."," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,865,5680306,Significantly increased,Serum 25(OH)D concentrations increased with vitamin D supplementation compared to placebo (pâ<â0.001)., Serum 25(OH)D concentrations ," the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks "," vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily ",0,
edin,732,2607225,Cannot tell based on the abstract,, Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,732,2607225,Significantly decreased,"Global quality of life, emotional functioning, cognitive functioning, pain, insomnia, appetite loss, anxiety, depression, intrusion and avoidance improved from baseline to 3 months. Financial difficulties worsened from baseline to 3 months. Global quality of life, physical functioning, role functioning, emotional functioning, social functioning, fatigue, nausea/vomiting, appetite loss, diarrhoea, financial difficulties, and depression improved from 3 to 24 months.,Appetite loss decreased from 3 to 6 months (mean=5.1â3.7, s.d.=14.2â11.1), worsened at 12 months (mean=5.8, s.d.=16.0) and decreased again at 24 months (mean=4.1, s.d.=12.7) in GR patients, whereas it improved from 3 to 6 and 12 months (mean=8.1, 4.0, 2.4; s.d.=17.7, 12.6, 10.8) and worsened at 24 months (mean=2.8, s.d.=10.7) in non-GR patients (F=4.1, d.f.=3/963, P=0.007).", Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
edin,967,5372931,Cannot tell based on the abstract,," flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes  ", nothing , cranberry juices ,0,
edin,967,5372931,Significantly increased,"Linear regression analysis was performed between the TP level in the intervention and the AUC of each class of compounds. The AUC for flavonols produced the highest r2 (0.97, p < 0.001), followed by the valerolactones (r2 = 0.89, p < 0.005), benzoic acids (r2 = 0.85, p < 0.01), cinnamic acids (r2 = 0.72, p < 0.05), phenylacetic acids (r2 = 0.71, p < 0.05), benzaldehydes (r2 = 0.65, p < 0.05); hippuric acids, pyrogallols, and catechols did not show a linear dose response."," flavonols, valerolactones, benzoic acids, cinnamic acids, phenylacetic acids, benzaldehydes  ", nothing , cranberry juices ,0,
edin,792,125315,Cannot tell based on the abstract,, The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,792,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>,<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", The median stay in hospital , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,934,4264479,Cannot tell based on the abstract,, blood-stage infection , nothing ," aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) ",0,
edin,934,4264479,No significant difference,"ll volunteers were diagnosed with malaria [see Table S5 for criteria for treatment and Table S6 for time to diagnosis (TTD) and parasitemia at diagnosis] with the exception of one volunteer in Group 2 (Volunteer 110), who was asymptomatic and blood film negative at all time-points, despite blood-stage infection confirmed by qPCR", blood-stage infection , nothing ," aseptic, cryopreserved P. falciparum sporozoites (PfSPZ Challenge) ",0,
edin,961,2656477,Cannot tell based on the abstract,, depression , no weight lost , lost weight ,0,
edin,961,2656477,No significant difference,"<td></td><td></td><td></td><td></td><td></td><td></td>,<td></td><td></td><td></td><td></td><td></td><td></td>", depression , no weight lost , lost weight ,0,
edin,660,2720945,Cannot tell based on the abstract,," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,660,2720945,Significantly decreased,"Table 3
Mean of sum of number, duration and severity of exacerbations during 6 months of treatment with cineole or placebo*,<td align=""left""><bold>Summarized parameter</bold><break><bold>(directional test)</bold></break></td><td></td><td></td><td align=""center"">0.0120</td>"," Mean of sum of number, duration and severity of exacerbations during 6 months of treatment ", placebo , cineole ,0,
edin,891,5519461,No significant difference,The eradication rates of the EAC and RAC regimens were not significantly different between patients with the homo EM genotype (p=0.999) or hetero IM or PM genotypes (p=0.286)., Eradication of H. pylori with homo EM genotype and those with hetero IM or PM genotype. ," amoxicillin (750 mg), clarithromycin (200 mg), and rabeprazole (10 mg) (RAC group), twice a day for one week. "," amoxicillin (750 mg), clarithromycin (200 mg), and either esomeprazole (20 mg) (EAC group), twice a day for one week. ",0,
edin,629,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,629,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,629,2688140,No significant difference,"Using Cox regression for 28-day mortality, the survival rate in the decremental PEEP titration group was not different (p = 0.725; hazard ratio = 1.168; 95% confidence interval = 0.493 to 2.768).,<td align=""left"">âMortality at 60 days</td><td align=""center"">15 (55.6)</td><td align=""center"">14 (46.7)</td><td align=""center"">0.599</td>,Table 2
Clinical outcomes according to treatment group", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
edin,679,2430614,Cannot tell based on the abstract,, parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children , artemether-lumefantrine (AL) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,679,2430614,No significant difference,There was no statistically significant differences in the parasitological or clinical failure rates by day 14 or day 28 between the AS+AQ and AL groups (Table 6)., parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children , artemether-lumefantrine (AL) , Artesunate+amodiaquine (AS+AQ) ,0,
edin,883,5539984,Cannot tell based on the abstract,, reduction of total needs and the increase of met needs , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,883,5539984,No significant difference,"However, as indicated by the non-significant group by time interaction, there was no difference between groups regarding the reduction of total needs (bÂ =Â 0.09; pÂ =Â 0.217) or the increase of met needs (bÂ =Â 0.01; pÂ =Â 0.621).", reduction of total needs and the increase of met needs , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,882,5539984,Cannot tell based on the abstract,, prevalence of psychiatric inpatient admission , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,882,5539984,No significant difference,"<td>number of psychiatric inpatient admissions [+ 1]</td><td>1.131</td><td>1.045</td><td>-</td><td>1.225</td>,The results of the mixed effects logistic regression model (not presented) did neither show differences of the prevalence of psychiatric inpatient admission between groups during the six months before baseline assessment (OR 0.99; pÂ =Â 0.985), nor a change over time (OR 0.62; pÂ =Â 0.086) in either groups or a difference between the groups (OR 0.97; pÂ =Â 0.878) during the study period.", prevalence of psychiatric inpatient admission , standard mental health care , The Network for Mental Health (NWpG-IC) ,0,
edin,900,1198254,Significantly increased,"Faecal recovery of ME-3 was documented by molecular methods only in fermented milk group, however the significant improvement of blood TAA (Total Antioxidative Activity) and TAS (Total Antioxidative Status) indices was seen both in case of fermented goat milk and capsules"", yet glutathione re-ox ratio values decreased only in case of fermented by ME-3 goat milk.", Total Antioxidative Activity , goat milk , L. fermentum ME-3 fermented goat milk ,0,
edin,923,5295802,Cannot tell based on the abstract,, cytokine levels at baseline , placebo , levocarnitine ,0,
edin,923,5295802,No significant difference,"here was no statistically significant difference in cytokine levels between symptom groups (severe vs. non-severe fatigue and severe vs. non-severe depression) at baseline based on the Wilcoxon rank sum test (p>0.05 for all cytokines, data not shown).", cytokine levels at baseline , placebo , levocarnitine ,0,
edin,636,4106715,Significantly increased,"3âAmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
edin,694,2858204,Significantly increased,"n the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03).", complete healing of the index ulcer at 1-year of follow-up , placebo , hyperbaric oxygen therapy ,0,
edin,925,5295802,Cannot tell based on the abstract,," all ten cytokines/growth factors -  IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF) ", before intervention , after intervention ,0,
edin,925,5295802,No significant difference,"There was no statistically significant difference in cytokine levels between symptom groups (severe vs. non-severe fatigue and severe vs. non-severe depression) at baseline based on the Wilcoxon rank sum test (p>0.05 for all cytokines, data not shown)."," all ten cytokines/growth factors -  IL-1, IL-1?, IL-6, IL-8, IL-1Ra, interferon-? (IFN-?), tumor necrosis factor-? (TNF-?), EGF, TGF-?, and vascular endothelial growth factor (VEGF) ", before intervention , after intervention ,0,
edin,763,2447617,Cannot tell based on the abstract,, The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,763,2447617,Significantly increased,The analysis using the dichotomization of GOS scores at 3 months post injury revealed a favorable outcome in 47% of the patients receiving progesterone and in 31% of the placebo group (P = 0.034)., The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
edin,794,2830179,Cannot tell based on the abstract,, Pain on rest (0-10) , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,794,2830179,Significantly decreased,"<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>,<td align=""left"">Pain on rest (0-10)</td><td align=""center"">3.0 (2.7)</td><td align=""center"">1.4 (1.8)</td><td align=""center"">1.1 (2.2)</td><td align=""center"">2.0 (2.6)</td><td align=""center"">-1.9 (2.3)</td><td align=""center"">0.6 (1.0)</td><td align=""center"">-2.0 (-3.8 to -0.2)</td>,<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>", Pain on rest (0-10) , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
edin,813,5602855,Cannot tell based on the abstract,, Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,813,5602855,No significant difference,No statistically significant changes were observed either in the number of visits to the municipal primary healthcare centre (pÂ =Â 0.39) or to special healthcare outpatient clinics (pÂ =Â 0.072) during the follow-up., Health care burden , inadequate motivation/capability , good motivation/capability ,0,
edin,936,4918678,Cannot tell based on the abstract,, Writing , nothing , soundfield amplification devices in the classroom ,0,
edin,936,4918678,No significant difference,"<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>,<th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th><th colspan=""2"" rowspan=""1""><hr></th>", Writing , nothing , soundfield amplification devices in the classroom ,0,
edin,896,4140547,Cannot tell based on the abstract,, Mean calculated GFR at 1 year. , tacrolimus groups , belatacept groups ,0,
edin,896,4140547,Significantly increased,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""5"" rowspan=""1""><hr></th>,<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""5"" rowspan=""1""><hr></th>", Mean calculated GFR at 1 year. , tacrolimus groups , belatacept groups ,0,
edin,644,1201146,Cannot tell based on the abstract,, Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,644,1201146,Significantly increased,"<td colspan=""3""><hr></td>", Pain on walking , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
edin,684,2447617,Significantly decreased,The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05)., The mortality rate , placebo , progesterone ,0,
edin,764,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 6 months post injury , placebo , progesterone ,0,
edin,716,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,742,1913177,Cannot tell based on the abstract,, Postoperative Mortality , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
edin,742,1913177,No significant difference,"Major wound complications were found in 10 of the 19 patients in the CST group: wound infection (n = 3), skin necrosis (n = 2), hematoma (n = 1). Four patients developed seroma; these were not associated with the aforementioned complications.,Major wound complications were found in 13 of the 18 patients in the e-PTFE group: wound infection (n = 2), skin necrosis (n = 3), hematoma (n = 1).", Postoperative Mortality , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
edin,892,5618071,Cannot tell based on the abstract,," ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC)  after 1 month ", before Non-Invasive Brain Stimulation (NIBS) , after Non-Invasive Brain Stimulation (NIBS) ,0,
edin,892,5618071,Significantly decreased,"As a global result (G1 + G2), a significant decrease in the total score was observed in ADI-R, ABC, and ATEC scales one month after the intervention (Wilcoxon matched pair test; ABC, Z = 3.823, p = 0.000131; ADI-R, 3.337, p = 0.000846; ATEC, Z = 3.723, p = 0.000196)."," ADI-R (algorithm for current condition), the Autism Behavioral Checklist (ABC), and the Autism Treatment Evaluation Checklist (ATEC)  after 1 month ", before Non-Invasive Brain Stimulation (NIBS) , after Non-Invasive Brain Stimulation (NIBS) ,0,
edin,665,3446002,Cannot tell based on the abstract,, Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,665,3446002,Significantly decreased,"Clofibrate group (group I) was given a single dose of 50 mg/kg clofibrate before starting phototherapy. I,<td align=""left"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">
<bold>TSB<xref ref-type=""table-fn"" rid=""TF0002"">*</xref> (mg/dl)</bold>
</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">17.24 (1.48)</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">17.42 (1.44)</td>,TSB: total serum bilirubin,<td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">
<bold>Control (II)</bold>
</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">30</td><td align=""center"" colspan=""1"" rowspan=""1"" style=""background-color: #aae1ff"">12.6 (1.44)</td>", Total serum bilirubin level , control group , single dose of 50 mg/kg clofibrate ,0,
edin,640,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,843,2891743,Significantly increased,"<td colspan=""4""><hr></td>,<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , normal saline 0.9% solution , glycine 1.5% solution as irrigating fluid ,0,
edin,1180,5002324,Significantly increased,"After training, participants in the balance-based exergaming group showed significant improvements in LOS performance, and in the eyes-closed condition of the OLS test.", the limits of stability (LOS) performance and one-leg stance (OLS) tests , a balance training group for an 8-week balance training period. , a balance-based exergaming group for an 8-week balance training period. ,0,
edin,1115,3423952,Cannot tell based on the abstract,," chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2,  ", no exercise , exercise ,0,
edin,1115,3423952,Significantly increased,"Main effects for PGE2 concentrations in synovial fluid were not detected (P > 0.05); however, after adjusting the data by subtracting the PRE value from each POST value, and evaluating changes relative to pre-exercise values, effects of exercise (P = 0.03) and joint (P = 0.04) were detected (Figure 2(b)).,Similar to synovial fluid CS concentrations, there were greater relative increases (P = 0.04) in PGE2 concentrations in hock joints when compared to carpus joints (Figure 2(b))."," chondroitin sulfate-846 (CS) in synovial fluid (SF) and adjusted-PGE2,  ", no exercise , exercise ,0,
edin,1061,3787573,No significant difference,"For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).", Western Ontario and McMaster Universities Osteoarthritis Index for stiffness , Exercise alone , NMES plus exercise ,0,
edin,1004,3442969,Cannot tell based on the abstract,, Disease control rates , CAPOX , FUFOX ,0,
edin,1004,3442969,No significant difference,"Disease control rates (DCR) were 77%, 81% and 88%, respectively, which was not statistically significant (Table3, pâ=â0.29).", Disease control rates , CAPOX , FUFOX ,0,
edin,1168,5354011,Cannot tell based on the abstract,, willingness?to?pay. , before treatment , after treatment  ,0,
edin,1168,5354011,Significantly increased,"The average maximum WTP for treatment for menorrhagia was approximately Â£27 (US$41) per month (see Table 2). The average combined MMAS score for treatment doubled from approximately 43 at preâtreatment to 85 following treatment, generating a statistically significant improvement in health status as measured by this instrument (P = 0.000).", willingness?to?pay. , before treatment , after treatment  ,0,
edin,1080,4565804,Significantly decreased,"Dogs in the Placebo group received significantly more morphine doses than the Gabapentin group (P=0.021), despite no significant differences in pain scores.", morphine doses , Placebo , gabapentin (10 mg/kg) ,0,
edin,987,2920262,Cannot tell based on the abstract,Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03., Improvement in HAD anxiety score , Usual care , Singing classes ,0,
edin,987,2920262,Significantly increased,Singers also had a significant fall in HAD anxiety score; -1.1(2.7) vs. +0.8(1.7) p = 0.03., Improvement in HAD anxiety score , Usual care , Singing classes ,0,
edin,1130,5225252,Significantly increased,"Gag-specific IFN-Î³ enzyme-linked immunospotâdetermined response rates and geometric mean responses were higher (96% and 248 spot-forming units, respectively) in groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) than those after a single dose of Ad35-GRIN (56% and 54 spot-forming units, respectively) or SeV-Gag (55% and 59 spot-forming units, respectively); responses persisted for â¥8 months after completion of the prime-boost regimen.", Gag-specific IFN-? enzyme-linked immunospotâdetermined response rates and geometric mean responses , a single dose of Ad35-GRIN or SeV-Gag , groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) ,0,
edin,1015,5101425,No significant difference,No significant difference was noted between the groups regarding the rate of bleeding after surgery (359.3 Â± 266.2 in group D vs. 406.3 Â± 341.6 in group P (control group); P = 0.208)., Bleeding rate after surgery , Placebo , Desmopressin ,0,
edin,1104,4109867,No significant difference,"Dietary SW supplementation had no effect on saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles."," saturated fatty acids (SFA), unsaturated fatty acids, poly unsaturated fatty acid (PUFA) or mono unsaturated fatty acid content in muscles ", basal diet , 2% seamustard ,0,
edin,1042,5746685,No significant difference,"There were no significant between-group differences in the primary outcome of change in BMI (basic â0.5 (1.9) kg/m2, enhanced â0.5 (1.6) kg/m2, p = 0.93).", Change in body mass index , Basic weight loss maintenance program , Enhanced weight loss maintenance program ,0,
edin,1082,5610854,Cannot tell based on the abstract,, intraocular pressure (IOP) , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1082,5610854,Significantly decreased,"7 of the 38 eyes (44.7%, CI: 28.9%â60.5%) in group 1 required a mean of 1.8 IOP-lowering medications while seven of the 111 eyes (6.3%, CI: 1.8%â10.8%) in group 2 required a mean of 1.1 medications (Pearson's chi-square valueâ=â30.940, p < 0.001).", intraocular pressure (IOP) , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1020,3159986,Cannot tell based on the abstract,, Lung function parameters , Baseline characteristics , Respiratory muscle endurance training ,0,
edin,1020,3159986,No significant difference,"Baseline lung function was normal for all patients with VC being 95.5 Â± 3.7%, FEV1 90.5 Â± 3.6%, PEF 86.9 Â± 4.5%, MVV 93.8 Â± 6.6%, and maximal inspiratory pressure (PImax) 75.1 Â± 5.4% predicted. RMET induced mild but not significant increases in VC (P1: 95.9 Â± 3.5%, P4: 99.2 Â± 4.1%, P = 0.39), FEV1 (P1: 93.1 Â± 2.7%, P4: 96.3 Â± 3.8%, P = 0.28), PEF (P1: 90.0 Â± 4.8%, P4: 95.7 Â± 5.4%, P = 0.07), MVV (P1: 95.6 Â± 6.0%, P4: 101.0 Â± 6.5%, P = 0.24), and PImax (P1: 79.2 Â± 5.4%, P4: 78.0 Â± 6.4%, P = 0.42).", Lung function parameters , Baseline characteristics , Respiratory muscle endurance training ,0,
edin,1128,5936036,No significant difference,There was no significant difference among the drop-out rates in the three groups., drop-out rates , the SCBT with medication group or regular medication group , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,976,3798949,Cannot tell based on the abstract,, Extra clinic visits and CT scans assessments , Commercial sponsored trials ," Academic, non-commercial sponsored trials ",0,
edin,976,3798949,Significantly decreased,"The contribution of extra clinic visits and investigations, in particular CT scans used for response assessment, was significantly higher for commercial compared with non-commercial trials.", Extra clinic visits and CT scans assessments , Commercial sponsored trials ," Academic, non-commercial sponsored trials ",0,
edin,1024,4895766,Cannot tell based on the abstract,, Control of infection , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1024,4895766,Significantly increased,"In Group A, diabetic wounds treated with Katupila paste got healed within 28 days with minimal scar formation without any complications, whereas in Group B, wound was healed completely only in two patients within 28 days.,The surrounded skin color became normal skin color within 7 days in maximum patients (76%) of Group A, whereas only 32% patients showed normal peri-wound skin color in Group B.", Control of infection , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1099,4109867,Cannot tell based on the abstract,, IgG concentrations , basal diet , 2% seamustard ,0,
edin,1099,4109867,Significantly increased,The SW supplementation significantly increased (p<0.05) IgG concentrations while IgM concentrations remained unaffected (Table 4)., IgG concentrations , basal diet , 2% seamustard ,0,
edin,1210,4306068,No significant difference,"The mean timing to analgesic administration for the displayed and non-displayed groups were 81.3âÂ±â41.2 (95% C.I 65.9, 96.7) and 88.7âÂ±â45.4 (95% C.I 69.0, 108.3), respectively (pâ>â0.05).", The mean timing to analgesic administration , not displayed in the control. , pain score display group ,0,
edin,1122,5489138,Cannot tell based on the abstract,"he 3-part composite measure was associated with more CDP events (41.4% and 63.9% of patients at 12 and 24 months, respectively) than the 2-part measure (EDSS/T25FW [38.5% and 59.5%, respectively]) and any single measure.", confirmed disability progression , 9-hole peg test [9HPT] ," timed 25-foot walk [T25FW], ",0,
edin,1122,5489138,Significantly increased,"3M CDP = 3-month confirmed disability progression;,The 3-part composite measure was associated with more CDP events (41.4% and 63.9% of patients at 12 and 24 months, respectively) than the 2-part measure (EDSS/T25FW [38.5% and 59.5%, respectively]) and any single measure.", confirmed disability progression , 9-hole peg test [9HPT] ," timed 25-foot walk [T25FW], ",0,
edin,1132,5225252,Cannot tell based on the abstract,, The GMTs ," SLA, SHA, SHSH, and placebo groups, ", ASH group ,0,
edin,1132,5225252,Significantly increased,"The GMTs were significantly higher (P < .0001, by the Kruskal-Wallis test) in the ASH group after the SeV boost than in the other groups (53, 53, 245, 50, and 59 in the SLA, SHA, ASH, SHSH, and placebo groups, respectively; Figure 4).", The GMTs ," SLA, SHA, SHSH, and placebo groups, ", ASH group ,0,
edin,1165,4223523,Cannot tell based on the abstract,, awake time , placebo , olanzapine ,0,
edin,1165,4223523,Significantly decreased,"As well as an increase in TST, olanzapine treated participants experienced significantly fewer awakenings (TableÂ  2) and less overall time awake compared to treatment with placebo (2-way repeated measures ANOVA; main effect of treatment, number of awakenings, F[1,23]â=â10.0, pâ=â0.004; awake time, F[1,23]â=â4.8, pâ=â0.037).", awake time , placebo , olanzapine ,0,
edin,1141,3895597,No significant difference,"The incidence of adverse events was similar in the 2 groups, and no severe adverse events involving either drug were observed.", The incidence of adverse events , octylonium 20 mg , tiropramide 100 ,0,
edin,1106,5064802,No significant difference,"Postoperative troponin T was 11 arbitrary units [5, 31; area-under-the-curve (interquartile range)] for controls, and no statistically significant changes were observed after helium preconditioning [He-pre: 11 (6, 18)], helium postconditioning [He-post: 11 (8, 15)], helium pre- and postconditioning [He-PP: 14 (6, 20)] and after sevoflurane preconditioning [APC: 12 (8, 24), pÂ =Â 0.13].", Postoperative troponin T , no helium , Helium preconditioning (3 Ã 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp. ,0,
edin,1177,3752932,Cannot tell based on the abstract,," mean volume voided/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes/24 h ", placebo , mirabegron (50 and 100 mg) ,0,
edin,1177,3752932,Significantly increased,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th>"," mean volume voided/micturition, mean level of urgency, mean number of urgency episodesand mean number of urgency incontinence episodes/24 h ", placebo , mirabegron (50 and 100 mg) ,0,
edin,1074,1562433,Significantly increased,"<td colspan=""4""><hr></td>", vastus medialis obliquus (VMO) EMG activity  , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,0,
edin,1107,5064802,No significant difference,"No effect was observed of helium preconditioning, postconditioning or the combination thereof on activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-Îµ in the human heart."," activation of p38 MAPK, ERK 1/2 or levels of HSP27 and PKC-? in the human heart ", no helium , Helium preconditioning (3 Ã 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp. ,0,
edin,1079,4667210,Significantly increased,"Although there was no significant difference in the appearance time of the MSG symptom complex between subjects orally administered G101 and those administered the placebo, its disappearance in < 3 h was observed in 69.9% of subjects in the G101 treatment group and in 38.0% of subjects in the placebo group (P = 0.0841).", disappearance in &amp;lt; 3 h  of the MSG symptom complex , maltodextrin (placebo) , Capsules (300 mg) containing Lactobacillus brevis G101 (1Ã1010 CFU/individual) ,0,
edin,1113,3423952,Significantly increased,"Exercise resulted in increased (P < 0.05) antioxidant defenses including erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1Î² in blood, and decreased plasma nitric oxide."," erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1? in blood ", no exercise , exercise ,0,
edin,1013,5018157,No significant difference,"The one-minute Apgar score was significantly lower for the preeclamptic parturients (8.4 Â± 0.7 versus 7.2 Â± 1.5) (P = 0.001), but there was no significant difference in the five-minute Apgar scores between the two groups.", Five-minute Apgar score , Low-dose bupivacaine spinal anesthesia in healthy parturients , Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients ,0,
edin,1086,4395717,Significantly decreased,"After the intervention, the error angle was significantly smaller in flexion and right left side-bending, and pain was significantly reduced in the upper thoracic manipulation group.", repositioning error in flexion and right and left side-bending and reduction in pain , cervical stability training (CST) , upper thoracic manipulation (UTM) ,0,
edin,979,5619630,Cannot tell based on the abstract,, Improvement in Presumptive Stressful Life Events Scale , Medication only , Medication plus exercise ,0,
edin,979,5619630,No significant difference,there was no significant difference between the groupsâ PSLES scores at any follow-up point., Improvement in Presumptive Stressful Life Events Scale , Medication only , Medication plus exercise ,0,
edin,1159,3296686,Cannot tell based on the abstract,, serum ALT and AST values , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1159,3296686,Significantly decreased,Pioglitazone treatment decreased at day-14 serum ALT levels (mean changeâ=â7.5 IU/ml; 95% CI: 2.1 to 12.9; Pâ=â0.012) and to a smaller degree serum AST levels (mean changeâ=â2.6 IU/ml; 95% CI: â0.6 to 5.8; Pâ=â0.096) ( Table 5 )., serum ALT and AST values , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,981,5490116,Cannot tell based on the abstract,, Glucometric random blood sugar at 24 hours , Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C) ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
edin,981,5490116,Significantly increased,Glucometric random blood sugar (GRBS) was significantly (P < 0.005) higher in Group B compared to Groups A and C at 24 h as shown in Table 2., Glucometric random blood sugar at 24 hours , Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C) ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
edin,1198,3743641,Cannot tell based on the abstract,, sexual function and total scores , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1198,3743641,Significantly increased,"Additionally, in SMART-3 (subjects with vulvovaginal atrophy), the Menopause-Specific Quality of Life questionnaire results at week 12 showed significant improvements in sexual function and total scores with both BZA/CE doses versus placebo or BZA 20 mg (P < 0.001).", sexual function and total scores , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1054,2223531,No significant difference,"he median AUC(inf) (area under the concentration vs time curve from zero to infinity) of etoposide was 77.7 mg l(-1) h after etoposide phosphate (95% CI 61.3-100.5) and 62.0 mg l(-1) h after oral etoposide (95% CI 52.2-76.9).,In conclusion, oral etoposide phosphate does not offer a clinically relevant benefit over oral etoposide.", Median AUC(inf) , Oral etoposide , Oral etoposide phosphate ,0,
edin,1001,3878029,No significant difference,The intervention had no effect on smoking status (p =â.73) or on the number of cigarettes smoked per day (p =â.56)., Cigarettes smoked per day , Relaxation , Hypnotherapy ,0,
edin,999,3074545,Significantly increased,"<td align=""left"">SF36</td><td></td><td></td><td></td><td></td><td></td><td></td>,<td></td><td></td><td></td><td></td><td></td><td></td><td></td>", Improvements in physical and mental wellbeing , Non-mentored group , Non-professional mentor support ,0,
edin,1158,3296686,Cannot tell based on the abstract,, day-14 fasting serum glucose  and  the 2-hr glucose (Glucose-120 min) after an OGTT  , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1158,3296686,Significantly decreased,Pioglitazone treatment decreased by day-14 fasting serum glucose (Glucose-0) (mean changeâ=â8.2 mg/dL; Pâ=â0.024) as well as the 2-hr glucose (Glucose-120 min) after an OGTT (mean changeâ=â18.8 mg/dL; Pâ=â0.001) ( Table 4 )., day-14 fasting serum glucose  and  the 2-hr glucose (Glucose-120 min) after an OGTT  , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1191,3743641,Cannot tell based on the abstract,, mean daily number of moderate to severe hot flushes at week 12 , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1191,3743641,Significantly decreased,"At week 12, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg were associated with a decrease (P < 0.001) in the adjusted mean daily number of moderate to severe hot flushes, reaching a 74% and a 80% reduction, respectively, representing a clinically meaningful reduction of approximately 7â8 hot flushes per day, compared with a 51% reduction (representing a reduction of approximately five hot flushes per day) in the placebo group (Figure 1).18", mean daily number of moderate to severe hot flushes at week 12 , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1075,1562433,No significant difference,"<td colspan=""4""><hr></td>", vastus lateralis longus (VLL) EMG activity , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,0,
edin,1038,4588874,Cannot tell based on the abstract,, Serious adverse events , Conventional tobacco cigarette , E-cigarettes  ,0,
edin,1038,4588874,No significant difference,There were no serious adverse events reported and no subjects were discontinued due to AEs., Serious adverse events , Conventional tobacco cigarette , E-cigarettes  ,0,
edin,1126,3611646,Cannot tell based on the abstract,, high density lipoprotein (HDL) , administered Sarkaradi Granules (SG). ," administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar. ",0,
edin,1126,3611646,Significantly increased,"With regard to the biochemical parameters, Group A showed highly significant decrease (P`0.01) in serum cholesterol, serum triglyceride, low density lipoprotein (LDL), and very low density lipoprotein (VLDL) levels, while high density lipoprotein (HDL) increased highly significantly (P`0.01) and a significant decrease (P`0.05) was found in blood urea (13.80%) as well as serum AChE (3.67%) within normal limits [Table 6].,Group A (Trial Group)
Patients of this group were administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar.", high density lipoprotein (HDL) , administered Sarkaradi Granules (SG). ," administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar. ",0,
edin,1057,3787573,No significant difference,"ollowing the interventions, a statistically significant improvement in both groups was observed in all outcomes assessed. For the comparison between the groups, no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC: pain (P = 0.26), function (P = 0.23), and stiffness (P = 0.63).", Numerical Rating Scale , Exercise alone , NMES plus exercise ,0,
edin,1142,3895597,Cannot tell based on the abstract,, the degree of symptom reduction in abdominal pain using symptom diaries from week 1  , octylonium 20 mg , tiropramide 100 ,0,
edin,1142,3895597,Significantly increased,"Furthermore, the degree of symptom reduction in abdominal pain using symptom diaries was higher in the tiropramide group than in the octylonium group from week 1 (P = 0.033).", the degree of symptom reduction in abdominal pain using symptom diaries from week 1  , octylonium 20 mg , tiropramide 100 ,0,
edin,1100,4109867,Cannot tell based on the abstract,, IgM concentrations , basal diet , 2% seamustard ,0,
edin,1100,4109867,No significant difference,The SW supplementation significantly increased (p<0.05) IgG concentrations while IgM concentrations remained unaffected (Table 4)., IgM concentrations , basal diet , 2% seamustard ,0,
edin,1145,5851630,Significantly increased,"However, in the ET+TA treatment, ABP values were greater after exercise, except for Fp1.", absolute beta power (ABP) after exercise , PlaceboâPL , Taurine combined with Ethanol (TA+ET) ,0,
edin,1192,3743641,Cannot tell based on the abstract,, mean proportion of superficial cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1192,3743641,Significantly increased,BZA 20 mg/CE 0.45 or 0.625 mg showed a significantly greater increase from baseline in the mean proportion of superficial cells compared with placebo (P < 0.001)., mean proportion of superficial cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1208,4526336,Significantly increased,"Compared to those with normal cognitive function, MCI participants generated a greater proportion of words out of the total number of words during the timed conversation sessions (p=0.01).", proportion of words out of the total number of words , healthy , mild cognitive impairment (MCI) ,0,
edin,1174,4821313,Significantly increased,There was a significant increase in serum creatinine and a decrease in eGFR 48 hr post-intervention in group 1 (short regimen) with no statically difference regarding those parameters group 2 (long regimen)., serum creatinine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,1084,5610854,Cannot tell based on the abstract,, The absolute risk for ?2 lost lines of vision , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1084,5610854,No significant difference,The absolute risk for â¥2 lost lines of vision in the trabeculectomy group was 18% (20 of 111) compared to 16% (6 of 38) in the LPI group., The absolute risk for ?2 lost lines of vision , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
edin,1156,3296686,Significantly increased,"Although Prednisone did increase serum HCV RNA at day-4 (nâ=â10; change from baselineâ=ââ42,786 IU/ml; 95% CI â85,500 to â15,700; Pâ=â0.049), the log10 HCV RNA titers were statistically not different from baseline day-0.", HCV RNA at day-14 , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
edin,1062,5100099,No significant difference,"There were no statistically significant differences on blood pH levels between the two modes of ventilation (7.32âÂ±â0.02 vs. 7.32âÂ±â0.04, Pâ=â0.34).", Blood pH levels , Conventional Ventilation , Neurally Adjusted Ventilatory Assist ,0,
edin,1028,4486943,Cannot tell based on the abstract,, Tobacco abstinence , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1028,4486943,No significant difference,"TableÂ 3
Estimates of abstinence at 6 and 12âmonths, N=1785,<td colspan=""1"" rowspan=""1"">âStandard</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">66.0 (61.2 to 70.9)</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">60.6 (55.6 to 65.6)</td><td colspan=""1"" rowspan=""1"">363</td><td colspan=""1"" rowspan=""1"">65.3 (60.4 to 70.2)</td><td colspan=""1"" rowspan=""1"">362</td><td colspan=""1"" rowspan=""1"">61.6 (56.6 to 66.6)</td>,<td colspan=""1"" rowspan=""1"">âStandard plus TEQ-10</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">69.6 (64.9 to 74.3)</td><td colspan=""1"" rowspan=""1"">368</td><td colspan=""1"" rowspan=""1"">65.2 (60.4 to 70.1)</td><td colspan=""1"" rowspan=""1"">370</td><td colspan=""1"" rowspan=""1"">67.0 (62.2 to 71.8)</td><td colspan=""1"" rowspan=""1"">371</td><td colspan=""1"" rowspan=""1"">63.1 (58.2 to 68.0)</td>,<td colspan=""1"" rowspan=""1"">âDifference compared to standard</td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">1.3 (â5.6 to 8.2)<break>p=0.7121</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">0.5 (â6.6 to 7.6)<break>p=0.8947</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">â2.7 (â10.0 to 4.6)<break>p=0.4655</break></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1"">â5.0 (â12.5 to 2.4)<break>p=0.1871</break></td>", Tobacco abstinence , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1111,4940009,No significant difference,"Overall, the incidence of POM in Group K was significantly less, when compared with Group N (P<0.05), but both groups were comparable based on the grade 2 of POM.", grade 2 of POM ," Group N, the same volume (5 mL) of normal saline was injected "," Group K, 0.5 mg/kg of ketamine was injected intravenously, ",0,
edin,1199,3743641,Cannot tell based on the abstract,, lumbar spine bone mineral density (BMD) , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1199,3743641,Significantly increased,"In addition, in SMART-1, a statistically significant increase in lumbar spine BMD from baseline to month 24 was observed for both the BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg treatment groups compared with a decrease in lumbar spine BMD in the placebo group (P < 0.001).", lumbar spine bone mineral density (BMD) , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1203,4280954,Cannot tell based on the abstract,, serum glucose ," received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)  "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food ",0,
edin,1203,4280954,Significantly decreased,The addition of flaxseed or/and vitamin E to the high-fat diet led to significant reductions of serum glucose levels compared with those in the DM group (Table II)., serum glucose ," received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)  "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; or enriched with vitamin E, 40 mg ?-tocopherol/100 g of food ",0,
edin,1193,3743641,Cannot tell based on the abstract,, reduction from baseline in the mean proportion of parabasal cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1193,3743641,Significantly decreased,Both BZA/CE groups also showed a significantly greater reduction from baseline in the mean proportion of parabasal cells (P < 0.001) and a significantly greater increase from baseline in the mean proportion of intermediate cells (P < 0.05) compared with placebo at weeks 4 and 12., reduction from baseline in the mean proportion of parabasal cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1129,5936036,Cannot tell based on the abstract,," quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met. ", the SCBT with medication group  , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,1129,5936036,No significant difference,"As stated in Table 1, participants in the SCBT group and SCBT with medication group were not significantly different in satisfaction factors, such as the quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met."," quality of treatment, the duration and the number of session, or whether their expectations for treatment had been met. ", the SCBT with medication group  , simplified cognitive behavioral therapy (SCBT) on generalized anxiety disorder (GAD) ,0,
edin,1025,4486943,Cannot tell based on the abstract,, Programme engagement , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1025,4486943,Significantly increased,"Programme engagement was measured as the number of counselling calls completed by participants:1 planned programme counselling calls,2 participant-initiated inbound calls, or3 IVR-transferred counselling calls (table 2). Overall, the average number of total calls completed was 3.9 (SD=1.7; range 2â19). There was a statistical difference between groups; the TEQ-10 and TEQ-20 groups completed slightly more calls than the standard study group due to the additional IVR-transferred counselling calls they received after a positive screen (p<0.001).", Programme engagement , Standard quitline treatment , Technology Enhanced Quitline-10 and Technology Enhanced Quitline-20 ,0,
edin,1017,5101425,Cannot tell based on the abstract,, Hb levels , Placebo , Desmopressin ,0,
edin,1017,5101425,No significant difference,"A paired T-test revealed that the Hb levels decreased significantly in each group after surgery (P = 0.0001), but the difference was not statistically significant between the groups (0.134).", Hb levels , Placebo , Desmopressin ,0,
edin,1144,4893237,Cannot tell based on the abstract,, mortality in old people with femoral neck fracture. , no comorbidities , pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL ,0,
edin,1144,4893237,Significantly increased,"In this study 13 participants died within 30Â days of sustaining the index hip fracture. T,The participants who died during hospitalization due to a cardiovascular event all had a history of cardiovascular disease. The three participants who died after discharge but within 30Â days of the index hip fracture did so due to a cerebrovascular event, a myocardial infarction and a pulmonary emboli, respectively.", mortality in old people with femoral neck fracture. , no comorbidities , pulmonary emboli or cancer or cardiac failure or cardiovascular disease or dementia or dependence in P-ADL ,0,
edin,1201,3743641,Cannot tell based on the abstract,," risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, ", placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1201,3743641,No significant difference,"No apparent increased risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, was observed with either dose strength of BZA/CE."," risk for serious adverse events, such as venous thromboembolism, cardiovascular events, endometrial cancer, or breast cancer, ", placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1114,3423952,Significantly decreased,"Exercise resulted in increased (P < 0.05) antioxidant defenses including erythrocyte SOD, total glutathione, glutathione peroxidase, gene transcripts for interferon-gamma, interleukin-10, and interleukin-1Î² in blood, and decreased plasma nitric oxide.", plasma nitric oxide , no exercise , exercise ,0,
edin,1022,4895766,Cannot tell based on the abstract,, Healing of diabetic wounds , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1022,4895766,Significantly increased,The strength and positive finding of this study is Katupila Kalka had the potential to cure the diabetic wounds early than Betadine ointment., Healing of diabetic wounds , Betadine ointment , Katupila Kalka with Tila Taila ,0,
edin,1136,4627811,Cannot tell based on the abstract,, Quality of life , continuous training (CT) 12-weeks inpatients NYHA II-III , high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III ,0,
edin,1136,4627811,No significant difference,There was no significant change in the SF-36 total score (Table 5)., Quality of life , continuous training (CT) 12-weeks inpatients NYHA II-III , high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III ,0,
edin,1189,5122238,Cannot tell based on the abstract,," Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate ", received normal saline , received 1 mg/kg and 2 mg/kg hydrocortisone ,0,
edin,1189,5122238,No significant difference,Mean central temperature from 0 to 60 min recovery in the three groups (P = 0.64)," Mean central temperature, Mean peripheral temperature, Mean blood pressure, Mean heart rate ", received normal saline , received 1 mg/kg and 2 mg/kg hydrocortisone ,0,
edin,1064,5100099,Significantly increased,"With regard to hemodynamics, systolic arterial pressures were higher using NAVA: +8.4Â % (95Â % CI: +3.3 to +13.6Â %, Pâ=â0.03).", Systolic arterial pressure , Conventional Ventilation , Neurally Adjusted Ventilatory Assist ,0,
edin,1041,5746685,No significant difference,"There was no significant weight rebound from the start of weight loss maintenance to 12 months for either group (mean: basic 1.3%, enhanced 1.5%) and limited change in secondary outcomes for either program.", Weight rebound after 12 months , Basic weight loss maintenance program , Enhanced weight loss maintenance program ,0,
edin,1173,4821313,Cannot tell based on the abstract,, the pH of urine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,1173,4821313,No significant difference,"Regarding the pH of urine, we found that it was (5.95 Â± 0.26) in group 1 and (5.97 Â± 0.24) in group 2, showing no statistical difference and highlighting the fact that both regimen had almost the same alkalinizing efficacy with no proven extra benefit for patients with pH values greater than 6.", the pH of urine , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
edin,971,3491047,No significant difference,"No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.", Total adherence to the program , Self-directed control (C) , Walking and Behavioural intervention (WB) ,0,
edin,968,5372931,Cannot tell based on the abstract,, 12 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,968,5372931,Significantly increased,"A positive, linear dose response for total excretion over 24 h of each urinary metabolite was assessed and of the 60 identified metabolites, 12 (poly)phenol metabolites displayed a positive linear dose-response curve (r2 â¥ 0.66) in urine with slopes significantly different from zero (p < 0.05); they were: 2,3-dihydrobenzoic acid (r2 = 0.79), 2,4-dihydrobenzoic acid (r2 = 0.77), dihydrocaffeic-3-O-sulfate (r2 = 0.66), ferulic-O-4-sulfate (r2 = 0.89), o-courmaric acid (r2 = 0.72), quercetin-3-O-Ã-d-glucuronide (r2 = 0.89), 2,5-dihydroxybenzoic acid (r2 = 0.80), chlorogenic acid (r2 = 0.72), p-coumaric acid (r2 = 0.90), sinapic acid (r2 = 0.85), benzoic acid (r2 = 0.99), isoferulic acid (r2 = 0.74).", 12 (poly)phenol metabolites , nothing , cranberry juices ,0,
edin,1157,3296686,Significantly decreased,"Pioglitazone was effective in decreasing serum HCV RNA at day-14 (nâ=â10; difference of meansâ=â205,618 IU/ml; 95% CI 26,600 to 384,600; P<0.001).", HCV RNA at day-14 , baseline , Prednisone (40 mg/day for 4 days) ,0,
edin,1101,4109867,Significantly decreased,Dietary SW significantly reduced meat cholesterol concentration (p<0.05)., Meat cholesterol concentration , basal diet , 2% seamustard ,0,
edin,969,3491047,Significantly increased,Short-term program adherence was greater in WB compared to C (p<0.012) after 3 months., Short-term adherence to the program at 3 months , Self-directed control (C) , Walking and Behavioural intervention (WB) ,0,
edin,1046,4748685,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = â9 mmHg; p = 0.03; 95 % CI = [â17.29, â0.71]), LDL (pseudo-median of the differences = â7.9 mg/dl; p = 0.04; 95 % CI = [â18.5, â0.5]) and triglyceride values (pseudo-median of the differences = â12.5 mg/dl; p = 0.04; 95 % CI = [â26, â0.5]) in the intervention group, while no such changes could be observed in the control group.", Triglyceride levels , Standard care , CAPSYS system ,0,
edin,1089,4082484,Significantly increased,"On the other hand, the consumption of the curry meal increased FMD from 5.2âÂ±â2.5% to 6.6âÂ±â2.0% (Pâ=â0.001), and the postprandial FMD after the curry meal was higher than that after the control meal (Pâ=â0.002).", postprandial FMD , spice-free control meal , single serving of curry meal ,0,
edin,1009,5003313,Cannot tell based on the abstract,, Symptom severity after 4 weeks  , No exercises , Stretching exercises ,0,
edin,1009,5003313,No significant difference,Also the results of t-test show that the changes in the severity of RLS symptoms before intervention and after 4 weeks were not statistically meaningful between intervention and control groups., Symptom severity after 4 weeks  , No exercises , Stretching exercises ,0,
edin,980,5619630,Cannot tell based on the abstract,, Relapse rates , Medication only , Medication plus exercise ,0,
edin,980,5619630,No significant difference,"Relapse rates were also recorded via subjective reports and as a measured increase of >50% from baseline HRSD scores (Neumeister et al, 1997). In total, nine patients relapsed, two from the medication-plus-exercise group (both in week 18) and seven from the medication-only group (one relapse in week 6, two in week 12 and four in week 24). This difference in relapse rates did not reach significance (Fisherâs exact test: one-tailed, P = 0.07; two-tailed, P = 0.14).", Relapse rates , Medication only , Medication plus exercise ,0,
edin,1195,3743641,Cannot tell based on the abstract,, vaginal pH , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1195,3743641,Significantly decreased,"Additionally, treatment with BZA 20 mg/CE 0.625 mg resulted in a significantly greater decrease from baseline in vaginal pH (P < 0.001) and a greater improvement in the womenâs most bothersome vulvovaginal atrophy symptoms (P < 0.05) compared with placebo (Figure 4).19", vaginal pH , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
edin,1202,4280954,Cannot tell based on the abstract,," DM + E group received a high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; "," ceived a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",0,
edin,1202,4280954,Significantly increased,"Serum and liver TBARS, as indices of lipid peroxidation, were significantly increased in the DM group compared with those in the control group, while the addition of flaxseed or a combination of flaxseed and Î±-tocopherol to the high-fat diet of the hamsters with DM significantly decreased these two markers compared with those in the unsupplemented DM group."," DM + E group received a high-fat diet enriched with vitamin E, 40 mg ?-tocopherol/100 g of food "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA; "," ceived a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA) ",0,
edin,993,3074545,Cannot tell based on the abstract,, Depression mean scores , Non-mentored group , Non-professional mentor support ,0,
edin,993,3074545,No significant difference,"Observed reduction in depression mean scores from 15.0 to 8.9 in the intervention arm compared favourably with non-mentored women (12.9 to 9.9), but the adjusted difference (AdjDiff) of -1.90, 95% CI -4.12 to 0.32, did not reach conventional statistical significance.", Depression mean scores , Non-mentored group , Non-professional mentor support ,0,
edin,1250,5225191,Cannot tell based on the abstract,, GASE-AD (antidepressant-specific side effects) , placebo pill , amitriptyline ,0,
edin,1250,5225191,Significantly increased,"After evocation, participants who underwent the conditioning procedure with amitriptyline reported significantly more antidepressant-specific side effects than those who never received amitriptyline, even though both groups received a placebo.", GASE-AD (antidepressant-specific side effects) , placebo pill , amitriptyline ,0,
edin,1321,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01), suggesting ameliorated cognitive performance. Such amelioration was correlated with the 2-hour final inhibition of plasma ghrelin concentration (r = 0.61, p = 0.01).,In a randomized crossover design, 12 healthy individuals (6M/6F; BMI 22.2âÂ±â0.4âkg/m2; 27âÂ±â1.3 years, meanâÂ±âSEM) underwent 50âg OGTT (A) and 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) to assess plasma glucose-, insulin-, and ghrelin excursions.", the 2-hour plasma ghrelin , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1306,5789132,Cannot tell based on the abstract,, The mean pain score using FRS scale ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
edin,1306,5789132,Significantly decreased,"The mean pain score using FRS scale for 26 gauge conventional syringe was found to be 3.25, whereas mean pain score for 30 gauge insulin syringe was found to be 1.35 (Table 1). The mean difference found was statistically significant (p = 0.05).", The mean pain score using FRS scale ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
edin,1293,3636800,No significant difference,"Although there were no significant differences in participantsâ quantitative feedback for the two delivery modalities, most participants reported preferring the native smartphone application (67%; n=16) and found it easier to use (71%; n=16). 33% of participants reported that they would be willing to complete mobile phone assessment for 5 weeks or longer.", the total quantitative feedback score , completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation , completing 6 days of assessment (four sets of questions per day) with a native smartphone application ,0,
edin,586,4819709,Cannot tell based on the abstract,, Standing still for a long time (&gt;â15 min ) without discomfort , surgery , Ultrasoundâguided foam sclerotherapy ,0,
edin,586,4819709,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">15Â·8</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">28Â·7</td>,Participants randomized to UGFS recalled being able to carry out 13 of the 15 behaviours significantly more quickly than those randomized to surgery (Table â 2 ). The two behaviours for which there was no evidence of a difference in the time to recover between the trial arms were âhaving a bath or showerâ and âwearing clothes that show the legsâ.", Standing still for a long time (&gt;â15 min ) without discomfort , surgery , Ultrasoundâguided foam sclerotherapy ,0,
edin,1223,3917123,Cannot tell based on the abstract,, Fatigue score in the sensory dimension , Placebo , Acupressure ,0,
edin,1223,3917123,Significantly decreased,"ost-hoc Duncan test showed that mean reduction of total fatigue score and mean reduction of fatigue scores in sensory and cognitive dimensions in the study group were more than in the placebo group, and they were more in the placebo group compared to the control group (P < 0.05).", Fatigue score in the sensory dimension , Placebo , Acupressure ,0,
edin,1213,5397544,Cannot tell based on the abstract,, Maximum amplitude values , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
edin,1213,5397544,No significant difference,There were no significant changes in Î±-angle and maximum amplitude values during or after laparoscopic fundoplication in both groups (Tables IV and V)., Maximum amplitude values , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
edin,1343,5320660,Cannot tell based on the abstract,, Mean overall satiety score , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1343,5320660,No significant difference,Mean overall satiety score did not differ within or between groups (Pâ=â0.230)., Mean overall satiety score , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1279,5928476,Significantly decreased,SureFil SDR and EverX Posterior bulk-fill composite resinsâ bond strengths were significantly higher than ProRoot MTA and Biodentine calcium silicate cements., bulk-fill composite resinsâ bond strengths , ProRoot MTA or Biodentine calcium silicate cements , SureFil SDR or EverX Posterior bulk-fill composite resinsâ bond ,0,
edin,724,2600646,Cannot tell based on the abstract,, mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,724,2600646,No significant difference,Final mean Hb levels were 7.15 mmol/l Â± 1.07 for the DP treatment group and 6.79 mmol/l Â± 1.24 for the AL group. A possible influence of anaemia on gametocyte carriage at enrollment was not observed in the present study (p > 0.05)., mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
edin,1238,5228611,Cannot tell based on the abstract,, quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1238,5228611,Significantly decreased,Participants in the E/C/F/TAF plus DRV group had statistically significant declines in both measures of quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) at week 48 vs. increases in the baseline regimen group (Fig. 4)., quantitative proteinuria (urine protein-to-creatinine ratio) and tubular proteinuria (retinol binding protein-to-creatinine ratio and beta 2 microglobulin-to-creatinine ratio) , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1219,5741263,Significantly increased,"In contrast to the reported positive effects of training on writing size, the current results showed increases in stroke duration and normalized jerk after amplitude training, which were absent in the placebo group.", Stroke duration , Placebo , Amplitude training ,0,
edin,637,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
edin,1243,3466198,Significantly decreased,The median vaginal and cervical pH was significantly lower 2 hours after application of Acidform and was associated with an increase in the bactericidal activity of CVL against E. coli., The median vaginal and cervical pH , hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days , Acidform twice daily for 14 consecutive days ,0,
edin,1278,3585965,Cannot tell based on the abstract,, the rate of absorption of methotrexate , GLPG0259  , GLPG0259 and methotrexate ,0,
edin,1278,3585965,No significant difference,"When methotrexate was co-administered with GLPG0259 50 mg, the rate of absorption of methotrexate was slightly but not statistically significantly decreased, with a point estimate for Cmax of 89.63% (figure 3, table IV).", the rate of absorption of methotrexate , GLPG0259  , GLPG0259 and methotrexate ,0,
edin,1264,3933059,Significantly decreased,Comparison of pre- vs. post-trial values revealed a significant reduction in both SBP (7%; P = 0.013) and DBP (6%; P < 0.010).," Systolic blood pressure (SBP), diastolic blood pressure (DBP) ", baseline , Pomegranate juice (PJ) ,0,
edin,1304,5451423,Cannot tell based on the abstract,," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to Japanese and Chinese subjects ,0,
edin,1304,5451423,No significant difference,"<td>AUC<sub>0-inf</sub> (nMol.h/L), MeanâÂ±âS.D. (% C.V.)</td><td>4103âÂ±â427 (10.41)</td>,No clinically meaningful interactions were observed when EG was co-administered with other commonly used medicinal products and no dose adjustment was recommended"," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to Japanese and Chinese subjects ,0,
edin,1285,4132637,No significant difference,"Regardless of revascularization or not, ticagrelor consistently reduced the primary outcome (HR 0.86 vs. 0.85, interaction P = 0.93), and all-cause death (HR 0.75 vs. 0.73, interaction P = 0.89) with no significant increase in overall major bleeding.", All-cause death , clopidogrel , ticagrelor ,0,
edin,1269,3655855,Cannot tell based on the abstract,," central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP  ", safflower oil placebo for 4 weeks , 1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks ,0,
edin,1269,3655855,No significant difference,"<td align=""left"">CRP (nmol/L)</td><td align=""center"">20.7</td><td align=""left"">21.8</td><td align=""center"">17.3</td><td align=""left"">18.7</td><td align=""left"">+0.12</td><td align=""left"">0.34</td><td align=""left"">0.53</td>,The effects of supplementation on components of the metabolic syndrome, plasma lipids, vascular measures, and cytokines are shown in TableÂ 3. The daily treatment dose of 1.7Â g of O3 for four weeks had no effect on any of these measures compared to the safflower placebo. Not shown are BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10, all of which also showed no effect."," central pulse wave velocity, augmentation index, aortic systolic blood pressure, BMI, waist, total cholesterol, serum glucose, IL-8, and IL-10,CRP  ", safflower oil placebo for 4 weeks , 1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks ,0,
edin,1267,4709985,Cannot tell based on the abstract,, would have liked more information on acupuncture , other educations , tertiary education ,0,
edin,1267,4709985,Significantly increased,"The role of educational status was examined in response these questions and we found women with tertiary education would have liked more information on acupuncture (pâ<â0.009), no other associations were found.", would have liked more information on acupuncture , other educations , tertiary education ,0,
edin,702,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,702,3187863,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25â1.69) and SU (37.9%; RR 1.45, 95% CI 1.22â1.73) (Table 2).", Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
edin,1342,5320660,Significantly decreased,"Within the HAM-RS2 group, the area under the curve (AUC) glucose (Pâ=â0.028), AUC leptin (Pâ=â0.022), and postprandial 120-min leptin (Pâ=â0.028) decreased independent of changes in body composition or overall energy intake at the end of 6Â weeks."," glucose, AUC leptin, and postprandial 120-min leptin ", muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1301,3924124,Cannot tell based on the abstract,, CD4/8 , received only general health guidance. ," 2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks ",0,
edin,1301,3924124,Significantly increased,"Significant (P < 0.05) interaction was observed for the secondary outcome measure CD4/8, which was used to represent participants' immunological function.,Significant (P < 0.05) effects were observed in CD4+ and CD4/8, which were maintained in the high adherence group, but tended to decrease in the low adherence and control groups", CD4/8 , received only general health guidance. ," 2-hour program comprising comprehensive health education and hot spa bathing, offered once every 2 weeks, in addition to individualized programs once a week, for 24 weeks ",0,
edin,1310,3258678,Significantly decreased,These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo., hippocampus volume (HV) change , 78-week treatment with placebo , 78-week treatment with tramiprosate 150 mg BID ,0,
edin,1331,4716419,No significant difference,"Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) were 46.9% and 37% in CYC and EC-MPS (risk difference=9.84; p=0.44)."," Composites of unfavourable outcomes (death, doubling of serum creatinine, non-remission and intolerance to treatment) ",  intravenous cyclophosphamide (CYC) 0.5â1?g/m2 monthly , enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months ,0,
edin,820,5294349,Cannot tell based on the abstract,, datasets of 3D coordinates , 2â4 stereo radiograph pair examinations , CT scan ,0,
edin,820,5294349,Invalid Prompt,, datasets of 3D coordinates , 2â4 stereo radiograph pair examinations , CT scan ,1," No datasets of 3D coordinates or anything similar was mentioned in results, discussion or conclusion section of the article. "
edin,768,3108665,Cannot tell based on the abstract,, Postoperative complications , No medication was given to the control group , somatostatin ,0,
edin,768,3108665,Significantly decreased,"Finally, with the help of logistic regression we concluded that the patients who did not receive somatostatin (control group) had a 6.2 times higher probability of developing complications than the treatment group.", Postoperative complications , No medication was given to the control group , somatostatin ,0,
edin,1292,5551214,Cannot tell based on the abstract,," Childhood Autism Rating Scale, Second Edition (CARS2) ", control group , horse riding intervention ,0,
edin,1292,5551214,Significantly decreased,"There was a significant interaction effect between pre- to post-test change in CARS2 scores and intervention condition (F(1, 22) = 7.219, p = 0.013, r = 0.5).,Whilst the control group had the same mean CARS2 scores at pre-test and post-test (42.61), the intervention groupâs mean score was significantly lower at post-test (40.05) than at pre-test (40.95) (Figure 1)."," Childhood Autism Rating Scale, Second Edition (CARS2) ", control group , horse riding intervention ,0,
edin,1322,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01), suggesting ameliorated cognitive performance.", P300 latency incremental values , 50?g OGTT  (A) ," B3: milk, apple, bread, and hazelnut chocolate cream ",0,
edin,1322,5494586,Significantly decreased,"P300 latency tended to decrease following each of the three breakfasts, but B3 was the only breakfast capable to elicit a statistically significant reduction in P300 latency with respect to A (p < 0.01),", P300 latency incremental values , 50?g OGTT  (A) ," B3: milk, apple, bread, and hazelnut chocolate cream ",0,
edin,1255,4864053,Cannot tell based on the abstract,, mean decrease in [11C]Ro15?4513 BP , placebo (starch) ," MSD, 100 mg l?dopa plus 25 mg carbidopa ",0,
edin,1255,4864053,Significantly decreased,"For a composite gray matter region, a oneâsample tâtest showed that lâdopa was associated with an 11% mean decrease in [11C]Ro15â4513 BP (tÂ =Â â2.29, 9 degrees of freedom, PÂ =Â 0.048).", mean decrease in [11C]Ro15?4513 BP , placebo (starch) ," MSD, 100 mg l?dopa plus 25 mg carbidopa ",0,
edin,1298,5951568,Cannot tell based on the abstract,, Overall pain scores , control , provided with written information about the electrodiagnostic testing ,0,
edin,1298,5951568,No significant difference,Overall pain scores between the intervention (20.91Â±2.33mm) and non-intervention group (25.30Â±2.44mm) in the NCS cohort did not differ significantly (p = 0.15)., Overall pain scores , control , provided with written information about the electrodiagnostic testing ,0,
edin,1271,4401879,No significant difference,"Serumlevels of fasting blood sugar, insulin and homeostatic model assessment of insulin resistance slightly decreased in zinc group, but these changes were not statistically significant."," fasting blood sugar, insulin and homeostatic model assessment of insulin resistance ", placebo for eight consecutive weeks , 30mg/day zinc gluconate for eight consecutive weeks ,0,
edin,734,2720945,Cannot tell based on the abstract,, Side effects , placebo , cineole ,0,
edin,734,2720945,No significant difference,"All patients receiving the study medication (including those with FEV1/VC > 0.7) were included in the safety examination. During treatment side effects were seen in 22 patients whereas in 17 cases adverse events were not related to the study medication. In the placebo group 11 adverse events were estimated not being related to the study medication whereas 2 cases were interpreted as being related to the study medication (heartburn). During treatment with cineole 9 cases of adverse events were reported whereas 6 adverse events were reported not being related to the study medication. In 3 patients (nausea, diarrhoea, heartburn) the adverse events were estimated being related to the study medication. The difference between the two treatment groups was neither clinically relevant nor statistically significant.", Side effects , placebo , cineole ,0,
edin,1226,4996255,Significantly increased,"Across the two Phase IIIa active comparator studies, patients consistently stated a preference for the Elliptaâ¢ DPI over HandiHalerÂ® regarding the number of steps to use (59% vs 17%), time taken to use (62% vs 14%), and ease of use (63% vs 15%) regardless of which inhaler contained active drug."," the number of steps to use, time taken to use and ease of use ", HandiHalerÂ® , Elliptaâ¢ DPI ,0,
edin,1240,5228611,Cannot tell based on the abstract,, HIV-1 RNA &amp;lt;50 copies per mililiter at week 24; , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1240,5228611,No significant difference,E/C/F/TAF plus DRV was noninferior to baseline regimens for the primary outcome (HIV-1 RNA <50 copies per mililiter at week 24; FDA-snapshot algorithm) using the full analysis set (96.6% vs. 91.3%; difference 5.3%; 95.001% CI: â3.4% to 17.4%) (Fig. 3)., HIV-1 RNA &amp;lt;50 copies per mililiter at week 24; , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1265,3933059,No significant difference,"However, changes in FMD (20%) as well as circulating levels of CRP, ICAM-1, VCAM-1, E-selectin, and IL-6 did not reach statistical significance (P = 0.172).", flow-mediated dilation (FMD) , baseline , Pomegranate juice (PJ) ,0,
edin,1312,3258678,Significantly increased,These adjusted models showed a trend toward a treatment effect for ADAS-cog (P = 0.098) and indicated significantly less HV loss for tramiprosate 100 mg (P = 0.035) and 150 mg (P = 0.009) compared to placebo., Alzheimer Disease Assessment Scale â cognitive subscale (ADAS-cog) , 78-week treatment with placebo , 78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID ,0,
edin,1281,4132637,Cannot tell based on the abstract,, The incidence of the primary composite endpoint , clopidogrel , ticagrelor ,0,
edin,1281,4132637,Significantly decreased,"The incidence of the primary composite endpoint was reduced with ticagrelor vs. clopidogrel (10.0 vs. 12.3%; HR 0.83; 95% CI = 0.74â0.93; P = 0.0013) (see Supplementary material online, Figure S1A).", The incidence of the primary composite endpoint , clopidogrel , ticagrelor ,0,
edin,1319,5494586,Cannot tell based on the abstract,, glucose incremental peaks , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1319,5494586,Significantly decreased,"As for the comparison among the incremental peak values of glycemia (Figure 1(a), 1(b), and 1(c)), the repeated measures ANOVA with Greenhouse-Geisser correction resulted significant (p < 0.001) and the Tukey-Kramer post hoc test revealed that B1 (36.2âÂ±â3.8âmg/dL), B2 (19.6âÂ±â2.9âmg/dL), and B3 (27.3âÂ±â4.0âmg/dL) had significantly smaller glucose incremental peaks than A (55.9âÂ±â6.1âmg/dL) with p values associated to such post hoc comparisons that were p = 0.04, p < 0.001, and p = 0.002, respectively.", glucose incremental peaks , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1291,5551214,Cannot tell based on the abstract,, the Aberrant Behaviour Checklist-Community Edition (ABC-C) , control group , horse riding intervention ,0,
edin,1291,5551214,No significant difference,"No significant Spearmanâs correlations were found between change and baseline scores on the CARS2, nor between change and baseline scores on the Hyperactivity subscale of the ABC-C.,The mixed ANOVA for the Irritability subscale of the ABC-C found no significant main or interaction effects (Table 2).", the Aberrant Behaviour Checklist-Community Edition (ABC-C) , control group , horse riding intervention ,0,
edin,710,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,710,4106715,No significant difference,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32â11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
edin,1253,3172326,Significantly increased,The interval time for the first analgesic request was 23.1 Â± 6.7 minutes for the case group and 18.1 Â± 7.3 minutes for the control (P = 0.02)., The interval time for the first analgesic request , 0.5 mg/kg of normal saline was injected , received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision ,0,
edin,548,2666722,Cannot tell based on the abstract,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,0,
edin,548,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1," Health care workers with IgG are only mentioned in methods section where groups are explained. In the results section IgG is not mentioned, there only higher risk of infection for workers working on the frontline"
edin,1340,4012222,Cannot tell based on the abstract,, Global performance status and STS , baseline , lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks. ,0,
edin,1340,4012222,No significant difference,"Global performance status and STS appeared somewhat better, but these changes did not achieve statistical significance (Fisherâs exact test p =â0.15 comparing categories of PS; mean reduction in STSâ=ââ1.2s, Pâ=â0.3).", Global performance status and STS , baseline , lower limb neuromuscular electrical stimulation (NMES) applied daily to both quadriceps muscles for six weeks. ,0,
edin,1320,5494586,Cannot tell based on the abstract,,  insulin excursions  , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1320,5494586,Significantly decreased,"All three commercial breakfasts showed somewhat smaller insulin excursions with respect to the one elicited by glucose administration (Figure 2(a), 2(b), and 2(c)).",  insulin excursions  , 50?g OGTT  (A) ," 3 breakfasts (B1: milk and cereals; B2: milk, apple, and chocolate cream-filled sponge cake; B3: milk, apple, bread, and hazelnut chocolate cream) ",0,
edin,1280,5928476,No significant difference,"SureFil SDR and EverX Posterior bulk-fill composite resinsâ bond strengths were significantly higher than ProRoot MTA and Biodentine calcium silicate cements. However, no statistically significant differences were observed between bulk-fill composite resins values and calcium silicate cement values.", bulk-fill composite resin values and calcium silicate cement values , ProRoot MTA or Biodentine calcium silicate cements , SureFil SDR or EverX Posterior bulk-fill composite resinsâ bond ,0,
edin,1245,3466198,Significantly decreased,"While there was no increase in inflammatory cytokines or chemokines, CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein, were significantly lower following Acidform compared to HEC placebo gel application."," CVL concentrations of lactoferrin and interleukin-1 receptor antagonist (IL-1ra), an anti-inflammatory protein, ", hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days , Acidform twice daily for 14 consecutive days ,0,
edin,1335,5673730,Significantly decreased,Significant numbers of babies were delivered after 38 weeks of pregnancy in Group-B (P=0.021)., numbers of babies were delivered after 38 weeks of pregnancy , insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B) , oral metformin 500 mg TDS (Group-A) ,0,
edin,1325,5236513,Significantly increased,"At the end of supplementation period, stool consistency in the Active group of the ITT population was significantly improved and classified as ânormalâ compared to Placebo (respectively 3.13 Â± 1.197 a.u. vs 2.58 Â± 1.020 a.u., P = 0.0003).", stool consistency , placebo , Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 ,0,
edin,1237,5228611,Cannot tell based on the abstract,, eGFR , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1237,5228611,No significant difference,There were no differences between the 2 groups in median changes from baseline in eGFR (week 48: +7.4 mL/min vs. +3.9 mL/min; P = 0.18)., eGFR , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
edin,1344,5320660,Cannot tell based on the abstract,, The mean score for the question âhow full do you feel?â , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1344,5320660,No significant difference,The mean score for the question âhow full do you feel?â in the HAM-RS2 group increased from baseline to the end of the study and approached significance (Pâ=â0.058) (data not shown)., The mean score for the question âhow full do you feel?â , muffins enriched with 0 g HAM-RS2 (control) , muffins enriched with 30 g HAM-RS2 ,0,
edin,1252,3172326,Significantly decreased,"For all of the evaluated times, the VAS score was significantly lower in the ketamine group compared to the control.", visual analogue scale (VAS). , 0.5 mg/kg of normal saline was injected , received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision ,0,
edin,1287,4132637,Significantly increased,"Major bleeding rate was similar between treatment groups (13.4 vs. 12.6%; HR 1.07; 95% CI = 0.95â1.19), but ticagrelor was associated with an increase in non-CABG major bleeding (4.8 vs. 3.8%; HR 1.28; 95% CI = 1.05â1.56).", non-CABG-related major bleeding , clopidogrel , ticagrelor ,0,
edin,1233,5506592,Significantly decreased,"In 2012, after the intervention, the proportion of households who purchased anti-mosquito products in the last month was significantly lower in intervention clusters (47.8%; 2503/5293) than in control clusters (53.3%; 2707/5079) (differenceÂ âÂ 0.05, 95% CIca â0.100 to â0.010).", the proportion of households who purchased anti-mosquito products in the last month , baseline , education and mobilisation activities ,0,
edin,654,1468428,Invalid Prompt,, You must have prompts generated from different sections. , 2 , 1 ,1, There is no question 
edin,1333,3917204,Cannot tell based on the abstract,, Clinical improvement in multi-rooted teeth  , received scaling and root planing with hand instruments , received treatment with rotary instruments ,0,
edin,1333,3917204,No significant difference,Clinical improvement was noticed in both moderately deep pocket sites and deep pocket areas. But comparison of groups showed them to be statistically nonsignificant [Tables 4 and 5]., Clinical improvement in multi-rooted teeth  , received scaling and root planing with hand instruments , received treatment with rotary instruments ,0,
edin,791,125315,Cannot tell based on the abstract,, The 28-day mortality , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,791,125315,No significant difference,There were eight deaths (40%) in the steroid therapy group and 12 (60%) deaths in the standard therapy group (P = 0.343)., The 28-day mortality , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
edin,1303,5451423,Cannot tell based on the abstract,," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to German subjects ,0,
edin,1303,5451423,No significant difference,"<td>AUC<sub>0-inf</sub> (nMol.h/L), MeanâÂ±âS.D. (% C.V.)</td><td>4103âÂ±â427 (10.41)</td>,The calculated pharmacokinetic parameters were closely related to previous studies conducted in white German subjects using 25âmg EG. The insignificant difference in ANOVA statistical results (TableÂ 2) of the pharmacokinetic evaluation in Egyptians and white German subjects13, 15, 20, 38 suggests that no dose adjustment should be considered with administration of 25âmg EG to Egyptian population.Table 2"," Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and AUC0-inf ", empagliflozin after administration to Egyptian volunteers , empagliflozin after administration to German subjects ,0,
edin,1225,3917123,Cannot tell based on the abstract,, Fatigue score in the sensory dimension , Placebo , Routine unit care ,0,
edin,1225,3917123,Significantly increased,"Post-hoc Duncan test showed that mean reduction of total fatigue score and mean reduction of fatigue scores in sensory and cognitive dimensions in the study group were more than in the placebo group, and they were more in the placebo group compared to the control group (P < 0.05).", Fatigue score in the sensory dimension , Placebo , Routine unit care ,0,
edin,1364,4365564,Cannot tell based on the abstract,, Complications related to approach method , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1364,4365564,No significant difference,"The rate of approach-related complications in all 304 patients was 9.9% (30/304) and was similar between the 2 groups, with 9.8% (20/205) in the investigational group and 10.1% (10/99) in the control group (Table 2).,<td align=""left"" colspan=""1"" rowspan=""1"">Retrograde ejaculation, no. (%)<xref ref-type=""table-fn"" rid=""TF0002"">a</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">3 (3.3)</td><td align=""center"" colspan=""1"" rowspan=""1"">3 (5.5)</td><td align=""center"" colspan=""1"" rowspan=""1"">.515</td>", Complications related to approach method , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1471,4367028,Cannot tell based on the abstract,, PACU stay , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1471,4367028,Significantly increased,Again PACU stay was longer (P < 0.05) in TBG >30Â° group compared to TBG <30Â° group [Table 6]., PACU stay , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1420,2361654,Cannot tell based on the abstract,, colposcopy referrals (sensitivity?) , cytological screening , primary hrHPV screening ,0,
edin,1420,2361654,Significantly increased,"Compared with the conventional arm, clearly more colposcopy referrals were made in the hrHPV screening arm (RR 1.51, CI 95% 1.03â2.22).", colposcopy referrals (sensitivity?) , cytological screening , primary hrHPV screening ,0,
edin,1498,3846239,Significantly decreased,The analgesic requirement was significantly lower in the B+D group compared with the B group., The analgesic requirement , bupivacaine  , bupivacaine plus dexamethasone  ,0,
edin,1515,2361520,Cannot tell based on the abstract,, time to disease progression or survival , receive delayed treatment , receive immediate treatment ,0,
edin,1515,2361520,No significant difference,The time to disease progression from randomisation to after chemotherapy was similar in the immediate- and delayed-treatment groups for both studies (Table 3), time to disease progression or survival , receive delayed treatment , receive immediate treatment ,0,
edin,1428,5553001,Cannot tell based on the abstract,, PTSD-Checklist-Civilian version (PCL-C) difference  , wait-list control condition ," Internet-based guided self-help program, including weekly support from a therapist via encrypted email ",0,
edin,1428,5553001,No significant difference,"Table 1
Baseline characteristics of parents.,<td colspan=""1"" rowspan=""1""><break></break></td><td colspan=""1"" rowspan=""1"">PCL-C<sup>j</sup></td><td colspan=""1"" rowspan=""1"">49.1 (10.3)</td><td colspan=""1"" rowspan=""1"">51.5 (9.4)</td><td colspan=""1"" rowspan=""1"">46.6 (10.7)</td><td colspan=""1"" rowspan=""1"">.06</td>", PTSD-Checklist-Civilian version (PCL-C) difference  , wait-list control condition ," Internet-based guided self-help program, including weekly support from a therapist via encrypted email ",0,
edin,1378,3628658,No significant difference,There was not statistical significance on union time and Harris values in the two position groups., Harris hip values and union time of fractures , Supine position , Lateral decubitus position ,0,
edin,1369,5311860,Cannot tell based on the abstract,," All responses, excluding Ã¢â¬Ëwatchful waitingÃ¢â¬â¢ ", Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
edin,1369,5311860,No significant difference,"However, when the term for âwatchful waitingâ is excluded from public health response, the results were not significant (TableÂ 5).Table 5"," All responses, excluding Ã¢â¬Ëwatchful waitingÃ¢â¬â¢ ", Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
edin,1380,4659198,Significantly decreased,"On the third day, the massage group showed significantly higher defecation frequency (pâ=â0.045) and significantly lower bilirubin levels (pâ=â0.03) compared with the control group.", Bilirubin levels after 3 days , Phototherapy only , Phototherapy plus massage ,0,
edin,1459,4600230,Cannot tell based on the abstract,, a pre-established pass/fail level of 50.0% in OSAUS score , clinical training only , simulation-based training followed by clinical training ,0,
edin,1459,4600230,Significantly increased,"A significantly higher number of participants from the intervention group passed a pre-established pass/fail level of 50.0% in OSAUS score compared with the control group (85.7% vs 8.3%, respectively; P < 0.001).", a pre-established pass/fail level of 50.0% in OSAUS score , clinical training only , simulation-based training followed by clinical training ,0,
edin,1507,5850185,Significantly increased,he subjects in the bilateral TENS+TOT group showed greater improvement in paretic ankle dorsiflexion strength (Î²=1.32; P=0.032) and in the completion time for the Timed Up and Go test (Î²=â1.54; P=0.004) than those in the unilateral TENS+TOT group., the TUG completion time at A1 and A2 , baseline , bilareal Transcutaneous electrical nerve stimulation (TENS) and taskÃ¢â¬?oriented training (TOT) ,0,
edin,1372,5285426,Significantly increased,Composite male urological and sexual function score changes from baseline were better in the robotic cohort (pÂ <Â 0.001)., Male sexual function scores , Laparoscopic surgery , Robotic surgery ,0,
edin,1412,5578640,Significantly increased,The ESAS QoL-score improved in the Vitamin D group the first month; -1.4; 95% CI -2.6 - (-0.21)., The ESAS QoL-score after 1 month , untreated (control) , vitamin D 4000 IE/day ,0,
edin,1482,4881089,Cannot tell based on the abstract,, prevalence rates of reported musculoskeletal symptoms , baseline ,  ergonomic intervention ,0,
edin,1482,4881089,No significant difference,McNemar test showed no significant difference in the prevalence rates of musculoskeletal symptoms in all regions before and after intervention., prevalence rates of reported musculoskeletal symptoms , baseline ,  ergonomic intervention ,0,
edin,1525,4092926,No significant difference,"There was no influence of the treatments on any of the mean values of the evaluated measures (p>0.05): 21.78 kg (body weight at slaughter), 8.65 kg (hot carcass weight), 8.59 kg (cold carcass weight), 40.27% (hot carcass yield), 39.20% (cold carcass yield), 7.73 cm2(rib eye area), 46.74 cm (carcass outer length), 45.68 cm (carcass internal length), 36.92 cm (leg length), 26.04 cm (leg perimeter), 48.66 cm (hind perimeter), 58.62 cm (thoracic perimeter), 0.20 (carcass compactness index), 68.48% (total muscle of the leg), 2.79% (total leg fat), 55.19% (subcutaneous leg fat), 28.82% (total bone), 81.66 g (femur weight), 14.88 cm (femur length), 0.38 (leg muscularity index), 2.53 (muscle:bone ratio) and 33.42 (muscle:fat ratio).", goats body weight at slaughter , soybean meal , sunflower cake ,0,
edin,1511,4134501,Cannot tell based on the abstract,, Partial responses , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1511,4134501,No significant difference,"At the end of cycle 3, 10 (67%) and 7 (58%) patients in Arms A and B, respectively, had achieved a partial response, whereas an additional 4 patients in each arm (27% and 33%, respectively) had stable disease.", Partial responses , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1497,4274342,Cannot tell based on the abstract,, pelvic organ prolapse , placebo , ospemifene 60 mg/day ,0,
edin,1497,4274342,No significant difference,"There were rare cases of pelvic organ prolapse in both the ospemifene and placebo groups. Two women had bladder prolapse (one ospemifene participant and one placebo participant), and one ospemifene participant had a report of cystocele.", pelvic organ prolapse , placebo , ospemifene 60 mg/day ,0,
edin,1512,2361520,No significant difference,"Median survival was not significantly better with immediate treatment (median 13.0 vs 11.0 months; hazard ratio, 1.15; 95% confidence interval (CI) 0.79â1.72; P=0.49).", Median survival , receive delayed treatment , receive immediate treatment ,0,
edin,1261,5414544,Significantly increased,"he rate of HBsAg positivity was significantly higher in Zimbabwe than Uganda (12.2 vs. 7.7%, adjusted odds ratioâ=â1.54, Pâ<â0.001) despite a similar prevalence of antibody to HBV core antigen (56.3 vs. 52.4%) in the two settings.", The rate of HBsAg positivity , Uganda , Zimbabwe ,0,
edin,1501,2627861,Cannot tell based on the abstract,, maternal blood lead concentrations , ingest placebo ," ingest 1,200 mg dietary calcium ",0,
edin,1501,2627861,Significantly decreased,"In the intent-to-treat analysis (n = 557), calcium supplementation was associated with an overall average reduction of 11% in maternal blood lead concentrations relative to placebo (p = 0.004) (Table 2).", maternal blood lead concentrations , ingest placebo ," ingest 1,200 mg dietary calcium ",0,
edin,1493,5021748,No significant difference,"he initial bolus heparin dosages required to produce an ACT 15Â min after the initial bolus that was identical to the control (333Â Â±Â 32Â s) were 120 U/kg (318Â Â±Â 29Â s) and 130 U/kg (339Â Â±Â 43Â s) for dabigatran, 130 U/kg (314Â Â±Â 31Â s) for rivaroxaban and 130 U/kg (317Â Â±Â 39Â s) for apixaban.,The NOAC groups required significantly larger doses of total heparin than the warfarin group.,The results of the comparison with warfarin (the control) indicated that dosages of 120 or 130 U/kg for dabigatran, and 130 U/kg for rivaroxaban and apixaban, were adequate initial heparin dosages.", heparin dosages required to produce an ACT 15 min after the initial bolus  that was identical to the control (110U/kg) , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1473,4222592,Significantly decreased,"ompared to the C test meal, the AA test meal increased satisfaction by 23% (P=0.05) and decreased the desire to eat by 28% (P=0.04) for the AUC(0-5h).", desire to eat  for the AUC(0-5h) , consumed a standardized breakfast  [Control (C)avocado-free] , consumed a standardized breakfast with Avocado Added (AA) ,0,
edin,1461,4600230,Cannot tell based on the abstract,, knowledge of equipment  , clinical training only , simulation-based training followed by clinical training ,0,
edin,1461,4600230,No significant difference,"There were statistically significant differences between the scores of the two groups (Figure 3) on image optimization (P < 0.001), systematic examination (P = 0.001), interpretation of images (P < 0.001), documentation of examination (P < 0.001), and medical decision-making (P = 0.005) but no difference was observed for knowledge of equipment (P = 0.095).", knowledge of equipment  , clinical training only , simulation-based training followed by clinical training ,0,
edin,1453,3406743,Cannot tell based on the abstract,, engaging in moderate physical activity , baseline , usual care (UCG) ,0,
edin,1453,3406743,No significant difference,"The EIG was approximately twice as likely to report engaging in moderate physical activity at follow-up as at baseline; 71% of women in this group reported moderate physical activity at baseline, and 84% at follow-up.,The UCG did not change between baseline and follow-up; 75% of women in this group reported moderate physical activity at baseline, and 77% at follow-up.", engaging in moderate physical activity , baseline , usual care (UCG) ,0,
edin,1495,4274342,Cannot tell based on the abstract,, vaginal bleeding , placebo , ospemifene 60 mg/day ,0,
edin,1495,4274342,No significant difference,"aginal bleeding or spotting was reported in 10 of 851 women (1.2%) with an intact uterus in the ospemifene 60 mg/day group (incidence rate, 2.17 per 100 patient-years) and in 5 of 543 women (0.9%) in the placebo group (incidence rate, 2.72 per 100 patient-years; P = 0.7; Table 3).", vaginal bleeding , placebo , ospemifene 60 mg/day ,0,
edin,1499,3846239,Significantly decreased,"At 1, 2, 4, 6, and 12 h post surgery, VAS pain values were significantly lower in the B+D group than in the B group."," At 1, 2, 4, 6, and 12 h post surgery, VAS pain scores ", bupivacaine  , bupivacaine plus dexamethasone  ,0,
edin,1444,5610684,Cannot tell based on the abstract,," tension, anxiety, well-being ", quietly read , use their own Facebook profile ,0,
edin,1444,5610684,No significant difference,"There were no significant condition differences for tension F(1, 91) = 1.56, p = 0.21, 95% CI [â0.29, 1.25], Î·2 = 0.02; anxiety F(1, 88) = 0.004, p = 0.95, 95% CI [â1.01, 0.95], Î·2 = 0.00; or well-being F(1, 91) = 0.33, p = 0.57, 95% CI [â0.49, 0.90], Î·2 = 0.004."," tension, anxiety, well-being ", quietly read , use their own Facebook profile ,0,
edin,1416,5456350,Cannot tell based on the abstract,, wanted to receive a DEKA Arm , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1416,5456350,No significant difference,"There were no significant differences in responses to survey items (pertaining to desire to receive a DEKA Arm, self-rated skill in use, perception of weight, ratings of socket comfort, or preferences for DEKA Arm over personal prosthesis) administered at the end of Part A and the end of Part B (Table 2).", wanted to receive a DEKA Arm , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1435,5336430,Significantly increased,"At 8Â weeks after the end of treatment, CCC was significantly higher with 5-FU 0.5%/salicylic acid 10% than with vehicle [49.5% vs. 18.2%, respectively; odds ratio (OR) 3.9 (95% CI) 1.7, 8.7; PÂ =Â 0.0006].", The percentage of patients with complete clinical clearance (CCC) 8 weeks after the end of treatment (primary endpoint) , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1523,4107254,Significantly increased,"Centers admitting â¥ 200 patients/year (70.7% vs. 45%; p = 0.039), and those with stroke units (95 vs. 20; p = 0.031) were more willing to join a randomized trial evaluating any of the methods.", willing to join a randomized trial evaluating any of the methods used in VTE prophylaxis in stroke patients , centers without stroke unit , centers with stroke unit ,0,
edin,1430,5566825,Cannot tell based on the abstract,, total duration of illnesses , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1430,5566825,Significantly decreased,"Evaluation of total duration of illnesses related to infection and allergy showed that of the total duration of 3983 days of illness, there were 1369 (34.37%) illness days in CP group whereas it was 2614 (65.62%) days in the control group. This difference was observed statistically significant (P < 0.01) and the proportionate difference was about 2 times (1.91) [Figure 3].", total duration of illnesses , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1503,5854362,Cannot tell based on the abstract,, anxiety and depressive symptoms  , placebo training ,  Cognitive Bias Modification for Interpretations (CBM-I) training ,0,
edin,1503,5854362,No significant difference,"Our first and primary hypothesis, that CBM-I would result in reduced anxiety and depressive symptoms compared to Placebo, was not confirmed, as no significant Condition x Time interactions were observed for SCARED and CDI scores.", anxiety and depressive symptoms  , placebo training ,  Cognitive Bias Modification for Interpretations (CBM-I) training ,0,
edin,1522,4107254,Cannot tell based on the abstract,, Dextrans administration , centers without stroke unit , centers with stroke unit ,0,
edin,1522,4107254,No significant difference,"Dextrans were less frequently used in centers with a stroke unit (6.6% vs. 13%, p = 0.05).", Dextrans administration , centers without stroke unit , centers with stroke unit ,0,
edin,1494,4274342,Cannot tell based on the abstract,, The mean (SD) increase in endometrial thickness based on TVUS , placebo , ospemifene 60 mg/day ,0,
edin,1494,4274342,Significantly increased,"The mean (SD) increase in endometrial thickness based on TVUS was 0.51 (1.5) versus 0.06 (1.2) mm at 12 weeks, 0.56 (1.6) versus 0.05 (1.3) mm at 6 months, and 0.81 (1.5) versus 0.07 (1.2) mm at 12 months for participants in the ospemifene and placebo groups, respectively. The differences between participants receiving ospemifene and participants receiving placebo were statistically significant (P â¤ 0.001, Welchâs test) at all three evaluations.", The mean (SD) increase in endometrial thickness based on TVUS , placebo , ospemifene 60 mg/day ,0,
edin,1510,4134501,No significant difference,The safety profiles were similar between arms and treatment was well tolerated., The safety profiles , pertuzumab 840Ã¢â¬â°mg q3w for six cycles (Arm B) , pertuzumab 840Ã¢â¬â°mg for cycle 1 and 420Ã¢â¬â°mg q3w for cycles 2Ã¢â¬â6 (Arm A) ,0,
edin,1393,4599543,Significantly decreased,"Postoperative bleeding was significantly (P=0.042) less in the treatment arm (median, 300Â mL; interquartile range, 200 to 400Â mL) than in the control arm (median, 355Â mL; interquartile range, 250 to 600Â mL).", postoperative bleeding , received saline solution (placebo) , received fibrinogen concentrate ,0,
edin,1466,2837815,No significant difference,The Merle dâAubigne Postel score was the maximum of 18 points for all patients in both groups., The Merle dÃ¢â¬â¢Aubigne Postel score , Palacos R acrylic bone cements (without antibiotics) , SmartSet HV acrylic bone cements (without antibiotics) ,0,
edin,1374,3628658,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Hospital stay , Supine position , Lateral decubitus position ,0,
edin,1359,3842830,Significantly decreased,"The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (â0.99 hours, Pâ=â.003) and istradefylline 40 mg/day (â0.96 hours, Pâ=â.003) groups compared with the placebo group (â0.23 hours).", Daily OFF time , Placebo , Istradefylline 20 mg or 40 mg ,0,
edin,1452,3406743,Cannot tell based on the abstract,, engaging in moderate physical activity , baseline ," enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance. ",0,
edin,1452,3406743,Significantly increased,"The EIG was approximately twice as likely to report engaging in moderate physical activity at follow-up as at baseline; 71% of women in this group reported moderate physical activity at baseline, and 84% at follow-up.", engaging in moderate physical activity , baseline ," enhanced intervention (EIG) - The enhanced intervention was delivered by CHWs as 3 individually tailored, one-on-one counseling sessions. The sessions occurred approximately 1 month, 2 months, and 6 months after screening. Each session averaged 50 minutes. Participants received transportation tokens and grocery store vouchers as incentives for attendance. ",0,
edin,1375,3628658,Significantly decreased,"The hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Loss of blood during surgery , Supine position , Lateral decubitus position ,0,
edin,1496,4274342,Cannot tell based on the abstract,, endometrial cancer , placebo , ospemifene 60 mg/day ,0,
edin,1496,4274342,No significant difference,There were no cases of endometrial cancer observed with exposure of up to 52 weeks in the ospemifene clinical trials., endometrial cancer , placebo , ospemifene 60 mg/day ,0,
edin,1441,5336430,Cannot tell based on the abstract,, DLQI total score 8 weeks after the end of treatment , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1441,5336430,No significant difference,"<td align=""left"" colspan=""4"">DLQI total score</td>", DLQI total score 8 weeks after the end of treatment , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1467,4367028,Cannot tell based on the abstract,, SBP and DBP , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ°  ,0,
edin,1467,4367028,No significant difference,"Baseline hemodynamic parameters like SBP, DBP, mean arterial pressure (MAP), pulse rate and also hemoglobin were found to be comparable [Table 3] among two groups.,Head down tilt was associated with a rising trend in SBP and DBP which was higher in TBG >30Â° than TBG <30Â° group however the results were not statistically significant [Table 4].", SBP and DBP , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ°  ,0,
edin,1401,5766333,Cannot tell based on the abstract,, the minimum pulse rate , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
edin,1401,5766333,Significantly decreased,"On the other hand, the minimum pulse rate was significantly lower in the Combination group than in the PF group (47 [34âââ61] bpm vs. 59 [36âââ72] bpm, P â<â0.001, median [range]),", the minimum pulse rate , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
edin,1460,4600230,Cannot tell based on the abstract,," image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making ", clinical training only , simulation-based training followed by clinical training ,0,
edin,1460,4600230,Significantly increased,"There were statistically significant differences between the scores of the two groups (Figure 3) on image optimization (P < 0.001), systematic examination (P = 0.001), interpretation of images (P < 0.001), documentation of examination (P < 0.001), and medical decision-making (P = 0.005) but no difference was observed for knowledge of equipment (P = 0.095)."," image optimization, systematic examination, interpretation of images, documentation of examination, and medical decision-making ", clinical training only , simulation-based training followed by clinical training ,0,
edin,1394,5724392,Cannot tell based on the abstract,"Final model-based TCD velocities (mean Â± standard error) on Standard versus Alternative Arm were 143 Â± 1.6 and 138 Â± 1.6 cm/sec, respectively, with difference (95% CI) = 4.54 (0.10, 8.98), non-inferiority p=8.82 Ã 10â16 and post-hoc superiority p=0.023.", transcranial Doppler (TCD) flow velocities , transfusions , hydroxyurea ,0,
edin,1394,5724392,Significantly increased,"The final model-based TCD velocities (mean Â± standard error) on the Standard Arm versus Alternative Arm were 143 Â± 1.6 and 138 Â± 1.6 cm/sec, respectively, with difference (95% CI) = 4.54 (0.10, 8.98), non-inferiority p=8.82 Ã 10â16 and a post-hoc superiority p=0.023.", transcranial Doppler (TCD) flow velocities , transfusions , hydroxyurea ,0,
edin,1456,3406743,Significantly increased,A culturally tailored adaptation of the WISEWOMAN program that used community health workers significantly improved both self-reported readiness to engage in physical activity and vigorous physical activity among low-income Latinas., readiness to engage in vigorous physical activity , baseline , enhanced intervention (EIG) ,0,
edin,1419,5456350,Cannot tell based on the abstract,, rated the DEKA function and the external battery life , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1419,5456350,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">&nbsp;&nbsp;&nbsp;&nbsp;DEKA arm function</td><td align=""center"" colspan=""1"" rowspan=""1"">31</td><td align=""center"" colspan=""1"" rowspan=""1"">5.3 (1.4)</td><td align=""center"" colspan=""1"" rowspan=""1"">17</td><td align=""center"" colspan=""1"" rowspan=""1"">5.8 (1.0)</td><td align=""center"" colspan=""1"" rowspan=""1"">14</td><td align=""center"" colspan=""1"" rowspan=""1"">4.7 (1.6)</td><td align=""center"" colspan=""1"" rowspan=""1""><bold>0.0468</bold></td>,<td align=""left"" colspan=""1"" rowspan=""1"">&nbsp;&nbsp;&nbsp;&nbsp;External Battery Life</td><td align=""center"" colspan=""1"" rowspan=""1"">32</td><td align=""center"" colspan=""1"" rowspan=""1"">5.7 (1.1)</td><td align=""center"" colspan=""1"" rowspan=""1"">18</td><td align=""center"" colspan=""1"" rowspan=""1"">5.8 (0.8)</td><td align=""center"" colspan=""1"" rowspan=""1"">14</td><td align=""center"" colspan=""1"" rowspan=""1"">5.5 (1.5)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.9928</td>", rated the DEKA function and the external battery life , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
edin,1470,4367028,Cannot tell based on the abstract,, Nitroglycerine and fentanyl use , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1470,4367028,Significantly increased,Nitroglycerine and fentanyl use in TBG >30Â° group was higher and statistically significant (P < 0.05) when compared with TBG <30Â° [Table 6]., Nitroglycerine and fentanyl use , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
edin,1370,5285426,No significant difference,"In females, there was no difference between the two groups in any of the components of urological or sexual function.", Urological function scores in females , Laparoscopic surgery , Robotic surgery ,0,
edin,1478,4673066,Cannot tell based on the abstract,, performance on the diagnostic performance test , traditional , schema-based lecture ,0,
edin,1478,4673066,Significantly increased,"Schema-based instruction was associated with increased performance on the diagnostic performance test (64â%âÂ±â22 vs 44â%âÂ±â25, pâ<â0.001).", performance on the diagnostic performance test , traditional , schema-based lecture ,0,
edin,1383,4659198,Cannot tell based on the abstract,, Baseline medical characteristics , Phototherapy only , Phototherapy plus massage ,0,
edin,1383,4659198,No significant difference,"TableÂ 1 shows the medical characteristics of participating neonates. We observed no significant differences between the two groups in terms of type of feeding, gestational age at birth, body weight at birth, body weight on the date of admission, phototherapy duration, or physical weight loss.Table 1", Baseline medical characteristics , Phototherapy only , Phototherapy plus massage ,0,
edin,1485,4881089,Cannot tell based on the abstract,, any of the scales of the Thai version of the COPSOQ questionnaire , baseline , control ,0,
edin,1485,4881089,No significant difference,Table 5 also shows that there was no significant difference in any of the scales of the Thai version of the COPSOQ questionnaire before and after intervention in the control group., any of the scales of the Thai version of the COPSOQ questionnaire , baseline , control ,0,
edin,1526,4092926,Cannot tell based on the abstract,," Weights, carcass yields, rib eye area of goats ", soybean meal , sunflower cake ,0,
edin,1526,4092926,No significant difference,Weights and carcass yields as well as rib eye area showed no differences (p>0.05) with the substitution of soybean meal by sunflower cake.," Weights, carcass yields, rib eye area of goats ", soybean meal , sunflower cake ,0,
edin,1434,5566825,Cannot tell based on the abstract,, CGI-I scale improvement , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1434,5566825,Significantly increased,Assessment of participants on CGI-I scale showed that a higher percentage of participants (66.12%) showed improvement on this scale in CP Group as compared to control group (51.43%) [Table 7]., CGI-I scale improvement , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
edin,1492,5021748,Cannot tell based on the abstract,, protamine usage for haemostasis , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1492,5021748,No significant difference,"No significant differences in protamine usage for haemostasis were found among the control and three NOAC groups (control, 13Â Â±Â 20; dabigatran, 26Â Â±Â 23; rivaroxaban, 25Â Â±Â 25; apixaban, 28Â Â±Â 28Â mg).", protamine usage for haemostasis , control (warfarin) , rivaroxaban or apixaban or dabigatran   ,0,
edin,1377,3628658,Significantly decreased,"he hospital stay, operating time, intraoperative blood loss, length of incision, X-ray fluoroscopy time, and out-of-bed activity time in the lateral decubitus position group were significantly lower than those in the supine position group.", Surgery time , Supine position , Lateral decubitus position ,0,
edin,1440,5336430,Cannot tell based on the abstract,, the TSQM convenience and side effect domain scores , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1440,5336430,No significant difference,"No statistically significant differences were observed between the study arms for the TSQM convenience (70.7 and 71.2, respectively) and side effect (92.4 and 96.4, respectively) domain scores.", the TSQM convenience and side effect domain scores , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
edin,1365,4365564,Significantly increased,There was a higher rate of superficial wound infection in the investigational group but no deep wound infections in either group., Rate of superficial wound infection , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
edin,1355,3179725,Significantly increased,"<td align=""left""><bold>After four treatments</bold></td><td></td><td></td><td></td>", Dyspnea improvement , Sham chest wall oscillation treatment , Active chest wall oscillation treatment ,0,
edin,1637,5420386,Significantly increased,"<td colspan=""5"">5D-ASC scale</td>"," ratings of blissful state, insightfulness, and changed meaning of percepts ", 100&amp;amp;nbsp;ÃÂ¼g dose of LSD , oral administration of 200 ÃÂ¼g LSD ,0,
edin,1623,3719224,Significantly increased,"Despite the similarity of two groups of intervention (n = 53) and control (n = 59) at baseline, there were significant differences between the two groups in mean scores of the variables, knowledge (4.62 Â± 1.38 vs. 3.53 Â± 1.61), perceived susceptibility (14.05 Â± 1.51 vs. 12.37 Â± 2.11), and perceived benefits (28.41 Â± 2.14 vs. 27.51 Â± 3.05), at follow-up time after 3 months (P < 0.05)."," the variables, knowledge ", received just routine education , received educational intervention plus routine education ,0,
edin,1551,4396724,Cannot tell based on the abstract,, Maximal heart rate at the end of the test , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1551,4396724,No significant difference,"Maximal heart rate achieved at the end of the graded exercise test, body mass, and waist circumference did not change significantly from baseline to one-month follow-up in either HIIT or MICT (P's > 0.05).", Maximal heart rate at the end of the test , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1632,5420386,No significant difference,"On the MEQ, 200Â Î¼g LSD induced mystical experiences that were comparable to those in patients who underwent LSD-assisted psychotherapy but were fewer than those reported for psilocybin in healthy subjects or patients.", Mystical Experience Questionnaire (MEQ) scores , placebo , oral administration of 100 and 200&amp;nbsp;ÃÂ¼g LSD ,0,
edin,1536,5941723,No significant difference,"There were no significant differences in number of sensations elicited, MASS index, range of spreading, and intensity of needle pain for 5âmm penetration versus 1âmm skin press and 10âmm penetration versus 2âmm skin press.", Needle pain intensity , Placebo , Acupuncture ,0,
edin,1531,5343624,Cannot tell based on the abstract,, Formation of new bone ,"  Synthetic bone substitute material (NanoBoneÃÂ®, NB)  "," Xenogeneic bone substitute material (Bio-OssÃÂ®, BO)  ",0,
edin,1531,5343624,No significant difference,"The radiologic analysis of the BO graft revealed volumetric reduction in all patients.,The volume reduction of the BO graft was not significant.,The radiologic analysis of the NB graft revealed volumetric reduction in all patients.,The volume reduction of the NB graft was not significant.", Formation of new bone ,"  Synthetic bone substitute material (NanoBoneÃÂ®, NB)  "," Xenogeneic bone substitute material (Bio-OssÃÂ®, BO)  ",0,
edin,1588,3810136,Cannot tell based on the abstract,, Free IGF-1 concentrations at day 4 and day 6 ," T-HS/SE, T-HS/EAA ", T-HS/Ctr ,0,
edin,1588,3810136,Significantly decreased,"In addition, lower free IGF-1 levels were measured in the T-HS/Ctr group than PF group at day 4 and it reached statistical difference by day 6 (p<0.01), indicating that the depressed IGF-1 expression was sustained 6 days following T-HS after eliminating the interference of reduced food intake.", Free IGF-1 concentrations at day 4 and day 6 ," T-HS/SE, T-HS/EAA ", T-HS/Ctr ,0,
edin,1667,5017045,Cannot tell based on the abstract,, number of operated patients , standard consultation , video-assisted remote consultations ,0,
edin,1667,5017045,No significant difference,There were no significant differences in the number of operated patients between the two groups (pâ=â0.432)., number of operated patients , standard consultation , video-assisted remote consultations ,0,
edin,1563,3094237,Cannot tell based on the abstract,, Adverse side effects , Placebo , L-lysine ,0,
edin,1563,3094237,No significant difference,"urthermore, the L-lysine treatment was not found to induce any adverse side effects including extrapyramidal effects.", Adverse side effects , Placebo , L-lysine ,0,
edin,1600,5434251,Cannot tell based on the abstract,, PTQ (perseverative thinking) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1600,5434251,No significant difference,"<td colspan=""2"" rowspan=""1"">PTQ<sup>g</sup> (perseverative thinking), mean (SD)</td><td colspan=""1"" rowspan=""1"">38.50 (10.97)</td><td colspan=""1"" rowspan=""1"">45.32 (9.95)</td><td colspan=""1"" rowspan=""1"">t<sub>35</sub>=â1.98; <italic>P</italic>=.06</td>", PTQ (perseverative thinking) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1561,5916905,No significant difference,"After BM-intervention, fat mass increased (+1.0âÂ±â1.8âkg; pâ<â0.05) and postprandial insulin sensitivity tended to decrease (ÎMatsudaISI: â0.89âÂ±â2.3; pâ=â0.06).,Daylong glycaemia, insulin secretion, changes in basal insulin sensitivity, and triglycerides did not differ between WM- and BM-interventions (all pâ>â0.05).",  Insulin sensitivity after meals , Orange juice intake with each meal (WM)  , Orange juice intake in-between meals (BM) ,0,
edin,1591,2714198,No significant difference,No difference in survival time was observed across the different groups., Survival time , Control groups , Suture groups ,0,
edin,1609,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Pregnancy , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,1574,5791393,Cannot tell based on the abstract,, Hospital stay after surgery , Without catheter (group I) , With catheter (group II) ,0,
edin,1574,5791393,No significant difference,"There was also no significant difference in the post-operative hospital stay between the groups, both in total and separately in women and in men.", Hospital stay after surgery , Without catheter (group I) , With catheter (group II) ,0,
edin,1564,3094237,Significantly decreased,"<td align=""left""><underline>PANSS</underline></td><td></td><td></td><td></td><td></td><td></td>", Symptom severity by PANSS measure , Placebo , L-lysine ,0,
edin,1583,5642191,Cannot tell based on the abstract,, Baseline characteristics , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1583,5642191,No significant difference,No differences in baseline characteristics were found between the three intervention groups (Table 1)., Baseline characteristics , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1575,5791393,No significant difference,"Catheterisation does not influence: the number of additional doses of ketoprofen and pethidine administered during the 1st day after the operation, the duration of hospitalization, the occurrence of fever, significant bacteriuria, the postoperative acute urinary retention and the post-void residual urine volume.", Fever , Without catheter (group I) , With catheter (group II) ,0,
edin,1666,5017045,Cannot tell based on the abstract,, The mean consultation duration in the subgroup patients who required casting , standard consultation (UNN) , video-assisted remote consultations  ,0,
edin,1666,5017045,Significantly increased,"In the subgroup analyses restricted to patients who required casting, we observed a significantly longer mean consultation time in the RMC group (29.0Â min) compared to the UNN group (22.6Â min, pâ=â0.0063).", The mean consultation duration in the subgroup patients who required casting , standard consultation (UNN) , video-assisted remote consultations  ,0,
edin,1672,2941605,Cannot tell based on the abstract,, Skin reaction , Vinorelbine 6mg/m2 , Cisplatin 40mg/m2 ,0,
edin,1672,2941605,Significantly increased,Skin reaction was also lower in the Vinorelbine arm when compared with the other arm., Skin reaction , Vinorelbine 6mg/m2 , Cisplatin 40mg/m2 ,0,
edin,1630,3640164,Cannot tell based on the abstract,," The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time ", spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1630,3640164,Significantly increased,"The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time were shorter in the spinal anesthesia group than in the PSNB group (P < 0.01)."," The duration of the procedure, time from anesthesia induction until start of surgery, and surgery time ", spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1604,4335741,Significantly decreased,"Further, laryngoscopy, jaw relaxation, and limb movement scores were similar in the R and A groups and there were no significant differences, but vocal cords were significantly more patent in group R than those in group A (P = 0. 028).", Vocal cords patency , Remifentanil , Alfentanil ,0,
edin,1675,4737200,Cannot tell based on the abstract,, second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1675,4737200,Significantly decreased,"For the second peak in EKAM during late stance, both of the lateral wedge insoles significantly reduced the magnitude of this peak in comparison to the control condition.", second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1675,4737200,Significantly decreased,"For the second peak in EKAM during late stance, both of the lateral wedge insoles significantly reduced the magnitude of this peak in comparison to the control condition.", second peak in EKAM during late stance , control condition , lateral wedge insoles ,0,
edin,1607,4335741,Cannot tell based on the abstract,, Scores for ease of laryngoscopy , Remifentanil , Alfentanil ,0,
edin,1607,4335741,No significant difference,"As shown in Table 3, the scores for ease of laryngoscopy (A), jaw relaxation (C), and limb movement (D) did not differ significantly between the two groups (Mann-Whitney test), but vocal cord patency (B) in group A was significantly higher than that in remifentanil group (P = 0. 028).", Scores for ease of laryngoscopy , Remifentanil , Alfentanil ,0,
edin,1611,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Live birth rate , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,1550,4396724,Cannot tell based on the abstract,, Changes in fitness measures , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1550,4396724,No significant difference,"There were no main effects for group or group by time interactions for these fitness parameter variables, indicating that there were no differences in the degree of change experienced between HIIT and MICT over time.", Changes in fitness measures , Traditional moderate-intensity continuous training , High-intensity interval training ,0,
edin,1658,2291328,Cannot tell based on the abstract,, hospitalization hospitalization for worsening CHF in CIBIS-III , 20 mg/day for enalapril , 10 mg/day for bisoprolol ,0,
edin,1658,2291328,No significant difference,"There was a non-significant increase in the number of patients having a hospitalization for worsening CHF in the bisoprolol-first group compared with the enalapril-first group (63 vs 51 patients, respectively, HR = 1.25 [0.87â1.81], p = 0.23).", hospitalization hospitalization for worsening CHF in CIBIS-III , 20 mg/day for enalapril , 10 mg/day for bisoprolol ,0,
edin,1597,2911596,Cannot tell based on the abstract,, HR values , Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1597,2911596,Significantly increased,"However, HR values were significantly different in SEVO and ISOF groups 70.6 Â± 13.0 versus 64.9 Â± 11.8, (P < .01), respectively (Figure 2).", HR values , Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1608,4086013,No significant difference,"We did not observe any differences between the ISM1 control group and GM501 study group with regard to fertilization, pregnancy, implantation rates, ongoing pregnancy, and babies born.", Fertilization , Standard sequential culture medium ISM1 , New universal medium (GM501) ,0,
edin,621,1852268,Cannot tell based on the abstract,, obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillinâtazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,621,1852268,No significant difference,"At the primary efficacy endpoint 2â4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillinâtazobactam were cured (95% confidence interval for the difference, adjusting for strata, â4% to 8.8%), indicating that cure rates for both treatment groups were equivalent.", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillinâtazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
edin,1676,4737200,Cannot tell based on the abstract,, mobility , control condition , barefoot conditions ,0,
edin,1676,4737200,No significant difference,There was no difference in the mobility or barefoot conditions in comparison to the control condition., mobility , control condition , barefoot conditions ,0,
edin,1655,2291328,Cannot tell based on the abstract,, heart rate reduction and blood pressure reduction in CIBIS-II study  , placebo , Bisoprolol ,0,
edin,1655,2291328,Significantly increased,Bisoprolol produced a significant reduction in heart rate associated with a non-significant increase in peak oxygen consumption., heart rate reduction and blood pressure reduction in CIBIS-II study  , placebo , Bisoprolol ,0,
edin,1601,5434251,Cannot tell based on the abstract,, SCS-D (self-compassion) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1601,5434251,No significant difference,"The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).", SCS-D (self-compassion) scores , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1571,4924222,No significant difference,"After adjustment for baseline measurements there was no time by treatment effect for central systolic or diastolic BP, AIx or cfPWV.", Augmentation index (AIx) , Usual diet ," Increased intake of fruits, vegetables and dairy ",0,
edin,1663,3489577,Significantly decreased,"Total-, LDL-cholesterol and waist circumference decreased significantly in the oat group compared to the control.", total cholesterol and LDL-C  , 100 grams of wheat flour-based noodles , 100 grams of instant oat cereal ,0,
edin,1647,5498096,Cannot tell based on the abstract,, pain intensity and disability index , baseline , stabilization in prone and supine group (SIPS) ,0,
edin,1647,5498096,No significant difference,"There was no significant difference when the pretreatment (F=0.57, P>0.05), 4th week (F=0.779, P>0.468) and 8 week (F=0.000, P>1.000) pain intensity and disability index were compared across the groups.", pain intensity and disability index , baseline , stabilization in prone and supine group (SIPS) ,0,
edin,1578,5074260,Cannot tell based on the abstract,, Change in levels of glycated haemoglobin after 26 weeks , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1578,5074260,Significantly decreased,"At 26âweeks, 77.6% of patients receiving IDeg and 35.5% of those receiving placebo had achieved an HbA1c level <7.0% (<53âmmol/mol); the likelihood of achieving HbA1c <7.0% was significantly higher for participants in the IDeg addâon group [odds ratio 7.79 (95% CI 4.57; 13.27); pâ<â0.0001].", Change in levels of glycated haemoglobin after 26 weeks , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1598,5434251,Cannot tell based on the abstract,, Number of practiced exercises  , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1598,5434251,No significant difference,"<td colspan=""1"" rowspan=""1"">Number of exercises practiced</td><td colspan=""1"" rowspan=""1"">7.88 (4.92)</td><td colspan=""1"" rowspan=""1"">10.06 (6.80)</td><td colspan=""1"" rowspan=""1"">62.67 (61.64)</td><td colspan=""1"" rowspan=""1"">48.71 (44.28)</td><td colspan=""1"" rowspan=""1""><italic>t</italic><sub>30</sub>=â0.72</td><td colspan=""1"" rowspan=""1"">.48</td><td colspan=""1"" rowspan=""1"">0.25 (â0.45 to 0.96)</td>,The effects of the post-hoc assessment of mindfulness home practice (number and duration of exercises practiced) and the four selected outcome questionnaires (PHQ-9, PTQ, FFA, and SCS-D) yielded near zero to small, nonsignificant effect sizes (see Table 2).", Number of practiced exercises  , Patients not receiving text message assistance during follow-up , Patients receiving text messageÃ¢â¬âbased feedback ,0,
edin,1679,4737200,Cannot tell based on the abstract,, knee adduction angular impulse (KAAI) , control condition , supported wedge ,0,
edin,1679,4737200,Significantly decreased,"For the knee adduction angular impulse (KAAI), the barefoot condition and the two lateral wedge conditions were significantly different in comparison to the control condition (barefoot â4.3%, pâ=â0.023; typical wedge â7.95%, pâ<â0.001; supported wedge â5.5%, pâ<â0.001).", knee adduction angular impulse (KAAI) , control condition , supported wedge ,0,
edin,1580,5074260,Cannot tell based on the abstract,, Overall confirmed hypoglycaemia , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1580,5074260,Significantly increased,"The number of patients experiencing confirmed hypoglycaemia during randomized treatment was higher with IDeg (17.3%) than with placebo (4.7%; Table S3, Supporting Information).", Overall confirmed hypoglycaemia , Liraglutide and metformin plus placebo , Liraglutide and metformin plus insulin degludec (IDeg) ,0,
edin,1674,4737200,Cannot tell based on the abstract,, early stance peak EKAM , control shoe , barefoot walking ,0,
edin,1674,4737200,Significantly decreased,"When we examined the effects of the conditions on measures of medial loading (Tables 1 and 2, Fig. 3), we found that barefoot walking had the greatest effect on early stance peak EKAM, lowering it by â7.6% (pâ<â0.001 vs. control shoe).", early stance peak EKAM , control shoe , barefoot walking ,0,
edin,1665,5017045,Cannot tell based on the abstract,, The mean consultation duration , standard consultation (UNN) , video-assisted remote consultations ,0,
edin,1665,5017045,No significant difference,The mean consultation duration was not significantly different between the groups (pâ=â0.60)., The mean consultation duration , standard consultation (UNN) , video-assisted remote consultations ,0,
edin,1631,3640164,Cannot tell based on the abstract,, he anesthesia-related side effects , spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1631,3640164,No significant difference,"The anesthesia-related side effects in the spinal anesthesia group were hypotension, bradycardia, shivering, vomiting, postoperative headache, and urinary retension, occurring in 15%, 10%, 5%, 5%, 10%, and 20% of patients, respectively. There was no incidence of side effects in the PSNB group, but it was not statistically significant.", he anesthesia-related side effects , spinal anesthesia with 2.5 ml of 0.5% bupivacaine   , popliteal sciatic nerve block (PSNB) with 30 ml of 0.75% ropivacaine mixed with 10 ml of normal saline solution using a nerve stimulator ,0,
edin,1554,1488892,Significantly increased,"Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively.", Increase in CD4 T lymphocyte count  , No treatment , IL-2 injection at 4.5 MIU dose ,0,
edin,1648,5498096,Cannot tell based on the abstract,, pain intensity and functional disability , stabilization in supine (SIS) or prone and supine (SIPS) position group , stabilization in prone (SIP) ,0,
edin,1648,5498096,No significant difference,"There was no significant difference when the pretreatment (F=0.57, P>0.05), 4th week (F=0.779, P>0.468) and 8 week (F=0.000, P>1.000) pain intensity and disability index were compared across the groups.", pain intensity and functional disability , stabilization in supine (SIS) or prone and supine (SIPS) position group , stabilization in prone (SIP) ,0,
edin,1656,2291328,Cannot tell based on the abstract,," heart rate, hospital admission, sudden cardiac death, hospital admission for worsening heart failure in CIBIS-II study  ", placebo , Bisoprolol ,0,
edin,1656,2291328,Significantly decreased,"Bisoprolol significantly reduced cardiovascular mortality (HR: 0.71 [0.56â0.9]), sudden cardiac death (HR: 0.56 [0.39â0.80]), hospital admission (HR: 0.80 [0.71â0.91]), and hospital admission for worsening heart failure (HR: 0.64 [0.53â0.79]) compared with placebo."," heart rate, hospital admission, sudden cardiac death, hospital admission for worsening heart failure in CIBIS-II study  ", placebo , Bisoprolol ,0,
edin,1584,5642191,Cannot tell based on the abstract,, SDQ change scores , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1584,5642191,No significant difference,"There were no differences in any of the SDQ change scores from pre to post between the fish and meat or fish and supplement group, neither before nor after adjusting for the participantsâ baseline scores or baseline and compliance scores (Table 2).Table 2.", SDQ change scores , Lunch meals with meat (meat group) or lunch meals with n-3 LCPUFAs supplements (supplements group) , Lunch meals with fatty fish (fish group) ,0,
edin,1555,1488892,Significantly increased,"Compared to the control group, significant increases in CD4 cell count were observed for both IL-2 dose groups: 104.2/mm3 (p = 0.008) and 128.4 cells/mm3 (p = 0.002) for the 4.5 and 7.5 MIU dose groups, respectively.", Increase in CD4 T lymphocyte count  , No treatment , IL-2 injection at 7.5 MIU dose ,0,
edin,1636,5420386,Cannot tell based on the abstract,, all of the scales , placebo , oral administration of 100 and 200&amp;amp;amp;amp;amp;nbsp;ÃÂ¼g LSD ,0,
edin,1636,5420386,Significantly increased,"<td colspan=""5"">MEQ30</td>", all of the scales , placebo , oral administration of 100 and 200&amp;amp;amp;amp;amp;nbsp;ÃÂ¼g LSD ,0,
edin,1537,5941723,Cannot tell based on the abstract,, Severe adverse events , Placebo , Acupuncture ,0,
edin,1537,5941723,No significant difference,There were no critical adverse events., Severe adverse events , Placebo , Acupuncture ,0,
edin,1616,3430047,Cannot tell based on the abstract,, PHS criteria and bupivacaine consumption , subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine) , subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine) ,0,
edin,1616,3430047,Significantly decreased,"Supplemental opioid demand, PHS criteria and bupivacaine consumption were statistically significant, as, rate of IV opioid consumption, PHS criteria and bupivacaine consumption in SPCA group was significantly lower than in SIA group. (Table 2).", PHS criteria and bupivacaine consumption , subpleural intermittent analgesia (SIA) (0.1cc/kg/6h of 0.5% bupivacaine) , subpleural patient-controlled analgesia (SPCA) (0.02 cc/kg/h of 0.5% bupivacaine) ,0,
edin,1649,2856148,Cannot tell based on the abstract,, acute exacerbation of COPD , Pressure support ventilation (PSV) , Noninvasive ventilation (NIV) ,0,
edin,1649,2856148,No significant difference,"No significant difference between the two groups in duration of MV (6.20 Â± 5.20 days vs. 7.47 Â± 6.38 days, P > 0.05), duration of weaning (35.17 Â± 16.98 and 47.05 Â± 20.98 hours, P > 0.05) or duration of ICU stay (8.47 Â± 4.79 and 10.80 Â± 5.28 days, P > 0.05) in Gp I and Gp II, respectively.", acute exacerbation of COPD , Pressure support ventilation (PSV) , Noninvasive ventilation (NIV) ,0,
edin,1596,2911596,Cannot tell based on the abstract,," HR, MAC and SE values after fentanyl boluses ", Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1596,2911596,No significant difference,"MAC and SE values were similar in SEVO and ISOF groups before fentanyl boluses [0.74 Â± 0.12 versus 0.77 Â± 0.17, (P = .32) and 43.5 Â± 8.1 versus 45.2 Â± 8.3, (P = .47), resp.]."," HR, MAC and SE values after fentanyl boluses ", Isoflurane-fentanyl anesthesia , Sevoflurane-fentanyl anesthesia ,0,
edin,1573,5791393,Cannot tell based on the abstract,, Pain intensity , Without catheter (group I) , With catheter (group II) ,0,
edin,1573,5791393,Significantly increased,It was confirmed that the catheterised patients had sensed more intensive pain than the non-catheterised subjects., Pain intensity , Without catheter (group I) , With catheter (group II) ,0,
edin,1721,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1845,5599918,Cannot tell based on the abstract,, Total dose of remifentanil , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1845,5599918,Significantly increased,"Apart from the total administered dose of remifentanil and ephedrine, there were no significant differences among the 3 groups. The total administered dose of remifentanil was higher in the IV-PCA group than in the E-PCA and dIV-PCA groups (Bonferroni corrected P = 0.017 and P < 0.001, respectively).", Total dose of remifentanil , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1688,5362210,Cannot tell based on the abstract,, Risk of severe brain injury or death , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1688,5362210,Significantly decreased,"Correlation analyses of the following variables showed a significant correlation (p<0.05) between gestational age, birth weight, clinical chorioamnionitis, surfactant, mechanical ventilation, use of vasopressors, blood transfusions, and the burden of cerebral hypoxia within the 4th quartile on one hand and the composite outcome of severe brain injury or death on the other.,As described in the methods, centre, gestational age below 26 weeks, and intervention were forced-entry variables in the model. The following variables remained statistically significant: intervention (OR (95% CI) 0.29 (0.12â0.69; p = 0.003,)), gestational age below 26 weeks (3.33 (1.38â8.06; p = 0.007)), use of vasopressors (3.26 (1.26â8.44; p = 0.014)), and blood transfusion (2.97 (1.22â7.23; p = 0.016)).", Risk of severe brain injury or death , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1797,4900317,No significant difference,"During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 Â± 0.94 mg vs. 18.83 Â± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 Â± 10 min vs. 195 Â± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in ICU or hospital stay duration.", Wound infection incidence , Presternal catheter with continuous saline infusion (Group C) , Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B) ,0,
edin,1716,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1694,3600348,Significantly increased,Five (83%) of the patients who failed the SBT in ATC group were reintubated. This represented a higher negative predictive value for ATC of 83% than for PSV which was 56%, Causes of reintubation , Pressure support ventilation , Automatic tube compensation ,0,
edin,1844,5599918,Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group."," Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries ", Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1745,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1745,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1809,3154934,Cannot tell based on the abstract,, Baseline characteristics , Placebo  , Vitamin A supplementation (VAS) ,0,
edin,1809,3154934,No significant difference,"There were no baseline differences between the children who had received neonatal VAS or placebo, continued to live in the study area and were met at follow-up (Table 1).", Baseline characteristics , Placebo  , Vitamin A supplementation (VAS) ,0,
edin,1753,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1753,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531).", Subjective well-being , Placebo , Haloperidol ,0,
edin,1766,4526979,Cannot tell based on the abstract,, Treatment categories change scores , Nonusers , Website users ,0,
edin,1766,4526979,No significant difference,"Summary change scores for treatment categories were also obtained. Between the intervention group and nonusers, there were minimal differences that did not reach statistical significance in core treatments (change scores 10.3% vs 4.7%, P=.17), adjunct treatments (change scores 3.1% vs 1.2%, P=.54), pharmacological treatments (change scores â1.7% vs â2.4%, P=.35), and nonpharmacological treatments (change scores 9.5% vs 4.0%, P=.29).", Treatment categories change scores , Nonusers , Website users ,0,
edin,1709,5742644,Cannot tell based on the abstract,, Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1709,5742644,No significant difference,Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâs > 0.093)., Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1722,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1722,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1697,4045368,Cannot tell based on the abstract,, Severity of the tibial plateau fractures , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1697,4045368,No significant difference,No significant differences were found between the two groups in the severity of the tibial plateau fractures according to the Schatzker (P = 0.556) or AO (P = 0.257) classifications systems (Figures 2 and 3)., Severity of the tibial plateau fractures , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1689,5362210,Significantly increased,"Significantly more infants with a cerebral burden of hypoxia within the 4th quartile versus infants within quartile 1â3 were diagnosed with severe intracranial haemorrhage (11/39 versus 11/117, p = 0.003), had low burst rate on EEG (12/28 versus 21/103, p = 0.015), or died (14/41 versus 18/123, p = 0.006), whereas none of these events were significantly associated with cerebral hyperoxia.", Burden of hypoxia within the 4th quartile versus quartile 1Ã¢â¬â3 , Blinded collection of NIRS values combined with treatment as usual , Cerebral NIRS monitoring in combination with an evidence based intervention guideline ,0,
edin,1821,5003869,Cannot tell based on the abstract,," Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1821,5003869,No significant difference,"For patients starting with RAS-inhibitors 22.6% of the patients in the intervention arm discontinued therapy compared to 27.9% of patients with usual care which is significantly lower (HR 0.77, 95% CI 0.69, 0.91). The result of the PP-analysis is comparable but not statistically significant. For statins and bisphosphonate users, discontinuation rates were not significantly different (HR 0.87, 95% CI 0.73, 1.10, respectively 0.73, 95% CI 0.56, 1.02)."," Therapy discontinuation in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1707,5556332,Cannot tell based on the abstract,, Satisfaction with pain control as reported by surgeons , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1707,5556332,Significantly increased,Surgeons reported more satisfaction with pain control in the medication group in 24 and 48 hours after surgery (P = 0.001) (Table 2)., Satisfaction with pain control as reported by surgeons , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1704,5556332,Significantly decreased,"Patients in the PAN group had significantly lower UPAT scores at 0, 2, 4, 6, 12, 24 and 48 hours after the surgery than those in the control group (P = 0.008, 0.021, 0.008, 0.047, 0.004, 0.001, and 0.001).", UPAT scores , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1817,5003869,Cannot tell based on the abstract,, Mean adherence rates , Usual care , Pharmacist telephone counseling ,0,
edin,1817,5003869,No significant difference,In the overall ITT analysis we found a mean adherence rate (MPRm) of 74.7% (SD 37.5) for intervention patients and 74.5% (SD 37.9) for control patients (see Table 2)., Mean adherence rates , Usual care , Pharmacist telephone counseling ,0,
edin,1759,4199180,Cannot tell based on the abstract,, Rate of morbidity and complications , Pentoxifylline alone (Group 1) , Pentoxifylline plus prednisolone (Group 2) ,0,
edin,1759,4199180,No significant difference,The morbidity/complication profiles among the two groups were comparable [Table 2]., Rate of morbidity and complications , Pentoxifylline alone (Group 1) , Pentoxifylline plus prednisolone (Group 2) ,0,
edin,1720,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1720,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1727,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1727,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1727,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1729,5742644,Cannot tell based on the abstract,, Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1729,5742644,No significant difference,Separate post hoc t-tests for each context revealed no difference between both stimulation outcomes (all pâs > 0.093)., Stimulation outcomes , Placebo , Haloperidol ,0,
edin,1802,4900317,No significant difference,"During the postoperative 48 h, there was marked reduction in morphine requirements in Group B compared to Group C, (8.6 Â± 0.94 mg vs. 18.83 Â± 3.4 mg respectively, P = 0.2), lower postoperative pain scores, shorter extubation time (117 Â± 10 min vs. 195 Â± 19 min, respectively, P = 0.03), better respiratory parameters (PaO2/FiO2, PaCO2 and pH), with no incidence of wound infection, no differences in ICU or hospital stay duration.", Wound infection incidence , Presternal catheter with continuous saline infusion (Group C) , Presternal catheter with continuous infusion of 5 mL/h bupivacaine 0.25% (Group B) ,0,
edin,1836,5599918,Cannot tell based on the abstract,, Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1836,5599918,Significantly decreased,"In addition, the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).", Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1696,4045368,Cannot tell based on the abstract,, Follow-up duration , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1696,4045368,No significant difference,"No difference was observed in the duration of follow-up between the locking plate and nonlocking plate groups (10.61 Â± 3.05 months versus 12.95 Â± 2.63 months, P = 0.158).", Follow-up duration , Nonlocking plate fixation , Locking plate fixation ,0,
edin,1765,4526979,No significant difference,"With the exception of health service navigation, mean effect sizes from all other heiQ domains showed a positive trend for My Joint Pain users compared to the nonusers, although the differences between groups did not reach statistical significance.", Domains examined for the heiQ , Nonusers , Website users ,0,
edin,1728,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1728,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531)", Subjective well-being , Placebo , Haloperidol ,0,
edin,1841,5599918,Cannot tell based on the abstract,, Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1841,5599918,Significantly decreased,"In addition, the patients in the E-PCA group required more ephedrine than those in the IV-PCA group (8.4 Â± 9.1 vs. 4.0 Â± 4.8 Î¼g; Bonferroni corrected P = 0.013).", Total dose of ephedrine , Conventional thoracic epidural patient-controlled analgesia (E-PCA group) , Fentanyl-based IV-PCA only (IV-PCA group) ,0,
edin,1782,5697397,Significantly increased,Native whey ingestion induced a greater phosphorylation of p70S6K than milk 180Â min after exercise (Pâ=â0.03)., Phosphorylation of p70S6K 3 hours after exercise , Milk protein  , Native whey protein ,0,
edin,1813,5003869,Cannot tell based on the abstract,"Comparing patients with counseling to patients with usual care (per protocol analysis), adherence was statistically significant higher for patients starting with RAS-inhibitors, statins and bisphosphonates."," Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1813,5003869,No significant difference,"The mean adherence rate in patients in the intervention arm starting with RAS-inhibitors was 84.1% (SD 31.6) compared to 78.5% (SD 36.6) in the usual care arm which is a significant improvement with a adherence difference based on mixed-effect models of 5.16% (95% CI 1.17, 10.03) (See,In statin users, patients in the intervention arm had a mean adherence rate of 80.5% (32.4) compared to 75.1% (36.8) in the usual care arm, which is a non-significant adherence difference of 4.08% (95% CI â0.81, 6.62).,n patients starting with bisphosphonates, the mean adherence rate in intervention arm (75.2%) was not different from the usual care arm (73.3%) neither was the proportion of adherent patients (70.2% respectively 67.1%)."," Adherence in patients starting with RAS-inhibitors, statins and bisphosphonates. ", Usual care , Pharmacist telephone counseling ,0,
edin,1780,4137650,Significantly decreased,The rise in HR (P = 0.08481) and rate pressure product (P = 0.0666) at the time of intubation were minimal and was statistically significant up to 15 min in Group D., Mean rate pressure product up to 15 min after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1718,5742644,Cannot tell based on the abstract,, Subjective well-being , Placebo , Haloperidol ,0,
edin,1718,5742644,No significant difference,"The 2 Ã 3 ANOVA on subjective well-being (mean rating across seven side effects) with drug (placebo/haloperidol) and time (before drug intake, after 2.5 h, at the end) revealed neither a main effect of drug nor an interaction between time and drug (all pâs > 0.531).", Subjective well-being , Placebo , Haloperidol ,0,
edin,1705,5556332,Significantly decreased,The mean dose of postoperative morphine consumption in the PAN group was 37% less than the control group (P = 0.001)., Consumption of morphine after the surgery , No PAN administered before the surgery ," Combination of pregabalin, acetaminophen, and naproxen (PAN) before the surgery ",0,
edin,1755,5742644,Cannot tell based on the abstract,, Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1755,5742644,No significant difference,"Under haloperidol, however, there was no significant habituation from phase I to phase III.", Habituation from phase I to phase III , Placebo , Haloperidol ,0,
edin,1756,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1711,5742644,No significant difference,"Finally, there were no adaptive coding effects in any brain regions.", Brain regions with adaptive coding  , Placebo , Haloperidol ,0,
edin,1837,5599918,Significantly decreased,"The postoperative pain intensity was significantly lower in the dIV-PCA and E-PCA groups than in the IV-PCA group, but comparable between the dIV-PCA group and the E-PCA group.", Pain intensity after surgery , Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1834,5599918,Significantly decreased,"Patients in the dIV-PCA and E-PCA groups needed significantly fewer additional analgesic rescues between 6 and 24 hours after surgery, and had a significantly lower number of bolus attempts and bolus deliveries during the first 24 hours after surgery than those in the IV-PCA group."," Need for additional analgesic rescues, number of bolus attempts, and bolus deliveries ", Fentanyl-based IV-PCA only (IV-PCA group) , Dexmedetomidine plus fentanyl-based IV-PCA (dIV-PCA group) and Conventional thoracic epidural patient-controlled analgesia (E-PCA group) ,0,
edin,1786,4878364,Significantly increased,"When compared to the control group, the exercise group experienced significant improvements in gait speed (F(4.078) = 8.265, p = 0.007),", Gait speed , No exercise , Exercise program ,0,
edin,1778,4137650,Significantly increased,The mean arterial pressure was significantly increased in patients receiving placebo (P < 0.0001) and esmolol (P < 0.0001) after laryngoscopy and intubation compared with baseline value and Group D (P = 0.6294). T, Mean systolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1792,3798206,Significantly increased,"In the pooled analysis of individual patient data comparing dabigatran with warfarin (SPAF and venous thromboembolism treatment indications), myocardial infarction occurrence favored warfarin (odds ratio [OR] 1.30, 95% confidence interval [CI] 0.96â1.76 for dabigatran 110 mg twice daily and OR 1.42, 95% CI 1.07â1.88 for dabigatran 150 mg twice daily).", Rates of myocardial infarction  , Warfarin , Dabigatran ,0,
edin,1814,5003869,Cannot tell based on the abstract,, Adherence in patients starting with antidepressants , Usual care , Pharmacist telephone counseling ,0,
edin,1814,5003869,No significant difference,"For antidepressants we found no significant difference in adherence rate between patients in the intervention arm (62.7% SD 41.7) and patients with usual care (66.8%, 40.9).", Adherence in patients starting with antidepressants , Usual care , Pharmacist telephone counseling ,0,
edin,1808,111193,Cannot tell based on the abstract,, Hospital stay , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1808,111193,No significant difference,Fifty percent in the ANH group received homologous blood transfusion during the hospital stay (771 mL pr. patient transfused) vs. 42 % in non-ANH group (800 mL pr. patient transfused) (ns)., Hospital stay , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1763,4526979,No significant difference,"Following 12 months of exposure to the website, there were significant improvements for users compared to nonusers in self-management (absolute change score 15% vs 2%, P=.001) and weight reduction (absolute change scores 3% vs â6%, P=.03) measured on the OAQI."," Self-management as measured on the OAQI, after 12 months ", Nonusers , Website users ,0,
edin,1822,3388481,Significantly increased,In the control group (n = 122) 27.3% (n = 33) had a statistically significant lower successful ECV procedure than NLP (P = 0.05) and hypnosis and NLP (P = 0.03)., Success of external cephalic version (ECV) procedure , Standard medical care alone , Hypnosis and Neurolinguistic Programming (NLP) ,0,
edin,1826,4733710,Cannot tell based on the abstract,, Hemoglobin at day 1 after surgery , Control group , Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group ,0,
edin,1826,4733710,No significant difference,"Peri-operative Transfusion Trigger Score of Emergency group and control group were compared in age, gender, body mass index, ASA score, and operation area; Heart rate, mean arterial pressure, SpO2, body temperature, and shock index when entering into the operation room; there was no statistical difference between the two groups for Hb values and APACHE II scores after entering into the operation room,Table 4
The two groups of patients are compared in vital signs and Hb (mean Â± SD)", Hemoglobin at day 1 after surgery , Control group , Peri-operative Transfusion Trigger Score of Emergency [POTTS-E] group ,0,
edin,1831,2967098,No significant difference,Comparison of the improvement rate in both study groups revealed no significant difference., Improvement rate , Low dose (5 mg/day) haloperidol , High dose (20 mg/day) haloperidol ,0,
edin,1767,4780150,No significant difference,"fter intervention, total body stores (TBS) and liver retinol concentrations did not differ between intervention and control groups;", Total body stores of vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ without vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ with vitamin A ,0,
edin,1768,4780150,No significant difference,"After intervention, total body stores (TBS) and liver retinol concentrations did not differ between intervention and control groups;", Vitamin A concentrations in the liver , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ without vitamin A , Sachets of Ã¢â¬ÅSprinklesÃ¢â¬ï¿½ with vitamin A ,0,
edin,1757,5742644,Cannot tell based on the abstract,, Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1757,5742644,No significant difference,"The mean proportion of hits for each condition is displayed in Table 3. A 2 Ã 3 Ã 2 way ANOVA on the mean hit rate revealed no main effect of stimulation magnitude, drug treatment and there was no interaction between any factors (all pâs > 0.081).", Discrimination between stimulation intensities , Placebo , Haloperidol ,0,
edin,1805,111193,Cannot tell based on the abstract,, Surgery duration , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1805,111193,No significant difference,Time used for anaesthesia (from patient enters the operating theatre to entering the recovery room) and duration of surgery was identical between groups., Surgery duration , No preoperative hemodilution (non-ANH) , Preoperative acute normovolaemic hemodilution (ANH) ,0,
edin,1779,4137650,Cannot tell based on the abstract,, Mean diastolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1779,4137650,Significantly increased,The DAP levels in Group D were significantly lower than Groups C and E at all times after intubation., Mean diastolic arterial pressure after intubation , Dexmedetomidine (Group D) , Placebo (Group C) and esmolol (Group E) ,0,
edin,1853,5145296,Cannot tell based on the abstract,, chronic cough ," PPIs, lifestyle changes, and placebo "," PPIs, lifestyle changes, and daily zinc capsules ",0,
edin,1853,5145296,Significantly decreased,"Based on the results obtained byFisherâs exact test, the statistical difference between the drug and placebo groups in terms of presentationsâ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).,<td colspan=""1"" rowspan=""1"">Chronic cough</td><td colspan=""1"" rowspan=""1"">50 (71.4)</td><td colspan=""1"" rowspan=""1"">12 (17.1)</td><td colspan=""1"" rowspan=""1"">0.001</td><td colspan=""1"" rowspan=""1"">44 (62.9)</td><td colspan=""1"" rowspan=""1"">26 (37.1)</td><td colspan=""1"" rowspan=""1"">0.001</td>", chronic cough ," PPIs, lifestyle changes, and placebo "," PPIs, lifestyle changes, and daily zinc capsules ",0,
edin,2071,3835146,Cannot tell based on the abstract,, C3 levels , placebo ," atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 Ãâ 9 mg/kg) ",0,
edin,2071,3835146,No significant difference,"C3 levels remained within the normal range throughout the study for most patients. At baseline, only three of 24 patients had C3 values below the normal range (0.9â1.8 g/L): one patient in the 9 mg/kg group, one patient in the 18 mg kg group and one patient in the 2 Ã 9 mg/kg group. All three of these patients showed transient increases in C3 to normal levels during treatment.", C3 levels , placebo ," atacicept (single dose: 3, 9 or 18 mg/kg; or multiple dose: 2 Ãâ 9 mg/kg) ",0,
edin,1971,4404560,Cannot tell based on the abstract,, the falls rate in the women only , routine activity , exercise  ,0,
edin,1971,4404560,No significant difference,There was no significant difference in the falls rate reduction in the women only analysis compared to the overall group., the falls rate in the women only , routine activity , exercise  ,0,
edin,2060,5404215,Cannot tell based on the abstract,, flow-mediated dilation (FMD) score at 240 min postconsumption , baseline , 3 ounces (85 g) ground peanuts ,0,
edin,2060,5404215,No significant difference,There were no significant differences in FMD between baseline and 240 min postconsumption of the peanut shake (Figure 2)., flow-mediated dilation (FMD) score at 240 min postconsumption , baseline , 3 ounces (85 g) ground peanuts ,0,
edin,2054,3793419,Cannot tell based on the abstract,, burning sensation ," Group 2-Patients were administered 0.5 ml intralesional injection Hyaluronidase 1,500 IU and 0.5 ml intralesional injection Hydrocortisone acetate 25 mg/ml in each buccal mucosa once a week "," tablet colchicine orally, 0.5 mg twice daily and 0.5 ml intralesional injection Hyaluronidase 1,500 IU into each buccal mucosa once a week ",0,
edin,2054,3793419,No significant difference,Almost all the patients in both the groups were relieved from burning sensation after treatment., burning sensation ," Group 2-Patients were administered 0.5 ml intralesional injection Hyaluronidase 1,500 IU and 0.5 ml intralesional injection Hydrocortisone acetate 25 mg/ml in each buccal mucosa once a week "," tablet colchicine orally, 0.5 mg twice daily and 0.5 ml intralesional injection Hyaluronidase 1,500 IU into each buccal mucosa once a week ",0,
edin,1900,5045666,Significantly increased,"The mean serum levels of both HDL-C and vitamin D showed a significant rise following the treatment in the study group (P = 0.007 and P < 0.001, respectively), whereas both variables decreased slightly in the control group (P = 0.27).", Mean serum levels of vitamin D , Placebo , Vitamin D supplement ,0,
edin,1925,4374260,Significantly decreased,Postmicturition dribble annoyed 12.8% of those who received 50 mg tramadol and 33.6% of those who received 100 mg tramadol (P < 0.001)., Postmicturition dribble , placebo  , 50 mg of tramadol and 100 mg of tramadol ,0,
edin,1973,5376493,Significantly increased,"Non-technical skills concerning situation awareness (p<.01, r=0.5) and teamwork (p<.01, r=0.45) improved from simulation I to II in the NTS group.", Non-technical skills concerning situation awareness and teamwork , medical seminar , non-technical skills seminar ,0,
edin,1913,5630555,No significant difference,"Although the titers of GADAb were not significantly different between the S and P groups during the study, the change ratio of the GADAb titers from baseline was significantly inversely correlated with the change ratio of the âC-peptide values from baseline in the S group (pÂ =Â 0.003); in particular, when the GADAb titers decreased from baseline, the âC-peptide values frequently increased.", The titers of GADAb , pioglitazone , sitagliptin ,0,
edin,1891,3687261,Cannot tell based on the abstract,, incremental areas under the curve ," placebo and sucralose, or sitagliptin and sucralose "," placebo and d-xylose, or sitagliptin and d-xylose ",0,
edin,1891,3687261,Invalid Prompt,, incremental areas under the curve ," placebo and sucralose, or sitagliptin and sucralose "," placebo and d-xylose, or sitagliptin and d-xylose ",1, incremental areas under the curve is mentioned in the methods section of the article. I was not able to find any data in results or conclusion section
edin,2093,5452066,Cannot tell based on the abstract,, Median OS , topotecan , PM01183 ,0,
edin,2093,5452066,No significant difference,"Median OS was 9.7âmonths (95% CI, 7.7â19.3âmonths) with PM01183, and 8.5âmonths (95% CI, 3.3â15.6âmonths) with topotecan (Pâ=â0.2871).", Median OS , topotecan , PM01183 ,0,
edin,2081,4628236,Cannot tell based on the abstract,, the slope of EDPVR , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2081,4628236,Significantly decreased,"In comparison with Co group the slope of EDPVR tended to increase (PÂ =Â 0.063) in diabetic animals, which was significantly reduced by cinaciguat (Fig.Â 6b).", the slope of EDPVR , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2039,4882968,No significant difference,"Before intervention, mean severity of mania in the experimental group (23.50 Â± 7.02) and control group (23.70 Â± 8.09) was not significant (P â¤ 0.89).", mean severity of mania , placebo , omega-3 supplement ,0,
edin,1999,5012042,No significant difference,"Circumferential and radial strains derived from FG acquisitions were slightly reduced compared to NF acquisitions (â16âÂ±â2Â % vs â17âÂ±â2Â %, pâ<â0.001; 40âÂ±â10Â % vs 44âÂ±â11Â %, pâ=â0.005, respectively).", Circumferential and radial strains , underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF)  , underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG) ,0,
edin,1901,5045666,Cannot tell based on the abstract,, Baseline levels of high-density lipoprotein cholesterol (HDL-C) and vitamin D , Placebo , Vitamin D supplement ,0,
edin,1901,5045666,No significant difference,"There was no statistically significant difference in the mean serum levels of HDL-C and vitamin D between the two groups after the intervention (P = 0.11 and P = 0.20, respectively).", Baseline levels of high-density lipoprotein cholesterol (HDL-C) and vitamin D , Placebo , Vitamin D supplement ,0,
edin,2079,4628236,Cannot tell based on the abstract,, Expression of MMP-9 and MMP-2 , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2079,4628236,No significant difference,"DM was associated with dysregulation of the MMP system indicated by markedly increased MMP-9/TIMP-1 and reduced MMP-2/TIMP-2 gene expression ratios (Fig.Â 4a).,Expression of MMP-9 showed a twofold increase in DM, while MMP-2 remained unchanged (Fig.Â 4c).,Cinaciguat did not significantly alter these parameters (Fig.Â 4c).", Expression of MMP-9 and MMP-2 , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2059,3655565,Cannot tell based on the abstract,," heart rate, respiratory rate, mean arterial pressure, peripheral oxygen saturation [SpO2], tidal volumes [V T], minute ventilation [V E], dynamic lung compliance [Cdyn], and rapid shallow breathing index the ratio of the frequency of breathing (f) divided by the tidal volume (V T) ", standard care  , two-day adjunctive acupressure with standard care  ,0,
edin,2059,3655565,No significant difference,"As Table 2 shows, there were no statistically significant differences between the three treatment arms on the outcome variables of interest at baseline.,To the best of our knowledge, this trial was the first to investigate the potential benefits of adjunctive acupressure on weaning indices in a group of stable, mechanically ventilated coma patients."," heart rate, respiratory rate, mean arterial pressure, peripheral oxygen saturation [SpO2], tidal volumes [V T], minute ventilation [V E], dynamic lung compliance [Cdyn], and rapid shallow breathing index the ratio of the frequency of breathing (f) divided by the tidal volume (V T) ", standard care  , two-day adjunctive acupressure with standard care  ,0,
edin,2026,3178704,Cannot tell based on the abstract,," body weight, BMI, body fat, muscle mass and VFA ", baseline , diet with resistance training (RT) ,0,
edin,2026,3178704,Significantly increased,"The RT group had increases in body weight, BMI, body fat, muscle mass and VFA as measured by CT following the 12-week program."," body weight, BMI, body fat, muscle mass and VFA ", baseline , diet with resistance training (RT) ,0,
edin,1857,4223282,Cannot tell based on the abstract,, men discussing and using condoms within stable relationships , no intervention , SASA! community mobilization intervention program ,0,
edin,1857,4223282,Significantly increased,"Positive impacts include increased discussion about, and use of, condoms within regular partnerships in the past year with men in intervention communities twice as likely to report condom use with their partner at last intercourse than men in control communities (aRR 2.03, 95% CI 1.22â3.39).", men discussing and using condoms within stable relationships , no intervention , SASA! community mobilization intervention program ,0,
edin,1944,4481831,Cannot tell based on the abstract,, durations of the gait phases , baseline , after Ice application ,0,
edin,1944,4481831,Cannot tell based on the abstract,, durations of the gait phases , baseline , after Ice application ,0,
edin,1944,4481831,No significant difference,Ice application did not affect the durations of the gait phases (Table 2)., durations of the gait phases , baseline , after Ice application ,0,
edin,1889,3687261,Significantly decreased,"Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (P < 0.01 for each) and were lowest after SX (P < 0.05 for each), while overall blood glucose was lower after SX than PC (P < 0.05).", peak blood glucose , placebo and sucralose , sitagliptin and d-xylose ,0,
edin,1876,3259296,Significantly decreased,"In study 1, the 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P < 0.0001), 0-60 min (P < 0.0001, P < 0.0001), 0-90 min (P < 0.0001, P < 0.0001) and 0-120 min (P = 0.0071, P = 0.0016). In study 2, the test meal exhibited significantly lower AUCg and AUCi values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P = 0.0005), 0-60 min (P = 0.0002, P = 0.0025), and 0-90 min (P = 0.0396, P = 0.0246)."," AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, and 0-90 min in study 2 ", sucrose-containing meal , xylose-containing test meal ,0,
edin,1881,5291156,Cannot tell based on the abstract,, pain evaluated by VAS in the presence of sedation , lidocaine spray and viscous solution , lidocaine spray ,0,
edin,1881,5291156,No significant difference,"There were almost no differences in pain evaluated by VAS (2.27âÂ±â2.88 vs. 2.33âÂ±â2.63, Pâ=â0.85), pharyngeal observation time (72.0âÂ±â34.7 vs. 67.0âÂ±â27.8 seconds, Pâ=â0.15), and the number of gag reflexes (2.12âÂ±â2.58 vs. 1.68âÂ±â2.27, Pâ=â0.10) in the two groups.,Subgroup analysis for presence of sedation (223 cases) revealed almost no differences between the 2 groups in the number of pharyngeal observation sites (8.48âÂ±â2.16 vs. 8.79âÂ±â1.85, Pâ=â0.25), pain evaluated by VAS (1.08âÂ±â2.06 vs. 1.33âÂ±â2.16, Pâ=â0.79), pharyngeal observation time (73.3âÂ±â36.6 vs. 68.3âÂ±â30.9 seconds, Pâ=â0.14), and number of gag reflexes (2.02âÂ±â2.44 vs. 1.86âÂ±â2.45, Pâ=â0.63) (Tableâ4).", pain evaluated by VAS in the presence of sedation , lidocaine spray and viscous solution , lidocaine spray ,0,
edin,1916,3276929,Significantly decreased,Morning stiffness decreased more (P<0.001) in yoga (post 1=68.6% and post 2=98.1%) than control group (post 1=38.6% and post 2=71.6%)., Morning stiffness in participants with OA knees , control , yoga ,0,
edin,1855,5145296,Cannot tell based on the abstract,, foreign body sensation ," PPIs, lifestyle changes, and placebo "," PPIs, lifestyle changes, and daily zinc capsules ",0,
edin,1855,5145296,Significantly increased,"Based on the results obtained byFisherâs exact test, the statistical difference between the drug and placebo groups in terms of presentationsâ frequencies was statistically significant in 6 items: Throat cleansing (p=0.05), chronic cough (p=0.04), postnasal drip (p=0.03), foreign body sensation (p=0.003), heart burn (p=0.003), and otitis media (p=0.003).", foreign body sensation ," PPIs, lifestyle changes, and placebo "," PPIs, lifestyle changes, and daily zinc capsules ",0,
edin,1940,5340016,Significantly decreased,"However, weekly PE has a higher response rate and superior down-staging effects.", down-staging effect , weekly paclitaxelÃ¢â¬âepirubicin (PE) regimen , receive 4Ã¢â¬â6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilÃ¢â¬âepirubicinÃ¢â¬âcyclophosphamide (FEC) regimen ,0,
edin,2072,3921228,Significantly increased,Significant pre-post scan decreases in anxiety ratings and increases in happiness ratings were evident in the experimental versus control group., happiness  , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,1992,3232004,Cannot tell based on the abstract,, The response rate , placebo , sertraline ,0,
edin,1992,3232004,No significant difference,"The response rate was slightly higher for sertraline than for placebo, but this difference was not statistically significant (25/43 (58%) vs 18/46 (39%) responders, Ï2(1)=1.39, P=0.24).", The response rate , placebo , sertraline ,0,
edin,1976,5376493,Cannot tell based on the abstract,," Ã¢â¬Ëcommand roles and responsibilitiesÃ¢â¬â¢, Ã¢â¬Ëspeaking upÃ¢â¬â¢, Ã¢â¬ËdebriefingÃ¢â¬â¢, Ã¢â¬Ëfeedback and critiqueÃ¢â¬â¢, Ã¢â¬Ërealistic appraisal of stressÃ¢â¬â¢, and Ã¢â¬Ëdenial of stressÃ¢â¬â¢ ", medical seminar , non-technical skills seminar ,0,
edin,1976,5376493,No significant difference,"Data for âcommand roles and responsibilitiesâ, âspeaking upâ, âdebriefingâ, âfeedback and critiqueâ, ârealistic appraisal of stressâ, and âdenial of stressâ showed no significant effects between or within groups over time (.06"," Ã¢â¬Ëcommand roles and responsibilitiesÃ¢â¬â¢, Ã¢â¬Ëspeaking upÃ¢â¬â¢, Ã¢â¬ËdebriefingÃ¢â¬â¢, Ã¢â¬Ëfeedback and critiqueÃ¢â¬â¢, Ã¢â¬Ërealistic appraisal of stressÃ¢â¬â¢, and Ã¢â¬Ëdenial of stressÃ¢â¬â¢ ", medical seminar , non-technical skills seminar ,0,
edin,1886,4188762,Cannot tell based on the abstract,, heart rate ," normal saline, lidocaine, or ketamine ", remifentanil ,0,
edin,1886,4188762,No significant difference,There were no significant differences in mean blood pressure and heart rate before injection of pretreatment drugs among the groups (Figs. 1 and 2)., heart rate ," normal saline, lidocaine, or ketamine ", remifentanil ,0,
edin,2095,5360580,No significant difference,"In an intention-to-treat analysis including both mild AD (20Â â¤Â MMSE-JÂ â¤Â 23) and MCI (24Â â¤Â MMSE-JÂ â¤Â 27), no significant difference was shown between the treatment and placebo groups in the primary and secondary outcomes, with no severe adverse events in either group.", occurrence of adverse events , placebo , 1 mg/day of Pls purified from scallop ,0,
edin,1996,5808396,No significant difference,"Participants receiving CPT experienced moderate reductions in felt stigma relative to those in individual support (Cohenâs Dâ=â0.44, pâ=âvalueâ=â0.02) following the end of treatment, though this difference was no longer significant six-months later (Cohenâs Dâ=â0.45, pâ=âvalueâ=â0.12).", felt stigma after 6 months of treatment , baseline , Cognitive Processing Therapy or individual support ,0,
edin,1965,4723180,Cannot tell based on the abstract,, passive drag ," Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head. "," Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerÃ¢â¬â¢s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head. ",0,
edin,1965,4723180,Significantly decreased,"Regarding the swimmerâs head position, passive drag was found to be significantly lower in the LA condition (with the arms in front of the head) for the HD and HM than the HU at all speeds (Figure 2).", passive drag ," Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head. "," Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerÃ¢â¬â¢s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head. ",0,
edin,1951,3085176,Significantly increased,"In the group receiving 100 mg hesperidin in addition to the 50 mg p-synephrine plus 600 mg naringin, the RMR increased by 183 kcal, an increase that was statistically significant with respect to the placebo control (p<0.02).", Resting metabolic rates (RMR) , placebo , 1000 mg hesperidin with 50 mg p-synephrine plus 600 mg naringin ,0,
edin,1932,4175246,Cannot tell based on the abstract,, anterior reach , baeeline , control group ,0,
edin,1932,4175246,Significantly increased,"After the intervention, anterior reach was significantly higher (p<0.05) in the control group.", anterior reach , baeeline , control group ,0,
edin,1959,4048120,Significantly increased,"At the moment of prosthetic loading, keratinized mucosa width and probing depth were higher in immediate implants than delayed implants, with statistically significant differences.", Keratinized mucosa width , implants were placed in healed sites , received implants immediately after extraction ,0,
edin,2094,5360580,Significantly increased,Patients with mild AD showed a significantly greater decrease in plasma PlsPE in the placebo group than in the treatment group., Plasma PlsPE , placebo , 1 mg/day of Pls purified from scallop ,0,
edin,2003,4845428,Significantly decreased,The levels of decompression determined by MRI + (PM or DTI) in the experimental group were significantly less than that determined by MRI + NE in the control group (pâ=â0.000)., levels of decompression  ,  MRI + NE , MRI + (PM or DTI) ,0,
edin,2032,4747995,No significant difference,"Productsâ systemic exposures were comparable, with 90Â % CIs around ratios for AUCinf (0.96; 90Â % CI 0.88â1.04) and Cmax (1.04; 90Â % CI 0.98â1.11) within standard bioequivalence bounds (90Â % CI 0.80â1.25).", Cmax , ch14.18-NCI , ch14.18-UTC ,0,
edin,2105,4760045,Significantly decreased,Postoperative VAS value at 18 h were significantly lower in group RD (P < 0.05)., VAS score , 30 ml 0.5% ropivacaine + 75 ÃÂ¼g clonidine (RC) , 30 ml 0.5% ropivacaine + 100 ÃÂ¼g of dexmedetomidine (RD) ,0,
edin,1945,4481831,Cannot tell based on the abstract,, peak value immediately after contact of the foot with the ground (PVF1) , baseline , after Ice application ,0,
edin,1945,4481831,Significantly increased,"The application of ice to the sole and calf increased PVF1 immediately following application (Table 3).,<td colspan=""1"" rowspan=""1""> PVF1 â Calf (BW)</td><td colspan=""1"" rowspan=""1""> 1.020Â±0.045</td><td colspan=""1"" rowspan=""1""> 1.030Â±0.045*</td><td colspan=""1"" rowspan=""1""> 1.017Â±0.039<sup>#</sup>
</td>", peak value immediately after contact of the foot with the ground (PVF1) , baseline , after Ice application ,0,
edin,1918,3276929,Significantly decreased,Diastolic blood pressure reduced (P<0.001) better in yoga group (post 1=â7.6% and post 2=â16.4%) than the control group (post 1=â2.1% and post 2=â5.0%)., Diastolic blood pressure , control , yoga ,0,
edin,1923,4374260,Significantly decreased,"On multivariate logistic regression analysis, baseline IELT was the only predictor of successful treatment of PE with both tramadol 50 mg (odds ratio [OR]: 1.05, 95% confidence interval [CI]: 1.03-1.07, P < 0.001) and tramadol 100 mg (OR: 1.07, 95% CI: 1.04-1.11, P < 0.001).,PE was successfully treated in only 2.4% of patients with placebo, in contrast to 53.6% and 85.6% with 50 and 100 mg tramadol, respectively (P < 0.001 for all comparisons).", premature ejaculation (PE). , placebo  , 50 mg of tramadol and 100 mg of tramadol ,0,
edin,2045,4121500,Cannot tell based on the abstract,," oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine ", group H - 1.0 ÃÂµg/kg , Group L - loading dose of 0.5 ÃÂµg/kg for 10 minutes ,0,
edin,2045,4121500,No significant difference,"Incidence of oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine did not show any significant differences."," oral dryness, tachycardia, excessive bradycardia and use of atropine and ephedrine ", group H - 1.0 ÃÂµg/kg , Group L - loading dose of 0.5 ÃÂµg/kg for 10 minutes ,0,
edin,2034,3101755,Significantly decreased,Total epidural dose of fentanyl and bupivacaine required in Group A was significantly lower in comparison with Group B in 24 hours., Total epidural dose of fentanyl and bupivacaine , control , magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours ,0,
edin,1887,2742700,No significant difference,"Of the 24 subjects who completed the study, only 20% achieved the target blood pressure of <130/80 and there was no statistical difference in mean systolic and diastolic blood pressures among the three groups (p > 0.05).", mean systolic and diastolic blood pressure , usual care , nurse educator-conducted class and home blood pressure monitorization ,0,
edin,1897,5389230,Cannot tell based on the abstract,, Extubation times , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,1897,5389230,No significant difference,"There was no statistically significant difference between the two groups regarding extubation, emergence, and discharge times with a P > 0.05 [Table 4].", Extubation times , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,2098,3190091,Cannot tell based on the abstract,, seeing HIV prevention posters displayed on the walls , control , study-specific prevention activities ,0,
edin,2098,3190091,No significant difference,"As expected, high proportions of patrons at both intervention and control beer halls reported seeing HIV prevention posters displayed on the walls (74.2 vs. 65.5%, respectively, PÂ =Â 0.005), as these were placed in both intervention and control beer halls.", seeing HIV prevention posters displayed on the walls , control , study-specific prevention activities ,0,
edin,2044,4121500,Cannot tell based on the abstract,," bradycardia, hypoxemia, hypotension and hypertension ", group H - 1.0 ÃÂµg/kg , Group L - loading dose of 0.5 ÃÂµg/kg for 10 minutes ,0,
edin,2044,4121500,No significant difference,"There were no significant differences between two groups in the incidence of bradycardia, hypoxemia, hypotension and hypertension (Table 3)."," bradycardia, hypoxemia, hypotension and hypertension ", group H - 1.0 ÃÂµg/kg , Group L - loading dose of 0.5 ÃÂµg/kg for 10 minutes ,0,
edin,1214,3743198,No significant difference,"The admission rate decreased by 8.3% in the intervention group (adjusted odds ratio 0.31, 95% confidence interval 0.13-0.70, p=0.005).", Admission rate , No standardized guidelines or educational programs , Educational program and ED protocol for syncope evaluation ,0,
edin,1880,5291156,Cannot tell based on the abstract,, percentage of images of suitable quality at the right pyriform sinus , lidocaine spray and viscous solution , lidocaine spray ,0,
edin,1880,5291156,Significantly decreased,"The percentage of suitable quality images at the right pyriform sinus was significantly lower in the spray group compared to the combination group (82.8â% vs. 91.2â%, Pâ=â0.02).", percentage of images of suitable quality at the right pyriform sinus , lidocaine spray and viscous solution , lidocaine spray ,0,
edin,2001,5012042,No significant difference,"Using the FG improved average navigator efficiency from 33âÂ±â15 to 58âÂ±â13Â % (pâ<â0.001) and improved SNR by 5Â % (pâ=â0.01) compared to acquisitions with NF.,There was no difference in navigator efficiency (pâ=â0.90) or SNR (pâ=â0.77) between untrained and trained participants for FG acquisitions.", navigator efficiency and signal-to-noise ratio (SNR) , no off-scanner training , xtensive off-scanner training with the FG using a MRI simulator ,0,
edin,2104,4760045,Cannot tell based on the abstract,, suffered from bradycardia , 30 ml 0.5% ropivacaine + 75 ÃÂ¼g clonidine (RC) , 30 ml 0.5% ropivacaine + 100 ÃÂ¼g of dexmedetomidine (RD) ,0,
edin,2104,4760045,Significantly increased,"Again group RD suffered from bradycardia, which was statistically higher (P < 0.05) than group RC.", suffered from bradycardia , 30 ml 0.5% ropivacaine + 75 ÃÂ¼g clonidine (RC) , 30 ml 0.5% ropivacaine + 100 ÃÂ¼g of dexmedetomidine (RD) ,0,
edin,1898,5389230,No significant difference,"Extubation, emergence, and discharge times were comparable in both groups, and none of the subjects reported any adverse effects.", Discharge times , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,2036,5609057,Cannot tell based on the abstract,, Mean score of general symptoms , placebo , extract of three Cretan herbs ,0,
edin,2036,5609057,Significantly decreased,"Mean score of general symptoms was 19.1 (SE: 0.9) in day one, dropping to 8.6 (SE: 0.6) and 3.1 (SE: 0.4) in days 4 and 7 respectively, illustrating a decrease by 55.0% in day 4 and by 83.8% in day 7 (pÂ <Â 0.001 for all paired differences).", Mean score of general symptoms , placebo , extract of three Cretan herbs ,0,
edin,1905,3000449,Cannot tell based on the abstract,, Patient being held responsible for the weight-related symptoms , Interaction with a non-obese patient in a digital environment , Interaction with an obese patient in a digital environment ,0,
edin,1905,3000449,Significantly increased,"That is, the obese patient was held significantly more responsible for causing her shortness of breath, F(1,73)=26.37, p<.0001, and her knee pain, F(1,73)=36.11, p<.0001, but there was no difference in student ratings of the obese and non-obese patients' responsibility for causing the eczema.", Patient being held responsible for the weight-related symptoms , Interaction with a non-obese patient in a digital environment , Interaction with an obese patient in a digital environment ,0,
edin,1875,3259296,Significantly decreased,"In study 1, the 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P < 0.0001), 0-60 min (P < 0.0001, P < 0.0001), 0-90 min (P < 0.0001, P < 0.0001) and 0-120 min (P = 0.0071, P = 0.0016).", glucose concentration at 120 minutes in study 1 , sucrose solution , xylose-containing solution ,0,
edin,2000,5012042,No significant difference,There were no differences in longitudinal strain (pâ=â0.38)., longitudinal strain , underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with no feedback (NF)  , underwent a respiratory navigator-gated 2D spiral cine displacement encoding with stimulated echoes (DENSE) CMR acquisition first with the feedback game (FG) ,0,
edin,2037,4477402,Significantly decreased,Length of ICU stay was significantly higher in late extubation group (4.2 Â± 1.2 days) than the UFE group (1.72 Â± 1.5 days) (P = 0.02)., Length of ICU , Late extubation  , Ultra fast-track extubation (UFE) ,0,
edin,2073,3921228,Cannot tell based on the abstract,, POMS depression , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,2073,3921228,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">POMS</td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>,The increase in happiness was significantly greater in the experimental compared to control group (t(19)â=â2.33, pâ=â0.01), while the change in POMS depression between groups failed to reach significance (t(19)â=â1.33, pâ=â0.10).", POMS depression , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,2074,3921228,Cannot tell based on the abstract,Significant pre-post scan decreases in anxiety ratings and increases in happiness ratings were evident in the experimental versus control group., state anxiety , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,2074,3921228,Significantly decreased,"Significant decreases were also found within the experimental group for ratings of POMS anger (t(13)â=â2.42, pâ=â0.015), trait anxiety (STAI-Trait subscale; t(13)â=â2.62, pâ=â0.01), state anxiety (STAI-Trait subscale; t(13)â=â2.34, pâ=â0.02), and VAS ratings of restlessness (t(13)â=â2.23, pâ=â0.02), anxiety (t(13)â=â4.37, p<0.001), and irritability (t(13)â=â2.14, pâ=â0.025), and the difference between the groups on state anxiety was significant t(19)â=â2.58, pâ=â0.03).", state anxiety , rtfMRI-nf from the horizontal segment of the intraparietal sulcus (HIPS , rtfMRI-nf from left amygdala (LA) ,0,
edin,1878,3259296,Significantly decreased,"In study 1, the 5 g xylose-containing solutions exhibited significantly lower area under the glucose curve (AUCg) and area under the insulin curve (AUCi) values for 0-15 min (P < 0.0001, P < 0.0001), 0-30 min (P < 0.0001, P < 0.0001), 0-45 min (P < 0.0001, P < 0.0001), 0-60 min (P < 0.0001, P < 0.0001), 0-90 min (P < 0.0001, P < 0.0001) and 0-120 min (P = 0.0071, P = 0.0016)."," AUCg and AUCi values for 0-15 min, 0-30 min, 0-45 min, 0-60 min, 0-90 min, and 0-120 min in study 1 ", sucrose solution , 5 g xylose-containing solution ,0,
edin,2035,3101755,Cannot tell based on the abstract,," pruritus, nausea, vomiting during first 24 h ", control , magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours ,0,
edin,2035,3101755,Significantly decreased,Pruritus was significantly less in Group A compared with Group B. The incidence of nausea and vomiting was also significantly less in Group A in comparison with the control.," pruritus, nausea, vomiting during first 24 h ", control , magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours ,0,
edin,2021,5614293,Significantly increased,"The mean score of final visual acuity was 0.293Â±0.11 in the IVT group, 0.25Â±0.10 in the IVB group and 0.48Â±0.15 in the IVB+IVT group. The differences between groups considering final visual acuity was significant (p<0.001).", The mean score of final visual acuity , intravitreal triamcinolone acetonide (IVT) or intravitreal bevacizumab (IVB) , combination of IVT and IVB ,0,
edin,1894,5389230,Cannot tell based on the abstract,, Emergence agitation  , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,1894,5389230,Significantly decreased,The median four-point agitation scales and the median scores of FLACC pain scales of Group D were significantly lower than those of Group C at the all six time points with P < 0.05., Emergence agitation  , Intranasal saline 0.9% (Group C) , Intranasal dexmedetomidine (Group D) ,0,
edin,2091,5452066,Cannot tell based on the abstract,, median PFS (Progression-free survival) , topotecan , PM01183 ,0,
edin,2091,5452066,Significantly increased,"Median PFS was 4.0âmonths (95% CI, 2.7â5.6âmonths) (Figure 2A). Median OS was 10.6âmonths (95% CI, 9.5â18.1âmonths). Table 2,In the second randomized stage, median PFS was significantly longer with PM01183: 3.9âmonths (95% CI, 2.5â5.7âmonths) versus 2.0âmonths (95% CI, 1.4â2.8âmonths) with topotecan (Pâ=â0.0067).", median PFS (Progression-free survival) , topotecan , PM01183 ,0,
edin,2057,4045752,No significant difference,The anti-HBs level in the therapeutic paracetamol group (4958 mIU/mL) was not different (pâ=â0.34) from the level in the control group., The anti-HBs level  , The control group received no paracetamol. , paracetamol for 6 hours after (therapeutic use)  vaccination ,0,
edin,1870,3657931,No significant difference,No significant difference in the induction dose of propofol was observed when assessed clinically (loss of verbal response) or by BIS monitoring., mean dose of propofol required for induction , propofol induction guided by clinical signs , propofol induction guided by BIS ,0,
edin,2086,4342682,Significantly increased,"A logistic regression analysis indicated that the odds of participants choosing the best treatment were 2.25 times higher in the unconscious-thought condition compared to the immediate-decision condition (b=.81, Wald=4.32, P=.04, 95% CI 1.048-4.836), and 2.39 times greater compared to the conscious-thought condition (b=.87, Wald=4.87, P=.027, 95% CI 1.103-5.186).", choosing the best treatment , conscious-thought condition , unconscious-thought condition ,0,
edin,2068,5659064,Cannot tell based on the abstract,, Inspiratory muscle strength , PLACEBO ," oral nutritional supplementation, enriched with leucine, vitamin D, and omegaÃ¢â¬ï¿½3 fatty acids (NUTRITION) ",0,
edin,2068,5659064,Significantly increased,Inspiratory muscle strength improved significantly only in NUTRITION (Figure 4)., Inspiratory muscle strength , PLACEBO ," oral nutritional supplementation, enriched with leucine, vitamin D, and omegaÃ¢â¬ï¿½3 fatty acids (NUTRITION) ",0,
edin,1938,5340016,Significantly decreased,"The overall clinical response rate was significantly higher in the PE arm than in the FEC arm (76.06% vs. 59.95%, PÂ =Â 0.001).", The clinical response rates , weekly paclitaxelÃ¢â¬âepirubicin (PE) regimen , receive 4Ã¢â¬â6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilÃ¢â¬âepirubicinÃ¢â¬âcyclophosphamide (FEC) regimen ,0,
edin,2024,3178704,Cannot tell based on the abstract,," weight, BMI, body fat, waist circumference, and visceral fat area (VFA) ", baseline , the diet only (DO) ,0,
edin,2024,3178704,Significantly increased,"Significant increases in weight, BMI, body fat, waist circumference, and visceral fat area (VFA) as measured by CT were observed in the DO group while their glucose area under the curve (AUC) decreased from the baseline value."," weight, BMI, body fat, waist circumference, and visceral fat area (VFA) ", baseline , the diet only (DO) ,0,
edin,1977,5376493,Cannot tell based on the abstract,, Ã¢â¬ËTeamworkÃ¢â¬â¢ over time , medical seminar , non-technical skills seminar ,0,
edin,1977,5376493,Significantly decreased,"Teamworkâ decreased significantly over time in the NTS group (t(42) = 2.26, p = .03, r = 0.33), but not in the control group (t(33) = 1.15, p=.26, r=0.20).", Ã¢â¬ËTeamworkÃ¢â¬â¢ over time , medical seminar , non-technical skills seminar ,0,
edin,2089,4471244,Cannot tell based on the abstract,, Mortality , placebo , thiamine ,0,
edin,2089,4471244,No significant difference,"Mortality in the thiamine and placebo groups was 13% and 46%, respectively (P = 0.10).", Mortality , placebo , thiamine ,0,
edin,1943,5340016,Significantly increased,"Consistently, the post-chemotherapy pathologic T and N stages were significantly lower in the PE arm than in the FEC arm (PÂ <Â 0.001).", the post-chemotherapy pathologic T and N stages , weekly paclitaxelÃ¢â¬âepirubicin (PE) regimen , receive 4Ã¢â¬â6 cycles of neoadjuvant chemotherapy with tri-weekly 5-fluorouracilÃ¢â¬âepirubicinÃ¢â¬âcyclophosphamide (FEC) regimen ,0,
edin,1309,3258678,Cannot tell based on the abstract,, Clinical Dementia Rating â Sum of Boxes (CDR-SB) , 78-week treatment with placebo , 78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID ,0,
edin,1309,3258678,No significant difference,"Neither the planned G Ã V interaction (P = 0.573) nor the planned contrast for the primary CDR-SB outcome at Week 78 (100 mg vs. Placebo: P = 0.405; 150 mg vs. Placebo: P = 0.837) revealed a statistically significant treatment effect.,No statistical difference relative to placebo was observed for any of the secondary CDR-SB outcomes.", Clinical Dementia Rating â Sum of Boxes (CDR-SB) , 78-week treatment with placebo , 78-week treatment with tramiprosate 100 mg or tramiprosate 150 mg BID ,0,
edin,1988,5193306,No significant difference,"All the participants in this study improved their IBS symptoms (pain, bloating, constipation and diarrhoea) and physical functioning at the end of the treatment from baseline, but this was not significantly different across the treatment arms."," irritable bowel syndrome (IBS) symptoms (pain, bloating, constipation and diarrhoea) ", standard Ã¢â¬Ëgut-directedÃ¢â¬â¢ hypnotherapy , Ã¢â¬ËindividualisedÃ¢â¬â¢ (holistic) hypnotherapy ,0,
edin,1937,4094699,Significantly increased,"By comparing the physical fitness indices, it was found that the increase of the results of sit-and-reach test in the intervention group had statistical significance (P = 0.001).", the results of sit-and-reach test , control , Baduanjin exercise ,0,
edin,2031,4747995,No significant difference,"Productsâ systemic exposures were comparable, with 90Â % CIs around ratios for AUCinf (0.96; 90Â % CI 0.88â1.04) and Cmax (1.04; 90Â % CI 0.98â1.11) within standard bioequivalence bounds (90Â % CI 0.80â1.25).", AUCinf , ch14.18-NCI , ch14.18-UTC ,0,
edin,1982,4227976,Significantly increased,A significant difference between the two groups regarding sexual satisfaction after the intervention (p=0.003) compared to the beginning of the study (p=0.356)., mean score of sexual satisfaction , control , Sildenafil citrate and Elaeagnus angustifolia flower extract ,0,
edin,1967,4723180,Cannot tell based on the abstract,, passive drag ," Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head. "," Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerÃ¢â¬â¢s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head. ",0,
edin,1967,4723180,Significantly decreased,"Regarding the swimmerâs head position, passive drag was found to be significantly lower in the LA condition (with the arms in front of the head) for the HD and HM than the HU at all speeds (Figure 2).", passive drag ," Head-up (HU): the swimmer looked directly forward, and his ears were above the forearms and fully extended over the head. "," Head-middle (HM): the swimmer looked downward at 90 degrees to the swimming direction, in a neutral position. The swimmerÃ¢â¬â¢s ears were covered by the forearms, which were fully extended over the head or Head-down (HD): the swimmer looked backwards, and his ears were below the forearms, which were fully extended over the head. ",0,
edin,2038,4477402,No significant difference,"In survival analysis there was no significant difference between ultra-fast and late extubation groups (Log-rank test, P = 0.9).", The length of survival , Late extubation  , Ultra fast-track extubation (UFE) ,0,
edin,1893,3687261,Significantly decreased,"Both peak blood glucose and the amplitude of glycemic excursion were lower after PX and SC than PC (P < 0.01 for each) and were lowest after SX (P < 0.05 for each), while overall blood glucose was lower after SX than PC (P < 0.05).", amplitude of glycemic excursion , placebo and sucralose , sitagliptin and d-xylose ,0,
edin,2076,4628236,Cannot tell based on the abstract,, expression of PDE-5 , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,2076,4628236,Significantly decreased,"Application of cinaciguat in diabetic animals significantly reduced the expression of PDE-5, markedly increased PKG activity (as indicated by elevated p-VASP/VASP ratio) (Fig.Â 3a), while the expression of PKG did not differ between the two diabetic groups (Fig.Â 3a).Fig.Â 3", expression of PDE-5 , placebo orally for 8 weeks , the sGC activator cinaciguat (10 mg/kg/day) orally for 8 weeks ,0,
edin,1964,3293139,Significantly decreased,"Responses to the COS-LC collected before the incidence round were statistically significantly different on the scales âanxietyâ, âbehaviourâ, âdejectionâ, âself-blameâ, âfocus on airway symptomsâ and âintrovertâ, with the control group reporting higher negative psychosocial consequences.", negative psychosocial consequences , control group , screen group ,0,
edin,1931,4175246,Cannot tell based on the abstract,," anterior, non-paretic and paretic reach ", baseline ,"  task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks ",0,
edin,1931,4175246,Significantly increased,"After intervention, anterior, non-paretic and paretic reach were significantly higher in the experimental group (p<0.05)."," anterior, non-paretic and paretic reach ", baseline ,"  task-oriented training program with WBV, which was performed for 15 minutes, five times per week, for four weeks ",0,
edin,1924,4374260,Significantly increased,"Weak scanty ejaculation was the main complaint in 7.2% versus 21.6% of those using 50 and 100 mg tramadol, respectively (P = 0.002).", Weak scanty ejaculation , placebo , 50 mg of tramadol and 100 mg of tramadol ,0,
edin,1960,4048120,No significant difference,"Peri-implant health showed no statistically significant differences for any of the studied parameters (crevicular fluid volume, plaque index, gingival retraction, keratinized mucosa, probing depth, modified gingival index and presence of mucositis) at the twelve-month follow-up.", Modified gingival index , implants were placed in healed sites , received implants immediately after extraction ,0,
edin,2019,4235088,Significantly decreased,"PHES significantly improved after medication in all the three groups (Gp-LPr: â3.8 Â± 3.9 to â1.6 Â± 3.0; Gp-L: â4.8 Â± 4.1 to â1.6 Â± 2.9; and Gp-Pr: â4.9 Â± 3.7 to â2.1 Â± 2.5, P < 0.001). After 8 weeks follow-up, improvement was maintained in Gp-LPr and Gp-Pr, but there was deterioration in those who did not receive probiotics (Gp-L: PHES score reversed to â4.8 Â± 4.2).", psychometric hepatic encephalopathy score (PHES) after 8 weeks , baseline , receive lactulose (30Ã¢â¬â60 mL/day) + probiotic (200 million colony forming units of seven bacteria species/day) (Gp-LPr)  or probiotic alone (Gp-Pr) ,0,
edin,2033,3101755,Significantly increased,A significant increase in the mean and maximum duration of analgesia in Group A in comparison with Group B (P<0.05) was observed., the mean and maximum duration of analgesia , control , magnesium sulfate injection 30 mg/kg i.v. bolus was followed by infusion of magnesium sulfate at 10 mg/kg/hr and continued up to 24 hours ,0,
edin,2119,5437665,Significantly decreased,"In addition, the physical activity level was significantly decreased in patients from simvastatin group when compared to those from red yeast rice group.", Level of physical activity , Red yeast rice , Simvastatin ,0,
edin,2207,4064763,Cannot tell based on the abstract,, Mean drug dose , 10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum , 10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate ,0,
edin,2207,4064763,Significantly increased,"Mean drug dose was 28.98 drops in group A, and 24.29 drops in group B, and the difference between the two groups was statistically significant (p= 0.042).", Mean drug dose , 10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum , 10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate ,0,
edin,2282,5589093,Cannot tell based on the abstract,, cardiorespiratory complications , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2282,5589093,No significant difference,"A difference between the proportions of cardiorespiratory complications in the usual care group (54%) compared to GDT (27%) was noticed, which did not achieve statistical significance (p = 0.066).", cardiorespiratory complications , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2199,5320759,No significant difference,"The intubation success rates at the first, second, and third attempts as well as the average intubation times were similar between the two groups (P > 0.05),"," The intubation success rates at the first, second, and third attempt ",  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2252,3467590,Significantly increased,"For A1c control, medication intensification increased in both groups (intervention, pre 26.4% vs post 32.6%, p=0.022; control, pre 24.8% vs post 31.1%, p=0.033) (intervention, adjusted OR (AOR) 1.37; 95% CI 1.06 to 1.76; control, AOR 1.41 (95% CI 1.06 to 1.89)); however, we observed no incremental benefit solely due to the intervention (group-by-time interaction, p=0.948).", medication intensification , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2305,3747462,Cannot tell based on the abstract,," RBCs count, PCV %, and Hb concentration ", control , Vaccinated group ,0,
edin,2305,3747462,Significantly increased,"Compared to normal control group (1) before challenge, red blood cell count (RBC), packed cell volume (PCV) %, and haemoglobin (Hb) concentration showed significant increase in glycyrrhizin-treated group (2) from the 1st till the 3rd week. G"," RBCs count, PCV %, and Hb concentration ", control , Vaccinated group ,0,
edin,2300,5509597,Significantly increased,he experimental group showed significant improvements in the variations of muscle activity and proprioception compared to the control group., muscle activity and proprioception , neurodevelopmental treatment , motor imagery training  ,0,
edin,2223,3804449,Significantly increased,"All caregiver outcome variables improved in the intervention group more than in the control. Home safety was significant at P â¤ 0.001, caregiver strain at P â¤ 0.001, and caregiver self-efficacy at P = 0.002.", caregiver self-efficacy , customary care ," Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items ",0,
edin,2212,5308129,Significantly increased,"In comparison with lactulose alone, PEG-lactulose could improve HESA score in 24 hours more effectively (p =0.04).", Hepatic Encephalopathy Scoring Algorithm (HESA) score ," 20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube "," PEGÃ¢â¬âlactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes  ",0,
edin,2281,5589093,Cannot tell based on the abstract,, electrolyte derangements , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2281,5589093,Significantly decreased,Patients in the usual care group were significantly more likely to develop electrolyte derangements: GDT (27%) vs. usual care (62%) (p = 0.012)., electrolyte derangements , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2271,5589093,Cannot tell based on the abstract,, intraoperative ephedrine , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2271,5589093,No significant difference,Eleven patients (42%) received intraoperative ephedrine in the GDT group vs. 7 patients (27%) in the usual care (p = 0.125)., intraoperative ephedrine , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2162,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Night-time cough frequency and severity , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2143,5867479,Significantly decreased,The concentrations of serum S100B and NGF in dexmedetomidine group was lower than those in control group (P<0.01)., Levels of NGF , Normal saline (control group) , Dexmedetomidine ,0,
edin,2217,3556334,Significantly decreased,"After 12âweeks, the vitamin D supplemented arm demonstrated significantly greater mean weight gain (kg)â+â3.75, (3.16 â 4.34) versusâ+â2.61 (95% CI 1.99 â 3.23) p 0.009 and lesser residual disease by chest radiograph; number of zones involved 1.35 v/s 1.82 p 0.004 (95% CI 0.15, 0.79) and 50% or greater reduction in cavity size 106 (89.8%) v/s 111 (94.8%), p 0.035.", number of zones involved , placebo for 2 doses ," 600,000Ã¢â¬â°IU of Intramuscular vitamin D3 ",0,
edin,2157,5174811,Significantly decreased,"ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Night-time cough frequency and severity , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2133,4860224,No significant difference,"Most were Hispanic (68%), single (61%), primiparous (39%), and without high school diploma (44%). 35 (21%) neonates in the intervention group and 41 (27%) in the control group were brought at least once for a NUC to the ED (p = 0.12).", Nonurgent ED visit , Routine anticipatory guidance program , Intensified anticipatory guidance program ,0,
edin,2175,5174811,Significantly decreased,"Data for 1792 patients were evaluated. E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (active-comparator study) , Aclidinium (active-comparator study) ,0,
edin,2299,5509597,No significant difference,"Only the experimental group showed significant improvements in proprioception.,The experimental group showed significant improvements in the variations of muscle activity and proprioception compared to the control group.", improvement in proprioception , baseline , control group ,0,
edin,2187,4509558,No significant difference,"At the end point, 22 patients (78.6Â %) in SG group and 23 patients (85.2Â %) in RYGB group achieved complete remission of diabetes mellitus with HbA1câ<â6.0Â % (Pâ=â0.525)", Glycated hemoglobin A1c (HbA1c) , Roux-en-Y gastric bypass (RYGB) procedure , laparoscopic sleeve gastrectomy (SG) ,0,
edin,2176,5174811,Significantly decreased,"n the active-comparator study, significantly greater improvements were observed with aclidinium versus placebo for severity of morning cough (â0.19 vs â0.02; p<0.01) and phlegm (â0.19 vs â0.02; p<0.05).", Morning cough severity and phlegm , Placebo (active-comparator study) , Aclidinium (active-comparator study) ,0,
edin,2274,5589093,Cannot tell based on the abstract,, volumes of crystalloid or colloid fluids on both postoperative Day 1 and Day 2 , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2274,5589093,No significant difference,"<td align=""left"" colspan=""5"" rowspan=""1""><bold>Day 2</bold></td>", volumes of crystalloid or colloid fluids on both postoperative Day 1 and Day 2 , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2231,4056626,Cannot tell based on the abstract,, cough reflex , propofol and remifentanil , 100 ÃÂ³/kg/min of racemic ketamine for 10&amp;nbsp;minutes  ,0,
edin,2231,4056626,Significantly decreased,"Following ketamine administration (T2), ICP did not modify (11.7âÂ±â7.3 vs. 11.0âÂ±â6.4Â mmHg; Pâ=â0.28); after ETS (T3) cough reflex was significantly reduced in comparison with controls (cough score 4 (IQR 3 to 4) vs. 2 (IQR1 to 2); P <0.0001) (FigureÂ 6).", cough reflex , propofol and remifentanil , 100 ÃÂ³/kg/min of racemic ketamine for 10&amp;nbsp;minutes  ,0,
edin,2286,5337766,Significantly increased,A significantly higher number of large-sized follicles was observed in group D than in group B (P=0.036)., number of large-sized follicles , groups B(hFSH) and C (rFSH) , group D Human Follicle Stimulating Hormone/ Recombinant human follicle stimulating hormone (hFSH/rFSH) ,0,
edin,2130,5787910,Cannot tell based on the abstract,, Frequency of side effects , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2130,5787910,Significantly increased,"As shown in Table 1, considering the significance level of 5%, a significant difference can be seen in the frequency of side effects dry mouth, dry nose, repeated rhinorrhea, and hair thinning and loss in both groups (P < 0.05), so that the frequency of side effects in the group receiving a higher dose of the drug (the second group) was more than the group receiving the low dose of the drug (the first group).", Frequency of side effects , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2269,5589093,Cannot tell based on the abstract,, intraoperative metaraminol , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2269,5589093,Significantly decreased,Three patients (12%) in the GDT group received intraoperative metaraminol vs. 23 patients (88%) in the usual care group (p<0.0001)., intraoperative metaraminol , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2147,5029935,No significant difference,"Higher LTOT duration analyzed as a continuous variable was not associated with any change in mortality rate (hazard ratio [HR] 1.00; (95% confidence interval [CI], 0.98 to 1.02) per 1 h/day increase above 15 h/day.,Mortality was similar between the groups for all-cause, respiratory and cardiovascular mortality.", Mortality rates , Long-term oxygen therapy 24 h/day , Long-term oxygen therapy 15 h/day ,0,
edin,2129,5787910,Cannot tell based on the abstract,, Patients' satisfaction score , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2129,5787910,Significantly decreased,"Considering the significance level of 5%, a significant difference can be observed between patients' satisfaction in the two treatment groups (P < 0.05), so the average of patients' satisfaction score in the first group (mean = 4.78, SD = 0.4) was significantly higher than the second group (mean = 4.43, SD = 0.6) (P = 0.02), which shows that the satisfaction of patients treated with lower doses of medication (Group I) was higher than patients treated with higher doses of the drug (Group II).", Patients' satisfaction score , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2296,5337626,Cannot tell based on the abstract,, the proportions of R0 resections ," control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. "," 7ÃÂ·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. ",0,
edin,2296,5337626,No significant difference,"When the comparison was repeated including only patients who underwent a resection (R0 vs R1), the proportions of R0 resections were again similar between the groups (321 [75%] of 429 patients in the chemotherapy alone group vs 305 [75%] of 405 in the chemotherapy plus bevacizumab group).", the proportions of R0 resections ," control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. "," 7ÃÂ·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. ",0,
edin,2246,5372977,Significantly increased,Six days of BR ingestion effectively improves high-intensity intermittent type exercise performance in trained soccer players., High-intensity intermittent running performance as assessed by the Yo-Yo IR1 , nitrate-depleted beetroot juice (PLA) for six subsequent days , ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days ,0,
edin,2244,5372977,Significantly increased,"Six days of BR ingestion increased plasma and salivary nitrate and nitrite concentrations in comparison to PLA (p < 0.001), and enhanced Yo-Yo IR1 test performance by 3.4 Â± 1.3% (from 1574 Â± 47 to 1623 Â± 48 m; p = 0.027).", plasma and salivary nitrate and nitrite concentrations , nitrate-depleted beetroot juice (PLA) for six subsequent days , ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days ,0,
edin,2256,3467590,Cannot tell based on the abstract,, haemogloblin A1c (%) among patients with worse glucose control - &amp;gt;9% , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2256,3467590,Significantly increased,"In the unadjusted analysis and among patients with worse glucose control (A1c >9%), intensification of medications to control A1c increased in both trial arms between baseline and follow-up (intervention, pre 34.8% vs post 62.5%, p=0.002; control, pre 35.7% vs post 61.4%, p=0.008; figure 3 top panel).", haemogloblin A1c (%) among patients with worse glucose control - &amp;gt;9% , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2289,5695666,Cannot tell based on the abstract,, weight  after 1 year , baseline , moderate-to-vigorous intensity physical activity (MVPA) ,0,
edin,2289,5695666,Significantly decreased,"Year 1 PA was significantly associated with 1-year weight change (r=0.23, p<0.0001), and this relationship was further strengthened after controlling for baseline PA and demographic factors (r=0.34, p<0.0001).", weight  after 1 year , baseline , moderate-to-vigorous intensity physical activity (MVPA) ,0,
edin,2292,1971065,Significantly increased,"At trial end, the proportions of participants in remission (SIGH-SAD less than 9) were significantly greater (Fisher's exact test), and SIGH-SAD scores, as percent individual score at randomization, were significantly lower (t-test), with active treatment than with control, both in an intent-to-treat analysis and an observed cases analysis.", amount of remission of Seasonal Affective Disorder (SAD) , control treatment , efficient light-emitting diodes (LEDs) ,0,
edin,2221,3804449,Cannot tell based on the abstract,, home environmental safety , customary care ," Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items ",0,
edin,2221,3804449,Significantly increased,"After controlling for the effects of caregiver age, and baseline measures of caregiver self-efficacy, baseline caregiver strain, and baseline home safety, caregivers who receive the Home Safety Toolkit will have improved home environmental safety higher postintervention self-efficacy, and lower postintervention caregiver strain than the control group which receives standard patient education.,Caregivers in the intervention group had significantly improved home environmental safety (P â¤ 0.000) higher caregiver self-efficacy (P â¤ 0.002), and lower caregiver strain (P â¤ 0.000) than caregivers in the control group.", home environmental safety , customary care ," Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items ",0,
edin,2227,4477338,Cannot tell based on the abstract,, percent suppression of Endogenous Glucose Production (EGP) , placebo ,  3.9 g/day EPA+DHA ,0,
edin,2227,4477338,Significantly increased,"Hepatic insulin sensitivity, determined from the suppression of endogenous glucose production by insulin, exhibited a small but significant improvement with EPA+DHA compared with placebo.", percent suppression of Endogenous Glucose Production (EGP) , placebo ,  3.9 g/day EPA+DHA ,0,
edin,2153,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Frequency of sputum production at night-time , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2173,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Frequency of sputum production at night-time , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2290,5695666,Cannot tell based on the abstract,, weight  after 1 year , moderate-to-vigorous intensity physical activity (MVPA) &amp;lt;50 min/week  , moderate-to-vigorous intensity physical activity (MVPA) 50 - 150 min/week  ,0,
edin,2290,5695666,Significantly decreased,"Year 1 PA was significantly associated with 1-year weight change (r=0.23, p<0.0001), and this relationship was further strengthened after controlling for baseline PA and demographic factors (r=0.34, p<0.0001).,The PA groups were as follows: <50 min/week (n=188), 50 to <150 min/week (n=167), 150 to <250 min/week (n=83), and â¥250 min/week (n=115). Participants engaging in 150 to <250 or â¥250 min/week of MVPA had significantly greater WL at 1-year compared to those engaging in <50 or 50 to <150 min/week. Similar findings were observed when the change in PA from baseline to 1-year was examined â participants with greater improvements in PA also had better WL at Year 1 (adjusted r=0.34, p<0.001).", weight  after 1 year , moderate-to-vigorous intensity physical activity (MVPA) &amp;lt;50 min/week  , moderate-to-vigorous intensity physical activity (MVPA) 50 - 150 min/week  ,0,
edin,2206,4064763,No significant difference,"After intervention, variables including: induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation), in the two groups, were found to be the same (P < 0.05)."," induction duration, duration of the 1st and the 2nd stages of labor, delivery method; and labor outcomes such as: hyper-stimulation of uterine, postpartum bleeding, 5-minute Apgar score, and infant's birth weight; and neonatal outcomes (admission to NICU, oxygen and intubation) ", 10 units of Oxytip (Caspian Tamin Company Iran) in 500 cc serum , 10 units of Syntocinon (Novartis Pharma Canada) in 500 cc Ringer lactate ,0,
edin,2169,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (ATTAIN) , Aclidinium 400Ã¢â¬â¦ÃÂµg (ATTAIN) ,0,
edin,2302,4025600,Cannot tell based on the abstract,," HbA1c, Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides  ", low-carbohydrate diet (LCD) , traditional low-fat diet (LFD) ,0,
edin,2302,4025600,No significant difference,"<td colspan=""1"" rowspan=""1"">â
<italic>P</italic> within group</td><td colspan=""1"" rowspan=""1"">NS</td><td colspan=""1"" rowspan=""1"">NS</td><td colspan=""1"" rowspan=""1""></td>"," HbA1c, Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides  ", low-carbohydrate diet (LCD) , traditional low-fat diet (LFD) ,0,
edin,2266,5589093,Significantly decreased,Intraoperative fluid balance was 1005mL (475:1873) in the GDT group vs. 3300mL (2474:3874) in the usual care group (p<0.0001)., intraoperative fluid balance , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2214,5308129,Cannot tell based on the abstract,, blood level of ammonia ," 20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube "," PEGÃ¢â¬âlactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes ",0,
edin,2214,5308129,No significant difference,"In addition, baseline lab data including blood level of ammonia was similar between PEG-lactulose group and lactulose group (tables 2 and 3).,<td colspan=""1"" rowspan=""1"">Length of hospital stay, mean (SE), day</td><td colspan=""1"" rowspan=""1"">7.8 (0.4)</td><td colspan=""1"" rowspan=""1"">8.9 (0.7)</td><td colspan=""1"" rowspan=""1"">6.8 (0.5)</td><td colspan=""1"" rowspan=""1"">*0.03</td>,There was no significant change in the blood level of ammonia after 24 hours between the treatment groups (p =0.858, table 3).", blood level of ammonia ," 20-30 grams of lactulose orally or by a nasogastric tube, or 200 grams of lactulose enema by a rectal tube "," PEGÃ¢â¬âlactulose group received the 20-30 grams of lactulose of oral or rectal lactulose, plus 280 grams of PEG in 4 liters of water orally as a single dose in 30-120 minutes ",0,
edin,2248,3373832,Cannot tell based on the abstract,, PRTEE , Waitlist , dextrose prolotherapy ,0,
edin,2248,3373832,Significantly increased,"Prolotherapy participants (n=10) reported improved PRTEE composite scores compared to Waitlist (n=12) at 4 and 16 weeks (p<0.05), and improved pain and function PRTEE subscale scores (p<0.05) at 4 and 16 weeks, respectively.", PRTEE , Waitlist , dextrose prolotherapy ,0,
edin,2215,4313493,Significantly decreased,IOP lowering with bimatoprost (8.9 Â± 1.598 mm Hg) was significantly (P < 0.0001) higher than brimonidine (6.55 Â± 1.26 mm Hg)., IOP (intraocular pressure) , group B brimonidine 0.2% eye drops twice daily for a period of 4 weeks , group A bimatoprost 0.03% eye drops once daily for a period of 4 weeks ,0,
edin,2291,1971065,Significantly increased,"At trial end, the proportions of participants in remission (SIGH-SAD less than 9) were significantly greater (Fisher's exact test),", amount of remission of Seasonal Affective Disorder (SAD) , control treatment , efficient light-emitting diodes (LEDs) ,0,
edin,2184,3118076,No significant difference,"The success rate in group I was found to be 80%, which was lower than the success rate in group II which was found to be 90%. On comparison, there is no statistically significant difference in success rate between the two study groups.", Rate of success , Delayed loading implants (group II) , Immediate loading implants (group I) ,0,
edin,2285,5337766,Significantly increased,The serum estradiol level was significantly higher in group D than in groups B and C (P=0.005)., The serum estradiol level , groups B ( hFSH) and C(rFSH) , group D Human Follicle Stimulating Hormone/  Recombinant human follicle stimulating hormone (hFSH/rFSH) ,0,
edin,2158,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Frequency of sputum production at night-time , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2197,5320759,No significant difference,The overall success rate of intubation was not significantly different between the two groups (P > 0.05)., success rate of intubation ,  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2194,3735552,Significantly decreased,"Mean duration of antibiotic exposure was reduced from 6.3 to 4.5 days under PCT guidance (â1.8 days; 95% CI â3.1, â0.5; Pâ=â0.039) for all LRTI and from 9.1 to 5.7 days for pneumonia (â3.4 days 95% CI â4.9, â1.7; P<0.001).", The mean duration of antibiotic exposure in the subgroup of community-acquired pneumonia (CAP) patients , standard care clinical guidelines , PCT guidance algorithm established for adult LRTI in the subgroup of community-acquired pneumonia (CAP) patients ,0,
edin,2254,3467590,No significant difference,"A wide-reach, low-intensity, web-based interactive multicomponent intervention had no significant incremental effect on medication intensification for control of glucose, blood pressure or lipids for patients with diabetes of physicians practising in the rural Southeastern USA.", intensification of medications to control BP , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2114,5437665,Significantly increased,"At the end of study, the fatigue score was significantly increased in patients treated with simvastatin, whereas no significant change was observed in patients receiving red yeast rice.", Fatigue score at week 4 , Red yeast rice , Simvastatin ,0,
edin,2307,3747462,Cannot tell based on the abstract,, activities of AST and ALT , control , Vaccinated group ,0,
edin,2307,3747462,Significantly increased,"Before challenge, compared to normal control group (1), activities of AST and ALT showed significant increases in vaccinated groups (3) at the 1st and 2nd weeks.", activities of AST and ALT , control , Vaccinated group ,0,
edin,2142,5867479,Significantly decreased,The concentrations of serum S100B and NGF in dexmedetomidine group was lower than those in control group (P<0.01)., Levels of S100B , Normal saline (control group) , Dexmedetomidine ,0,
edin,2188,4509558,No significant difference,"Change in HbA1c, FBG and C peptide were comparable in the two groups."," HbA1c, FBG and C peptid ", Roux-en-Y gastric bypass (RYGB) procedure , laparoscopic sleeve gastrectomy (SG) ,0,
edin,2170,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (active-comparator study) , Aclidinium (active-comparator study) ,0,
edin,2279,5589093,Cannot tell based on the abstract,, delayed gastric emptying , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2279,5589093,No significant difference,Three patients (12%) in the GDT group developed delayed gastric emptying vs. 6 patients (23%) in the usual care group (p = 0.213)., delayed gastric emptying , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2306,3747462,Cannot tell based on the abstract,, Serum Creatinine and Uric Acid , control , Vaccinated group ,0,
edin,2306,3747462,Significantly increased,"Before challenge, compared to normal control group (1), vaccinated group (3) showed significant increase in uric acid and creatinine at the 1st week and at the 1st and 2nd weeks, respectively.", Serum Creatinine and Uric Acid , control , Vaccinated group ,0,
edin,2262,4379665,Significantly increased,The following post hoc Tukey's test confirmed that Group 2 (SAF) exhibited significantly least (P < 0.01) debris extrusion between the three groups tested., debris extrusion ," Group 2: Self-adjusting file (SAF; ReDent-Nova, RaÃ¢â¬â¢anana, Israel) (1.5 mm) Group 3: ProTaper NEXT X1 and X2 (PTN; Dentsply Tulsa Dental, Tulsa, OK) (25/06) "," Group 1: WaveOne (primary) single reciprocating file (WO; Dentsply Maillefer, Ballaigues, Switzerland) (25/08),  ",0,
edin,2249,3373832,Cannot tell based on the abstract,, pain and function PRTEE subscale scores at 4 and 16 weeks , Waitlist , dextrose prolotherapy ,0,
edin,2249,3373832,Significantly increased,"Prolotherapy participants (n=10) reported improved PRTEE composite scores compared to Waitlist (n=12) at 4 and 16 weeks (p<0.05),", pain and function PRTEE subscale scores at 4 and 16 weeks , Waitlist , dextrose prolotherapy ,0,
edin,2202,5372065,Cannot tell based on the abstract,, weight loss , baseline ," Phase I (months 1Ã¢â¬â6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7Ã¢â¬â12), option of a 16-week weight loss intervention, Phase III (months 13Ã¢â¬â24), weight loss maintenance intervention  ",0,
edin,2202,5372065,Significantly decreased,"<td colspan=""1"" rowspan=""1"">Weight, kg</td><td colspan=""1"" rowspan=""1"">248</td><td colspan=""1"" rowspan=""1"">â0.7 (â1.2 to â0.3)**</td><td colspan=""1"" rowspan=""1"">250</td><td colspan=""1"" rowspan=""1"">â1.7 (â2.5 to â1.0)***</td><td colspan=""1"" rowspan=""1"">247</td><td colspan=""1"" rowspan=""1"">â1.6 (â2.5 to â0.8)***</td>,*p<0.05; **p<0.01; ***p<0.001.,Participants with diabetes had significant, sustained, and progressive weight loss compared with baseline at 6, 12, and 24âmonths (mean â1.2âkg, â1.5âkg, and â3.7âkg, respectively) across all intervention groups.,At 24-month follow-up (data not shown), it was â5.2âkg (95% CI â9.6 to â0.8, p=0.2) for the group weight loss program (n=18); â2.2âkg (95% CI â4.6 to 0.1, p=0.06) for the combination weight loss program (n=25); and â3.8âkg (95% CI â5.9 to â1.8, p<0.001) for the maintenance of lifestyle intervention program (n=50).", weight loss , baseline ," Phase I (months 1Ã¢â¬â6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7Ã¢â¬â12), option of a 16-week weight loss intervention, Phase III (months 13Ã¢â¬â24), weight loss maintenance intervention  ",0,
edin,2228,3329148,Significantly increased,The H. pylori eradication rate of group A was slightly higher than group B (P < 0.05) and both of them were obviously higher than group C (P < 0.05)., H. pylori eradication rate ," Group B received 20Ã¢â¬â°mg of Esomeprazole, 1000Ã¢â¬â°mg of Amoxicillin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days. "," group A received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days. ",0,
edin,2272,5589093,Cannot tell based on the abstract,, dopamine and/or dobutamine , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2272,5589093,Significantly increased,"Similarly, the use of dopamine and/or dobutamine was significantly higher in the GDT group compared to the usual care group: 12 patients (46%) vs. 1 patient (4%) (p = 0.007). Use of intraoperative beta-blockers was similar between groups.", dopamine and/or dobutamine , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2222,3804449,Significantly increased,"All caregiver outcome variables improved in the intervention group more than in the control. Home safety was significant at P â¤ 0.001, caregiver strain at P â¤ 0.001, and caregiver self-efficacy at P = 0.002.", caregiver strain  , customary care ," Home Safety Toolkit (HST), including a new booklet based on health literacy principles, and sample safety items ",0,
edin,2238,3210325,Cannot tell based on the abstract,, Depression ratings , received an Attention bias modification procedure designed to induce a bias in attention toward negative material , received an Attention bias modification procedure designed to induce a bias in attention toward positive pictures ,0,
edin,2238,3210325,Significantly decreased,"Depression ratings also increased more following negative ABM [t(56) = â7.1, p < .001, Cohen's d = .95] than positive ABM [t(58) = â3.6, p < .001, Cohen's d = .47].", Depression ratings , received an Attention bias modification procedure designed to induce a bias in attention toward negative material , received an Attention bias modification procedure designed to induce a bias in attention toward positive pictures ,0,
edin,2198,5320759,Significantly increased,"The incidences of dry throat, sore throat, and hoarseness were higher in the T group (all P < 0.05)."," the frequencies of dry throat, sore throat and hoarseness ",  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2127,5787910,No significant difference,The average severity of acne in the two treatment groups did not differ significantly within any of the study periods., Mean acne severity , Low-dose isotretinoin  , Conventional isotretinoin dose ,0,
edin,2203,5372065,Cannot tell based on the abstract,," Systolic BP, mmÃ¢â¬â¦Hg ", baseline ," Phase I (months 1Ã¢â¬â6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7Ã¢â¬â12), option of a 16-week weight loss intervention, Phase III (months 13Ã¢â¬â24), weight loss maintenance intervention  ",0,
edin,2203,5372065,Significantly decreased,"<td colspan=""1"" rowspan=""1"">Systolic BP, mmâHg</td><td colspan=""1"" rowspan=""1"">249</td><td colspan=""1"" rowspan=""1"">â6.4 (â8.7 to â4.1)***</td><td colspan=""1"" rowspan=""1"">251</td><td colspan=""1"" rowspan=""1"">â6.2 (â9.0 to â3.3)***</td><td colspan=""1"" rowspan=""1"">250</td><td colspan=""1"" rowspan=""1"">â7.3 (â9.9 to â4.6)***</td>,Among all participants, there was a statistically significant reduction in systolic BP of about 6 to 7âmmHg across all follow-up time points."," Systolic BP, mmÃ¢â¬â¦Hg ", baseline ," Phase I (months 1Ã¢â¬â6), an individually tailored intervention promoting a Mediterranean-style dietary and Phase II (months 7Ã¢â¬â12), option of a 16-week weight loss intervention, Phase III (months 13Ã¢â¬â24), weight loss maintenance intervention  ",0,
edin,2179,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (ATTAIN) , Aclidinium 400Ã¢â¬â¦ÃÂµg (ATTAIN) ,0,
edin,2200,5320759,Significantly increased,"he intubation success rates at the first, second, and third attempts as well as the average intubation times were similar between the two groups (P > 0.05), but in patients receiving successful intubation at the second attempt, the intubation time was longer in the T group (P = 0.0006).", The intubation time at the second attempt ,  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2295,5337626,Cannot tell based on the abstract,, patients achieving pathological tumour responses ," control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. "," 7ÃÂ·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. ",0,
edin,2295,5337626,No significant difference,The proportion of patients achieving pathological tumour responses were also similar between the groups (147 [33%] of 452 patients in the chemotherapy alone group vs 135 [30%] of 443 in the chemotherapy plus bevacizumab group; p=0Â·51)., patients achieving pathological tumour responses ," control group (chemotherapy alone) received three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. "," 7ÃÂ·5 mg/kg intravenous bevacizumab on day 1 of every cycle of chemotherapy and for six further doses once every 21 days following chemotherapy and three pre-operative and three post-operative cycles of epirubicin, cisplatin, and capecitabine chemotherapy: 50 mg/m2 epirubicin and 60 mg/m2 cisplatin on day 1 and 1250 mg/m2 oral capecitabine on days 1Ã¢â¬â21. ",0,
edin,2284,5337766,Significantly increased,The duration of stimulation was significantly longer in group C than in groups A and D (P=0.030)., The duration of stimulation , groups A (hMG) and D (hFSH/rFSH) , group C Human Follicle Stimulating Hormone (hFSH) ,0,
edin,2250,3373832,Cannot tell based on the abstract,, pain and function PRTEE subscale scores at 4 and 16 weeks , baseline , dextrose prolotherapy ,0,
edin,2250,3373832,Significantly increased,"Prolotherapy participants (n=10) reported improved PRTEE composite scores compared to Waitlist (n=12) at 4 and 16 weeks (p<0.05), and improved pain and function PRTEE subscale scores (p<0.05) at 4 and 16 weeks, respectively.", pain and function PRTEE subscale scores at 4 and 16 weeks , baseline , dextrose prolotherapy ,0,
edin,2165,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (active-comparator study) , Aclidinium (active-comparator study) ,0,
edin,2230,3329148,No significant difference,There was no significant difference in total score descending of symptoms between each group (P > 0.05)., total score descending of symptoms ," Group C received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for standard 10-day therapy. "," group A received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days and Group B received 20Ã¢â¬â°mg of Esomeprazole, 1000Ã¢â¬â°mg of Amoxicillin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days. ",0,
edin,2118,5437665,Significantly increased,"At the end of study, the fatigue score was significantly increased in patients treated with simvastatin, whereas no significant change was observed in patients receiving red yeast rice.", Fatigue score at week 4 , Red yeast rice , Simvastatin ,0,
edin,2196,5320759,No significant difference,"Among the cases of successful intubation, the intubation time was not significantly different between the two groups (P > 0.05).", intubation time ,  midline approach technique group (R group) , transillumination-assisted technique group (T group)  ,0,
edin,2178,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Frequency of sputum production at night-time , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2229,3329148,Significantly increased,The H. pylori eradication rate of group A was slightly higher than group B (P < 0.05) and both of them were obviously higher than group C (P < 0.05)., H. pylori eradication rate ," Group C received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for standard 10-day therapy. "," group A received 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days and Group B received 20Ã¢â¬â°mg of Esomeprazole, 1000Ã¢â¬â°mg of Amoxicillin for the first 5 days, followed by 20Ã¢â¬â°mg of Esomeprazole, 500Ã¢â¬â°mg of Clarithromycin, and 1000Ã¢â¬â°mg of Amoxicillin for the remaining 5 days. ",0,
edin,2258,5223669,Significantly increased,"With all available data (n=233), applying the cLDA model yielded an LDL improvement of 8.9âmg/dL (95% CI â16.7 to â1.0; p=0.03) for GMC compared with usual care.", LDL measured by cLDA , usual care , Group Medical Clinics (GMC) ,0,
edin,2123,2815285,Cannot tell based on the abstract,, Blood volume in the retroperitoneal hematoma , Hypertonic saline plus dextran (group III) , Lactated Ringer (group II)  ,0,
edin,2123,2815285,Significantly increased,"Significantly higher VRPH was observed in LR-treated animals when compared to the HSD group, indicating more pronounced rebleeding (p<0.05 NT vs. LR and HSD; p<0.05 LR vs. HSD) (panel C).", Blood volume in the retroperitoneal hematoma , Hypertonic saline plus dextran (group III) , Lactated Ringer (group II)  ,0,
edin,2121,5437665,Cannot tell based on the abstract,," Concentrations of ALT, AST, Cr, or CPK ", Red yeast rice , Simvastatin ,0,
edin,2121,5437665,No significant difference,"No significant increases of in the concentrations of ALT, AST, Cr, or CPK from baseline were observed in either arm (Fig. 4)."," Concentrations of ALT, AST, Cr, or CPK ", Red yeast rice , Simvastatin ,0,
edin,2273,5589093,Cannot tell based on the abstract,, intraoperative beta-blockers , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2273,5589093,No significant difference,Use of intraoperative beta-blockers was similar between groups., intraoperative beta-blockers , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2141,5387905,Cannot tell based on the abstract,, Mean pain scores 2 hours after the procedure ,  Ibuprofen group , Diclofenac potassium group and paracetamol group ,0,
edin,2141,5387905,No significant difference,"For both paracetamol and diclofenac potassium groups at 2 hours postoperatively, there were no significant decreases in mean pain scores compared with the ibuprofen group (p-values from one-way ANOVA: 1.000, 0.06, Table 1).", Mean pain scores 2 hours after the procedure ,  Ibuprofen group , Diclofenac potassium group and paracetamol group ,0,
edin,2259,5223669,No significant difference,"The less efficient, LDA analysis yielded an LDL improvement of 7.2âmg/dL (95% CI â17.2 to 2.8; p=0.15) for GMC compared with usual care.", LDL measured by LDA  , usual care , Group Medical Clinics (GMC) ,0,
edin,2226,4477338,Cannot tell based on the abstract,," Total cholesterol, HDL and LDL ", placebo ,  3.9 g/day EPA+DHA ,0,
edin,2226,4477338,No significant difference,"Total cholesterol, HDL and LDL, did not change in either group."," Total cholesterol, HDL and LDL ", placebo ,  3.9 g/day EPA+DHA ,0,
edin,2255,3467590,No significant difference,"A wide-reach, low-intensity, web-based interactive multicomponent intervention had no significant incremental effect on medication intensification for control of glucose, blood pressure or lipids for patients with diabetes of physicians practising in the rural Southeastern USA.", intensification of medications to control LDL , baseline ," web-based continuing medical education (CME), performance feedback and quality improvement tools in experimental group and control group ",0,
edin,2182,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Night-time cough frequency and severity , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2154,5174811,Significantly decreased,"E-RS cough/sputum domain scores were significantly reduced with aclidinium 400âÂµg versus placebo in ATTAIN (â0.7 vs â0.3, respectively; p<0.01) and the active-comparator study (â0.6 vs â0.2, respectively; p<0.01).", E-RS cough/sputum domain scores , Placebo (ATTAIN) , Aclidinium 400Ã¢â¬â¦ÃÂµg (ATTAIN) ,0,
edin,2120,5437665,Cannot tell based on the abstract,, Effects in reduction of lipids levels , Red yeast rice , Simvastatin ,0,
edin,2120,5437665,No significant difference,"The administration of both simvastatin (20Â mg daily) or red yeast rice (1200Â mg daily) resulted in significant reductions in TC (â19.6% vs. -18.5% of baseline level for simvastatin and red yeast rice groups respectively, PÂ <Â .001 vs. baseline for both) and LDL-C (â30.9% vs.-33.4% of baseline level for simvastatin and red yeast rice groups respectively, PÂ <Â .001 vs. baseline for both) after 4Â weeks of treatment (Fig. 3a-b) that were not significantly different between the two groups (PÂ =Â 0.84 for the comparison of the percentage drop in the TC level and PÂ =Â 0.64 for the comparison of the percentage drop in the LDL-C level; Fig. 3c). The improvements in TG and HDL-C concentrations were not significant in either treatment group (Fig. 3a-b).Fig. 3,Comparison of lipid levels at week 4 and baseline in the simvastatin and red yeast rice groups (meanÂ Â±Â SD). No significant changes in TG or HDL levels were observed in either arm;", Effects in reduction of lipids levels , Red yeast rice , Simvastatin ,0,
edin,2280,5589093,Cannot tell based on the abstract,, blood transfusion , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2280,5589093,Significantly decreased,Patients in the usual care group were significantly more likely to receive blood transfusion: GDT (nil) vs. usual care (35%) (p = 0.0005)., blood transfusion , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2167,5174811,Significantly decreased,"In ACCORD, aclidinium reduced night-time cough frequency (â0.36 vs 0.1 for placebo; p<0.001) and severity (â0.24 vs â0.1 for placebo; p<0.05), and frequency of night-time sputum production (â0.37 vs 0.05 for placebo; p<0.001).", Night-time cough frequency and severity , Placebo (ACCORD) , Aclidinium (ACCORD) ,0,
edin,2277,5589093,Cannot tell based on the abstract,, most severe complications , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2277,5589093,No significant difference,Assessment of most severe complications demonstrated no significant differences between the GDT group and usual care group (p = 0.414)., most severe complications , pancreaticoduodenectomy , pancreaticoduodenectomy with a cardiac output goal directed therapy (GDT) ,0,
edin,2136,5444773,Cannot tell based on the abstract,,  Surfactant protein B expression , Pressure-controlled ventilation (PCV) , Pressure support ventilation (PSV) ,0,
edin,2136,5444773,Significantly increased,"In the presence of IAH, PSV improved oxygenation; decreased alveolar collapse, interstitial edema, and diffuse alveolar damage; and increased expression of surfactant protein B as compared to PCV.",  Surfactant protein B expression , Pressure-controlled ventilation (PCV) , Pressure support ventilation (PSV) ,0,
edin,2309,3065646,Cannot tell based on the abstract,," Glasgow outcome scale (GOS), Barthel index (BI), modified Rankin Scale (mRS) ", conventional craniotomy (CC) , minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) with a HV &amp;lt;50 mL ,0,
edin,2309,3065646,Significantly increased,"<td align=""left"" colspan=""4"">mRS</td>"," Glasgow outcome scale (GOS), Barthel index (BI), modified Rankin Scale (mRS) ", conventional craniotomy (CC) , minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) with a HV &amp;lt;50 mL ,0,
edin,2117,5437665,Cannot tell based on the abstract,," Concentrations of ALT, AST, Cr, or CPK ", Red yeast rice , Simvastatin ,0,
edin,2117,5437665,No significant difference,"No significant increases of in the concentrations of ALT, AST, Cr, or CPK from baseline were observed in either arm (Fig. 4)."," Concentrations of ALT, AST, Cr, or CPK ", Red yeast rice , Simvastatin ,0,
edin,2310,3065646,Cannot tell based on the abstract,, case fatality 1 year after stroke , conventional craniotomy (CC) , minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) ,0,
edin,2310,3065646,No significant difference,"There were no sharp differences in case fatality between the MISPTT group and the CC group 1Â year after stroke (17.2 and 25.9%, respectively, PÂ =Â 0.243);", case fatality 1 year after stroke , conventional craniotomy (CC) , minimally invasive stereotactic puncture and thrombolysis therapy (MISPTT) ,0,
edin,2245,5372977,Significantly decreased,Mean HR was lower in the BR (172 Â± 2) vs. PLA trial (175 Â± 2; p = 0.014)., Mean HR , nitrate-depleted beetroot juice (PLA) for six subsequent days , ingested nitrate-rich (140 mL; ~800 mg nitrate/day; BR) for six subsequent days ,0,
edin,2418,3771300,Significantly decreased,"The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone (P = 0.099).", index lesion cure rate after 6 months follow-up ," WR 279,396 (15% paromomycin + 0.5% gentamicin) ", Paromomycin Alone (15% paromomycin) for 20 days ,0,
edin,2428,3614647,Significantly decreased,"Maca-GO significantly reduced both frequency and severity of individual menopausal symptoms (hot flushes and night sweating in particular) resulting in significant (P<0.001) alleviation of KMI (from 22 to 10), thus, offering an attractive non-hormonal addition to the choices available to early-postmenopausal women in the form of a natural plant alternative to Hormone Replacement Therapy (HRT) â hence, reducing dependence on hormone therapy programs.", severity of individual menopausal symptoms (hot flushes and night sweating in particular) , Placebo , Pre-Gelatinized Organic Maca (Maca-GO) treatment ,0,
edin,2465,5482825,No significant difference,"Change in total cholesterol (pâ=â0.3), low-density lipoprotein (pâ=â0.7), high-densityÂ lipoprotein (pâ=â0.2), and triglycerides (pâ=â0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ=â0.6), monocyte chemoattractant protein-1 (pâ=â0.9), tumour necrosis factor Î± (pâ=â0.2), C-reactive protein (pâ=â0.6) and nuclear factor kappa beta (pâ=â0.2).", C-reactive protein , high AGE diet , Low advanced glycation end products (AGEs) diet ,0,
edin,2385,2662857,Significantly increased,"After 40 sessions, mean physician CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0008), receptive language (p < 0.0001), social interaction (p = 0.0473), and eye contact (p = 0.0102); 9/30 children (30%) in the treatment group were rated as ""very much improved"" or ""much improved"" compared to 2/26 (8%) of controls (p = 0.0471); 24/30 (80%) in the treatment group improved compared to 10/26 (38%) of controls (p = 0.0024).", mean physician Clinical Global Impression (CGI) scale - eye contact , control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2472,4365008,No significant difference,"Similarly, the antioxidant enzymes GPx and SOD activity were unchanged by treatments.", glutathione peroxidase (GPx) and superoxide dismutase (SOD) levels , 10 mg rosuvastatin over 4 months , 10 mg rosuvastatin over 4 months with zinc (30 mg/d) and selenium (150 ÃÂ¼g/d) supplementation. ,0,
edin,2443,2001223,Significantly increased,"Furthermore, when analyzed by Ki67 immunohistochemistry, letrozole was significantly more effective than tamoxifen in reducing tumor proliferation (PÂ =Â 0.0009).", reducing tumor proliferation , tamoxifen , aromatase inhibitors (AIs) - letrozole ,0,
edin,2497,3661884,Significantly increased,Both groups showed significant increases in flexibility but in different joints (SSGpre vs. SSGpost; PIGpre vs. PIGpost)., flexibility of joints , baseline , the static stretching (SSG) or passive interval (PIG) ,0,
edin,2349,5331772,No significant difference,"In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).", Intercellular adhesion molecule-1 (ICAM-1) , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2506,5738810,No significant difference,"The three other parameters evaluated by veterinary subjective assessment (lameness, pain at palpation and joint mobility) did not show statistical differences."," lameness, pain at palpation and joint mobility at T0 and T3 ", an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2505,5738810,Significantly decreased,"After 3Â months of feeding, there was a significant reduction of pain at manipulation in the CCOT group, but not in the control group.", Pain at manipulation , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2523,4759876,Cannot tell based on the abstract,, The total blood loss after Total knee arthroplasty (TKA) , intraarticular indwelling closed suction drainage method , subcutaneous indwelling closed suction drainage method  ,0,
edin,2523,4759876,Significantly decreased,The total blood loss after TKA was significantly different between two groups (P = 0.04). The total blood loss (visible drained blood + hidden loss) was less in subcutaneous drainage group., The total blood loss after Total knee arthroplasty (TKA) , intraarticular indwelling closed suction drainage method , subcutaneous indwelling closed suction drainage method  ,0,
edin,2451,4574984,Cannot tell based on the abstract,, numbers overall complications ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2451,4574984,No significant difference,Overall complications occurred in 74% of the patients. There was no difference between intervention and control group (p = 0.79)., numbers overall complications ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2445,2639700,Cannot tell based on the abstract,, mean weekly steps during the first month ," groups with exercise energy expenditure of 4 , 8 , or 12 kcal/kg/week (KKW) ", non-exercise control group ,0,
edin,2445,2639700,Significantly increased,"There were no significant differences in mean weekly steps during the first month among any of the exercise intervention groups, but the non-exercise control group (6098 (2065)) had significantly (P<0.05 for each) more steps compared to all of the exercise groups.", mean weekly steps during the first month ," groups with exercise energy expenditure of 4 , 8 , or 12 kcal/kg/week (KKW) ", non-exercise control group ,0,
edin,2386,2662857,Significantly increased,"Mean parental CGI scores significantly improved in the treatment group compared to controls in overall functioning (p = 0.0336), receptive language (p = 0.0168), and eye contact (p = 0.0322).", Mean parental CGI scores - overall functioning  , control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2496,3661884,No significant difference,"Both groups showed significant increases in strength (SSGpre vs. SSGpost; PIGpre vs. PIGpost) in the same exercises for leg extension (LE) and Low Row (LR). Specifically, in the SSG group, the parameters for LE were (p = 0.0015 and ES = 2.28 - Large), and the parameters for LR were (p = 0.002 and ES = 1.95 - Large). Moreover, in the PIG group, the parameters for LE were (p = 0.009 and ES = 1.95 - Large), and the parameters for LR were (p = 0.0001 and ES = 2.88 - Large). No differences were found between the groups (SSGpost vs. PIGpost).", strength in the exercises for leg extension (LE) and Low Row (LR) , passive interval (PIG) , the static stretching (SSG)  ,0,
edin,2414,4842481,Cannot tell based on the abstract,, compliance coefficient (CC) , control group , WBV training ,0,
edin,2414,4842481,No significant difference,"Similarly, there was no significant interaction effect (p = 0.237) or main effect for compliance coefficient (CC) (Table 2) between the WBV and control groups (p = 0.496).", compliance coefficient (CC) , control group , WBV training ,0,
edin,2332,4602159,Cannot tell based on the abstract,," apnea, laryngospasm, bronchospasm, vomiting ", intravenous lidocaine , topical lidocaine ,0,
edin,2332,4602159,No significant difference,"Other variables including apnea, laryngospasm, bronchospasm, desaturation, and vomiting were not statistically different."," apnea, laryngospasm, bronchospasm, vomiting ", intravenous lidocaine , topical lidocaine ,0,
edin,2501,4266420,Cannot tell based on the abstract,The subjective fatigue of the MBT group was lower than that of the CON (P<0.05) or trail running shoe groups (P<0.05) on day 3., The subjective fatigue on day 3. , control , trail running shoes  ,0,
edin,2501,4266420,No significant difference,No difference between the CON and TR groups was found (P=0.64; Figure 2)., The subjective fatigue on day 3. , control , trail running shoes  ,0,
edin,2340,4749757,Significantly increased,"132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks.", Improvement in Berg Balance Scale (BBS) Score  during 24 weeks , Placebo , Prolonged-release fampridine ,0,
edin,2467,5622764,Cannot tell based on the abstract,, coefficient of variation , placebo (Plac) , StomacolÃÂ® tablets (1.53 g of ÃÂ²-glucan) ,0,
edin,2467,5622764,Significantly increased,"Indeed, whereas glucose variability tended to increase between the first and last two CGM days on Plac (coefficient of variation from 34.3 Â± 1.9 to 39.1 Â± 3.0%; p < 0.05), it remained unchanged on Î²-glucan (from 38.2 Â± 3.2 to 38.9 Â± 2.1%; p = ns (non-significant)), suggesting a time dependent positive effect in maintaining a stable glucose level.", coefficient of variation , placebo (Plac) , StomacolÃÂ® tablets (1.53 g of ÃÂ²-glucan) ,0,
edin,2508,5738810,Cannot tell based on the abstract,, Coll2Ã¢â¬â1 and Coll2Ã¢â¬â1 NO2 serum concentrations , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2508,5738810,No significant difference,Coll2â1 and Coll2â1 NO2 serum concentrations were not significantly different between control and CCOT groups at T0 and T3., Coll2Ã¢â¬â1 and Coll2Ã¢â¬â1 NO2 serum concentrations , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2406,2806387,Significantly increased,The intensity of the unpleasant sensation was rated significantly higher after injection of saline from prefilled syringes compared to saline from polyethylene (p = 0.001)., The intensity of an unpleasant sensation , saline 9 mg/ml for injection in polyethylene package , saline 9 mg/ml syringes ,0,
edin,2390,2662857,Significantly increased,"On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group.", Aberrant Behavior Checklist (ABC) total score - irritability , control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2502,5738810,Cannot tell based on the abstract,, change in dogsÃ¢â¬â¢ body weight , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2502,5738810,No significant difference,There was no significant change in dogsâ body weight nor evidence of side effects over the duration of the study., change in dogsÃ¢â¬â¢ body weight , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2367,4763632,Significantly increased,New dot/globule formation was observed more frequently in the covered and uncovered nevi of PUVA group., Formation of new dot-globule  , Narrowband ultraviolet B (NB-UVB) , Psoralen-ultraviolet A (PUVA) ,0,
edin,2339,4749757,Significantly increased,"PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks.", Improvement in Timed Up and Go (TUG) speed  during 24 weeks , Placebo , Prolonged-release fampridine ,0,
edin,2417,4662683,Significantly increased,"Onset time of swallowing therapy after stroke was effective on swallowing recovery on the main outcome variables. So that in first group patients, recovery was rather than other groups P < 0.050.", recovery ,  (3) late group (1-month after stroke) with swallowing therapy  ,  (2) medium group (2 weeks after stroke) with swallowing therapy  ,0,
edin,2357,5331772,Cannot tell based on the abstract,, VO2max , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2357,5331772,Significantly increased,"The KruskalâWallis test showed VO2max changes (pre- to post-test) were significantly different between groups (P < 0.001).,Tukey's post hoc test revealed increased VO2max in both âexercise + gingerâ (P < 0.000) and âexercise + placeboâ (P < 0.000) groups, in comparison to âgingerâ group.", VO2max , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2351,5331772,Cannot tell based on the abstract,, Baseline characteristics , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2351,5331772,No significant difference,There was no significant difference between three groups regarding the baseline characteristics [Tables 1 and 2]., Baseline characteristics , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2355,5331772,No significant difference,"In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).", Serum interleukin-10 (IL-10) , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2425,3614647,Significantly increased,"Maca-GO significantly stimulated production of E2 (P<0.001) with a simultaneous suppression (P<0.05) of blood FSH, increase (P<0.05) in HDL.", estradiol (E2) level  in group APMM , Placebo , Pre-Gelatinized Organic Maca (Maca-GO) treatment ,0,
edin,2318,3668955,Cannot tell based on the abstract,, Relief of plantar pain , sham trigger point dry needling , real trigger point dry needling ,0,
edin,2318,3668955,No significant difference,"At the primary end-point, significant effects favored real dry needling over sham dry needling for pain (adjusted mean difference: VAS first-step pain -14.4 mm, 95% CI -23.5 to -5.2, p=0.002; FHSQ foot pain 10.0 points, 95% CI 1.0 to 19.1, p=0.029), although the between-group difference was lower than the minimal important difference.", Relief of plantar pain , sham trigger point dry needling , real trigger point dry needling ,0,
edin,2398,3210361,Significantly decreased,"Critically, ketamine also impaired accuracy on the perceptual timing task while having no effect on performance of the colour perception task.", accuracy in the timing task , placebo , ketamine (100&amp;nbsp;ng/ml blood plasma level) ,0,
edin,2478,5742427,Significantly decreased,"The experimental group and control group showed a significant difference in perceived stress (F = 60.11, p < .001),,The results revealed that aromatherapy alleviated stress and improved sleep quality in intensive care unit patients after 2 days of the experimental treatment.", perceived stress , sleep without receiving the lavender aroma oil , deep breathing with essential oils ,0,
edin,2391,2662857,Significantly increased,"On the ABC, significant improvements were observed in the treatment group in total score, irritability, stereotypy, hyperactivity, and speech (p < 0.03 for each), but not in the control group."," Aberrant Behavior Checklist (ABC) total score - irritability, stereotypy, hyperactivity, and speech ", baseline and control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2348,5331772,Significantly decreased,Paired t-test revealed a significant decrease in the density of type 1 monocytes chemo tactic protein (MCP-1) in HIIT + ginger (P = 0.026) and HIIT + placebo (P = 0.001) groups., Density of type 1 monocytes chemo tactic protein (MCP-1) , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2354,5331772,No significant difference,"In spite of this, analysis of variance showed no significant differences in three groups regarding the three indices such as intercellular adhesion molecule-1 (ICAM-1) (P = 0.093), MCP-1(P = 0.075), and serum interleukin-10 (IL-10) (P = 0.164).", Intercellular adhesion molecule-1 (ICAM-1) , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2356,5331772,Cannot tell based on the abstract,, Baseline characteristics , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2356,5331772,No significant difference,There was no significant difference between three groups regarding the baseline characteristics [Tables 1 and 2]., Baseline characteristics , Ginger alone , High-intensity interval training (HIIT) plus either ginger or placebo ,0,
edin,2315,5031764,Significantly increased,Statistical analyses showed a significant decrease in the levels of impulsivity and aggressiveness in the experimental group compared with the control group., decrease in the levels of impulsivity and aggressiveness in experimental group , decrease in the levels of impulsivity and aggressiveness in control grup , mindfulness training psycho-educative program ,0,
edin,2453,4574984,Cannot tell based on the abstract,, overall mortality ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2453,4574984,No significant difference,The overall mortality did not differ significantly between the two groups (Log-Rank-test p = 0.197) (Fig 7)., overall mortality ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2462,5482825,No significant difference,"Change in total cholesterol (pâ=â0.3), low-density lipoprotein (pâ=â0.7), high-densityÂ lipoprotein (pâ=â0.2), and triglycerides (pâ=â0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ=â0.6), monocyte chemoattractant protein-1 (pâ=â0.9), tumour necrosis factor Î± (pâ=â0.2), C-reactive protein (pâ=â0.6) and nuclear factor kappa beta (pâ=â0.2).", interleukin-6 , high AGE diet , Low advanced glycation end products (AGEs) diet ,0,
edin,2323,5300822,Cannot tell based on the abstract,, reduce muscle damage. , post-exercise  vibration stimulation  , pre-exercise vibration stimulation ,0,
edin,2323,5300822,Significantly increased,Pre-induced muscle damage vibration stimulation is more effective than post-induced muscle damage vibration stimulation for preventing muscle damage., reduce muscle damage. , post-exercise  vibration stimulation  , pre-exercise vibration stimulation ,0,
edin,2456,5482825,No significant difference,"Low AGE diets did not change systolic (pâ=â0.2) and diastolic blood pressure (pâ=â0.3), mean arterial pressure (pâ=â0.8) and pulse pressure (pâ=â0.2) compared to high AGE diets.", mean arterial pressure , high AGE diet , Low advanced glycation end products (AGEs) diet ,0,
edin,2392,2662857,Significantly increased,"On the ATEC, sensory/cognitive awareness significantly improved (p = 0.0367) in the treatment group compared to the control group.",  Autism Treatment Evaluation Checklist (ATEC) - sensory/cognitive awareness , control group , 40 hourly treatments of either hyperbaric treatment ,0,
edin,2482,5742427,Significantly decreased,"The experimental group and control group showed a significant difference in perceived stress (F = 60.11, p < .001), objective stress index (F = 25.65, p < .001), systolic blood pressure (F = 9.09, p < .001), diastolic blood pressure (F = 2.47, p = .046), heart rate (F = 5.71, p < .001), and sleep quality (F = 109.46, p < .001).",  heart rate , sleep without receiving the lavender aroma oil , deep breathing with essential oils ,0,
edin,2402,3210361,Cannot tell based on the abstract,,  benefit of temporally valid cues at the short interval , placebo , ketamine (100ng/ml blood plasma level) ,0,
edin,2402,3210361,Significantly increased,"Specifically, the benefit of temporally valid cues was significant at the short (t(10)â=ââ4.71, pâ=â0.001) but not long (t(10)â=ââ0.48, ns) interval (TableÂ 1): when a target does not appear after the short interval as expected it must, by process of elimination, appear at the longer one.",  benefit of temporally valid cues at the short interval , placebo , ketamine (100ng/ml blood plasma level) ,0,
edin,2434,5054611,Cannot tell based on the abstract,, The mean peak inspiratory pressure and plateau pressure , The Laryngeal Tube Suction Disposable (LTS-D)  , the Supreme Laryngeal Mask Airway (SLMA) ,0,
edin,2434,5054611,Significantly decreased,The mean peak inspiratory pressure and plateau pressure in patients with SLMA was significantly lower than in patients with LTS-D (pâ=â0.006) and (pâ=â0.008)., The mean peak inspiratory pressure and plateau pressure , The Laryngeal Tube Suction Disposable (LTS-D)  , the Supreme Laryngeal Mask Airway (SLMA) ,0,
edin,2288,4392900,Significantly decreased,"After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo.", incidence rate of type 2 diabetes , placebo , intent-to-treat population using multiple imputation (ITT-MI)  of subjects with prediabetes and/or MetS ,0,
edin,2338,4749757,Significantly increased,"A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds â©¾7 (p = 0.0275), â©¾8 (p = 0.0153) and â©¾9 points (p = 0.0088) and TUG speed thresholds â©¾10% (p = 0.0021) and â©¾15% (p = 0.0262).", Improvement in the 12-item MS Walking Scale (MSWS-12) Score during 24 weeks , Placebo , Prolonged-release fampridine ,0,
edin,2423,3445058,No significant difference,"<th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th align=""center"" colspan=""3"" rowspan=""1"">% MVIC<hr></th><th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th>"," The supraspinatus, infraspinatus, and anterior deltoid muscle electromyographic (EMG) activity ", upright active forward exercises , gravity-minimized exercises  ,0,
edin,2328,4538249,Cannot tell based on the abstract,, Increase of glycaemic control. , A 1-year follow-up of the RxING study , RxING study first six month ,0,
edin,2328,4538249,Significantly increased,"In the RxING study, HbA1c was reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9) at 26âweeks, a change of 1.8% (95% CI 1.4 to 2, p<0.001). Twelve months after completing the study, HbA1c increased from 7.3% (SD 0.9) at study end to 8.1% (SD 1.3), a change of 0.8% (95% CI â1.1 to â0.5, p<0.001; figure 2).", Increase of glycaemic control. , A 1-year follow-up of the RxING study , RxING study first six month ,0,
edin,2394,5040779,Cannot tell based on the abstract,," success rate of intubation on the first, second, and third attempts ", Macintosh blade , McGRATH MAC and C-MAC ,0,
edin,2394,5040779,Significantly increased,"The success rate of intubation on the first, second, and third attempts increased significantly with the McGRATH MAC and C-MAC compared to the Macintosh blade in the normal airway (P < 0.001 on the first attempt, P < 0.001 on the second attempt, and P = 0.012 on the third attempt)."," success rate of intubation on the first, second, and third attempts ", Macintosh blade , McGRATH MAC and C-MAC ,0,
edin,2359,4794540,Cannot tell based on the abstract,, General health , Prescribed medication without yogic intervention , Yogic intervention and medication ,0,
edin,2359,4794540,Significantly increased,"Significant improvement in domains of anxiety (P<0.01), depression (P<0.02), positive well-being (P<0.01), general health (P<0.04) and vitality (P<0.02) in intervention group was noted after six months of yogic intervention when compared to control group (Table 3).", General health , Prescribed medication without yogic intervention , Yogic intervention and medication ,0,
edin,2364,4763632,Cannot tell based on the abstract,Overall demoscopic changes were observed in 34/37 (91.8%) of the uncovered nevi compared to 16/37 (43.2%) of the covered nevi (P value 0.0001)., Demoscopic changes , Narrowband ultraviolet B (NB-UVB) , Psoralen-ultraviolet A (PUVA) ,0,
edin,2364,4763632,Significantly increased,"The prevalence of overall dermoscopic changes was significantly higher in the PUVA-exposed nevi (100% for PUVA, 88.8% for NB-UVB, P value 0.041).", Demoscopic changes , Narrowband ultraviolet B (NB-UVB) , Psoralen-ultraviolet A (PUVA) ,0,
edin,2415,4662683,Significantly increased,"Onset time of swallowing therapy after stroke was effective on swallowing recovery on the main outcome variables. So that in first group patients, recovery was rather than other groups P < 0.050.", recovery ,  (2) medium group (2 weeks after stroke); and (3) late group (1-month after stroke) with swallowing therapy  , early initiation group (3 days after stroke) with swallowing therapy  ,0,
edin,2316,5031764,Significantly decreased,Statistical analyses showed a significant decrease in the levels of impulsivity and aggressiveness in the experimental group compared with the control group., impulsivity and aggressiveness dimensions for experiemental group , impulsivity and aggressiveness dimensions for control group , Wilcoxon test ,0,
edin,2452,4574984,Significantly decreased,Patients in the intervention group reported significantly less postoperative pain (p = 0.03) than the control group., level of postoperative pain ," control group, which received standard care "," intervention group, i.e. patient empowerment through information booklet and diary keeping  ",0,
edin,2510,4516063,Significantly increased,"Comparing the shear bond strength values, All Bond 2 (Group III) demonstrated fairly higher bond strength values at different levels of dentin. Generally comparing All Bond 2 with the other two experimental groups revealed highly significant statistical results.", bond strength values ," Group I, II and Group III (positive control) ", All Bond 2 (Group III) ,0,
edin,2341,4749757,Cannot tell based on the abstract,, Adverse Events , Placebo , Prolonged-release fampridine ,0,
edin,2341,4749757,No significant difference,The proportion of patients with any AE was similar in placebo-treated patients (49 (77%)) versus patients receiving PR-fampridine (51 (75%))., Adverse Events , Placebo , Prolonged-release fampridine ,0,
edin,2397,5040779,Significantly increased,"The McGRATH MAC and C-MAC significantly increased the success rate of intubation, improved the Cormack-Lehane grade, and decreased the difficulty score compared to the Macintosh blade in both airway settings.", The Cormack-Lehane grade , Macintosh blade , McGRATH MAC and C-MAC ,0,
edin,2469,5622764,Significantly increased,"There was an increase in basic measures of glycaemic control (maximal glucose value 341 Â± 15 vs. 378 Â± 13 mg/dL for Plac and Î²-glucan, p = 0.004), and average daily risk range (62 Â± 5 vs. 79 Â± 4 mg/dL for Plac and Î²-glucan, p = 0.003) favouring Plac over Î²-glucan, but no increase in the M-value (the weighted average of the glucose values) or other more complex measures.", average daily risk range , placebo (Plac) , StomacolÃÂ® tablets (1.53 g of ÃÂ²-glucan) ,0,
edin,2314,4051747,Cannot tell based on the abstract,,"  prenatal knowledge, attitudes,behaviors and beliefs related to text4baby ","  prenatal knowledge, attitudes,behaviors beliefs in usual care ", Text4baby mHealth program ,0,
edin,2314,4051747,Significantly increased,"There were significant improvements in several outcome attitudes, beliefs, and behaviors from BL to FL.","  prenatal knowledge, attitudes,behaviors and beliefs related to text4baby ","  prenatal knowledge, attitudes,behaviors beliefs in usual care ", Text4baby mHealth program ,0,
edin,2416,4662683,Significantly decreased,"Furthermore, the frequency of pneumonia in the early group was less than other groups and in the early group no patients experienced pneumonia P = 0.002.", number of patients experienced pneumonia ,  (2) medium group (2 weeks after stroke); and (3) late group (1-month after stroke) with swallowing therapy  , early initiation group (3 days after stroke) with swallowing therapy  ,0,
edin,2524,4759876,Cannot tell based on the abstract,, The mean visible blood drainage during the first 24 h and between 24 and 48 h after TKA , intraarticular indwelling closed suction drainage method , subcutaneous indwelling closed suction drainage method  ,0,
edin,2524,4759876,Significantly decreased,"The mean visible blood drainage in subcutaneous drainage group was significantly less than intraarticular drainage group, both during the first 24 h and between 24 and 48 h (P < 0.001).", The mean visible blood drainage during the first 24 h and between 24 and 48 h after TKA , intraarticular indwelling closed suction drainage method , subcutaneous indwelling closed suction drainage method  ,0,
edin,2442,2001223,Significantly increased,"Significantly more letrozole-treated patients underwent breast-conserving surgery (45 vs. 35%, respectively; PÂ =Â 0.022).", numbers of breast-conserving surgery , tamoxifen , aromatase inhibitors (AIs) - letrozole ,0,
edin,2514,5038569,Significantly decreased,"he mean Â± standard deviation CMT decreased from 604Â±199 Î¼m at baseline to 319Â±115 Î¼m (P=0.001) at 1 month and to 351Â±205 Î¼m (P=0.026) at 4 months.,The mean BCVA did not improve significantly from baseline (1.00 LogMAR) to the 1-month (0.74 LogMAR; P=0.2) and 4-month (0.71 LogMAR; P=0.13) visits.", central macular thickness (CMT) at 1 month and at 4 months , baseline , intravitreal injections of ziv-aflibercept (1.25 mg/0.05 mL) ,0,
edin,2504,5738810,Cannot tell based on the abstract,, PVF change with time , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2504,5738810,No significant difference,The PVF change (Î T3-T0) was not different between groups (pâ=â0.319) (Fig.Â 2).Fig. 2, PVF change with time , an experimental diet (control) ," an experimental diet supplemented with Curcuminoids extract, hydrolyzed COllagen and green Tea extract (CCOT) ",0,
edin,2363,4763632,Significantly increased,Overall demoscopic changes were observed in 34/37 (91.8%) of the uncovered nevi compared to 16/37 (43.2%) of the covered nevi (P value 0.0001)., Demoscopic changes , All covered nevi , All uncovered nevi ,0,
edin,2458,5482825,No significant difference,"Change in total cholesterol (pâ=â0.3), low-density lipoprotein (pâ=â0.7), high-densityÂ lipoprotein (pâ=â0.2), and triglycerides (pâ=â0.4) also did not differ and there was no difference in inflammatory markers: interleukin-6 (pâ=â0.6), monocyte chemoattractant protein-1 (pâ=â0.9), tumour necrosis factor Î± (pâ=â0.2), C-reactive protein (pâ=â0.6) and nuclear factor kappa beta (pâ=â0.2).", total cholesterol , high AGE diet , Low advanced glycation end products (AGEs) diet ,0,
edin,2329,4538249,Cannot tell based on the abstract,, reduced cardiovascular risk. , base line , RxING study first six month ,0,
edin,2329,4538249,Significantly decreased,"Patientsâ risk of cardiovascular events in the next 10âyears was reduced from 31% (SD 17.3) at baseline to 26.7% (SD 14.5) at study end, an absolute reduction of 4.3% (a 14% relative reduction) (95% CI 0.6 to 9.5, p=0.026).", reduced cardiovascular risk. , base line , RxING study first six month ,0,
edin,2424,3614647,Significantly decreased,"Maca-GO significantly stimulated production of E2 (P<0.001) with a simultaneous suppression (P<0.05) of blood FSH, increase (P<0.05) in HDL.", Follicle Stimulating Hormone (FSH) level in group APMM , Placebo , Pre-Gelatinized Organic Maca (Maca-GO) treatment ,0,
edin,2380,4652407,No significant difference,"No significant differences (pâ>0.05) in insulin, cholesterol measurements (total cholesterol, LDL-C, HDL-C, triglycerides and cholesterol ratios) and atherogenic index between or within groups were observed.", Atherogenic index , Any other food , Commercially produced Scoparia dulcis porridge (SDC) ,0,
edin,2431,5054611,Cannot tell based on the abstract,,  successfull insertion , the Supreme Laryngeal Mask Airway (SLMA) , The Laryngeal Tube Suction Disposable (LTS-D) ,0,
edin,2431,5054611,No significant difference,Gastric tube insertion was successful in all patients in both groups.,  successfull insertion , the Supreme Laryngeal Mask Airway (SLMA) , The Laryngeal Tube Suction Disposable (LTS-D) ,0,
edin,2610,3549413,Cannot tell based on the abstract,, bone mineral density (BMD) At the 6-month time point , baseline , placebo ,0,
edin,2610,3549413,No significant difference,"At the 6-month time point, subjects supplemented with the GBB (nÂ =Â 30) maintained femoral neck BMD, whereas in the placebo group (nÂ =Â 28), BMD significantly decreased (pÂ =Â 0.007, Fig.Â 2a),,The difference in femoral neck BMD between groups remained statistically significant in the intention to treat (ITT) analysis (pÂ =Â 0.05); however, when baseline BMD was factored into the analysis, statistical significance was no longer quite achieved (pÂ =Â 0.058).", bone mineral density (BMD) At the 6-month time point , baseline , placebo ,0,
edin,2632,5767990,Cannot tell based on the abstract,, The mean GI after 3 months , Group B: SRP with placebo gel , Group A: scaling and root planing (SRP) with A. aspera gel ,0,
edin,2632,5767990,Significantly decreased,"The mean GIs in the test and control groups at baseline were 2.60 and 2.57, respectively, and after 3 months were 1.35 and 2.32, respectively, which showed statistically significant results (P < 0.001).,The clinical parameter difference in both the test and control groups from baseline to 3 months showed that the mean GIs in the test and control groups were 1.25 and 0.25, respectively, the mean PDs in the test and control groups were 2.24 and 0.34, respectively, and the mean CALs in the test and control groups were 0.73 and 0.20, respectively, which showed statistically significant results (P < 0.001)", The mean GI after 3 months , Group B: SRP with placebo gel , Group A: scaling and root planing (SRP) with A. aspera gel ,0,
edin,2570,4280425,Significantly decreased,"Total morbidity was 27.5% in the case of patients with conventional surgery, vs. 10.9% with laparoscopic intervention (p < 0.05).", Total morbidity , conventional surgery , laparoscopy within the group with ASA 4Ã¢â¬â5 ,0,
edin,2601,3620559,No significant difference,"Stratifying outcomes by anti-MÃ¼llerian hormone (AMH), as indicator of ovarian reserve, and by body mass index (BMI) the oocyte yields, still, did not differ (AMH, r (17)â=ââ0.20, pâ=â0.44; BMI, r (17) =0.02, pâ=â0.96).",  oocyte yield among women with normal ovarian reserve , 17 G/ 35 mm (standard) needle , 20 G/ 35 mm (thin) needle ,0,
edin,2571,4280425,Cannot tell based on the abstract,, Complications , conventional surgery , laparoscopy within the group with ASA 4Ã¢â¬â5 ,0,
edin,2571,4280425,Significantly decreased,"We found a statistically significant difference in the number of complications in favour of laparoscopy, 10.9% vs. 27.5% for conventional operations.", Complications , conventional surgery , laparoscopy within the group with ASA 4Ã¢â¬â5 ,0,
edin,2625,5446666,No significant difference,"There were also no significant differences between the intervention and control groups at 4 weeks on any of the subscales of the MHC-SF (psychological: P=.95, social: P=.42, emotional: P=.95).", Subscales of Mental Health Continuum-Short Form (MHC-SF) , control group , Web-based self-guided app recommendation service (Ã¢â¬ÅThe ToolboxÃ¢â¬ï¿½) ,0,
edin,2537,5057302,Cannot tell based on the abstract,, Improvement in symptom score , Placebo , Sublingual immunotherapy (SLIT) 10 000 AUN/ml ,0,
edin,2537,5057302,Significantly decreased,"Regarding the primary endpoint, in all treatment groups, a decrease in symptom scores after 5 months of treatment compared to the baseline measurement at screening was observed (32.6% in the placebo group up to 58.4% in the 40 000 AUN/ml group; Table 2).", Improvement in symptom score , Placebo , Sublingual immunotherapy (SLIT) 10 000 AUN/ml ,0,
edin,2563,4814821,Significantly decreased,Telemonitoring was also associated with a reduced number of all-cause re-admissions (0.23âvs. 0.68/patient; pâ=â0.002) and emergency room visits (0.36âvs. 0.91/patient; pâ=â0.006)., ER visits for all causes , usual group , telemonitoring group ,0,
edin,2592,4590407,Cannot tell based on the abstract,, The EG had increased in the soft tissue (primarily FFM) , baseline , 10 mg Zn/day ,0,
edin,2592,4590407,Significantly increased,The EG had increased in the soft tissue (primarily FFM) body composition after oral zinc supplementation compared with before supplementation (p<0.0001)., The EG had increased in the soft tissue (primarily FFM) , baseline , 10 mg Zn/day ,0,
edin,2631,5767990,Cannot tell based on the abstract,, probing depth (PD) , Group B: SRP with placebo gel , Group A: scaling and root planing (SRP) with A. aspera gel ,0,
edin,2631,5767990,Significantly decreased,"The mean PDs in the test and control groups at baseline were 5.16 and 4.44, respectively, and after 3 months were 2.92 and 4.10, respectively, which showed statistically significant results (P < 0.001).", probing depth (PD) , Group B: SRP with placebo gel , Group A: scaling and root planing (SRP) with A. aspera gel ,0,
edin,2566,3961219,Cannot tell based on the abstract,, The mean normalized AUC values for the first phase , baseline , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2566,3961219,Significantly increased,"The mean normalized AUC values for subjects treated with placebo or BBIC at doses of 800, 1,200, 1,600 or 2,000 CI units were 1.00Â±0.13, 1.08Â±0.31, 1.60Â±0.27, 2.53Â±0.27 and 2.03Â±0.34, respectively (Fig. 4). The difference among the treatment groups was statistically significant (P=0.006 by one-way ANOVA).,For the first phase I trial, the normalized AUC for the serum BBI level was moderately correlated with the BBIC dose, with a correlation coefficient of 0.65 and a slope value of 0.0007 (Fig. 3).", The mean normalized AUC values for the first phase , baseline , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2591,4590407,Significantly increased,The body mass index-for-age increased after oral zinc supplementation in the EG (p=0.005)., The body mass index-for-age , sorbitol 10% , 10 mg Zn/day ,0,
edin,2623,2409647,Cannot tell based on the abstract,, the bone marker urinary CTx over the 96-week study period , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2623,2409647,Significantly decreased,"Patients receiving oral ibandronate 50âmg showed a significant decrease from baseline in the bone marker urinary CTx over the 96-week study period compared with placebo (median change â77.3% and +11.0%, P<0.001) (Figure 2Figure 2", the bone marker urinary CTx over the 96-week study period , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2572,4884360,No significant difference,"The CARs for weeks 5â52 were 10.0Â %, 12.4Â %, and 15.3Â % in the NRT, NRT+, and VR groups, respectively; no group differences were observed.", carbon monoxide-confirmed continuous abstinence rates (CAR) , varenicline (VR) ," standard nicotine patch (NRT), extended use of combined formulations of nicotine replacement therapy (NRT+) ",0,
edin,2597,3620559,No significant difference,The standard diameter needle was used to collect a total of 215 oocytes from 355 aspirated follicles (60.6%) compared to 203 oocytes from 352 aspirated follicles (57.7%) with the thinner needle (pâ=â0.23)., The number of oocytes per the number of aspirated follicles , 17 G/ 35 mm (standard) needle , 20 G/ 35 mm (thin) needle ,0,
edin,2552,4714728,Significantly increased,Results indicated that patients in Group B showed higher mean scores (90.3Â±5.4) than Group A (80.4Â±11.5) in terms of ConstantâMurley score (P=0.001)., mean scores of ConstantÃ¢â¬âMurley score , Group A was treated using a hook plate , Group B with autogenous semitendinosus graft and endobutton technique ,0,
edin,2624,5446666,No significant difference,Results demonstrated no significant effect of âThe Toolboxâ intervention on participant well-being at 4 weeks compared with the control group (P=.66)., well-being at 4 weeks , control group , Web-based self-guided app recommendation service (Ã¢â¬ÅThe ToolboxÃ¢â¬ï¿½) ,0,
edin,1993,5808396,Significantly decreased,"Participants receiving CPT experienced moderate reductions in felt stigma relative to those in individual support (Cohenâs Dâ=â0.44, pâ=âvalueâ=â0.02) following the end of treatment,", felt stigma after treatment , individual support , Cognitive Processing Therapy ,0,
edin,2575,3400348,Significantly increased,"Treatment with telmisartan-HCTZ induced significantly greater reductions in BP (â31.1/â18.3âmmâHg) than valsartan-HCTZ (â28.4/â16.3âmmâHg; SBP P = 0.0265, diastolic BP P = 0.0041).",  mean reduction in BP for both systolic blood pressure (SBP) and diastolic blood pressure (DBP)  , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2596,3263888,No significant difference,Lifestyle intervention resulted in higher IS (P = 0.02) and lower unadjusted AIGR0â30 (P = 0.08) during the 4-year follow-up., AIGR0Ã¢â¬â30 during the 4-year follow-up , control  , lifestyle intervention  ,0,
edin,2615,2887326,Significantly increased,The prominent efficacy rate was 19% (7 of 37) in the Hochu-ekki-to group and 5% (2 of 40) in the placebo group (P = 0.06)., The prominent efficacy rate , placebo , Hochu-ekki-to ,0,
edin,2626,5446666,Significantly increased,"Repeat engagement with the study platform resulted in a significant difference in mood, energy, rest, and sleep trajectories between intervention and control groups as measured by EMAs (P<.01)."," mood, energy, rest, and sleep ", control group , Web-based self-guided app recommendation service (Ã¢â¬ÅThe ToolboxÃ¢â¬ï¿½) ,0,
edin,2621,2409647,Cannot tell based on the abstract,, the mean number of measurement periods with events per patient , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2621,2409647,Significantly decreased,"Supportive analyses of new bone events demonstrated that the mean number of events and the mean number of measurement periods with events per patient were significantly reduced in the ibandronate group compared with placebo (P=0.008 and 0.015, respectively, Table 3 Table 3", the mean number of measurement periods with events per patient , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2636,3580611,Significantly increased,"The 30-day rate of stroke or death was 14.7% in the PTAS group (nonfatal stroke, 12.5%; fatal stroke, 2.2%) and 5.8% in the medical-management group (nonfatal stroke, 5.3%; non-stroke-related death, 0.4%) (P = 0.002).", The 30-day rate of stroke or death , medical-management group , percutaneous transluminal angioplasty and stenting (PTAS) ,0,
edin,2541,3376507,Significantly decreased,"Intention-to-treat analysis showed that both intervention groups reduced their BMI compared with the controls (basic: â0.72, SD 1.1 kg/m2, enhanced: â1.0, SD 1.4, control: 0.15, SD 0.82; P < .001)", Body mass index , Wait-list control group , Standard version or enhanced version of commercial Web-based weight-loss program ,0,
edin,2577,3400348,Cannot tell based on the abstract,, DBP change among non-Black patients , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2577,3400348,Significantly increased,"Among non-Black patients, T80/H25 resulted in significantly greater DBP reductions from baseline (adjusted mean DBP change â18.3âmmâHg) than V160/H25 (adjusted mean DBP change â16.5âmmâHg; P = 0.0229).", DBP change among non-Black patients , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2585,4191553,Cannot tell based on the abstract,," Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, and 6 months at the distal one third radius ", placebo , denosumab 60 mg sc every 6 months ,0,
edin,2585,4191553,Significantly increased,"The difference between the two groups was significant as early as 3 months at the lumbar spine, total hip, and femoral neck (P < .0001) and 6 months at the distal one third radius (P < .0001).,Mean BMD percentage change from baseline at 24 months was 9.1% and 0.1% at the lumbar spine in the denosumab and placebo groups, 4.6% and â1.1% at the total hip, 4.0% and â1.1% at the femoral neck, and 0.5% and â1.8% at distal one third radius, respectively (Figure 3, AâD),The difference between the denosumab and alendronate groups was significant as early as 3 months at the lumbar spine and total hip (P < .05), at 12 and 24 months at the femoral neck (P < .05), and from 18 months at the distal one third radius (P < .05)."," Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, and 6 months at the distal one third radius ", placebo , denosumab 60 mg sc every 6 months ,0,
edin,2567,3961219,Cannot tell based on the abstract,, The mean normalized AUC values for the first and second clinical trials , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2567,3961219,Cannot tell based on the abstract,, The mean normalized AUC values for the first and second clinical trials , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2567,3961219,Significantly increased,"The mean normalized AUC value for BBIC-treated subjects (all doses combined) was 1.808 and 1.325 for the first and second clinical trials, respectively, and the difference was statistically significant (P=0.031)", The mean normalized AUC values for the first and second clinical trials , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2616,2887326,Significantly decreased,The aggravated rate was significantly (P < 0.05) lower in the Hochu-ekki-to group (3%; 1 of 37) than in the placebo group (18%; 7 of 39).," the aggravated rate, defined as ratio of patients whose TEA had increased more than 50% at 24 weeks from the beginning of the study ", placebo , Hochu-ekki-to ,0,
edin,2620,2409647,Cannot tell based on the abstract,, the number of skeletal fractures , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2620,2409647,No significant difference,There was no significant difference in the number of skeletal fractures with ibandronate compared with placebo (P=0.195)., the number of skeletal fractures , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2619,2409647,Cannot tell based on the abstract,, bone events requiring surgery , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2619,2409647,No significant difference,"<td align=""left"" charoff=""50"" valign=""top"">Need for surgery</td><td align=""center"" char=""."" charoff=""50"" valign=""top"">0.44</td><td align=""center"" char=""."" charoff=""50"" valign=""top"">0.40, <italic>P</italic>=0.098<sup>*</sup></td>", bone events requiring surgery , placebo , oral ibandronate 50Ã¢â¬â°mg ,0,
edin,2531,3881871,Significantly increased,A statistically significant increase in a* and b* chromatic parameters of the MTA Fillapex Group was measured., Chromatic alterations , ZnOE-based sealer (Roth-811) , MTA Fillapex sealer ,0,
edin,2612,3549413,Cannot tell based on the abstract,, Endometrial Thickness , baseline , calcium only or the geniVidaÃ¢âÂ¢ bone blend (GBB) ,0,
edin,2612,3549413,No significant difference,At no time point did endometrial thickness (ET) differ between the groups., Endometrial Thickness , baseline , calcium only or the geniVidaÃ¢âÂ¢ bone blend (GBB) ,0,
edin,2643,5831281,Cannot tell based on the abstract,, the mean intensity of pruritus , placebo , 1 week with clemastine and levocetirizine ,0,
edin,2643,5831281,No significant difference,"Regarding the studied subgroups, the mean intensity of pruritus according to the VAS before treatment was 5.6 Â±2.7 points in the clemastine group, 4.7 Â±3.2 points in the levocetirizine group and 3.6 Â±1.9 points in the placebo group (p = 0.07).", the mean intensity of pruritus , placebo , 1 week with clemastine and levocetirizine ,0,
edin,2550,2801838,Significantly increased,"At week 12, the human milk group had a sixfold higher geometric mean serum lutein (69.3Â mcg/l; 95% CI 40.3â119) than the unfortified formula group (11.3Â mcg/l; 95% CI 8.1â15.8).", Mean lutein concentration at week 12 , Unfortified formula group , Breastfed infants ,0,
edin,2578,5615289,Cannot tell based on the abstract,, The onset of tolerable and intolerable mucositis  , povidone-iodine , honey mitigates ,0,
edin,2578,5615289,Significantly decreased,The onset of tolerable and intolerable mucositis was delayed in the patients using honey and was significant for week 2 (p < 0.0001) and 3 (p < 0.003)., The onset of tolerable and intolerable mucositis  , povidone-iodine , honey mitigates ,0,
edin,2603,5446455,Significantly decreased,"When the groups were compared at the end of the study, a significant decrease was observed in VAS, PDI and HIT values in the individuals in the BAT and aerobic exercise groups."," Visual Analog Scale (VAS), Pain Disability Index (PDI) and Headache Impact Tests (HIT) ", baseline , control ,0,
edin,2581,5615289,Cannot tell based on the abstract,, The incidence of intolerable mucositis (only grade 3) at the end of week 7  , povidone-iodine , honey mitigates ,0,
edin,2581,5615289,No significant difference,"The incidence of intolerable mucositis (only grade 3) were seen earlier and at the end of week 3 in controls (16% (4/24), p = 0.03) and reached a peak in both the groups at the end of week 7 (12/24 in controls vs. 8/25 in honey (p = 0.2)).", The incidence of intolerable mucositis (only grade 3) at the end of week 7  , povidone-iodine , honey mitigates ,0,
edin,2589,3850342,Significantly increased,"We observed a significantly higher percentage of excellent embryos in ISM1 (42.7%) compared to G-1TM v5 (39%, p<0.05).", percentage of excellent embryos ," routine lab culture medium (G-1TM v5; Vitrolife, ", culture in ISM1 (MediCult) ,0,
edin,2576,3400348,Cannot tell based on the abstract,, reduction in BP for systolic blood pressure (SBP) and diastolic blood pressure (DBP)  , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2576,3400348,Significantly increased,T80/H25 resulted in significantly greater BP reductions from baseline (adjusted mean SBP/DBP change â31.6/â18.0âmmâHg) than V160/H25 (adjusted mean SBP/DBP change â28.0/â15.8âmmâHg; P = 0.0063 for difference in SBP and P = 0.0041 for DBP)., reduction in BP for systolic blood pressure (SBP) and diastolic blood pressure (DBP)  , valsartan 160Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg , telmisartan 80Ã¢â¬â°mg combined with hydrochlorothiazide (HCTZ) 25Ã¢â¬â°mg ,0,
edin,2629,5556716,Significantly decreased,"Likewise, among the Plane II fracture patients, those who underwent ultrasound-guided reduction were less dissatisfied than those who underwent blind reduction (p=0.043).", level of patients dissatisfaction , control group (blind reduction) Plane II fracture , ultrasound-guided reduction Plane II fracture ,0,
edin,2544,3376507,Significantly increased,"Intention-to-treat analysis showed that both intervention groups reduced their BMI compared with the controls (basic: â0.72, SD 1.1 kg/m2, enhanced: â1.0, SD 1.4, control: 0.15, SD 0.82; P < .001) and lost significant weight (basic: â2.1, SD 3.3 kg, enhanced: â3.0, SD 4.1, control: 0.4, SD 2.3; P < .001) with changes in waist circumference (basic: â2.0, SD 3.5 cm, enhanced: â3.2, SD 4.7, control: 0.5, SD 3.0; P < .001) and waist-to-height ratio (basic: â0.01, SD 0.02, enhanced: â0.02, SD 0.03, control: 0.0, SD 0.02; P < .001), but no differences were observed between the basic and enhanced groups.", Improvement in waist-to-height ratio , Wait-list control group , Standard version or enhanced version of commercial Web-based weight-loss program ,0,
edin,2640,5101645,Significantly increased,The sedation scores were higher in the BD group than in the other two groups at all time points (P < 0.001)., The sedation scores , the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg) , the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg dexmedetomidine ,0,
edin,2540,5057302,Cannot tell based on the abstract,," Safety laboratory parameters, ECG, and physical exam. ", Placebo , Sublingual immunotherapy (SLIT)  ,0,
edin,2540,5057302,No significant difference,"No clinically significant changes were observed in safety laboratory (haematology and blood chemistry) parameters, urinalysis, vital signs, physical examination and ECG."," Safety laboratory parameters, ECG, and physical exam. ", Placebo , Sublingual immunotherapy (SLIT)  ,0,
edin,2586,4191553,Cannot tell based on the abstract,," Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, at 12 and 24 months at the femoral neck, and from 18 months at the distal one third radius ", oral alendronate 35 mg weekly , denosumab 60 mg sc every 6 months ,0,
edin,2586,4191553,Significantly increased,"As the referential comparison, the difference between the alendronate and placebo groups was significant as early as 3 months at the lumbar spine, total hip, and femoral neck (P < .01) and 6 months at the distal one third radius (P < .01). The difference between the denosumab and alendronate groups was significant as early as 3 months at the lumbar spine and total hip (P < .05), at 12 and 24 months at the femoral neck (P < .05), and from 18 months at the distal one third radius (P < .05)."," Bone mineral density after 3 months at the lumbar spine, total hip, and femoral neck, at 12 and 24 months at the femoral neck, and from 18 months at the distal one third radius ", oral alendronate 35 mg weekly , denosumab 60 mg sc every 6 months ,0,
edin,2639,5021260,Cannot tell based on the abstract,, The median coverage , low vaccine coverage rings , high coverage rings ,0,
edin,2639,5021260,Significantly increased,"The median coverage in the high coverage rings (coverage â¥ 30%) was 41% (interquartile range 34%â44%), compared to 0% (interquartile range 0%â6%) in the low vaccine coverage rings (coverage â¤ 12%).", The median coverage , low vaccine coverage rings , high coverage rings ,0,
edin,2609,5446455,Cannot tell based on the abstract,, VT: Vitality , baseline , aerobic exercise  ,0,
edin,2609,5446455,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1""><bold>AE Group</bold></td><td align=""center"" colspan=""1"" rowspan=""1"">42.56Â±6.13</td><td align=""center"" colspan=""1"" rowspan=""1"">0.334</td><td align=""center"" colspan=""1"" rowspan=""1"">0.718</td><td align=""center"" colspan=""1"" rowspan=""1"">51.30Â±8.13</td><td align=""center"" colspan=""1"" rowspan=""1"">4.08</td><td align=""center"" colspan=""1"" rowspan=""1"">0.02</td>", VT: Vitality , baseline , aerobic exercise  ,0,
edin,2554,4714728,Significantly increased,"Group B patients scored higher in terms of pain (P=0.002), activities (P=0.02), range of motion (P<0.001), and strength (P=0.004).", activities , Group A was treated using a hook plate , Group B with autogenous semitendinosus graft and endobutton technique ,0,
edin,2647,4639339,Significantly increased,The use of Midazolam as a benzodiazepine with known sedative and muscle relaxant effects can increase the success rate of enema reduction in intussusception., reduction in intussusception , placebo ," Midazolam at the concentration of 1.0 mg/kg (up to 3 mg) was infused, and then barium reduction was performed under fluoroscopy guideline ",0,
edin,2569,4280425,Significantly decreased,"The results favour laparoscopy within the group with ASA 1â3 in terms of several parameters, namely: duration of hospitalization â 7.7 days in the case of laparoscopic intervention, vs. 10.6 days for conventional surgery (p < 0.05);", duration of hospitalization , conventional surgery , laparoscopy within the group with ASA 1Ã¢â¬â3 ,0,
edin,2642,5101645,Cannot tell based on the abstract,, the mean pain scores , the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg)  ,  the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg dexmedetomidine ,0,
edin,2642,5101645,No significant difference,There was no significant difference in the mean postoperative pain scores between different time points in each group., the mean pain scores , the bupivacaine-fentanyl group (Group BF) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg fentanyl and the bupivacaine group (Group B) received 0.25% bupivacaine (1 ml/kg)  ,  the bupivacaine-dexmedetomidine group (Group BD) received 0.25% bupivacaine (1 mL/kg) plus 2 ÃÂµg/kg dexmedetomidine ,0,
edin,2580,5615289,Cannot tell based on the abstract,,  the incidence of grade 2 mucositis at week 2 , povidone-iodine , honey mitigates ,0,
edin,2580,5615289,Significantly decreased,"With continuation of the treatment, the incidence of grade 2 mucositis appeared only in the controls (32% (8/25) vs. 0% (0/25)) and was significant (p = 0.002) at week 2.",  the incidence of grade 2 mucositis at week 2 , povidone-iodine , honey mitigates ,0,
edin,2602,5446455,Significantly decreased,"When the groups were compared at the end of the study, a significant decrease was observed in VAS, PDI and HIT values in the individuals in the BAT and aerobic exercise groups."," Visual Analog Scale (VAS), Pain Disability Index (PDI) and Headache Impact Tests (HIT) ", baseline , Body Awareness Therapy (BAT) and aerobic exercise  ,0,
edin,2565,3961219,Cannot tell based on the abstract,, The mean normalized area under the curve (AUC) values for the second phase , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2565,3961219,No significant difference,"For the second phase I trial, the normalized AUC for the serum BBI level was only weakly correlated with the BBIC dose, with a correlation coefficient of 0.36 and a slope value of 0.0003 (Fig. 3).,The mean normalized AUC values for the subjects treated with placebo or BBIC at doses of 800, 1,200, 1,600 or 2,000 CI units were 1.00Â±0.24, 0.91Â±0.39, 1.51Â±0.29, 1.39Â±0.12 and 1.49Â±0.33, respectively (Fig. 4), and the difference was not statistically significant (P=0.446 by one-way ANOVA).", The mean normalized area under the curve (AUC) values for the second phase , placebo , Bowman-Birk inhibitor concentrate (BBIC) ,0,
edin,2590,3850342,Significantly increased,Babies born after culture in ISM1 had both higher birth weight (3.03 kg) and length (48.8 cm) compared to G-1TM v5 babies that had a birth weight of 2.66 kg and a length of 46.0 cm (p<0.001 for both).,"  the length, weight babies born  "," routine lab culture medium (G-1TM v5; Vitrolife, ", culture in ISM1 (MediCult) ,0,
edin,2558,4204994,Significantly decreased,Low-dose Epoetin beta decreased PMI on days 4 and 11 to 46.0 (12.8)% (p<0.00001) and 46.1 (10.4)% (p<0.00001)., percentages of migrated isoforms (PMI) on days 4 and 11 , placebo on all days ," low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13) ",0,
edin,2561,4814821,Cannot tell based on the abstract,, time to first COPD-related emergency room (ER) visit , usual group , telemonitoring group ,0,
edin,2561,4814821,Significantly increased,"In addition, telemonitoring intervention was associated with increased time to first COPD-related ER visit (Fig. 3), with an HR of 0.50 (95% CIâ=â0.24â1.04) over the six months of follow-up.", time to first COPD-related emergency room (ER) visit , usual group , telemonitoring group ,0,
edin,2559,4204994,Significantly decreased,"In both rhEPO groups, PMI on day 25 was still decreased (high-dose Epoetin beta: 72.9 (19.4)% (pâ=â0.029); low-dose Epoetin beta: 73.1 (17.8)% (pâ=â0.039)).", percentages of migrated isoforms (PMI) on day 25 , placebo on all days ," high-dose Epoetin beta (30.000 IU on days 1, 2 and 3 and placebo on days 5, 7, 9, 11 and 13) and low-dose Epoetin beta (5000 IU on days 1, 3, 5, 7, 9, 11 and 13),  ",0,
edin,2583,4191553,Significantly increased,"Denosumab significantly reduced the risk of new or worsening vertebral fracture by 65.7%, with incidences of 3.6% in denosumab and 10.3% in placebo at 24 months (hazard ratio 0.343; 95% confidence interval 0.194â0.606, P = .0001).", the reduction in risk of 24-month incidence of new or worsening vertebral fracture , placebo , denosumab 60 mg sc every 6 months  ,0,
edin,2582,5615289,Cannot tell based on the abstract,, weight loss , povidone-iodine , honey mitigates ,0,
edin,2582,5615289,Significantly decreased,"Additionally, it was observed that when compared to the povidone-iodine (4.86 Â± 1.73) group, the weight loss was less in the honey cohorts (2.77 Â± 0.85) and was statistically significant (p < 0.001).", weight loss , povidone-iodine , honey mitigates ,0,
edin,2608,5446455,Cannot tell based on the abstract,, VT: Vitality , control , aerobic exercise  ,0,
edin,2608,5446455,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1""><bold>AE Group</bold></td><td align=""center"" colspan=""1"" rowspan=""1"">42.56Â±6.13</td><td align=""center"" colspan=""1"" rowspan=""1"">0.334</td><td align=""center"" colspan=""1"" rowspan=""1"">0.718</td><td align=""center"" colspan=""1"" rowspan=""1"">51.30Â±8.13</td><td align=""center"" colspan=""1"" rowspan=""1"">4.08</td><td align=""center"" colspan=""1"" rowspan=""1"">0.02</td>", VT: Vitality , control , aerobic exercise  ,0,
edin,2535,4593658,No significant difference,"The serum Cr increased and GFR decreased significantly during the intervention in three groups (P < 0.010). However, the amounts of these changes were equal between groups (P > 0.050).", Glomerular filtration rate , Only normal saline (Group C) , N-acetylcysteine plus normal saline (Group A) and Ascorbic acid plus normal saline (Group B) ,0,
edin,2634,4802087,Cannot tell based on the abstract,, Forced Expiratory Volume in the first second (FEV1) , placebo ," 100,000 IU of oral vitamin D per month, for 6 months ",0,
edin,2634,4802087,Significantly increased,"Also, after the study, in the study group, FEV1 was increased and the number of COPD exacerbations was decreased significantly (Table 4).,<td align=""left"" colspan=""1"" rowspan=""3"">COPD exacerbation (MÂ±SD)</td><td align=""left"" colspan=""1"" rowspan=""1"">Before</td><td align=""left"" colspan=""1"" rowspan=""1"">18.02Â±3.3</td><td align=""left"" colspan=""1"" rowspan=""1"">18.7Â±3.8</td><td align=""left"" colspan=""1"" rowspan=""1"">0.38</td>", Forced Expiratory Volume in the first second (FEV1) , placebo ," 100,000 IU of oral vitamin D per month, for 6 months ",0,
edin,2698,3919744,Cannot tell based on the abstract,, COP path length in the AP plane , Exercises with whole-body vibration (Groups II and III) and exercises without the application of concurrent vibration (Group IV) , Exercises with whole-body vibration (Group I) ,0,
edin,2698,3919744,Significantly increased,Group I was the only group where the COP path length in the AP plane was significantly increased after the last session of the 4-week whole-body vibration training (pâ=â0.046) (fig. 4, COP path length in the AP plane , Exercises with whole-body vibration (Groups II and III) and exercises without the application of concurrent vibration (Group IV) , Exercises with whole-body vibration (Group I) ,0,
edin,2784,5579675,Significantly decreased,"VAS scores for hunger, prospective eating, and desire to eat were all reduced (p < 0.05).","  Hunger, Prospective eating, desire to eat (Pre, immediately before, after, and 30 min post exercise). ", placebo (PLC) , 2 g of YM ,0,
edin,2658,3219777,Cannot tell based on the abstract,, Observer's Assessment of Alertness/Sedation scores after incision , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2658,3219777,Significantly decreased,"In the Control group, the VNRS value at 1 min after incision significantly increased and OAA/S values at 3, 5, and 30 min after incision significantly decreased compared to baseline values, while there were no significant changes in the ketamine group.", Observer's Assessment of Alertness/Sedation scores after incision , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2673,5385703,No significant difference,"Despite a continuous reduction in VASI score in both groups, according to both physician (P = 0.13) and patient (P = 0.374) assessment oral simvastatin was not statistically more effective than conventional treatment of vitiligo.", Vitiligo Area Scoring Index score , Topical betamethasone valerate cream (Group A) , Betamethasone valerate cream plus oral simvastatin (Group B) ,0,
edin,2655,3137994,No significant difference,There is no significant difference in the mortality rate between the âsurgicalâ and non-âsurgicalâ groups of Iranian patients with SAH., Mortality rate , Medical treatment , Surgical treatment ,0,
edin,2707,3599990,No significant difference,"Mean differences between self-reported and measured weight (pâ=â0.4004), height (pâ=â0.5342) and body mass index (BMI) (pâ=â0.4409) were not statistically different between the informed and uninformed group", Differences between self-reported and measured body mass index , Uninformed group , Informed group ,0,
edin,2778,4972969,Cannot tell based on the abstract,," Within the No-IMID subgroup - the proportion of emergency and priority patients admitted, detained or referred ", Control , on-site support (OSS) ,0,
edin,2778,4972969,Significantly increased,"Within the No-IMID subgroup, the incremental effect of OSS was statistically significant for only two indicators; increases in the proportion of emergency and priority patients admitted, detained or referred (Indicator 2, aRRRâ=â2.12, 99 % CIâ=â1.05-4.28, pâ=â0.006),"," Within the No-IMID subgroup - the proportion of emergency and priority patients admitted, detained or referred ", Control , on-site support (OSS) ,0,
edin,2765,4715405,Cannot tell based on the abstract,"In intervention group, mean level of blood glucose, 2 hours after lunch at 28 weeks of pregnancy was significantly lower than the control group (P<0.05).", MeanÃÂ±SD level of blood glucose before sleeping at 28 weeks of pregnancy , three times of telephone call was established to record blood sugar levels , telephone intervention was performed for 10 weeks ,0,
edin,2765,4715405,No significant difference,MeanÂ±SD level of blood glucose before sleeping at 28 weeks of pregnancy was 124.7Â±13.9 mg/dl in control and 113.2Â±15.8 mg/dl in intervention group (p=0.1)., MeanÃÂ±SD level of blood glucose before sleeping at 28 weeks of pregnancy , three times of telephone call was established to record blood sugar levels , telephone intervention was performed for 10 weeks ,0,
edin,2701,3919744,No significant difference,Most changes in the values of the center of pressure (COP) path lengths in the sagittal and frontal plane were statistically insignificant., Sagittal and frontal planes COP path length values , Exercises without the application of concurrent vibration (Group IV) ," Exercises with whole-body vibration (Group I, II and III) ",0,
edin,2660,3219777,Cannot tell based on the abstract,, Satisfaction scale of physicians and patients , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2660,3219777,No significant difference,The satisfaction scale (1 to 4) of the surgeons and the patients were high in both groups (4 vs. 4)., Satisfaction scale of physicians and patients , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2680,4517027,Significantly increased,"Breakfast was also beneficial for appetite control before lunch irrespective of size (all p < 0.05, d > 0.43).", Appetite control , No breakfast before exercise , Pre-exercise breakfast ,0,
edin,2762,3688436,No significant difference,"Over the course of 4 weeks, we failed to find that donepezil produced any significant difference in the YMRS (6.71 units difference, t = â1.44, P = 0.16) or the BPRS scale (1.29 units difference, t = â0.33, P = 0.75) as compared to placebo.", YMRS and the BPRS scale over the course of 4 weeks , placebo in addition to lithium , donepezil in addition to lithium ,0,
edin,2732,3348688,Significantly increased,"The bending stiffness anterior-posterior (treatment group 17.48 Nm vs. control group 8.3 Nm), medial-lateral (treatment group 18,9 Nm vs. control group 7.92 Nm) and the torsional stiffness (treatment group 41.17N/Â° vs. control group 16.41N/Â°) are significantly higher in the treatment group than in the control group."," The bending stiffness anterior-posterior, medial-lateral and the torsional stiffness  ", no injection (B) , triple injection of 1 mL rhBMP-2/NaCl (4 mg rhBMP-2/ml) (A)  ,0,
edin,2720,5856914,Significantly increased,"The CANDEN spine inflammation score had high responsiveness, similar to the SPARCC MRI spine index (Guyattâs responsiveness index 1.88 and 1.67, respectively), and discriminated between adalimumab and placebo treatment already at 6 weeksâ follow-up (P=0.03).", The CANDEN spine inflammation score , placebo , adalimumab ,0,
edin,2712,3452084,Significantly increased,"<td align=""left"" colspan=""4"">TOTPAR</td>", Time course of total pain relief (TOTPAR) ,  placebo (PLA) ," paracetamol 1,000mgÃ¢â¬âcaffeine 130mg (PCF)  and naproxen sodium 550 mg (NAP) ",0,
edin,2699,3919744,Cannot tell based on the abstract,, Vibration frequency , Exercises with whole-body vibration (Groups II and III)  , Exercises with whole-body vibration (Group I) ,0,
edin,2699,3919744,No significant difference,"The Mann Whitney U test did not show a significant influence of vibration frequency and amplitude on the path length of the COP and rambling and trembling paths (p>0.05) between the pre-test measurements and those made directly after the first session of whole-body vibration, immediately after the last set of exercises of the 4-week whole-body vibration training and one week after.", Vibration frequency , Exercises with whole-body vibration (Groups II and III)  , Exercises with whole-body vibration (Group I) ,0,
edin,2693,1796543,Cannot tell based on the abstract,, Changes in TLR5 and TLR10 , Placebo , Imiquimod 5% cream ,0,
edin,2693,1796543,No significant difference,There was no change in the expression levels of TLR5 and TLR10 upon treatment with imiquimod., Changes in TLR5 and TLR10 , Placebo , Imiquimod 5% cream ,0,
edin,2787,2430617,Cannot tell based on the abstract,, adverse events , placebo ," 30 ÃÂµg YIC, 60 ÃÂµg of YIC ",0,
edin,2787,2430617,No significant difference,"The occurrence of serious adverse events calculated according to the intent-to-treat principle was 5.1% (4/79), 3.6% (3/83), and 5.0% (4/80) in the placebo, 30 Âµg YIC and 60 Âµg YIC groups respectively (p>0.05).", adverse events , placebo ," 30 ÃÂµg YIC, 60 ÃÂµg of YIC ",0,
edin,2683,5529957,No significant difference,"Cardiac index improved in inoperable patients by a least-squares mean difference of +0.6âL/min/m2 (95% CI 0.4 to 0.7; p<0.0001), while in persistent/recurrent patients the change was +0.2âL/min/m2 (95% CI â0.1 to 0.5; p=0.17).", Improvement of cardiac index in persistent/recurrent patients , Placebo group , Riociguat group ,0,
edin,2745,3604854,No significant difference,The mean preoperative refraction in LDMMC eyes was â3.08 (SD 1.65) sphere and 0.92 (SD 0.88) cylinder. These values for SDMMC eyes were â3.25 (SD 1.80) sphere and 0.81 (SD 0.84) cylinder., The mean preoperative refraction and cylinder , standard dose MMC (SDMMC , low dose intraoperative MMC (LDMMC) ,0,
edin,2665,2806530,Significantly decreased,Results showed significant reductions in TCI after alcohol administration in female participants exclusively., Transcallosal inhibition in women , Placebo , Alcohol ,0,
edin,2713,3843300,Significantly decreased,"The serum level of blood urea nitrogen (BUN) and creatinine (Cr) in the control group increased significantly (P < 0.05), and administration of NAC (150 mg/kg) decreased the serum levels of Cr and BUN.", serum level of blood urea nitrogen (BUN) and creatinine (Cr) , control , sham-operated group ,0,
edin,2740,2212351,Significantly decreased,"Similarly, fasting blood glucose (FBG) levels decreased significantly between 1 and 12 months in group M (p<0.05), and decreased significantly during the entire 12 month period in group D (p<0.01).", fasting blood glucose (FBG) , no intervention , diabetic meal delivery for 12 months (group M) ,0,
edin,2756,4053826,No significant difference,"There was no difference with respect to pain scores on movement, nor with respect to patient satisfaction.", pain score on movement , the 0.9% saline continuous infusion (the control group) , the ropivacaine continuous infusion (the Ropi group) ,0,
edin,2747,3604854,No significant difference,Mean postoperative cylinder 3 and 6 month after PRK was 0.435 (SD 0.218) and 0.423 (SD 0.255)., Mean postoperative cylinder 3 and 6 month after PRK , standard dose MMC (SDMMC , low dose intraoperative MMC (LDMMC) ,0,
edin,2744,2212351,Cannot tell based on the abstract,, serum lipids , conventional dietary education (group C) , individual dietary counseling for 12 months (group D) or diabetic meal delivery for 12 months (group M) ,0,
edin,2744,2212351,No significant difference,"There were no significant changes in serum lipids levels in the three intervention groups, although serum TG levels were tended to decrease in groups M and D.", serum lipids , conventional dietary education (group C) , individual dietary counseling for 12 months (group D) or diabetic meal delivery for 12 months (group M) ,0,
edin,2722,4362117,Cannot tell based on the abstract,, percentage of Prevotella intermedia (Pi) and Porphyromonas gingivalis (Pg) , control group (CG) received only scaling and root planing (SRP) , One month after systemic doxycycline during the reevaluation visit 45 days after the completion of scaling and root planing (SRP) ,0,
edin,2722,4362117,Significantly decreased,"One month after the administration of doxycycline, both Pg, and Pi showed significant reduction in the percentage of site for TG compared with CG (p<0.01 and p=0.04).", percentage of Prevotella intermedia (Pi) and Porphyromonas gingivalis (Pg) , control group (CG) received only scaling and root planing (SRP) , One month after systemic doxycycline during the reevaluation visit 45 days after the completion of scaling and root planing (SRP) ,0,
edin,2811,5491994,Cannot tell based on the abstract,, rating the quality of the physicianÃ¢â¬â¢s explanation , control group ," explanation of patients anatomy, disease state, and treatment options using the education model as an aid ",0,
edin,2811,5491994,Significantly increased,"Patient responses in the 3D model group increased significantly when rating the quality of the physicianâs explanation, their own understanding of their anatomy, their own understanding of their disease state, and their understanding of the proposed surgical treatment.", rating the quality of the physicianÃ¢â¬â¢s explanation , control group ," explanation of patients anatomy, disease state, and treatment options using the education model as an aid ",0,
edin,2766,4715405,Significantly increased,Mean differences in levels of fasting blood glucose between 28 weeks and 32 and between 28 and 36 weeks of pregnancy were significantly higher in the intervention than the control group (P<0.05)., MeanÃÂ±SD of differences in levels of fasting blood glucose between 28 and 32 weeks and between 28 and 36 weeks of pregnancy , three times of telephone call was established to record blood sugar levels , telephone intervention was performed for 10 weeks ,0,
edin,2798,3329100,Significantly increased,"Findings of the study revealed a significant effect of the interval training program on VO2max, SBP, and DBP and WBC count at P<0.05 and VO2max is negatively related to the WBC count (r=â0.339) at P<0.01."," volume of O2 maximum (VO2max), systolic blood pressure (SBP) , white blood cell (WBC) and diastolic blood pressure (DBP) ", the age-matched controls hypertensive  group , 8-week interval training (60-79% HR max reserve) program of between 45 minutes to 60 minutes ,0,
edin,2678,4517027,Cannot tell based on the abstract,, Alertness after exercise , No breakfast before exercise , Pre-exercise breakfast ,0,
edin,2678,4517027,Significantly increased,Energy intake at breakfast prior to exercise was also significantly related to post-exercise alertness (r (43) = 0.315; p = 0.037) and overall mood (r (43) = 0.372; p = 0.013)., Alertness after exercise , No breakfast before exercise , Pre-exercise breakfast ,0,
edin,2771,5735486,Cannot tell based on the abstract,, MAP and HR , Group C receiving identical-looking placebo , Group F receiving preoperative flupirtine ,0,
edin,2771,5735486,No significant difference,MAP and HR between two groups were found to be quite comparable among two groups (P > 0.05) [Figures 1 and 2]., MAP and HR , Group C receiving identical-looking placebo , Group F receiving preoperative flupirtine ,0,
edin,2813,4247720,Significantly increased,"The rate of memory retention, computed by dividing Logical Memory delayed recall by immediate recall, showed a significant interaction (pâ<â.05) in analysis of covariance.,Simple main effects showed that the rate of memory retention of the intervention group improved after the program completion (pâ<â.05).", rate of retention , control group , cognitive intervention through a training program for picture book reading for In the participants with mild cognitive impairment (MCI) ,0,
edin,2661,5777197,Significantly increased,Hazard of death in the first four months was greatest in subjects receiving continuous high-dose lenalidomide; hazards of death thereafter were similar., Risk of death in the first four months , Sequential azacitidine and lenalidomide group and azacitidine only group , High-dose continuous lenalidomide group ,0,
edin,2788,4884260,No significant difference,Regarding the difference between groups for analgesic requirement there were two major points - on one hand it was statistically significant p < 0.05 whereas on the other hand time to first analgesic administration was not statistically significant p = 0.40., analgesic requirement , Local Infiltration Group received 0.2 ml/kg 0.25% bupivacaine , Caudal Group received 1 ml/kg of 0.25% bupivacaine ,0,
edin,2689,5529957,Significantly decreased,"Mean pulmonary artery pressure decreased in inoperable and persistent/recurrent patients(â4.7âmmâHg (95% CI â6.9 to â2.6; p<0.0001 and â4.8âmmâHg (â8.2 to â1.5; p=0.0055), respectively).", Mean pulmonary artery pressure , Placebo group , Riociguat group ,0,
edin,2799,4918317,Cannot tell based on the abstract,, The survival times , placebo , Long-chain omega-3 polyunsaturated fatty acids (PUFAs) ,0,
edin,2799,4918317,Significantly increased,"The survival times were significantly different between the treatment groups, with a more rapid conversion time for the placebo group compared with the omega-3 PUFA group (log-rank test: Ï2=9.84, P=0.002) (Fig. 2)", The survival times , placebo , Long-chain omega-3 polyunsaturated fatty acids (PUFAs) ,0,
edin,2797,5079604,Significantly increased,Subjects who remained in remission had a higher DI (P = 0.02) and incremental AUCi (P < 0.001) than those with hyperglycemia relapse without significant changes in Si., Disposition index (DI) and incremental area under the curve for insulin (AUCi)  , patients with hyperglycemia relapse without significant changes in insulin sensitivity (Si) , subjects who remained in remission ,0,
edin,2723,5268424,Cannot tell based on the abstract,, score on the general dimension scale of negative affects (referred to as NA from here onward) , control , view a video featuring individuals that live in extreme poverty ,0,
edin,2723,5268424,Significantly increased,"These tables show that the Poverty treatment yields a higher score on the general dimension scale of negative affects (referred to as NA from here onward), compared to the Neutral treatment (p<0.01).", score on the general dimension scale of negative affects (referred to as NA from here onward) , control , view a video featuring individuals that live in extreme poverty ,0,
edin,2780,5579675,Significantly increased,Combining YM intake with prolonged exercise at targeted âfat-lossââ intensities augments FAO and improves measures of satiety and mood state., fatty acid oxidation (FAO) , placebo (PLC) , 2 g of YM ,0,
edin,2666,2806530,Cannot tell based on the abstract,, Transcallosal inhibition in men , Placebo , Alcohol ,0,
edin,2666,2806530,No significant difference,"Post hoc analyses demonstrated that alcohol significantly reduced TCI in females (F(1, 11)â=â12.52; pâ=â0.005; Î·p2â=â0.53) but not in males (F(1, 9)â=â0.10; pâ=â0.76; Fig.Â 1). Fig.Â 1", Transcallosal inhibition in men , Placebo , Alcohol ,0,
edin,2700,3919744,Cannot tell based on the abstract,, Amplitude parameters , Exercises with whole-body vibration (Groups II and III)  , Exercises with whole-body vibration (Group I) ,0,
edin,2700,3919744,No significant difference,"The Mann Whitney U test did not show a significant influence of vibration frequency and amplitude on the path length of the COP and rambling and trembling paths (p>0.05) between the pre-test measurements and those made directly after the first session of whole-body vibration, immediately after the last set of exercises of the 4-week whole-body vibration training and one week after.", Amplitude parameters , Exercises with whole-body vibration (Groups II and III)  , Exercises with whole-body vibration (Group I) ,0,
edin,2742,2212351,Significantly decreased,"Similarly, fasting blood glucose (FBG) levels decreased significantly between 1 and 12 months in group M (p<0.05), and decreased significantly during the entire 12 month period in group D (p<0.01).", fasting blood glucose (FBG) levels , no intervention , individual dietary counseling for 12 months (group D) ,0,
edin,2696,3019750,No significant difference,No significant differences were found between G1 and G2 for enamel hardness and wear., Enamel wear , Saliva in situ (G1) , Saliva with fluoride (G2) ,0,
edin,2697,3919744,No significant difference,Most changes in the values of the center of pressure (COP) path lengths in the sagittal and frontal plane were statistically insignificant., Sagittal and frontal planes COP path length values , Exercises without the application of concurrent vibration (Group IV) ," Exercises with whole-body vibration (Group I, II and III) ",0,
edin,2748,3604854,Cannot tell based on the abstract,, haze formation rate , standard dose MMC (SDMMC , low dose intraoperative MMC (LDMMC) ,0,
edin,2748,3604854,No significant difference,Comparison of haze formation rate in these two groups by Mann-Whitney test demonstrated no significant difference in results (P = 0.104 3rd month and P = 0.156 6th month after operation), haze formation rate , standard dose MMC (SDMMC , low dose intraoperative MMC (LDMMC) ,0,
edin,2777,4972969,Cannot tell based on the abstract,, proportion of patients with a negative malaria test result prescribed an antimalarial  in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group , Control , on-site support (OSS) ,0,
edin,2777,4972969,Significantly increased,"Within the IMID-MLP, the incremental effect of OSS was statistically significant for three indicators; increases in estimated proportion of malaria cases who received an appropriate antimalarial (Indicator 5, aRRRâ=â1.26, 99 % CIâ=â1.02-1.56, pâ=â0.005) and estimated proportion of patients with acid-fast bacilli (AFB) smear negative results who received empiric treatment for acute respiratory infection (indicator 11, aRRRâ=â2.04, 99 % CIâ=â1.06-3.94, pâ=â0.005) and decrease in proportion of patients with a negative malaria test result prescribed an antimalarial (Indicator 6, aRRRâ=â0.49, 99 % CIâ=â0.26-0.92, pâ=â0.004).", proportion of patients with a negative malaria test result prescribed an antimalarial  in integrated management of infectious diseases (IMID)- mid-level practitioners (MLP) group , Control , on-site support (OSS) ,0,
edin,2721,4362117,Cannot tell based on the abstract,, decline in the percentage of sites harboring Tannerella forsythia (Tf) , control group (CG) received only scaling and root planing (SRP) , One month after administeration systemic doxycycline after the completion of scaling and root planing (SRP) ,0,
edin,2721,4362117,Significantly increased,"In the first month after administering doxycycline, a significantly higher decline in the percentage of sites harboring Tf was observed for TG compared with CG (p=0.02).", decline in the percentage of sites harboring Tannerella forsythia (Tf) , control group (CG) received only scaling and root planing (SRP) , One month after administeration systemic doxycycline after the completion of scaling and root planing (SRP) ,0,
edin,2755,4053826,Significantly decreased,Pain scores at rest were lower for the ropivacaine group and reached significance after 8 and 16 hours (P<0.01)., pain scores at rest at 8 hours and at 16 hours  , the 0.9% saline continuous infusion (the control group) , the ropivacaine continuous infusion (the Ropi group) ,0,
edin,2664,2806530,Cannot tell based on the abstract,, Blood alcohol concentration , Placebo , Alcohol ,0,
edin,2664,2806530,Cannot tell based on the abstract,, Blood alcohol concentration , Placebo , Alcohol ,0,
edin,2664,2806530,No significant difference,"BAC values did not differ between males (mean Â± SD, 0.69âÂ±â0.04) and females (mean Â± SD, 0.603âÂ±â0.05; pâ=â0.17).", Blood alcohol concentration , Placebo , Alcohol ,0,
edin,2761,3688436,Significantly increased,"There was a difference of 0.57 units (t = 2.09, P = 0.04) in the speech item and a difference of 0.29 units in the sexual interest item (t = 2.11, P = 0.04) in the donepezil group as compared to the placebo group.", speech item and the sexual interest item , placebo in addition to lithium , donepezil in addition to lithium ,0,
edin,2657,3219777,Significantly decreased,"The VNRS values at 1, 3, and 5 min after incision and OAA/S scores at 5 min after remifentanil infusion, and 1, 3, and 5 min after incision were lower in the Ketamine group than in the Control group.", Verbal numerical rating scales after incision , Midazolam plus remifentanil , Midazolam plus remifentanil plus ketamine ,0,
edin,2760,3688436,No significant difference,"The total YMRS difference on the first day approached the conventional significance level (1.97 units, t = 1.84, P = 0.07).", Young Mania Rating Scale (YMRS) on the first day , placebo in addition to lithium , donepezil in addition to lithium ,0,
edin,2843,5422432,Cannot tell based on the abstract,, nominal gains at post-intervention , control , Active experiencing (AE) ,0,
edin,2843,5422432,Significantly increased,"Task switching also showed nominal gains at post-intervention (mean = 0.14, p = 0.04, Î±â = 0.01) and follow-up (mean = 0.16, p = 0.04, Î±â = 0.01), whereas category fluency only improved at follow-up (0.21, p = 0.005, Î±â = 0.01; BS 95% CI: 0.09/0.36).", nominal gains at post-intervention , control , Active experiencing (AE) ,0,
edin,2870,4112748,Cannot tell based on the abstract,, The frequency of rescue medication , baseline , frovatriptan and rizatriptan ,0,
edin,2870,4112748,No significant difference,"The frequency of rescue medication was lower in patients during frovatriptan treatment (seven of 20) compared to rizatriptan treatment (13 of 20), this difference just failing to reach statistical significance (P=0.058).", The frequency of rescue medication , baseline , frovatriptan and rizatriptan ,0,
edin,2903,4155124,Significantly decreased,"The ND significantly decreased cathepsin S levels (from 20.1 (+/-4.0 SD) to 19.7Â Î¼g/L (+/-4.3 SD)) compared with control group (from 18.2 (+/-2.9 SD) to 19.1Â Î¼g/L (+/-3.8 SD)). This difference remained after adjusting for sex and change in insulin sensitivity (Pâ=â0.03), and near significant after adjusting for baseline cathepsin S levels (Pâ=â0.06), but not for change in weight or LDL-C.", insulin sensitivity , baseline , healthy Nordic diet (ND) ,0,
edin,2864,5126155,Cannot tell based on the abstract,, The stability of pacing during follow-up ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2864,5126155,No significant difference,"The stability of pacing during follow-up was very high (99.0% in trial and 98.1% in control groups), and the difference was not significant (P = 0.621).", The stability of pacing during follow-up ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2825,3831918,Cannot tell based on the abstract,," pulse wave velocit (PWV), elastic modulus (Ep),  forward expansion wave that decelerates flow and reduces pressure (W2), negative area (NA), and (RC) reflection coefficient  ", pneumatic cuff was applied to the calf and inflated to 0 mmHg , pneumatic cuff was applied to the calf and inflated to 70 mmHg ,0,
edin,2825,3831918,Significantly increased,"There were significant differences in PWV, Ep, W2, NA, and RC across conditions (Table 3 and Fig. 1, P < 0.05)."," pulse wave velocit (PWV), elastic modulus (Ep),  forward expansion wave that decelerates flow and reduces pressure (W2), negative area (NA), and (RC) reflection coefficient  ", pneumatic cuff was applied to the calf and inflated to 0 mmHg , pneumatic cuff was applied to the calf and inflated to 70 mmHg ,0,
edin,2845,5422432,Cannot tell based on the abstract,, category fluency at follow-up , control , Active experiencing (AE) ,0,
edin,2845,5422432,Significantly increased,"Task switching also showed nominal gains at post-intervention (mean = 0.14, p = 0.04, Î±â = 0.01) and follow-up (mean = 0.16, p = 0.04, Î±â = 0.01), whereas category fluency only improved at follow-up (0.21, p = 0.005, Î±â = 0.01; BS 95% CI: 0.09/0.36).", category fluency at follow-up , control , Active experiencing (AE) ,0,
edin,2850,5586978,Significantly increased,"Compared to group B, group A, which had less time on postoperative mechanical ventilation, had a higher VAS score.", The visual analog scale (VAS) scores , baseline , The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A ,0,
edin,2857,4631853,Cannot tell based on the abstract,, pain level , propofol (1.5Ã¢â¬â°mg/kg) combination in Group II  ," propofol (1.5Ã¢â¬â°mg/kg) in Group Ãâ¢, remifentanil (0.05Ã¢â¬â°ÃÂ¼g/kg), fentanyl (1Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group III ",0,
edin,2857,4631853,Significantly increased,"Also there was statistically significant difference between the groups during the follow-up (monitorization) period in terms of pain levels (p < 0.05). The patients in Group I suffered from the pain most, whereas the patients in Group II had the least pain (Table 3).", pain level , propofol (1.5Ã¢â¬â°mg/kg) combination in Group II  ," propofol (1.5Ã¢â¬â°mg/kg) in Group Ãâ¢, remifentanil (0.05Ã¢â¬â°ÃÂ¼g/kg), fentanyl (1Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group III ",0,
edin,2841,5422432,Cannot tell based on the abstract,, Story recall improved at post-intervention , control , Active experiencing (AE) ,0,
edin,2841,5422432,Significantly decreased,"Story recall improved at post-intervention (mean = 0.32, p < 0.001, Î±â = 0.01; BS 95% CI: 0.21/0.42), as did thematic recall (mean = 0.18, p = 0.03, Î±â = 0.01; BS 95% CI: 0.04/0.32), although the effect did not survive correction for multiple comparisons.", Story recall improved at post-intervention , control , Active experiencing (AE) ,0,
edin,2840,5722109,Cannot tell based on the abstract,, success rate of inferior alveolar nerve block (IANB) in posterior mandible teeth with symptomatic irreversible pulpitis. , epinephrine 1:200000 and 0.4 mL normal saline (A-saline group) , 3.2 mL 4% articaine with epinephrine 1:200000 and 0.4 mL 50 mg/mL ketamine hydrochloride (A-ketamine group) ,0,
edin,2840,5722109,No significant difference,The success rate of IANB was 55.0% for A-ketamine and 42.9% for A-saline group. There was no statistically significant difference in success rates between the two groups (P=0.437)., success rate of inferior alveolar nerve block (IANB) in posterior mandible teeth with symptomatic irreversible pulpitis. , epinephrine 1:200000 and 0.4 mL normal saline (A-saline group) , 3.2 mL 4% articaine with epinephrine 1:200000 and 0.4 mL 50 mg/mL ketamine hydrochloride (A-ketamine group) ,0,
edin,2922,5771895,Cannot tell based on the abstract,, average severity scores of hot flashes and night sweats , placebo ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  or  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ",0,
edin,2922,5771895,Significantly decreased,"As reported previously for the entire KEEPS cohort,27 the average severity scores of hot flashes and night sweats were significantly reduced by both HT formulations when compared with PBO (Pâ<â0.001 for both), with no difference between the o-CEE and t-E2 groups (Pâ=â0.343 and Pâ=â0.919, respectively; Table 2).", average severity scores of hot flashes and night sweats , placebo ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  or  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ",0,
edin,2828,5297995,Cannot tell based on the abstract,, coronal growth of approximal gingival margin on the neighboring teeth , stock , zirconia implant abutments ,0,
edin,2828,5297995,Significantly increased,"Clinical examination revealed a significant (Tâ=â24; pâ<â.05) coronal growth of approximal gingival margin (0.32 mm; 95% CI [0,06 mm; 0,58mm]; SD 0.88 mm) on the neighboring teeth after 12 months.", coronal growth of approximal gingival margin on the neighboring teeth , stock , zirconia implant abutments ,0,
edin,2837,4888158,Cannot tell based on the abstract,, residual antimicrobial activity of CHX at one week and at three and six weeks ,  Resilon/RealSeal SE samples , gutta-percha/AH26  ,0,
edin,2837,4888158,Significantly increased,"The results showed that residual antimicrobial activity of CHX was significantly higher in gutta-percha/AH26 samples than in Resilon/RealSeal SE samples (P=0.02 at one week and P=0.003 at three and six weeks, respectively).", residual antimicrobial activity of CHX at one week and at three and six weeks ,  Resilon/RealSeal SE samples , gutta-percha/AH26  ,0,
edin,2844,5422432,Cannot tell based on the abstract,, nominal gains at follow-up , control , Active experiencing (AE) ,0,
edin,2844,5422432,Significantly increased,"Task switching also showed nominal gains at post-intervention (mean = 0.14, p = 0.04, Î±â = 0.01) and follow-up (mean = 0.16, p = 0.04, Î±â = 0.01), whereas category fluency only improved at follow-up (0.21, p = 0.005, Î±â = 0.01; BS 95% CI: 0.09/0.36).", nominal gains at follow-up , control , Active experiencing (AE) ,0,
edin,2895,3267052,Significantly decreased,The % BOP (5 months) and cumulative plaque scores (8 months) were lowered more in the FV group (p < 0.05)., cumulative plaque scores , placebo , fruit/vegetable (FV) ,0,
edin,2923,5771895,Cannot tell based on the abstract,, average severity scores of hot flashes and night sweats , oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)   ",0,
edin,2923,5771895,Significantly decreased,"As reported previously for the entire KEEPS cohort,27 the average severity scores of hot flashes and night sweats were significantly reduced by both HT formulations when compared with PBO (Pâ<â0.001 for both), with no difference between the o-CEE and t-E2 groups (Pâ=â0.343 and Pâ=â0.919, respectively; Table 2).", average severity scores of hot flashes and night sweats , oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)   ",0,
edin,2919,5771895,Cannot tell based on the abstract,, the number of women with improved sleep quality ,  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)  or placebo (PBO) ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2919,5771895,Significantly increased,"When compared with PBO, the reduction in the percentage of women with poor sleep quality (ie, the number of women with improved sleep quality) was significantly greater in the t-E2 group (Pâ=â0.003) and modestly but not significantly greater in the o-CEE group (Pâ=â0.07).", the number of women with improved sleep quality ,  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)  or placebo (PBO) ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2831,5297995,Cannot tell based on the abstract,, coronal growth of approximal gingival margin on the neighboring teeth , After the intake (T 0) and implant placement , followÃ¢â¬ï¿½up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration ,0,
edin,2831,5297995,Significantly increased,"Clinical examination revealed a significant (Tâ=â24; pâ<â.05) coronal growth of approximal gingival margin (0.32 mm; 95% CI [0,06 mm; 0,58mm]; SD 0.88 mm) on the neighboring teeth after 12 months.", coronal growth of approximal gingival margin on the neighboring teeth , After the intake (T 0) and implant placement , followÃ¢â¬ï¿½up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration ,0,
edin,2894,3267052,Significantly decreased,"Gingival crevicular fluid volumes diminished more in supplement groups than placebo (FVB; p < 0.05) at 2 months, but not at later times.", Gingival crevicular fluid (GCF) volumes , placebo , fruit/vegetable (FV) and FVB ,0,
edin,2829,5297995,Cannot tell based on the abstract,," embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant ", After the intake (T 0) and implant placement , followÃ¢â¬ï¿½up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration ,0,
edin,2829,5297995,Significantly decreased,"Patients experienced significantly less embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant at T 1 (pâ<â.01) and T 12 (pâ<â.05) than they had expected at T 0."," embarrassment and problems with taste, speech, gum color, tooth color and the visibility of the implant ", After the intake (T 0) and implant placement , followÃ¢â¬ï¿½up appointments were planned at two weeks (T 1) and 12 months (T 12) after delivery of the restoration ,0,
edin,2877,5106877,Significantly increased,"There is no difference between serums Vit D level in case and control group at the beginning of the study, however at the end of the study serum Vit D level was significantly higher in the case group.", serums Vit D level , placebo , Vit D as 50 000 IU/week ,0,
edin,2822,3831918,Cannot tell based on the abstract,," retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate ", baseline ," pneumatic cuff was applied to the calf and inflated to 0, 35, and 70 mmHg ",0,
edin,2822,3831918,Significantly decreased,"There were significant differences in retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate across conditions (Table 3 and Fig. 1, P < 0.05).,<td align=""left"" colspan=""1"" rowspan=""1"">Mean shear rate, sec<sup>â1</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">102 Â± 9</td><td align=""center"" colspan=""1"" rowspan=""1"">69 Â± 7<xref ref-type=""table-fn"" rid=""tf3-1"">1</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">37 Â± 8<xref ref-type=""table-fn"" rid=""tf3-1"">1</xref>,<xref ref-type=""table-fn"" rid=""tf3-2"">2</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">0.001</td>"," retrograde shear rate, diastolic antegrade shear rate, and consequently mean shear rate ", baseline ," pneumatic cuff was applied to the calf and inflated to 0, 35, and 70 mmHg ",0,
edin,2830,5297995,Cannot tell based on the abstract,, bone apposition , stock , zirconia implant abutments ,0,
edin,2830,5297995,No significant difference,"The difference in bone apposition between the 2 groups (stock: 0.06 mm, 95% CI [â0.05 mm; 0.16 mm], standard deviation 0.23mm versus CAD/CAM customized: 0.11 mm, 95% CI [0.02 mm; 0.20 mm]; standard deviation 0.20 mm) was not statistically significant.", bone apposition , stock , zirconia implant abutments ,0,
edin,2921,5771895,Cannot tell based on the abstract,, sleep disturbances ,  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2921,5771895,Significantly increased,"Among the three domains, only sleep disturbances showed a statistically significant difference between the two HT formulations (Pâ=â0.029), with t-E2 improving more during follow-up than o-CEE (Table 2).", sleep disturbances ,  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)   ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2852,5586978,Cannot tell based on the abstract,,  the VAS scores after surgery , conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B , The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A ,0,
edin,2852,5586978,Significantly decreased,"After surgery, the VAS scores in group A were better than that in group B (P<0.05), while the Cobb angle and ESR of the two groups showed no difference.",  the VAS scores after surgery , conventional anterior extraperitoneal approach focal cleaning combined with posterior internal fixation in period I - group B , The mini-open anterior approach focal cleaning combined with posterior internal fixation in period I - group A ,0,
edin,2859,5870330,Significantly increased,"Furthermore, the fracture resistance of G4 and G5 was significantly higher than G3 and G6 (P < 0.05),", fracture resistance , G3 was prepared with an occlusal extension that extended one-third of buccolingual width and 2 mm in depth , G4 was prepared with the occlusal extension of 1mm in depth and width. G5: The occlusal extension was 1mm in depth and 2 mm in width ,0,
edin,2892,3267052,Significantly decreased,The % BOP (5 months) and cumulative plaque scores (8 months) were lowered more in the FV group (p < 0.05)., bleeding on probing (% BOP) and cumulative plaque scores  ," fruit/vegetable/berry (FVB), placebo ", fruit/vegetable (FV) ,0,
edin,2890,3267052,Significantly increased,"Clinical outcomes improved in all groups at 2 months, with additional improvement in PPD versus placebo for FV (p < 0.03).", mean probing pocket depth (PPD) , placebo ,"  fruit/vegetable (FV), fruit/vegetable/berry (FVB) ",0,
edin,2913,5459456,Cannot tell based on the abstract,," inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments ", control , ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC ,0,
edin,2913,5459456,No significant difference,"There were no significant differences among the control, ACVC, and ACVC-HA groups inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments."," inflexion-extension and lateral bending for the C2-C6, C2-C4, C4-C5, and C5-C6 segments ", control , ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating or ACVC ,0,
edin,2915,5459456,Cannot tell based on the abstract,, new bone formation around the screws and bone-implant contact (BIC) in both sections , ACVC , ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating ,0,
edin,2915,5459456,Significantly increased,"In the sections located at the self-drilling fixation screw level (Fig 8E and 8G), we found significantly more new bone formation around the screws for the ACVC-HA group (Fig 8G) than for the ACVC group (Fig 8E).,These findings indicate that, compared with the ACVC group, the ACVC-HA group had a significantly higher bone-implant contact (BIC) in both sections respectively located at the vertebral body component and screw level (Fig 8I), which is an appropriate index for measuring bone ingrowth into the implant.", new bone formation around the screws and bone-implant contact (BIC) in both sections , ACVC , ACVC-HA - artificial cervical vertebra and intervertebral complex (ACVC) with an HA biocoating ,0,
edin,2918,4021263,Cannot tell based on the abstract,, M. tuberculosis or nontuberculous mycobacteria detection , self-expectoration (ES) , sputum induction with 7% saline nebulization in clinic (SI)  ,0,
edin,2918,4021263,No significant difference,"Among the 51 confirmed APTB cases, M. tuberculosis or nontuberculous mycobacteria was identified in one or more samples from 27 (52.9%) patients, 14 (58.3%) from the SI group and 13 (48.1%) from the ES group (p=0.46).", M. tuberculosis or nontuberculous mycobacteria detection , self-expectoration (ES) , sputum induction with 7% saline nebulization in clinic (SI)  ,0,
edin,2842,5422432,Cannot tell based on the abstract,, thematic recall , control , Active experiencing (AE) ,0,
edin,2842,5422432,Significantly increased,"Story recall improved at post-intervention (mean = 0.32, p < 0.001, Î±â = 0.01; BS 95% CI: 0.21/0.42), as did thematic recall (mean = 0.18, p = 0.03, Î±â = 0.01; BS 95% CI: 0.04/0.32), although the effect did not survive correction for multiple comparisons.", thematic recall , control , Active experiencing (AE) ,0,
edin,2881,5129820,No significant difference,"There were no statistically significant differences in time to worsening or improvement rates of TOI, FOSI and FACT-O scores in the overall, BRCAm and germline BRCAm populations.", The Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Ovarian Symptom Index (FOSI) , placebo , olaparib 400Ã¢â¬â°mg b.i.d. (capsules) ,0,
edin,2866,4112748,No significant difference,"Although the time to maximum concentration was similar for both drugs (2.7 versus 2.3 hours), the terminal half-life for frovatriptan was longer than rizatriptan (29.3 versus 3.2 hours, P<0.0001).", the time to maximum concentration , rizatriptan , frovatriptan ,0,
edin,2874,4776123,Cannot tell based on the abstract,, global LCF of CereN , control before scanning , conrtol after scanning ,0,
edin,2874,4776123,Cannot tell based on the abstract,, global LCF of CereN , control before scanning , conrtol after scanning ,0,
edin,2874,4776123,Significantly increased,"After the Fisher r-to-z translation, a repeated measure ANOVA revealed that both groups improved their LCFs in CereN as indicated by a significant main effect of time (F = 6.903, p = 0.015).,Paired-sample t-tests revealed that the global LCF of CereN (T = 2.30, p = 0.03) was significantly increased after the training scan compared with the before-training scan in the control group but not in the training group.", global LCF of CereN , control before scanning , conrtol after scanning ,0,
edin,2909,4069273,Cannot tell based on the abstract,, Exercise , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2909,4069273,Significantly increased,"Exercise had a statistically significant difference between the intervention and the control groups (pâ<â0.001).,After 3Â month follow up, the percentage of participants who exercised more than 5 times/week in the intervention group (29.2%) was more than the control group (9.2%).", Exercise , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2920,5771895,Cannot tell based on the abstract,," domain scores pertaining to sleep efficiency, sleep duration, or daytime dysfunction ",  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)  ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2920,5771895,No significant difference,"There were no significant differences between groups for the changes in domain scores pertaining to sleep efficiency (Pâ=â0.45), sleep duration (Pâ=â0.38), or daytime dysfunction (Pâ=â0.26) across follow-up."," domain scores pertaining to sleep efficiency, sleep duration, or daytime dysfunction ",  oral conjugated equine estrogens (o-CEE; 0.45Ã¢â¬Å mg/d)  ," transdermal 17ÃÂ²-estradiol (t-E2; 50Ã¢â¬Å ÃÂ¼g/d) plus cyclic progesterone (Prometrium, 200Ã¢â¬Å mg)  ",0,
edin,2863,5126155,Cannot tell based on the abstract,, The effective sensitivity rate ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2863,5126155,No significant difference,"The effective sensitivity rate immediately after the procedure was 94.8% and 93.6% in the trial and control groups, respectively, with no significant difference (P = 0.716).", The effective sensitivity rate ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2885,4249579,Significantly increased,"Dihydroartemisinin-piperaquine coadministration significantly increased plasma primaquine levels; geometric mean ratios (90% confidence interval [CI]) of primaquine combined versus primaquine alone for maximum concentration (Cmax), area under the concentration-time curve from 0 h to the end of the study (AUC0âlast), and area under the concentration-time curve from 0 h to infinity (AUC0ââ) were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively.", maximum observed plasma concentration after oral administration (Cmax) and predicted area under the plasma concentration time curve after the last dose from zero time to infinity (AUC0Ã¢â¬âlast)values , primaquine phosphate , primaquine phosphate and dihydroartemisinin-piperaquine ,0,
edin,2823,3831918,Significantly increased,Cuff inflation resulted in stepwise increases in retrograde shear rate (P < 0.05 for main effect)., retrograde shear , pneumatic cuff was applied to the calf and inflated to 0 mmHg , pneumatic cuff was applied to the calf and inflated to 70 mmHg ,0,
edin,2821,4450208,Significantly increased,"Regarding the effect of the program on both genders, the change was very similar, but the boys increased assertive social interaction strategies, attention, and emotional clarity significantly more than the girls."," assertive social interaction strategies, attention, and emotional clarity ",  a program of emotional intelligence (EI) 20 one-hour sessions - girls ,  a program of emotional intelligence (EI) 20 one-hour sessions - boys ,0,
edin,2856,4631853,Cannot tell based on the abstract,, total propofol doses , fentanyl (1Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group III ," propofol (1.5Ã¢â¬â°mg/kg) in Group Ãâ¢, remifentanil (0.05Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group II ",0,
edin,2856,4631853,Significantly decreased,"In terms of total propofol doses administered during the follow-up (monitorization), the difference between Group I and Group II and between Group I and Group III and Groups II and III was statistically significant (p < 0.001) (p < 0.003).,The comparison of the groups in terms of the total dose of propofol revealed that it was 375âmg in Group I, 150âmg in Group II, and 245âmg in Group III (Figure 1).", total propofol doses , fentanyl (1Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group III ," propofol (1.5Ã¢â¬â°mg/kg) in Group Ãâ¢, remifentanil (0.05Ã¢â¬â°ÃÂ¼g/kg) + propofol (1.5Ã¢â¬â°mg/kg) combination in Group II ",0,
edin,2908,4069273,Significantly decreased,"Participants in the intervention group had significantly lower glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), plaque index score, gingival index score, pocket depth, clinical attachment level (CAL), and percentage of bleeding on probing (BOP) when compared to the control group."," pocket depth, clinical attachment level (CAL), and percentage of bleeding on probing (BOP) ", received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2818,4450208,Cannot tell based on the abstract,, the effects of the program 1 year after completing the intervention , control ,  a program of emotional intelligence (EI) 20 one-hour sessions ,0,
edin,2818,4450208,Significantly increased,"Subsequently, in order to assess the maintenance of the effects of the program 1 year after completing the intervention, the pretest-follow-up change was analyzed.,The results of the descriptive analysis (mean and SD) and pretest-follow-up ANCOVAs (with the pretest scores as covariates, see Table 4) confirmed statistically significant differences in the pretest-follow-up change between the experimental and control groups.,In particular, we noted a significant increase in the mean scores of the experimental group (Me) compared with the control group (Mc) in EI due to the significant improvement in all three factors, emotional attention (Me = 2.43, Mc = -1.26), emotional clarity (Me = 2.86, Mc = 0.02), and emotional repair (Me = 3.24, Mc = 0.05).", the effects of the program 1 year after completing the intervention , control ,  a program of emotional intelligence (EI) 20 one-hour sessions ,0,
edin,2872,4776123,Cannot tell based on the abstract,,   improving of level laterality cofactor (LCF) in cerebellum network included bilateral cerebellum hemispheres (CereN) , baseline , right- and left- frontoparietal networks (FPNs) and control ,0,
edin,2872,4776123,Significantly increased,"After the Fisher r-to-z translation, a repeated measure ANOVA revealed that both groups improved their LCFs in CereN as indicated by a significant main effect of time (F = 6.903, p = 0.015).",   improving of level laterality cofactor (LCF) in cerebellum network included bilateral cerebellum hemispheres (CereN) , baseline , right- and left- frontoparietal networks (FPNs) and control ,0,
edin,2873,4776123,Cannot tell based on the abstract,,   improving of level laterality cofactor (LCF)  , baseline , right lateral  frontoparietal networks (rFPN) left lateral  frontoparietal networks (lFPN) ,0,
edin,2873,4776123,Significantly increased,"In addition, a significant training main effect on the LCF in rFPN (F = 5.897, p = 0.021) and lFPN (F = 7.641, p = 0.01), as well as interactions of LCF of lFPN (F = 8.908, p = 0.006), were observed.",   improving of level laterality cofactor (LCF)  , baseline , right lateral  frontoparietal networks (rFPN) left lateral  frontoparietal networks (lFPN) ,0,
edin,2848,5422432,Cannot tell based on the abstract,, story recall at post-intervention , baseline , Active Control ,0,
edin,2848,5422432,Significantly increased,"Story recall improved at post-intervention (mean = 0.32, p < 0.001, Î±â = 0.01; BS 95% CI: 0.21/0.42), as did thematic recall (mean = 0.18, p = 0.03, Î±â = 0.01; BS 95% CI: 0.04/0.32), although the effect did not survive correction for multiple comparisons.", story recall at post-intervention , baseline , Active Control ,0,
edin,2906,4069273,Significantly decreased,"articipants in the intervention group had significantly lower glycosylated hemoglobin (HbA1c), fasting plasma glucose (FPG), plaque index score, gingival index score, pocket depth, clinical attachment level (CAL), and percentage of bleeding on probing (BOP) when compared to the control group.", the plaque index score and gingival index score , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2910,4069273,Cannot tell based on the abstract,, The percentage of participants who modified diet , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2910,4069273,Significantly increased,he percentage of participants in the intervention group (93.8%) who modified diet was higher than the control group (70.8%) with a statistically significant difference (pâ=â0.001)., The percentage of participants who modified diet , received a routine program ," attended a 20 minute lifestyle and oral health education program, individual lifestyle counseling using motivational interviewing (MI), application of self regulation manual, and individual oral hygiene instruction ",0,
edin,2889,4249579,Cannot tell based on the abstract,, t1/2 , primaquine phosphate , primaquine phosphate and dihydroartemisinin-piperaquine ,0,
edin,2889,4249579,Significantly decreased,"Combined administration with dihydroartemisinin-piperaquine resulted in significantly lower primaquine CL/F (P = 0.0229) and V/F (P = 0.0013) values than administration alone, leading to significantly higher Cmax (P = 0.0019) and AUC0âlast (P = 0.0200) values. This also resulted in a shorter primaquine t1/2 (P = 0.0005) than with administration alone. Geometric mean ratios (90% CI) of primaquine administered with and without dihydroartemisinin-piperaquine for Cmax, AUC0âlast, and AUC0ââ were 148% (117 to 187%), 129% (103 to 163%), and 128% (102 to 161%), respectively (Fig. 2).", t1/2 , primaquine phosphate , primaquine phosphate and dihydroartemisinin-piperaquine ,0,
edin,2897,4729786,Cannot tell based on the abstract,," mood scales, stress scales ", positive training (vice versa) ," negative training (pull negative, push positive pictures) ",0,
edin,2897,4729786,No significant difference,The analyses revealed neither an immediate training effect on the mood scales nor on the stress scales (pÂ >Â .398).," mood scales, stress scales ", positive training (vice versa) ," negative training (pull negative, push positive pictures) ",0,
edin,2916,4021263,Significantly increased,"Among the APTB, more adequate specimens were collected from SI (41/65, 63.1%) than ES (34/80, 42.5%) (p=0.01).", APTB adequate specimens collection  , self-expectoration (ES) , sputum induction with 7% saline nebulization in clinic (SI)  ,0,
edin,2862,5126155,No significant difference,"Effective pacing rates of trial and control groups were comparable both in the full analysis set and the per protocol set (81.4% vs. 79.5%, P = 0.712 and 95.4% vs. 89.5%, P = 0.143, respectively).", The effective pacing rate immediately after the procedure ," pacemaker Talos DR (Biotronik, Berlin, Germany) "," pacemaker Qinming8631 DR (Qinming Medical, Baoji, China) ",0,
edin,2820,4450208,Significantly decreased,"In the follow-up phase, the positive effects of the intervention were generally maintained and, moreover, the use of aggressive strategies as an interpersonal conflict-resolution technique was significantly reduced.", the use of aggressive strategies as an interpersonal conflict-resolution technique , control ,  a program of emotional intelligence (EI) 20 one-hour sessions ,0,
edin,2836,4888158,Cannot tell based on the abstract,"The antimicrobial activity of CHX gradually decreased in a time-dependent manner but it maintained over 95% of its antimicrobial activity after six weeks. Moreover, Resilon/RealSeal SE significantly decreased the antimicrobial activity of CHX in comparison with gutta-percha/AH26 (P<0.05).", The antimicrobial activity , baseline , 2% CHX ,0,
edin,2836,4888158,Significantly increased,"The results showed that residual antimicrobial activity of CHX was significantly higher in gutta-percha/AH26 samples than in Resilon/RealSeal SE samples (P=0.02 at one week and P=0.003 at three and six weeks, respectively).", The antimicrobial activity , baseline , 2% CHX ,0,
edin,3064,5377263,Significantly increased,"Compared with patients in the control group, the levels of Th1 and Th1/Th2 in the observation group significantly increased, yet their Th2 decreased. The levels of IL-2 and TNF-Î± were also observed to be significantly elevated, yet IL-10 decreased.", IL-2 and TNF-ÃÂ± , injected with placebo saline solution in the articular cavity ," HBD-3 (standard, 10 ÃÂµg:50 ÃÂµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days. ",0,
edin,2935,5601935,No significant difference,"Number of follicles in ovaries, total number of oocytes or M2 oocytes and quality of fetuses has no significant differences between two groups (p>0.05).", Quality of fetuses , Human menopausal gonadotropin (HMG) plus r-FSH , Recombinant- follicle stimulating hormone (r-FSH) plus recombinant-luteinizing hormone (rLH) ,0,
edin,2949,5600923,Significantly decreased,"The rate of local recurrence was 44.9 and 68.7% in AG and CG, respectively (P < 0.01).", Rate of local recurrence , Placebo (CG group) , Alginate oligosaccharide (AOS; AG group) ,0,
edin,2940,2744923,Cannot tell based on the abstract,, Effectiveness at day 42 , Sulphadoxine-pyrimethamine (SP)  , Chlorproguanil-dapsone (CPD) ,0,
edin,2940,2744923,No significant difference,"<td align=""center"" colspan=""6""><bold>CPD</bold></td>", Effectiveness at day 42 , Sulphadoxine-pyrimethamine (SP)  , Chlorproguanil-dapsone (CPD) ,0,
edin,2999,3220859,Cannot tell based on the abstract,, glucose infusion rate (GIR) ," glargine, NPH insuline ",  detemir ,0,
edin,2999,3220859,Significantly decreased,"Bivariate correlations of BMI and GIR split by treatment showed an inverse correlation that was significant only with detemir (r = â0.68, P = 0.003), but not with glargine (r = â0.41, P = 0.11) and NPH (r = â0.37, P = 0.15) (Supplementary Fig. 1),On the basis of BMI status, with all three basal insulins, GIR was lower in people with BMI >29 kg/m2 compared with people with BMI <29 kg/m2 (Fig. 1), but statistical significance was achieved with detemir treatment only (598 Â± 604 and 1,564 Â± 649 mg/kg, respectively; P = 0.03) and not with NPH (1,058 Â± 859 and 1,282 Â± 532 mg/kg) and glargine (1,408 Â± 563 and 1,668 Â± 807 mg/kg) (both P > 0.2).", glucose infusion rate (GIR) ," glargine, NPH insuline ",  detemir ,0,
edin,3067,5377263,Cannot tell based on the abstract,, implant infection , injected with placebo saline solution in the articular cavity ," HBD-3 (standard, 10 ÃÂµg:50 ÃÂµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days. ",0,
edin,3067,5377263,No significant difference,"There were 3 cases of implant infection in control group (9.4%), 1 case in observation group (3.1%), there was no statistical significance (P=0.306, unilateral) by Fisher's exact probability method.", implant infection , injected with placebo saline solution in the articular cavity ," HBD-3 (standard, 10 ÃÂµg:50 ÃÂµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days. ",0,
edin,3035,3506580,Cannot tell based on the abstract,, mean pain intensity , baseline , Transcranial direct current stimulation (tDCS) ,0,
edin,3035,3506580,No significant difference,"There was no significant difference of the perceived mean pain intensity before and after tDCS stimulation for the factors time (PREPOST: F(1,13)â=â0.85; pâ=â0.374) and stimulation modality (STIM: F(2,26)â=â0.93; pâ=â0.379) and no interaction between STIM*PREPOST (F(2,26)â=â1.18; pâ=â0.323).", mean pain intensity , baseline , Transcranial direct current stimulation (tDCS) ,0,
edin,3072,5870915,Cannot tell based on the abstract,, The daily body weight gain from SD 1 to SD 29 , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,3072,5870915,Significantly increased,The daily body weight gain from SD 1 to SD 29 was significantly higher in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Fig. 5, The daily body weight gain from SD 1 to SD 29 , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,3084,5148913,Cannot tell based on the abstract,, abnormalities in haematology or blood chemistry parameters , BDP 100 ÃÂ¼g (four puffs twice a day) , BDP/FF 200/6 ÃÂ¼g pMDI extrafine (two puffs twice a day) ,0,
edin,3084,5148913,No significant difference,No clinically significant abnormalities in haematology or blood chemistry parameters were reported during the study., abnormalities in haematology or blood chemistry parameters , BDP 100 ÃÂ¼g (four puffs twice a day) , BDP/FF 200/6 ÃÂ¼g pMDI extrafine (two puffs twice a day) ,0,
edin,3032,5864139,No significant difference,"Cases of pancreatic cancer were numerically fewer with sitagliptin (9 [0.1%]) versus placebo (14 [0.2%]) (hazard ratio 0.66 [95% CI 0.28â1.51], P = 0.32; 0.042 vs. 0.066 events/100 patient-years).", Cases of pancreatic cancer , placebo ," sitagliptin, 23 (0.3%) ",0,
edin,2925,4286912,Cannot tell based on the abstract,, Antigens of co-administered vaccines , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,0,
edin,2925,4286912,No significant difference,"Co-administered vaccine antigens
One month post-primary and post-booster vaccination, all children were seroprotected against diphtheria, tetanus and poliovirus types 1, 2 and 3, and all infants were seropositive for antibodies against the three pertussis antigens and polyribosylribitol phosphate from Hib. All infants except one were seroprotected against hepatitis B surface antigen (HBs) at one month post-primary vaccination. Three children had anti-HBs antibody concentrations which were initially measured between 10 and 100 mIU/mL. Out of these 3 children, upon retesting using Immuliteâ¢, one was found to be seroprotected while the other 2 had anti-HBs antibody concentrations <10 mIU/mL. This was further followed up by investigators and one child was subsequently re-vaccinated. Efforts to reach the other child for re-vaccination were unsuccessful. Three months after the second dose of the HRV vaccine, â¥81.9% of infants were seropositive for anti-HRV antibodies (data not shown).", Antigens of co-administered vaccines , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,0,
edin,3074,3650212,Cannot tell based on the abstract,, The tipping , a combination of the FA with high-pull headgear worn at night , using the FA alone ,0,
edin,3074,3650212,Significantly increased,"The tipping was only significant in group 1, and it was significantly larger in this group than in group 2 (p < 0.001).", The tipping , a combination of the FA with high-pull headgear worn at night , using the FA alone ,0,
edin,3001,4730432,Significantly increased,"A statistically significant increase in the intention to obtain clinical trial information at the three and six month time points was observed in the intervention group, but not the control group.", intention to seek information about clinical trials , baseline , church-based educational intervention ,0,
edin,3051,3177395,Cannot tell based on the abstract,, dental plaque on smooth and approximal tooth surfaces after 14 days , baseline , received herbal extract dentifrices or used a conventional dentifrice ,0,
edin,3051,3177395,Significantly decreased,"After 14 days, significant reduction of dental plaque on smooth and approximal tooth surfaces compared to baseline was observed in all groups (P <60; 0.001).", dental plaque on smooth and approximal tooth surfaces after 14 days , baseline , received herbal extract dentifrices or used a conventional dentifrice ,0,
edin,2992,3671204,Significantly increased,"After six weeks, pain scores increased from 5.3 to 6.6 (p=0.04).", pain scores after six weeks , baseline ,  physical activity (PA) program for patients with knee and/or hip osteoarthritis (OA) ,0,
edin,3063,5377263,Significantly increased,"Compared with patients in the control group, the levels of Th1 and Th1/Th2 in the observation group significantly increased, yet their Th2 decreased.", Th1 and Th1/Th2 , injected with placebo saline solution in the articular cavity ," HBD-3 (standard, 10 ÃÂµg:50 ÃÂµg:1 mg, Art no., CSB-P12186-3; Beijing Biodee Biotechnology Co., Ltd., Beijing, China) of 10 ml once a day, for 7 days. ",0,
edin,3044,3321528,Cannot tell based on the abstract,, handgrip strength , non-dominant hand , dominant hand ,0,
edin,3044,3321528,No significant difference,"A significant difference was found in handgrip strength between patients diagnosed with ICU-AW in comparison to those without an ICU-AW diagnosis (6.6 Â± 4.4 versus 23.4 Â± 8.9âkg, P < 0.01), even when the comparison was adjusted for gender and age (P < 0.01). This was also the case when handgrip performance was expressed in relative values (29.0 Â± 22.4% predicted versus 66.0 Â± 22.2% predicted, P < 0.01).

In concern to between-sides comparison, patients tended to perform better with the dominant rather than the non-dominant hand (16.2 Â± 11.1 versus 14.2 Â± 9.9âkg, resp., P = 0.09).", handgrip strength , non-dominant hand , dominant hand ,0,
edin,3076,3650212,Cannot tell based on the abstract,, Treatment time , a combination of the FA with high-pull headgear worn at night , using the FA alone ,0,
edin,3076,3650212,Significantly increased,Treatment time was significantly greater in group 1 than in group 2 (7.44 Â± 1.30 months versus 6.27 Â± 1.11 months; p < 0.001)., Treatment time , a combination of the FA with high-pull headgear worn at night , using the FA alone ,0,
edin,3013,3636767,Cannot tell based on the abstract,," patients, who achieve the BP target of systolic/diastolic BP &amp;lt; 140/90 mmHg ", telmisartan 80 mg  , telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) ,0,
edin,3013,3636767,Significantly increased,"Across the entire study population, at week 7, single-pill T80/H25 combination therapy significantly reduced the adjusted mean Â± standard error seated trough cuff systolic/diastolic BP from baseline (â37.0 Â± 0.62/â18.6 Â± 0.38 mmHg) as compared with T80 monotherapy (â28.5 Â± 0.88/â15.4 Â± 0.55 mmHg [adjusted mean difference â8.5/â3.2 mmHg; 95% CI â10.6, â6.4/â4.5, â1.9; P < 0.0001]) and allowed more patients to achieve the BP target of systolic/diastolic BP < 140/90 mmHg (55.5% versus 34.7%; OR, 2.39; 95% CI 1.76, 3.26; P < 0.0001).9"," patients, who achieve the BP target of systolic/diastolic BP &amp;lt; 140/90 mmHg ", telmisartan 80 mg  , telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) ,0,
edin,2968,4152682,Significantly decreased,"Pulse rate (95.9 Â± 11.2 bpm vs. 102.9 Â± 8.8 bpm, P = 0.001) systolic and diastolic BP were significantly higher in Group N.", Pulse rate and blood pressure after surgery , Normal saline followed by general anesthesia (Group N) , Transversus abdominis plane block with 0.25% bupivacaine (Group B) ,0,
edin,2998,4586379,Cannot tell based on the abstract,," The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels ", control , Hydroxychloroquine (HCQ) ,0,
edin,2998,4586379,Significantly increased,"The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels were significantly better in CKD mice treated with HCQ. *P < 0.05 compared with CKD placebo mice."," The elasticity of the major vessels, i.e., the movement of vessel wall between the systole and diastole, as well as blood velocity within these vessels ", control , Hydroxychloroquine (HCQ) ,0,
edin,2987,2836298,No significant difference,"Continued abstinence at 12 months confirmed through CO was 7.4% in the III, 5.4% in the IGI, and 1% in the MI. No significant differences were noted between III and MI on the one hand, and between IGI and MI on the other [RR 7.04 (0.9-7.2) and RR 5.1 (0.6-41.9), respectively].,No differences were noted between IGI and III [RR 0.7 (0.2-2.2)].", Continued abstinence at 1 year , Intensive individual intervention (III) , Intensive group intervention (IGI) ,0,
edin,2982,4323894,No significant difference,"here were 63.2% of patients in cooling group attained good GOS at 6 months compared to only 15.4% in noncooling group (P = 0.007). Interestingly, the analysis at 6 months post-trauma disclosed mild-cooling-treated patients did better than no cooling (70% vs. 15.4% attained good GOS, P = 0.013) and apparently, the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).", Improvement in Glasgow outcome score at 6 months post-trauma , Mild-cooling , Deep-cooling ,0,
edin,3052,3177395,Cannot tell based on the abstract,, mean values of plaque indices after 14 days , used a conventional dentifrice , received herbal extract dentifrices  ,0,
edin,3052,3177395,Significantly decreased,"However, in the conventional group, mean values of plaque indices were significantly higher than in the herbal groups.", mean values of plaque indices after 14 days , used a conventional dentifrice , received herbal extract dentifrices  ,0,
edin,2927,4286912,Cannot tell based on the abstract,, Reactogenicity and safety profiles , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,0,
edin,2927,4286912,Invalid Prompt,, Reactogenicity and safety profiles , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,1, Reactogenicity and safety profiles are mentioned in the methods and materials section of the article but there is no significant information in results or conclusion section. Results section contains only a list of complications. 
edin,2983,4323894,No significant difference,"There were 63.2% of patients in cooling group attained good GOS at 6 months compared to only 15.4% in noncooling group (P = 0.007).,Interestingly, the analysis at 6 months post-trauma disclosed mild-cooling-treated patients did better than no cooling (70% vs. 15.4% attained good GOS, P = 0.013) and apparently, the deep-cooling-treated patients failed to be better than either no cooling (P = 0.074) or mild cooling group (P = 0.650).", Improvement in Glasgow outcome score at 6 months post-trauma , No cooling , Deep-cooling ,0,
edin,2946,4993942,Cannot tell based on the abstract,, Complications , Panretinal photocoagulation (PRP) with red laser , Panretinal photocoagulation (PRP) with green laser ,0,
edin,2946,4993942,No significant difference,No complication occurred in both groups during laser and in follow-up period., Complications , Panretinal photocoagulation (PRP) with red laser , Panretinal photocoagulation (PRP) with green laser ,0,
edin,3024,4240932,Cannot tell based on the abstract,"he significant change value on the before-after BICAMS points were considered to be 8, 13, and 7 points for the symbol digit modality test (SDMT), the California verbal learning test (CVLT), and the brief visual-spatial memory test revised (BVMT-R), respectively.", Brief International Cognitive Assessment for MS (BICAMS) test , placebo ," B. papyrifera (capsule 300 mg, twice a day) ",0,
edin,3024,4240932,Significantly increased,"BICAMS battery changes were considered as significant if SDMT changed 8 points, CVLT, 13 points, and BVMT-R, 7 points.,We observed that 12 patients (31.6%) from the treatment group and 8 patients (21.1%) from the placebo group had a significant change value in SDMT test.

CVLT test also showed a significant change in 17 and 12 patients (44.7% and 31.6%) in the treatment and placebo groups, respectively.

BVMT-R was improved significantly in 13 patients (34.2%) who took BP compared to the placebo group which had no improvement at all.,Although the number of patients who improved after receiving the drug in the treatment group was more than the placebo group in CVLT and SDMT, such a difference was not statistically significant (P = 0.2000 for SDMT, P = 0.1700 for CVLT); regarding BVMT-R, our findings were statistically significant (P < 0.001).", Brief International Cognitive Assessment for MS (BICAMS) test , placebo ," B. papyrifera (capsule 300 mg, twice a day) ",0,
edin,3048,5735476,Significantly increased,"Time for rescue analgesia in Group D5-377.46 Â± 60.05, in Group D10-401.60 Â± 61.11, and in Group D15-517.96 Â± 97.30, which is statistically highly significant (P < 0.000).", Time for rescue analgesia ," Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 ÃÂ¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 ÃÂ¼g (0.5 ml) ", Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 ÃÂ¼g (0.5 ml) ,0,
edin,2939,2744923,Cannot tell based on the abstract,, Effectiveness at day 28 , Sulphadoxine-pyrimethamine (SP)  , Chlorproguanil-dapsone (CPD) ,0,
edin,2939,2744923,Significantly increased,"<td align=""center"" colspan=""6""><bold>AL</bold></td>", Effectiveness at day 28 , Sulphadoxine-pyrimethamine (SP)  , Chlorproguanil-dapsone (CPD) ,0,
edin,3020,3152513,Cannot tell based on the abstract,, MADRS remission rates in patients with baseline MADRS total scores Ã¢â°Â¥20 ," placebo, or oral olanzapine 5-20 mg once daily for 3 weeks ", flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter) ,0,
edin,3020,3152513,Significantly increased,"In patients with baseline MADRS total scores â¥20, MADRS remission rates (defined as MADRS total score â¤12) with asenapine were significantly greater than placebo on days 7 (57% vs 17%; P = 0.004) and 21 (70% vs 33%; P = 0.012); remission rate with asenapine on day 7 was significantly greater than olanzapine (57% vs 25%; P = 0.006) and showed a trend towards statistical significance on day 21 (70% vs 48%; P = 0.066).", MADRS remission rates in patients with baseline MADRS total scores Ã¢â°Â¥20 ," placebo, or oral olanzapine 5-20 mg once daily for 3 weeks ", flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter) ,0,
edin,3027,5156617,Significantly decreased,"A total of 19 subjects (31 eyes) completed the trial after five subjects (eight eyes) dropped out. In the patients who completed the study by wearing lenses for 4 weeks, the myopic refractive error decreased significantly by 2.60 Â± 2.21 D (p < 0.001), from -3.65 Â± 1.62 to -1.05 Â± 1.64 D. The astigmatic refractive error were also significantly decreased by 0.63 Â± 0.98 D (p = 0.001), from 2.07 Â± 0.83 to 1.44 Â± 0.99 D.", The mean astigmatic refractive error , baseline , astigmatism of 1.25 to 4.0 D ,0,
edin,3002,4730432,No significant difference,"A statistically significant increase in the intention to obtain clinical trial information at the three and six month time points was observed in the intervention group, but not the control group.", intention to seek information about clinical trials , baseline , control ,0,
edin,3087,4530661,Significantly decreased,"Although soy milk did not have any effect on BP, probiotic soymilk significantly decreased systolic (14.7 Â± 0.48 vs. 13.05 Â± 0.16, P = 0.001) and diastolic BP (10 Â± 0.7 vs. 9.1 Â± 1, P = 0.031).", systolic and diastolic BP , consumed 200 ml/day of soy milk for 8 weeks , consumed 200 ml/day of probiotic soy milk containing Lactobacillus planetarium A7  for 8 weeks ,0,
edin,2967,4152682,Significantly decreased,"Pulse rate (95.9 Â± 11.2 bpm vs. 102.9 Â± 8.8 bpm, P = 0.001) systolic and diastolic BP were significantly higher in Group N.", Pulse rate during surgery , Normal saline followed by general anesthesia (Group N) , Transversus abdominis plane block with 0.25% bupivacaine (Group B) ,0,
edin,3050,5735476,Cannot tell based on the abstract,, mean arterial pressure (MAP) falls , baseline ," Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 ÃÂ¼g (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 ÃÂ¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 ÃÂ¼g (0.5 ml) ",0,
edin,3050,5735476,Significantly increased,"MAP falls significantly at 30th, 45th, and 60th min from basal rate within the groups, we have noticed hypotension in 4 (13.3%) patients in Group D5, 6 (20.0%) patients in Group D10, 13 (43.3%) patients in Group D15, which is statistically significant (P = 0.020) [Table 3].", mean arterial pressure (MAP) falls , baseline ," Group BD15 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 15 ÃÂ¼g (0.5 ml), Group BD5 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 5 ÃÂ¼g (0.5ml) , Group BD10 (n = 30): intrathecal bupivacaine 12.5 mg (2.5 ml) + dexmedetomidine 10 ÃÂ¼g (0.5 ml) ",0,
edin,3071,5870915,Cannot tell based on the abstract,, the number of days with diarrhoea and the number of piglets that had diarrhoea , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,3071,5870915,Significantly decreased,"The area under the curve for the FS, the number of days with diarrhoea and the number of piglets that had diarrhoea were significantly reduced in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Table 2).Fig. 3", the number of days with diarrhoea and the number of piglets that had diarrhoea , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,2958,3597059,Cannot tell based on the abstract,, Baseline characteristics , Control (C group) , Crystalloid (RS group) and colloid (HES group) ,0,
edin,2958,3597059,No significant difference,Baseline hemodynamic variables were comparable among the groups (P > 0.05)., Baseline characteristics , Control (C group) , Crystalloid (RS group) and colloid (HES group) ,0,
edin,3016,4630743,Significantly decreased,Only 3.61% patients complained of intolerable pain during dilatation in the study group while in control group 48.74% complained of intolerable pain and required anesthesia., Pain on cervical dilatation , 400 mg of metronidazole tablets (as a placebo) , 400 ÃÂ¼g of misoprostol ,0,
edin,2948,5600923,Significantly decreased,"After 2-year therapy, the mean tumor volume was 214.6 Â± 145.7 c.c. in AG and 467.2 Â± 225.3 c.c in CG (P < 0.01).", Tumor volume after 2 years of therapy , Placebo (CG group) , Alginate oligosaccharide (AOS; AG group) ,0,
edin,2964,4770250,No significant difference,"DRCFI was well tolerated with a similar incidence of systemic adverse events to the placebo group, but fewer pulmonary adverse events.", Systemic adverse events , Placebo , Dual release ciprofloxacin for inhalation (DRCFI) ,0,
edin,3012,5043523,No significant difference,"There were no significant differences between the three groups in terms of changes in folate intakes from baseline to month 6. Similarly, there were no changes in reported intake of food groups high in folate.", folate intakes , control or not at risk , knowledge of MTHFR 677CÃ¢â¬â°Ã¢â âÃ¢â¬â°T genotype ,0,
edin,3031,4483405,No significant difference,"Both groups exhibited significant decreases in pain post-intervention. Moreover, the range of motion of internal and external rotation increased significantly post-intervention in both groups. However, there was no significant difference between groups with respect to pain improvement or range of motion.", pain or  range of motion (ROM) improvement , Kaltenborn mobilization , Maitland mobilization ,0,
edin,3070,5870915,Cannot tell based on the abstract,, the number of piglets that excreted countable oocyst numbers , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,3070,5870915,No significant difference,"The area under the curve for OpG, the number of days with McMaster countable excretion and the number of piglets that excreted countable oocyst numbers were significantly reduced in the ForcerisÂ® and BaycoxÂ® groups compared to the Control group without statistical difference between the treatment groups (Table 2).", the number of piglets that excreted countable oocyst numbers , untreated , 45 mg toltrazuril + 200 mg gleptoferron (ForcerisÃÂ®) or with 20 mg toltrazuril/kg body weight as an oral suspension (BaycoxÃÂ® 5%) ,0,
edin,2926,4286912,No significant difference,No serious adverse events considered causally related to vaccination were reported throughout the study., Serious adverse events , PHiD-CV Commercial lot (Com group) , PHiD-CV Phase III Clinical (Clin group) ,0,
edin,3036,3506580,Cannot tell based on the abstract,, heat pain thresholds (HPT) , baseline , Transcranial direct current stimulation (tDCS) ,0,
edin,3036,3506580,No significant difference,"There were no significant differences of HPT before and after tDCS (PREPOST: F(1,9)â=â0.82; pâ=â0.389) and between treatment modalities (STIM: F(2,18)â=â1.27; pâ=â0.306).", heat pain thresholds (HPT) , baseline , Transcranial direct current stimulation (tDCS) ,0,
edin,2943,4993942,Significantly increased,"The mean subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increased significantly in each eye 6 weeks after PRP (P values in red laser group: <0.01, 0.03, and <0.01, resp., and in green laser group <0.01, <0.01, and <0.01).", Subfoveal choroidal thickness , Panretinal photocoagulation (PRP) with red laser , Panretinal photocoagulation (PRP) with green laser ,0,
edin,3062,4726501,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Intention-to-treat analysis</td><td align=""center"" colspan=""1"" rowspan=""1""></td><td align=""right"" colspan=""1"" rowspan=""1""></td><td align=""center"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>", the incidence of positive urine dipstick albumin , no aspirin ," receive aspirin (81 mg or 100 mg daily, ",0,
edin,3054,3177395,Cannot tell based on the abstract,, Mean values of the SBI after 42 days , used a conventional dentifrice , received herbal extract dentifrices  ,0,
edin,3054,3177395,Significantly decreased,"The most anti inflammatory effect had been achieved in herbal test groups, where mean values of GI and SBI indices were significantly lower than those of the conventional group (P <60; 0.001).", Mean values of the SBI after 42 days , used a conventional dentifrice , received herbal extract dentifrices  ,0,
edin,2995,5980459,Significantly increased,Abomasal outflow fluid pH was higher in steers treated with famotidine for up to 4 hours after a single dose but the effect decreased with subsequent doses., pH of abomasal outflow fluid for 4 hours , saline control , famotidine administered at 0.4 mg/kg ,0,
edin,2945,4993942,No significant difference,"There was no difference between red and green laser considering subfoveal choroidal, central retinal, and peripapillary nerve fiber layer (RNFL) thickness increase after PRP (P values: 0.184, 0.404, and 0.726, resp.).", Peripapillary nerve fiber layer thickness , Panretinal photocoagulation (PRP) with red laser , Panretinal photocoagulation (PRP) with green laser ,0,
edin,2974,5452353,Significantly increased,"Plasma NO3 â were 10.3Â Î¼mol greater with POMx vs. PLAC (95% CI, 0.8, 19.7,F 1,7â=â7.83, pâ<â0.04).", Levels of NO3 Ã¢Ëâ in plasma , Placebo (PLAC) , Pomegranate extract (POMx) ,0,
edin,3081,5148913,Significantly increased,"The primary endpoint [change from baseline over the entire treatment period in average pre-dose morning peak expiratory flow (PEF)] demonstrated the superiority of BDP/FF over BDP monotherapy, with an adjusted mean difference of 19Â L/min, which is above the minimal important clinical difference reported for this parameter. O", adjusted mean change of PEF , BDP 100 ÃÂ¼g (four puffs twice a day) , BDP/FF 200/6 ÃÂ¼g pMDI extrafine (two puffs twice a day) ,0,
edin,3005,4347450,Cannot tell based on the abstract,, Judge 2's performance quality ratings between time 2 and 3 , waitlist condition , cognitive behavioral (CB) group-delivered intervention ,0,
edin,3005,4347450,No significant difference,"For Judge 2's performance quality ratings, both the interaction between group and time [F(2, 120) = 0.36, p > 0.05] and main effect for group were not significant [F(1, 60) = 1.36, p > 0.05].", Judge 2's performance quality ratings between time 2 and 3 , waitlist condition , cognitive behavioral (CB) group-delivered intervention ,0,
edin,2860,5870330,Significantly increased,"G1 showed the highest fracture resistance value (1737.1 N) while G3 had the lowest mean value (522.9 N). Furthermore, the fracture resistance of G4 and G5 was significantly higher than G3 and G6 (P < 0.05), where in both groups, the preparation of the occlusal extension mostly remained in the enamel layer.", fracture resistance , G6: The occlusal extension was 2 mm in depth and 1 mm in width. , G4 was prepared with the occlusal extension of 1mm in depth and width. G5: The occlusal extension was 1mm in depth and 2 mm in width ,0,
edin,3028,5156617,Cannot tell based on the abstract,"The mean uncorrected and corrected visual acuities before wearing the lenses were 2.14 Â± 0.80 logarithm of the logMAR (logMAR) and 0.05 Â± 0.13 logMAR, respectively, which changed to 0.12 Â± 0.30 logarithm of the logMAR (p < 0.001) and 0.01 Â± 0.04 logMAR (p = 0.156) after 4 weeks.", The mean uncorrected and corrected visual acuities , baseline , myopia of -0.75 to -6.0 diopters (D) and astigmatism of 1.25 to 4.0 D ,0,
edin,3028,5156617,No significant difference,"The mean uncorrected and corrected visual acuities at the screening visit were 2.14 Â± 0.80 and 0.05 Â± 0.13 logMAR, respectively. The equivalent values after wearing the toric orthokeratology lenses for 4 weeks were 0.12 Â± 0.30 and 0.01 Â± 0.04 logarithm of the minimal angle of resolution (logMAR), respectively. The difference in uncorrected visual acuity was -2.03 Â± 0.91 logMAR, which was statistically significant (p < 0.001). The difference in corrected visual acuity was -0.04 Â± 0.14 logMAR, which was not statistically significant (p = 0.156) (Table 3).", The mean uncorrected and corrected visual acuities , baseline , myopia of -0.75 to -6.0 diopters (D) and astigmatism of 1.25 to 4.0 D ,0,
edin,3165,3652505,Cannot tell based on the abstract,The number sized framing effect was also tested to be significant (P < 0.01)., number size framing effect ," Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 197 didnât suffer from keratitis but 9 were found visual acuity declined. Doctor B: Of 200 patients, 190 didnât suffer from keratitis but 2 were found visual acuity declined. Which doctor you will choose? "," Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 191 were not found postoperative visual acuity declined but 3 suffered from keratitis; Doctor B: Of 200 patients, 198 were not found postoperative visual acuity declined but 10 suffered from keratitis. Which doctor you will choose? ",0,
edin,3165,3652505,Significantly decreased,"Table 5 described the effect of number size framing. The results revealed that the number size framing effect was significant in medical situation (t = -7.5, P < 0.001).

Table 1,<td colspan=""1"" rowspan=""1"">Framing 2: Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 197 didnât suffer from keratitis but 9 were found visual acuity declined. Doctor B: Of 200 patients, 190 didnât suffer from keratitis but 2 were found visual acuity declined. Which doctor you will choose? </td><td colspan=""1"" rowspan=""1"">4.14 Â± 1.39</td>", number size framing effect ," Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 197 didnât suffer from keratitis but 9 were found visual acuity declined. Doctor B: Of 200 patients, 190 didnât suffer from keratitis but 2 were found visual acuity declined. Which doctor you will choose? "," Eye surgery may lead to two potential sequelas: one is a minor decline of visual acuity and the other is keratitis. Imagine you will take this kind of surgery and two doctorsâ medical records revealed that: Doctor A: Of 200 patients, 191 were not found postoperative visual acuity declined but 3 suffered from keratitis; Doctor B: Of 200 patients, 198 were not found postoperative visual acuity declined but 10 suffered from keratitis. Which doctor you will choose? ",0,
edin,3181,4563303,Cannot tell based on the abstract,, Timed Up and Go (TUG) (sec)â¡ , visual disuse group (VDG) , visual feedback group (VFG) ,0,
edin,3181,4563303,Significantly decreased,"Changes in TUG and BBS between pre-test and post-test were statistically significant in both groups and there was an interaction between the groups and time.,<td align=""left"" colspan=""1"" rowspan=""1"">TUG (sec)<sup>â¡</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">15.62Â±4.89</td><td align=""center"" colspan=""1"" rowspan=""1"">9.93Â±3.93<sup>â </sup></td><td align=""center"" colspan=""1"" rowspan=""1"">21.84Â±12.61</td><td align=""center"" colspan=""1"" rowspan=""1"">19.33Â±12.07<sup>â </sup></td>", Timed Up and Go (TUG) (sec)â¡ , visual disuse group (VDG) , visual feedback group (VFG) ,0,
edin,3153,5094682,No significant difference,"The mean changes in eGFR were 0 Â± 14 and â7 Â± 16 mL/min/1.73 m2 (p = 0.09, between groups) for the acarbose and pioglitazone groups, respectively.", glomerular filtration rate (eGFR) , pioglitazone , acarbose ,0,
edin,3157,5094682,Significantly increased,"Significant body weight gain was observed in the pioglitazone group as compared with the acarbose group (1.3 Â± 2.8 vs. â0.6 Â± 1.5 kg, p = 0.002).


Conclusion", body weight , acarbose ,  pioglitazone ,0,
edin,3201,4787139,Cannot tell based on the abstract,, heart rate (HR) , baseline ," MDZ:FEN, DEX 0.25 Î¼g/kg (DEX half) ",0,
edin,3201,4787139,Significantly decreased,"HR values in âDEX fullâ group were significantly lower than in MDZ:FEN and âDEX halfâ group at 10 min (P = 0.001). MDZ: FEN group patients had lower HR than DEX full and DEX half group patients in the post-operative period (150, 180, 210 min) [Figure 1]. Two cases in the âDex fullâ group required injection atropine for treatment of HR less than 50/min.", heart rate (HR) , baseline ," MDZ:FEN, DEX 0.25 Î¼g/kg (DEX half) ",0,
edin,3126,5200917,Cannot tell based on the abstract,, reaction time in simple speeded response task  , placebo , tolcapone ,0,
edin,3126,5200917,No significant difference,"Moreover, in a simple speeded response task, no difference was seen in reaction time for either visual or auditory responding on tolcapone compared to placebo (all T(14)Â â¤Â 1.1, pÂ â¥Â 0.3),", reaction time in simple speeded response task  , placebo , tolcapone ,0,
edin,3141,3845560,Cannot tell based on the abstract,, Distant metastasis , flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy , 2 cycles of sinusoidal chronomodulated infusion (Arm A) ,0,
edin,3141,3845560,No significant difference,Distant metastasis represented the major failure pattern and occurred in 27 (21.8%) patients: 16 (25.4%) in Arm A and 11 (18.0%) in Arm B (P = 0.597) (Table 4)., Distant metastasis , flat intermittent constant rate infusion (Arm B) of DDP and 5-FU followed by radical radiotherapy , 2 cycles of sinusoidal chronomodulated infusion (Arm A) ,0,
edin,3208,2784386,Significantly increased,"In non-ICU subjects, treatment success was significantly higher for micafungin versus liposomal amphotericin B (85% (n = 108/127) versus 72.1% (n = 98/136); P = 0.0113).", treatment success in non-ICU subjects , liposomal amphotericin B (3 mg/kg/day) , micafungin (100 mg/day for subjects &amp;gt; 40 kg; 2 mg/kg/day for subjects â¤ 40 kg) ,0,
edin,3170,3536709,Cannot tell based on the abstract,, difference in the weight ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3170,3536709,No significant difference,In spite of lower energy intake during LPVD there was no difference in the weight of the subjects compared to ND (75.6 Â± 7.9 kg vs. 76.2 Â± 7.6 kg)., difference in the weight ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3160,5842771,No significant difference,"After 12 weeks of treatment, the average MMSE scores, ADL scores, and CDR scores in the two groups were significantly improved. But, compared to the control group, the experimental group had a significantly higher average MMSE score (p<0.00001), lower average ADL score (p=0.00002), and lower average CDR score (p=0.030).", Clinical Dementia Rating Scale (CDR) score , memantine 5â20 mg/d ," Î²-asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5â20 mg/d ",0,
edin,3174,3503942,Significantly decreased,"The changes in visual analog scale were estimated to be 6.86Â±0.90 before first therapy, 2.86Â±0.90 after first therapy, and 1.86Â±0.69 after third therapy in case of ESWT group, whereas the figures were estimated to be 7.20Â±1.30 before first therapy, 4.60Â±0.55 after first therapy, and 2.80Â±0.84 after third therapy in case of TPI+TENS group, and the changes between the groups were significantly different (p=0.010).", The changes in visual analog scale ,  trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS) , extracorporeal shock wave therapy (ESWT) ,0,
edin,3162,3652505,Cannot tell based on the abstract,Doctorsâ advices were respectively described in a baneful or beneficial frame and the former one resulted in a better compliance (P < 0.05)., better compliance ," question:  Doctors tells you that although you particularly like to eat bacon, if you continue to eat, your body cholesterol content will significantly rise, and thus the possibility of suffering from cardiovascular disease would be greatly increased. Would you continue to eat bacon? "," question:  Doctor tells you that although you particularly like to eat bacon, if you stop eating, your body cholesterol content would be significantly reduced, and thus the possibility of suffering from cardiovascular disease would be greatly reduced. Would you continue to eat bacon? ",0,
edin,3162,3652505,Significantly increased,"As shown in Table 2 that if the doctorâ advise was respectively described in the benefit of compliance and the aftermath of violation, the former one lead to a better compliance (t = 2.14, P = 0.035).,<td colspan=""1"" rowspan=""1"">Negative: Doctors tells you that although you particularly like to eat bacon, if you continue to eat, your body cholesterol content will significantly rise, and thus the possibility of suffering from cardiovascular disease would be greatly increased. Would you continue to eat bacon? </td><td colspan=""1"" rowspan=""1"">2.10 Â± 0.89</td>", better compliance ," question:  Doctors tells you that although you particularly like to eat bacon, if you continue to eat, your body cholesterol content will significantly rise, and thus the possibility of suffering from cardiovascular disease would be greatly increased. Would you continue to eat bacon? "," question:  Doctor tells you that although you particularly like to eat bacon, if you stop eating, your body cholesterol content would be significantly reduced, and thus the possibility of suffering from cardiovascular disease would be greatly reduced. Would you continue to eat bacon? ",0,
edin,3132,4078065,Cannot tell based on the abstract,, ApoA-I and HDL-mediated cholesterol effluxes , placebo , 3.2 g/day citrulline ,0,
edin,3132,4078065,Significantly increased,"Citrulline enhanced both apoA-I- and HDL-mediated cholesterol efflux from THP-1 macrophages by 96.1Â Â±Â 26.1% (p<0.05) and 14.4Â Â±Â 2.5% (p<0.05), respectively, compared to control (Fig.Â 3A and B).", ApoA-I and HDL-mediated cholesterol effluxes , placebo , 3.2 g/day citrulline ,0,
edin,3171,3536709,No significant difference,"Diet caused no significant difference in venous blood pH, strong ion difference (SID), total concentration of weak acids (Atot), partial pressure of CO2 (pCO2) or HCO3- at rest or during cycling between LPVD and ND.", strong ion difference (SID) ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3119,4188585,No significant difference,No differences in SPID between treatments were observed at 2 and 3 months after patch application., The maximum difference in summed pain intensity differences (SPID) , placebo , capsaicin ,0,
edin,3204,4787139,Significantly increased,"DEX fullâ group had a higher incidence of bradycardia, hypotension, level 4 sedation (Ramsay Sedation Scale) and lower surgeon satisfaction."," bradycardia, hypotension and level 4 sedation ", baseline , DEX full ,0,
edin,3175,3503942,No significant difference,The changes in McGill pain questionnaire (p=0.816) and pain rating scale (p=0.644) between the groups were not significantly different., The changes in McGill pain questionnaire ,  trigger point injections (TPI)+transcutaneous electrical nerve stimulation (TENS) , extracorporeal shock wave therapy (ESWT) ,0,
edin,3146,4435250,Significantly increased,"omen in the MHC/WHC arm were more likely to report increases in relationship equity, relative to those in the CHC arm, and had a higher odds of reporting no victimization during the previous 3 months (MHC/WHC vs WHC: odds ratio =3.05, 95% CI: 1.55, 6.0, P=0.001; CHC vs MHC/WHC: odds ratio =0.38, 95% CI: 0.20, 0.74, P=0.004).", relationship equity , Couples Health CoOp [CHC] ,  females in group Menâs Health CoOp/Womenâs Health CoOp [MHC/WHC] ,0,
edin,3095,5091897,Cannot tell based on the abstract,, household smoking bans follow up 3 and 6 months  , Control Group , Intervention group ,0,
edin,3095,5091897,Significantly increased,"<td align=""center"" colspan=""9"" rowspan=""1""><bold>Primary outcome</bold></td>", household smoking bans follow up 3 and 6 months  , Control Group , Intervention group ,0,
edin,3191,4836241,Significantly decreased,"The posttherapeutic serum follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) level and endometrial thickness decreased significantly in all the three groups (P < 0.05)."," follicle-stimulating hormone (FSH), luteinizing hormone (LH) "," Kuntai, Control "," Tibolone,  ",0,
edin,3199,4568196,No significant difference,"Despite the significant effect of HDEL on increasing TAC in 3 weeks [P = 0.050 (4%)], the level of TAC remained the same in 6 weeks.",  total antioxidant capacity (TAC) , baseline ,  hypocaloric diet enriched with legumes (HDEL) ,0,
edin,3166,3536709,Cannot tell based on the abstract,, Energy intake ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3166,3536709,Significantly decreased,"Energy intake was significantly lower during LPVD compared to ND (2400 Â± 338 kcal vs. 2793 Â± 554 kcal, p=0.033).", Energy intake ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3097,5306984,Significantly increased,We conclude that arm training using the AA robotic device is safe and able to reduce motor deficits more effectively than matched conventional arm training in subacute phase of stroke., subacute stroke patients , conventional arm training (control group) , ArmAssist (AA group) ,0,
edin,3107,3994428,Significantly decreased,"Six-month mortality was 6.5% in the ICP group and 9.1% in the control group (Pâ<â0.05),", Mortality , control group , ICP monitoring ,0,
edin,3135,5156970,Significantly increased,"The onset of relief occurred significantly sooner, and duration of relief was significantly longer in azithromycin group. Movement, abdominal pain, bloating, and gas were significantly better in azithromycin group.", relief of overall symptoms , baseline , azithromycin ,0,
edin,3113,5516192,Cannot tell based on the abstract,, The incision length , traditional cold instruments (scalpel and scissors) , electrosurgical device ,0,
edin,3113,5516192,No significant difference,"The incision length was not significantly different; cold 15.7 (5.2) cm, electroincision 15.6 (4.2) cm, 95% CI â1.6â1.8, Pâ=â.91.", The incision length , traditional cold instruments (scalpel and scissors) , electrosurgical device ,0,
edin,3127,5200917,Cannot tell based on the abstract,, blood pressure , placebo , tolcapone ,0,
edin,3127,5200917,No significant difference,"Finally, no differential changes in blood pressure were seen on tolcapone versus placebo (T(15)Â =Â 1.31, pÂ =Â 0.21),", blood pressure , placebo , tolcapone ,0,
edin,3098,5306984,Significantly increased,We conclude that arm training using the AA robotic device is safe and able to reduce motor deficits more effectively than matched conventional arm training in subacute phase of stroke., subacute stroke patients , conventional arm training (control group) , ArmAssist AA group ,0,
edin,3123,3775615,Cannot tell based on the abstract,,  HBeAg levels , adefovir (ADV) (10 mg/day) , lamivudine (LAM) (100 mg/day ,0,
edin,3123,3775615,No significant difference,"As described in Figure 2, HBeAg levels in the LAM + ADV group were 1.81Â±1.01, 1.52Â±0.86, 1.26Â±0.93, and 0.71Â±0.93 at weeks 12, 24, 52, and 104 of treatment, respectively.,In the ETV group, the levels of HBeAg were 1.66Â±0.99, 1.43Â±0.92, 1.12Â±0.91, and 0.69Â±0.83 at weeks 12, 24, 52, and 104, respectively. There were no statistically significant differences between these 2 groups (P=0.668, 0.729, 0.614, and 0.955 at weeks 12, 24, 52, and 104, respectively).",  HBeAg levels , adefovir (ADV) (10 mg/day) , lamivudine (LAM) (100 mg/day ,0,
edin,3180,4563303,Cannot tell based on the abstract,, Right (cm)â¡ , visual disuse group (VDG) , visual feedback group (VFG) ,0,
edin,3180,4563303,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"">Right (cm)<sup>â¡</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">3.40Â±1.58</td><td align=""center"" colspan=""1"" rowspan=""1"">4.11Â±2.35<sup>â </sup></td><td align=""center"" colspan=""1"" rowspan=""1"">1.95Â±0.92</td><td align=""center"" colspan=""1"" rowspan=""1"">3.16Â±1.15<sup>â </sup></td>", Right (cm)â¡ , visual disuse group (VDG) , visual feedback group (VFG) ,0,
edin,3103,4450164,Cannot tell based on the abstract,, ureteropelvic junction obstruction , stentless cases , internal drainage group ,0,
edin,3103,4450164,No significant difference,"Intraoperative assessments showed ureteropelvic junction segmental atresia in 45 cases and aberrant vessels in 25 patients.,One patient had distal ureter obstruction because of distal ureter stone, that was treated by Trans-ureteral lithotripsy (TULP) and stent support.", ureteropelvic junction obstruction , stentless cases , internal drainage group ,0,
edin,3195,3661337,No significant difference,The SPTT group showed fewer subjects having any fall (19.23% vs. 33.33% Standard PT; pâ<â0.227) and fewer having an injurious fall (7.69% vs. 18.18%; pâ<â0.243).,  fewer having an injurious fall , baseline , surface perturbation treadmill training (SPTT) ,0,
edin,3125,4815378,Significantly increased,Mean weight changes of neonates 7 weeks after the intervention compared to those in the beginning of the intervention were significantly more in palady group compared to the cup group (cup = 146.7 and palady = 198.8; P < 0.001)., Mean weight changes of neonates 7 weeks , cup ,  palady ,0,
edin,3190,4836241,Significantly increased,"After therapy, serum E2 level in Tibolone group was obviously higher than the other two groups (P < 0.05),", estradiol (E2) leve ," Kuntai, Control "," Tibolone,  ",0,
edin,3158,5842771,Significantly increased,"But, compared to the control group, the experimental group had a significantly higher average MMSE score (p<0.00001),", The Mini Mental State Examination (MMSE) , memantine 5â20 mg/d ," Î²-asarone 10 mg/d, tenuigenin 10 mg/d, and memantine 5â20 mg/d ",0,
edin,3194,3661337,Cannot tell based on the abstract,, falls , baseline , surface perturbation treadmill training (SPTT) ,0,
edin,3194,3661337,No significant difference,"Over a period of 3Â months, 5 of 26 (19.2%) subjects in the SPTT group and 11 of 33 (33.3%) subjects in the Standard PT group had fallen at least once (Chi2â=â1.46; pâ<â0.23); 2 of 26 (7.7%) in the SPTT group and 6 of 33 (18.2%) in the Standard PT group had an injurious fall (Chi2â=â1.37; pâ<â0.25) (see FigureÂ 2).", falls , baseline , surface perturbation treadmill training (SPTT) ,0,
edin,3187,4836241,Significantly increased,"At the 4th week after GnRH-a therapy, KMI and hot flash/sweating score results were as follows: Control group > Kuntai group > Tibolone group (P < 0.05);", KMI and hot flash/sweating score ," Kuntai, Tibolone ",  Control ,0,
edin,3169,3536709,Cannot tell based on the abstract,,  the amount of fat ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3169,3536709,Significantly decreased,"As well, the amount of fat differed between LPVD and ND (24.7 Â± 2.3% vs. 28.1 Â± 3.1%, p=0.015).",  the amount of fat ,  normally diet (ND) , low-protein vegetarian diet (LPVD) ,0,
edin,3142,5014878,Significantly increased,Mean antibody reactivity against the associated HPV type rose from 1125 median fluorescence intensity (MFI) pre-vaccination to 4690 MFI post-vaccination (pÂ <Â 0.001)., Mean antibody reactivity against the associated HPV , baseline , quadrivalent HPV vaccine (GardasilÂ®) ,0,
edin,3148,4083640,Significantly decreased,"On postoperative day 5, the self-reported pain intensity was significantly lower in the NBP group than in the CT group (visual analog scale score, 1.50 vs. 3.29; p = 0.04).", postoperative pain on day 5 , conventional thoracotomy (CT) , neurovascular bundle preservation (NBP) ,0,
edin,3227,3089991,Cannot tell based on the abstract,, Face and scalp sensations , Sham rTMS , Prefrontal rTMS ,0,
edin,3227,3089991,No significant difference,"Only 40% of participants guessed correctly (p =â0.27), suggesting that the sham condition was reasonably matched to real TMS with respect to face and scalp sensations.", Face and scalp sensations , Sham rTMS , Prefrontal rTMS ,0,
edin,3273,5682159,Cannot tell based on the abstract,, Overall satisfaction of the patients , Vycross 20 mg/ml HA (VYC-20) , Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26) ,0,
edin,3273,5682159,No significant difference,"Overall, the majority of subjects were satisfied with both treatments throughout the study with a trend in favor of CPM-26.", Overall satisfaction of the patients , Vycross 20 mg/ml HA (VYC-20) , Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26) ,0,
edin,3275,5682159,Cannot tell based on the abstract,, Improvement according to the patients at the M12 and M18 visits , Vycross 20 mg/ml HA (VYC-20) , Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26) ,0,
edin,3275,5682159,Significantly increased,"At both the M12 and M18 visits, more CPM-26-treated subjects considered themselves much improved or very much improved compared with VYC-20-treated subjects", Improvement according to the patients at the M12 and M18 visits , Vycross 20 mg/ml HA (VYC-20) , Cohesive Polydensified Matrix 26 mg/ml HA (CPM-26) ,0,
edin,3218,3994324,No significant difference,"No significant difference in mean adherence over the monitoring period was identified with 77.2% (CI, 73.0, 81.4) for the control group and 74.8% (CI, 69.7, 79.9) for the intervention group (pâ=â0.47).", Adherence , Standard clinical care , Novel glaucoma education and motivational support package using behaviour change counselling ,0,
edin,3251,5457851,Cannot tell based on the abstract,, Time of onset of anesthesia ," 2% lidocaine with 1:200,000 epinephrine  "," 2% lidocaine with 1:80,000 epinephrine  ",0,
edin,3251,5457851,No significant difference,"The meanâÂ±âSD time of onset was 4.9âÂ±â4.1âminutes in the L80 group and 5.2âÂ±â4.1âminutes in the L200 group, with no significant difference between the groups (Pâ=â.447)", Time of onset of anesthesia ," 2% lidocaine with 1:200,000 epinephrine  "," 2% lidocaine with 1:80,000 epinephrine  ",0,
edin,3287,4610927,Significantly decreased,The value difference of the Touch-Test sensory evaluation was significantly higher negative in group RH than in the other two groups., Value of the Touch-Test sensory evaluation after surgery , Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL)  , Remifentanil 0.3 (group RH) ,0,
edin,3266,3712888,Significantly decreased,"Considering a 6-month treatment period, the recurrence rate in the vitamin C group (16.2%) was significantly lower (P = 0.024) than in the placebo group (32.4%).", Recurrence of bacterial vaginosis after 6 months , Placebo , Vaginal vitamin C ,0,
edin,3294,3504074,Significantly increased,"In total, 239 patients were enrolled in each arm. PASI 75 was significantly higher at week 24 for the combination therapy group compared with the monotherapy group (77Â·3% vs. 60Â·3%; P < 0Â·0001). Other PASI improvement scores at week 12 [PASI 75, 70Â·2% vs. 54Â·3% (P = 0Â·01); PASI 50, 92Â·4% vs. 83Â·8% (P = 0Â·01); and PASI 90, 34Â·0% vs. 23Â·1% (P = 0Â·03)] showed similar results as did week 24 PASI 50 (91Â·6% vs. 84Â·6%; P = 0Â·01) and PASI 90 (53Â·8% vs. 34Â·2%; P = 0Â·01).",  Improvement in Psoriasis Area and Severity Index â¥50% and â¥90% after 24 weeks , Eetanercept alone , Etanercept plus methotrexate ,0,
edin,3317,5219826,Significantly increased,"EDOF was significantly better than AOMF for HCVA at 40Â cm (0.42Â Â±Â 0.18 vs. 0.48Â Â±Â 0.22, pÂ =Â 0.024), stereopsis (98Â Â±Â 88 vs. 141Â Â±Â 114, pÂ <Â 0.001), clarity-of-vision at intermediate (8.5Â Â±Â 1.6 vs. 7.7Â Â±Â 1.9, pÂ =Â 0.006) and near (7.3Â Â±Â 2.5 vs. 6.2Â Â±Â 2.5, pÂ =Â 0.005), lack-of-ghosting (pÂ =Â 0.012), overall vision satisfaction (7.5Â Â±Â 1.7 vs. 6.4Â Â±Â 2.2, pÂ <Â 0.001) and ocular comfort (9.0Â Â±Â 1.0 vs. 8.3Â Â±Â 1.7, pÂ =Â 0.002).", Intermediate and near clarity-of-vision , Center-near lens (AOMF) , Extended depth-of-focus (EDOF) ,0,
edin,3229,3346674,Significantly increased,"Although improvement in the severity of DD was observed in both treatment groups (P < 0.001), patients receiving Calendula ointment had significantly fewer rash sites compared to Aloe group (P = 0.001).", Improvement of rash sites , Calendula ointment , Aloe cream ,0,
edin,3276,4276527,Significantly decreased,"Compared to premenopausal, healthy lean postmenopausal women had increased postprandial glucose and insulin and trend for higher TG, but similar dietary FA oxidation and storage.,Short-term E2 reduced postprandial TG and insulin, but had no effect on oxidation or storage of dietary FA. E2 increased the proportion of small adipocytes in femoral (but not abdominal) SAT.", Postprandial triglycerides , Placebo , Short-term estradiol (E2) ,0,
edin,3267,3712888,Cannot tell based on the abstract,, Baseline characteristics  , Placebo , Vaginal vitamin C ,0,
edin,3267,3712888,Significantly decreased,"The pH-lowering effect of vitamin C was detected after a prophylaxis period of 3 months, with a reduction of 3.8% compared with the baseline value and becoming statistically significant compared with placebo (Fig. 3) after four cycles of treatments (P = 0.032, Mann-Whitney test).", Baseline characteristics  , Placebo , Vaginal vitamin C ,0,
edin,3283,4610927,No significant difference,There was no significant difference among the three groups related to demographic and anesthetic parameters except the end-tidal concentration of desflurane., Demographic and anesthetic parameters , Remifentanil 0.3 + ketamine 0.5 (group KRH) , Remifentanil 0.05 (Group RL) or remifentanil 0.3 (group RH) ,0,
edin,3248,5851532,Significantly increased,"Compared to the provider-collected cervical hrHPV DNA sample (gold standard), the self-collected vaginal hrHPV DNA test demonstrated a sensitivity of 71.4% (95% CI: 0.52, 0.91; p = 0.0495) and specificity of 98.2% (95% CI: 0.96, 1.00; p<0.0001).", Sensitivity and specificity , Provider-collected cervical swabs , Self-collected vaginal specimens ,0,
edin,3250,5457851,Cannot tell based on the abstract,, Self-reported pain intensity ," 2% lidocaine with 1:200,000 epinephrine  "," 2% lidocaine with 1:80,000 epinephrine  ",0,
edin,3250,5457851,No significant difference,"Although the participants in the L200 group reported having experienced more intense pain than those in the L80 group (Pâ=â.055), the upper limit of the 1-sided confidence interval was 12.9âmm, which is lower than the noninferiority tolerance of 15âmm (Table 2).", Self-reported pain intensity ," 2% lidocaine with 1:200,000 epinephrine  "," 2% lidocaine with 1:80,000 epinephrine  ",0,
edin,3302,4450462,Significantly increased,"After 20 weeks, body weight change with the intervention was â6.4âkg (95% confidence interval (CI) â9.4 to â3.4, P<0.001) in an effect size analysis.", Reduction in body weight after 20 weeks , Only vitamin B12 supplement , Prescribed diet plus vitamin B12 supplement ,0,
edin,3308,3662597,No significant difference,"There was no groupâÃâtime interaction for HR, BP, blood glucose, lipids, NOx, hs-CRP, cortisol concentrations or body fat.", Lipid parameters , Placebo group , Multi-ingredient performance supplement (MIPS) group ,0,
edin,3252,5457851,Cannot tell based on the abstract,, Time of anesthesia action ," 2% lidocaine with 1:200,000 epinephrine  "," 2% lidocaine with 1:80,000 epinephrine  ",0,
edin,3252,5457851,No significant difference,"he meanâÂ±âSD duration of action of anesthesia was 183.5âÂ±â5.0âminutes in the L80 group and 182.2âÂ±â5.4âminutes in the L200 group, with no significant difference between the groups (Pâ=â.758)", Time of anesthesia action ," 2% lidocaine with 1:200,000 epinephrine  "," 2% lidocaine with 1:80,000 epinephrine  ",0,
edin,3293,3504074,Significantly increased,"In total, 239 patients were enrolled in each arm. PASI 75 was significantly higher at week 24 for the combination therapy group compared with the monotherapy group (77Â·3% vs. 60Â·3%; P < 0Â·0001).",  Improvement in Psoriasis Area and Severity Index â¥75% after 24 weeks , Eetanercept alone , Etanercept plus methotrexate ,0,
edin,3268,3712888,Cannot tell based on the abstract,, Signs and symptoms of bacterial vaginosis , Placebo , Vaginal vitamin C ,0,
edin,3268,3712888,No significant difference,"he two groups were homogeneous for age, height and weight distribution. BV signs and symptoms (itching, burning, dysuria, odour, erythema, oedema and fissures) were fairly similar across treatment groups, as summarised in Table 1.,BV signs and symptoms did not show any statistically significant differences through the treatment study period (from baseline to the follow-up visit), or in comparison of the treatment groups at the evaluated time points.", Signs and symptoms of bacterial vaginosis , Placebo , Vaginal vitamin C ,0,
edin,3217,4495314,Cannot tell based on the abstract,, Proportion of emotionally distressed parents at 6 months ," Standard care (Control group, CG) "," Extended postpartum care (Intervention group, IG) ",0,
edin,3217,4495314,No significant difference,Midwives identified 20% of mothers and 9% of fathers as highly distressed at 6âmonths postpartum. There was no difference between groups regarding the proportion of emotionally distressed mothers and fathers., Proportion of emotionally distressed parents at 6 months ," Standard care (Control group, CG) "," Extended postpartum care (Intervention group, IG) ",0,
edin,3213,4495314,Cannot tell based on the abstract,, Baseline age and level of education of the mothers ," Standard care (Control group, CG) "," Extended postpartum care (Intervention group, IG) ",0,
edin,3213,4495314,Significantly decreased,"There was a small but significant difference in socio-demographic characteristics between IG and CG mothers [F(3,313)â=â3.562, pâ=â0.015; Wilksâ Îâ=â0.967; Î·p2=0.033], such that CG mothers were significantly older [F(1,315)â=â7.227, pâ=â0.008; Î·p2=0.022] and had a higher level of education [F(1,315)â=â4.348, pâ=â0.038; Î·p2=0.014].", Baseline age and level of education of the mothers ," Standard care (Control group, CG) "," Extended postpartum care (Intervention group, IG) ",0,
edin,3220,3994324,Significantly increased,"Participants in the intervention group were more satisfied with information about glaucoma medication with a mean score of 14.47/17 (CI, 13.85, 15.0) compared with control group which was 8.51 (CI, 7.72, 9.30).", Satisfaction with information given about travoprost , Standard clinical care , Novel glaucoma education and motivational support package using behaviour change counselling ,0,
edin,3264,4464926,No significant difference,"No statistically significant differences were observed for pain (p<0.06), trismus (p<0.71) and swelling (p<0.05) between the test and the control group.", Trismus , Partial closure of the wound , Hermetical closure of the wound ,0,
edin,3280,4276527,Cannot tell based on the abstract,, Serum leptin , Placebo , Short-term estradiol (E2) ,0,
edin,3280,4276527,Significantly increased,"Compared with placebo, 2 weeks of E2 increased serum leptin (Table 1), reduced postprandial TG and insulin responses (Figures 2B and 3D; p<0.05),", Serum leptin , Placebo , Short-term estradiol (E2) ,0,
edin,3234,5720557,Significantly decreased,The use of nonâcoplanar beams was more common with Perspecta plans (82% vs. 27%). The mean target dose differed by less than 2% between rival plans., Use of nonÃ¢â¬ï¿½coplanar beams , Perspecta plans , Pinnacle plan ,0,
edin,3219,3994324,No significant difference,"Similarly, there was no significant difference in percentage intraocular pressure reduction; 27.6% (CI, 23.5, 31.7) for the control group and 25.3% (CI, 21.06, 29.54) for the intervention group (pâ=â0.45).", Decrease in intraocular pressure , Standard clinical care , Novel glaucoma education and motivational support package using behaviour change counselling ,0,
edin,3254,5457851,Cannot tell based on the abstract,, Overall satisfaction score of the participants and operators ," 2% lidocaine with 1:200,000 epinephrine  "," 2% lidocaine with 1:80,000 epinephrine  ",0,
edin,3254,5457851,No significant difference,"The meanâÂ±âSD overall satisfaction score of the operators was 3.9âÂ±â0.9 in the L80 group and 3.8âÂ±â1.0 in the L200 group, with no significant difference between the groups (Pâ=â.548) (Table 3). The meanâÂ±âSD overall satisfaction score of the participants was 3.6âÂ±â0.1 in the L80 group and 3.7âÂ±â0.1 in the L200 group, with no significant difference between the groups (Pâ=â.693) (Table 3). T", Overall satisfaction score of the participants and operators ," 2% lidocaine with 1:200,000 epinephrine  "," 2% lidocaine with 1:80,000 epinephrine  ",0,
edin,3221,3994324,Cannot tell based on the abstract,, Baseline intraocular pressure , Standard clinical care , Novel glaucoma education and motivational support package using behaviour change counselling ,0,
edin,3221,3994324,No significant difference,"The mean IOP at baseline for subsequently treated right and/or left eyes was 23.7Â mmHg (95% CI, 22.6, 24.8) for the control group and 22.4Â mmHg (95% CI, 21.3, 23.5) for the intervention group which was not statistically different (pâ=â0.096, 1.3, CI â0.2, 2.9).,There was no significant difference in percentage reduction in IOP from baseline to visit-3 between the two groups with control group being 27.6% (SD, 19.2) and intervention group being 25.3% (SD 19.7) (2.3 mean difference, CI â3.6, 8.2, pâ=â0.448).", Baseline intraocular pressure , Standard clinical care , Novel glaucoma education and motivational support package using behaviour change counselling ,0,
edin,3246,2972614,Cannot tell based on the abstract,, Adverse effects , Placebo laser therapy (Group II) , Laser therapy (Group I) ,0,
edin,3246,2972614,No significant difference,. All patients were able to complete the therapy program without any adverse effects., Adverse effects , Placebo laser therapy (Group II) , Laser therapy (Group I) ,0,
edin,3310,3662597,No significant difference,"There was no groupâÃâtime interaction for HR, BP, blood glucose, lipids, NOx, hs-CRP, cortisol concentrations or body", Body fat , Placebo group , Multi-ingredient performance supplement (MIPS) group ,0,
edin,3309,3662597,No significant difference,"There was no groupâÃâtime interaction for HR, BP, blood glucose, lipids, NOx, hs-CRP, cortisol concentrations or body fat."," Levels of nitrate/nitrite (NOx), cortisol, and high sensitivity C-reactive protein (hs-CRP) ", Placebo group , Multi-ingredient performance supplement (MIPS) group ,0,
edin,3285,4610927,Significantly increased,"Additional analgesic consumption, numerical rating scale scores at 6 and 24 h, and cumulative fentanyl dose were significantly higher in group RH than in the other two groups.", Cumulative fentanyl dose , Remifentanil 0.3 + ketamine 0.5 (group KRH) or remifentanil 0.05 (Group RL)  , Remifentanil 0.3 (group RH) ,0,
edin,3318,5219826,Significantly increased,"EDOF was significantly better than AOMF for HCVA at 40Â cm (0.42Â Â±Â 0.18 vs. 0.48Â Â±Â 0.22, pÂ =Â 0.024), stereopsis (98Â Â±Â 88 vs. 141Â Â±Â 114, pÂ <Â 0.001), clarity-of-vision at intermediate (8.5Â Â±Â 1.6 vs. 7.7Â Â±Â 1.9, pÂ =Â 0.006) and near (7.3Â Â±Â 2.5 vs. 6.2Â Â±Â 2.5, pÂ =Â 0.005), lack-of-ghosting (pÂ =Â 0.012), overall vision satisfaction (7.5Â Â±Â 1.7 vs. 6.4Â Â±Â 2.2, pÂ <Â 0.001) and ocular comfort (9.0Â Â±Â 1.0 vs. 8.3Â Â±Â 1.7, pÂ =Â 0.002).", Stereopsis and lack-of-ghosting , Center-near lens (AOMF) , Extended depth-of-focus (EDOF) ,0,
edin,3241,3958613,Significantly decreased,"The rate of high on-treatment platelet reactivity (PRU >235) was significant lower in the 5 mg prasugrel group than that in the 75 mg clopidogrel group (15.0% vs. 56.5%, p=0.010).", P2Y12 reaction unit (PRU) values higher than 235 , Clopidogrel 75 mg , Prasugrel 5 mg  ,0,
edin,3296,3504074,Significantly increased,Significantly more patients receiving combination therapy than monotherapy had static Physicianâs Global Assessment of clear/almost clear at week 12 (65Â·5% vs. 47Â·0%; P = 0Â·01) and week 24 (71Â·8% vs. 54Â·3%; P = 0Â·01)., Physicianâs Global Assessment of clear/almost clear , Eetanercept alone , Etanercept plus methotrexate ,0,
edin,3331,5410668,Cannot tell based on the abstract,," carbon, calcium, nitrogen, phosphorus and strontium ", control , G2- brushing with SensodyneÂ®Rapid Relief; ,0,
edin,3331,5410668,Significantly increased,"Evaluation regarding the chemical elements present in the specimen from Group 2 shows a statistically significant difference (p <0.05) in the experimental faces when comparing to the positive control faces for carbon, calcium, nitrogen, phosphorus and strontium.,These data are corroborated taking into account the formulation of Sensodyne Rapid ReliefÂ® dentifrice (8% strontium acetate, calcium carbonate, sodium fluoride; 1,040 ppm fluoride), and the clear deposition of obliterating particles in the dentinal tubules of the experimental regions."," carbon, calcium, nitrogen, phosphorus and strontium ", control , G2- brushing with SensodyneÂ®Rapid Relief; ,0,
edin,3396,5623480,Cannot tell based on the abstract,," Primary outcome: the proportion of patients who did not have 70% resolution of ST-segment elevation and did not meet the criteria for Thrombolysis In Myocardial Infarction (TIMI) flow 3 at initial angiography. Secondary outcome: the composite of death, MI, stent thrombosis, stroke or urgent revascularisation and major or minor bleeding at 30 days. ", Prehospital administration of ticagrelor , in-hospital administration of ticagrelor ,0,
edin,3396,5623480,No significant difference,"No significant interactions between randomised treatment and gender in terms of these outcomes were found in the unadjusted or adjusted model (test for interaction in the multivariable models; p=0.94 for all-cause mortality, p=0.55 for absence of TIMI flow grade 3 in the IRA at initial angiography, p=0.71 for absence of â¥70%âresolution of pre-PCI ST-segment elevation, and p=0.31 for TIMI major bleeding at 30 days) (see online supplementary tables 1â3)."," Primary outcome: the proportion of patients who did not have 70% resolution of ST-segment elevation and did not meet the criteria for Thrombolysis In Myocardial Infarction (TIMI) flow 3 at initial angiography. Secondary outcome: the composite of death, MI, stent thrombosis, stroke or urgent revascularisation and major or minor bleeding at 30 days. ", Prehospital administration of ticagrelor , in-hospital administration of ticagrelor ,0,
edin,3458,4842387,Significantly increased,"dvanced group had more cases of severe SML (severity â©¾ 3) (44/47) and severe SAD (43/47) than the placebo group (39/51 and 37/51, < 0.05, < 0.05, resp.) before the treatment. BrainPower Advanced intervention, however, improved a greater proportion of the severe SML (29.5%)(13/44) (P < 0.01) and SAD (34.9%)(15/43)(P < 0.01) than placebo (5.1% (2/39) and 13.5% (5/37), resp.).", subjective attention/concentration deficits (SAD) , placebo , BrainPower Advanced capsules ,0,
edin,3445,3517846,Cannot tell based on the abstract,,  glycemic index (GI)  , baseline , Group 2 ,0,
edin,3445,3517846,Significantly decreased,"There was a significant decrease in the GI of the diet throughout the intervention period only in Group 2 (51.29 Â± 7.28 to 47.18 Â± 6.93, P = 0.001).",  glycemic index (GI)  , baseline , Group 2 ,0,
edin,3345,4297469,No significant difference,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P < 0.005), more non-office-based contacts (1.95 Â± 3.29 vs. 1.01 Â± 2.64; P < 0.001), more Internet sessions (11.02 Â± 15.28 vs. 0.06 Â± 0.31; P < 0.001) and more in-clinic discussions (1.84 Â± 4.20 vs. 1.28 Â± 2.92; P < 0.03), but with numerically fewer hospitalizations (0.67 Â± 1.18 vs. 0.85 Â± 1.43, P = 0.23) and shorter length-of-stay (6.31 Â± 15.5 vs. 8.26 Â± 18.6; P = 0.27), although not significant.,From a payer perspective, FU-related costs were similar while the total cost per patient (including other physician visits, examinations, and hospitalizations) was numerically (but not significantly) lower."," hospitalizations,  shorter length-of-stay ", regular in-office FU (HM OFF) , Home Monitoring facilitated FU (HM ON) ,0,
edin,3327,4832354,Significantly increased,"PâDA users perceived themselves to be significantly more 1) informed about the treatment choice (Pâ=â.008), 2) aware of options (Pâ=â.009), 3) knowledgeable about treatment benefits (Pâ=â.020), and 4) knowledgeable about treatment risks/side effects (Pâ=â.001) in comparison with controls."," informed about the treatment choice,  aware of options,  knowledgeable about treatment benefits, and knowledgeable about treatment risks/side effects  ", control , Patient decision aids (PÃ¢â¬ï¿½DAs) ,0,
edin,3363,5167461,Cannot tell based on the abstract,, forced expiratory volume in one second (FEV1) , twice-daily SFC 50 Î¼g/500 Î¼g , IND/GLY 110 Î¼g/50 Î¼g ,0,
edin,3363,5167461,Significantly increased,"Pre-dose trough FEV1 improved significantly with IND/GLY versus SFC in the overall population (treatment difference, 0.10 L; P<0.0001)", forced expiratory volume in one second (FEV1) , twice-daily SFC 50 Î¼g/500 Î¼g , IND/GLY 110 Î¼g/50 Î¼g ,0,
edin,3450,4685630,Significantly increased,"Service costs were significantly higher for PACTâ+âTAU (mean difference Â£4,489, pâ<â0.001), but the difference in societal costs was smaller and non-significant (mean difference Â£1,385, pâ=â0.788) due to lower informal care rates for PACTâ+âTAU.", Service costs , societal costs , Pre-School Autism Communication Trial (PACT)+  treatment as usual (TAU) ,0,
edin,3346,4297469,No significant difference,"For the whole study population, the total FU cost for providers was not different for HM ON vs. OFF [mean (95% CI): â¬204 (169â238) vs. â¬213 (182â243); range for difference (â¬â36 to 54), NS].",  total FU cost for providers , regular in-office FU (HM OFF) , Home Monitoring facilitated FU (HM ON) ,0,
edin,3338,4893393,Significantly decreased,"ntravenous lidocaine was superior regarding the reduction of the intensity of pain, the allodynia, and the hyperalgesia compared to placebo.", intensity of pain , placebo , lidocaine (5âmgs/kg) ,0,
edin,3358,3215167,Cannot tell based on the abstract,," pH, HCO3-, &amp;amp; BE ", placebo (plain flour) ," 750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 gÂ·kg-1 of NaHCO3 ",0,
edin,3358,3215167,Significantly increased,"There were significant interactions (p < 0.01) and main effects for condition (p < 0.001) and time (p < 0.001) for all acid-base variables (pH, HCO3-, & BE)."," pH, HCO3-, &amp;amp; BE ", placebo (plain flour) ," 750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 gÂ·kg-1 of NaHCO3 ",0,
edin,3359,3215167,Cannot tell based on the abstract,, incidence and severity of GI discomfort , placebo (plain flour) ," 750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 gÂ·kg-1 of NaHCO3 ",0,
edin,3359,3215167,No significant difference,A large degree of intra-subject variability was evident in both the incidence and severity of GI discomfort (Figure 2). There were no significant interactions (p > 0.98) or main effects for condition (p > 0.80) or time (p > 0.57) for either incidence or severity., incidence and severity of GI discomfort , placebo (plain flour) ," 750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 gÂ·kg-1 of NaHCO3 ",0,
edin,3444,3517846,Cannot tell based on the abstract,, gaining weight , gestational diabetes mellitus (GDM) , type 2 DM ,0,
edin,3444,3517846,Significantly increased,Women with type 2 DM gained more weight during pregnancy (7.5 Â± 7.41âkg) when compared to women with GDM (4.35 Â± 6.59âkg) (P = 0.023);, gaining weight , gestational diabetes mellitus (GDM) , type 2 DM ,0,
edin,3343,4297469,Significantly increased,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P < 0.005), more non-office-based contacts (1.95 Â± 3.29 vs. 1.01 Â± 2.64; P < 0.001), more Internet sessions (11.02 Â± 15.28 vs. 0.06 Â± 0.31; P < 0.001) and more in-clinic discussions (1.84 Â± 4.20 vs. 1.28 Â± 2.92; P < 0.03),", Internet sessions , regular in-office FU (HM OFF) , Home Monitoring facilitated FU (HM ON) ,0,
edin,3324,5295657,No significant difference,"The mean LDL/HDL ratio decreased during the study (P < 0.001); however, there was not any significant difference between the two groups (P > 0.05).", The mean LDL/HDL ratio , 40 mg/day of lovastatin , 40 mg/day of Lovastatin plus 2 g/day powder of Kelussia odoratissima ,0,
edin,3443,3517846,Cannot tell based on the abstract,, The proportion of women who started using insulin during the intervention , Group 2: low GI foods , Group 1: all types of CHO ,0,
edin,3443,3517846,No significant difference,"The proportion of women who started using insulin during the intervention was similar between study groups in both types of DM (P â¥ 0.40), without differences in insulin doses (Group 1: 42.7 Â± 26.4âu/d and Group 2: 35.5 Â± 21.5âu/d) (P = 0.18).", The proportion of women who started using insulin during the intervention , Group 2: low GI foods , Group 1: all types of CHO ,0,
edin,3381,3564767,Cannot tell based on the abstract,, Smoking status , nothing (waiting list group)   , two sessions of 1.5âhours each of the Pick-Klop game or two sessions of 1.5âhours each of psychoeducation ,0,
edin,3381,3564767,Significantly decreased,"Compared with the participants in the waiting-list group, those in the Pick-Klop group were less likely to be smokers (pâ=â0.04, ORâ=â0.32, and CIâ=â[0.11; 0.96]).", Smoking status , nothing (waiting list group)   , two sessions of 1.5âhours each of the Pick-Klop game or two sessions of 1.5âhours each of psychoeducation ,0,
edin,3453,3702153,Cannot tell based on the abstract,, Chi-square test - frequency distribution of the redness , control , position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore ,0,
edin,3453,3702153,Significantly increased,"Chi-square test showed that the frequency distribution of the redness changes, 96 hours after intervention, has significant difference for both groups (p < 0.001).,At the end of the 5th day (120 hours after intervention), 29 people from the treating group and 15 people from the placebo group had recovered (46.7% vs. 50%). Chi-square showed here too that the frequency distribution of the redness changes of the ulcer is different in the two groups, 5 days after 5 days (p < 0.001).

By 144 hours (6th days), all the patients recovered in treating group and 23 patients recovered in placebo group (76.7%). Chi-square test indicated that the frequency distribution of the redness changes has significant difference in this stage, too (p < 0.001).", Chi-square test - frequency distribution of the redness , control , position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore ,0,
edin,3374,4768887,Cannot tell based on the abstract,, overall sensitivity and an accuracy in the detection of the metastasis , computed tomography (CT) , Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT) ,0,
edin,3374,4768887,Significantly increased,"On a station-based analysis, PET/CT displayed an overall sensitivity of 86.5% and an accuracy of 92.2% in the detection of the metastasis. CT showed a lower sensitivity of 67.3% (P=0.006) and an accuracy of 87.2% (P=0.024).", overall sensitivity and an accuracy in the detection of the metastasis , computed tomography (CT) , Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT) ,0,
edin,3352,4389977,Cannot tell based on the abstract,, Self-Assessment Questionnaire score at Visit 2 , placebo , oral marine protein supplement (MPS) ,0,
edin,3352,4389977,Significantly increased,"Subjects treated with MPS obtained significantly higher total scores on the Self-Assessment Questionnaire at Visit 2 (f (1,58) = 8.27, P = 0.006; MPS: 61.20 Â± 7; placebo: 55.57 Â± 8)", Self-Assessment Questionnaire score at Visit 2 , placebo , oral marine protein supplement (MPS) ,0,
edin,3417,4067355,Cannot tell based on the abstract,"Compared to imputed placebo, all NOACs reduced the risk of stroke (ORs between 0.24 and 0.42, all p<0.001) and all-cause mortality (ORs between 0.55 and 0.59, all p<0.05).",  risk of stroke ,  rivaroxaban , edoxaban  ,0,
edin,3417,4067355,Significantly increased,"There were no significant differences between the higher dose of edoxaban (60 mg) and any other NOAC in the efficacy outcomes, apart from a slightly higher risk of stroke with edoxaban than rivaroxaban (pâ=â0.032).",  risk of stroke ,  rivaroxaban , edoxaban  ,0,
edin,3326,5149084,Significantly decreased,"Laser group showed the statistically highest mean percentage (%) of reduction in pain scores and ulcer size than the other groups. T,All treatment modalities reduced pain and ulcer size than placebo group.", mean ulcer size , control , Group I -  herbal combination of Acacia nilotica and Licorice (A and L) ,0,
edin,3384,4310883,Cannot tell based on the abstract,, disposition of patients from the OR to the intensive care unit , preâalvimopan , alvimopan ,0,
edin,3384,4310883,Significantly increased,"There was increased disposition of patients from the OR to the intensive care unit in the alvimopan group (44% vs. 66%, p = 0.048).", disposition of patients from the OR to the intensive care unit , preâalvimopan , alvimopan ,0,
edin,3415,4067355,Cannot tell based on the abstract,," the risk of stroke/systemic embolism , stroke, hemorrhagic stroke and systemic embolism ",  warfarin , non vitamin K antagonist oral anticoagulant (NOAC) ,0,
edin,3415,4067355,Significantly decreased,"NOACs as a whole reduced the risk of stroke/systemic embolism (by 21%; p<0.001), stroke (by 20%; p<0.001), hemorrhagic stroke (by 50%; p<0.001) and systemic embolism (by 40%; pâ=â0.006)."," the risk of stroke/systemic embolism , stroke, hemorrhagic stroke and systemic embolism ",  warfarin , non vitamin K antagonist oral anticoagulant (NOAC) ,0,
edin,3291,3427491,No significant difference,"No statistically significant differences were observed in overall survival (15.6 and 17.2Â months; pÂ =Â 0.475); progression-free survival (7.7 and 8.7Â months; pÂ =Â 0.292), and response duration (6.4 and 7.6Â months; pÂ =Â 0.372) for TOMOX and FOLFOX4, respectively.", Response duration , FOLFOX4 , TOMOX ,0,
edin,3341,4297469,Significantly increased,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P < 0.005),", unscheduled visits , regular in-office FU (HM OFF) , Home Monitoring facilitated FU (HM ON) ,0,
edin,3385,4310883,Cannot tell based on the abstract,, use of robotic technique , preâalvimopan , alvimopan ,0,
edin,3385,4310883,Significantly increased,"Additionally, use of robotic technique increased markedly in the alvimopan group (8% vs. 25%, p = 0.030).", use of robotic technique , preâalvimopan , alvimopan ,0,
edin,3360,2788265,No significant difference,"Median progression-free survival was estimated with 4.0, 5.6, and 6.0 months (P=0.21).", Progression-free survival ," gemcitabine (300âmgâmâ2), and cisplatin (30âmgâmâ2) on days 1, 8, 22, and 29 (RT-GC arm), or the same concurrent treatment followed by sequential full-dose gemcitabine (1000âmgâmâ2) and cisplatin (50âmgâmâ2) every 2 weeks (RT-GC+GC arm) "," 5-fluorouracil (350âmgâmâ2 per day on each day of radiotherapy, RT-5-FU arm) ",0,
edin,3432,4234827,Cannot tell based on the abstract,, number of procedures performed , early tracheotomy  , late tracheotomy ,0,
edin,3432,4234827,Significantly increased,"The tracheotomy was performed in 99 patients in the early group (98%; 95% CI 93%, 99.8%) whereas it was performed in 76 patients in the patients randomized to the late group (73.1%; 95% CI 63%, 81%) (P <0.001).", number of procedures performed , early tracheotomy  , late tracheotomy ,0,
edin,3405,4544133,Significantly decreased,"CRP levels significantly decreased from beginning to the end of 4 weeks in both atorvastatin and rosuvastatin groups (from 35.48 to 23.07 mg/l and from 35.88 to 19.91 mg/l respectively, both P < 0.001). However, there was significant difference between the levels of CRP in patients of the rosuvastatin group as compared to the atorvastatin group (19.91 Â± 6.32 vs 23.07 Â± 7.47, P < 0.05). I", CRP levels , baseline ," atorvastatin 40 mg daily,  rosuvastatin 20 mg daily for 4 weeks ",0,
edin,3372,4768887,No significant difference,"Compared to the CT group, the right-sided approach was more frequently used (42.6% versus 25.5%, P=0.065) in the PET/CT group", use of right-sided approach  , computed tomography (CT) , Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT) ,0,
edin,3434,4234827,Significantly decreased,"Mortality at day 90 was similar in both groups (25.7% versus 29.9%), but duration of sedation was shorter in the early tracheotomy group median 11Â days (range 2 to 92) days compared to 14Â days (range 0 to 79) in the late group (P <0.02).", The duration of sedation , late tracheotomy ,  early tracheotomy  ,0,
edin,3337,4069535,Cannot tell based on the abstract,, Pulse pressure variation (PPV) and stroke volume variation (SVV) ,  fluid resuscitation and norepinephrine infusion (SD0) , Dexmedetomidine ,0,
edin,3337,4069535,No significant difference,Dexmedetomidine infusion did not affect PPV and SVV., Pulse pressure variation (PPV) and stroke volume variation (SVV) ,  fluid resuscitation and norepinephrine infusion (SD0) , Dexmedetomidine ,0,
edin,3431,4183082,Cannot tell based on the abstract,, Muscle ache and fasciculation , Cisatracurium group , Succinylcholine group ,0,
edin,3431,4183082,Significantly increased,Muscle ache and fasciculation was experienced in 85% of the patients in Succinylcholine group and 27.5% of the Cisatracurium group (P = 0.002)., Muscle ache and fasciculation , Cisatracurium group , Succinylcholine group ,0,
edin,3439,3704267,Significantly increased,. Continuous abstinence rates from months 24 to 36 (45.8% vs 4.0%) and months 24 to 48 (44.3% vs 5.1%) were also higher in participants receiving behavioral intervention than in those control group., The rates of continuous abstinence at the 48 month follow-up , control group , behavioral intervention ,0,
edin,3323,5295657,No significant difference,The mean of FBS did not change between and within groups (P > 0.05)., fasting blood sugar (FBS) , 40 mg/day of lovastatin , 40 mg/day of Lovastatin plus 2 g/day powder of Kelussia odoratissima ,0,
edin,3425,4183082,Significantly increased,Number of patients who developed sore throat was significantly higher in the Succinylcholine group (75%) compared to Cisatracurium group (27.5%) at the time of entrance to the recovery room (P = 0.001). These numbers decreased at 2 hours postâoperation (42% versus 17.5%) but the difference was still statistically significant (P < 0.05)., sore throat 2 hours postâoperation , Cisatracurium group , Succinylcholine group ,0,
edin,3430,4183082,Cannot tell based on the abstract,, developed fasciculation , Cisatracurium group , Succinylcholine group ,0,
edin,3430,4183082,Significantly increased,"97.5% of the patients who had received Succinylcholine developed fasciculation, while none of the patients in the Cisatraciruim arm showed similar problem (P < 0.001).", developed fasciculation , Cisatracurium group , Succinylcholine group ,0,
edin,3354,5919699,Significantly increased,"Intention-to-treat analysis indicated that moderate physical activity level increased significantly by 269.4 Â± 260.6 minutes per week in the exercise group (mean between-group difference, 254.6 minutes; 95% confidence interval, 172.7â434.7; p < 0.001).", moderate physical activity , usual care , 6-week home-based exercise program ,0,
edin,3371,5374834,Cannot tell based on the abstract,, the level of sedation ,  hyoscine group ,  ketamine group ,0,
edin,3371,5374834,Significantly decreased,"Moreover, there was a significant difference between the two groups regarding the level of sedation where it was lower in ketamine group compared to hyoscine group (P < 0.001), which was assessed by modified observer's assessment of alertness/sedation score [Figure 4].", the level of sedation ,  hyoscine group ,  ketamine group ,0,
edin,3420,5768344,Cannot tell based on the abstract,, Dose reductions , adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC)  , docetaxel-doxorubicin-cyclophosphamide (TAC) ,0,
edin,3420,5768344,Significantly increased,"Dose reductions of more than 10% occurred more frequently for TAC (39 out of 1817 cycles, 2.1%) than for ddAC (13 out of 1914 cycles, 0.7%, P < 0.001).


Adverse events (AEs)", Dose reductions , adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC)  , docetaxel-doxorubicin-cyclophosphamide (TAC) ,0,
edin,3321,5295657,Significantly increased,The HDL-C rate was higher in intervention group compared to control group (P < 0.05)., HDL-C rate , 40 mg/day of lovastatin , 40 mg/day of Lovastatin plus 2 g/day powder of Kelussia odoratissima ,0,
edin,3342,4297469,Significantly increased,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P < 0.005), more non-office-based contacts (1.95 Â± 3.29 vs. 1.01 Â± 2.64; P < 0.001),", non-office-based contacts , regular in-office FU (HM OFF) , Home Monitoring facilitated FU (HM ON) ,0,
edin,3369,5374834,Significantly increased,"There was a significant difference between the two groups in the severity of CRBD measured by visual analog scale score only 30 min after drug administration where it was higher in ketamine group (44.50 Â± 7.70) compared to hyoscine group (36.00 Â± 8.55) (P < 0.001),", severity of postoperative catheter-related bladder discomfort (CRBD) , hyoscine group , ketamine group ,0,
edin,3399,4320136,No significant difference,"Total amount of iron absorbed from raw and cooked bananas was similar (0.77Â±0.33 mg vs. 0.86Â±0.41 mg, respectively).", Total amount of absorbed iron  ,  500 g/day of cooked banana for 4 days ,  480 g/day of raw banana for 6 days ,0,
edin,3412,4067355,Significantly decreased,"Compared to imputed placebo, all NOACs reduced the risk of stroke (ORs between 0.24 and 0.42, all p<0.001) and all-cause mortality (ORs between 0.55 and 0.59, all p<0.05)."," the risk of stroke, all-cause mortality ", placebo , non vitamin K antagonist oral anticoagulant (NOAC) ,0,
edin,3410,4302388,No significant difference,"After adjustment, whole-blood Se concentration was higher in women consuming Brazil nuts (P=Â 0Â·040) and in those consuming more than two seafood portions per week (P=Â 0Â·054).", whole-blood Se concentration , baseline ," Brazil nuts, consuming more than two seafood portions per week ",0,
edin,3325,5149084,Significantly decreased,A and L group showed a lower mean % of reduction in pain scores than laser and Amlexanox groups with a 22.2+10.5 and 43.4+15.8 mean % reduction in pain scores at day 2 and day 5 respectively., mean pain scores , Group I -  herbal combination of Acacia nilotica and Licorice (A and L) ," Group II  - 2 mg Amlexanox paste respectively, group III received diode laser ",0,
edin,3448,4685630,No significant difference,"Clinically meaningful symptom improvement was evident for 53Â % of PACTâ+âTAU versus 41Â % of TAU (odds ratio 1.91, pâ=â0.074).", Clinically meaningful symptom , treatment as usual (TAU) , Pre-School Autism Communication Trial (PACT)+  treatment as usual (TAU) ,0,
edin,3376,4768887,Significantly increased,"Although the overall survival between the two groups was similar, the PET/CT group had a longer disease-free survival (DFS) than the CT group (27.1 months versus 18.9 months; P=0.019), especially in the subgroup of node-positive patients (22.5 months versus 13.5 months; P=0.02).", Disease-free survival (DFS) , computed tomography (CT) , Fluorodeoxyglucose-positron emission tomography (PET)/computed tomography (CT) ,0,
edin,3357,3215167,Significantly increased,Interactions indicated significant elevation in blood alkalosis for only the NaHCO3 condition when compared to both placebo and EG from 15 to 120 minutes., NaHCO3 condition , placebo (plain flour) ," 750 mL of water with either 9 g of EG (manufacturer recommendations), 0.1 gÂ·kg-1 of NaHCO3 ",0,
edin,3383,4310883,Significantly decreased,"Costs were significantly lower in the alvimopan group than the control groups (2012 USD 32,443 vs. 40,604 p <0.001).", Costs , control , alvimopan ,0,
edin,3394,3206382,Significantly decreased,"Gastrointestinal adverse events occurred in 26.9% and 50.9% of IPC and ferrous sulfate patients, respectively (P = 0.012)", gastrointestinal adverse event , baseline ," Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5âmg iron/kg/day) ",0,
edin,3389,3206382,Significantly increased,"Mean increases in Hb to months 1 and 4 with IPC were 1.2 Â± 0.9âg/dL and 2.3 Â± 1.3âg/dL, respectively, (both P = 0.001 versus baseline)", improvement in Hb by month 1 , baseline ," Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5âmg iron/kg/day) ",0,
edin,3451,3702153,Cannot tell based on the abstract,, precise Fischer tests 48 hours after treatment  -  reduction of redness , control , position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore ,0,
edin,3451,3702153,Significantly increased,"According to precise Fischer tests, the difference between the two group was totally significant (p < 0.001) 48 hours after treatment intervention, 23 people (76.7%) of the treating group who had received fish oil had reduction in redness, although none of the patients in placebo group showed such recovery.", precise Fischer tests 48 hours after treatment  -  reduction of redness , control , position was changed every 2-3 hours and the bed sore was washed with water and cotton-wool and fish oil with thickness of 2-3 mm was applied on the place of sore ,0,
edin,3344,4297469,Significantly increased,"Resource use with HM ON was clearly different: less FU visits (3.79 Â± 1.67 vs. 5.53 Â± 2.32; P < 0.001) despite a small increase of unscheduled visits (0.95 Â± 1.50 vs. 0.62 Â± 1.25; P < 0.005), more non-office-based contacts (1.95 Â± 3.29 vs. 1.01 Â± 2.64; P < 0.001), more Internet sessions (11.02 Â± 15.28 vs. 0.06 Â± 0.31; P < 0.001) and more in-clinic discussions (1.84 Â± 4.20 vs. 1.28 Â± 2.92; P < 0.03),", in-clinic discussions , regular in-office FU (HM OFF) , Home Monitoring facilitated FU (HM ON) ,0,
edin,3355,5919699,Significantly increased,"Physical fitness measured by using the step test (-3.9 vs. 2.6, p = 0.012) and push-up test (3.0 vs. -1.2, p = 0.012) also improved significantly in the exercise group compared to the control group.", the step test and  push-up test , usual care , 6-week home-based exercise program ,0,
edin,3353,4389977,Significantly increased,MPS use also resulted in significantly less hair shedding (P = 0.002) and higher total Self-Assessment (P = 0.006) and Quality of Life Questionnaires scores (P = 0.035)., total scores on the Quality of Life Questionnaire , placebo , oral marine protein supplement (MPS) ,0,
edin,3446,3517846,Cannot tell based on the abstract,, clinical outcomes , 2 DM , GDM ,0,
edin,3446,3517846,No significant difference,No differences were found in these clinical outcomes between women with GDM and type 2 DM within each study group (P > 0.05)., clinical outcomes , 2 DM , GDM ,0,
edin,3340,4297469,Cannot tell based on the abstract,, clinically relevant finding/action (âactionable visitsâ) , regular in-office FU (HM OFF) , Home Monitoring facilitated FU (HM ON) ,0,
edin,3340,4297469,Significantly increased,"In the HM ON group, 32.0% of in-office FU visits (193/603) resulted in a clinically relevant finding/action (âactionable visitsâ) compared with 26.8% (213/795) in the HM OFF group (P < 0.05).", clinically relevant finding/action (âactionable visitsâ) , regular in-office FU (HM OFF) , Home Monitoring facilitated FU (HM ON) ,0,
edin,3411,4302388,Significantly decreased,"On excluding non-compliers with Se treatment, Se supplementation also significantly reduced the OR for PE/PIH (OR 0Â·30, 95Â % CI 0Â·09, 1Â·00, P=Â 0Â·049).", developing pre-eclampsia and pregnancy-induced hypertension (PE/PIH) , non-consumers ," Brazil nuts, consuming more than two seafood portions per week ",0,
edin,3460,4842387,Cannot tell based on the abstract,, combined total scores of the memory function , placebo , BrainPower Advanced capsules ,0,
edin,3460,4842387,Significantly increased,Ridit scoring test showed that the improvement in the combined total scores of the memory function subtests was significantly better after the BrainPower Advanced intervention (mean = 0.56 Â± 0.287) than after the placebo intervention (0.445 Â± 0.276) (P < 0.05) (Table 6(c))., combined total scores of the memory function , placebo , BrainPower Advanced capsules ,0,
edin,3350,4389977,Significantly decreased,MPS use also resulted in significantly less hair shedding (P = 0.002) and higher total Self-Assessment (P = 0.006) and Quality of Life Questionnaires scores (P = 0.035)., hair shedding counts following hair washing , placebo , oral marine protein supplement (MPS) ,0,
edin,3393,3206382,Cannot tell based on the abstract,, serum ferritin level by month 4 , baseline ," Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5âmg iron/kg/day) ",0,
edin,3393,3206382,Significantly decreased,"The increase in serum ferritin level from baseline to month 4 was almost twofold lower in the IPC group versus ferrous sulfate (22.7 Â± 26.1âÎ¼g/mL versus 42.5 Â± 62.0âÎ¼g/mL, P = 0.001).", serum ferritin level by month 4 , baseline ," Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5âmg iron/kg/day) ",0,
edin,3370,5374834,Cannot tell based on the abstract,, rise in heart rate (HR) , ketamine group ,  hyoscine group ,0,
edin,3370,5374834,Significantly increased,There was a statistically significant rise in HR in hyoscine group patients compared to ketamine group over time (P < 0.001, rise in heart rate (HR) , ketamine group ,  hyoscine group ,0,
edin,3397,4320136,Cannot tell based on the abstract,, Ferritin concentration , 480 g/day of raw banana for 6 days ,  500 g/day of cooked banana for 4 days ,0,
edin,3397,4320136,Significantly increased,Ferritin concentration was significantly higher in the group that received the cooked banana compared to the group that received the raw banana with added iron (p<0.05)., Ferritin concentration , 480 g/day of raw banana for 6 days ,  500 g/day of cooked banana for 4 days ,0,
edin,3392,3206382,Cannot tell based on the abstract,,  transferrin saturation (TSAT) , baseline ," Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5âmg iron/kg/day) ",0,
edin,3392,3206382,No significant difference,"In terms of iron status parameters, TSAT improved from approximately 5% in each group at baseline to >20% at month 4 (IPC 5.1 Â± 3.3% to 20.2 Â± 15.5%, P = 0.001; ferrous sulfate 5.4 Â± 3.5% to 22.4 Â± 13.2%, P = 0.001) with no significant difference between the groups.",  transferrin saturation (TSAT) , baseline ," Iron polymaltose complex (IPC), ferrous sulfate twice daily, (both 5âmg iron/kg/day) ",0,
edin,3459,4842387,Cannot tell based on the abstract,," audio/visual memory, abstract thinking, memory retrieval, and combined total function test scores ", placebo , BrainPower Advanced capsules  ,0,
edin,3459,4842387,Significantly increased,"Both the BrainPower Advanced and the placebo groups produced significant improvements (129%â150%) (P < 0.01, each) of the subtests and combined total scores in the older adults, with the BrainPower Advanced group producing better improvements (1.50-, 1.35-, 1.43-, and 1.29-fold relative to the baseline values of audio/visual memory, abstract thinking, memory retrieval, and combined total function test scores) than the placebo group (1.35-, 1.27-, 1.13-, and 1.27-fold, resp.) (Tables 6(a) and 6(b))."," audio/visual memory, abstract thinking, memory retrieval, and combined total function test scores ", placebo , BrainPower Advanced capsules  ,0,
edin,3398,4320136,Significantly increased,Percent iron absorption was significantly higher in raw bananas (49.3Â±21.3%) compared with cooked banana (33.9Â±16.2%) (p=0.035)., Percent iron absorption ,  500 g/day of cooked banana for 4 days ,  480 g/day of raw banana for 6 days ,0,
edin,3322,5295657,No significant difference,"The mean LDL/HDL ratio decreased during the study (P < 0.001); however, there was not any significant difference between the two groups (P > 0.05).", The mean LDL/HDL ratio , baseline ," 40 mg/day of Lovastatin plus 2 g/day powder of Kelussia odoratissima, 40 mg/day of lovastatin ",0,
edin,3348,4389977,Significantly increased,MPS-treated subjects achieved a significant increase in the number of terminal hairs within the target area (P < 0.0001) which was significantly greater than placebo (P < 0.0001)., mean number of terminal hairs , placebo , oral marine protein supplement (MPS) ,0,
edin,3549,522822,Cannot tell based on the abstract,," serum total cholesterol, LDL, HDL and triglycerides ", baseline , 12.7 g of psyllium hydrophilic mucilloid ,0,
edin,3549,522822,No significant difference,"Values for total, LDL, HDL cholesterol and triglycerides at baseline, eight and sixteen weeks for various subgroupings are tabulated in tables 1, 2, 3 and 4, respectively. Data for changes from baseline for total, LDL and HDL cholesterol and triglycerides are listed in table 5.,<td align=""left"">TRIGLYCERIDES</td><td align=""left"">0.094</td><td align=""left"">p = 0.22</td><td align=""left"">0.082</td><td align=""left"">p = 0.22</td>"," serum total cholesterol, LDL, HDL and triglycerides ", baseline , 12.7 g of psyllium hydrophilic mucilloid ,0,
edin,3567,4284021,Significantly decreased,"<td align=""left"" colspan=""1"" rowspan=""1"">LDL-C</td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td>", Apolipoprotein B-100 (apo B) , placebo , evacetrapib (10â600âmg) ,0,
edin,3561,2755038,Cannot tell based on the abstract,, risks of 70% restenosis , angioplasty alone , endovascular arm ,0,
edin,3561,2755038,Significantly decreased,"Of the patients who were assigned to endovascular treatment, the risks of 70% or more restenosis (adjusted HR 0Â·43, 0Â·19â0Â·97; p=0Â·04) and 50% or more restenosis (0Â·37, 0Â·21â0Â·62; p=0Â·0003) were significantly lower in those patients treated with a stent than in those treated by angioplasty alone (table 4, figure 2).", risks of 70% restenosis , angioplasty alone , endovascular arm ,0,
edin,3539,3434899,Cannot tell based on the abstract,, effectiveness according to chi-square test , prednisolon 0.3 mg/kg for 6 weeks ,  NBUVB -  9 J/cm2 for 6 weeks ,0,
edin,3539,3434899,Significantly increased,"According to chi-square test, NBUVB was significantly more effective than systemic steroid in treatment of generalized lichen planus (p = 0.008) (Table 2).", effectiveness according to chi-square test , prednisolon 0.3 mg/kg for 6 weeks ,  NBUVB -  9 J/cm2 for 6 weeks ,0,
edin,3574,4263705,No significant difference,"No statistically significant intervention effects were observed at the center level; the intervention increased the facility-level workplace social capital, and its horizontal and vertical dimensions by 1.0 (pâ=â0.24), 0.4 (pâ=â0.46) and 0.8 (pâ=â0.16), respectively."," scores of WSC total scale, horizontal and vertical dimensions ", control group - remaining participants , control group - those who lost to follow-up ,0,
edin,3552,4298817,Significantly increased,"Changes observed in the NIH-CPSI of group ML at six weeks were greater than those at baseline (group L, -3.2 vs. group ML, -7.2; p<0.05).,Significant improvements were seen in the NIH-CPSI voiding (group L, -0.5 vs. group ML, -1.7; p<0.05) and quality of life domains (group L, -1.0 vs. group ML, -1.8; p<0.05).", National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) ," levofloxacin (500 mg/d) (group L, 40 patients) for 6 weeks ", levofloxacin (500 mg/d) and mirodenafil (50 mg/d) (group ML) for six weeks ,0,
edin,3516,4263705,Invalid Prompt,, a , c , b ,1, There is no information.
edin,3525,2464595,No significant difference,Major and minor complications were similar in the two groups., overall complications , received only inguino-femoral lymph node dissection , received intraoperative application of a fibrin sealant following inguino-femoral lymph node dissection ,0,
edin,3594,4757976,Cannot tell based on the abstract,, PBMC ,  linseed oil (LO) , echium oil (EO)  ,0,
edin,3594,4757976,Significantly increased,"DHA did not accumulate with EO or LO and instead decreased in plasma, RBC, and PBMC; however, the decrease in plasma was lower with EO vs. LO (Pâ=â0.008),Overall, final EPA and DPA in plasma, RBC and PBMC were in similar order: FOâ>âEOâ>âLOâ>âOO (Pââ¤â0.001; not for DPA in RBC; TableÂ 4).", PBMC ,  linseed oil (LO) , echium oil (EO)  ,0,
edin,3496,3410988,Cannot tell based on the abstract,," Baseline characteristics regarding the patient's age, gender, or educational level of the parents ", Placebo , Memantine ,0,
edin,3496,3410988,No significant difference,"There were no differences expected between the placebo and memantine groups on age or gender, given the matched-pair design. In each group, 62% of the participants were female. The mean age of the participants in the placebo group (22 years and 7 months, range 18â31) did not differ from the mean age of the participants in the memantine group (23 years and 3 months; range 18â30; t(36)=â0.552, P=0.59). Parent's years of education was used to index the socioeconomic status. There were no significant differences between the placebo and memantine groups on the years of education of the mothers or fathers (mother: t(36)=1.43, P=0.16; father: t(36)=â0.43, P=0.67)."," Baseline characteristics regarding the patient's age, gender, or educational level of the parents ", Placebo , Memantine ,0,
edin,3476,4569275,Cannot tell based on the abstract,, Reported use of condom or increase in number of sexual partners , Placebo group , Vaccine group ,0,
edin,3476,4569275,No significant difference,"Most participants reported no change in frequency of sex (75.4%), number of sexual partners (79.7%) or condom use (78.8%) between the year before and year after their last Phambili visit (table 5)", Reported use of condom or increase in number of sexual partners , Placebo group , Vaccine group ,0,
edin,3543,3963555,Cannot tell based on the abstract,," wheezing and coughing frequency, triggers and severity ", control , fraction of exhaled nitric oxide (FeNO group) ,0,
edin,3543,3963555,No significant difference,"There was also no difference in wheezing and coughing frequency, triggers and severity between groups as evaluated by the specific domains of the standardised questionnaire."," wheezing and coughing frequency, triggers and severity ", control , fraction of exhaled nitric oxide (FeNO group) ,0,
edin,3507,3441250,Significantly increased,"At 2 hours the proportion of patients experiencing nausea (38.2â% vs 17.9%, Pâ=â0.03) and the mean nausea score were increased in the colloid compared to crystalloid group respectively (1.49âÂ±â0.3 vs 0.68âÂ±â0.2, Pâ=â0.028).", Nausea at 2 hours , Intravenous crystalloid , Intravenous colloid ,0,
edin,3562,4284021,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"">LDL-C</td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td>",  high-density lipoprotein-cholesterol (HDL-C) , placebo , evacetrapib (10â600âmg) ,0,
edin,3490,3936610,Cannot tell based on the abstract,, Change of MAP , Group C (control) , Group D (dexmedetomidine) ,0,
edin,3490,3936610,No significant difference,"There was no significant change of MAP in either group among patients, who did not require administration of ephedrine (Fig. 1).", Change of MAP , Group C (control) , Group D (dexmedetomidine) ,0,
edin,3508,3441250,No significant difference,The incidence of vomiting and anti-emetic usage was low and did not differ between the groups., Incidence of vomiting , Intravenous crystalloid , Intravenous colloid ,0,
edin,3584,4731690,No significant difference,"There was no significant difference in HAS shrinkage with alteplase in proximal (vs distal) or more (vs less) extensive HAS (p = 0.516 and p = 0.580, respectively).", HAS shrinkage and alteplase effect , distal extensive HAS , proximal extensive HAS ,0,
edin,3510,3441250,No significant difference,The incidence of vomiting and anti-emetic usage was low and did not differ between the groups., Use of anti-emetic drugs , Intravenous crystalloid , Intravenous colloid ,0,
edin,3514,3661239,Significantly increased,"Improvement in post-test performance of group A was significantly greater than of group B, demonstrating the effectiveness of POPS.", Post-test scores , group B , group A ,0,
edin,3467,3914427,Cannot tell based on the abstract,, Satisfaction with sexual relationship , Placebo , Physta plus Polygonum minus ,0,
edin,3467,3914427,Significantly decreased,Sexual relationship satisfaction was significantly lower in the active group compared to the placebo group at baseline and at 12 weeks (P < 0.0001)., Satisfaction with sexual relationship , Placebo , Physta plus Polygonum minus ,0,
edin,3548,4255428,Significantly increased,"The program identified alcohol use in pregnancy among 21% of users, a higher rate than the 13% (pâ<â.01) found via screening by clinic staff.", alcohol use in pregnancy , screening with the help of clinical staff , screening method with Screening and Brief Intervention (SBI) program ,0,
edin,3602,4489004,Cannot tell based on the abstract,, cost , abatacept , TNFi ,0,
edin,3602,4489004,No significant difference,"The uncorrected difference in cost was significant between the abatacept and rituximab groups (mean differenceâ=ââ¬5,586, 95% CIâ=ââ¬3,681 to â¬7,491, P <0.001) and between the TNFi and rituximab groups (mean differenceâ=ââ¬3,758, 95% CIâ=ââ¬1,661 to â¬5,856, Pâ=â0.001), but not between the TNFi and abatacept groups (mean differenceâ=ââ¬1,828, 95% CIâ=âââ¬294 to â¬3,950, Pâ=â0.090).Figure 4", cost , abatacept , TNFi ,0,
edin,3509,3441250,No significant difference,"Sore throat, dizziness, headache and general well being were not different between the groups."," Sore throat, dizziness, cephalea, and general well being ", Intravenous crystalloid , Intravenous colloid ,0,
edin,3480,4223943,Cannot tell based on the abstract,, Delivery by C-section , No intervention (control group) , Training-based strategies (experimental group) ,0,
edin,3480,4223943,No significant difference,"Based on the results, only 23.4% of women said they would choose cesarean delivery next time, as there was no significant difference between intervention and control groups [Table 7].", Delivery by C-section , No intervention (control group) , Training-based strategies (experimental group) ,0,
edin,3597,2998470,Significantly increased,"There were significant differences in BII at the End-of-Study Visit between subjects reporting improvement versus subjects reporting no improvement (Studies 1 and 2, P < .0001)",  Benign Prostatic Hyperplasia Impact Index (BII) , subjects reporting no improvement , subjects reporting improvement ,0,
edin,3538,3434899,Cannot tell based on the abstract,, duration of the disease , prednisolon 0.3 mg/kg for 6 weeks ,  NBUVB -  9 J/cm2 for 6 weeks ,0,
edin,3538,3434899,No significant difference,"In addition, before initiation of the treatment, ANOVA did not show significant differences regarding duration of the disease between the two groups (p = 0.910).", duration of the disease , prednisolon 0.3 mg/kg for 6 weeks ,  NBUVB -  9 J/cm2 for 6 weeks ,0,
edin,3497,3410988,Cannot tell based on the abstract,, Overall adverse events , Placebo , Memantine ,0,
edin,3497,3410988,No significant difference,There were no laboratory adverse events and no serious adverse events., Overall adverse events , Placebo , Memantine ,0,
edin,3556,2755038,Cannot tell based on the abstract,, history of peripheral vascular disease , angioplasty alone , endovascular arm ,0,
edin,3556,2755038,Significantly decreased,"In the endovascular arm, patients who were treated with stenting were less likely to have a history of peripheral vascular disease than were patients treated with angioplasty alone (4 of 50 [8%] vs 38 of 145 [26%]; p=0Â·005).", history of peripheral vascular disease , angioplasty alone , endovascular arm ,0,
edin,3473,4569275,Cannot tell based on the abstract,, Estimated infection hazard ratios for women , Placebo group , Vaccine group ,0,
edin,3473,4569275,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Women</td><td align=""center"" colspan=""1"" rowspan=""1"">1.42 (0.85, 2.35)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">0.18</td><td align=""center"" colspan=""1"" rowspan=""1"">1.12 (0.73, 1.72)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">0.62</td>", Estimated infection hazard ratios for women , Placebo group , Vaccine group ,0,
edin,3484,5498715,Significantly decreased,"Four months after the intervention, an increase in the mean scores of total PA (p<0.001, ES=4.77), physical fitness tests including flexibility (p<0.001, ES=1.59), muscular endurance (p<0.001, ES=2.0), cardiorespiratory endurance (p<0.001, ES=0.51), and a decrease in mean scores of agility test (p<0.001, ES= â 0.51) and sedentary behavior (p<0.01, ES=â 0.74) was observed in the intervention group compared to the control group", Sedentary behavior and agility test , Standard education session , Motivational interviewing through self-determination theory sessions ,0,
edin,3563,4284021,Significantly decreased,"<td align=""left"" colspan=""1"" rowspan=""1"">LDL-C</td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td>",  low-density lipoprotein cholesterol (LDL-C) , placebo , evacetrapib (10â600âmg) ,0,
edin,3477,5593355,Significantly increased,"Patients randomised to adaptive servo ventilation who crossed over to the control group were at higher risk of cardiovascular death than controls, while control patients with crossover to adaptive servo ventilation showed a trend towards lower risk of cardiovascular death than patients randomised to adaptive servo ventilation.", Risk of cardiovascular death , Control group , ASV group ,0,
edin,3586,3712961,No significant difference,"The average proportions with HIV RNA <50 copies/mL during the intervention phase were 0.51 in DAART and 0.40 in SAT (difference 0.11, 95% CI: â0.020 to 0.24).", HIV RNA &amp;lt;50 copies/mL , self-administered therapy (SAT) , directly administered antiretroviral therapy (DAART) ,0,
edin,3471,3914427,Significantly increased,"Significant improvements were noted in scores for the Sexual Intercourse Attempt diary, Erection Hardness Scale, Sexual Health Inventory of Men, and Aging Male Symptom scale (P < 0.05 for all)", Improvement in Aging Male Symptom scale , Placebo , Physta plus Polygonum minus ,0,
edin,3504,5684963,Cannot tell based on the abstract,, Mean amplitude of glycemic excursion , Low glycemic index intervention , High glycemic index intervention ,0,
edin,3504,5684963,Significantly increased,"However, the HGI treatment produced a significantly greater MAGE than the LGI treatment over the 48Â h period (pÂ =Â 0.03).,MAGE: Mean Amplitude of Glycemic Excursion.", Mean amplitude of glycemic excursion , Low glycemic index intervention , High glycemic index intervention ,0,
edin,3601,4489004,Significantly increased,"However, our analysis revealed that rituximab therapy is significantly more cost-effective than both abatacept and TNFi over a willingness-to-pay range of 0 to 80,000 euros.", cost , rituximab , TNFi ,0,
edin,3577,3782468,Cannot tell based on the abstract,,  blurred vision severity ," bright white light (10,000 lux), dim red light (&amp;amp;amp;lt; 500 lux) pre-treatment  ","  bright white light (10,000 lux), dim red light (&amp;amp;amp;lt; 500 lux) post-treatment ",0,
edin,3577,3782468,Significantly increased,"Across both groups, the average post-treatment eye strain severity (M = .4, SD = 1.0) was greater than pre-treatment severity (M = .1, SD = .5); likewise, average post-treatment blurred vision severity (M = .2, SD = .5) was greater than the pre-treatment mean (M = .1, SD = .4).",  blurred vision severity ," bright white light (10,000 lux), dim red light (&amp;amp;amp;lt; 500 lux) pre-treatment  ","  bright white light (10,000 lux), dim red light (&amp;amp;amp;lt; 500 lux) post-treatment ",0,
edin,3462,3441250,Cannot tell based on the abstract,, Frequency of nausea , colloid , crystalloid ,0,
edin,3462,3441250,Significantly decreased,"At 2 hours the proportion of the patients experiencing nausea (38.2 vs 17.9%, Pâ=â0.03) (Figure 2, Panel A) and the mean nausea score (1.49âÂ±â0.3 vs 0.68âÂ±â0.2, Pâ=â0.028) (Figure 2, Panel B) and were increased in the colloid group compared to crystalloid respectively.", Frequency of nausea , colloid , crystalloid ,0,
edin,3505,2710065,No significant difference,No statistically significant difference was observed between these groups based on the microbiological and clinical parameters., Microbiological and clinical parameters , No prophylaxis , Single-dose intravenous antibiotic prophylaxis ,0,
edin,3571,5176312,Significantly increased,Participants in the WSTP group improved their total and Advanced-level WST scores by 7.1% and 30.1% relative to baseline (p < 0.001) and retained their scores at one year follow-up.," the Advanced-level subtotal Wheelchair Skills Test (WST) - baseline,  post-training ", Educational Control (EC) , Wheelchair Skills Training Program (WSTP) ,0,
edin,3593,4757976,No significant difference,"Following EO, final DHA was not greater compared to LO.", DHA ,  linseed oil (LO) , echium oil (EO)  ,0,
edin,3499,3410988,Cannot tell based on the abstract,, DAS-II Recall of Digits score , Placebo , Memantine ,0,
edin,3499,3410988,No significant difference,"As can be seen in Figure 2b, various outcome measures had Cohen's d values approaching a moderate effect size (>0.30), and the CVLT-II Free Recall Total Score as well as the DAS-II Recall of Digits score had Cohen's d values of >0.5.,Finally, a contrast effect bordering statistical significance was found for the DAS-II Recall of Digits score (F(1,â34)=2.83, P=0.051).", DAS-II Recall of Digits score , Placebo , Memantine ,0,
edin,3472,4569275,Cannot tell based on the abstract,, Estimated infection hazard ratios for men , Placebo group , Vaccine group ,0,
edin,3472,4569275,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"">Men</td><td align=""center"" colspan=""1"" rowspan=""1"">2.46 (1.22, 4.93)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">0.01</td><td align=""center"" colspan=""1"" rowspan=""1"">2.75 (1.49, 5.06)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">0.001</td>,The effect on HIV-1 acquisition by vaccination status was more pronounced in men [HR = 2.75, 95% CI: (1.49, 5.06)], and less for women [HR = 1.12, 95% CI: (0.73, 1.72)], Fig 2", Estimated infection hazard ratios for men , Placebo group , Vaccine group ,0,
edin,3526,2464595,No significant difference,"Thirty patients were then randomized; the median time to drain removal in the control group (n = 14) was 30 days (range, 13â74) compared to 29 days (range, 11â45) in the fibrin sealant group (n = 16; P = 0.6).", the time to drain removal , received only inguino-femoral lymph node dissection , received intraoperative application of a fibrin sealant following inguino-femoral lymph node dissection ,0,
edin,3498,3410988,Cannot tell based on the abstract,, CVLT-II Free Recall Total Score , Placebo , Memantine ,0,
edin,3498,3410988,Significantly increased,"Additionally, significant contrast effect was found for one secondary measure of memory functioning, the CVLT-II Free Recall Total score (F(1,â32)=3.02, *P=0.046),Pre/post difference scores on the CVLT-II Free Recall Total Score were 5.84 (90% CI=3.47â8.21) for the memantine group and 2.53 (90% CI=0.33â4.72) for the placebo group, showing that the memantine group scored disproportionately better than the placebo group at 16 weeks.", CVLT-II Free Recall Total Score , Placebo , Memantine ,0,
edin,3529,4425923,Significantly decreased,"Among oncologists and pulmonologists, 78% (95% CI: 72-85) would offer the treatment to the non-smoker and 66% (95% CI: 58-74) to the smoker (Chi-2â=â5.4, dfâ=â1, pâ=â0.019).", receiving the treatment for cancer among oncologists and pulmonologists  , non-smoking , smoking ,0,
edin,3530,5976501,Significantly increased,"Next, we found that the intake of 5-ALA was significantly associated with improved coping ability (p = 0.004) and improved self-perception of effort spent (p = 0.002).", self-perception of effort spent  , baseline , 5-aminolevulinic acid (5-ALA) ,0,
edin,3779,2655271,Cannot tell based on the abstract,, Expression of EGFR and Raf in CL187 cells , 60Co Î³ ray , 125I seeds ,0,
edin,3779,2655271,Significantly increased,"<td align=""left""><sup>125</sup>I irradiation + Anti-EGFR mAb</td><td align=""left"">2.27 Â± 0.13<sup>c</sup></td><td align=""left"">13.74 Â± 1.82<sup>f</sup></td>,Under low dose rate irradiation, expression of EGFR (74.27 Â± 5.63%) and Raf (53.84 Â± 2.31%) was significantly higher than in the control group (Fig. 5 and Table 3).", Expression of EGFR and Raf in CL187 cells , 60Co Î³ ray , 125I seeds ,0,
edin,3759,3395326,No significant difference,"Gender, BMI, ASA score, total and hidden blood losses, calculated blood loss, preop PLT, PT, PTT, and INR were similar between groups.", average total blood loss , control , epoetin-Î± ,0,
edin,3645,4467206,Cannot tell based on the abstract,," SF-36 mental component summary (MCS),  sense of coherence (SOC) ", salutogenic dialogue (IT) , therapeutic acupuncture (TA) ,0,
edin,3645,4467206,No significant difference,Pairwise comparisons between treatment groups showed that CT had significantly worse MCS and SOC values than did IT and TA (all pâ=â.001). No differences were found between IT and TA on any variable.," SF-36 mental component summary (MCS),  sense of coherence (SOC) ", salutogenic dialogue (IT) , therapeutic acupuncture (TA) ,0,
edin,3765,5117579,Significantly decreased,The incidence of hypotension was significantly lower in Group A (16.1%) than in Group B (48.4%) during infusion of dexmedetomidine (pâ=â0.01)., The incidence of hypotension , Group B received same dose of dexmedetomidine by intravenous administration before 5&amp;nbsp;min of intrathecal bupivacaine injection ," Group A, 1&amp;nbsp;Î¼g/kg of dexmedetomidine was intravenously 10&amp;nbsp;min, followed by the maintenance infusion of dexmedetomidine 0.2&amp;nbsp;Î¼g/kg/hr after 5&amp;nbsp;min of intrathecal bupivacaine injection ",0,
edin,3612,4128673,Cannot tell based on the abstract,, biopsy-proven acute rejection (BPAR) , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3612,4128673,No significant difference,The two arms showed no significant difference at the primary endpoint of biopsy-proven acute rejection (BPAR)., biopsy-proven acute rejection (BPAR) , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3661,2956327,Significantly increased,"While there was no significant difference between website use categories in the amount of Phase I change in body weight (P = .45) or income (P = .78), minimal website users (n = 75) were significantly more likely to have attended fewer Phase I sessions (P = .001) and had a higher initial body mass index (BMI) (P < .001).", initial body mass index (BMI) ," weight loss program  in the consistent , and some user group ", weight loss program - minimal user group ,0,
edin,3676,4251531,No significant difference,The sum CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group but significantly in the placebo group (P=0.05). The difference in increase between groups did not meet the level of significance (P=0.12)., The sum CTC-NCI toxicity score , placebo ,  intramuscular injections of 0.035 mg/kg of body weight BP-C1 ,0,
edin,3630,2194675,Significantly increased,"Consumption of PS-FO resulted in higher Î²-carotene (P = 0.0139) and retinol (P = 0.0425) levels than PS-SO and PS-OO, respectively.", plasma Î²-carotene concentrations , PS-sunflower oil (SO)  , plant sterol (PS)  from fish oil (FO) ,0,
edin,3683,3780629,Significantly decreased,"Significant reductions were also observed following the combined intervention on secondary measures associated with depression: disability, anxiety, and repetitive negative thinking (Cohenâs d = 1.51â2.23). T"," disability, anxiety, and repetitive negative thinking ", baseline , CBM-I (cognitive-bias modification (CBM) + Internet-based cognitive behavioral therapy (iCBT) ,0,
edin,3746,3546023,Cannot tell based on the abstract,, The percentage of NK cells , 200âmg/day palmvitee nonsmokers , 200âmg/day palmvitee smokers  ,0,
edin,3746,3546023,Significantly decreased,"The percentage of NK cells were lower in smokers compared to nonsmokers (pâ<â0.0001) at baseline (S1: pâ<â0.05, S2: pâ<â0.005, S3: pâ<â0.01) and after palmvitee supplementation (Tableâ 8 and Tableâ 9).", The percentage of NK cells , 200âmg/day palmvitee nonsmokers , 200âmg/day palmvitee smokers  ,0,
edin,3754,3529678,Cannot tell based on the abstract,, General Health , baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3754,3529678,Significantly increased,"From baseline to 6 weeks there was an improvement in physical (3.3) and mental HRQoL scores (4.4). We also observed improvements in physical functioning (2.2), bodily pain (5.8), general health (3.7), vitality (4.8); and role-physical (3.1), social functioning (4.3), role-emotional (3.7) and mental health (4.8; Table 4).", General Health , baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3621,2211287,Significantly increased,Changes in MR (kcal/min and kcal/min/kg ffm) from baseline were significantly higher in normal weight subjects (n = 11) across all times following consumption of the HPHF meal versus the HPLF meal., Changes in metabolic rate (MR) (kcal/min and kcal/min/kg ffm) ," normal weight group -  high protein, low fat meal "," normal weight group -  high protein, high fat meal ",0,
edin,3615,4128673,Cannot tell based on the abstract,,  the serum creatinine at 12 months post-transplant , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3615,4128673,No significant difference,"At 12 months post-transplant, the serum creatinine in the lowATG was 1.4Â±0.44 mg/dl compared with 1.33Â±0.0.36 in the sATG group (pâ=â0.56).",  the serum creatinine at 12 months post-transplant , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3642,3664086,No significant difference,No significant difference was identified in quality of life score and side effects (Pâ>â0.05)., quality of life score and side effects ," neoadjuvant DE combined with rh-endostatin (7.5&amp;amp;amp;amp;nbsp;mg/m2, d1-d14, every 3&amp;amp;amp;amp;nbsp;weeks) "," neoadjuvant DE (docetaxel: 75&amp;amp;amp;amp;nbsp;mg/m2, d1, epirubicin: 75&amp;amp;amp;amp;nbsp;mg/m2, d1, every 3&amp;amp;amp;amp;nbsp;weeks) ",0,
edin,3633,2194675,No significant difference,"In contrast, plasminogen activator inhibitor 1 (PAI-1) concentrations were lower (P = 0.0282) in the PS-FO-fed than the PS-SO, but not the PS-OO (P = 0.7487) groups.", plasminogen activator inhibitor 1 (PAI-1) concentrations , PS-olive oil (OO) , plant sterol (PS)  from fish oil (FO) ,0,
edin,3751,3529678,Significantly decreased,"From baseline to six weeks, improvements were observed for minutes moderate-vigorous physical activity (150.7 minutes), processed meat intake (â1.2 serves/week), vegetable intake (1 serve/day), alcohol intake (â0.4 standard drinks/day), body mass index (â1.4 kg/m2), and waist circumference (â5.1 cm).,Further, compared with baseline, participants were more likely to meet Australian recommendations post-intervention for: moderate-vigorous physical activity (27.3 vs 59.1%); fruit intake (68.2 vs 81.8%); vegetable intake (4.6 vs 18.2%); alcohol consumption (59.1 vs 72.7%); body mass index (31.8 vs 45.5%) and waist circumference (18.2 vs 27.3%)."," Waist circumference, cm ", baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3715,3781545,Significantly decreased,"Liraglutide-treated subjects also had a significant improvement in SSPG concentration (â3.2 vs. 0.2 mmol/L; P < 0.001) and significantly (P â¤ 0.04) greater lowering of systolic blood pressure (â8.1 vs. â2.6 mmHg), fasting glucose (â0.5 vs. 0 mmol/L), and triglyceride (â0.4 vs. â0.1 mmol/L) concentration."," systolic blood pressure, fasting glucose , and triglyceride ", placebo , liraglutide 1.8 mg ,0,
edin,3662,2956327,Cannot tell based on the abstract,, initial weight loss regained ," weight loss program  in the some, and minimal user group ", weight loss program -in the consistent user group ,0,
edin,3662,2956327,Significantly decreased,"Mean weight change in Phase II, both absolute weight and proportion of initial weight loss regained, was significantly lower (less weight regained) in the consistent website-use category (P = .003 [Figure 2] and P = .001 [Figure 3])", initial weight loss regained ," weight loss program  in the some, and minimal user group ", weight loss program -in the consistent user group ,0,
edin,3755,3529678,Cannot tell based on the abstract,, Vitality , baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3755,3529678,Significantly increased,"We also observed improvements in physical functioning (2.2), bodily pain (5.8), general health (3.7), vitality (4.8); and role-physical (3.1), social functioning (4.3), role-emotional (3.7) and mental health (4.8; Table 4).", Vitality , baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3770,5732563,Cannot tell based on the abstract,, analgesic spread (spinal level/minute) ," catheter, given in 5 mL increments spaced 2 minutes apart ", 10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle ,0,
edin,3770,5732563,No significant difference,"The estimated difference in analgesic spread (spinal level/minute), as defined by loss of sharpness of pinprick, was 0.63 (95% CI: â0.12 to 0.19) and did not significantly differ between groups (p=0.166; Figure 2 and Table 2).", analgesic spread (spinal level/minute) ," catheter, given in 5 mL increments spaced 2 minutes apart ", 10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle ,0,
edin,3741,3546023,Significantly increased,Urine cotinine levels and serum Î±1-antitrypsin were significantly higher in smokers compared to nonsmokers., Urine cotinine levels  , 200âmg/day palmvitee  nonsmokers , 200âmg/day palmvitee smokers  ,0,
edin,3748,3529678,Significantly decreased,"From baseline to six weeks, improvements were observed for minutes moderate-vigorous physical activity (150.7 minutes), processed meat intake (â1.2 serves/week), vegetable intake (1 serve/day), alcohol intake (â0.4 standard drinks/day), body mass index (â1.4 kg/m2), and waist circumference (â5.1 cm)."," Processed meat, serves/week ", baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3619,2211287,No significant difference,"However, when metabolic rate was expressed per kg fat free mass (ffm), no significant difference was found in postprandial energy expenditure between the overweight and normal groups.",  change in energy expenditure ," normal weight group following consumption of the high protein, low fat meal "," normal weight group following consumption of the high protein, high fat meal ",0,
edin,3625,3290117,No significant difference,"There were no initial differences between groups in regards to tumor size, C-peptide, BMI, and Kiâ67.,C-peptide (ng/mL) was equivalent between the two groups (4.55 NC + BC versus 4.74 NC, P = 0.85).", C-peptide (ng/mL) , Neoadjuvant chemotherapy (NC) alone , NC with supervised bootcamp (NC + BC) ,0,
edin,3611,4831612,Significantly decreased,"Between each two groups, there were differences in preparation time (P < 0.05), with Reciproc being the fastest.", preparation time ," K-file, Mtwo ", Reciproc ,0,
edin,3632,2194675,Significantly decreased,"In contrast, plasminogen activator inhibitor 1 (PAI-1) concentrations were lower (P = 0.0282) in the PS-FO-fed than the PS-SO, but not the PS-OO (P = 0.7487) groups.", plasminogen activator inhibitor 1 (PAI-1) concentrations , PS-sunflower oil (SO)  , plant sterol (PS)  from fish oil (FO) ,0,
edin,3771,5732563,No significant difference,The time to VRS â¤3 and level of sensory block 20 minutes after dosing were also similar between groups., The time to VRS â¤3 and level of sensory block 20 minutes after dosing ," catheter, given in 5 mL increments spaced 2 minutes apart ", 10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle ,0,
edin,3713,3781545,Cannot tell based on the abstract,, gastrointestinal side effect , placebo , liraglutide 1.8 mg ,0,
edin,3713,3781545,Significantly increased,The majority of individuals (79%) treated with liraglutide experienced at least one gastrointestinal side effect compared with 46% treated with placebo (P = 0.02)., gastrointestinal side effect , placebo , liraglutide 1.8 mg ,0,
edin,3722,4776542,Cannot tell based on the abstract,, postoperative nausea and vomiting (PONV) , saline 0.90% in group S ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O ",0,
edin,3722,4776542,Significantly decreased,"Subsequently, the difference was not significant between group M and group O. However, PONV in both of them were significantly less as compared to group S [Table 3].", postoperative nausea and vomiting (PONV) , saline 0.90% in group S ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O ",0,
edin,3723,4776542,Cannot tell based on the abstract,, The overall patient satisfaction ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S ", midazolam 0.75 mg/kg and ondansetron 4 mg in group MO ,0,
edin,3723,4776542,Significantly increased,"The overall patient satisfaction was significantly higher in the group MO compared the other groups [P < 0.001, Table 2].", The overall patient satisfaction ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S ", midazolam 0.75 mg/kg and ondansetron 4 mg in group MO ,0,
edin,3614,4128673,Cannot tell based on the abstract,, Delayed graft function , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3614,4128673,No significant difference,Delayed graft function occurred in 40% of patients in the lowATG group compared with 14.3% in the sATG group (pâ=â0.05)., Delayed graft function , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3635,4558976,Cannot tell based on the abstract,, AAA extinction learning , placebo , tiapride ,0,
edin,3635,4558976,No significant difference,"When considering only extinction learning in a novel context (ABA condition), the TIA group was significantly impaired compared to PLAC [t(38) = 1.989 p = 0.027; TIA 24.00% Â± 3.81; PLAC 15.00% Â± 2.43], while there was no significant difference in AAA extinction learning between groups [t(38) = 0.673 p = 0.252; TIA 18.25% Â± 2.93; PLAC 16.00% Â± 1.59âall t-tests one-tailed].", AAA extinction learning , placebo , tiapride ,0,
edin,3669,4185107,No significant difference,"There were no statistically significant differences in the overall rate of early postoperative complications between the study and control group: 25.6 and 34.1Â % respectively; pÂ =Â 0.245,", overall rate of early postoperative complications , control , gentamicin collagen implant (GCI) ,0,
edin,3733,3382694,Cannot tell based on the abstract,, skin-to-stone distance (SSD) ,  failure group ," Extracorporeal Shock Wave Lithotripsy (ESWL) group B, stone size10 mm -  success  group ",0,
edin,3733,3382694,Significantly increased,"The mean SSD in the success and failure groups, respectively, was 102.4Â±12.88 mm vs. 110.8Â±5.66 mm in group A (p=0.043) and 97.8Â±12.97 mm vs. 107.9Â±13.02 mm in group B (p=0.013) (Table 3)", skin-to-stone distance (SSD) ,  failure group ," Extracorporeal Shock Wave Lithotripsy (ESWL) group B, stone size10 mm -  success  group ",0,
edin,3668,5753687,Cannot tell based on the abstract,, CD endoscopic index of severity (CDEIS) after Colonoscopy  , control ," umbilical cord mesenchymal stem cells (UC-MSCs) 1Ã106 UC-MSCs/kg, with one infusion per week ",0,
edin,3668,5753687,Significantly increased,"Colonoscopy showed that the CDEIS in the UC-MSC group was 9.2Â±1.5 and 3.4Â±1.2 before treatment and at the 12-month follow-up, respectively (Fig. 3).", CD endoscopic index of severity (CDEIS) after Colonoscopy  , control ," umbilical cord mesenchymal stem cells (UC-MSCs) 1Ã106 UC-MSCs/kg, with one infusion per week ",0,
edin,3608,4831612,Significantly increased,"Considering cleanliness, at coronal third Reciproc was better than K-file (P < 0.001), but not more effective than Mtwo (P = 0.080).", cleaning efficacy in the coronal third ,  K-file , Reciproc ,0,
edin,3620,2211287,No significant difference,Changes in MR (kcal/min and kcal/min/kg ffm) from the baseline rate did not significantly differ in the underweight (n = 3) or in the overweight subjects (n = 5) following consumption of either meal at any time., Changes in metabolic rate (MR) (kcal/min and kcal/min/kg ffm) , overweight , underweight ,0,
edin,3675,4251531,No significant difference,"The sum CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group but significantly in the placebo group (P=0.05). The difference in increase between groups did not meet the level of significance (P=0.12). The sum toxicity score was reduced in the patients receiving 64 days of BP-C1 from 9.2 at screening to 8.9 at Day 48, but it increased again to 10.1 by Day 64 and 10.6 during the 28-day follow-up.", The sum CTC-NCI toxicity score , baseline , placebo ,0,
edin,3624,3290117,No significant difference,Mean Ki-67 for NC + BC was 7% versus 29% with NC (P = 0.14)., Mean Ki-67 , Neoadjuvant chemotherapy (NC) alone , NC with supervised bootcamp (NC + BC) ,0,
edin,3766,5117579,No significant difference,The incidence of bradycardia and desaturation did not significantly differ between the two groups., The incidence of bradycardia and desaturation , Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection ," Group A, 1Î¼g/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2Î¼g/kg/hr after 5min of intrathecal bupivacaine injection ",0,
edin,3658,3532974,Cannot tell based on the abstract,, changes in medication usage  , baseline , âFlorenceâ- interactive mobile phone texting service ,0,
edin,3658,3532974,Significantly increased,"Significantly more changes, 0.31 vs 0.08 (p<0.05; CI for difference 0.16 to 0.32) were made to the medications of intervention patients, compared with control patients over the 3-month programme, respectively.", changes in medication usage  , baseline , âFlorenceâ- interactive mobile phone texting service ,0,
edin,3724,4776542,Cannot tell based on the abstract,,  visual analog scale (VAS) of nausea ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S ", midazolam 0.75 mg/kg and ondansetron 4 mg in group MO ,0,
edin,3724,4776542,Significantly decreased,VAS of nausea in group MO was significantly less than other groups (P < 0.001).,  visual analog scale (VAS) of nausea ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, and saline 0.90% in group S ", midazolam 0.75 mg/kg and ondansetron 4 mg in group MO ,0,
edin,3610,4831612,No significant difference,"Regarding shaping ability, no differences were found between Reciproc and Mtwo (P = 1.00).", shaping ability , K-file  ," Reciproc, Mtwo ",0,
edin,3777,2655271,Cannot tell based on the abstract,, Apoptosis rates of CL187 cancer cells , 60Co Î³ ray , 125I seeds ,0,
edin,3777,2655271,Significantly increased,"he apoptotic rates were detected by flow cytometry. In 2 Gy (D), 5 Gy (E), and 10 Gy (F) groups, the CL187 cells had higher apoptosis rates when compared with control groups (C).", Apoptosis rates of CL187 cancer cells , 60Co Î³ ray , 125I seeds ,0,
edin,3761,3395326,Cannot tell based on the abstract,, mean hemoglobin level at admission at the discharge , control , epoetin-Î± ,0,
edin,3761,3395326,Significantly increased,"At admission, the mean hemoglobin level was higher in the epoetin-Î± group (13.8âg/dL versus 12.2âg/dL) (P = 0.001); the discharge hemoglobin level was higher in the epoetin-Î± group (10.6âg/dL versus 9.69âg/dL) (P < 0.001).", mean hemoglobin level at admission at the discharge , control , epoetin-Î± ,0,
edin,3616,4128673,No significant difference,"No statistically significant differences were found in graft survival, patient survival or infections between the two groups, though there was a non-significant increase in leukopenia (43%v s. 30%), CMV (8% vs. 0) and BK (4% vs. 0) infections in sATG group vs. lowATG.", leukopenia , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3760,3395326,Cannot tell based on the abstract,, mean hemoglobin level at admission , control , epoetin-Î± ,0,
edin,3760,3395326,Significantly increased,"At admission, the mean hemoglobin level was higher in the epoetin-Î± group (13.8âg/dL versus 12.2âg/dL) (P = 0.001);", mean hemoglobin level at admission , control , epoetin-Î± ,0,
edin,3742,3546023,Significantly increased,Urine cotinine levels and serum Î±1-antitrypsin were significantly higher in smokers compared to nonsmokers.,  serum Î±1-antitrypsin , 200âmg/day palmvitee  nonsmokers , 200âmg/day palmvitee smokers  ,0,
edin,3684,3780629,Cannot tell based on the abstract,," The Beck Depression Inventoryâ2nd edition (BDI-II), nine-item Depression Scale of the Patient Health Questionnaire (PHQ-9), and The 10-item Kessler Psychological Distress Scale (K10) ", baseline , CBM-I  ,0,
edin,3684,3780629,Significantly decreased,"Following CBM-I, the reductions in BDI-II, PHQ-9, and K10 scores in the intervention group were all significant and corresponded to medium-large effects."," The Beck Depression Inventoryâ2nd edition (BDI-II), nine-item Depression Scale of the Patient Health Questionnaire (PHQ-9), and The 10-item Kessler Psychological Distress Scale (K10) ", baseline , CBM-I  ,0,
edin,3739,4115605,Cannot tell based on the abstract,, adverse events , placebo , droxidopa dose optimization (100â600 mg 3 times daily) ,0,
edin,3739,4115605,No significant difference,"During double-blind treatment, 15 droxidopa (18.5% of 81) and 12 placebo (14.8% of 81) recipients reported AEs (see table e-3), most frequently headache (in 7.4% of droxidopa and no placebo recipients), dizziness (in 3.7% vs 1.2%), fatigue (2.5% vs 2.5%), syncope (2.5% vs 1.2%), and falls (0.0% vs 3.7%)", adverse events , placebo , droxidopa dose optimization (100â600 mg 3 times daily) ,0,
edin,3686,4871571,Cannot tell based on the abstract,, The concentration of CN54rgp140 antibodies , baseline , two CN54rgp140/GLA-AF immunizations ,0,
edin,3686,4871571,Significantly increased,The concentration of CN54rgp140 antibodies increased significantly from a median of 0.861 (range 0.197â4.449 Î¼g/ml) after the HIV-DNA and HIV-MVA vaccinations to a median of 9.866 (range 0.134â129.6 Î¼g/ml) after the first dose of CN54rgp140/GLA-AF (p<0.001) and then increased further to a median of 17.75 Î¼g/ml (range 0.277 to 219.8 Î¼g/ml) after the second Env protein immunization (p<0.001)., The concentration of CN54rgp140 antibodies , baseline , two CN54rgp140/GLA-AF immunizations ,0,
edin,3734,3382694,Cannot tell based on the abstract,, skin-to-stone distance (SSD) ,  failure group ," Extracorporeal Shock Wave Lithotripsy (ESWL) in group A, stone size â¤10 mm - success group ",0,
edin,3734,3382694,Significantly increased,"The mean SSD in the success and failure groups, respectively, was 102.4Â±12.88 mm vs. 110.8Â±5.66 mm in group A (p=0.043) and 97.8Â±12.97 mm vs. 107.9Â±13.02 mm in group B (p=0.013) (Table 3). All the secondary signs showed statistically significant differences in terms of outcome of ESWL (Table 3).", skin-to-stone distance (SSD) ,  failure group ," Extracorporeal Shock Wave Lithotripsy (ESWL) in group A, stone size â¤10 mm - success group ",0,
edin,3721,4776542,No significant difference,"The incidence of PONV was significantly smaller in group MO than group M and group O, while there was no significant difference between group M and group O during the first 24 h postoperatively.", postoperative nausea and vomiting (PONV) , midazolam 0.75 mg/kg in group M , ondansetron 4 mg in group O ,0,
edin,3763,3395326,Cannot tell based on the abstract,, patients required blood transfusion , control , epoetin-Î± ,0,
edin,3763,3395326,Significantly decreased,"In the epoetin-Î± group, 0% of the patients (0 of 28) required blood transfusion. This was significantly lower than the control group where 53% of the patients (28 of 53) received at least one unit of blood transfusion (P = 0.0001).", patients required blood transfusion , control , epoetin-Î± ,0,
edin,3690,3511949,Significantly decreased,"After the intra-articular injection, there was statistically significant decrease in visual analog scale (VAS) scores in Groups M and T, when compared to Group C. The decrease of VAS scores seen at the first 2 weeks continued steadily up to the end of 12th week.",  visual analog scale (VAS) scores at the end of 12th week , Group C received saline plus bupivacaine intra-articularly ," Group M - morphine plus bupivacaine intra-articularly, Group T - triamcinolone plus bupivacaine intra-articularly  ",0,
edin,3679,4251531,Significantly decreased,âBreast cancer-related pain and discomfortâ and âBreast cancer treatment problem last weekâ were significantly reduced (P=0.02) in the BP-C1 group but increased slightly in the placebo group; between-group differences were significant in favor of BP-C1 (P=0.05)., Ã¢â¬ÅBreast cancer-related pain and discomfortÃ¢â¬ï¿½ and Ã¢â¬ÅBreast cancer treatment problem last weekÃ¢â¬ï¿½ , placebo ,  intramuscular injections of 0.035 mg/kg of body weight BP-C1 ,0,
edin,3613,4128673,Cannot tell based on the abstract,, Patient survival at 1 year , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3613,4128673,No significant difference,Patient survival at 1 year in the lowATG group was 85% compared with 100% in the sATG (pâ=â0.11), Patient survival at 1 year , lower dose 2.25 mg/kg (lowATG) , standard dose ATG (total dose 3.75 mg/kg)(sATG) ,0,
edin,3704,5972262,Cannot tell based on the abstract,," bispectral index (BIS)  at sputum suction (T5), extubation (T6) and 1 min (T7), 5 min (T8), ", 100 ml 0.9% saline (group C) , creatine phosphate sodium (1.0 g/100 ml 0.9% saline; group P) ,0,
edin,3704,5972262,Significantly increased,"Compared with group C, the BIS values at T5, T6, T7, and T8 in group P were significantly higher (Pâ<â0.001 for all comparisons; one-way ANOVA)."," bispectral index (BIS)  at sputum suction (T5), extubation (T6) and 1 min (T7), 5 min (T8), ", 100 ml 0.9% saline (group C) , creatine phosphate sodium (1.0 g/100 ml 0.9% saline; group P) ,0,
edin,3767,5117579,Cannot tell based on the abstract,, The mean HR and  mean blood pressure (MBP) , Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection ," Group A, 1Î¼g/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2Î¼g/kg/hr after 5min of intrathecal bupivacaine injection ",0,
edin,3767,5117579,No significant difference,"he MBP and HR in the PACU were did not statistically differ between the two groups.,The mean HR (Group A vs. Group B, 57.88âÂ±â6.16 vs. 59.49âÂ±â8.13, pâ=â0.133) and MBP (Group A vs. Group B, 80.07âÂ±â12.48 vs. 77.49âÂ±â9.36, pâ=â0.121) were not significantly different.", The mean HR and  mean blood pressure (MBP) , Group B received same dose of dexmedetomidine by intravenous administration before 5min of intrathecal bupivacaine injection ," Group A, 1Î¼g/kg of dexmedetomidine was intravenously 10min, followed by the maintenance infusion of dexmedetomidine 0.2Î¼g/kg/hr after 5min of intrathecal bupivacaine injection ",0,
edin,3719,4776542,Cannot tell based on the abstract,,  postanesthesia care unit (PACU) time ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, midazolam 0.75 mg/kg and ondansetron 4 mg in group MO ",  saline 0.90% in group S ,0,
edin,3719,4776542,No significant difference,PACU time was not significantly different between the four groups [Table 2].,  postanesthesia care unit (PACU) time ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O, midazolam 0.75 mg/kg and ondansetron 4 mg in group MO ",  saline 0.90% in group S ,0,
edin,3699,4839526,Significantly increased,"Duloxetine was not significantly different from placebo on the DSST or UPSA, but was superior to placebo on the PDQ, CGI-I, and MADRS.", The patient-reported perceived deficits questionnaire (PDQ) , placebo , duloxetine 60âmg ,0,
edin,3736,4115605,Significantly increased,"Improvement in symptom-impact subscore favored droxidopa by 1.06 units (p = 0.003), with maximum change for âstanding a long time.â", Improvement in symptom-impact subscore , placebo , droxidopa dose optimization (100â600 mg 3 times daily) ,0,
edin,3689,3511949,Cannot tell based on the abstract,,  visual analog scale (VAS) scores at every visit over 12 weeks , Group T - triamcinolone plus bupivacaine intra-articularly  ," Group M - morphine plus bupivacaine intra-articularly,  ",0,
edin,3689,3511949,No significant difference,"The morphine and steroid groups had significantly decreased VAS scores at every visit over 12 weeks. The morphine and steroid groups were compared with each other, and their scores were similar (P > 0.05). Variance analysis of repeated measurements revealed decreased VAS scores of both morphine and steroid groups than the control group and this decrease continued until the end of 12th week [P < 0.001,,Figure 1
VAS scores versus time in the groups. *Significance of Group M versus Group T, P > 0.05. â ",  visual analog scale (VAS) scores at every visit over 12 weeks , Group T - triamcinolone plus bupivacaine intra-articularly  ," Group M - morphine plus bupivacaine intra-articularly,  ",0,
edin,3756,3529678,Cannot tell based on the abstract,, Physical HRQoL , baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3756,3529678,Significantly increased,"<td align=""left"" valign=""bottom"">Physical HRQoL<hr></td><td align=""char"" char=""("" valign=""bottom"">48.6 (1.6)<hr></td><td align=""char"" char=""("" valign=""bottom"">51.9 (6.6)<hr></td><td align=""char"" char=""("" valign=""bottom"">3.3 (03 6.3)<hr></td><td align=""char"" char=""."" valign=""bottom"">0.03<hr></td>,From baseline to 6 weeks there was an improvement in physical (3.3) and mental HRQoL scores (4.4).", Physical HRQoL , baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3674,4251531,No significant difference,The sum CTC-NCI toxicity score increased nonsignificantly in the BP-C1 group but significantly in the placebo group (P=0.05)., The sum CTC-NCI toxicity score , baseline ,  intramuscular injections of 0.035 mg/kg of body weight BP-C1 ,0,
edin,3627,2194675,No significant difference,"There were no differences between PS-containing diet effects on total cholesterol, LDL-cholesterol, or high-density lipoprotein (HDL)-cholesterol levels."," total cholesterol, LDL-cholesterol, or high-density lipoprotein (HDL)-cholesterol levels ", PS-sunflower oil (SO) and PS-olive oil (OO) , plant sterol (PS)  from fish oil (FO) ,0,
edin,3769,5732563,No significant difference,"he estimated difference in the rate of pain relief (VRS/minute) was 0.04 (95% CI: â0.01 to 0.11; p=0.109),", rate of pain relief (VRS/minute) ," catheter, given in 5 mL increments spaced 2 minutes apart ", 10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle ,0,
edin,3623,3290117,No significant difference,Final tumor size was 2.59 cm in the NC + BC group versus 3.16 cm for NC (P = 0.76), Final tumor size , Neoadjuvant chemotherapy (NC) alone , NC with supervised bootcamp (NC + BC) ,0,
edin,3647,3716527,Cannot tell based on the abstract,," helping to diagnosed and communication, specific medical and mental health problems ", attention-comparison group (where only daily activities were monitored) ," intervention group (where mood, stress and daily activities were monitored with program mobiletype) ",0,
edin,3647,3716527,Significantly increased,"Finally, GPs indicated that the mobiletype program helped in their diagnosis (pâ=â.002, dâ=â0.69) and communication (pâ=â.031, dâ=â0.47), as well as their patientâs specific medical (pâ=â.023, dâ=â0.52) and mental health problems (pâ=â.011, dâ=â0.56), significantly more than when using the attention comparison."," helping to diagnosed and communication, specific medical and mental health problems ", attention-comparison group (where only daily activities were monitored) ," intervention group (where mood, stress and daily activities were monitored with program mobiletype) ",0,
edin,3709,3781545,Significantly decreased,Liraglutide-treated subjects also had a significant improvement in SSPG concentration (â3.2 vs. 0.2 mmol/L; P < 0.001), steady-state plasma glucose (SSPG) concentration , placebo , liraglutide 1.8 mg ,0,
edin,3609,4831612,No significant difference,"Regarding shaping ability, no differences were found between Reciproc and Mtwo (P = 1.00).", shaping ability , Mtwo , Reciproc ,0,
edin,3737,4115605,Significantly increased,"Mean standing systolic blood pressure (BP) increased by 11.2 vs 3.9 mm Hg (p < 0.001), and mean supine systolic BP by 7.6 vs 0.8 mm Hg (p < 0.001)."," Mean standing systolic blood pressure (BP), mean supine systolic BP ", placebo , droxidopa dose optimization (100â600 mg 3 times daily) ,0,
edin,3671,4185107,No significant difference,The total rate of SSI and organ space SSI were 22.2 and 15.8Â % without differences between the study and control group., The total rate of SSI and organ space surgical site infections (SSI) , control , gentamicin collagen implant (GCI) ,0,
edin,3643,4467206,Significantly increased,"<td valign=""middle"">SOC</td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td><td valign=""middle""></td>"," SF-36 mental component summary (MCS),  sense of coherence (SOC) ",  conventional treatment (CT) ," therapeutic acupuncture (TA) , salutogenic dialogue (IT) ",0,
edin,3743,3546023,Significantly increased,Natural killer cells were decreased; CD4+ cells and B cells were increased in smokers compared to nonsmokers but were unaffected with vitamin E supplementation except in the percentage of B cells which were increased in nonsmokers supplemented palmvitee compared to placebo., The percentage of B cells , baseline , 200âmg/day palmvitee nonsmokers  ,0,
edin,3753,3529678,Cannot tell based on the abstract,, Bodily Pain , baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3753,3529678,Significantly decreased,"We also observed improvements in physical functioning (2.2), bodily pain (5.8), general health (3.7), vitality (4.8); and role-physical (3.1), social functioning (4.3), role-emotional (3.7) and mental health (4.8; Table 4).,<td align=""left"" valign=""bottom"">Bodily Pain<hr></td><td align=""char"" char=""("" valign=""bottom"">45.0 (11.4)<hr></td><td align=""char"" char=""("" valign=""bottom"">50.7 (9.7)<hr></td><td align=""char"" char=""("" valign=""bottom"">5.8 (1.4 10.1)<hr></td><td align=""char"" char=""."" valign=""bottom"">0.01<hr></td>", Bodily Pain , baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3660,2956327,Significantly increased,"While there was no significant difference between website use categories in the amount of Phase I change in body weight (P = .45) or income (P = .78), minimal website users (n = 75) were significantly more likely to have attended fewer Phase I sessions (P = .001)", attending Phase I sessions ," weight loss program  in the consistent , and some user group ", weight loss program - minimal user group ,0,
edin,3717,4772687,Cannot tell based on the abstract,, mean modified psoriasis area and severity index (mPASI) score , Cal/BD ointment at week 1 and week 4 , Cal/BD aerosol foam at week 1 and week 4 ,0,
edin,3717,4772687,Significantly decreased,"mPASI further demonstrated statistically significant improvement in disease status for patients using Cal/BD aerosol foam versus those using ointment.,There was a significant difference in adjusted mean mPASI score between Cal/BD aerosol foam and Cal/BD ointment at week 1 (mean difference â0.7; 95% CI â1.1, â0.3; pâ=â0.001) and week 4 (mean difference â0.6; 95% CI â1.1, â0.2; pâ=â0.005; Figure 4).", mean modified psoriasis area and severity index (mPASI) score , Cal/BD ointment at week 1 and week 4 , Cal/BD aerosol foam at week 1 and week 4 ,0,
edin,3772,5732563,Cannot tell based on the abstract,, maternal mean arterial blood pressure or maternal heart rate ," catheter, given in 5 mL increments spaced 2 minutes apart ", 10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle ,0,
edin,3772,5732563,No significant difference,"No significant difference was observed in the estimated slope differences of maternal mean arterial blood pressure (0.25, p=0.188; Figure 3) or maternal heart rate (0.03, p=0.807; Figure 4).", maternal mean arterial blood pressure or maternal heart rate ," catheter, given in 5 mL increments spaced 2 minutes apart ", 10 mL loading dose (0.125% bupivacaine with fentanyl 2 Âµg/mL) through either the epidural needle ,0,
edin,3648,3716527,Cannot tell based on the abstract,, post-test in the GP Confidence scale , attention-comparison group (where only daily activities were monitored) ," intervention group (where mood, stress and daily activities were monitored with program mobiletype) ",0,
edin,3648,3716527,No significant difference,"The difference between groups at post-test in the GP Confidence scale (Cronbachâs alpha [Î±]â=â0.93) were tested by regression analysis, adjusting for pre-test GP Confidence scale score. After adjusting for baseline values, the difference between intervention and comparison groupâs doctors confidence was not significant (Î²â=â1.05, pâ=â.131).", post-test in the GP Confidence scale , attention-comparison group (where only daily activities were monitored) ," intervention group (where mood, stress and daily activities were monitored with program mobiletype) ",0,
edin,3698,4839526,Significantly increased,"Vortioxetine was statistically superior to placebo on the DSST (P<0.05), PDQ (P<0.01), CGI-I (P<0.001), MADRS (P<0.05), and UPSA (P<0.001).",  CGI-I score , placebo , vortioxetine (10â20âmg) ,0,
edin,3708,3781545,Significantly decreased,Liraglutide-treated subjects also had a significant improvement in SSPG concentration (â3.2 vs. 0.2 mmol/L; P < 0.001), steady-state plasma glucose (SSPG) concentration , baseline , liraglutide 1.8 mg ,0,
edin,3678,4251531,Cannot tell based on the abstract,, Ã¢â¬ÅBreast cancer-related pain and discomfortÃ¢â¬ï¿½ and Ã¢â¬ÅBreast cancer treatment problem last weekÃ¢â¬ï¿½ , baseline , placebo ,0,
edin,3678,4251531,No significant difference,"âBreast cancer-related pain and discomfort last weekâ was significantly reduced (P=0.02) in the BP-C1 group and slightly increased in the placebo group during the initial 32 days of treatment (Table 4).,Comparison of the groups detected a significant difference in change of âBreast cancer-related painâ in favor of BP-C1 (P=0.05). A similar pattern was detected for âBreast cancer treatment problems last week.â This variable was significantly reduced in the BP-C1 group (P=0.02) and slightly increased in the placebo group.", Ã¢â¬ÅBreast cancer-related pain and discomfortÃ¢â¬ï¿½ and Ã¢â¬ÅBreast cancer treatment problem last weekÃ¢â¬ï¿½ , baseline , placebo ,0,
edin,3641,3664086,No significant difference,Five patients in the rh-endostatin plus chemotherapy arm achieved pathologic complete response compared with 2 in the chemotherapy arm (Pâ=â0.428)., achieving pathologic complete response ," neoadjuvant DE combined with rh-endostatin (7.5&amp;amp;amp;nbsp;mg/m2, d1-d14, every 3&amp;amp;amp;nbsp;weeks) "," neoadjuvant DE (docetaxel: 75&amp;amp;amp;nbsp;mg/m2, d1, epirubicin: 75&amp;amp;amp;nbsp;mg/m2, d1, every 3&amp;amp;amp;nbsp;weeks) ",0,
edin,3701,4839526,Cannot tell based on the abstract,, Trail Making Test B Total Time , placebo , duloxetine 60âmg ,0,
edin,3701,4839526,No significant difference,"Trail Making Test B Total Time (Î â9.67, 95% CI: â15.38, â3.96; P<0.001; ANCOVA, OC) was significantly improved with vortioxetine compared with placebo. None of the other secondary end points of cognitive function improved significantly with vortioxetine. No significant benefit was found with duloxetine compared with placebo on any of the secondary measures of cognitive function.", Trail Making Test B Total Time , placebo , duloxetine 60âmg ,0,
edin,3744,3546023,Cannot tell based on the abstract,Natural killer cells were decreased; CD4+ cells and B cells were increased in smokers compared to nonsmokers but were unaffected with vitamin E supplementation except in the percentage of B cells which were increased in nonsmokers supplemented palmvitee compared to placebo, The percentage of B cells , baseline , 200âmg/day palmvitee smokers  ,0,
edin,3744,3546023,No significant difference,"The percentage of B cells in smokers was higher compared to nonsmokers (pâ<â0.0001) and also in S1 (pâ<â0.005), S2 (pâ<â0.0005) and S3 groups (pâ<â0.005) (Tableâ 2). After palmvitee supplementation, B cells percentage was significantly increased in nonsmokers at 24âweeks (pâ<â0.05) but not in the smokers (Tableâ 6).", The percentage of B cells , baseline , 200âmg/day palmvitee smokers  ,0,
edin,3670,4185107,No significant difference,The reoperation rate was similar in both groups: 12.8 versus 9.4Â %; pÂ =Â 0.628; RR 1.359; (95Â % CI 0.575â3.212)., The reoperation rate , control , gentamicin collagen implant (GCI) ,0,
edin,3749,3529678,Cannot tell based on the abstract,," Vegetables, serves/day ", baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3749,3529678,Significantly increased,"Further, from baseline to 6 weeks, participants were more likely to meet the Australian recommendations for moderate-vigorous physical activity (27.3 to 59.1%), red meat (86.4 to 90.9%), fruit (68.2 to 81.8%),vegetables (4.6 to 18.2%), alcohol (59.1 to 72.7%), BMI (31.8 to 45.5%) and waist circumference (18.2 to 27.3%; Table 3).,<td align=""left"" valign=""bottom"">âVegetables, serves/day<hr></td><td align=""char"" char=""("" valign=""bottom"">2.5 (1.3)<hr></td><td align=""char"" char=""("" valign=""bottom"">3.5 (1.1)<hr></td><td align=""char"" char=""("" valign=""bottom"">1.0 (0.4 1.6)<hr></td><td align=""char"" char=""."" valign=""bottom"">&lt;0.01<hr></td>"," Vegetables, serves/day ", baseline , telephone-delivered multiple health behaviour change intervention ,0,
edin,3688,4871571,No significant difference,The vaccine was safe and well tolerated except for one episode of asymptomatic hypoglycaemia that was classified as severe adverse event., adverse events , baseline , two CN54rgp140/GLA-AF immunizations ,0,
edin,3738,4115605,Cannot tell based on the abstract,, systolic BP while supine , placebo , droxidopa dose optimization (100â600 mg 3 times daily) ,0,
edin,3738,4115605,Significantly increased,"From randomization to end of study, systolic BP while supine increased by 7.6 (19.2) mm Hg in droxidopa recipients vs 0.8 (14.5) in placebo recipients, a difference of 6.8 mm Hg (95% CI 1.53â12.07; p < 0.001), to mean (SD) values of 133.7 (23.3) and 125.9 (22.2) mm Hg, respectively.", systolic BP while supine , placebo , droxidopa dose optimization (100â600 mg 3 times daily) ,0,
edin,3720,4776542,Significantly decreased,"The incidence of PONV was significantly smaller in group MO than group M and group O,", postoperative nausea and vomiting (PONV) ," midazolam 0.75 mg/kg in group M, ondansetron 4 mg in group O,  and saline 0.90% in group S ", midazolam 0.75 mg/kg and ondansetron 4 mg in group MO ,0,
edin,3960,4440033,Cannot tell based on the abstract,, Serum 25-OHD after 12 weeks , Calcium  , Vitamin D + Calcium ,0,
edin,3960,4440033,No significant difference,"<td align=""center"" colspan=""1"" rowspan=""1"">Vitamin D + C</td><td align=""center"" colspan=""1"" rowspan=""1"">15.80 (9.37)</td><td align=""center"" colspan=""1"" rowspan=""1"">22.90 (13.85)</td><td align=""center"" colspan=""1"" rowspan=""1"">25.10 (35.57)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.001</td>", Serum 25-OHD after 12 weeks , Calcium  , Vitamin D + Calcium ,0,
edin,3856,4141382,Cannot tell based on the abstract,, Dipyrone needed , Caudal Sufentanil  , Caudal Sufentanil + neostigmine  ,0,
edin,3856,4141382,No significant difference,"The number of postoperative doses of dipyrone in 24 h, administered at the discretion of a trained nurse, was similar among the patients in Group IVSu, Group CSu, and Group CSuAdr (P > 0.05) [Table 3].", Dipyrone needed , Caudal Sufentanil  , Caudal Sufentanil + neostigmine  ,0,
edin,3979,4260664,Cannot tell based on the abstract,, Baseline characteristics , Treatment-as-usual , Internet-based cognitive behavior therapy ,0,
edin,3979,4260664,No significant difference,A comparison of baseline scores revealed no significant difference between treatment groups and the randomization as expected produced a similar distribution across conditions (see Table 1)., Baseline characteristics , Treatment-as-usual , Internet-based cognitive behavior therapy ,0,
edin,3981,3376478,Cannot tell based on the abstract,, Association of parental beliefs with change in parental monitoring , Control group , Parental monitoring ,0,
edin,3981,3376478,No significant difference,"Although there were several differences in demographic predictors of intercepts, compared to the intervention group model, the model for parent-reported open communication within the control group indicated nearly identical patterns of associations between parenting beliefs and open communication intercepts and slopes", Association of parental beliefs with change in parental monitoring , Control group , Parental monitoring ,0,
edin,3865,4280721,Cannot tell based on the abstract,, severity of pain in primary dysmenorrhea , mefenamic acid , extracts of vitagnus or fennelin ,0,
edin,3865,4280721,No significant difference,"In this study, pain intensity was evaluated within a cycle (zero cycle) before treatment with oral drops, mefenamic acid, and placebo drops, and the mean pain intensity of the four groups was not significantly different at the end of the cycle;", severity of pain in primary dysmenorrhea , mefenamic acid , extracts of vitagnus or fennelin ,0,
edin,4000,5504600,No significant difference,Mean maximum pain intensity during exercise in the first 24Â h after surgery was 3.8âÂ±â1.9 (tapentadol) and 3.8âÂ±â2.1 (oxycodone/naloxone). Statistically tapentadol was non-inferior but not superior to oxycodone/naloxone, Pain intensity during exercise in the first 24h of post operatory , extended-release oxycodone/naloxone , perioperative oral extended-release tapentadol ,0,
edin,3802,3890270,Cannot tell based on the abstract,, Reported calorie intake , Baseline (No exercise) , Aerobic interval training  ,0,
edin,3802,3890270,No significant difference,"Although there was no significant change in body mass and only a small non-significant fall in self-reported calorie intake, waist circumference fell by 3â4 cm and total body fat fell by an amount equivalent to a 1.0 kg loss in fat mass.", Reported calorie intake , Baseline (No exercise) , Aerobic interval training  ,0,
edin,3884,5564101,No significant difference,"However, the extent of pulpal anesthesia, surgical duration, and duration of soft tissue anesthesia were not significantly different.", the duration of anesthesia ," 2% lidocaine along with 1:100,000 epinephrine "," 4% lidocaine along with 1:100,000 epinephrine ",0,
edin,3973,5307611,Cannot tell based on the abstract,, Mean scores of the constructs of the Protection Motivation Theory at baseline , Control group , Theory-based educational intervention ,0,
edin,3973,5307611,Significantly increased,"Before the intervention, no significant difference in mean (SD) scores of the constructs of the Protection Motivation Theory was found between the two groups (p>0.05). However, there was a significant difference between mean (SD) scores of all the variables in the two groups after the intervention (p<0.05) (Table 2).,<td colspan=""1"" rowspan=""1"">
</td><td colspan=""1"" rowspan=""1"">
P-value
</td><td colspan=""1"" rowspan=""1"">0.754 </td><td colspan=""1"" rowspan=""1"">&lt;0.001 </td>", Mean scores of the constructs of the Protection Motivation Theory at baseline , Control group , Theory-based educational intervention ,0,
edin,3872,4683729,Cannot tell based on the abstract,, effectiveness of preventive interventions on Latinos with mental disorders , no prevention , universal prevention ,0,
edin,3872,4683729,Invalid Prompt,, effectiveness of preventive interventions on Latinos with mental disorders , no prevention , universal prevention ,1," This article doesn't include the results section, and there is not enough information in the abstract. "
edin,3815,5153686,Cannot tell based on the abstract,, Opioid usage , Ropivacaine (0.5%) 20ml , Ropivacaine (0.33%) 30ml ,0,
edin,3815,5153686,Significantly decreased,"Total postoperative opioid use in group A was slightly higher. Group B used 26Â mg less morphine than group A (â26.1, â75.9 to 23.8), while group C used 23Â mg less than group A (â22.7, â74.72 to 29.34).", Opioid usage , Ropivacaine (0.5%) 20ml , Ropivacaine (0.33%) 30ml ,0,
edin,3878,4357072,Significantly decreased,"Subjects in both the groups showed significant improvement in symptom scores; however, the overall treatment response was higher in the pimecrolimus group compared with the triamcinolone acetonide group.", improvement in symptom scores , triamcinolone acetonide oral paste 0.1% , topical pimecrolimus cream 1% ,0,
edin,3936,4960789,Cannot tell based on the abstract,, Peripheral intravenous catheter failure rates per 1000 hours , Flush frequency every 6 hours , Flush frequency every 24 hours ,0,
edin,3936,4960789,No significant difference,"The overall PIVC failure rate was 46Â % or 6.13/1000 device hours, with occlusion and phlebitis the most common reasons for PIVC failure.,The incidence rate of PIVC failure in patients assigned to 24Â hour flushing was 5.1 per 1000Â hours compared with 7.3 per 1000Â hours in those assigned to 6Â hour flushing (pâ=â0.054, log-rank, TableÂ 2 and Fig.Â 2).", Peripheral intravenous catheter failure rates per 1000 hours , Flush frequency every 6 hours , Flush frequency every 24 hours ,0,
edin,3889,5797014,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""middle""><bold>CA72-4</bold></td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""middle""></td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""middle""></td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""middle""></td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""middle""></td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""middle""></td>", cancer specific survival ," CEA, CA19-9 and CA72-4 alone ", three-tumor marker classifier ,0,
edin,3860,3383212,Cannot tell based on the abstract,, Adverse reactions , Generic desogestrel  , Brand-name desogestrel  ,0,
edin,3860,3383212,No significant difference,"No serious adverse events occurred during the trial.,A total of 59 side-effects, in 29 women, were observed (including the analytic alterations) and these occurred. Events were recorded in 28 of the subjects with the test formulation and 31 with the reference formulation.", Adverse reactions , Generic desogestrel  , Brand-name desogestrel  ,0,
edin,3935,4960789,No significant difference,"PIVC failure rates per 1000Â hours were not significantly different for the volume intervention (4.84 [3Â mL] versus 7.44 [10Â mL], pâ=â0.06, log-rank). PIVC failure rates per 1000Â hours were also not significantly different for the frequency intervention (5.06 [24Â hour] versus 7.34 [6Â hour], pâ=â0.05, log-rank).", Peripheral intravenous catheter failure rates per 1000 hours , 0.9&amp;nbsp;% sodium chloride 3&amp;nbsp;mL flush , 0.9&amp;nbsp;% sodium chloride 10&amp;nbsp;mL flush ,0,
edin,3920,4697245,Cannot tell based on the abstract,, Changes in diastolic blood pressure 1 minute after induction of anaesthesia , Placebo , Alfentanil ,0,
edin,3920,4697245,Significantly increased,The mean diastolic blood pressure showed significant statistical differences between the two groups only 1 min after induction of anaesthesia (P = 0.04) and 1 min after endotracheal intubation (P = 0.00) [Figure 2]., Changes in diastolic blood pressure 1 minute after induction of anaesthesia , Placebo , Alfentanil ,0,
edin,3991,5486467,Significantly increased,The change in serum phosphorus level was significantly greater in each PA21 group than in the placebo group (analysis of covariance: PÂ <Â 0.001 for all groups)., Time course of mean serum phosphorus levels , placebo , PA21 ,0,
edin,3921,4697245,Significantly decreased,"Changes in diastolic blood pressure were significantly less in alfentanil group, 1 min after induction of anaesthesia and 1 min after endotracheal intubation.", Changes in diastolic blood pressure 1 minute after endotracheal extubation , Placebo , Alfentanil ,0,
edin,3997,5504600,No significant difference,"Vomiting on day 1 occurred in 11%, constipation in 35% of the tapentadol patients and in 16% and 30% of the oxycodone/naloxone patients (pâ=â0.60 and 0.33), respectively.", Incidence of constipation , extended-release oxycodone/naloxone , perioperative oral extended-release tapentadol ,0,
edin,3842,3160381,Cannot tell based on the abstract,, Vital capacity (after 12 months) , Placebo , Pirfenidone (high-dose)  ,0,
edin,3842,3160381,No significant difference,"In the placebo group, a â¥ 5% decline in VC at month 3 was still present at month 12 at highly rate (positive predictive value; 86.1% (31/36)) and no decline at month 3 was stable at month 12 at a rate of about 50% (negative predictive value; 50.8% (34/67)). On the other hand, in the treated (high- and low-dose pirfenidone) groups, decline at month 3 was still highly present (positive predictive value; 87.1% (27/31), nearly equal to one in the placebo group), and no decline at month 3 was also still stable at month 12 in relatively highly rate (negative predictive value; 71.7% (91/127) (Table 1 ). To put it briefly, the positive predictive values for pirfenidone and placebo groups were 87.1% and 86.1% respectively, and the difference was not significant.", Vital capacity (after 12 months) , Placebo , Pirfenidone (high-dose)  ,0,
edin,3990,5486467,Cannot tell based on the abstract,, Cumulative achievement rates of target serum phosphorus levels , placebo , PA21 ,0,
edin,3990,5486467,Significantly increased,"The cumulative achievement rates for target serum phosphorus level (â¤6Â mg/dL) at each time-point are shown in Fig.Â 4. The cumulative achievement rates were significantly higher in all the PA21 groups than in the placebo group (all PÂ <Â 0.001, Fisherâs exact test).Fig.Â 4", Cumulative achievement rates of target serum phosphorus levels , placebo , PA21 ,0,
edin,3862,3383212,Cannot tell based on the abstract,, T max , Generic desogestrel  , Brand-name desogestrel  ,0,
edin,3862,3383212,Invalid Prompt,, T max , Generic desogestrel  , Brand-name desogestrel  ,1, I wasn't able to find T max anywhere in the article
edin,3995,3972946,Significantly decreased,Total analgesic requirements on postoperative 1st and 24th hours in Group P were lower than in Group C., Total analgesic requirements on postoperative 1st and 24th hours , Conventional Postoperative Epidural Analgesia (Group C) , Preemptive Thoracic Epidural Analgesia (Group P) ,0,
edin,3785,3432828,Cannot tell based on the abstract,, Equol concentrations , Isoflavone diet (GI) , Isoflavone + Fructooligosaccharides diet (GIF) ,0,
edin,3785,3432828,Significantly increased,"Concentrations of equol, a metabolite of daidzein, were significantly higher in rats fed the GIF diet than in those fed GI diet (Fig.Â 2C; p<0.05).", Equol concentrations , Isoflavone diet (GI) , Isoflavone + Fructooligosaccharides diet (GIF) ,0,
edin,3853,4141382,Cannot tell based on the abstract,, Anesthetics during surgery , Caudal Sufentanil + Adrenaline , Caudal Sufentanil + neostigmine ,0,
edin,3853,4141382,Significantly decreased,"The isoflurane consumption (ml/kg/h) was similar among the patients from Group IVSu, Group CSuNeo, and Group CSuNeoAdr (P > 0.05). Their intraoperative anesthetic consumption was lesser when compared to patients who received caudal sufentanil alone or in combination with adrenaline (Group CSu = Group CSuAdr) (P < 0.02) [Table 3].", Anesthetics during surgery , Caudal Sufentanil + Adrenaline , Caudal Sufentanil + neostigmine ,0,
edin,3986,3738485,Significantly increased,"Within each group, HIV viral load significantly reduced at the end of the study (P < 0.001 and P = 0.04 for spirulina and soya beans groups respectively). Between the groups, the viral load was similar at baseline but significantly reduced in the spirulina group at the end of the study (P = 0.02).", Decrease in HIV viral load , Soya Beans , Spirulina Platensis ,0,
edin,3940,5560591,Significantly decreased,"Similarly, total morphine requirement was significantly lower in the EA group with the value of 21.38 (SD = 14.38) mg compared to the control group with the value of 33.94 (SD = 20.24) mg within 24 hours postoperatively.", Total need of morphine  , Control group , 2 Hertz EA stimulation ,0,
edin,3855,4141382,Cannot tell based on the abstract,, Time needed for rescue analgesics  , Caudal Sufentanil  , Caudal Sufentanil + neostigmine + Adrenaline ,0,
edin,3855,4141382,Significantly increased,"he time to first administration of rescue analgesics for patients who received caudal sufentanil plus neostigmine (Group CSuNeo and Group CSuNeoAdr) was similar, but higher when compared to the other groups (10-11 h, P < 0.05) [Table 3].", Time needed for rescue analgesics  , Caudal Sufentanil  , Caudal Sufentanil + neostigmine + Adrenaline ,0,
edin,3919,3914313,No significant difference,No severe adverse effects were reported., Severe adverse effects , Placebo , Shensong Yangxin ,0,
edin,3822,3952602,Cannot tell based on the abstract,, Viral load &amp;lt;200 copies/mL , Abacavir , Nevirapine ,0,
edin,3822,3952602,No significant difference,"The viral load in the majority of participants with suppression was <200 copies/mL in both arms (91% and 95% of those <1000 copies/mL in the ABC and NVP arms, respectively).", Viral load &amp;lt;200 copies/mL , Abacavir , Nevirapine ,0,
edin,3905,3694465,Significantly decreased,"None in the intervention group placed their hands in the abdominal region, compared to 5/18 in the control group (pâ=â0.045).", Placement of hands in the abdominal region , General instructions , Specific instructions ,0,
edin,3945,5593668,Cannot tell based on the abstract,, Peritoneal recurrence related to PECAM1 expression , Surgery alone , Adjuvant S-1 therapy after sugery ,0,
edin,3945,5593668,No significant difference,PECAM1 showed a significant correlation to peritoneal recurrence in both surgery alone (FDR P = 0.005) and S-1 treated patients (FDR P = 0.031)., Peritoneal recurrence related to PECAM1 expression , Surgery alone , Adjuvant S-1 therapy after sugery ,0,
edin,3845,3160381,Cannot tell based on the abstract,, Vital capacity (after 3 months) , Placebo , Pirfenidone (low-dose)  ,0,
edin,3845,3160381,No significant difference,"n the placebo group, a â¥ 5% decline in VC at month 3 was still present at month 12 at highly rate (positive predictive value; 86.1% (31/36)) and no decline at month 3 was stable at month 12 at a rate of about 50% (negative predictive value; 50.8% (34/67)). On the other hand, in the treated (high- and low-dose pirfenidone) groups, decline at month 3 was still highly present (positive predictive value; 87.1% (27/31), nearly equal to one in the placebo group), and no decline at month 3 was also still stable at month 12 in relatively highly rate (negative predictive value; 71.7% (91/127) (Table 1 ). To put it briefly, the positive predictive values for pirfenidone and placebo groups were 87.1% and 86.1% respectively, and the difference was not significant.", Vital capacity (after 3 months) , Placebo , Pirfenidone (low-dose)  ,0,
edin,3927,5220753,No significant difference,"he overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P > 0.05 considered significant for all comparisons.", Target lesion revascularization and target vessel revascularization , Control , Eptifibatide ,0,
edin,3875,4683729,Cannot tell based on the abstract,, effectiveness of preventive interventions on Latinos with mental disorders , enhanced psychoeducation , the newly refined HOLA ,0,
edin,3875,4683729,Invalid Prompt,, effectiveness of preventive interventions on Latinos with mental disorders , enhanced psychoeducation , the newly refined HOLA ,1, There is no results section of the article. 
edin,3914,5103331,Cannot tell based on the abstract,, Improvement in visual analogue scale scores after 8 weeks , Sham catgut implantation group , Active catgut implantation group ,0,
edin,3914,5103331,Significantly increased,"For the analysis based on VAS scores, the difference between the treatment group and the sham-controlled group was not significant until 8Â weeks after the 2-week treatment regimen (tâ=ââ2.424, Pâ=â0.017; TableÂ 4).,<td>Treatment group (<italic>n</italic>â=â64)</td><td>7.036âÂ±â1.839</td><td>5.302âÂ±â1.86</td><td>3.75âÂ±â1.93</td><td>83.933âÂ±â10.076</td><td>78.67âÂ±â8.57</td><td>73.73âÂ±â10.48</td>,<td>Sham-controlled group (<italic>n</italic>â=â64)</td><td>6.648âÂ±â1.379</td><td>5.204âÂ±â1.72</td><td>4.535âÂ±â1.724</td><td>88.801âÂ±â8.872</td><td>84.471âÂ±â6.883</td><td>79.807âÂ±â6.221</td>,<td>Statistical analysis</td><td>Uâ=â1739.500</td><td>
<italic>t</italic> =0.324</td><td>
<italic>t</italic>â=ââ2.424</td><td>tâ=ââ1.405</td><td>
<italic>t</italic>â=ââ2.045</td><td>
<italic>t</italic>â=ââ2.246</td>,<td>
<italic>P</italic> value</td><td>0.136</td><td>0.751</td><td>0.017</td><td>0.171</td><td>0.050</td><td>0.033</td>", Improvement in visual analogue scale scores after 8 weeks , Sham catgut implantation group , Active catgut implantation group ,0,
edin,3980,3376478,No significant difference,Similar effects were found in both the intervention and control group models regarding open communication., Open communication , Control group , Parental monitoring ,0,
edin,3906,4231047,Significantly increased,"Minimal mean hepatic threshold dose 6 weeks after radiotherapy (primary endpoint) was significantly higher in the study treatment-group compared with the control (19.1 Gy versus 14.6 Gy, pâ=â0.011).", Minimal mean hepatic threshold dose 6 weeks after radiotherapy , No medication ," Pentoxifylline, ursodeoxycholic acid, and low-dose low molecular weight heparin. ",0,
edin,3868,3637600,Cannot tell based on the abstract,, Chronic diseases prevention and management , Preliminary clinical evaluation , Practical training ,0,
edin,3868,3637600,Invalid Prompt,, Chronic diseases prevention and management , Preliminary clinical evaluation , Practical training ,1, There is no results section
edin,3911,5103331,Cannot tell based on the abstract,, Improvement of Rhinoconjunctivitis Quality of Life Questionnaire score after 8 weeks , Sham catgut implantation group , Active catgut implantation group ,0,
edin,3911,5103331,Significantly decreased,"However, the RQLQ scores between the two groups after 2Â weeks of treatment completion significantly differed (tâ=ââ2.045, Pâ=â0.05), and this difference could be observed until the end of the 8-week follow-up (tâ=ââ2.246, Pâ=â0.033).Table 4", Improvement of Rhinoconjunctivitis Quality of Life Questionnaire score after 8 weeks , Sham catgut implantation group , Active catgut implantation group ,0,
edin,3903,4709811,Cannot tell based on the abstract,, Vaginal pH , Conjugated estrogen (Premarin) , Hyaluronic acid ,0,
edin,3903,4709811,No significant difference,"Also, studies showed that comparing the results of intra-group (before and after treatment), the amount of PH of both groups reduced, moving towards acidity (P<0.001) and no significant difference was obtained when the results of both groups were compared (P>0.05) (table 4).", Vaginal pH , Conjugated estrogen (Premarin) , Hyaluronic acid ,0,
edin,3892,3984270,Cannot tell based on the abstract,, short-term graft function , control group , Î±-melanocyte stimulating hormone (Î±-MSH) ,0,
edin,3892,3984270,No significant difference,"Thus, in a porcine experimental model Î±-MSH did not reduce renal inflammation and did not improve short-term graft function following DBD kidney transplantation.", short-term graft function , control group , Î±-melanocyte stimulating hormone (Î±-MSH) ,0,
edin,3917,3914313,Significantly increased,"Results showed that the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group were all significantly higher than those in the control group at the end of treatment (P < 0.05 or 0.01, resp.).", Lowest heart rate  , Placebo , Shensong Yangxin ,0,
edin,3812,3864139,Cannot tell based on the abstract,, Epistaxis intensity(outside OR) , Endotracheal tube , Laryngeal mask  ,0,
edin,3812,3864139,Significantly increased,"Thus, outside the OR, the incidence of the first episode of epistaxis in the ETT group was lower than that in the LMA group (RD: â26.5%; 95% CI: â42.2% to â10.7%; P < 0.001; Table 3).", Epistaxis intensity(outside OR) , Endotracheal tube , Laryngeal mask  ,0,
edin,3902,4709811,Significantly increased,"Improvement in urinary incontinence, dryness, maturation index (P<0.05) and composite score of vaginal symptoms (P<0.001) in the hyaluronic acid group was better than those in the Premarin group.", Improvement in the composite score of vaginal symptoms , Conjugated estrogen (Premarin) , Hyaluronic acid ,0,
edin,3887,5564101,Cannot tell based on the abstract,, The number of cases requiring additional anesthetic ," 4% lidocaine along with 1:100,000 epinephrine "," 2% lidocaine along with 1:100,000 epinephrine ",0,
edin,3887,5564101,Significantly increased,The proportion of cases requiring additional anesthetic was significantly greater in the 2% lidocaine group than in the 4% group (26/36 vs. 16/31; P = 0.006)., The number of cases requiring additional anesthetic ," 4% lidocaine along with 1:100,000 epinephrine "," 2% lidocaine along with 1:100,000 epinephrine ",0,
edin,3999,5504600,No significant difference,"Vomiting on day 1 occurred in 11%, constipation in 35% of the tapentadol patients and in 16% and 30% of the oxycodone/naloxone patients (pâ=â0.60 and 0.33), respectively.", Incidence of Vomiting on day 1 , extended-release oxycodone/naloxone , perioperative oral extended-release tapentadol ,0,
edin,3794,5550381,Significantly decreased,"BVL was lower for teriflunomide 14 mg vs placebo at year 1 (36.9% relative reduction, p = 0.0001)", Loss of Brain volume , Placebo , Teriflunomide 14 mg (1 year) + presence of on-study disability worsening ,0,
edin,3925,5220753,No significant difference,"The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P > 0.05 considered significant for all comparisons.", Mortality rate , Control , Eptifibatide ,0,
edin,3969,4412792,Cannot tell based on the abstract,, Amount of PAX2+/p-ERK+-positive cells , Hydralazine , Enalapril ,0,
edin,3969,4412792,Significantly increased,"The number of double-positive PAX2+/p-ERK+ cells per Bowmanâs capsule cross section increased along Bowmanâs capsule in untreated (0.86Â±0.13 vs. 0, p < 0.001, normal) and in hydralazine-treated mice with FSGS (0.75Â±0.13, p < 0.001 vs. normal) at day 7. Enalapril further increased the number of PAX2+/p-ERK+-positive cells approximately two-fold at day 7 (1.40Â±0.16, p < 0.01 vs. hydralazine-treated FSGS mice) (Figure 8(f)).", Amount of PAX2+/p-ERK+-positive cells , Hydralazine , Enalapril ,0,
edin,3807,3734718,Significantly decreased,"The HAART arm was characterized by significant improvements in CD4 cell count (154.4 cells/Î¼l/year, P<0.001) and reduction in plasma viral load within 3 to 6 months (-0.431+ 0.004 log10 IU/month, P<0.001).", Viral load , No treatment , Highly active antiretroviral treatment ,0,
edin,3786,3432828,Cannot tell based on the abstract,, Calcium absorption , Control diet (GC) , Fructooligosaccharides diet (GF) and Isoflavone + Fructooligosaccharides diet (GIF) ,0,
edin,3786,3432828,Significantly increased,"Absorption (%) of Ca appeared to decrease after GX; however, the absorption in rats fed the FOS diet (GF and GIF) was significantly higher than that in rats fed the control diet (GC) (p<0.05),", Calcium absorption , Control diet (GC) , Fructooligosaccharides diet (GF) and Isoflavone + Fructooligosaccharides diet (GIF) ,0,
edin,3937,4960789,No significant difference,"PIVC average dwell was 3.1Â days. PIVC failure rates per 1000Â hours were not significantly different for the volume intervention (4.84 [3Â mL] versus 7.44 [10Â mL], pâ=â0.06, log-rank). PIVC failure rates per 1000Â hours were also not significantly different for the frequency intervention (5.06 [24Â hour] versus 7.34 [6Â hour], pâ=â0.05, log-rank).", Peripheral intravenous catheter failure rates per 1000 hours , Flush volume , Flush frequency ,0,
edin,3984,3738485,No significant difference,Serum albumin level did not increase significantly within groups (P < 0.90 vs. P < 0.82) with no difference between groups (P = 0.39)., Increase in serum albumin levels , Soya Beans , Spirulina Platensis ,0,
edin,3965,4412792,Significantly decreased,Both glomerulosclerosis and urinary albumin-to-creatinine ratio were less in the ACE-inhibition arm at day 14., Glomerulosclerosis at day 14 , Hydralazine , Enalapril ,0,
edin,3867,3637600,Cannot tell based on the abstract,, Chronic diseases prevention and management , Preliminary clinical evaluation , patient-centered care ,0,
edin,3867,3637600,Invalid Prompt,, Chronic diseases prevention and management , Preliminary clinical evaluation , patient-centered care ,1, There is no results section 
edin,3846,4402460,Cannot tell based on the abstract,, IL-8. , No treatment , Bevacizumab (1 dose) ,0,
edin,3846,4402460,No significant difference,"Among those nine genes (FLT1, IL-8, PDGFA, CTGF, ROBO4, ENPEP, THBS1, ANGPT2 and CYR61), only for PDGFA, a relevant difference was found in bevacizumab-induced changes in expression between patients with and without a pCR (P=0.1).,Six circulating markers (PDGF-AA, PDGF-BB, thrombospondin-1, IL-8, angiopoietin-2 and CYR61), selected based on the microarray results and literature, were quantified by ELISA. None of these markers showed significant changes in circulating levels between T0 and T1.", IL-8. , No treatment , Bevacizumab (1 dose) ,0,
edin,3758,3395326,No significant difference,"Gender, BMI, ASA score, total and hidden blood losses, calculated blood loss, preop PLT, PT, PTT, and INR were similar between groups.", hidden blood loss , control , epoetin-Î± ,0,
edin,3930,4793655,Cannot tell based on the abstract,, Sway in the A/P direction , Repulsive cuing , Attractive cuing ,0,
edin,3930,4793655,Significantly increased,Sway in the A/P direction (A/P RMS) was significantly smaller (~1Â°) for repulsive versus attractive cues (pâ<â0.001);, Sway in the A/P direction , Repulsive cuing , Attractive cuing ,0,
edin,3837,5832511,Cannot tell based on the abstract,, Iron levels (at 2 weeks) , Lipid based nutrients , ARV ,0,
edin,3837,5832511,No significant difference,"For iron, no interactions by treatment (ARV and LNS) or with treatment and TP and/or FTP were significant indicating that the effects of ARV and LNS at 2, 6, and 24Â weeks were not different from each other (Table S2).", Iron levels (at 2 weeks) , Lipid based nutrients , ARV ,0,
edin,3972,2748711,Cannot tell based on the abstract,, Matrix metalloproteinases in cerebrospinal fluid in late treatment , Placebo , Dexamethasone ,0,
edin,3972,2748711,No significant difference,MMP-9 concentrations at later time points were not statistically different between the two groups., Matrix metalloproteinases in cerebrospinal fluid in late treatment , Placebo , Dexamethasone ,0,
edin,3816,5153686,Cannot tell based on the abstract,, Opioid usage , Ropivacaine (0.5%) 20ml , Ropivacaine (0.25%) 40ml ,0,
edin,3816,5153686,Significantly decreased,"Total postoperative opioid use in group A was slightly higher. Group B used 26Â mg less morphine than group A (â26.1, â75.9 to 23.8), while group C used 23Â mg less than group A (â22.7, â74.72 to 29.34).", Opioid usage , Ropivacaine (0.5%) 20ml , Ropivacaine (0.25%) 40ml ,0,
edin,3994,3972946,Significantly decreased,Patient's demand and pump's delivery count for bolus dose in Group P were lower than in Group C in all measurement times., Patient's demand and pump's delivery count for bolus dose , Conventional Postoperative Epidural Analgesia (Group C) , Preemptive Thoracic Epidural Analgesia (Group P) ,0,
edin,3916,3914313,Significantly increased,"Compared with pretreatment, the average heart rate, the fastest heart rate, and the lowest heart rate in the trial group all increased significantly after treatment (P < 0.05 or 0.01, resp.).", Fastest heart rate  , Placebo , Shensong Yangxin ,0,
edin,3821,3952602,Cannot tell based on the abstract,, Resuppression  , Abacavir , Nevirapine ,0,
edin,3821,3952602,No significant difference,"Nineteen of 70 (27%) of individuals (12/46 ABC vs 7/24 NVP; P = .82) with viral load >1000 copies/mL at week 48 experienced resuppression by week 96, indicating issues with adherence.", Resuppression  , Abacavir , Nevirapine ,0,
edin,3928,5220753,No significant difference,"The overall rates of major adverse events such as mortality, Stent thrombosis (ST), Myocardial Infarction (MI), target lesion revascularization (TLR), target vessel revascularization (TVR), CVA, and emergency CABG within 24 h after stent implantation were low and comparable between the two groups; P > 0.05 considered significant for all comparisons.", Emergency CABG , Control , Eptifibatide ,0,
edin,3804,3734718,Cannot tell based on the abstract,, CD4 reduction , No treatment , Polyherbal formulation ,0,
edin,3804,3734718,Significantly increased,"The slow kinetics of the CD4 cell reduction in the PHF arm, 14.3 Â± 6.1 cells/Î¼l lost per year (R2 = 0.029, P=0.021), contrasted that of the HAART and the difference between the two arms was statistically significant at all the time points (P<0.001) subsequent to the baseline.", CD4 reduction , No treatment , Polyherbal formulation ,0,
edin,3880,4357072,No significant difference,"On intergroup comparison, there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18) and erythematous area (P = 0.07)", reduction in erythematous area , triamcinolone acetonide oral paste 0.1% , topical pimecrolimus cream 1% ,0,
edin,3876,4226329,Significantly increased,"The MPH-treated group reduced their ADHD symptoms during the trial (P = 0.011) and had a significantly higher proportion of drug-negative urines compared with the placebo group (P = 0.047),", decrease on attention deficit hyperactivity disorder symptoms , placebo , methylphenidate ,0,
edin,3863,4280721,Cannot tell based on the abstract,, severity of pain in primary dysmenorrhea , placebo , extracts of fennelin ,0,
edin,3863,4280721,No significant difference,"In this study, pain intensity was evaluated within a cycle (zero cycle) before treatment with oral drops, mefenamic acid, and placebo drops, and the mean pain intensity of the four groups was not significantly different at the end of the cycle", severity of pain in primary dysmenorrhea , placebo , extracts of fennelin ,0,
edin,3968,4412792,Cannot tell based on the abstract,, Decrease in blood pressure  , Hydralazine , Enalapril ,0,
edin,3968,4412792,No significant difference,"The decrease in systolic BP and diastolic BP was similar in FSGS mice treated with hydralazine and enalapril on day 4 (111/66 mmHg, enalapril; 118/75 mmHg, hydralazine, p > 0.05), day 6 (101/63 mmHg, enalapril; 114/77 mmHg, hydralazine, p > 0.05) and day 13 (90/58 mmHg, enalapril; 97/66 mmHg, hydralazine, p > 0.05). These data show a similar BP-lowering effect with hydralazine and enalapril in this FSGS model.", Decrease in blood pressure  , Hydralazine , Enalapril ,0,
edin,4099,5440738,No significant difference,"Patients assigned to the text messaging adjunct also generally attended more sessions (median=6 sessions) during this period than patients assigned to the control condition (median =2.5 sessions), but the effect was not significant (Wilcoxon-Mann-Whitney z=â1.65, P=.10).", attending of sessions , standard group CBT for depression standard group ,  CBT for depression  with the addition of a text messaging adjunct ,0,
edin,4093,5137281,Cannot tell based on the abstract,, global CBF , placebo , pramipexole (PX) ,0,
edin,4093,5137281,No significant difference,"If global CBF was included as confounding variable in the analysis, we found further decreases in CBF in the left fusiform gyrus, right cuneus, and superior temporal gyrus (global CBF was not significantly different between the treatments, all P>.5).", global CBF , placebo , pramipexole (PX) ,0,
edin,4096,5137281,Cannot tell based on the abstract,," CBF  in the bilateral caudate nuclei, left brainstem (including substantia nigra), and the left SMA and middle frontal gyrus ", placebo , pramipexole (PX) ,0,
edin,4096,5137281,Significantly increased,"PX increased CBF relative to placebo in the bilateral caudate nuclei, left brainstem (including substantia nigra, 7% CBF change), and the left SMA and middle frontal gyrus (BA 11) if global CBF was included in the GLM."," CBF  in the bilateral caudate nuclei, left brainstem (including substantia nigra), and the left SMA and middle frontal gyrus ", placebo , pramipexole (PX) ,0,
edin,4011,5153622,Cannot tell based on the abstract,,  International Prostate Symptom Score (IPSS-T (total) ,  placebo  , onabotulinumtoxinA (100âU) ,0,
edin,4011,5153622,Significantly increased,"Interestingly, there was a significantly greater reduction in IPSS-T in the placebo group than in the onabotulinumtoxinA group (pâ=â0.026).",  International Prostate Symptom Score (IPSS-T (total) ,  placebo  , onabotulinumtoxinA (100âU) ,0,
edin,4100,5440738,Significantly increased,"Intent-to-treat analyses on therapy attendance during 16 sessions of weekly therapy found that patients assigned to the text messaging adjunct stayed in therapy significantly longer (median of 13.5 weeks before dropping out) than patients assigned to the control condition (median of 3 weeks before dropping out; Wilcoxon-Mann-Whitney z=â2.21, P=.03).", time staying in therapy , standard group CBT for depression standard group ,  CBT for depression  with the addition of a text messaging adjunct ,0,
edin,4013,5153622,Cannot tell based on the abstract,, maximum flow rate , baseline , onabotulinumtoxinA (100âU)  ,0,
edin,4013,5153622,Significantly increased,"Among the videourdynamic parameters measured, maximum flow rate and voiding efficiency were significantly elevated after treatment in both groups,", maximum flow rate , baseline , onabotulinumtoxinA (100âU)  ,0,
edin,4127,4093188,Significantly increased,"A comparison of half carcasses across the groups has shown no difference between the control group and the one with supplements, while the weight of half carcasses in the grazing group was smaller in comparison with groups C and S (p<0.001).", the weight of half carcasses ," G, outdoor with no supplement "," group C, indoor with no supplement; S, indoor with supplement, ",0,
edin,4083,4301837,Cannot tell based on the abstract,, 24-h urinary cortisol , placebo , LCI699 ,0,
edin,4083,4301837,Significantly decreased,"Significant reductions in 24-h urinary cortisol (34â42%) were observed following single LCI699 doses of 30, 100 or 200Â mg (vs 33% increase with placebo relative to time-matched baseline; Pââ¤â0.001), but with no clear dose-dependence (results not shown).", 24-h urinary cortisol , placebo , LCI699 ,0,
edin,4012,5153622,Cannot tell based on the abstract,, detrusor pressure , baseline , onabotulinumtoxinA (100âU) ,0,
edin,4012,5153622,Significantly decreased,"Nevertheless, significant improvements in videourodynamic parameters including detrusor pressure (from 40.3âÂ±â23.0 to 31.6âÂ±â22.3 cmH2O), maximum flow rate (from 6.4âÂ±â5.4 to 11.1âÂ±â10.1âmL/s) and voided volume (from 119.9âÂ±â82.2 to 191.0âÂ±â140.1âmL) were only found in the onabotulinumtoxinA group.", detrusor pressure , baseline , onabotulinumtoxinA (100âU) ,0,
edin,4129,4093188,Cannot tell based on the abstract,, internal fat depot  -  kidney with pelvic fat , baseline ," G, outdoor with no supplement ",0,
edin,4129,4093188,Significantly decreased,"Grazing had a lesser effect on internal fat depot (kidney with pelvic fat; p<0.05) than on intermuscular (p<0.001) and on subcutaneous (p<0.001) fat, in keeping with the findings of other authors (KuÅºnicka, 2006; Joy et al., 2008; Carrasco et al., 2009b).", internal fat depot  -  kidney with pelvic fat , baseline ," G, outdoor with no supplement ",0,
edin,4102,5440738,No significant difference,"Both patients assigned to the text messaging adjunct (B=â.29, 95% CI â0.38 to â0.19, z=â5.80, P<.001) and patients assigned to the control conditions (B=â.20, 95% CI â0.32 to â0.07, z=â3.12, P=.002) experienced significant decreases in depressive symptom severity over the course of treatment; however, the conditions did not significantly differ in their degree of symptom reduction.", depressive symptom severity , baseline , standard group CBT for depression standard group ,0,
edin,4089,4301837,Cannot tell based on the abstract,, Levels of the cortisol precursor 11-deoxycortisol , placebo , eplerenon ,0,
edin,4089,4301837,Significantly increased,"Levels of the cortisol precursor 11-deoxycortisol increased with LCI699 at dosesââ¥â100Â mg (942% and 584% with 100Â mg and 200Â mg, respectively; Pâ<â0.001 vs placebo), likely due to off-target inhibition of 11-Î² hydroxylase (results not shown).", Levels of the cortisol precursor 11-deoxycortisol , placebo , eplerenon ,0,
edin,4054,5458653,Significantly decreased,"Vildagliptin did not significantly alter the mean plasma glucose level (175.5 Â± 54.4 mg/dL vs. 179.1 Â± 73.4 mg/dL) or HbA1c (8.01% vs. 8.02%) after 12 weeks. With alogliptin, mean plasma glucose increased from 175.4 Â± 50.9 mg/dL to 195.3 Â± 55.0 mg/dL after 12 weeks and HbA1c increased significantly from 8.0% to 8.3% (P < 0.05).,The reduction of HbA1c was significantly greater in the vildagliptin group than the alogliptin group (P = 0.008),", HbA1c , alogliptin (25 mg once daily) , vildagliptin (50 mg twice daily) for 12weeks ,0,
edin,3836,5832511,Cannot tell based on the abstract,, CD4 count , Lipid based nutrient , ARV ,0,
edin,3836,5832511,Significantly increased,Significant differences were only observed for the CD4 counts with higher counts for the groups that received ARV., CD4 count , Lipid based nutrient , ARV ,0,
edin,4111,5399146,Cannot tell based on the abstract,," circadian variation of F1+2, a marker of thrombin generation, and D-dimer, a marker of activated coagulation and fibrinolysis ", placebo for  tetraplegic patients , 2âmg of melatonin given 4 days for tetraplegic patients ,0,
edin,4111,5399146,No significant difference,"The circadian patterns of the F1+2, a marker of thrombin generation, and D-dimer, a marker of activated coagulation and fibrinolysis, were apparently similar (P>0.05) between the tetraplegic groups, that is, irrespective of whether they were given melatonin (Figures 2a and c)."," circadian variation of F1+2, a marker of thrombin generation, and D-dimer, a marker of activated coagulation and fibrinolysis ", placebo for  tetraplegic patients , 2âmg of melatonin given 4 days for tetraplegic patients ,0,
edin,4123,5846302,Significantly decreased,"Median time to hemostasis was 1.5 min with Verisetâ¢ hemostatic patch, compared to 3.0 min with TachoSilÂ® (p<0.0001).", Median time to hemostasis , TachoSilÂ® (control) , Verisetâ¢ hemostatic patch ,0,
edin,4010,5515187,Cannot tell based on the abstract,, systolic and diastolic BP , routine care from health-care center ," 6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring ",0,
edin,4010,5515187,Significantly decreased,"As shown in table 3, results show that there is a significant difference between systolic BP of intervention and control group overall (P = 0.045).

Trend of these changes is significant in two groups too (P < 0.001) so that systolic BP decrease as 7 mmHg in the intervention group, while this decrease is 3 mmHg in control group after 6 months (P < 0.001).,there is a significant difference in diastolic BP between the groups (P = 0.010) and follow-up time in the intervention group (P = 0.013).,After 6 months, there was a significant reduction in systolic (P < 0.001) and diastolic BP (P = 0.010) in the intervention group.", systolic and diastolic BP , routine care from health-care center ," 6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring ",0,
edin,4103,5440738,No significant difference,"Both patients assigned to the text messaging adjunct (B=â.29, 95% CI â0.38 to â0.19, z=â5.80, P<.001) and patients assigned to the control conditions (B=â.20, 95% CI â0.32 to â0.07, z=â3.12, P=.002) experienced significant decreases in depressive symptom severity over the course of treatment; however, the conditions did not significantly differ in their degree of symptom reduction.", the degree of symptom reduction , CBT for depression with the addition of a text messaging adjunct , standard group CBT for depression standard group ,0,
edin,4058,4755968,Cannot tell based on the abstract,, fatigue after the training session , virtual-reality (VR) balance training ," Biodex Balance System (BBS)  balance training,  ",0,
edin,4058,4755968,Significantly increased,There was a significant difference between the groups regarding the participantsâ sense of fatigue after the training session (p< 0.05) with higher fatigue reported by of the BBSG. T, fatigue after the training session , virtual-reality (VR) balance training ," Biodex Balance System (BBS)  balance training,  ",0,
edin,4077,3346068,Cannot tell based on the abstract,," mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied) ", bupivacaine HCl 150 mg group at day 8 , liposome bupivacaine 532 mg at day 8 ,0,
edin,4077,3346068,Significantly increased,"Statistically significant differences in favor of liposome bupivacaine were also observed in study 3, where mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied), were 9.2 in the liposome bupivacaine 532 mg group and 8.3 in the bupivacaine HCl 150 mg group (P = 0.045) at day 8, and in study 4 where mean ratings in the liposome bupivacaine 266 mg and bupivacaine HCl 75 mg groups were 7.4 and 6.0, respectively (P = 0.03) at 96 hours."," mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied) ", bupivacaine HCl 150 mg group at day 8 , liposome bupivacaine 532 mg at day 8 ,0,
edin,4047,2741450,Significantly decreased,"However, there was a significant decrease in systolic blood pressure in the pedometer group (112.8 Â± 2.44 mm Hg) compared to the control group (117.3 Â± 2.03 mm Hg) (p = 0.003).", Systolic blood pressure , baseline , record the number of steps on a daily basis for 12 weeks ,0,
edin,4035,5747102,Significantly decreased,"The ADAS-cog scores for AG group showed obvious decreases at T2 and â(T2-T0)when compared with DG group, and significant between-group differences were detected (all pÂ <â0.05).", The Assessment Scale-Cognitive (ADAS-cog) scores at 12-week follow-up period (T2) , donepezil hydrochloride once daily (5&amp;nbsp;mg/day for the first 4&amp;nbsp;weeks and 10&amp;nbsp;mg/day thereafter) , acupuncture three times per week ,0,
edin,4088,4301837,Cannot tell based on the abstract,, ACTH-stimulated aldosterone levels , placebo , eplerenon ,0,
edin,4088,4301837,Significantly decreased,"For ACTH-stimulated aldosterone levels (FigureÂ 7A), LCI699 0.5â3Â mg resulted in peak inhibition of 41â64% from baseline (Day â2) on Day 6 (vs 7% reduction with placebo; Pâ<â0.001).", ACTH-stimulated aldosterone levels , placebo , eplerenon ,0,
edin,4080,4369830,Cannot tell based on the abstract,, overall survival (OS)  in patients with metastatic colorectal cancer (mCRC) , placebo , Regorafenib (RE) ,0,
edin,4080,4369830,Significantly increased,"Treatment cycles consisted of 160Â mg of regorafenib (or matching placebo) once daily for three weeks on/one week off. The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HRâ=â0.77, pâ=â0.0052, median OS: 6.4Â months vs. 5.0Â months for the placebo group) in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies.", overall survival (OS)  in patients with metastatic colorectal cancer (mCRC) , placebo , Regorafenib (RE) ,0,
edin,4028,2887151,Cannot tell based on the abstract,," prothrombin time (PT),  Activated Partial Thromboplastin Time (APTT), activity, antithrombin (AT), platelet count, fibrinogen, thrombin-antithrombin complexes (TAT) complexes, or D-dimer levels "," 40, 50, 60 mg SC enoxaparin for a period of 24 hours ", 70 mg SC enoxaparin for a period of 24 hours ,0,
edin,4028,2887151,No significant difference,"No significant difference was found in the PT, aPTT, AT, platelet count, fibrinogen, TAT complexes, or D-dimer levels between the four groups."," prothrombin time (PT),  Activated Partial Thromboplastin Time (APTT), activity, antithrombin (AT), platelet count, fibrinogen, thrombin-antithrombin complexes (TAT) complexes, or D-dimer levels "," 40, 50, 60 mg SC enoxaparin for a period of 24 hours ", 70 mg SC enoxaparin for a period of 24 hours ,0,
edin,4106,4161265,Cannot tell based on the abstract,, Mean Pain intensity rating , saline , Acetylsalicylic acid ,0,
edin,4106,4161265,No significant difference,Mean Pain intensity rating (Â±SEM) for the ASA session was 61.7âÂ±â2.73 and for the saline session 62.1âÂ±â2.71. A paired t-test comparing the average pain ratings of both sessions failed to reach significance (pâ>â0.05)., Mean Pain intensity rating , saline , Acetylsalicylic acid ,0,
edin,4059,4755968,Cannot tell based on the abstract,, enjoyment attribute , virtual-reality (VR) balance training ," Biodex Balance System (BBS)  balance training,  ",0,
edin,4059,4755968,Significantly decreased,"There was a significant difference between the groups in the enjoyment attribute (p< 0.05), with higher enjoyment reported by the VRG.", enjoyment attribute , virtual-reality (VR) balance training ," Biodex Balance System (BBS)  balance training,  ",0,
edin,4084,4301837,Cannot tell based on the abstract,, Levels of the cortisol precursor 11-deoxycortisol , placebo , LCI699 ,0,
edin,4084,4301837,Cannot tell based on the abstract,, Levels of the cortisol precursor 11-deoxycortisol , placebo , LCI699 ,0,
edin,4084,4301837,Significantly increased,"Levels of the cortisol precursor 11-deoxycortisol increased with LCI699 at dosesââ¥â100Â mg (942% and 584% with 100Â mg and 200Â mg, respectively; Pâ<â0.001 vs placebo), likely due to off-target inhibition of 11-Î² hydroxylase (results not shown).", Levels of the cortisol precursor 11-deoxycortisol , placebo , LCI699 ,0,
edin,4073,3346068,Cannot tell based on the abstract,, the proportion of patients avoiding rescue medication through 72 hours after surgery ,  placebo , liposome bupivacaine 266 mg ,0,
edin,4073,3346068,Significantly decreased,"In study 9 (hemorrhoidectomy), the proportion of patients avoiding rescue medication through 72 hours after surgery was significantly lower in favor of liposome bupivacaine 266 mg (28% avoided use of rescue opioids) compared with placebo (10% avoided use of rescue opioids; P = 0.0007).", the proportion of patients avoiding rescue medication through 72 hours after surgery ,  placebo , liposome bupivacaine 266 mg ,0,
edin,4094,5137281,Cannot tell based on the abstract,, perfusion of the left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex , placebo , quetiapine (QT) ,0,
edin,4094,5137281,Significantly increased,QT increased perfusion relative to placebo in the left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex (4% CBF change)., perfusion of the left middle and right superior prefrontal cortex and left caudate nucleus and at the border of left posterior part of the putamen and insular cortex , placebo , quetiapine (QT) ,0,
edin,4116,5529983,Significantly decreased,"Compared with standard care alone, CTCA was associated with less marked improvements in physical limitation (difference â1.74 (95% CIs, â3.34 to â0.14), p=0.0329), angina frequency (difference â1.55 (â2.85 to â0.25), p=0.0198) and quality of life (difference â3.48 (â4.95 to â2.01), p<0.0001) at 6âmonths."," improvements in physical limitation , angina frequency  and quality of life ", standard care , standard care plus CT coronary angiography (CTCA) ,0,
edin,4076,3346068,Cannot tell based on the abstract,, Ã¢â¬ÅsatisfiedÃ¢â¬ï¿½ or Ã¢â¬Åextremely satisfiedÃ¢â¬ï¿½ with their postoperative analgesia at 72 hours after surgery ,  placebo , liposome bupivacaine 266 mg   ,0,
edin,4076,3346068,Significantly increased,"At 24 hours after surgery in this study, 95% of patients in the liposome bupivacaine 266 mg group were âsatisfiedâ or âextremely satisfiedâ with their postoperative analgesia compared with 72% in the placebo group (P = 0.0007). At 72 hours after surgery, percentages were 95% and 73%, respectively (P = 0.0007).", Ã¢â¬ÅsatisfiedÃ¢â¬ï¿½ or Ã¢â¬Åextremely satisfiedÃ¢â¬ï¿½ with their postoperative analgesia at 72 hours after surgery ,  placebo , liposome bupivacaine 266 mg   ,0,
edin,4046,2741450,Cannot tell based on the abstract,," waist, BMI, waist/hip ratio, HR or % body fat ", was not able to record their steps daily , record the number of steps on a daily basis for 12 weeks ,0,
edin,4046,2741450,No significant difference,"There was no significant differences within groups or between groups in waist, BMI, waist/hip ratio, HR or % body fat at 12 weeks."," waist, BMI, waist/hip ratio, HR or % body fat ", was not able to record their steps daily , record the number of steps on a daily basis for 12 weeks ,0,
edin,4039,5409664,Significantly decreased,"In plasma phospholipids the n-6/n-3 fatty acids ratio declined from 15.47 Â± 5.51 to 10.62 Â± 5.07 (p = 0.005), and from 18.15 Â± 5.04 to 13.50 Â± 4.81 (p = 0.005) in groups I and II respectively. T", phospholipids the n-6/n-3 fatty acids ratio , baseline ," 12 week supplementation with fish oil (group I), fish oil with primrose evening oil (group II) ",0,
edin,4105,4161265,Cannot tell based on the abstract,, activity of the secondary somatosensory cortex (SII) , saline , Acetylsalicylic acid ,0,
edin,4105,4161265,Significantly decreased,Increased BOLD signal intensity in the anterior cingulate cortex (left) and secondary somatosensory cortex (right) during nociceptive input (ammoniaâ>âair puffs) after saline treatment compared to ASA condition., activity of the secondary somatosensory cortex (SII) , saline , Acetylsalicylic acid ,0,
edin,4075,3346068,Cannot tell based on the abstract,, Ã¢â¬ÅsatisfiedÃ¢â¬ï¿½ or Ã¢â¬Åextremely satisfiedÃ¢â¬ï¿½ with their postoperative analgesia at 24 hours after surgery ,  placebo , liposome bupivacaine 266 mg  ,0,
edin,4075,3346068,Significantly increased,"In the studies that included assessment of patient ratings of postsurgical analgesia (studies 1, 6, 7, 8, 9, and 10), the liposome bupivacaine group in study 9 showed statistically significantly better patient satisfaction scores than the comparator. At 24 hours after surgery in this study, 95% of patients in the liposome bupivacaine 266 mg group were âsatisfiedâ or âextremely satisfiedâ with their postoperative analgesia compared with 72% in the placebo group (P = 0.0007).", Ã¢â¬ÅsatisfiedÃ¢â¬ï¿½ or Ã¢â¬Åextremely satisfiedÃ¢â¬ï¿½ with their postoperative analgesia at 24 hours after surgery ,  placebo , liposome bupivacaine 266 mg  ,0,
edin,4125,5846302,Cannot tell based on the abstract,, difference in any surgical procedure or  target bleeding site (TBS) characteristic , TachoSilÂ® (control) , Verisetâ¢ hemostatic patch ,0,
edin,4125,5846302,No significant difference,There was no significant difference between the two treatment groups in any surgical procedure or TBS characteristic, difference in any surgical procedure or  target bleeding site (TBS) characteristic , TachoSilÂ® (control) , Verisetâ¢ hemostatic patch ,0,
edin,4068,2429977,Cannot tell based on the abstract,, death/periprocedural MI/stroke or transient ischaemic attack/re-intervention within 7 days ," group B (âselectiveââclopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in  subgroup of patients who underwent PCI ", group A (ânon-selectiveââclopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI ,0,
edin,4068,2429977,No significant difference,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""1"" rowspan=""1"">Group A (non-selective clopidogrel before CAG)</th><th align=""left"" colspan=""1"" rowspan=""1"">Group B (selective clopidogrel before PCI)</th><th align=""left"" colspan=""1"" rowspan=""1""><italic>P</italic>-value</th>,TableÂ 3
Periprocedural ischaemic events in both groups", death/periprocedural MI/stroke or transient ischaemic attack/re-intervention within 7 days ," group B (âselectiveââclopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; in  subgroup of patients who underwent PCI ", group A (ânon-selectiveââclopidogrel 600 mg 6 h before CAG; in subgroup of patients who underwent PCI ,0,
edin,4053,5458653,Significantly decreased,"At 12 weeks after switching from vildagliptin to high-dose sitagliptin (100 mg daily), HbA1c was increased to 8.3%, but it was significantly (P < 0.05) reduced to the baseline level of 8.0% after switching from alogliptin."," mean plasma glucose level, HbA1c ", baseline , switching from vildagliptin to high-dose sitagliptin (100 mg daily) ,0,
edin,4095,5137281,Cannot tell based on the abstract,, CBF , quetiapine (QT) , pramipexole (PX) ,0,
edin,4095,5137281,No significant difference,No CBF increases were detected when comparing QT with PX at P<.001 or P<.005., CBF , quetiapine (QT) , pramipexole (PX) ,0,
edin,4023,4414618,Cannot tell based on the abstract,, force of pressure on the piston , non- low frequency transcutaneous electrical nerve stimulation (TENS) ,  low frequency transcutaneous electrical nerve stimulation (TENS) ,0,
edin,4023,4414618,Significantly decreased,"Post-hoc comparisons showed that the experimental group pressed the piston more frequently weaker in the final (14.98 Â± 7.16%) and in manipulation (25.29 Â± 6.53) compared to the baseline (51.52 Â± 1.47%) session (p < 0.001 and p = 0.004, respectively) (Fig 2C).", force of pressure on the piston , non- low frequency transcutaneous electrical nerve stimulation (TENS) ,  low frequency transcutaneous electrical nerve stimulation (TENS) ,0,
edin,4034,5429471,No significant difference,"The control group showed the highest bond strength with significant differences with other groups (P<0.05). Among the experimental groups, the saline group had no significant difference with CHX (P=0.09)", bond strength , chlorhexidine (CHX) , saline ,0,
edin,4045,2741450,Cannot tell based on the abstract,, steps/day , baseline , was not able to record their steps daily ,0,
edin,4045,2741450,No significant difference,"Baseline characteristics of participants, such as steps/day, height, weight, age did not significantly differ between the groups (Table 1).", steps/day , baseline , was not able to record their steps daily ,0,
edin,4044,2741450,Cannot tell based on the abstract,, steps/day , baseline , record the number of steps on a daily basis for 12 weeks ,0,
edin,4044,2741450,Significantly increased,"At 12 weeks, the pedometer group had a 32% higher number of steps/day than the control group.,The control group remained unchanged in the number of steps during the 12-week intervention. For the pedometer group, the daily average number of steps at weeks six (8321 Â± 884 steps per day) and twelve (9703 Â± 921 steps per day) were significantly higher than the baseline daily average of 6242 Â± 541 steps per day (p = 0.046 and p = 0.035, respectively). At week twelve, the pedometer group was taking an average of 3461 steps per day more (36% increase) than at baseline.", steps/day , baseline , record the number of steps on a daily basis for 12 weeks ,0,
edin,4007,5515187,Cannot tell based on the abstract,, self-efficacy , routine care from health-care center ," 6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring ",0,
edin,4007,5515187,Significantly increased,"As shown in table 2, a significant difference is in the mean of self-efficacy between the groups (P < 0.001) and follow-up time (P < 0.001). So that the mean of self-efficacy improve immediately after intervention and 6 months later in comparison to control group after adjusting for baseline.", self-efficacy , routine care from health-care center ," 6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring ",0,
edin,4015,5153622,Cannot tell based on the abstract,, post-void residual volume , onabotulinumtoxinA (100âU) ,   placebo ,0,
edin,4015,5153622,Significantly increased,"Among the videourdynamic parameters measured, maximum flow rate and voiding efficiency were significantly elevated after treatment in both groups, whereas improvements in voided volume and post-void residual volume were only observed in the onabotulinumtoxinA and placebo groups, respectively.,Reduction in post-void residual volume, however, was significantly greater in the placebo group (from 415.0âÂ±â304.0 to 131âÂ±â169.1âmL) than in the onabotulinumtoxinA group (from 350.0âÂ±â174.6 to 293âÂ±â233.1âmL) (pâ=â0.046)", post-void residual volume , onabotulinumtoxinA (100âU) ,   placebo ,0,
edin,4052,5458653,Significantly decreased,"At 12 weeks after switching from vildagliptin to high-dose sitagliptin (100 mg daily), HbA1c was increased to 8.3%, but it was significantly (P < 0.05) reduced to the baseline level of 8.0% after switching from alogliptin"," mean plasma glucose level, HbA1c ", baseline , alogliptin (25 mg once daily) ,0,
edin,4081,4369830,Cannot tell based on the abstract,, progression-free survival (PFS)  in patients with metastatic colorectal cancer (mCRC) , placebo , Regorafenib (RE) ,0,
edin,4081,4369830,Significantly increased,"The study met its primary endpoint, showing statistically significant improvement in overall survival (OS) by 29% (HRâ=â0.77, pâ=â0.0052, median OS: 6.4Â months vs. 5.0Â months for the placebo group) in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies. Additionally, findings from the secondary endpoints of the CORRECT study showed statistically significant improvement in progression-free survival (PFS) (HRâ=â0.49, pâ<â0.000001, median PFS: 1.9Â months vs. 1.7Â months) and an improvement in disease control rate (44.8% vs. 15.3%) in patients treated with regorafenib compared to those treated with placebo.", progression-free survival (PFS)  in patients with metastatic colorectal cancer (mCRC) , placebo , Regorafenib (RE) ,0,
edin,4078,3346068,Cannot tell based on the abstract,," mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied) at 96 hours ", bupivacaine HCl 75 mg ,  liposome bupivacaine 266 mg  ,0,
edin,4078,3346068,Significantly increased,"Statistically significant differences in favor of liposome bupivacaine were also observed in study 3, where mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied), were 9.2 in the liposome bupivacaine 532 mg group and 8.3 in the bupivacaine HCl 150 mg group (P = 0.045) at day 8, and in study 4 where mean ratings in the liposome bupivacaine 266 mg and bupivacaine HCl 75 mg groups were 7.4 and 6.0, respectively (P = 0.03) at 96 hours."," mean satisfaction ratings, based on an 11-point NRS (0 = completely unsatisfied; 10 = completely satisfied) at 96 hours ", bupivacaine HCl 75 mg ,  liposome bupivacaine 266 mg  ,0,
edin,4018,3420321,Cannot tell based on the abstract,, Impulse values , placebo , Î²-alanine (nâ=â7; 6.4âgÂ·d-1 over 4âweeks) ,0,
edin,4018,3420321,Significantly increased,"Impulse values pre- and post-supplementation are shown in Table 3. The 3.7âÂ±â1.3 kNÂ·s-1 gain (+13.9%) in the Î²-alanine group was significantly different (tâ=â(11) 3.1, pâ<â0.05) to the change in the placebo group (â1.1âÂ±â1.5 kNÂ·s-1).", Impulse values , placebo , Î²-alanine (nâ=â7; 6.4âgÂ·d-1 over 4âweeks) ,0,
edin,4041,3733287,Cannot tell based on the abstract,, Quality of life (QOL) , did not receive the intervention , psycho-educational intervention ,0,
edin,4041,3733287,Significantly increased,"The total score of QOL in two groups are presented in the Table 2. Low mean scores for quality of life in both physical and mental component revealed an inferior quality of life for depressed patients before intervention. It showed that there was a statistically significant difference within two groups in seven aspects of QOL which are physical function, limitation of role performance due to physical pain, limitation of role performance due to psychological problem, social function, pain, psychological health, vitality, but only in one aspect there was not a statistically significant difference which was role performance limitation due to physical problems (P < 0.117). Also the result showed that there was a statistically significant difference between two groups in all aspects of QOL (P < .0.001) [Table 3].", Quality of life (QOL) , did not receive the intervention , psycho-educational intervention ,0,
edin,4033,5429471,Cannot tell based on the abstract,, bond strength , sodium hypochlorite , saline ,0,
edin,4033,5429471,Significantly increased,"Also, significant differences were noted in bond strength between saline and Smear Clear (P=0.007) and saline and sodium hypochlorite (P=0.001) groups.,In the current study, the push-out bond strength of the MTA group exposed to saline was the highest. Immersion in Smear Clear, CHX and NaOCl irrigants decreased the bond strength of MTA to dentin following the first 10 minutes of its setting.", bond strength , sodium hypochlorite , saline ,0,
edin,4061,4717319,Significantly increased,"In the double-blind phase, lurasidone significantly delayed time to relapse compared with placebo (log-rank test, p=0.039), reflecting a 33.7% reduction in risk of relapse (Cox hazard ratio (95% confidence interval), 0.663 (0.447â0.983); p=0.041).", time to relapse , placebo ," (40â80 mg/d, flexibly dosed) for an additional 28-week treatment period ",0,
edin,4024,4414618,Cannot tell based on the abstract,, CSP duration , baseline ,  low frequency transcutaneous electrical nerve stimulation (TENS) ,0,
edin,4024,4414618,Significantly decreased,"st-hoc comparisons showed that the experimental group presented shorter FDIcsp duration in the final (146.17 Â± 3.94 ms) than in the baseline (156.76 Â± 4.39 ms; p = 0.005) session,", CSP duration , baseline ,  low frequency transcutaneous electrical nerve stimulation (TENS) ,0,
edin,4016,5153622,No significant difference,"There were no significant differences in subjective or objective parameters between patients who received onabotulinumtoxinA and those who received saline injection therapy, and the overall success rate was 43.5% (reduction in Patient perception of Bladder Condition by â¥2: onabotulinumtoxinA 36.8% vs placebo 54.2%, pâ=â0.114).",  Patient perception of Bladder Condition ,   placebo ,  onabotulinumtoxinA (100âU) ,0,
edin,4132,4093188,Significantly increased,The concentrations of Se and Zn in the blood plasma of ram-lambs from the supplemented group were significantly higher than for the control and grazing lambs., The concentrations of Se and Zn in the blood plasma of ram-lambs ," G, outdoor with no supplement, group C, indoor with no supplement;  "," S, indoor with supplement, ",0,
edin,4108,3382640,Significantly decreased,"The results showed that caffeinated coffee significantly reduced SDLP as compared to decaffeinated coffee, both in the first (pâ=â0.024) and second hour (pâ=â0.019) after the break.", standard deviation of lateral position (SDLP) in the first and second hour after the break , decaffeinated coffee , a single cup of coffee (80 mg caffeine) ,0,
edin,4043,4319305,No significant difference,"The WaveOne group presented a larger amount of debris than the Reciproc Group, however, without statistically significant difference (P > 0.05).", amount of debris , no instrumentation was performed ," The WaveOne group,  Reciproc Group ",0,
edin,4131,4093188,Significantly increased,"The pelvic limb of grazing lambs contained less fat compared to the control and supplemented groups (p<0.001).,The lambs from group G were grazed every day", The fat of pelvic limb   ," G, outdoor with no supplement "," group C, indoor with no supplement; S, indoor with supplement, ",0,
edin,4001,4879328,Cannot tell based on the abstract,, weight loss , no continued contact ," Get Healthy, Stay Healthyâ (GHSH) ",0,
edin,4001,4879328,Significantly increased,"Intervention group improvements were significantly greater than controls for weight loss (â1.35 kg, 95% CI: â2.24, â0.46, P=.003), but not for waist circumference ( P=.115; Table 3).", weight loss , no continued contact ," Get Healthy, Stay Healthyâ (GHSH) ",0,
edin,4122,4274545,Cannot tell based on the abstract,, Mortality , not receive any prebiotic , prebiotic mixture (SCGOS/LCFOS; 9:1) ,0,
edin,4122,4274545,No significant difference,Mortality was similar between the two groups; only one neonate died in each group [P - 0.66; Table 1]., Mortality , not receive any prebiotic , prebiotic mixture (SCGOS/LCFOS; 9:1) ,0,
edin,4097,5137281,Cannot tell based on the abstract,, CBF in the left cerebellum and brainstem (including substantia nigra) and right hypothalamus , quetiapine (QT) , pramipexole (PX) ,0,
edin,4097,5137281,Significantly increased,"PX showed elevated CBF compared with QT in the left cerebellum and brainstem (including substantia nigra, 8% CBF change) and right hypothalamus.", CBF in the left cerebellum and brainstem (including substantia nigra) and right hypothalamus , quetiapine (QT) , pramipexole (PX) ,0,
edin,4042,4319305,No significant difference,"The WaveOne group presented a larger amount of debris than the Reciproc Group, however, without statistically significant difference (P > 0.05).", amount of debris , Reciproc Group , The WaveOne group ,0,
edin,4009,5515187,Significantly increased,After 6 months intervention self-efficacy (< 0.001) and physical activity (< 0.001) improvement of in the intervention group was significantly different in comparison with the control group., average of physical activity , routine care from health-care center ," 6 weekly sessions including exercises, weight control, medication adherence, and home self-monitoring ",0,
edin,4029,3813772,Cannot tell based on the abstract,, Mu rhythm desynchronization of hand area of cortex in child ,  no touching , adult reach towards and touch an object using her hand  ,0,
edin,4029,3813772,Significantly increased,"Specifically, the mu rhythm showed greater desynchronization over hand areas for the infants who observed hand actions,", Mu rhythm desynchronization of hand area of cortex in child ,  no touching , adult reach towards and touch an object using her hand  ,0,
edin,4067,2429977,No significant difference,Periprocedural troponin elevation (>3Ã ULN) was detected in 2.6% group A vs. 3.3% group B (P = 0.475; 90% CI â2.5â1.0)., Periprocedural troponin elevation ," group B (âselectiveââclopidogrel 600 mg in the cath-lab after CAG, only in case of PCI; ", group A (ânon-selectiveââclopidogrel 600 mg &amp;amp;amp;amp;gt;6 h before CAG; ,0,
edin,4140,3713866,No significant difference,The difference between saliva secretion rates before and after medications was not significant for bromhexine users at two steps of the study (P=0.35);, Salivary secretion , No treatment , Bromhexine ,0,
edin,4244,5350209,No significant difference,"We found that compared with the control condition, the beverage was consumed at a slower rate in the two health-warning conditions, which surprisingly did not differ from each other.", Speed of alcohol consumption , Visual warning (text) , Visual warning (image) ,0,
edin,4226,3633335,Significantly decreased,"The incidence of nausea was 55% in group I, 42.5% in group II, 30% in group III, 27.5% in group IV, 30% in group V, and 30% in group VI. Groups III and V had a lower incidence of nausea than group I (P < 0.05).,Group I, anesthesia was maintained with sevoflurane;,Group III, anesthesia was maintained with propofol", Nausea , Sevoflurane alone , Propofol alone ,0,
edin,4269,2360030,Cannot tell based on the abstract,, Hand-foot syndrome , Oxaliplatin , Irinotecan ,0,
edin,4269,2360030,Significantly decreased,"Handâfoot syndrome (palmarâplantar erythrodysesthesia-HFS) was classified as 3 grades: grade 1 (numbness, dysesthesia, painless swelling or erythema not disrupting normal activity); grade 2 (painful erythema with swelling affecting daily living activities); grade 3 (desquamation, ulceration, blistering or severe pain or any symptoms leading to an inability to work or perform daily living activities).,No HFS was reported in the TEGAFIRI group whereas grade 1â2 HFS was evident in 10% of the TEGAFOX group.", Hand-foot syndrome , Oxaliplatin , Irinotecan ,0,
edin,4270,2360030,Cannot tell based on the abstract,, Grade 3â4 toxicity , Oxaliplatin , Irinotecan ,0,
edin,4270,2360030,No significant difference,"Sequential grade 3â4 toxicity (as defined in the Materials and methods section) was recorded in four (5.9, 95% CL, from 1.6 to 14.4%) TEGAFIRI patients and three (4.1, 95% CL, from 0.9 to 11.5%) TEGAFOX patients.", Grade 3â4 toxicity , Oxaliplatin , Irinotecan ,0,
edin,4197,5728078,No significant difference,"In both groups triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, fasting glucose, haemoglobin A1c, homeostasis model assessment index and diastolic blood pressure did not significantly change.", Low-density lipoprotein cholesterol , No Vitamin D supplementation , Vitamin D supplementation ,0,
edin,4272,4984795,Cannot tell based on the abstract,, Liver metastasis , High  Ang-2  , Low  Ang-2  ,0,
edin,4272,4984795,Significantly decreased,"In non-Asian patients, the frequency of liver metastasis in the high vs low Ang-2 group was 45% and 27%, respectively. In Asian patients, the frequency of liver metastasis at baseline in the high vs low Ang-2 group was 37% and 23%, respectively. Logistic regression analysis confirmed that Ang-2 levels were strongly correlated with the frequency of liver metastasis at any time (Figure 4).", Liver metastasis , High  Ang-2  , Low  Ang-2  ,0,
edin,4143,3713866,Cannot tell based on the abstract,, Difficulties with chewing , No treatment , Policarpine ,0,
edin,4143,3713866,Significantly decreased,"All the (100%) pilocarpine users and 14.3% of bromhexine users demonstrated improvement of chewing difficulties,All the differences mentioned were statistically significant with P-values of 0.0001, 0.04, 0.005, 0.0001 and 0.004 for improvement in chewing, swallowing, speech, tasting problems and burning sensation, respectively", Difficulties with chewing , No treatment , Policarpine ,0,
edin,4309,3937058,Cannot tell based on the abstract,, confidence to use reminder/recall systems , in-person , webinar consultations ,0,
edin,4309,3937058,No significant difference,"<td align=""left"">âReminder/recall training</td><td align=""center"">4.4 (0.7)</td><td align=""center"">4.5 (0.9)</td>,In-person and webinar conditions had comparable satisfaction scores (all comparisons pâ>â0.05).", confidence to use reminder/recall systems , in-person , webinar consultations ,0,
edin,4218,4950066,Cannot tell based on the abstract,, Blood pressure  , Placebo , Vitamin D3 (cholecalciferol) supplementation ,0,
edin,4218,4950066,No significant difference,"Among the secondary outcomes, there were no differences comparing D2 with placebo (Figure 4A) or D3 with placebo (Figure 4B) for anthropometric measures, blood pressure, hsCRP, CVD risk, assessed by UKPDS risk engine, hepatic markers, or fructosamine.", Blood pressure  , Placebo , Vitamin D3 (cholecalciferol) supplementation ,0,
edin,4229,2361515,Cannot tell based on the abstract,, Time to tumor progression , Irinotecan + Raltitrexed , Oxaliplatin + Raltitrexed ,0,
edin,4229,2361515,No significant difference,Median time to progression was 8.2 months for arm A and 8.8 months for arm B., Time to tumor progression , Irinotecan + Raltitrexed , Oxaliplatin + Raltitrexed ,0,
edin,4234,5846971,Significantly decreased,"Between 3 and 9 months, environmental quality of life decreased among RT1 compared to RT2 and RT3 (groupâÃâtime pâ=â.025).", Quality of life 3-9 months , Resistance training (Twice a week) , Resistance training (Once a week) ,0,
edin,4254,3897026,No significant difference,"There were no differences in the recovery time (17.3 Â± 3.4 in the case group vs. 16.3 Â± 3 in the control group, P < 0.05), postoperative pain scores (5 Â± 1 in the case group vs. 5.6 Â± 2 in the control group, P < 0.05),", Post-Surgical Pain , Control , Ketamine ,0,
edin,4171,3314673,Cannot tell based on the abstract,, Perceived stress scale , No program , Second Life program ,0,
edin,4171,3314673,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">PSS</td><td align=""left"" colspan=""1"" rowspan=""1"">15.7Â±5.9</td><td align=""left"" colspan=""1"" rowspan=""1"">15Â±6.7</td><td align=""left"" colspan=""1"" rowspan=""1"">â0.7</td><td align=""left"" colspan=""1"" rowspan=""1"">0.501</td>,PSSâ=âperceived stress scale,", Perceived stress scale , No program , Second Life program ,0,
edin,4308,3937058,Significantly decreased,"Delivery cost per clinic was $152 for in-person consultations versus $100 for webinar consultations.,In-person and webinar delivery modes were both well received, but webinar AFIX consultations cost substantially less.", cost of intervention  , $152.45 for the in-person , $99.95 for the webinar ,0,
edin,4280,3678237,Cannot tell based on the abstract,, Motor arm Score improvement , Control , Erythropoietin ,0,
edin,4280,3678237,Significantly increased,"In this study, erythropoietin group had better outcome in comparison to control group. Total NIHSS was significantly lower in erythropoietin group. This effectwas of value in LOC Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).", Motor arm Score improvement , Control , Erythropoietin ,0,
edin,4267,2360030,Cannot tell based on the abstract,, Response duration , Oxaliplatin , Irinotecan ,0,
edin,4267,2360030,No significant difference,The median duration of response was 6 (range: 3â15) for TEGAFIRI and 6 months (range: 3â23) for TEGAFOX group., Response duration , Oxaliplatin , Irinotecan ,0,
edin,4236,5846971,Significantly increased,Sense of coherence increased in RT2 compared to the control group and RT3 (groupâÃâtime pâ=â.032)., Sense of coherence , Resistance training (Three times a week) , Resistance training (Twice a week) ,0,
edin,4161,4758401,Cannot tell based on the abstract,, Elevation of glucose and glucagon after 1 hour , Insulin alone , Insulin + Pramlintide (all doses) ,0,
edin,4161,4758401,No significant difference,"Compared with placebo/insulin, all three pramlintide/insulin ratios produced marked and statistically equivalent reductions of increments of glucose and glucagon in the first hour, with levels subsequently increasing", Elevation of glucose and glucagon after 1 hour , Insulin alone , Insulin + Pramlintide (all doses) ,0,
edin,4187,2723123,Significantly decreased,"Statistically significant differences for mineral loss and lesion depth were found between the toothpaste and the mouth rinse as well as between the toothpaste and the control group, but not between the mouth rinse and the control group.,Within the limitations of this study, the results suggest that treatment of demineralised dentin with a toothpaste containing 5000 ppm fluoride may considerably reduce mineral loss and lesion depth on exposed dentin.", Depth of the lesion , Control (distilled water) , Fluoride toothpaste (5000 ppm)  ,0,
edin,4255,3897026,No significant difference,"There were no differences in the recovery time (17.3 Â± 3.4 in the case group vs. 16.3 Â± 3 in the control group, P < 0.05), postoperative pain scores (5 Â± 1 in the case group vs. 5.6 Â± 2 in the control group, P < 0.05), the consumption of anesthetic (9376.9 Â± 1245.8 in the case group vs. 9012.9 Â± 1620 in the control group, P < 0.05),", Anesthetic usage , Control , Ketamine ,0,
edin,4302,165418,Significantly increased,A trend towards a superior improvement in glycemic control was found in the paroxetine group (p = 0.08)., glycemic control , placebo , paroxetine ,0,
edin,4170,4632405,Significantly increased,JinqiÂ JiangtangÂ tabletÂ effectivelyÂ reducedÂ theÂ incidenceÂ ofÂ diabetes mellitusÂ and enhanced reversionÂ rate.Â comparedÂ withÂ theÂ controlÂ group (p< 0.05);, Pre-diabetes reversion , Placebo , JQJT tablets ,0,
edin,4273,1913602,Significantly decreased,"After adjusting for age, body mass index, an asset index, smoking, secondhand tobacco smoke, apparent temperature, season, day of week, time of day, and a random subject intercept, the improved stove intervention was associated with 3.7 mm Hg lower SBP [95% confidence interval (CI), â8.1 to 0.6] and 3.0 mm Hg lower DBP (95% CI, â5.7 to â0.4) compared with controls.", Systolic blood pressure  , Control , Improved cookstove ,0,
edin,4139,3713866,Significantly increased,"The difference between saliva secretion rates before and after medications was not significant for bromhexine users at two steps of the study (P=0.35); however, it was significant for pilocarpine users (P=0.0001).,Pilocarpine is probably more effective in improving xerostomia and its associated problems compared with bromhexine, although the use of the latter was also shown to ease some of the consequences of radiotherapy in the head and neck region.", Salivary secretion , No treatment , Pilocarpine ,0,
edin,4185,2723123,Significantly decreased,"Within the limitations of this study, the results suggest that treatment of demineralised dentin with a toothpaste containing 5000 ppm fluoride may considerably reduce mineral loss and lesion depth on exposed dentin.", Dentin mineral loss , Control  , Fluoride mouth rinse (250 ppm)  ,0,
edin,4135,5704449,Cannot tell based on the abstract,, Weight gained , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4135,5704449,No significant difference,"There were no significant differences between the groups regarding maternal weight gain and BMI during the exercise programme period, TableÂ 2.Table 2", Weight gained , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4158,3984795,Cannot tell based on the abstract,, Lipid profile improvement , Placebo , Omega-3 ,0,
edin,4158,3984795,Significantly increased,"In the omega-3 group, total cholesterol, triglycerides, LDL, and VLDL decreased and HDL increased significantly by 6.7% (P < 0.01). HDL increased by 23.2% and LDL decreased by 10.7%; triglycerides decreased by 7.78% and VLDL by 7.78% (P < 0.01) in the probiotic with omega-3 group, compared with baseline levels (Table 1).", Lipid profile improvement , Placebo , Omega-3 ,0,
edin,4177,4292865,Cannot tell based on the abstract,, Hemorrhage  , C-mode Endoscopic sphincterotomy , E-mode Endoscopic sphincterotomy ,0,
edin,4177,4292865,No significant difference,"There was no case of clinically evident hemorrhage in either group at the time of EST, 24 hours after EST, or within 7 days of randomization.", Hemorrhage  , C-mode Endoscopic sphincterotomy , E-mode Endoscopic sphincterotomy ,0,
edin,4174,3314673,Significantly decreased,There was a significant decrease of 2.8 points on the SCL-90-R Global Severity Index (p<0.05)., Anxiety Index of the SCL-90-r , No program , Second Life program ,0,
edin,4258,4648234,No significant difference,"Raw agreement between the expert group and sponsors was 0.74 in the concept and 0.78 in the ad hoc arm. Chance-corrected agreement was higher in the ad hoc (kappa: 0.34 (95% confidence interval = 0.10â0.58)) than in the concept arm (0.27 (0.06â0.50)), but the difference was not significant (p = 0.67).", Agreement between  Experts and Sponsors , Intuitive approach (ad hoc) , New law criteria (Concept) ,0,
edin,4193,5022334,No significant difference,"The differences between the two groups in the estimated intraoperative blood loss, postoperative hospital stay time, numbers of lymph node removed, postoperative thyroglobulin levels, and complications were not statistically significant (all P > 0.05).", Complications , Conventional open thyroidectomy  , Thyroidectomy via BABA ,0,
edin,4282,3678237,Significantly increased,"Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in NIHSS (P= 0.0001). This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).", Sensory score improvement , Control , Erythropoietin ,0,
edin,4237,5947263,Cannot tell based on the abstract,, AUC (FEV1)/h , Approved inhaler , Procaterol hydrochloride inhaler ,0,
edin,4237,5947263,No significant difference,"The mean Â± SD AUC (FEV1)/h was 2.41 Â± 0.73 L for the new DPI and 2.37 Â± 0.75 L for the approved DPI. The mean of differences in AUC (FEV1)/h between the 2 DPIs was 0.04 Â± 0.09 L (Table 2).,Results of ANOVA showed no significant group or carryover effects for either AUC (FEV1)/h and maximum FEV1 (P = .50 and P = .59, respectively), and no significant period effects for either AUC (FEV1)/h and maximum FEV1 (P = .19 and P = .42, respectively) (Table 3).", AUC (FEV1)/h , Approved inhaler , Procaterol hydrochloride inhaler ,0,
edin,4179,4292865,Cannot tell based on the abstract,, Perforation , C-mode Endoscopic sphincterotomy , E-mode Endoscopic sphincterotomy ,0,
edin,4179,4292865,No significant difference,No patients experienced perforation., Perforation , C-mode Endoscopic sphincterotomy , E-mode Endoscopic sphincterotomy ,0,
edin,4235,5846971,Significantly increased,"Between baseline and 9 months, environmental quality of life increased in RT2 compared to all other groups (groupâÃâtime pâ=â.011).", Quality of life 0-9 months , Resistance training (Three times a week) , Resistance training (Twice a week) ,0,
edin,4279,3678237,Significantly increased,"Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in NIHSS (P= 0.0001). This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).", Facial palsy score improvement , Control , Erythropoietin ,0,
edin,4142,3713866,Significantly decreased,"Users of both drugs showed significant differences in improvement of xerostomia, chewing, swallowing, tasting and mouth burning", Xerostomia  , No treatment , Bromhexine ,0,
edin,4205,4253794,Significantly increased,Intubation time was longer in the GVL group (9.80 Â± 1.27 s) than in the MDL group (8.20 Â± 1.17 s) (P < 0.05)., Time needed to intubate , Macintosh direct laryngoscope , GlideScope video-laryngoscope ,0,
edin,4208,4253794,Significantly decreased,"MAP, pulse rate, and RPP were lower in the GVL than the MDL group after endotracheal intubation (P < 0.05).", Mean arterial blood pressure (after 5 minutes) , Macintosh direct laryngoscope , GlideScope video-laryngoscope ,0,
edin,4213,4610679,Cannot tell based on the abstract,, Glucose measurement frequency , No HRA , Health risk assessment (HRA) ,0,
edin,4213,4610679,Significantly decreased,"<td align=""left"" colspan=""1"" rowspan=""1"">Glucose measurement in past 3 y</td><td align=""left"" colspan=""1"" rowspan=""1"">670 (81.0)</td><td align=""left"" colspan=""1"" rowspan=""1"">1,014 (76.8)</td><td align=""left"" colspan=""1"" rowspan=""1"">1.29 (1.03â1.62)</td><td align=""left"" colspan=""1"" rowspan=""1"">0.03</td>", Glucose measurement frequency , No HRA , Health risk assessment (HRA) ,0,
edin,4233,5846971,Significantly increased,"After 3 months, there was an intervention effect on environmental quality of life (groupâÃâtime pâ=â.048).", Quality of life after 3 months , No training , Resistance training (Twice a week) ,0,
edin,4285,3557008,Cannot tell based on the abstract,, Heart rate , Control (nothing) , Saline ,0,
edin,4285,3557008,No significant difference,No significant change in PR was detected in normal saline group (93.9 Â± 18.3 vs. 93.8 Â± 17.2 beats/min; P = 0.938) or the Ephedrine group (100.1 Â± 20.9 vs. 97.6 Â± 12.9; P = 0.341)., Heart rate , Control (nothing) , Saline ,0,
edin,4188,5022334,Significantly increased,"he mean operative time of the robotic group was longer than that of the conventional open approach group (118.8 Â± 16.5 min vs. 90.7 Â± 10.3 min, P < 0.05).", Surgery time , Conventional open thyroidectomy  , Thyroidectomy via BABA ,0,
edin,4145,4636858,No significant difference,"MRI plaques number reduced in groups significantly (2.29 vs. 2.17) without significant difference between the groups (P = 0.782). Six months after trial completion, plaques number increased in groups without significantly difference (0.72 vs. 0.77, P = 0.611)", Multiple sclerosis plaques  , No treatment , Mitoxantrone + methylprednisolone ,0,
edin,4150,4164149,No significant difference,"In addition, rates of initial positive Î²-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% CI â9.5, 4.3),", Positive Î²-hCG at start , Vaginal progesterone , Subcutaneous progesterone ,0,
edin,4134,5704449,Cannot tell based on the abstract,, Triglycerides  , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4134,5704449,Significantly decreased,"<td>âTriglycerides, mg/dL</td><td>139 (62)</td><td>116 (37)</td><td>195 (45)</td><td>199 (42)</td><td>â28 (1 to 55)</td><td>0.03</td>", Triglycerides  , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4189,5022334,Significantly decreased,"The study showed significant differences between the two groups in terms of the VASs (2.1 Â± 1.0 vs. 3.8 Â± 1.2, P < 0.05)", Visual analogue scale , Conventional open thyroidectomy  , Thyroidectomy via BABA ,0,
edin,4175,4292865,No significant difference,"The complications occurred in 20 (11.2%) patients from the E-mode group: pancreatitis in 6 (3.4%) and endoscopically evident bleeding in 14 (7.8%). In contrast, the complications occurred in 25 (13.8%) patients from the C-mode group: pancreatitis in 7 (3.9%) and endoscopically evident bleeding in 18 (9.9%), although these findings were not statistically significant.", Pancreatitis , C-mode Endoscopic sphincterotomy , E-mode Endoscopic sphincterotomy ,0,
edin,4301,165418,Cannot tell based on the abstract,, improvement in GHbA1c , placebo , paroxetine ,0,
edin,4301,165418,No significant difference,"After ten weeks we found that the mean decrease of the GHbA1c value in the paroxetine group was 0.44%-units (Table 2). There was a trend towards a more beneficial outcome in the paroxetine group, as GHbA1c in the placebo group decreased only 0.07%-units (U = 9.0, p = 0,08).", improvement in GHbA1c , placebo , paroxetine ,0,
edin,4202,5124283,No significant difference,"However, the plasma CXCL4L1, CXCL1, macrophage migration inhibitory factor (MIF) and human plasminogen activator inhibitor 1 (PAI-1) levels did not significantly change following anthocyanin supplementation.", Macrophage migration inhibitory factor  , Placebo , Purified anthocyanins ,0,
edin,4133,5704449,Cannot tell based on the abstract,, Low density lipoprotein , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4133,5704449,Significantly decreased,"At the end of the intervention programme, the multivariable analysis, which we adjusted for baseline levels, showed a difference between groups in LDL-c (-8Â mg/dL, 95%CI -3 to â29; Pâ<â0.001) and TG (â6Â mg/dL, 95%CI 1 to 11; Pâ=â0.03).", Low density lipoprotein , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4263,5471755,Cannot tell based on the abstract,, Abdominal discomfort , Control , MLC601 ,0,
edin,4263,5471755,No significant difference,"Only 5 patients (14.7%) reported AEs in the MLC601 group, including nausea (8.8%), diarrhea (8.8%), constipation (5.8%), abdominal discomfort (2.9%), and anorexia.", Abdominal discomfort , Control , MLC601 ,0,
edin,4228,2361515,Cannot tell based on the abstract,, Duration of response , Irinotecan + Raltitrexed , Oxaliplatin + Raltitrexed ,0,
edin,4228,2361515,No significant difference,"Median duration of response was 7.9 and 9.2 months, respectively (P=0.696, log-rank test).", Duration of response , Irinotecan + Raltitrexed , Oxaliplatin + Raltitrexed ,0,
edin,4275,1913602,Significantly decreased,"After adjusting for age, body mass index, an asset index, smoking, secondhand tobacco smoke, apparent temperature, season, day of week, time of day, and a random subject intercept, the improved stove intervention was associated with 3.7 mm Hg lower SBP [95% confidence interval (CI), â8.1 to 0.6] and 3.0 mm Hg lower DBP (95% CI, â5.7 to â0.4) compared with controls.", Systolic blood pressure  , Improved cookstove + No smoking , Improved cookstove + smoking ,0,
edin,4290,4558453,Cannot tell based on the abstract,, Heart Rate in virtual immersive environment , No exercise , Exercise of moderate intensity ,0,
edin,4290,4558453,Significantly increased,"Heart rates showed significant increases from rest to No-Exercise and Exercise trials (F (3,51) = 39.63, p < 0.05), and these changes were consistent across the three levels of virtual environment exposure (Table 1).", Heart Rate in virtual immersive environment , No exercise , Exercise of moderate intensity ,0,
edin,4172,3314673,Significantly decreased,There was a significant decrease of 2.8 points on the SCL-90-R Global Severity Index (p<0.05)., Global Severity Index of the SCL 90-r , No program , Second Life program ,0,
edin,4192,5022334,No significant difference,"The differences between the two groups in the estimated intraoperative blood loss, postoperative hospital stay time, numbers of lymph node removed, postoperative thyroglobulin levels, and complications were not statistically significant (all P > 0.05).", Amount of lymph nodes removed , Conventional open thyroidectomy  , Thyroidectomy via BABA ,0,
edin,4153,4164149,Cannot tell based on the abstract,, Babies born alive , Vaginal progesterone , Subcutaneous progesterone ,0,
edin,4153,4164149,No significant difference,"No statistically significant differences between Prolutex and Endometrin were seen for any of the secondary efficacy variables, including rates of initial positive serum Î²-hCG, clinical pregnancy at 6â7 weeks of gestation, live birth,", Babies born alive , Vaginal progesterone , Subcutaneous progesterone ,0,
edin,4232,5846971,Significantly increased,"After 3 months, there was an intervention effect on environmental quality of life (groupâÃâtime pâ=â.048).", Quality of life after 3 months , No training , Resistance training (Once a week) ,0,
edin,4184,2723123,Significantly decreased,"Statistically significant differences for mineral loss and lesion depth were found between the toothpaste and the mouth rinse as well as between the toothpaste and the control group, but not between the mouth rinse and the control group.,Within the limitations of this study, the results suggest that treatment of demineralised dentin with a toothpaste containing 5000 ppm fluoride may considerably reduce mineral loss and lesion depth on exposed dentin.", Dentin mineral loss , Control (distilled water) , Fluoride toothpaste (5000 ppm)  ,0,
edin,4293,4704894,Cannot tell based on the abstract,, Intervention engagement for all groups over time , TTM based posts (later) , TTM based posts (beginning) ,0,
edin,4293,4704894,Significantly decreased,"As can be seen in Figure 1, intervention engagement with TTM posts decreased over time in each of the seven Facebook groups (range of correlation coefficients from -.81 to -.55; all P<.001) and the number of comments varied by group (F 6,505=29.7; P<.001).", Intervention engagement for all groups over time , TTM based posts (later) , TTM based posts (beginning) ,0,
edin,4223,3633335,Significantly decreased,"We found that the incidence of vomiting was lower in group II (17.5%), group IV (7.5%), and group VI (10%) compared with group I (55%), group III (27.5%), and group V (30%), respectively (P < 0.05). The incidence of vomiting was also lower in group III (27.5%) and group V (30%) when compared with group I (55%) (P < 0.05).,We conclude that compared with sevoflurane anesthesia alone, anesthesia with either propofol alone or propofol combined with sevoflurane resulted in a reduced incidence of vomiting and nausea during the first 24 h after surgery", Vomiting , Sevoflurane alone , Propofol alone ,0,
edin,4281,3678237,Significantly increased,"Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in NIHSS (P= 0.0001). This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023).", Best language score improvement , Control , Erythropoietin ,0,
edin,4155,3984795,Cannot tell based on the abstract,, Fasting blood glucose , Placebo , Probiotic (VSL#3) ,0,
edin,4155,3984795,Significantly decreased,"Fasting blood glucose (FBG) rose slightly in the placebo group but reduced significantly (P < 0.05) in the probiotic, omega-3, and probiotic + omega-3 combination groups.", Fasting blood glucose , Placebo , Probiotic (VSL#3) ,0,
edin,4231,2361515,Cannot tell based on the abstract,, Asthenia  , Irinotecan + Raltitrexed , Oxaliplatin + Raltitrexed ,0,
edin,4231,2361515,No significant difference,"Overall, asthenia was detected in 17 patients (35%) in arm A and in 24 patients (52%) in arm B. However, these differences were not significant from a statistical point of view (P=NS).", Asthenia  , Irinotecan + Raltitrexed , Oxaliplatin + Raltitrexed ,0,
edin,4278,3678237,Significantly increased,"Evaluations revealed that in days14 and 28 during follow-up, Erythropoietin was effective in NIHSS (P= 0.0001). This effect was of value in level of consciousness Commands (P= 0.024), facial palsy (P= 0.003), motor arm (P= 0.0001), motor leg (P= 0.0001), sensory (P= 0.009), and best language (P= 0.023)", Consciousness Commands improvement , Control , Erythropoietin ,0,
edin,4215,4950066,No significant difference,"There was no effect of vitamin D supplementation on HbA1c: D2 versus placebo: â0.05% [95% confidence interval (CI) â0.11, 0.02] or â0.51 mmol/mol (95% CI â1.16, 0.14; p = 0.13); D3 versus placebo: 0.02% (95% CI â0.04, 0.08) or 0.19 mmol/mol (95% CI â0.46, 0.83; p = 0.57).", Glycated hemoglobin , Placebo , Vitamin D3 (cholecalciferol) supplementation ,0,
edin,4210,4610679,Significantly increased,"At 2 y, favourable health behaviours and use of preventive care were more frequent in the intervention than in the control group (based on z-statistics from generalised estimating equation models). For example, 70% compared to 62% were physically active (odds ratio 1.43, 95% CI 1.16â1.77, p = 0.001),", Physical activity , No HRA , Health risk assessment (HRA) ,0,
edin,4164,4758401,Cannot tell based on the abstract,, Glucagon AUC 0â3 h , Insulin alone , Insulin + Pramlintide (all doses) ,0,
edin,4164,4758401,Significantly decreased,"Reductions of AUC0â3 h for glucagon for the 6, 9 and 12 mcg/U were 57, 59 and 55% (Table 1; all doses vs placebo: p < 0.05).", Glucagon AUC 0â3 h , Insulin alone , Insulin + Pramlintide (all doses) ,0,
edin,4239,5947263,Cannot tell based on the abstract,, Period effects for AUC (FEV1)/h , Approved inhaler , Procaterol hydrochloride inhaler ,0,
edin,4239,5947263,No significant difference,"Results of ANOVA showed no significant group or carryover effects for either AUC (FEV1)/h and maximum FEV1 (P = .50 and P = .59, respectively), and no significant period effects for either AUC (FEV1)/h and maximum FEV1 (P = .19 and P = .42, respectively) (Table 3).", Period effects for AUC (FEV1)/h , Approved inhaler , Procaterol hydrochloride inhaler ,0,
edin,4224,3633335,No significant difference,"he incidence of nausea was 55% in group I, 42.5% in group II, 30% in group III, 27.5% in group IV, 30% in group V, and 30% in group VI. Groups III and V had a lower incidence of nausea than group I (P < 0.05).,We conclude that compared with sevoflurane anesthesia alone, anesthesia with either propofol alone or propofol combined with sevoflurane resulted in a reduced incidence of vomiting and nausea during the first 24 h after surgery.,Administration of ondansetron effectively reduced the incidence of vomiting but not that of nausea for all three types of general anesthesia.", Nausea , Sevoflurane alone , Sevoflurane + Ondansetron ,0,
edin,4156,3984795,Cannot tell based on the abstract,, Fasting blood glucose , Placebo , Omega-3 ,0,
edin,4156,3984795,Significantly decreased,"Fasting blood glucose (FBG) rose slightly in the placebo group but reduced significantly (P < 0.05) in the probiotic, omega-3, and probiotic + omega-3 combination groups.", Fasting blood glucose , Placebo , Omega-3 ,0,
edin,4253,3897026,No significant difference,"There were no differences in the recovery time (17.3 Â± 3.4 in the case group vs. 16.3 Â± 3 in the control group, P < 0.05),", Recovery time , Control , Ketamine ,0,
edin,4137,5704449,Cannot tell based on the abstract,, Baby's weight at birth , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4137,5704449,No significant difference,"here was no significant difference between the experimental and control groups regarding mean birth weight (3133âÂ±â406Â g versus 3013âÂ±â494Â g, Pâ=â0.34), low birth weight (< 2500Â g; (nâ=â3 versus nâ=â2) or high birth weight (> 4000Â g; nâ=â1 versus nâ=â0).", Baby's weight at birth , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4181,3926947,Significantly decreased,There was less need for reminders in the IVR group (pâ=â0.000)., Need for reminders , Questionnaire sent by post , Interactive Voice Response ,0,
edin,4230,2361515,Significantly decreased,"In all, 14 patients (29%) from arm A and 24 patients (52%) from arm B had some grade of diarrhoea (P<0.03).", Diarrhoea of some grade , Irinotecan + Raltitrexed , Oxaliplatin + Raltitrexed ,0,
edin,4249,5015408,Cannot tell based on the abstract,, HASBLED score of â¥3 , No system , Electronic alert system ,0,
edin,4249,5015408,No significant difference,"On the other hand, 391 (44.0%) patients had a HASBLED score of â¥3. There was no difference in the proportion of patients with HASBLED score of â¥3 between the alert (208; 45.7%) and the control (183; 42.2%) groups (P=0.287).", HASBLED score of â¥3 , No system , Electronic alert system ,0,
edin,4277,1913602,Cannot tell based on the abstract,, Personal PM 2.5 , Control , Improved cookstove ,0,
edin,4277,1913602,Significantly decreased,Personal PM2.5 was about 61% lower on average and had a narrower distribution among the plancha improved stove group compared with the open fire group, Personal PM 2.5 , Control , Improved cookstove ,0,
edin,4138,5704449,Cannot tell based on the abstract,, Need for C-section , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4138,5704449,No significant difference,"The experimental group showed a higher percentage in of Caesarean sections in comparison to the control group without significant differences (27% compared with 13%, Pâ=â0.89).", Need for C-section , Prenatal care only , Aerobic and resistance exercice + prenatal care ,0,
edin,4306,3937058,Significantly increased,"Clinics that received in-person and webinar consultations reported similar levels of participation on key programmatic activities with one exception: more webinar clinics reported improving documentation of previously administered, âhistoricalâ vaccine doses."," documentation for the previously given, âhistoricalâ vaccine doses ", in-person , webinar consultations ,0,
edin,4176,4292865,No significant difference,"The complications occurred in 20 (11.2%) patients from the E-mode group: pancreatitis in 6 (3.4%) and endoscopically evident bleeding in 14 (7.8%). In contrast, the complications occurred in 25 (13.8%) patients from the C-mode group: pancreatitis in 7 (3.9%) and endoscopically evident bleeding in 18 (9.9%), although these findings were not statistically significant.", Evident bleeding , C-mode Endoscopic sphincterotomy , E-mode Endoscopic sphincterotomy ,0,
edin,4074,3346068,Cannot tell based on the abstract,, patient satisfaction scores ,  placebo , liposome bupivacaine 266 mg ,0,
edin,4074,3346068,Significantly increased,"In the studies that included assessment of patient ratings of postsurgical analgesia (studies 1, 6, 7, 8, 9, and 10), the liposome bupivacaine group in study 9 showed statistically significantly better patient satisfaction scores than the comparator.", patient satisfaction scores ,  placebo , liposome bupivacaine 266 mg ,0,
edin,4222,3633335,Significantly decreased,"We conclude that compared with sevoflurane anesthesia alone, anesthesia with either propofol alone or propofol combined with sevoflurane resulted in a reduced incidence of vomiting and nausea during the first 24 h after surgery. Administration of ondansetron effectively reduced the incidence of vomiting but not that of nausea for all three types of general anesthesia.", Vomiting , Propofol alone , Propofol + Ondansetron ,0,
edin,4154,4164149,No significant difference,"In addition, rates of initial positive Î²-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% CI â9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% CI â10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% CI â7.6, 4.0), live birth (41.1 versus 43.1%; 95% CI â8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% CI â8.4, 5.4) were comparable.", Babies taken home , Vaginal progesterone , Subcutaneous progesterone ,0,
edin,4167,4632405,No significant difference,theÂ scoresÂ ofÂ SF-36Â ofÂ twoÂ groupsÂ hadÂ noÂ significantÂ difference P> 0.05);, SF-36 questionnaire , Placebo , JQJT tablets ,0,
edin,4212,4610679,Significantly decreased,"At 8 y, based on an intention-to-treat analysis, the estimated proportion alive was 77.9% in the intervention and 72.8% in the control group, for an absolute mortality difference of 4.9% (95% CI 1.3%â8.5%, p = 0.009; based on z-test for risk difference).", Mortality rate (after 8 years) , No HRA , Health risk assessment (HRA) ,0,
edin,4206,4253794,No significant difference,"MAP, heart rate, and RPP returned to pre-intubation values at 3 and 4 minutes after intubation in the GVL and MDL groups, respectively (P < 0.05).", Increase in Rate pressure product (First 3 minutes) , Macintosh direct laryngoscope , GlideScope video-laryngoscope ,0,
edin,4151,4164149,No significant difference,"In addition, rates of initial positive Î²-hCG (56.4% subcutaneous versus 59.0% vaginal; 95% CI â9.5, 4.3), clinical intrauterine pregnancy with fetal cardiac activity (42.6 versus 46.4%; 95% CI â10.8, 3.2), implantation defined as number of gestational sacs divided by number of embryos transferred (33.2 versus 35.1%; 95% CI â7.6, 4.0), live birth (41.1 versus 43.1%; 95% CI â8.9, 4.9) and take-home baby (41.1 versus 42.6%; 95% CI â8.4, 5.4) were comparable.", Pregnancy with fetal cardiac activity (in uterus) , Vaginal progesterone , Subcutaneous progesterone ,0,
edin,4311,4139980,Cannot tell based on the abstract,, Serum lipids at 8 weeks , Placebo therapy , Omega-3 therapy ,0,
edin,4311,4139980,No significant difference,"After 8 weeks, there were no significant differences in serum HDL-C, LDL-C, total cholesterol and triglycerides.", Serum lipids at 8 weeks , Placebo therapy , Omega-3 therapy ,0,
edin,4340,5122613,No significant difference,No adverse effects related to study products were observed., Adverse events , Placebo , Digestion-resistant maltodextrin ,0,
edin,4333,3511947,Significantly increased,The durations of complete analgesia and effective analgesia were longer for all patients in group III compared with group II (P < 0.05) and group I (P < 0.005) patients., Complete analgesia and effective analgesia duration , Fentanyl and normal saline (group II) , Fentanyl and neostigmine (group III) ,0,
edin,4396,5590362,Cannot tell based on the abstract,The lowest mean pain score recorded in the massage group (0.92) whereas it was 4.84 in the breastfeeding group and 6.16 in the control group. ANOVA test and post-hoc statistics revealed that both interventions resulted in a significant reduction of the pain scores., Mean pain score , Massage (group 2) , Breastfeeding (group 1) ,0,
edin,4396,5590362,Significantly increased,"Mean scores of pain were 0.92, 6.16, and 4.84 in the massage, control, and breastfeeding groups, respectively, which showed a significant difference in pain scores (F = 437.50, P < 0.01).", Mean pain score , Massage (group 2) , Breastfeeding (group 1) ,0,
edin,4327,3557743,Cannot tell based on the abstract,, Days of post-surgical hospitalization  , Roux-en-Y gastric bypass , Laparoscopic sleeve gastrectomy ,0,
edin,4327,3557743,No significant difference,The median length of hospitalization after the operation was 6.0 (4-9) days in the RYGB group and 6.0 (range 4-77) days in the LSG group (p > 0.05)., Days of post-surgical hospitalization  , Roux-en-Y gastric bypass , Laparoscopic sleeve gastrectomy ,0,
edin,4380,3199060,Cannot tell based on the abstract,, Baseline characteristics , Traditional controllers , Motion-based controllers ,0,
edin,4380,3199060,No significant difference,There were no significant differences between groups on any sociodemographic variables., Baseline characteristics , Traditional controllers , Motion-based controllers ,0,
edin,4384,5986454,No significant difference,here was no significant difference in subjective feelings and body temperature between the test drink conditions., Subjective feelings and body temperature , Isoenergetic placebo drink , Acidified milk protein drink ,0,
edin,4351,5103733,Cannot tell based on the abstract,, Serum levels of CK , Control group , Esmolol group ,0,
edin,4351,5103733,Significantly increased,"The serum levels of CK (Fig. 2B) did not show any significant difference between the two groups at four of the five time points (baseline, before aortic cannulation, before aortic cross-clamp and 120 min after the release of aortic cross-clamp); however, the levels were significantly higher in the esmolol group compared with the control group (esmolol group, 125.67Â±30.81 IU/ml; control group, 89.67Â±23.31 IU/ml; P=0.002).", Serum levels of CK , Control group , Esmolol group ,0,
edin,4379,3199060,Significantly increased,"n interaction was found such that in one pair, motion control (mean [SD] 0.96 [0.20]âkcal Â· kgâ1 Â· hrâ1) produced 0.10âkcal Â· kgâ1 Â· hrâ1 (95% confidence interval 0.03 to 0.17) greater energy expenditure than traditional control (0.86 [0.17]âkcal Â· kgâ1 Â· hrâ1, P = .048).", Energy expenditure , Traditional controllers , Motion-based controllers ,0,
edin,4391,5018700,No significant difference,The incidence of complications was comparable among the groups., Rate of complications , Fentanyl (Group F) , Oxycodone (Group O/70 and Group O/100) ,0,
edin,4386,5986454,Cannot tell based on the abstract,, RMSSD and HF , Isoenergetic placebo drink , Acidified milk protein drink ,0,
edin,4386,5986454,Significantly increased,"Among the HRV indices calculated, RMSSD and HF were significantly higher when they ingested the milk protein drink compared with the placebo drink (p = 0.019 and p = 0.029, respectively), as shown in Figure 4.", RMSSD and HF , Isoenergetic placebo drink , Acidified milk protein drink ,0,
edin,4406,4540107,Significantly decreased,Plasma TNF-Î± was significantly decreased in the DM60 group compared to the placebo group., Plasma TNF-Î± , Placebo , Dextromethorphan (DM60) ,0,
edin,4363,5588713,Cannot tell based on the abstract,, Coagulation parameters , Placebo , Nanoparticles ,0,
edin,4363,5588713,No significant difference,Comparison of coagulation parameters after bronchial segmental challenge with saline (placebo) or 100Â Î¼g nanoparticles showed no significant differences between those groups., Coagulation parameters , Placebo , Nanoparticles ,0,
edin,4339,5122613,Significantly decreased,"In the RMD group, the total CTT, left SCTT and rectosigmoidal SCTT decreased significantly compared to baseline (pÂ <Â 0.01 each; â13.3, â4.7, â8.7Â h, respectively).", Left SCTT , Placebo , Digestion-resistant maltodextrin ,0,
edin,4438,4128609,Cannot tell based on the abstract,, Mean âoffâ-time percentage during waking hours , Pramipexole immediate-release , Pramipexole extended-release ,0,
edin,4438,4128609,No significant difference,"The mean (SE) âoffâ-time percentage during waking hours at baseline for advanced PD patients was 27.78 (0.81) for ER and 30.80 (1.21) for IR, and decreased to 21.68 (1.53) at week 18 for ER and 22.46 (1.61) for IR, respectively (no statistical difference for superiority).", Mean âoffâ-time percentage during waking hours , Pramipexole immediate-release , Pramipexole extended-release ,0,
edin,4335,3511947,Cannot tell based on the abstract,"The total number of epidural top ups (rescue analgesia) required was less in group II (P < 0.05) and group III (P < 0.005) patients, compared with the control group.", Need of rescue analgesia , Normal saline (group I) , Fentanyl and neostigmine (group III) ,0,
edin,4335,3511947,Significantly decreased,The total number of epidural top ups (rescue analgesia) required was less in the fentanyl group (P < 0.05) and fentanylâneostigmine group (P < 0.005) compared with the control group., Need of rescue analgesia , Normal saline (group I) , Fentanyl and neostigmine (group III) ,0,
edin,4418,4317856,No significant difference,"In an efficacy analysis of 94 patients (DZ, 48; D, 46), the median progression-free survival was 2.7 months (95% confidence interval [CI], 1.5â3.5 months) for the DZ group and 2.6 months (95% CI, 1.5â3.4 months) for the D group (stratified log-rank test, P = 0.89).", Median progression-free survival , Docetaxel alone (group D) , Docetaxel with zoledronic acid (group DZ) ,0,
edin,4397,5590362,Significantly decreased,The lowest mean pain score recorded in the massage group (0.92) whereas it was 4.84 in the breastfeeding group and 6.16 in the control group. ANOVA test and post-hoc statistics revealed that both interventions resulted in a significant reduction of the pain scores., Mean pain score , Control (group 3) , Breastfeeding (group 1) ,0,
edin,4444,3941910,Significantly increased,"The results showed that MS media containing 1.5 mg/L kinetin along with 0.15 or 0.3 mg/L NAA produced the highest percentage of proliferated shoots. In addition, the percentage of proliferated shoots in MS medium containing 2.0 or 2.5 mg/L benzylaminopurine (BAP) + 0.15 mg/L NAA was significantly higher than the other treatments.", Number of proliferated shoots ," kinetin (1.5 mg/L) + NAA (0.3 mg/L), and/or MS media containing 0.15 mg/L NAA along with kinetin 1.5 or 2.0 mg/L ", MS medium containing 1.5 mg/L kinetin + 0.15 mg/L NAA ,0,
edin,4441,5047020,Significantly increased,"In hydroxyethyl starch (Voluven) and normal saline groups, base excess level after solution therapy increased about 9.65 and 5.46 volumes, respectively, in which augmentation in hydroxyethyl starch (Voluven) group is significantly higher than normal saline group (P â¤ 0.001).", Level of base excess after therapy , Normal saline , Hydroxyethyl starch (Voluven) ,0,
edin,4334,3511947,Significantly increased,The durations of complete analgesia and effective analgesia were longer for all patients in group III compared with group II (P < 0.05) and group I (P < 0.005) patients., Complete analgesia and effective analgesia duration , Normal saline (group I) , Fentanyl and neostigmine (group III) ,0,
edin,4374,5054596,Cannot tell based on the abstract,, IoF-scores improvement , Control , Direct grasping ,0,
edin,4374,5054596,Significantly increased,"A repeated measures ANOVA on the IoF-scores demonstrated a main effect of test, in that the four training groups and control group improved on IoF-scores on the posttest, RT1 and RT2 compared with the pretest and also improved from posttest to RT1 and RT2 (pâsâ<â.001 in pairwise comparison) (TableÂ 1).", IoF-scores improvement , Control , Direct grasping ,0,
edin,4331,3557743,No significant difference,There was no significant difference in the overall prevalence of comorbidities and nutritional deficiencies., Comorbidities , Roux-en-Y gastric bypass , Laparoscopic sleeve gastrectomy ,0,
edin,4326,3043099,Cannot tell based on the abstract,, Glucose area under the curve , NonHispanic whites , Mexican Americans ,0,
edin,4326,3043099,No significant difference,The pre-intervention IVGTT revealed no significant differences in glucose area under the curve between ethnic groups ( Figure 1 )., Glucose area under the curve , NonHispanic whites , Mexican Americans ,0,
edin,4404,4540107,Significantly decreased,"After 12 weeks, the DM60 group had significantly longer treatment retention and lower plasma morphine levels than did the placebo group.", Morphine levels in plasma , Placebo , Dextromethorphan (DM60) ,0,
edin,4328,3557743,No significant difference,"There was no 30-day mortality and no significant difference in major complication rate (0% after RYGB and 8.3% after LSG, p > 0.05) or minor complication rate (16.6% after RYGB and 10.1% after LSG, p > 0.05).", Rate of minor and major complications  , Roux-en-Y gastric bypass , Laparoscopic sleeve gastrectomy ,0,
edin,4354,4030712,Significantly decreased,"Analysis of variance demonstrated an overall treatment effect on distal radius BMD (p = 0.005), with the active treatment groups showing a lower rate of BMD loss when compared to the placebo group.", Rate of bone mineral density loss , Placebo , Calcium and vitamin D3 supplementation ,0,
edin,4350,5103733,Significantly decreased,"However, the serum level of cardiac troponin I was higher in patients of the control group compared with those of the esmolol group during the preoperative period (P<0.05).", Cardiac troponin I during the preoperative period , Control group , Esmolol group ,0,
edin,4394,4892327,Significantly increased,"Also, results indicated a significant increase in Bax/Bcl-2 ratio in ischemia group, compared to sham-operated group (P<0.001).", Bax/Bcl-2 ratio , Sham group , Ischemia group ,0,
edin,4312,4139980,Cannot tell based on the abstract,, Serum hemoglobin and ferritin levels at 8 weeks , Placebo therapy , Omega-3 therapy ,0,
edin,4312,4139980,No significant difference,Serum iron and ferritin level and hemoglobin had no significant differences as did for Erythropoietin need during study [Table 2]., Serum hemoglobin and ferritin levels at 8 weeks , Placebo therapy , Omega-3 therapy ,0,
edin,4313,4139980,No significant difference,Erythropoietin requirements also had no significant differences., Need of erythropoietin , Placebo therapy , Omega-3 therapy ,0,
edin,4419,4317856,No significant difference,"The median overall survival was 10.4 months (95% CI, 7.0â15.8 months) for the DZ group and 9.7 months (95% CI, 6.1â12.5 months) for the D group (stratified log-rank test, P = 0.62).", Median overall survival , Docetaxel alone (group D) , Docetaxel with zoledronic acid (group DZ) ,0,
edin,4411,5564145,Cannot tell based on the abstract,, Onset of local anesthesia , Single cartridges of 4% articaine , Double cartridges of 4% articaine ,0,
edin,4411,5564145,No significant difference,Table 2 shows the onset of local anesthesia and there was no significant difference (P > 0.05) between the groups despite the fact that the DC group had early onset of anesthesia compared to the SC group., Onset of local anesthesia , Single cartridges of 4% articaine , Double cartridges of 4% articaine ,0,
edin,4352,5292014,Significantly increased,"NCOVA showed that after adjusting for effects of pretest scores, the difference between mean scores on the scale of lifestyle related to vaginal health in the intervention group (28.48 Â± 0.38) and control group (23.65 Â± 1.23) was significant (P < 0.001).,According to the findings, educational intervention is beneficial in promoting three aspects of women's lifestyle related to vaginal health.", Improvement in mean scores of lifestyle-related vaginal health scale , Routine treatment , Educational intervention ,0,
edin,4435,4128609,No significant difference,"Non-inferiority was based on the primary endpoint, the change from baseline to end of maintenance (week 18) in the UPDRS (Parts IIâ+âIII) total score.,For the primary endpoint, the adjusted mean changes (standard error) of UPDRS Parts IIâ+âIII at week 18 were -13.81 (0.655) and -13.05 (0.643) for ER and IR formulations, respectively, using ANCOVA adjusted for treatment and centre (fixed effect) and baseline (covariate).", UPDRS total score , Pramipexole immediate-release , Pramipexole extended-release ,0,
edin,4382,5986454,Significantly increased,"Subjects showed a significant improvement in performance in the UchidaâKraepelin test, the primary outcome measured, when they consumed the acidified milk protein drink compared with the placebo control condition.", Improvement in UchidaâKraepelin test score  , Isoenergetic placebo drink , Acidified milk protein drink ,0,
edin,4367,4396730,Cannot tell based on the abstract,, LDL-C and blood pressure , Placebo , Sulodexide composed of 80% fast-moving heparin and 20% dermatan sulfate ,0,
edin,4367,4396730,No significant difference,"Moreover, body weight, fasting plasma glucose, hemoglobin A1C, LDL-cholesterol, systolic blood pressure, and diastolic blood pressure were comparable in both groups and did not change significantly throughout the study (Table 2).", LDL-C and blood pressure , Placebo , Sulodexide composed of 80% fast-moving heparin and 20% dermatan sulfate ,0,
edin,4332,3511947,Significantly decreased,Overall 24-h visual analog score in group III was significantly less than in those who received fentanyl alone (P = 0.00)., 24-h visual analog score , Fentanyl and normal saline (group II) , Fentanyl and neostigmine (group III) ,0,
edin,4376,5054596,Cannot tell based on the abstract,, Force required to pick-up an object , Combination , Indirect grasping ,0,
edin,4376,5054596,Significantly decreased,"A large main effect of group was found for the grasp force when grasping the object, which showed that the IG group required less force than the COM group in order to pick up an object (pâ<â0.05 in pairwise comparisons).", Force required to pick-up an object , Combination , Indirect grasping ,0,
edin,4388,5018700,No significant difference,"The 2 oxycodone groups showed no significant differences in MBP, HR, SpO2, and BIS compared to Group F at the time points assessed. T", Heart rate , Fentanyl (Group F) , Oxycodone (Group O/70 and Group O/100) ,0,
edin,4387,5018700,No significant difference,"The 2 oxycodone groups showed no significant differences in MBP, HR, SpO2, and BIS compared to Group F at the time points assessed.", Mean blood pressure , Fentanyl (Group F) , Oxycodone (Group O/70 and Group O/100) ,0,
edin,4442,5047020,Cannot tell based on the abstract,, Incidence of adverse events , Normal saline , Hydroxyethyl starch (Voluven) ,0,
edin,4442,5047020,Cannot tell based on the abstract,, Incidence of adverse events , Normal saline , Hydroxyethyl starch (Voluven) ,0,
edin,4442,5047020,No significant difference,"Besides, in neither of the two groups, adverse reaction to the received solutions was observed.", Incidence of adverse events , Normal saline , Hydroxyethyl starch (Voluven) ,0,
edin,4399,5590362,Cannot tell based on the abstract,, Weight at randomization , Control (group 3) , Breastfeeding (group 1) or Massage (group 2) ,0,
edin,4399,5590362,No significant difference,"As mentioned before, randomization was successful as there was no significant difference in groups concerning age, sex, and weight.", Weight at randomization , Control (group 3) , Breastfeeding (group 1) or Massage (group 2) ,0,
edin,4410,5564145,Significantly increased,The DC of 4 % articaine had a significantly higher success rate (83.3%) than did the SC (53.3%; P < 0.05)., Success rate , Single cartridges of 4% articaine , Double cartridges of 4% articaine ,0,
edin,4362,5588713,Cannot tell based on the abstract,, Leukocytes in blood , Placebo , Nanoparticles ,0,
edin,4362,5588713,Significantly increased,There was a significant dose-dependent increase in blood neutrophils (Spearman pÂ =Â 0.0468) and a trend towards increased blood leukocytes (pÂ =Â 0.061) after challenge with carbon nanoparticles as compared to placebo., Leukocytes in blood , Placebo , Nanoparticles ,0,
edin,4381,3199060,Cannot tell based on the abstract,, Enjoyment by playing Resident evil , Traditional controllers , Motion-based controllers ,0,
edin,4381,3199060,Significantly increased,The motion-controlled Resident Evil game produced a 1.39 (95% CI 0.84â1.95) point higher enjoyment rating (on a scale of 1â7) than the traditionally controlled Resident Evil game., Enjoyment by playing Resident evil , Traditional controllers , Motion-based controllers ,0,
edin,4361,5588713,Cannot tell based on the abstract,, Adverse events , Placebo , Nanoparticles ,0,
edin,4361,5588713,No significant difference,"Interim analysis, as assessed by the DSMB, after completion of each dose-group showed no significant adverse events, symptoms, or doubling of white blood cell counts.", Adverse events , Placebo , Nanoparticles ,0,
edin,4349,5103733,Significantly increased,"No significant differences in hemodynamic parameters, including the central venous pressure and heart rate, were detected between patients in the two groups during the perioperative period or within the first 12 h post-surgery (P>0.05), except for the mean arterial pressure, which was higher in the esmolol group compared with the control group at 5 and 12 h post-surgery (P<0.05).", Mean arterial pressure after the surgery , Control group , Esmolol group ,0,
edin,4348,5103733,No significant difference,"No significant differences in hemodynamic parameters, including the central venous pressure and heart rate, were detected between patients in the two groups during the perioperative period or within the first 12 h post-surgery (P>0.05),", Heart rate , Control group , Esmolol group ,0,
edin,4323,4283272,Cannot tell based on the abstract,, Hypoglyacemic events , Placebo , Sitagliptin and lansoprazole ,0,
edin,4323,4283272,No significant difference,The frequencies of various adverse events and the frequencies of hypoglyacemic events did not differ significantly between the two groups (table 3)., Hypoglyacemic events , Placebo , Sitagliptin and lansoprazole ,0,
edin,4342,5551190,Cannot tell based on the abstract,, Distance ran , Nature-based images , Self-selected entertainment ,0,
edin,4342,5551190,Significantly increased,"Distance run was influenced by the designs, F (29) = 10.572, p < 0.05, pÆ2 = 0.2 with participants in the self-selected entertainment condition (3066.8 Â± 688.5 m) running longer distances than the static image condition (2767.2 Â± 662.6 m) (p < 0.05).", Distance ran , Nature-based images , Self-selected entertainment ,0,
edin,4341,5122613,Cannot tell based on the abstract,, Baseline characteristics and diet , Placebo , Digestion-resistant maltodextrin ,0,
edin,4341,5122613,No significant difference,"The two study groups were well balanced with respect to demographics and baseline characteristics, and no significant difference was found in any of the variables between groups.", Baseline characteristics and diet , Placebo , Digestion-resistant maltodextrin ,0,
edin,4353,5292014,Cannot tell based on the abstract,, Demographic characteristics and vaginitis relapse , Routine treatment , Educational intervention ,0,
edin,4353,5292014,No significant difference,"<td colspan=""1"" rowspan=""1"" style=""padding-left: 20pt;"">Two times</td><td colspan=""1"" rowspan=""1"" style=""text-align: center;"">72 (41.1)</td><td colspan=""1"" rowspan=""1"" style=""text-align: center;"">56 (32.6)</td><td colspan=""1"" rowspan=""1"" style=""text-align: center;""></td>", Demographic characteristics and vaginitis relapse , Routine treatment , Educational intervention ,0,
edin,4412,5564145,Cannot tell based on the abstract,, Duration of surgery , Single cartridges of 4% articaine , Double cartridges of 4% articaine ,0,
edin,4412,5564145,No significant difference,"However, the difference in surgical time between SC and DC had no statistical significance (P > 0.05).", Duration of surgery , Single cartridges of 4% articaine , Double cartridges of 4% articaine ,0,
edin,4407,4540107,No significant difference,"However, changes in plasma cytokine levels, BDNF levels, and the methadone dose required in the three groups were not significantly different.", Methadone requirement , Placebo , Dextromethorphan (DM60 and DM120) ,0,
edin,4432,5726464,Cannot tell based on the abstract,, Glucose and insulin , Placebo , Vitamin D plus calcium supplementation ,0,
edin,4432,5726464,No significant difference,"Between-arm differences were not significant for glucose, insulin, or HOMA-IR changes at either week 24 or week 48 (P > .05 for all).", Glucose and insulin , Placebo , Vitamin D plus calcium supplementation ,0,
edin,4416,3829814,Cannot tell based on the abstract,,  Lung function and asthma symptoms , Placebo , Lactobacillus casei Shirota ,0,
edin,4416,3829814,No significant difference,"There were no differences between the two groups for TNSS, PNIF, asthma symptoms or lung function at any of the time points following the nasal allergen challenge before or after the intervention period (Fig. 2).",  Lung function and asthma symptoms , Placebo , Lactobacillus casei Shirota ,0,
edin,4390,5018700,No significant difference,"The 2 oxycodone groups showed no significant differences in MBP, HR, SpO2, and BIS compared to Group F at the time points assessed.", Bispectral index , Fentanyl (Group F) , Oxycodone (Group O/70 and Group O/100) ,0,
edin,4415,3829814,Significantly increased,"Delivery of probiotic also suppressed production of sCD23 (pâ=â0.0081), TGF-Î² (pâ=â0.0283) and induced increased production of IFN-Î³ (pâ=â0.0351) in supernatants of cultured peripheral blood.", Production of IFN-Î³ , Placebo , Lactobacillus casei Shirota ,0,
edin,4359,4395675,Cannot tell based on the abstract,, Overall balance ability , Gait training alone , Gait training with constrained induced movement therapy ,0,
edin,4359,4395675,Significantly increased,"The experimental group showed an improvement of 28.6% in dynamic balance as determined by the TIS, and of 34.3% in movement distances of the paretic side as determined by the LOS, and the changes in dynamic balance were significantly larger in the experimental group than in the control group, which showed no significant improvements in balance ability after gait training.", Overall balance ability , Gait training alone , Gait training with constrained induced movement therapy ,0,
edin,4316,5920342,Cannot tell based on the abstract,, Time of hospitalization after the surgery , No monitoring , Soleus muscle H-reflex monitoring ,0,
edin,4316,5920342,Significantly decreased,"The operation time in observation group (65.5Â±2.1 min) was shorter than that in control group (76.5Â±3.2 min) (t=18.176, P<0.05); the intraoperative blood loss amount in observation group (28.9Â±1.7 ml) was less than that in control group (56.8Â±5.6 ml) (t=30.151, P<0.05); the postoperative hospitalization time in observation group (5.9Â±1.1 days) was shorter than that in control group (8.1Â±1.5 days) (t=7.378, P<0.05; Fig. 1).", Time of hospitalization after the surgery , No monitoring , Soleus muscle H-reflex monitoring ,0,
edin,4373,5054596,Cannot tell based on the abstract,"On a kinematic level movement times decreased and hook closing velocities increased over time.,During training movement times decreased and the indirect grasping group showed advantages. It is advisable to start body-powered training with indirect grasping tasks but also to practice hook-object orientations.", Movement times ," Direct grasping, fixation, or combination ", Indirect grasping ,0,
edin,4373,5054596,Significantly decreased,"On a kinematic level movement times decreased and hook closing velocities increased over time. The indirect grasping group showed significantly shorter plateau times than the other training groups,During training movement times decreased and the indirect grasping group showed advantages.", Movement times ," Direct grasping, fixation, or combination ", Indirect grasping ,0,
edin,4319,4283272,Cannot tell based on the abstract,, C-peptide AUC , Placebo , Sitagliptin and lansoprazole ,0,
edin,4319,4283272,No significant difference,"During the course of the study, the C-peptide AUC fell to a similar extent and significantly from baseline in each group (table 2); comparison of these differences was not significant (p=0Â·91; figure 2A)", C-peptide AUC , Placebo , Sitagliptin and lansoprazole ,0,
edin,4385,5986454,Cannot tell based on the abstract,, Net incremental area under the curve , Isoenergetic placebo drink , Acidified milk protein drink ,0,
edin,4385,5986454,Significantly increased,"To assess the postprandial effect of the drinks throughout the testing time, the net incremental area under the curve (niAUC), calculated from the pre- and postprandial time points, were tested.,The niAUC was significantly higher when subjects consumed the acidified milk protein drink compared to the placebo drink (p = 0.044).", Net incremental area under the curve , Isoenergetic placebo drink , Acidified milk protein drink ,0,
edin,4371,4198846,Significantly increased,The total ITAQ score also showed significant improvement in both groups over the three months and the degree of improvement was significantly greater in the CRT group than in the TAU group., Improvement in the Insight and Treatment Attitude Questionnaire , Treatment as usual , Cognitive remediation therapy ,0,
edin,4392,4892327,Significantly increased,"The number of active caspase-3-positive neurons in CA1 area were significantly increased in ischemia group, compared to sham-operated group (P<0.001)", Active caspase-3-positive neurons in CA1 area , Sham group , Ischemia group ,0,
edin,4439,2686715,Significantly increased,Highly significant improvements in motor performance were observed with MPH compared to baseline ratings on all the 17 subtests of the MFNU 1â2 hr after administration of MPH., Motor performance improvement , Placebo , Methylphenidate ,0,
edin,4347,5103733,No significant difference,"No significant differences in hemodynamic parameters, including the central venous pressure and heart rate, were detected between patients in the two groups during the perioperative period or within the first 12 h post-surgery (P>0.05),", Central venous pressure , Control group , Esmolol group ,0,
edin,4557,4855961,Significantly increased,"The postsupplementation levels of 25(OH)D were higher in Group 2K (42.86 Â± 12.83) than in Group 1K (36.96 Â± 10.56) with P value of 0.023.,We concluded that Vitamin D supplementation with 2000 IU/day or 60,000 IU/month is very effective and safe in achieving Vitamin D sufficiency in pregnant women.",  25-hydroxyvitamin D , Control , 60.000 IU monthly ,0,
edin,4654,5457252,Cannot tell based on the abstract,, Shear bond strength , Control , 1.0 M EDC treatment  ,0,
edin,4654,5457252,Significantly decreased,"The SBS was significantly influenced by the 1.0 M EDC concentration (P < 0.0001); specifically, the mean SBS dropped dramatically compared with the other groups.", Shear bond strength , Control , 1.0 M EDC treatment  ,0,
edin,4635,4823346,Cannot tell based on the abstract,, Return to work , Semi-rigid ankle support  , Tape ,0,
edin,4635,4823346,No significant difference,"<td align=""left"">&nbsp;Below level</td><td align=""left"">15&nbsp;% (8/55)</td><td align=""left"">12&nbsp;% (5/41)</td><td align=""left"">11&nbsp;% (5/44)</td><td align=""left""></td>,TableÂ 3", Return to work , Semi-rigid ankle support  , Tape ,0,
edin,4616,2427034,Significantly increased,The A2143G mutation rate among the 23S rRNA-positive subjects in the OAC group [31.7% (13/41)] was significantly higher than that in the OA group [10.2% (16/157)] and the placebo group [13.8% (36/260)]., A2143G mutation , Placebo , Amoxicillin + Omeprazole + Clarithromycin ,0,
edin,4589,4149239,No significant difference,<td>C-peptide</td><td></td><td></td><td></td><td></td><td></td>, Glucagon-like peptide-1 , Voglibose , Sitagliptin ,0,
edin,4650,3095445,Cannot tell based on the abstract,, Postmicturition score improvement , Control , Naftopidil 75 mg ,0,
edin,4650,3095445,Significantly increased,"The 75âmg group showed improvement in all of these in a time-dependent and dose-dependent manner (baseline versus 4 weeks after treatment: P < .001 in all; 4 weeks after treatment versus 8 weeks after treatment: P = .019, P = .057, P = .047, P = .057, and P = .003, resp.), although the difference in the storage and postmicturition scores were of borderline significance between at 4 weeks and 8 weeks (Figures 1(b) and 1(d)).", Postmicturition score improvement , Control , Naftopidil 75 mg ,0,
edin,4491,5880177,Cannot tell based on the abstract,, Risk of death , Being on Class 3 , Being on Class 1 ,0,
edin,4491,5880177,Significantly increased,"As compared with class 3, class 1 (OR: 2.76; 95% CI [1.38â5.82]) was associated with higher risk of death.", Risk of death , Being on Class 3 , Being on Class 1 ,0,
edin,4584,4941128,Cannot tell based on the abstract,, Tremor improvement , Control , Adaptive deep brain stimulation ,0,
edin,4584,4941128,Significantly increased,"Remaining items, including tremor, speech, facial expression and freezing, improved by 55Â±12%.,There was a substantial improvement with aDBS in every participant (43% reduction: t3=3.24, p=0.04; Cohen's d=1.62).", Tremor improvement , Control , Adaptive deep brain stimulation ,0,
edin,4488,5448649,Cannot tell based on the abstract,, IFNÃ¢â¬ï¿½ÃÂ³ spot numbers , Control , Cyclophosphamide ,0,
edin,4488,5448649,No significant difference,"The numbers of wells positive for IFNâÎ³ spots among total wells examined were 16 of 93 (17%) or 16 of 105 (15%) wells in preâvaccination PBMC, 23 of 78 (29%) or 20 of 93 (22%) at the 6th vaccination, and 31 of 58 (58%) or 20 of 44 (45%) at the 12th vaccination in the PPV/CPA or PPV alone, respectively,Although not statistically significant (P = 0.334), the increase of IFNâÎ³ spot numbers per well in the PPV/CPA tended to be greater than that in the PPV alone at the 12th vaccination (Fig. 2a).", IFNÃ¢â¬ï¿½ÃÂ³ spot numbers , Control , Cyclophosphamide ,0,
edin,4562,4359119,Cannot tell based on the abstract,, Mental health score , MOR approach , PASTOR approach ,0,
edin,4562,4359119,No significant difference,"For mental health score (SF 12), and total activity sub score (FFkA), as well as further endurance related responses to pain (AEQ) there were no differences between both groups at the end of rehabilitation, as well as at the 12-month follow-up (Table 6, Table 8).", Mental health score , MOR approach , PASTOR approach ,0,
edin,4524,5010179,Cannot tell based on the abstract,, Recurrence-free survival , Control , Uracil-tegafur and leucovorin ,0,
edin,4524,5010179,Significantly increased,"The recurrence-free survival curves of the UFT/LV group (red line) and surgery alone group (black line) group are shown. The 3-year recurrence-free rate was significantly higher in the UFT/LV group than in the surgery alone group (38.6% vs. 32.3%, P = 0.003).", Recurrence-free survival , Control , Uracil-tegafur and leucovorin ,0,
edin,4494,5874317,Cannot tell based on the abstract,, Knee flexion (1-rep Max) , Unilateral training , Bilateral training ,0,
edin,4494,5874317,Significantly increased,"Results from between-group analyses are illustrated in Figure 2. The beneficial changes in 1RM_KE (8.1% [CL90%: 4.2; 11.8]; QC = 99/0/0%; p = 0.074) and 1RM_KF (6.7% [CL90%: 2.8; 10.4]; QC = 98/1/0%; p = 0.004),", Knee flexion (1-rep Max) , Unilateral training , Bilateral training ,0,
edin,4461,5360998,Cannot tell based on the abstract,, Good TMT-A results , Being in the Stop gruop , Being in the Safe gruop ,0,
edin,4461,5360998,Significantly decreased,"TMT-A, TMT-B, and MOCA-K showed significant differences between the three groups.,Additionally, the caution group showed higher ability in the TMT-B and MOCA-K than the stop group.,<td align=""left"" colspan=""1"" rowspan=""2"" valign=""top"">TMT</td><td align=""left"" colspan=""1"" rowspan=""1"">TMT-A (second)</td><td align=""center"" colspan=""1"" rowspan=""1"">46.88 Â± 13.45<sup>a*</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">62.65 Â± 30.39</td><td align=""center"" colspan=""1"" rowspan=""1"">83.25 Â± 30.00<sup>a*</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">4.362*</td>", Good TMT-A results , Being in the Stop gruop , Being in the Safe gruop ,0,
edin,4588,4149239,No significant difference,<td>C-peptide</td><td></td><td></td><td></td><td></td><td></td>, Gastric inhibitory polypeptide , Voglibose , Sitagliptin ,0,
edin,4609,2630316,Cannot tell based on the abstract,,  Health related quality of life (physical) , Care at clinic , Care at home ,0,
edin,4609,2630316,No significant difference,Health related quality of life scores physical (PCS) and mental component scores (MCS) were not statistically different between the groups,  Health related quality of life (physical) , Care at clinic , Care at home ,0,
edin,4652,3095445,Cannot tell based on the abstract,, Postmicturition score improvement , Control , Naftopidil 50 mg ,0,
edin,4652,3095445,Significantly decreased,"In the 50âmg group, all of these scores reduced 4 weeks after treatment compared with those at baseline (P = .004, P = .015, P = .020, P = .041, and P < .001, resp.); these scores were not different between 4 weeks and 8 weeks after treatment (Figures 1(a)â1(e)), although the difference was of borderline significance regarding the QOL score (P = .053).", Postmicturition score improvement , Control , Naftopidil 50 mg ,0,
edin,4556,4855961,Cannot tell based on the abstract,"Group 2 (n = 21), 30,000 IU",  25-hydroxyvitamin D , Control , 30.000 IU monthly ,0,
edin,4556,4855961,Significantly increased,"ne of the primary objectives of the study was to find the difference in the postsupplementation levels of 25(OH)D between Group 1K and 2K regimen. As shown in Table 3, there was a significant difference (P = 0.023) between these two groups with Group 2K showing higher levels.",  25-hydroxyvitamin D , Control , 30.000 IU monthly ,0,
edin,4651,3095445,Cannot tell based on the abstract,, Storage score improvement , Control , Naftopidil 50 mg ,0,
edin,4651,3095445,Significantly decreased,"n the 50âmg group, all of these scores reduced 4 weeks after treatment compared with those at baseline (P = .004, P = .015, P = .020, P = .041, and P < .001, resp.); these scores were not different between 4 weeks and 8 weeks after treatment (Figures 1(a)â1(e)), although the difference was of borderline significance regarding the QOL score (P = .053).", Storage score improvement , Control , Naftopidil 50 mg ,0,
edin,4532,1831486,Cannot tell based on the abstract,, Nicotine replacement therapy , Control , 1 auricular acupressure bead ,0,
edin,4532,1831486,No significant difference,"Reporting of NRT consumption was poor, with much missing data, but reporting of ratings of withdrawal symptom scores was nearly complete. However, these showed no significant changes or differences between groups for any week.", Nicotine replacement therapy , Control , 1 auricular acupressure bead ,0,
edin,4548,2892494,Significantly decreased,"Compared with patients with PSP â¥ 71 group, the hazard for new hospitalization was 8.351 times greater (P = 0.0001) for patients with the poorest functioning (PSP 1 to 30) and 1.977 times greater (P = 0.0295) for patients with PSP of 31-70 compared to the â¥ 71 group.", Hospitalization , Low PSP Score , High PSP Score ,0,
edin,4483,3289190,Significantly increased,The results showed that the Pilates training group improved flexibility significantly (P<0.001) during time intervals., Flexibility , Control , Pilates 4 weeks ,0,
edin,4560,4359119,Cannot tell based on the abstract,, Fear-avoidance responses improvement , MOR approach , PASTOR approach ,0,
edin,4560,4359119,Significantly increased,"In the ANCOVA there were significant adjusted between-group differences in favour of PASTOR for physical health status (SF 12), all cognitive and behavioural pain coping strategies (FESV) as well as the most fear-avoidance responses (AEQ) with the subscales help-/hopelessness, anxiety/depression, avoidance of social activities and physical activities at the end of rehabilitation, as well as at the 12-month follow-up (Tables 6â8).", Fear-avoidance responses improvement , MOR approach , PASTOR approach ,0,
edin,4622,3576519,Cannot tell based on the abstract,, Nasal congestion , Placebo , Oral vaccine ,0,
edin,4622,3576519,Significantly increased,"The cumulative frequency of abdominal pain, diarrhoea, and nasal congestion after all three vaccinations was significantly higher in vaccinees than placebo recipients (21 [16Â·8%] of 125 vs one [2Â·4%] of 41, p=0Â·017; 24 [19Â·2%] of 125 vs two [4Â·9%] of 41, p=0Â·027; 41 [32Â·8%] of 125 vs six [14Â·6%] of 41, p=0Â·028; respectively; appendix).", Nasal congestion , Placebo , Oral vaccine ,0,
edin,4617,2427034,Significantly increased,The frequency of the AAGGG â CTTCA (2222â2226) and AACC â GAAG (2081â2084) sequence alterations in the OAC group was also significantly higher than those in the OA group and the placebo group., AAGGG â CTTCA sequence alterations , Amoxicillin + Omeprazole , Amoxicillin + Omeprazole + Clarithromycin ,0,
edin,4450,3961596,Cannot tell based on the abstract,, Fasting glucose , Placebo , Luseogliflozin ,0,
edin,4450,3961596,No significant difference,"Although plasma glucose levels decreased slightly at some time points with luseogliflozin administration compared with placebo, luseogliflozin did not produce clinically significant decreases in fasting plasma glucose levels.Fig.Â 5", Fasting glucose , Placebo , Luseogliflozin ,0,
edin,4546,3459547,Cannot tell based on the abstract,, Remission period , Control , Olopatadine 5 mg ,0,
edin,4546,3459547,Significantly increased,"The average remission period was 19.1 days in the 10-mg group, 23.7 days in the 5-mg group, and 11.8 days in the no-medication group. The average remission period was also compared for the three groups. The average period in the 10-mg and 5-mg groups was significantly longer than that in the no-medication group (10 mg, P < 0.01; 5 mg, P < 0.001).", Remission period , Control , Olopatadine 5 mg ,0,
edin,4596,1839864,Cannot tell based on the abstract,, Incorrect identification of cardiac causes of death , Printed instruction material , Interactive workshop ,0,
edin,4596,1839864,Significantly decreased,"Of note, the workshop group showed a dramatic reduction of incorrect identification of cardiac causes of death from 56 to 6% (p<0.001). TableÂ 3", Incorrect identification of cardiac causes of death , Printed instruction material , Interactive workshop ,0,
edin,4517,4030092,No significant difference,"In the lipid trial, the general pattern of results showed no evidence of benefit of intensive regimens (whether single or combined) compared with combined standard lipid and glycemia treatment.", Lipid levels , Standard treatment of glycemia and lipids , Intensive treatment of glycemia and lipids ,0,
edin,4602,4232010,Significantly increased,"The SPTP conferred significant benefit in MOBID-2 scores compared with the control group [average treatment effect (ATE) â1.388; pâ<â0.001] at week 8, and MOBID-2 scores worsened during the washout period (ATEâ=ââ0.701; pâ=â0.022).",  MOBID-2 score improvement after 8 weeks , Control , Pregabalin  ,0,
edin,4496,5874317,Cannot tell based on the abstract,, Squat jump , Unilateral training , Bilateral training ,0,
edin,4496,5874317,No significant difference,"SJ (m)	0.35 Â± 0.05	0.37 Â± 0.04*	6.5 (2.6; 10.6)	0.36 (0.15; 0.58)	90/10/0%	Likely	0.36 Â± 0.05	0.34 Â± 0.04	â6.0 (â12.8; 1.2)	â0.45 (â0.99; 0.09)	3/18/79%	Likely harmful,Although both training groups improved CMJ, CMJd, CMJnd, SJnd, and HC3Jnd, only the TG improved SJ and HCMJ, whereas only the UG improved SJd, H3Jd, H3Jnd, and HC3Jd test results. Moreover, improvements in CMJ, SJ and HCMJ were greater in the TG, whereas CMJd, CMJnd, SJd, H3Jd, H3Jnd, and HC3Jd improvements were greater in the UG.", Squat jump , Unilateral training , Bilateral training ,0,
edin,4466,4411465,Significantly increased,"In SG, a significant advantage is observed for nausea (Î² S â Î² P = â0.398âu, P < 0.001),",  Improvement of nausea  , Placebo , Ginger and artichoke supplementation ,0,
edin,4452,5697645,Significantly increased,"Additionally, the proportion of patients achieving HbA1c <6.5% was significantly higher in the evogliptin group than in the placebo group (33.3% vs 15.2%; P = .008).", Reaching Glycated hemoglobin &amp;lt;6.5% , Placebo , Evogliptin ,0,
edin,4522,2689169,Significantly decreased,"Both the GlidescopeÂ® and the AWSÂ® performed better than the Macintosh, and demonstrate considerable promise in this context. The AWSÂ® had the least number of dental compressions in all three scenarios, and in the cervical spine immobilization scenario it required fewer maneuvers to optimize the view of the glottis.", Severity of dental compression , Macintosh laryngoscope , Glydescope laryngoscope ,0,
edin,4470,3612585,Cannot tell based on the abstract,, Complete response (no emesis + no rescue medication) , Oral Palonosetron 0.25 mg , Oral Palonosetron 0.5 mg ,0,
edin,4470,3612585,No significant difference,"The CR (defined as no emesis and no rescue medication) rates were generally similar in all treatment groups during the acute (0â24Â h) and delayed (24â120Â h) phases, as well as the overall 0â120Â h time interval (Fig.Â 2).", Complete response (no emesis + no rescue medication) , Oral Palonosetron 0.25 mg , Oral Palonosetron 0.5 mg ,0,
edin,4520,2689169,Cannot tell based on the abstract,, Time to intubate , Macintosh laryngoscope , Glydescope laryngoscope ,0,
edin,4520,2689169,No significant difference,"<td align=""left"">Duration (sec, 1<sup>st </sup>attempt)</td><td align=""left"">8 (7, 13)</td><td align=""left"">11 (7, 17)</td><td align=""left"">7 (6, 12)</td><td align=""left"">P = 0.1</td>,There was no significant difference in the duration of tracheal intubation attempts between the GlidescopeÂ® and AWSÂ® devices (Table 2).", Time to intubate , Macintosh laryngoscope , Glydescope laryngoscope ,0,
edin,4558,4855961,Cannot tell based on the abstract,, Pregnancy outcomes , 30.000 IU monthly , 60.000 IU monthly ,0,
edin,4558,4855961,No significant difference,"With respect to the safety of Vitamin D supplementation, overall there were few adverse outcomes in the study population; however the difference in pregnancy outcomes between various study groups did not reach statistical significance.", Pregnancy outcomes , 30.000 IU monthly , 60.000 IU monthly ,0,
edin,4576,4973627,Cannot tell based on the abstract,, General mortality	 , Control , Physical activity alone ,0,
edin,4576,4973627,No significant difference,"Compared with PAâ/HEâ, ageâsexâraceâadjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for allâcause mortality associated with PAâ/HE+, PA+/HEâ, and PA+/HE+ were 0.96 (0.76â1.21), 0.61 (0.52â0.71), and 0.62 (0.52â0.75), respectively (Table 2 and Figure 1).", General mortality	 , Control , Physical activity alone ,0,
edin,4503,4701182,Cannot tell based on the abstract,, Mortality , Tipranavir/Ritonavir (500/100) , Lopinavir/Ritonavir (400/100) ,0,
edin,4503,4701182,No significant difference,"Deathsc	5 (2.7%)	2 (1.1%)	2 (1.1%),Fatalities during the trial were uncommon among these treatment-naive patients; a total of nine (1.6%) deaths were reported, of which eight were during treatment or within 30 days following drug discontinuation.", Mortality , Tipranavir/Ritonavir (500/100) , Lopinavir/Ritonavir (400/100) ,0,
edin,4559,4359119,Significantly increased,"The adjusted between-group difference in the FFbH-R at 12 months was 6.58 (95% CI 3.38 to 9.78) using complete data and 3.56 (95% CI 0.45 to 6.67) using available da-ta, corresponding to significant small-to-medium effect sizes of d=0.42 (p<0.001) and d=0.10 (p=0.025) in favour of PASTOR.,Participants were assessed with self-report measures at baseline, discharge, and 12 months for functional ability (primary outcome) using the Hannover Functional Ability Questionnaire (FFbH-R) and vari-ous secondary outcomes (e.g. pain, health status, physical activity, pain coping, pain-related cognitions).", Functional ability , MOR approach , PASTOR approach ,0,
edin,4663,3056480,Cannot tell based on the abstract,, SEAR Sexual Relationship Satisfaction domain , Sildenafil 50 mg , Sildenafil 100 mg ,0,
edin,4663,3056480,Significantly increased,"The 100-mg fixed dose was significantly more effective than the 50-mg fixed dose in improving the IIEF Overall Satisfaction domain score; the SEAR Sexual Relationship Satisfaction domain, Overall Relationship Satisfaction subscale and Total scores; all SEX-Q domain scores; and the SEX-Q total score (Table 2).", SEAR Sexual Relationship Satisfaction domain , Sildenafil 50 mg , Sildenafil 100 mg ,0,
edin,4624,3576519,Cannot tell based on the abstract,, Interleukin 2 response  , Placebo , Oral vaccine ,0,
edin,4624,3576519,No significant difference,Interleukin-2 responses were much the same (appendix)., Interleukin 2 response  , Placebo , Oral vaccine ,0,
edin,4582,4941128,Cannot tell based on the abstract,, Limb bradykinesia improvement , Control , Adaptive deep brain stimulation ,0,
edin,4582,4941128,No significant difference,"For limb bradykinesia and axial symptoms, the reductions were 37Â±10% and 39Â±5%, respectively.", Limb bradykinesia improvement , Control , Adaptive deep brain stimulation ,0,
edin,4583,4941128,Cannot tell based on the abstract,, Axial symptoms improvement , Control , Adaptive deep brain stimulation ,0,
edin,4583,4941128,No significant difference,"For limb bradykinesia and axial symptoms, the reductions were 37Â±10% and 39Â±5%, respectively.", Axial symptoms improvement , Control , Adaptive deep brain stimulation ,0,
edin,4507,4450858,Significantly decreased,"Most women required oxytocin (77Â %). The outpatient group were 24Â % less likely to require oxytocin (risk difference â23.6Â %, 95Â % CI â43.8 to â3.5).", Need of oxytocin , Conventional inpatient procedures , Balloon catheter ripening (at home) ,0,
edin,4533,1831486,No significant difference,"Reporting of NRT consumption was poor, with much missing data, but reporting of ratings of withdrawal symptom scores was nearly complete. However, these showed no significant changes or differences between groups for any week.", Nicotine replacement therapy , 2 auricular acupressure beads , 1 auricular acupressure bead ,0,
edin,4498,5874317,Cannot tell based on the abstract,, Horizontal triple jump (non-dominant leg)  , Unilateral training , Bilateral training ,0,
edin,4498,5874317,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">H3Jnd (m)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">6.29 Â± 0.30</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">6.29 Â± 0.31</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">0.0 (â0.4; 0.3)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">â0.01 (â0.07; 0.05)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">0/100/0%</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">Most Likely trivial</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">5.97 Â± 0.33</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">6.35 Â± 0.34<sup>*</sup></td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">6.4 (2.7; 10.3)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">0.99 (0.42; 1.55)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">98/1/0%</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">Very Likely</td>", Horizontal triple jump (non-dominant leg)  , Unilateral training , Bilateral training ,0,
edin,4565,4639584,Cannot tell based on the abstract,, Weight after 8 weeks , Normal flour , Fiber enriched flour ,0,
edin,4565,4639584,Significantly decreased,"Weight and BMI resulted significantly lower in Group A after the 4-week placebo period (change from baseline â1.35Â kg, p<0.01; â0.57Â kg/m2, p<0.01, respectively). We observed a further decrease in weight and BMI in this group after the period of fiber-enriched diet (change from placebo â1.4Â kg, pÂ =Â 0.01; â0.22Â kg/m2, pÂ =Â 0.02, respectively). In Group B we observed a significant reduction of weight and BMI after the fiber enriched period (change from baseline â1.52Â kg, p<0.01; â0.58Â kg/m2, p<0.01, respectively), and an additional slight decrease of weight after the period of placebo diet (â0.78Â kg, pÂ =Â 0.05).", Weight after 8 weeks , Normal flour , Fiber enriched flour ,0,
edin,4610,2630316,Cannot tell based on the abstract,,  Health related quality of life (mental) , Care at clinic , Care at home ,0,
edin,4610,2630316,No significant difference,Health related quality of life scores physical (PCS) and mental component scores (MCS) were not statistically different between the groups,  Health related quality of life (mental) , Care at clinic , Care at home ,0,
edin,4577,4973627,Cannot tell based on the abstract,"Compared with PAâ/HEâ, ageâsexâraceâadjusted hazard ratios and 95% confidence intervals for allâcause mortality for PAâ/HE+, PA+/HEâ, and PA+/HE+ groups were 0.96 (0.76â1.21), 0.61 (0.52â0.71), and 0.62 (0.52â0.75), respectively.", General mortality	 , Control , Healthy eating alone ,0,
edin,4577,4973627,No significant difference,"Compared with PAâ/HEâ, ageâsexâraceâadjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for allâcause mortality associated with PAâ/HE+, PA+/HEâ, and PA+/HE+ were 0.96 (0.76â1.21), 0.61 (0.52â0.71), and 0.62 (0.52â0.75), respectively (Table 2 and Figure 1).,<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">PAâ/HE+ (<italic>n</italic>â=â162)</td><td align=""char"" char=""("" colspan=""1"" rowspan=""1"" valign=""top"">61% (98)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"" valign=""top"">0.90 (0.71â1.13); <italic>P</italic>â=â0.358</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"" valign=""top"">0.96 (0.76â1.21); <italic>P</italic>â=â0.719</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"" valign=""top"">0.97 (0.76â1.23); <italic>P</italic>â=â0.779</td>", General mortality	 , Control , Healthy eating alone ,0,
edin,4623,3576519,Cannot tell based on the abstract,, Interferon Î³ response  , Placebo , Oral vaccine ,0,
edin,4623,3576519,Significantly increased,"Interferon-Î³ T-cell response to recombinant H5 haemagglutinin protein or peptide pools ranged from 38% (nine of 24 vaccinees) with 107 VP to 70% (16 of 23 vaccines) with 1011 VP, compared with only 5% (two of 41) of placebo recipients (figure 2).", Interferon Î³ response  , Placebo , Oral vaccine ,0,
edin,4513,4030092,Significantly decreased,"In the BP trial, risk of the primary outcome was lower in the groups intensively treated for glycemia (hazard ratio [HR] 0.67; 95% CI 0.50â0.91), BP (HR 0.74; 95% CI 0.55â1.00), or both (HR 0.71; 95% CI 0.52â0.96) compared with combined standard BP and glycemia treatment."," Primary outcomes (CVD deaths, nonfatal MI, nonfatal stroke) ", Standard treatment of glycemia and BP , Intensive treatment of BP ,0,
edin,4545,3459547,Cannot tell based on the abstract,, Remission period , Control , Olopatadine 10 mg ,0,
edin,4545,3459547,Significantly increased,"The average remission period was 19.1 days in the 10-mg group, 23.7 days in the 5-mg group, and 11.8 days in the no-medication group. The average remission period was also compared for the three groups. The average period in the 10-mg and 5-mg groups was significantly longer than that in the no-medication group (10 mg, P < 0.01; 5 mg, P < 0.001).", Remission period , Control , Olopatadine 10 mg ,0,
edin,4473,3612585,No significant difference,"Acute CR rates were 73.5, 76.3, 74.1, and 70.4Â % for all patients receiving the palonosetron 0.25, 0.50, and 0.75Â mg oral doses, and for IV palonosetron 0.25Â mg, respectively; delayed CR (24â120Â h) rates were 59.4, 62.5, 60.1, and 65.4Â %, and overall CR (0â120Â h) rates were 53.5, 58.8, 53.2, and 59.3Â %, respectively.", Complete response (no emesis + no rescue medication) , Oral Palonosetron 0.25 mg , IV Palonosetron 0.5 mg ,0,
edin,4642,4273016,Cannot tell based on the abstract,, Psychological distress , Control , Stress managin training ,0,
edin,4642,4273016,Significantly decreased,"<td align=""left"" colspan=""1"" rowspan=""1"" style=""padding-left:10pt"">Psychological distress</td><td align=""right"" colspan=""1"" rowspan=""1"">2.0</td><td align=""left"" colspan=""1"" rowspan=""1"">(0.56)</td><td align=""right"" colspan=""1"" rowspan=""1"">2.0</td><td align=""left"" colspan=""1"" rowspan=""1"">(0.48)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.157</td><td align=""center"" colspan=""1"" rowspan=""1"">0.032</td>,Non-completers had significantly higher psychological distress scores (t=2.04, p=0.043) and lower scores for seeking social support (t=â2.63, p=0.009) and changing a point of view compared to completers (t=â2.70, p=0.008).", Psychological distress , Control , Stress managin training ,0,
edin,4567,4639584,Cannot tell based on the abstract,, Fasting glucose , Normal flour , Fiber enriched flour ,0,
edin,4567,4639584,No significant difference,Fasting glucose and fasting insulin did not change significantly in both groups during the 8 weeks of the study., Fasting glucose , Normal flour , Fiber enriched flour ,0,
edin,4649,3095445,Cannot tell based on the abstract,, Voiding score improvement , Control , Naftopidil 75 mg ,0,
edin,4649,3095445,Significantly increased,"The alteration of the total IPSS, storage score, voiding score, postmicturition score (domain for feeling of incomplete emptying), and QOL score was presented in Figures 1(a)â1(e). The 75âmg group showed improvement in all of these in a time-dependent and dose-dependent manner (baseline versus 4 weeks after treatment: P < .001 in all; 4 weeks after treatment versus 8 weeks after treatment: P = .019, P = .057, P = .047, P = .057, and P = .003, resp.),", Voiding score improvement , Control , Naftopidil 75 mg ,0,
edin,4569,4639584,Cannot tell based on the abstract,, LDL , Normal flour , Fiber enriched flour ,0,
edin,4569,4639584,Significantly decreased,"A significant decrease in LDL cholesterol concentration was observed in Group A and Group B after the fiber-enriched period (Group A: â13.27Â mg/dl, p<0.01 vs placebo; Group B â12.63Â mg/dl, pÂ =Â 0.002 vs basal).", LDL , Normal flour , Fiber enriched flour ,0,
edin,4614,2427034,Cannot tell based on the abstract,"The presence of 23S rRNA due to H. pylori infection in the OA group remained lower than that in the placebo group 7.3 yrs after OA-therapy [51.1% (157/307) vs. 83.9% (260/310), p = 0.0000].", 23S rRNA , Placebo , Amoxicillin + Omeprazole + Clarithromycin ,0,
edin,4614,2427034,Significantly decreased,"<td></td><td align=""left""><italic>23S rRNA</italic></td><td align=""left"">83.9 (260/310)</td><td align=""left"">51.1<sup>1 </sup>(157/307)</td><td align=""left"">26.8<sup>2 </sup>(41/153)</td><td align=""left"">59.5 (458/770)</td>,OAC group vs. placebo group, OR = 2.89, 95%CI [1.28â6.46];", 23S rRNA , Placebo , Amoxicillin + Omeprazole + Clarithromycin ,0,
edin,4644,4273016,Cannot tell based on the abstract,, Work engagement , Control , Stress managin training ,0,
edin,4644,4273016,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"" style=""padding-left:10pt"">Work engagement</td><td align=""right"" colspan=""1"" rowspan=""1"">2.7</td><td align=""left"" colspan=""1"" rowspan=""1"">(0.92)</td><td align=""right"" colspan=""1"" rowspan=""1"">3.0</td><td align=""left"" colspan=""1"" rowspan=""1"">(0.91)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.028</td><td align=""center"" colspan=""1"" rowspan=""1"">0.033</td>,Although the intervention group had significantly higher scores on work engagement compared to the wait-list control group (t=â2.2, p=0.00), no other significant differences were found between the groups (p>0.05).", Work engagement , Control , Stress managin training ,0,
edin,4611,2630316,Cannot tell based on the abstract,, Waiting time , Care at clinic , Care at home ,0,
edin,4611,2630316,Significantly increased,Individuals receiving clinic care reported less waiting time for nurse with 80% of the home having 30 minutes or less compared to 98% of clinic group (p = 0.03)., Waiting time , Care at clinic , Care at home ,0,
edin,4630,5866927,Cannot tell based on the abstract,, Vineland motor improvement  , Placebo , AUCB ,0,
edin,4630,5866927,Significantly decreased,"There were statistically significant (pâ<â.05) group X treatment interactions for the Vineland ABC, Communication, Motor, and Daily subscales which indicated that changes over time between these scores depended on the order that AUCB was administered.,<td align=""left"" colspan=""1"" rowspan=""1"" style=""padding-left:10%"" valign=""top"">Placebo</td><td align=""char"" char=""Â±"" colspan=""1"" rowspan=""1"" valign=""top"">77.67âÂ±â13.57</td><td align=""char"" char=""Â±"" colspan=""1"" rowspan=""1"" valign=""top"">79.57âÂ±â11.51</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">.029</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">.020</td><td align=""char"" char=""Â±"" colspan=""1"" rowspan=""1"" valign=""top"">76.67âÂ±â7.61</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">.022</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">.010</td>,The results of these ANCOVAs (Table 4) showed that all Vineland subscales had lower mean scores for the AUCB group than the placebo group at both 12 and 24 weeks.", Vineland motor improvement  , Placebo , AUCB ,0,
edin,4581,4941128,Significantly increased,UPDRS scores were 43% (p=0.04; Cohenâs d=1.62) better with aDBS than without stimulation., Overall UPDRS improvement , Control , Adaptive deep brain stimulation ,0,
edin,4640,5656562,Cannot tell based on the abstract,, Sildenafil levels , CYP2C9 Poor metabolizers   , CYP2C9 Intermediate metabolizers  ,0,
edin,4640,5656562,No significant difference,No association was observed between the CYP2C9 inferred phenotype and the sildenafil concentration:dose ratio (Figure 2)., Sildenafil levels , CYP2C9 Poor metabolizers   , CYP2C9 Intermediate metabolizers  ,0,
edin,4490,5880177,Cannot tell based on the abstract,, Risk of death , Being on Class 2 , Being on Class 1 ,0,
edin,4490,5880177,Significantly increased,"As compared with class 3, class 1 (OR: 2.76; 95% CI [1.38â5.82]) was associated with higher risk of death. Class 1 was associated with higher risk of death than class 2 (OR: 1.72; 95% CI [1.09â2.68]).", Risk of death , Being on Class 2 , Being on Class 1 ,0,
edin,4501,4701182,No significant difference,"At week 48, VL<50 copies/mL was 68.4%, 69.9%, and 72.4% in TPV/r100, TPV/r200, and LPV/r groups, respectively, and TPV/r groups showed non-inferiority to LPV/r.", Viral load improvement , Tipranavir/Ritonavir (500/200) , Tipranavir/Ritonavir (500/100) ,0,
edin,4506,4786378,No significant difference,"For the knowledge tests, there was no statistically significant difference between the groups (P = 0.14).", Score on knowledge test , Conventional training , Virtual reality training ,0,
edin,4595,1839864,Cannot tell based on the abstract,, Correct identification of cause of death , Printed instruction material , Interactive workshop ,0,
edin,4595,1839864,Significantly increased,"<td colspan=""4"">Correctly identified cause of death</td>,Group I statistically significant improvement than group II in correct identification of cause of death (91 vs 55%, p<0.001),", Correct identification of cause of death , Printed instruction material , Interactive workshop ,0,
edin,4638,5656562,Cannot tell based on the abstract,, Sildenafil levels , CYP2C9 Extensive metabolizers   , CYP2C9 Intermediate metabolizers  ,0,
edin,4638,5656562,Significantly decreased,We observed that increasing levels of predicted metabolizing capacity appeared to be associated with decreasing levels of dose-adjusted sildenafil concentrations (F test P = 0.0238; Figure 4)., Sildenafil levels , CYP2C9 Extensive metabolizers   , CYP2C9 Intermediate metabolizers  ,0,
edin,4612,2630316,Cannot tell based on the abstract,, Patient satisfaction , Care at clinic , Care at home ,0,
edin,4612,2630316,No significant difference,"oth home and clinic groups reported high satisfaction levels with the information they receive on how to care for their leg ulcers (98% vs. 96% very/quite satisfied, respectively).", Patient satisfaction , Care at clinic , Care at home ,0,
edin,4446,3961596,No significant difference,"There were no serious adverse events, adverse events leading to discontinuation, or episodes of hypoglycemia.", Serious adverse effects  , Placebo , Luseogliflozin ,0,
edin,4539,5107204,Cannot tell based on the abstract,, Psychomotor activities , Placebo , Bilastine 20 mg ,0,
edin,4539,5107204,No significant difference,"Psychomotor activities were evaluated using objective DSST and subjective SSS.,The meanÂ Â±Â SD of DSST and SSS at predose in Part I were 59.0Â Â±Â 8.7 and 2.2Â Â±Â 0.4 in placebo (nÂ =Â 9), 58.6Â Â±Â 9.3 and 2.3Â Â±Â 0.9 in 10Â mg (nÂ =Â 9), 58.6Â Â±Â 9.1 and 2.7Â Â±Â 0.7 in 20Â mg (nÂ =Â 9), and 57.4Â Â±Â 8.9 and 2.9Â Â±Â 0.3 in 50Â mg group (nÂ =Â 9), respectively. Changes in DSST or SSS from predose at 2 and 24Â h after single oral doses of 10â50Â mg were not significant differences from placebo (data not shown).,No significant differences were observed for SSS at any time points between the drug-treated groups and placebo group (Fig.Â 4b).Fig.Â 4", Psychomotor activities , Placebo , Bilastine 20 mg ,0,
edin,4605,3724560,Cannot tell based on the abstract,, Risk of falling , Usual care , Integrative medicine ,0,
edin,4605,3724560,Significantly increased,"There was a higher risk for falls in the IM than in the UC (odds ratio 3.30; 95% confidence interval: 0.43; 25.26), but hospital admissions were in general comparable for both groups (IM: 0.7 Â± 1.1; UC 1.0 Â± 1.8).", Risk of falling , Usual care , Integrative medicine ,0,
edin,4544,3459547,Cannot tell based on the abstract,, Itch control time , Olopatadine 5 mg , Olopatadine 10 mg ,0,
edin,4544,3459547,No significant difference,The suppressive effects of both the 5 mg and 10 mg olopatadine treatments on the VAS itch score were more significant and longer lasting over a period of 4 weeks than the no-medication treatment. Both the 5-mg group and the 10-mg group showed improved urticarial symptoms and maintained their VAS itch score within normal limits compared to the no-medication group. The differences between the 5-mg and 10-mg groups were not significant., Itch control time , Olopatadine 5 mg , Olopatadine 10 mg ,0,
edin,4749,5331968,Cannot tell based on the abstract,," Heart rate, beats/mind - ratio between low frequency power (LF) and HF (LF:HF) of the autonomous nervous system, log m/s2c ", baseline , blue (Castelldefels beach) ,0,
edin,4749,5331968,Significantly decreased,"<td align=""justify"" colspan=""2"" rowspan=""1"">TMD</td><td align=""justify"" colspan=""1"" rowspan=""1""></td><td align=""justify"" colspan=""1"" rowspan=""1""></td><td align=""justify"" colspan=""1"" rowspan=""1""></td><td align=""justify"" colspan=""1"" rowspan=""1""></td><td align=""justify"" colspan=""1"" rowspan=""1""></td><td align=""justify"" colspan=""1"" rowspan=""1""></td><td align=""justify"" colspan=""1"" rowspan=""1""></td><td align=""justify"" colspan=""1"" rowspan=""1""></td>"," Heart rate, beats/mind - ratio between low frequency power (LF) and HF (LF:HF) of the autonomous nervous system, log m/s2c ", baseline , blue (Castelldefels beach) ,0,
edin,4688,5509647,Significantly decreased,"Alcohol consumption resulted in a significant impairment of mean (tâ=â2.456, dfâ=â13, pâ=â0.029) and maximum potentiation (tâ=ââ2.945, dfâ=â13, pâ=â0.011) compared to the placebo beverage in the DLPFC and globally.", mean  and maximum potentiation , placebo , consumption of an alcohol (1.5âg/l of body water) ,0,
edin,4726,5539943,Cannot tell based on the abstract,, Motivational Interviewing (MI) knowledge , baseline ," Language Enhanced Attention and Focus MI training condition (MI-LEAF), MI training (MI-AU) ",0,
edin,4726,5539943,Significantly increased,"The MI Knowledge Test was used as the outcome measure to estimate the impact of training. It was administered at baseline and post-training, and results indicate a significant increase in MI knowledge (b = 0.111, SE = 0.015, t = 7.146, p < 0.001) for all participants with no significant differences between training conditions (b = â0.041, SE = 0.031, t = â1.328, p = 0.186).", Motivational Interviewing (MI) knowledge , baseline ," Language Enhanced Attention and Focus MI training condition (MI-LEAF), MI training (MI-AU) ",0,
edin,4677,1774569,No significant difference,"Risk of non-completion of detoxification was reduced if allocated buprenorphine (68% vs 88%, RR 0.58 CI 0.35â0.96, p = 0.065).", Risk of non-completion of detoxification , oral dihydrocodeine , buprenorphine ,0,
edin,4672,5472412,Significantly decreased,"Additionally, olopatadine HCl 0.77% substantially reduced conjunctival redness and total redness over vehicle and olopatadine 0.2% at onset and 24-hour duration of action.", total redness at onset of action and 24 hours post-dosing , vehicle , Olopatadine HCl 0.77% ,0,
edin,4665,5129854,Significantly decreased,"At week 6, mean diurnal IOP with BBFC+PGA was lower than with vehicle+PGA (17.1Â±0.4âmmâHg vs 20.5Â±0.4âmmâHg; between-group difference, â3.4Â±0.5âmmâHg; P<0.0001; 95% confidence interval, â4.5 to â2.4âmmâHg).", diurnal intraocular pressure (IOP) , vehicle adjunctive treatment and  prostaglandin analog (PGA) , fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) ,0,
edin,4709,3982948,Cannot tell based on the abstract,, The occurrence of apnea , routine , CPAP ,0,
edin,4709,3982948,No significant difference,The occurrence of apnea was high in both groups (33.6% in the CPAP group and 42.4% in the routine group)., The occurrence of apnea , routine , CPAP ,0,
edin,4699,5312688,Cannot tell based on the abstract,,  The Community Programs for Clinical Research on AIDS (CPCRA) Adherence Self-Report Questionnaire , standard care , interactive short message service (SMS) ,0,
edin,4699,5312688,Significantly increased,"The participants reported VAS score of 98.72% in the SMS group at the end of the study, significantly higher than that in the control group (93.11%; P=0.006). Similar effect on CPCRA adherence was noticed.",  The Community Programs for Clinical Research on AIDS (CPCRA) Adherence Self-Report Questionnaire , standard care , interactive short message service (SMS) ,0,
edin,4756,3214443,Cannot tell based on the abstract,, The mean difference in the reduction of both SBP and DBP ,"  Yoga (NG IV) for 30 to 45 minutes/day, five days/week ","  Salt Intake Reduction (NG III) to at least half of their previous intake, ",0,
edin,4756,3214443,Significantly increased,"the mean reduction in the SBP and DBP values of the physical exercise group when compared with those of the salt reduction group, was significantly higher (P<0.001).", The mean difference in the reduction of both SBP and DBP ,"  Yoga (NG IV) for 30 to 45 minutes/day, five days/week ","  Salt Intake Reduction (NG III) to at least half of their previous intake, ",0,
edin,4752,4941182,No significant difference,Rates of safety events of special interest were generally similar between tofacitinib doses and subpopulations;, Rates of safety events , tofacitinib 5 or 10âmg twice daily   bDMARD-IR patients  , tofacitinib 5 or 10âmg twice daily  bDMARD-naive ,0,
edin,4733,3293068,Cannot tell based on the abstract,, bloatedness  at 3 hours post dehydrating exercise ," bottled water (BW), carbohydrate-electrolyte sport drink (SD) "," pure coconut water (VitaCocoÂ®: CW), coconut water from concentrate (CWC) ",0,
edin,4733,3293068,Significantly increased,"Over the two hour rehydration period, the bloatedness decreased for all four conditions but remained statistically significant at 3 hours post dehydrating exercise for VitaCocoÂ® (p = 0.012) and coconut water from concentrate (p = 0.034).,<td align=""left"">3 hours Post DHE</td><td align=""center"">2.33 Â± 1.23</td><td align=""center"">1.42 Â± 0.67</td><td align=""center"">2.45 Â± 1.21</td><td align=""center"">1.25 Â± 0.62</td>,Bloatedness: 3 hours Post DHE > Immediately Post DHE for VitaCocoÂ® (p = 0.012) and coconut water from concentrate (p = 0.034)", bloatedness  at 3 hours post dehydrating exercise ," bottled water (BW), carbohydrate-electrolyte sport drink (SD) "," pure coconut water (VitaCocoÂ®: CW), coconut water from concentrate (CWC) ",0,
edin,4680,5721317,Cannot tell based on the abstract,, Preoperative mechanical alignment - varus , measured resection (MR) , gap balancing (GB) technique ,0,
edin,4680,5721317,No significant difference,Preoperative mechanical alignment was 5.2Â° Â± 4.5Â° varus in the GB group and 5.4Â° Â± 4.8Â° in the MR group., Preoperative mechanical alignment - varus , measured resection (MR) , gap balancing (GB) technique ,0,
edin,4670,5472412,Significantly increased,Olopatadine HCl 0.77% was superior to vehicle (P<0.0001) at onset and 24-hour duration of action (difference in means: â1.14 to â1.52) and to olopatadine 0.2% (P=0.0009) at 24-hour duration of action in relieving ocular itch., 24-hour duration of action in relieving ocular itch , olopatadine 0.2% , Olopatadine HCl 0.77% ,0,
edin,4762,4079189,Significantly decreased,"The mean number of bleeding days significantly declined from 10.6âÂ±â2.7Â days to 8.2âÂ±â1.9Â days after 3Â months treatment with the syrup (pâ=â0.01) and consequently the participants in the intervention group used fewer pads after 3Â months (16.4âÂ±â10.7) compared with the number of pads used at the beginning of the treatment (22.7âÂ±â12.0, pâ=â0.01).", The  consequently number of pads , baseline , 15&amp;amp;nbsp;ml oral myrtle syrup daily (5&amp;amp;nbsp;ml three times a day) for 7&amp;amp;nbsp;days ,0,
edin,4702,3154486,Cannot tell based on the abstract,," differences in the changes of the anthropometric measurements, RMR, and physical activity level ","  chocolate, or potato crisps, control "," ~1100âkJ/d of hazelnuts, ",0,
edin,4702,3154486,No significant difference,"Although there was an apparent decrease in physical activity level in the control group, there were no statistically significant differences in the changes of the anthropometric measurements, RMR, and physical activity level from baseline to 12 weeks between the groups (all P â¥ 0.106, Table 3)."," differences in the changes of the anthropometric measurements, RMR, and physical activity level ","  chocolate, or potato crisps, control "," ~1100âkJ/d of hazelnuts, ",0,
edin,4714,3573831,Significantly decreased,"On average, breast exposure dose in lumbar spine imaging in both projections (anteroposterior (AP) and lateral) was found reduced by approximately 80% (p < 0,001) when shielding with 0.5 mm lead equivalent was used (from 0.45Â±0.25 mGy to 0.09Â±0.07 mGy on the right and from 0.26Â±0.14 mGy to 0.06Â±0.04 mGy on the left breast)", left breast exposure dose in lumbar spine imaging in both projections (anteroposterior (AP) and lateral) , baseline , breast shielding ,0,
edin,4686,4329963,Significantly increased,"Analysis of covariance showed that after adjusting for effects of pretest scores, the difference between mean post-test scores of health-promoting lifestyle scale, health-related QoL scale, and all constructs of Pender's health promotion model (self-efficacy, perceived affect, perceived social support, and perceived barriers) in the intervention group 1 and control group were significant (P< 0.0001). In addition, changes in mean scores of lifestyle scale (42.4 Â± 13.6), QoL scale (29.1 Â± 14.2), self-efficacy (16.1 Â± 2.6), perceived affect (16.1 Â± 8), social support (35.4 Â± 12.4), and barriers (17.2 Â± 15.8) before and after intervention were significant in the intervention group 2 (P < 0.0001)."," mean post-test scores of health-promoting lifestyle scale, health-related QoL scale, and all constructs of Pender's health promotion model (self-efficacy, perceived affect, perceived social support, and perceived barriers) ", baseline , a group for training of methamphetamine users who were in recovery phase (intervention group 1) and control ,0,
edin,4707,3982948,No significant difference,"The routine (n=99) and CPAP (n=98) infants studied presented no statistically significant differences regarding birth characteristics, complications during the prenatal period, the need for mechanical ventilation during the first 5 days of life (19.2 vs 23.4%, P=0.50), use of surfactant (18.2 vs 17.3% P=0.92), or respiratory morbidity and mortality until discharge."," birth characteristics, complications during the prenatal period, the need for mechanical ventilation during the first 5 days of life, use of surfactant ", routine , CPAP ,0,
edin,4706,5384532,Cannot tell based on the abstract,, The total number of days on which MRSA-positive admitted patients were not isolated , Conventional laboratory-based culture screens (CS) , rapid point-of-care screening (POCS) ,0,
edin,4706,5384532,Significantly decreased,The total number of days on which MRSA-positive admitted patients were not isolated was 257 (67% of their total stay of 378.3 days) in the control arm and 205 (40.6% of their total stay of 504.8 days) in the intervention arm (PÂ <Â 0.001)., The total number of days on which MRSA-positive admitted patients were not isolated , Conventional laboratory-based culture screens (CS) , rapid point-of-care screening (POCS) ,0,
edin,4731,3798588,Cannot tell based on the abstract,, consumption of at least 800 mg/day of dietary calcium , control , Current health education programs for osteoporosis prevention ,0,
edin,4731,3798588,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">Elderly men (C1) women (B)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">22 (43.1%)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">23 (46.9%)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">ns</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">29 (56.9%)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">21 (42.9%)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">ns</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">0.030</td>,Regarding nutrient intakes, consumption of at least 800 mg/day of dietary calcium was more likely (P = 0.074) to be implemented in the intervention group than in the control group.", consumption of at least 800 mg/day of dietary calcium , control , Current health education programs for osteoporosis prevention ,0,
edin,4678,1774569,Significantly increased,"<td align=""center"">2</td><td align=""center"">8</td>", clean urine sample , oral dihydrocodeine , buprenorphine ,0,
edin,4735,3293068,Cannot tell based on the abstract,, Plasma osmolality , bottled water (BW) , coconut water from concentrate (CWC) ,0,
edin,4735,3293068,Significantly increased,"Plasma osmolality displayed similar results as noted for body mass and fluid retention, with greater values for coconut water from concentrate compared only to bottled water (p = 0.049; when expressed as change from pre dehydrating exercise at 3 hours post dehydrating exercise)", Plasma osmolality , bottled water (BW) , coconut water from concentrate (CWC) ,0,
edin,4690,5509647,Significantly decreased,"Additionally, the effect of alcohol on PAS-induced potentiation of theta-gamma coupling (an index associated with learning and memory) was examined prior to and following PAS.,Alcohol also suppressed the potentiation of theta-gamma coupling by PAS.", theta- gamma coupling following PAS , baseline , consumption of an alcohol (1.5âg/l of body water) ,0,
edin,4763,3896966,Significantly decreased,"In confirmation of diet formulation and compound delivery, both the PS and EZ treatments lowered (pâ<â0.05) intestinal cholesterol absorption (24 and 31%, respectively), blood non-HDL cholesterol (61 and 66%, respectively), and hepatic cholesterol (45 and 55%, respectively) compared with the HF-fed animals."," intestinal cholesterol absorption, blood non-HDL cholesterol, and hepatic cholesterol ", high fat (HF) diet ," phytosterols (PS), ezetimibe (EZ) ",0,
edin,4704,3154486,Cannot tell based on the abstract,, Plasma total cholesterol ,  chocolate , ~1100âkJ/d of hazelnuts ,0,
edin,4704,3154486,Significantly decreased,"Plasma total cholesterol in the hazelnut group was lower compared to the chocolate group (P = 0.006), with a tendency for the hazelnut group to be lower than the control (Pâ = 0.057).", Plasma total cholesterol ,  chocolate , ~1100âkJ/d of hazelnuts ,0,
edin,4682,5721317,Cannot tell based on the abstract,, With survival for aseptic reasons , measured resection (MR) , gap balancing (GB) technique ,0,
edin,4682,5721317,No significant difference,"With survival for aseptic reasons as the endpoint of interest, survival rates were 94.6% (95% CI, 87.5% and 97.7%) and 91.6% (84.0% - 95.7%) for the GB group and the MR group, respectively (p = 0.386).", With survival for aseptic reasons , measured resection (MR) , gap balancing (GB) technique ,0,
edin,4713,3573831,Significantly decreased,"On average, breast exposure dose in lumbar spine imaging in both projections (anteroposterior (AP) and lateral) was found reduced by approximately 80% (p < 0,001) when shielding with 0.5 mm lead equivalent was used (from 0.45Â±0.25 mGy to 0.09Â±0.07 mGy on the right and from 0.26Â±0.14 mGy to 0.06Â±0.04 mGy on the left breast). No correlation between the body mass index (BMI) and the breast surface radiation dose was observed.", right breast exposure dose in lumbar spine imaging in both projections (anteroposterior (AP) and lateral) , baseline , breast shielding ,0,
edin,4758,2848004,Significantly increased,Trough FEV1 after one dose was significantly higher with indacaterol than placebo (p < 0.001)., FEV1 after one dose , placebo , indacaterol 150 Î¼g o.d ,0,
edin,4754,3214443,Cannot tell based on the abstract,"All three intervention groups showed significant reduction in BP (SBP/DBP mmHg: 5.3/6.0 in NG II, 2.5/2.0 in NG III, and 2.3/2.4 in NG IV, respectively), while the Control Group showed no significant difference.", The mean difference in the reduction of both SBP and DBP , Salt Intake Reduction (NG III) to at least half of their previous intake; ," Physical Exercise (NG II)-brisk walking for 50 to 60 minutes, three to four days/week; ",0,
edin,4754,3214443,Significantly increased,"In the per protocol population, that is, the 94 subjects who had successfully completed the interventions in the groups assigned to them and in the Intention-to-Intervene population of all 98 subjects, who were initially enrolled and randomized, the mean reduction in the SBP and DBP values of the physical exercise group when compared with those of the salt reduction group, was significantly higher (P<0.001).", The mean difference in the reduction of both SBP and DBP , Salt Intake Reduction (NG III) to at least half of their previous intake; ," Physical Exercise (NG II)-brisk walking for 50 to 60 minutes, three to four days/week; ",0,
edin,4675,2944304,Significantly increased,"Geometric mean time to recovery of the train-of-four ratio to 0.9 was 15-fold faster with sugammadex (4.5 minutes) compared with neostigmine (66.2 minutes; p < 0.0001) (median, 3.3 minutes with sugammadex versus 49.9 minutes with neostigmine).", Geometric mean time to recovery of the train-of-four ratio to 0.9 , neostigmine 70 Î¼g/kg with glycopyrrolate 14 Î¼g/kg at 1-2 post-tetanic counts , sugammadex 4 mg/kg ,0,
edin,4693,5986478,Cannot tell based on the abstract,," The serum level of the circulating BCAAs isoleucine, valine and leucine ", non-seafood diet period , the lean-seafood diet period (postprandial state) ,0,
edin,4693,5986478,Significantly decreased,"The serum level of the circulating BCAAs isoleucine, valine and leucine was decreased during the postprandial state after lean-seafood intake."," The serum level of the circulating BCAAs isoleucine, valine and leucine ", non-seafood diet period , the lean-seafood diet period (postprandial state) ,0,
edin,4701,3154486,Cannot tell based on the abstract,," vitamin E intake , the percentage of energy derived from total fat , monounsaturated fatty acids (MUFAs) , and polyun-saturated fatty acids (PUFAs) ","  chocolate, or potato crisps, control "," ~1100âkJ/d of hazelnuts, ",0,
edin,4701,3154486,Significantly increased,"On the other hand, vitamin E intake (all P â¤ 0.007), the percentage of energy derived from total fat (all P â¤ 0.011), MUFA (all P â¤ 0.001), and PUFA (all P â¤ 0.011) increased at 12 weeks in the hazelnut group compared to all other groups, with the exception of one pairwise comparison (hazelnut versus control; P = 0.057) for PUFA."," vitamin E intake , the percentage of energy derived from total fat , monounsaturated fatty acids (MUFAs) , and polyun-saturated fatty acids (PUFAs) ","  chocolate, or potato crisps, control "," ~1100âkJ/d of hazelnuts, ",0,
edin,4767,3896966,Cannot tell based on the abstract,, desmosterol  , high fat (HF) diet ," phytosterols (PS), ezetimibe (EZ) ",0,
edin,4767,3896966,Invalid Prompt,, desmosterol  , high fat (HF) diet ," phytosterols (PS), ezetimibe (EZ) ",1," PS feeding led to an expected increase (pâ<â0.05) in RBC campesterol and sitosterol concentrations compared with the HF and EZ groups (Figure 2) but also reduced (pâ<â0.05) RBC desmosterol concentrations compared with the other groups. EZ supplementation increased (pâ<â0.05) RBC desmosterol and lathosterol concentrations compared with the HF and PS groups (Figure 2).

In first part, PS  reduces desmosterol and in second part EZ increases it. "
edin,4718,5292678,No significant difference,"There were no differences in cumulative incidence of relapse (74% vs 68% hazard ratio (HR) 0.93 (0.77â1.14), P=0.5); survival from relapse (7% vs 9% HR 0.96 (0.77â1.19), P=0.7); relapse-free (31% vs 32% HR 1.02 (0.83â1.24), P=0.9) or overall survival (23% vs 22% HR 1.08 (0.93â1.26), P=0.3).", overall survival , daunorubicin/ara-C (DA)  ,  daunorubicin/clofarabine (DClo) ,0,
edin,4667,5129854,Significantly decreased,"At week 6, mean diurnal IOP with BBFC+PGA was lower than with vehicle+PGA (17.1Â±0.4âmmâHg vs 20.5Â±0.4âmmâHg; between-group difference, â3.4Â±0.5âmmâHg; P<0.0001; 95% confidence interval, â4.5 to â2.4âmmâHg). BBFC+PGA reduced mean diurnal IOP by 5.7âmmâHg (25%) from the baseline IOP achieved with PGA monotherapy.", The percent diurnal IOP change , vehicle adjunctive treatment and  prostaglandin analog (PGA) , fixed-combination brinzolamide/brimonidine (BBFC) adjunctive to a prostaglandin analog (PGA) ,0,
edin,4685,3929824,Cannot tell based on the abstract,, Rhodes index scores , the acupressure ,  ginger ,0,
edin,4685,3929824,Significantly increased,The mean difference Rhodes index scores calculated by mean Rhodes index scores in pre intervention (three days before intervention) minus mean Rhodes index scores in post intervention (four days after intervention). It was significantly greater in ginger group than acupressure and control groups., Rhodes index scores , the acupressure ,  ginger ,0,
edin,4698,5312688,Significantly increased,"For the adherence measures, compared with the control group, participants in the intervention group had significantly higher VAS mean score (Z=2.735, P=0.006) and lower suboptimal adherence rate (Z=2.208, P=0.027) at the end of the study.", VAS mean score , standard care , interactive short message service (SMS) ,0,
edin,4736,3293068,Cannot tell based on the abstract,, body mass , bottled water (BW) , coconut water from concentrate (CWC) ,0,
edin,4736,3293068,Significantly increased,"However, body mass (p = 0.023) was slightly greater with coconut water from concentrate compared only to bottled water (when expressed as change from pre dehydrating exercise at 3 hours post dehydrating exercise).", body mass , bottled water (BW) , coconut water from concentrate (CWC) ,0,
edin,4697,5312688,Significantly increased,Repeated-measures analysis showed that both HIV-related and ART medication knowledge of the intervention group showed better improvement over time than those of the control group after the intervention (P<0.0001)., HIV-related and ART medication knowledge , standard care , interactive short message service (SMS) ,0,
edin,4700,3154486,Cannot tell based on the abstract,, total energy derived from saturated fatty acids (SAFAs)  and carbohydrate ,"  chocolate, or potato crisps, control "," ~1100âkJ/d of hazelnuts, ",0,
edin,4700,3154486,Significantly decreased,The results from pairwise comparison showed that the percentage of total energy derived from SAFA (all P â¤ 0.045) and carbohydrate (all P â¤ 0.006) in the hazelnut group was significantly lower than all the other groups., total energy derived from saturated fatty acids (SAFAs)  and carbohydrate ,"  chocolate, or potato crisps, control "," ~1100âkJ/d of hazelnuts, ",0,
edin,4668,5472412,Significantly increased,Olopatadine HCl 0.77% was superior to vehicle (P<0.0001) at onset and 24-hour duration of action (difference in means: â1.14 to â1.52) and to olopatadine 0.2% (P=0.0009) at 24-hour duration of action in relieving ocular itch., 24-hour duration of action in relieving ocular itch , vehicle (at onset and 24 hours) , Olopatadine HCl 0.77% ,0,
edin,4734,3293068,No significant difference,No differences were noted between coconut water (CW or CWC) and SD for any measures of fluid retention (p > 0.05)., fluid retention (based on body mass) ," bottled water (BW), carbohydrate-electrolyte sport drink (SD) "," pure coconut water (VitaCocoÂ®: CW), coconut water from concentrate (CWC) ",0,
edin,4739,3293068,Cannot tell based on the abstract,," heart rate, systolic blood pressure, or diastolic blood pressure "," bottled water (BW), carbohydrate-electrolyte sport drink (SD) "," pure coconut water (VitaCocoÂ®: CW), coconut water from concentrate (CWC) ",0,
edin,4739,3293068,No significant difference,"No differences were noted between conditions for heart rate, systolic blood pressure, or diastolic blood pressure (p > 0.05)."," heart rate, systolic blood pressure, or diastolic blood pressure "," bottled water (BW), carbohydrate-electrolyte sport drink (SD) "," pure coconut water (VitaCocoÂ®: CW), coconut water from concentrate (CWC) ",0,
edin,4744,5653840,Significantly increased,Subjects performed a 6â8 week home trial using direct and pattern recognition control with a custom prostheses made from commercially available parts. Subjects showed statistically better performance in the Southampton Hand Assessment Procedure (pâ=â0.04) and the Clothespin relocation task (pâ=â0.02)., improving of Clothespin Relocation Task , direct control , recognition control ,0,
edin,4757,2848004,Significantly increased,"Trough FEV1 (LSM Â± SEM) at Week 12 was 1.48 Â± 0.018 L for indacaterol and 1.35 Â± 0.019 L for placebo, a clinically relevant difference of 130 Â± 24 mL (p < 0.001).", forced expiratory volume in 1 s (FEV1) at Week 12 , placebo , indacaterol 150 Î¼g o.d ,0,
edin,4671,5472412,Significantly decreased,"Additionally, olopatadine HCl 0.77% substantially reduced conjunctival redness and total redness over vehicle and olopatadine 0.2% at onset and 24-hour duration of action.", conjunctival redness at onset and 24 hours , olopatadine 0.2% , Olopatadine HCl 0.77% ,0,
edin,4696,5986478,Cannot tell based on the abstract,," level of ceramide 18:1/14:0, LPC 20:4 and 22:5, LPE 18:0, PA 34:2, 36:1 , 36:2, 36:1 , PE 34:0 , 34:1, 34:2, 36:3 , 40:4 , 40:5 , PE 40:4, PE 40:5, PC 34:3 , PC 36:4 , PC 36:5 , PC 38:5 , PC 40:5  and PC 40:8 . ", the lean-seafood diet period , 120 min postprandial the non-seafood diet ,0,
edin,4696,5986478,Significantly increased,"Furthermore, 120 min postprandial the non-seafood diet significantly increased level of ceramide 18:1/14:0 (p = 0.01, Figure 2A), LPC 20:4 (p = 0.01, Figure 2C) and 22:5 (p = 0.03, Figure 2D), LPE 18:0 (p = 0.009), PA 34:2 (p = 0.01), 36:1 (p = 0.01), 36:2 (p = 0.02), 36:1 (p = 0.01), PE 34:0 (p = 0.01), 34:1 (p = 0.004), 34:2 (p = 0.03), 36:3 (p = 0.01), 40:4 (p = 0.005), 40:5 (p = 0.04), PE 40:4 (p = 0.005), PE 40:5 (p = 0.04), PC 34:3 (p = 0.02), PC 36:4 (p = 0.007), PC 36:5 (p = 0.004), PC 38:5 (p = 0.005), PC 40:5 (p = 0.04) and PC 40:8 (p = 0.04) (Table S3)."," level of ceramide 18:1/14:0, LPC 20:4 and 22:5, LPE 18:0, PA 34:2, 36:1 , 36:2, 36:1 , PE 34:0 , 34:1, 34:2, 36:3 , 40:4 , 40:5 , PE 40:4, PE 40:5, PC 34:3 , PC 36:4 , PC 36:5 , PC 38:5 , PC 40:5  and PC 40:8 . ", the lean-seafood diet period , 120 min postprandial the non-seafood diet ,0,
edin,4679,5721317,Significantly increased,"Mean KS was 82 (95% confidence interval (CI), 80 â 83) and 77 (95% CI, 76 â 79) in the GB and MR group, respectively. The TOST test and linear mixed model both revealed statistical significance (p < 0.001).", Knee Society Knee Score (KS) 10 years postoperatively using the two one-sided test (TOST) , measured resection (MR) , gap balancing (GB) technique ,0,
edin,4748,5331968,Cannot tell based on the abstract,," Heart rate, beats/mind - high frequency power (HF) of the autonomous nervous system, log m/s2c ", baseline , green (Collserola Natural Park) ,0,
edin,4748,5331968,No significant difference,"<td align=""justify"" colspan=""1"" rowspan=""1"">âHF, log m/s<sup>2</sup><xref ref-type=""table-fn"" rid=""t003fn004""><sup>c</sup></xref></td><td align=""justify"" colspan=""1"" rowspan=""1"">25</td><td align=""justify"" colspan=""1"" rowspan=""1"" style=""background-color:#BFBFBF"">-0.32 (-0.58, -0.06)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"" style=""background-color:#BFBFBF"">0.02</td><td align=""justify"" colspan=""1"" rowspan=""1"">0.01 (-0.24, 0.26)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">0.93</td>"," Heart rate, beats/mind - high frequency power (HF) of the autonomous nervous system, log m/s2c ", baseline , green (Collserola Natural Park) ,0,
edin,4760,2848004,No significant difference,"The overall rates of AEs were comparable between the groups (indacaterol 49.3%, placebo 46.8%)", The overall rate of adverse events (ASs) , placebo , indacaterol 150 Î¼g o.d ,0,
edin,4732,3293068,No significant difference,No differences were noted between coconut water (CW or CWC) and SD for any measures of fluid retention (p > 0.05)., measures of fluid retention , carbohydrate-electrolyte sport drink (SD) ," pure coconut water (VitaCocoÂ®: CW), coconut water from concentrate (CWC ",0,
edin,4795,2613135,Significantly increased,Detailed analyses showed that Cmax of EudorlinÂ® extra was higher than that of NurofenÂ® forte (36.62 vs. 32.92 Î¼g/ml; p = 0.0014), Cmax , 400 mg NurofenÂ® forte and 400 mg MigrÃ¤ninÂ® , 400 mg EudorlinÂ® extra* (Ibuprofen) ,0,
edin,4889,3546025,Significantly increased,"While EAAMR did not promote a significant preservation of lean tissue, the reduction in adipose tissue was greater in EAAMR compared to CMR. Interestingly, these results corresponded to an increase in the acute skeletal muscle protein FSR.", Skeletal muscle protein FSR , competitive meal replacement (CMR) , essential amino acid meal replacement (EAAMR) ,0,
edin,4884,3546025,No significant difference,"By design, both groups lost ~7% of total body weight.", absolute amount of weight loss , competitive meal replacement (CMR) , essential amino acid meal replacement (EAAMR) ,0,
edin,4842,4138551,Cannot tell based on the abstract,"QP and SP were equally effective in distalizing maxillary molars (3.5 and 4Â mm, respectively) between T1 and T2; however, the maxillary first molar showed less distal tipping (4.6Â° vs. 9.6Â°) and more extrusion (1.1 vs. 0.2Â mm) in the QP group than in the SP group,", molar extrusion , group 2   treated with the Quad Pendulum (QP) and fixed appliances , group 1 treated with the Segmented Pendulum (SP) and fixed appliances; ,0,
edin,4842,4138551,Significantly decreased,"However, QP showed greater molar extrusion (1.8âÂ±â0.7Â mm) than SP (1.0âÂ±â0.4Â mm) at the end of treatment (pâ<â0.001).", molar extrusion , group 2   treated with the Quad Pendulum (QP) and fixed appliances , group 1 treated with the Segmented Pendulum (SP) and fixed appliances; ,0,
edin,5056,4080584,Significantly increased,"Adjustment for age and BMI made no substantive difference to outcomes, and there were no cluster effects. For HRQoL, after adjustment for baseline scores, the intervention group showed significantly higher scores on all three PedsQL scores (physical functioning: MâÂ±âSEâ=â83.9âÂ±â0.7, pâ=â.005; psychosocial: 79.9âÂ±â0.8, pâ=â.001; total score: 81.3âÂ±â0.7, pâ=â.001) than the control group (80.9âÂ±â0.8; 76.1âÂ±â0.9 and 77.8âÂ±â0.8).", total score , control group , intervention group ,0,
edin,4831,2748072,No significant difference,"There were no significant differences in the other direct cost categories (outpatient clinic and admittance related costs), indirect costs, and total costs."," outpatient clinic and admittance related costs, indirect costs, and total costs ", small-incision cholecystectomy , laparoscopic ,0,
edin,5024,4129110,No significant difference,No significant changes in BMI or body composition were found., BMI , moderate-intensity aerobic and resistance training (ART) , high-intensity functional training (HIFT) ,0,
edin,4802,5515881,Significantly increased,"Moreover, the balance group significantly improved in memory and spatial cognition.,These results suggest that balance training is capable of improving particularly memory and spatial cognition.", memory score , relaxation group , demanding balance training program ,0,
edin,4966,5462678,Cannot tell based on the abstract,, effect of balance taping for prevention of menstrual pain in female middle school students after 4 hours , medication , balance taping ,0,
edin,4966,5462678,Significantly increased,"The balance taping group showed a statistically significant difference in pain compared with the medication group from 4 hours after the taping, and it lasted until 24 hours after the taping.,<td align=""left"" colspan=""1"" rowspan=""1"">Taping**</td><td align=""center"" colspan=""1"" rowspan=""1"">6.91 Â± 0.98</td><td align=""center"" colspan=""1"" rowspan=""1"">3.94 Â± 1.84</td><td align=""center"" colspan=""1"" rowspan=""1"">1.67 Â± 1.65</td><td align=""center"" colspan=""1"" rowspan=""1"">0.82 Â± 1.07</td><td align=""center"" colspan=""1"" rowspan=""1"">0.36 Â± 0.70</td>", effect of balance taping for prevention of menstrual pain in female middle school students after 4 hours , medication , balance taping ,0,
edin,4907,3339723,Cannot tell based on the abstract,, adverse effects , conventional therapy plus hydrocortisone IV (100 mg in 2 ml 8 hourly for 48 h) ," recumbent positioning, IV or oral hydration, analgesics with caffeine, stool softeners, and soft diet) plus 2 ml  ",0,
edin,4907,3339723,No significant difference,No adverse effects were noted and no patient was re-referred to hospital for relapse of headache., adverse effects , conventional therapy plus hydrocortisone IV (100 mg in 2 ml 8 hourly for 48 h) ," recumbent positioning, IV or oral hydration, analgesics with caffeine, stool softeners, and soft diet) plus 2 ml  ",0,
edin,4829,2748072,Cannot tell based on the abstract,, Operation theatre costs , small-incision cholecystectomy , laparoscopic ,0,
edin,4829,2748072,Significantly increased,"The difference in operation theatre cost is in favor of the SIC group however. Operation theatre costs are over 23% more expensive in the LC group compared to the SIC group (LC: 1112 euro compared to SIC: 901 euro; difference 211 euro, p < 0.001).", Operation theatre costs , small-incision cholecystectomy , laparoscopic ,0,
edin,4892,1175929,Cannot tell based on the abstract,, C-reactive protein , baseline , endotoxin intravenously (2 ng/kg Escherichia coli O113) ,0,
edin,4892,1175929,No significant difference,"In the control individuals no elevations in temperature (from 36.9 Â± 0.1 to 37.0 Â± 0.1Â°C), clinical symptoms, cytokine levels (TNF-Î± <8 pg/ml, IL-1Î² <8 pg/ml) or C-reative protein (<5 mg/ml) were observed (Fig. 1).", C-reactive protein , baseline , endotoxin intravenously (2 ng/kg Escherichia coli O113) ,0,
edin,4822,3904487,Significantly increased,"The duration of sedation in piperine receiving group was greater that the placebo group (188Â±59 vs. 102Â±43 min, p<0.0001).", The duration of sedation , placebo and midazolam (10 mg) , piperine (15 mg) and midazolam (10 mg) ,0,
edin,5030,4215680,Cannot tell based on the abstract,Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured CBP plus IBS., bacteriological methods , no treatment , rifaximin followed by the probiotic VSL#3 ,0,
edin,5030,4215680,Significantly increased,Long-term treatment with rifaximin and the probiotic VSL#3 is effective in lowering the progression of prostatitis into more complicated forms of male accessory gland infections in infertile patients with bacteriologically cured CBP plus IBS., bacteriological methods , no treatment , rifaximin followed by the probiotic VSL#3 ,0,
edin,5058,4080584,Significantly increased,"For HRQoL, after adjustment for baseline scores, the intervention group showed significantly higher scores on all three PedsQL scores (physical functioning: MâÂ±âSEâ=â83.9âÂ±â0.7, pâ=â.005; psychosocial: 79.9âÂ±â0.8, pâ=â.001; total score: 81.3âÂ±â0.7, pâ=â.001) than the control group (80.9âÂ±â0.8; 76.1âÂ±â0.9 and 77.8âÂ±â0.8).", physical functioning , control group , intervention group ,0,
edin,5025,4129110,Significantly decreased,Workouts were shorter for HIFT than ART (p < .001)., Time spent completing daily workouts , moderate-intensity aerobic and resistance training (ART) , high-intensity functional training (HIFT) ,0,
edin,4847,4535555,Significantly increased,"On acute imaging, mean % encirclements by LGE and T2W signal were 72% and 80% in the robotic group vs. 60% (P = 0.002) and 76%(P = 0.45) for standard ablation.", mean circumferential extent obtained by a combination of LGE&amp;amp;T2 signal overlay , standard navigation , robotic-assisted navigation (Hansen SenseiÂ® X) ,0,
edin,5022,4129110,Cannot tell based on the abstract,"Participants provided mostly intrinsic reasons for exercise initiation. Eighteen participants adhered (ART = 9, 81.8%; HIFT = 9, 75%). HIFT dropouts (p = .012) and ART participants (p = .009) reported lower baseline exercise enjoyment than HIFT participants, although ART participants improved enjoyment at posttest (p = .005).", exercise initiation , moderate-intensity aerobic and resistance training (ART) , high-intensity functional training (HIFT) ,0,
edin,5022,4129110,No significant difference,"Twenty-two participants provided reasons for exercise initiation, with many listing multiple reasons. Overall, 9 participants (39.1%) listed only intrinsic reasons and 13 (56.5%) listed both intrinsic and extrinsic reasons. For the ART participants, extrinsic reasons included wanting to lose weight (nâ=â7) and to work with a trainer (nâ=â2). Intrinsic reasons included to have motivation to exercise (nâ=â4), to develop an exercise habit (nâ=â3), to improve fitness/get into shape (nâ=â3), to learn new exercises/gain knowledge (nâ=â3), to lose stress (nâ=â1), and to learn about nutrition (nâ=â1). HIFT participants were also extrinsically motivated to participate by wanting to lose weight (nâ=â5). Intrinsic reasons included to have the motivation to exercise (nâ=â4), to develop an exercise habit (nâ=â3), to improve health (nâ=â3), to see results (nâ=â3), to improve fitness/get into shape (nâ=â2), and to be exposed to a new type of exercise (nâ=â1).", exercise initiation , moderate-intensity aerobic and resistance training (ART) , high-intensity functional training (HIFT) ,0,
edin,4960,5555437,Cannot tell based on the abstract,, Median progression-free survival , 45 Gy radiotherapy in 30 twice-daily fractions of 1Â·5 Gy over 19 days , 66 Gy in 33 once-daily fractions of 2 Gy over 45 days ,0,
edin,4960,5555437,No significant difference,Median progression-free survival was 15Â·4 months (95% CI 13Â·7â19Â·8) in the twice-daily group and 14Â·3 months (12Â·0â17Â·0) in the once-daily group (hazard ratio 1Â·12 [95% CI 0Â·92â1Â·38]; p=0Â·26)., Median progression-free survival , 45 Gy radiotherapy in 30 twice-daily fractions of 1Â·5 Gy over 19 days , 66 Gy in 33 once-daily fractions of 2 Gy over 45 days ,0,
edin,5020,3925077,Cannot tell based on the abstract,, probability of antibiotic prophylaxis being cost-effective from a societal perspective , placebo , low dose penicillin V ,0,
edin,5020,3925077,Significantly increased,"If a break-even (no-investment) criterion is required then prophylaxis is 62% likely to be cost-effective from an NHS perspective and 73% from a secondary, societal perspective.", probability of antibiotic prophylaxis being cost-effective from a societal perspective , placebo , low dose penicillin V ,0,
edin,4778,3466131,No significant difference,"After a median follow-up of 42âmonths, median PFS was 10.2 and 10.8âmonths (pâ=â0.74), while median OS was 20.0 and 25.3âmonths (pâ=â0.099), for groups A and B, respectively.", overall survival (OS) ," group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2âweeks; FOLFIRI-bevacizumab) "," group A (irinotecan, capecitabine, bevacizumab, every 3âweeks; XELIRI-bevacizumab) ",0,
edin,4914,400417,No significant difference,Fewer than 20% of patients in each arm of the study achieved an ACR 20 response at 24 weeks (P = 0.71)., the proportion of patients achieving an American College of Rheumatology (ACR) 20 response at 24 weeks , placebo , 30 Î¼g IFN-Î²-1a by weekly self-injection for 24 weeks ,0,
edin,4888,3546025,Cannot tell based on the abstract,, muscle phenyalanine enrichments , competitive meal replacement (CMR) , essential amino acid meal replacement (EAAMR) ,0,
edin,4888,3546025,Significantly increased,"Upon ingestion of each product, muscle phenyalanine enrichments increased (pâ<â0.05) dramatically in EAAMR compared to no change with CMR (pâ>â0.05).", muscle phenyalanine enrichments , competitive meal replacement (CMR) , essential amino acid meal replacement (EAAMR) ,0,
edin,4978,5694844,Cannot tell based on the abstract,, Microleakage of Two Bulk Fill and One Conventional Composite in Class II Restorations of Primary Posterior Teeth , Z250 conventional composite , SonicFill bulk fill ,0,
edin,4978,5694844,No significant difference,No significant difference was noted among the three groups in terms of microleakage in the gingival (P=0.252) or occlusal (P=0.516) margins (Table 2)., Microleakage of Two Bulk Fill and One Conventional Composite in Class II Restorations of Primary Posterior Teeth , Z250 conventional composite , SonicFill bulk fill ,0,
edin,4970,3608893,Significantly increased,"Significantly more PCD than DSME participants lost â©¾5% of initial weight (54.0% vs 14.0%, P<0.0001) and â©¾10% (26.0% vs 6.0%, P<0.0001).", Loss in initial weight , self-management education (DSME) , portion-controlled diet (PCD) ,0,
edin,5005,3682293,Cannot tell based on the abstract,," mean oxygenation index after adjusting for age, blood products, and ECC time ", propofol , sevoflurane ,0,
edin,5005,3682293,No significant difference,"The mean oxygenation index in the sevoflurane group was 42 points higher on POD1 compared with the propofol group in the unadjusted model (P = 0.04) (Table 4).,After adjusting for age, blood products, and ECC time, the difference decreased to 27 points and was no longer significant."," mean oxygenation index after adjusting for age, blood products, and ECC time ", propofol , sevoflurane ,0,
edin,4850,5425769,No significant difference,We found no overall significant effect of the Sonas programme with regard to communication ability as measured by the HCS., Holden Communication Scale (HCS)  , baseline , Sonas programme ,0,
edin,4921,4260384,No significant difference,"he probing depth changes were significant (P < 0.01) for both groups, but the difference was nonsignificant.", probing depth changes ," Group A, which were treated with the envelope type of CAF ", Group B were treated with envelope type of CAF along with the Type I collagen membrane (NEOMEM) ,0,
edin,4833,4984426,No significant difference,"The mean maximum Clinical Opiate Withdrawal Scale scores were similar, and numerically lower on buccal buprenorphine.", median maximum COWS scores , Full Î¼-opioid agonist* ,  Buccal buprenorphine (BBUP) ,0,
edin,4834,4984426,No significant difference,There were no significant differences in pain ratings between treatments., pain ratings , Full Î¼-opioid agonist* ,  Buccal buprenorphine (BBUP) ,0,
edin,5011,4764962,Significantly decreased,"The results revealed a significant difference between the preoperative and postoperative Wexner scores of incontinence in all the 3 groups. Additionally, the difference between the preoperative and postoperative scores was significant only in Group I and Group III, but not in Group II. The reduction in the Wexner score was significantly less in Group III.", Wexner score ," Group III, only surgical management was performed "," Group II, biofeedback therapy was applied only 6 months after the surgery ",0,
edin,4975,5958473,Significantly increased,"Varenicline in combination with behavioral support resulted in high abstinence rates inpatients hospitalized for exacerbation of COPD, asthma attack, or CAP, and improved QoL.", high abstinence rates of smoking in smokers hospitalized due to community-acquired pneumonia (CAP) , Varenicline , Varenicline in combination with behavioral support ,0,
edin,4997,3407981,Significantly increased,"Blood glucose levels (30 min after beverage ingestion) differed across all treatments (CHO > HCLP > LCHP; p < 0.05),", Glucose levels obtained 30 min post-feeding , LHCP , HCLP ,0,
edin,4845,4535555,Significantly increased,Late gadolinium enhancement remained the predominant signal with 56% encirclement in the robotic group vs. 45% in the standard group (P = 0.04)., Late gadolinium enhancement  , standard navigation , robotic-assisted navigation (Hansen SenseiÂ® X) ,0,
edin,4964,5462678,Significantly increased,"The balance-taping group showed a difference in pain from 1 hour after the taping compared with the control group, and the pain was significantly reduced until 24 hours after the taping.,Balance taping was shown to be effective in relieving menstrual pain.", effect of balance taping for prevention of menstrual pain in female middle school students after 24 hours , control , balance taping ,0,
edin,4843,4138551,Significantly increased,"At T3, the QP group maintained greater increase in lower anterior facial height and molar extrusion and decrease in overbite than the SP group.", The overbite , group 2   treated with the Quad Pendulum (QP) and fixed appliances , group 1 treated with the Segmented Pendulum (SP) and fixed appliances; ,0,
edin,4926,4493951,Significantly increased,"In the PACU, group H2 had a higher sedation score than groups H1 and H0 (Pâ<â0.001).", The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period ," H0 (saline), H1(haloperidol 1 mg), ",  and H2 (haloperidol 2 mg) ,0,
edin,4814,5124485,No significant difference,"At a median follow-up of 48 months (IQR:31â56), median PFS was 39 months (IQR:16â46) in the TMZ arm and 46 months (IQR:19â48) in the RT group (hazard ratio 1.16, 95% CI, 0.9â1.5; p=0.22).", median  progression-free survival (PFS) , standard radiotherapy (RT)  (50.4 Gy/28 fractions) ," temozolomide (TMZ)  (75 mg/m2 daily Ã 21 days, q28 days, max. 12 cycles) ",0,
edin,5059,4080584,Significantly increased,"For HRQoL, after adjustment for baseline scores, the intervention group showed significantly higher scores on all three PedsQL scores (physical functioning: MâÂ±âSEâ=â83.9âÂ±â0.7, pâ=â.005; psychosocial: 79.9âÂ±â0.8, pâ=â.001; total score: 81.3âÂ±â0.7, pâ=â.001) than the control group (80.9âÂ±â0.8; 76.1âÂ±â0.9 and 77.8âÂ±â0.8). T", psychosocial functioning , control group , intervention group ,0,
edin,4989,2885597,Significantly decreased,"Significant reductions in total cholesterol, triglycerides and non-high density lipoprotein cholesterol were observed in the combination treatment group. The serum activities of alkaline phosphatase, gamma-glutamyl transpeptidase and alanine aminotranferase also decreased in this group compared with baseline (-32.6%; p=0.012, -44%; p=0.031 and -16.9%; p=0.029, respectively).", alkaline phosphatase , UDCA monotherapy , fenofibrate plus UDCA ,0,
edin,4941,4907437,No significant difference,"There was no significant difference between groups in pain-related disability at 6 or 12 mo (12 mo: difference â1.0, intervention versus control, 95% CI â4.9 to 3.0), pain intensity, or the census global health question", pain-related disability at 12 mo , usual care and a relaxation CD , COPERS intervention ,0,
edin,4992,2360567,Significantly increased,Tumour-specific survival in the IL-2 group and the control group was 98 vs 81% after 1 year and 86 vs 73% after 5 years (P=0.04)., Tumour-specific survival after 5 years , immunomonitoring without immunomodulation , preoperative administration of interleukin-2 (IL-2) ,0,
edin,5021,4129110,Significantly increased,"HIFT participants spent significantly less time exercising per week, yet were able to maintain exercise enjoyment and were more likely to intend to continue.", intend to continue , moderate-intensity aerobic and resistance training (ART) , high-intensity functional training (HIFT) ,0,
edin,4977,5958473,Cannot tell based on the abstract,"Varenicline in combination with behavioral support resulted in high abstinence rates inpatients hospitalized for exacerbation of COPD, asthma attack, or CAP, and improved QoL.", improved quality of Life (QoL) , Varenicline , Varenicline in combination with behavioral support ,0,
edin,4977,5958473,No significant difference,Smoking cessation improved QoL in both groups. The comparison of mean scores between baseline and week 52 showed statistically significant changes for all SF36 domains (Table 2). These figures must be viewed with caution due to the small number of eight completers in group B., improved quality of Life (QoL) , Varenicline , Varenicline in combination with behavioral support ,0,
edin,4929,4331939,Significantly increased,"A comparison of the experimental and the control groups showed more significant improvements in the VAS, PRS, and ODI for the experimental group than for the control group.", pain rating scale [PRS] ,  normal saline-pharmacopuncture-treated group , Chukyu (spinehealing)- pharmacopuncture-treated group  ,0,
edin,4799,5515881,Cannot tell based on the abstract,, dynamic balance performance on the stability platform , relaxation group , demanding balance training program ,0,
edin,4799,5515881,Cannot tell based on the abstract,, dynamic balance performance on the stability platform , relaxation group , demanding balance training program ,0,
edin,4799,5515881,Significantly increased,"The balance training increased participantsâ dynamic balance performance on the stability platform as indicated by a significant effect of group, F(1, 36)â=â8.72, pâ=â0.005.", dynamic balance performance on the stability platform , relaxation group , demanding balance training program ,0,
edin,5046,2363617,Cannot tell based on the abstract,"According to the criteria of the 5th edition, 39% of the node-positive patients had another N stage compared to the 4th: 21% had a lower and 18% had a higher stage. 5-year survival rates according to the 4th edition N0, N1 and N2 groups were respectively 72%, 34% and 27%. According to the 5th edition these percentages were for the N0, N1, N2, N3 and Nx groups respectively 75%, 38%, 19%, 8% and 65%.", N1 and N2 groups , 4th edition (1987) , 5th edition (1997) of the TNM classification for gastric cancer ,0,
edin,5046,2363617,Significantly increased,"According to the criteria of the 5th edition, 39% of the node-positive patients had another N stage compared to the 4th: 21% had a lower and 18% had a higher stage. 5-year survival rates according to the 4th edition N0, N1 and N2 groups were respectively 72%, 34% and 27%. According to the 5th edition these percentages were for the N0, N1, N2, N3 and Nx groups respectively 75%, 38%, 19%, 8% and 65%. The former 1987 N1 and N2 group were significantly split into three new N 1997 groups (P = 0.006, respectively P< 0.0005).", N1 and N2 groups , 4th edition (1987) , 5th edition (1997) of the TNM classification for gastric cancer ,0,
edin,5034,5106769,Significantly increased,"Additionally, PSR times and DG thresholds improved significantly from baseline compared to placebo at 6- and 12-month visits (pâ<â0.001 for all).", disability glare (DG) performance , placebo , macular carotenoids (MC): 20 mg Lâ+â4 mg total Z (2 mg Zâ+â2 mg MZ; nâ=â25) ,0,
edin,4938,3262135,Cannot tell based on the abstract,NSAID consumption was lower in the Bupivacaine group compared with the NaCl group (PÂ <Â 0.01).," One&amp;nbsp;h postoperative, NSAID consumption ", Control group , Bupivacaine group ,0,
edin,4938,3262135,Significantly decreased,"OneÂ h postoperative, NSAID consumption was reported by 64 (67%) patients in the Control group, 42 (47%) patients in the Bupi group and 38 (42%) patients in the Ropi group. Significantly, more patients in the Control group used NSAIDâs compared with the Bupi group (PÂ <Â 0.01)."," One&amp;nbsp;h postoperative, NSAID consumption ", Control group , Bupivacaine group ,0,
edin,4775,5119624,Significantly increased,"ORR was also higher in the talimogene laherparepvec arm (40.5% versus 2.3%; P<0.0001), and 27 patients in the talimogene laherparepvec arm had a complete response, compared with none in GM-CSF-treated patients.", overall response rate (ORR) , granulocyte-macrophage colony-stimulating factor (GM-CSF) , Talimogene laherparepvec ,0,
edin,5027,4215680,Cannot tell based on the abstract,, positive sperm culture (with CFU &amp;gt; 105 mlâ1) , no treatment , rifaximin followed by the probiotic VSL#3 ,0,
edin,5027,4215680,Significantly decreased,"Overall, the treatment with rifaximin and VSL#3 was beneficial in terms of lowering the frequency of bacteriospermia when it was started immediately after the initial germ eradication rather than 6 months later. Indeed, patients of group â6Tx/6-â had the lowest frequency of positive sperm culture compared with patients of group â6-/6Txâ who received the treatment during the last 6 months of observation. The highest frequency was found in patients who were not prescribed any treatment and conversely, the lowest frequency was found among patients of group â12Txâ who received the treatment for all 12 months (Table 2).", positive sperm culture (with CFU &amp;gt; 105 mlâ1) , no treatment , rifaximin followed by the probiotic VSL#3 ,0,
edin,4792,3693661,No significant difference,"Variations within group had been changed in FBS; sodium, phosphorus and osmolarity levels were not changed significantly."," FBS, sodium, phosphorus and osmolarity levels ", baseline ," fasting + exercise (FE),  fasting + non exercise (FNE) ",0,
edin,4809,3591547,Cannot tell based on the abstract,," stopping the anesthesia drugs up to opening eyes, return to verbal response, and discharge from the recovery "," Remifentanil 0.5 Î¼g/kg, infusion of Remifentanil 0.1 Î¼g/kg/min "," 10 Î¼g/kg of Alfentanil, infusion of Alfentanil 1 Î¼g/kg/min ",0,
edin,4809,3591547,No significant difference,"There was no significant difference in stopping the anesthesia drugs up to opening eyes, return to verbal response, and discharge from the recovery between two groups."," stopping the anesthesia drugs up to opening eyes, return to verbal response, and discharge from the recovery "," Remifentanil 0.5 Î¼g/kg, infusion of Remifentanil 0.1 Î¼g/kg/min "," 10 Î¼g/kg of Alfentanil, infusion of Alfentanil 1 Î¼g/kg/min ",0,
edin,4771,5395991,No significant difference,"The primary macular hole closure and reattachment rates were not significantly different in both groups (P=0.056, respectively).", The primary reattachment rate , ILM peeling , internal limiting membrane (ILM) flap technique ,0,
edin,4800,5515881,Cannot tell based on the abstract,, center of pressure (CoP) sway velocity , relaxation group , demanding balance training program ,0,
edin,4800,5515881,No significant difference,"There was no significant training effect on neither the CoP sway velocity as assessed with the forceplate, F(1, 36)â<â0.001, pâ=â0.962, group differenceâ=ââ0.001, 95% CIâ=â[â0.08, 0.08], dâ=ââ0.01, nor on functional balance, as measured with the BESS, F(1, 36)â=â0.16, pâ=â0.704, group differenceâ=ââ0.52, 95% CIâ=â[â0.3.25, 2.22], dâ=ââ0.09.", center of pressure (CoP) sway velocity , relaxation group , demanding balance training program ,0,
edin,4805,4968829,Cannot tell based on the abstract,, peak HR in younger subjects , cycling   , rowing ,0,
edin,4805,4968829,No significant difference,"While older subjects demonstrated no significant difference in peak HR during cycling and rowing (p>0.05),", peak HR in younger subjects , cycling   , rowing ,0,
edin,4949,4616122,Significantly decreased,"The scores for the Visual Analogue Scale, Pain Disability Assessment Scale, and affective subscale of the Short-Form McGill Pain Questionnaire and number of nonorganic pain drawings in the good outcome group were significantly lower than those in the poor outcome group", Pain Disability Assessment Scale , poor outcome group , good outcome group ,0,
edin,4912,3215945,Cannot tell based on the abstract,," The levels of urine N-telopeptide, serum osteocalcin, and serum bone-specific alkaline phosphatase (BSAP) ", placebo , zoledronic acid (4âmg) IV infusion ,0,
edin,4912,3215945,Significantly decreased,"he levels of urine N-telopeptide, serum osteocalcin, and serum bone-specific alkaline phosphatase (BSAP) were 49 Â± 6.6%, 51.6 Â± 6.1%, and 38.8 Â± 7.5%, lower than baseline in the zoledronic acid group (Table 2). These changes were significantly lower than the percent changes in placebo at significance level 0.05."," The levels of urine N-telopeptide, serum osteocalcin, and serum bone-specific alkaline phosphatase (BSAP) ", placebo , zoledronic acid (4âmg) IV infusion ,0,
edin,4817,5331731,Significantly increased,"Econometric analysis shows that PBF led to increased job satisfaction and decreased attrition on a subset of measures, with little effect on motivation.", job satisfaction ,  and control 2 (C2; pure control) , Performance-based financing (PBF) ,0,
edin,4891,1175929,Cannot tell based on the abstract,," TNF-Î± plasma levels,  IL-1Î² ", baseline , endotoxin intravenously (2 ng/kg Escherichia coli O113) ,0,
edin,4891,1175929,Significantly increased,"The clinical onset of inflammation was accompanied by a sudden rise in TNF-Î± plasma levels at 60 min (373 Â± 71 pg/ml), which reached its zenith at 90 min (856 Â± 158 pg/ml), closely followed by a rise in IL-1Î² that was maximal at 120 min (23.9 Â± 2.2 pg/ml)."," TNF-Î± plasma levels,  IL-1Î² ", baseline , endotoxin intravenously (2 ng/kg Escherichia coli O113) ,0,
edin,4957,5555437,Cannot tell based on the abstract,, overall survival 5 years , 45 Gy radiotherapy in 30 twice-daily fractions of 1Â·5 Gy over 19 days , 66 Gy in 33 once-daily fractions of 2 Gy over 45 days ,0,
edin,4957,5555437,No significant difference,5-year overall survival was 34% (95% CI 27â41) in the twice-daily group and 31% (25â37) in the once-daily group (absolute difference 2Â·8% [95% CI â6Â·4% to 12Â·0%])., overall survival 5 years , 45 Gy radiotherapy in 30 twice-daily fractions of 1Â·5 Gy over 19 days , 66 Gy in 33 once-daily fractions of 2 Gy over 45 days ,0,
edin,4927,4493951,Cannot tell based on the abstract,, The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period ,"  H1(haloperidol 1 mg), ", H0 (saline) ,0,
edin,4927,4493951,No significant difference,"The change in the sedation score in the PACU clearly differed among the groups according to the dose of haloperidol. Group H2 had an overall higher sedation score than groups H1 and H0 over the 2-h observation period (Pâ<â0.001, Fig.Â 2), while there was no significant difference between groups H1 and H0. In addition, three patients in group H2 required treatment with ephedrine in the PACU, due to hypotension (systolic 75â80/diastolic 50â55 mmHg).", The sedation score recorded in the postanesthesia care unit (PACU) over the 2-h observation period ,"  H1(haloperidol 1 mg), ", H0 (saline) ,0,
edin,4954,4269914,Significantly increased,"There was also a positive, although statistically insignificant, increase of 2.6Â L% in serum testosterone levels in the experimental group.", serum testosterone levels , control group with Carborade DrinkÂ® alone ," experimental group was supplemented with 500 mg of SAA per kg of body mass, dissolved in 250 ml of a Carborade DrinkÂ®; ",0,
edin,4860,4141579,Significantly increased,"The mean values of high-density lipoprotein were also significantly higher in the first and 2nd years in the carb counting group (p=0.02 and p=0.043, respectively).", Mean  high-density lipoprotein (HDL) levels , control , carb counting ,0,
edin,4806,4968829,Significantly increased,Rowing VO2max was higher than cycling VO2max in both groups (p<0.05)., VO2max in older and younger subjects , cycling ,   rowing ,0,
edin,5047,2363617,Significantly increased,"In addition, the new TNM stage was also a better prognosticator.", better prognosticator , 4th edition (1987) , 5th edition (1997) of the TNM classification for gastric cancer ,0,
edin,4869,4958948,Cannot tell based on the abstract,, HDL cholesterol , baseline , Active Body Control ,0,
edin,4869,4958948,Significantly increased,"ABC program led to significant reductions of systolic and diastolic blood pressure (â7.69%, pâ<â0.001; and â9.47%, pâ<â0.001), serum triglyceride levels (â34.57%, pâ<â0.001), total cholesterol (â8.70%, pâ<â0.001), LDL cholesterol (â13.69%, pâ<â0.001), HbA1c (â3.70%, relative value, pâ<â0.001), fasting blood glucose (â6.10%, pâ<â0.001), fasting insulin (â40.86%, pâ<â0.001) and HOMA-I (â45.71%, pâ<â0.001), whereas HDL cholesterol increased (14.85%, pâ<â0.001).", HDL cholesterol , baseline , Active Body Control ,0,
edin,4768,5395991,No significant difference,"o significant differences were found in the pre- and postoperative BCVA at 1 and 3 months after surgery in either group (inverted ILM flap technique group, preoperatively 1.04Â±0.55, 1 month 0.95Â±0.30, 3 months 0.83Â±0.22; ILM peeling group, preoperatively 1.00Â±0.44, 1 month 1.05Â±0.38, 3 months 1.06Â±0.49; P>0.05, respectively).", best-corrected visual acuity (BCVA) , ILM peeling , internal limiting membrane (ILM) flap technique ,0,
edin,4786,3457720,Cannot tell based on the abstract,, systolic blood pressure at week seven , control , therapeutic massage (TM) ,0,
edin,4786,3457720,Significantly decreased,"There was no significant group difference in systolic blood pressure at week six, but by week seven the TM group was significantly lower.", systolic blood pressure at week seven , control , therapeutic massage (TM) ,0,
edin,5052,4461930,Significantly decreased,"Assignment to the active treatment arms was associated with reduction in plasma amyloid-Î² (AÎ²) peptides, increase in ventricular volume, decrease in cerebrospinal fluid phosphorylated tau (p-tau) and several other laboratory measures and adverse event categories.", plasma amyloid-Î² (AÎ²) peptides , placebo , semagacestat 140 mg ,0,
edin,4794,1713239,Significantly increased,"At 1 minute after inhalation, statistically significant decreases in Borg score were observed for budesonide/formoterol and salbutamol (p = 0.0233 and p < 0.0001, respectively, versus placebo), with similar rapid increases in FEV1 (both active treatments p < 0.0001 versus placebo)", Forced expiratory volume (FEV1) , placebo , budesonide/formoterol and salbutamol ,0,
edin,5010,4764962,Significantly decreased,"Additionally, the difference between the preoperative and postoperative scores was significant only in Group I and Group III, but not in Group II. The reduction in the Wexner score was significantly less in Group III.", Wexner score ," Group III, only surgical management was performed "," Group I, biofeedback therapy was performed 3 months before and 6 months after the surgery ",0,
edin,5037,5741844,No significant difference,"The results of the study showed the least amount of the smear layer at coronal, middle and apical thirds of the root canals in groups 2, which was not significantly different from the negative control group (P<0.5).", Root canal walls without any smear layer , Positive and Negative control groups ," Group 1, 2, 3, 4 ",0,
edin,5050,4461930,Significantly increased,"Assignment to the active treatment arms was associated with reduction in plasma amyloid-Î² (AÎ²) peptides, increase in ventricular volume, decrease in cerebrospinal fluid phosphorylated tau (p-tau) and several other laboratory measures and adverse event categories.", ventricular volume , placebo , semagacestat 100 mg ,0,
edin,4897,1175929,Cannot tell based on the abstract,, Heart rate , baseline , endotoxin intravenously (2 ng/kg Escherichia coli O113) ,0,
edin,4897,1175929,Significantly increased,Heart rate remained unchanged in the control group (from 66 Â± 4 to 65 Â± 2 beats/min; not significant) and increased from 63 Â± 3 to 91 Â± 3 beats/min at 6 hours in the LPS group (P < 0.0001)., Heart rate , baseline , endotoxin intravenously (2 ng/kg Escherichia coli O113) ,0,
edin,4943,4907437,No significant difference,"There was no significant difference between groups in pain-related disability at 6 or 12 mo (12 mo: difference â1.0, intervention versus control, 95% CI â4.9 to 3.0), pain intensity, or the census global health question.,For secondary outcomes, we found sustained benefits on depression and social integration at 6 and 12 mo, but there was no effect on anxiety, pain-related self-efficacy, pain acceptance, pain intensity, or the census global health question at 12 mo.", census global health question at 6- or 12-mo follow-up , control group , COPERS intervention ,0,
edin,4980,5694844,Cannot tell based on the abstract,, Microleakage of Two Bulk Fill and One Conventional Composite in Class II Restorations of Primary Posterior Teeth , Z250 conventional composite , 3M bulk fill ,0,
edin,4980,5694844,No significant difference,"Table 2.
Dye penetration depth in millimeters (indicative of microleakage) in the three groups

Composite	Margin	Mean (Î¼m)	Minimum (Î¼m)	Maximum (Î¼m)	Std. deviation
Bulk-fill (3M)	Gingival	523.40	0.00	1508.00	543.50
Occlusal	93.80	0.00	808.00	214.17
Bulk-fill (SonicFill)	Gingival	290.25	0.00	860.00	343.07
Occlusal	127.35	0.00	1254.00	302.04
Conventional (Z250)	Gingival	590.20	0.00	1498.00	597.78
Occlusal	145.45	0.00	507.00	199.14,No significant difference was noted among the three groups in terms of microleakage in the gingival (P=0.252) or occlusal (P=0.516) margins (Table 2). Microleakage (dye penetration depth) in the gingival margin of all groups was significantly greater than that in the occlusal margin (P=0.001 for 3M bulk fill, P=0.049 for SonicFill and P=0.001 for Z250 conventional composite).,Bulk fill composites have similar properties to conventional composites in terms of microleakage and may be preferred for class II restoration of primary posterior teeth to decrease working time given that their other properties are also favorable.", Microleakage of Two Bulk Fill and One Conventional Composite in Class II Restorations of Primary Posterior Teeth , Z250 conventional composite , 3M bulk fill ,0,
edin,4924,4493951,Significantly decreased,"The total incidence of PONV over 24 h was significantly lower in groups H1 (29Â %) and H2 (24Â %) than in group H0 (54Â %; Pâ=â0.003),", the incidence of postoperative nausea and vomiting (PONV) , H0 (saline) ," H1(haloperidol 1 mg), and H2 (haloperidol 2 mg) ",0,
edin,4844,4535555,Significantly increased,"On acute imaging, mean % encirclements by LGE and T2W signal were 72% and 80% in the robotic group vs. 60% (P = 0.002) and 76%(P = 0.45) for standard ablation", mean % encirclements by  late gadolinium enhancement (LGE) and T2W signal , standard navigation , robotic-assisted navigation (Hansen SenseiÂ® X) ,0,
edin,4846,4535555,No significant difference,"At 6 months follow-up, arrhythmia-free patients had an almost similar mean LGE encirclement (robotic 64%, standard 60%, P = 0.45) but in recurrences, LGE was higher in the robotic group (43% vs. 30%, P = 0.001).", mean LGE encirclement at 6 months follow-up , standard navigation , robotic-assisted navigation (Hansen SenseiÂ® X) ,0,
edin,4789,3693661,No significant difference,"The mean of weight, BMI, WHR, body fat, protein, mineral and total water showed no difference between groups (P > 0.05)."," weight, BMI, WHR ", baseline ," fasting + exercise (FE), fasting + non exercise (FNE) ",0,
edin,4854,5425769,Cannot tell based on the abstract,, Mini-Mental State Examination (MMSE) scores , control , Sonas programme ,0,
edin,4854,5425769,No significant difference,"When stratifying on MMSE (moderate and severe; cut-off of 10 points), a significant difference was found between the Sonas group and the reading group among those with an MMSE score of 0â10 at T0 (p = 0.011) and at T1 (p = 0.044), while among those with an MMSE score of 11â20, there was a significant difference between the Sonas and the reading group at baseline (p = 0.026). No difference was found between the Sonas and the control group.", Mini-Mental State Examination (MMSE) scores , control , Sonas programme ,0,
edin,4923,4260384,Significantly increased,"The width of keratinized tissue was also significantly (P < 0.001) increased in both groups, but the increase was significantly greater (P < 0.001) in group B (2.30 Â± 1.06 mm) than in group A (1.21 Â± 0.67 mm", keratinized tissue ," Group A, which were treated with the envelope type of CAF ", Group B were treated with envelope type of CAF along with the Type I collagen membrane (NEOMEM) ,0,
edin,4959,5555437,Cannot tell based on the abstract,"The primary endpoint was overall survival, defined as time from randomisation until death from any cause, analysed by modified intention-to-treat. A 12% higher overall survival at 2 years in the once-daily group versus the twice-daily group was considered to be clinically significant to show superiority of the once-daily regimen.", median survival , 45 Gy radiotherapy in 30 twice-daily fractions of 1Â·5 Gy over 19 days , 66 Gy in 33 once-daily fractions of 2 Gy over 45 days ,0,
edin,4959,5555437,No significant difference,"In our survival analysis (which included 273 patients in the twice-daily group and 270 in the once-daily group), median overall survival was 30 months (95% CI 24â34) in the twice-daily group and 25 months (21â31) in the once-daily group (hazard ratio 1Â·18 [95% CI 0Â·95â1Â·45]; p=0Â·14; figure 2A).", median survival , 45 Gy radiotherapy in 30 twice-daily fractions of 1Â·5 Gy over 19 days , 66 Gy in 33 once-daily fractions of 2 Gy over 45 days ,0,
edin,4871,4958948,Cannot tell based on the abstract,," Bile acids (BAs), glycine and taurine conjugated BAs ", baseline , Active Body Control ,0,
edin,4871,4958948,Significantly decreased,"We observed a significant decrease of total BA levels in participants of the ABC arm (â34.59%, pâ=â0.007) that resulted mainly from a decrease of glycine and taurine conjugated BAs (â49.11%, pâ=â0.002 and â54.46%, pâ=â0.001) (Fig. 1b and Supplementary Table S2)."," Bile acids (BAs), glycine and taurine conjugated BAs ", baseline , Active Body Control ,0,
edin,4872,4958948,Cannot tell based on the abstract,," CDCA, CA and UDCA ", baseline , Active Body Control ,0,
edin,4872,4958948,Significantly decreased,"Regarding different BA-fractions, lifestyle-induced weight loss was accompanied by a significant decrease of total CDCA (â52.38%, pâ=â0.001), CA (â31.49%, pâ=â0.018) and UDCA (â49.37%, pâ=â0.002) (Fig. 1c and Supplementary Table S2)."," CDCA, CA and UDCA ", baseline , Active Body Control ,0,
edin,5013,5009836,No significant difference,"There was also no difference between groups with respect to bradycardia, APGAR scores, and nausea and vomiting.", incidence of maternal nausea and vomiting , crystalloid preload - Lactated Ringer's solution (1500 ml) ," colloid preload - hydroxyethyl starch (6% in normal saline, 500 ml) ",0,
edin,4870,4958948,Cannot tell based on the abstract,," systolic and diastolic blood pressure, serum triglyceride levels , total cholesterol , LDL cholesterol , HbA1c , fasting blood glucose, fasting insulin  and HOMA-I ", baseline , Control ,0,
edin,4870,4958948,Significantly decreased,"ABC program led to significant reductions of systolic and diastolic blood pressure (â7.69%, pâ<â0.001; and â9.47%, pâ<â0.001), serum triglyceride levels (â34.57%, pâ<â0.001), total cholesterol (â8.70%, pâ<â0.001), LDL cholesterol (â13.69%, pâ<â0.001), HbA1c (â3.70%, relative value, pâ<â0.001), fasting blood glucose (â6.10%, pâ<â0.001), fasting insulin (â40.86%, pâ<â0.001) and HOMA-I (â45.71%, pâ<â0.001),"," systolic and diastolic blood pressure, serum triglyceride levels , total cholesterol , LDL cholesterol , HbA1c , fasting blood glucose, fasting insulin  and HOMA-I ", baseline , Control ,0,
edin,4937,3262135,Significantly decreased,NSAID consumption was lower in the Bupivacaine group compared with the NaCl group (PÂ <Â 0.01)., used NSAIDâs , Control group , Bupivacaine group ,0,
edin,5036,5741844,No significant difference,"The results of the study showed the least amount of the smear layer at coronal, middle and apical thirds of the root canals in groups 2, which was not significantly different from the negative control group (P<0.5)."," amount of the smear layer at coronal, middle and apical thirds of the root canals ", negative control group , Group 2: XPF with 1 mL of 17% EDTA for one minute ,0,
edin,4812,3635629,No significant difference,"Transfusion requirements, excluding FFP in pump prime, and postoperative bleeding were comparable between the control and treatment groups of infants and children.", FFP transfusion , control , 20% albumin (50-100 mL) or fresh frozen plasma (FFP) (1-2 units) ,0,
edin,4883,3774725,Significantly increased,"For patients resolving in the first three months, the adjusted Hazard Ratio (aHR) was 0.85 (95% Confidence Interval [CI]: 0.64-1.13) suggesting that PN had no effect on resolution time during this period.,Beyond three months, however, navigated patients resolved more quickly to diagnostic resolution compared with the control group (aHR 2.8, 95%CI: 1.30-6.13). Th", effect on resolution time beyond first three months , Control , patient navigation (PN) program ,0,
edin,4951,4616122,Significantly decreased,"The scores for the Visual Analogue Scale, Pain Disability Assessment Scale, and affective subscale of the Short-Form McGill Pain Questionnaire and number of nonorganic pain drawings in the good outcome group were significantly lower than those in the poor outcome group", number of nonorganic pain drawings , poor outcome group , good outcome group ,0,
edin,4798,3108651,Cannot tell based on the abstract,, grade 3â4 neutropenia , 400  mg/day imatinib , 800 mg/day imatinib ,0,
edin,4798,3108651,No significant difference,"On the other hand, no increase in grade 3â4 neutropenia was documented after crossover to the higher dosage (P = 0.002).", grade 3â4 neutropenia , 400  mg/day imatinib , 800 mg/day imatinib ,0,
edin,4876,4958948,Cannot tell based on the abstract,," total GLP-1, FGF-19 levels ", baseline , Control ,0,
edin,4876,4958948,No significant difference,"Lifestyle-induced weight loss had no effect on circulating FGF-19 levels (Fig. 2a), while total GLP-1 decreased significantly (pâ=â0.003; Fig. 2b). Both parameters remained stable in the control arm."," total GLP-1, FGF-19 levels ", baseline , Control ,0,
edin,4838,4138551,Significantly increased,"QP and SP were equally effective in distalizing maxillary molars (3.5 and 4Â mm, respectively) between T1 and T2; however, the maxillary first molar showed less distal tipping (4.6Â° vs. 9.6Â°) and more extrusion (1.1 vs. 0.2Â mm) in the QP group than in the SP group, as well as the vertical facial dimension, which increased more in the QP group (1.2Â°) than in the SP group (0.7Â°).", molar tipping , group 2   treated with the Quad Pendulum (QP) and fixed appliances , group 1 treated with the Segmented Pendulum (SP) and fixed appliances; ,0,
edin,4939,3262135,Cannot tell based on the abstract,," One h postoperative, NSAID consumption ", Control group , Ropivacaine ,0,
edin,4939,3262135,No significant difference,"OneÂ h postoperative, NSAID consumption was reported by 64 (67%) patients in the Control group, 42 (47%) patients in the Bupi group and 38 (42%) patients in the Ropi group. Significantly, more patients in the Control group used NSAIDâs compared with the Bupi group (PÂ <Â 0.01).,No significant differences were found comparing the Control group to the Ropi group or the Ropi group to the Bupi group."," One h postoperative, NSAID consumption ", Control group , Ropivacaine ,0,
edin,4769,5395991,Significantly increased,The primary macular hole closure rates were 100% in the inverted ILM flap technique group and 55.5% in the ILM peeling group., The primary macular hole closure rates , ILM peeling , internal limiting membrane (ILM) flap technique ,0,
edin,5159,2713840,Cannot tell based on the abstract,, Success rate , Shoulder type covered stent , Uncovered nitinol stent ,0,
edin,5159,2713840,No significant difference,"The clinical success rate was 80.0% (24/30): 100% for type A, 68.8% for type B, and 83.3% for type C (Table 3); the differences were statistically insignificant (p=0.191", Success rate , Shoulder type covered stent , Uncovered nitinol stent ,0,
edin,5165,3785902,No significant difference,"We concluded that propofol can reduce SBP, DBP, MAP, HR & cough production at the time of injection but there were no significant changes in these parameters after extubation.", Cough  , Control , Propofol ,0,
edin,5120,3980039,Cannot tell based on the abstract,"In Study 3, beta cell glucose sensitivity was minimally affected, but the insulin secretion rate at 9Â mmol/l glucose increased to similar degrees from baseline with canagliflozin and sitagliptin [LSM (SEM) changes 38 (8) and 28 (9) pmolÂ minâ1Â mâ2, respectively; pâ<â0.05 for both].", Total insulin secretion , Sitagliptin , Canagliflozin 300 mg ,0,
edin,5120,3980039,Significantly decreased,"Consistent with the greater reductions in plasma glucose concentrations in the canagliflozin group, total insulin secretion was reduced with canagliflozin treatment compared with sitagliptin (pâ=â0.005) (TableÂ 5)", Total insulin secretion , Sitagliptin , Canagliflozin 300 mg ,0,
edin,5169,5091022,No significant difference,"The total bleeding measured at the suction drains within 48Â h was higher in Group II, with a statistically significant difference (pÂ =Â 0.005); in the first 24Â h, there was major bleeding in Group II (mean 893Â mL), with a significant difference (pÂ =Â 0.004). Between 24 and 48Â h, there was no statistically significant difference in both groups (pÂ =Â 0.710). The total estimated bleeding was higher in Group I, with mean of 463Â mL, versus 409Â mL in Group II, with no statistical significance (pÂ =Â 0.394).", Total blood suctioned after 48 hrs , 4.8 mm drain , 3.2 mm drain ,0,
edin,5226,4815882,Cannot tell based on the abstract,, Time to progression  , Placebo , Simvastatine ,0,
edin,5226,4815882,No significant difference,"No significant differences were observed between the simvastatin and placebo groups regarding two of the secondary end points, OS and TTP.", Time to progression  , Placebo , Simvastatine ,0,
edin,5151,1852293,Significantly increased,"Using five diagnostic criteria, 18% of CVC patients were cured and 70.8% either cured and/or improved compared to 1.6% and 12% of placebo patients respectively (p < 0.0001).", Cured patients using 5 criteria , Placebo , Clindamycin cream ,0,
edin,5094,3279644,Cannot tell based on the abstract,,  MEP amplitudes , anodal-tDCS&amp;nbsp;+&amp;nbsp;iTBS condition , cathodal-tDCS + iTBS ,0,
edin,5094,3279644,Significantly increased,"Post hoc t tests showed that baseline MEP amplitudes did not differ between conditions (all PÂ >Â 0.05).,However, in the cathodal-tDCSÂ +Â iTBS condition, MEPs after stimulation were larger than in the sham-tDCSÂ +Â iTBS condition (tÂ =Â 2.983, dfÂ =Â 8, PÂ =Â 0.020) and the anodal-tDCSÂ +Â iTBS condition (PÂ =Â 0.080, trend level).",  MEP amplitudes , anodal-tDCS&amp;nbsp;+&amp;nbsp;iTBS condition , cathodal-tDCS + iTBS ,0,
edin,5204,4311411,Cannot tell based on the abstract,, Sensitive Conduction Velocity  , Placebo ," High dose (baclofen, naltrexone, sorbitol) ",0,
edin,5204,4311411,Significantly increased,"DML was significantly decreased in the HD group when compared to Placebo (8%, Pâ=â0.038), and SCV was significantly increased in HD when compared to Placebo (26.6%, Pâ=â3.70Ã10â4) and PLI (20.1%, Pâ=â0.03).", Sensitive Conduction Velocity  , Placebo ," High dose (baclofen, naltrexone, sorbitol) ",0,
edin,5063,5610548,Cannot tell based on the abstract,, Sialylated HMOs , Iron and folic acid , LipÃ­d based nutrient suplement ,0,
edin,5063,5610548,No significant difference,"At 6 mo postpartum, there were no significant differences in mean concentrations of total HMOs, sialylated or fucosylated HMOs, lactoferrin, lactalbumin, lysozymes, antitrypsin, IgA, or osteopontin between the 3 intervention groups in either the unadjusted or adjusted models (each P > 0.10) (Table 2).", Sialylated HMOs , Iron and folic acid , LipÃ­d based nutrient suplement ,0,
edin,5083,5617873,Cannot tell based on the abstract,, Compulsion scale , Placbeo , Aripiprazole ,0,
edin,5083,5617873,No significant difference,"<td align=""left"">CY-BOCS (compulsion scale only)</td><td align=""char"" char=""."">5.4 (0.9)</td><td align=""left"">â1.3 (0.5)</td><td align=""char"" char=""."">6.3 (0.9)</td><td align=""left"">â2.0 (0.5)</td><td align=""left"">â0.69 (â2.03, 0.66)<sup>b</sup>
<break>0.311</break></td>", Compulsion scale , Placbeo , Aripiprazole ,0,
edin,5103,3682900,No significant difference,Ultra-high dose intravenous N-acetylcysteine did not alter creatinine or cystatin C levels., Creatitine after 2 days , Control , N-acetylcysteine ,0,
edin,5194,3781502,Cannot tell based on the abstract,, Weight , Exenatide , Lixisenatide ,0,
edin,5194,3781502,No significant difference,"Body weight decreased from baseline in both the lixisenatide once-daily group and exenatide twice-daily group. Mean (Â±SD) body weight decreased from 94.5 (Â±19.4) to 91.7 (Â±18.9) kg with lixisenatide and from 96.7 (Â±22.8) to 92.9 (Â±22.3) kg with exenatide (Fig. 1C). The LS mean (Â±SE) body weight reduction at week 24 (LOCF) was â2.96 (Â±0.23) kg for lixisenatide compared with â3.98 (Â±0.23) kg for exenatide. The LS mean change difference between the two groups was 1.02 kg (95% CI, 0.456â1.581). Overall, 25.1% of lixisenatide-treated patients and 31.4% of exenatide-treated patients had â¥5% weight loss from baseline to week 24.", Weight , Exenatide , Lixisenatide ,0,
edin,5069,2949642,Significantly increased,"Tamoxifen-treated patients with estrogen receptor-positive tumors expressing none or low levels of HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival (DRFS) (hazard ratio = 0.38, 95% confidence interval = 0.23 to 0.60, P = 0.000048).", Distant recurrence-free survival , Control , Tamoxifen + No HOXB13 ,0,
edin,5125,5865731,Cannot tell based on the abstract,, Anxiety , Contractive posture , Expansive posture ,0,
edin,5125,5865731,No significant difference,"However, there were no main effects of condition for BISS and negative ES (insecurity, anxiety, disgust, shame, sadness, anger, and total score).,<td align=""left"" colspan=""1"" rowspan=""1"">&nbsp;&nbsp;&nbsp;&nbsp;Anxiety</td><td align=""center"" colspan=""1"" rowspan=""1"">2.00 (1.13)</td><td align=""center"" colspan=""1"" rowspan=""1"">2.09 (1.31)</td><td align=""center"" colspan=""1"" rowspan=""1"">2.77 (1.35)</td><td align=""center"" colspan=""1"" rowspan=""1"">2.62 (1.78)</td><td align=""center"" colspan=""1"" rowspan=""1""><italic>F</italic>(1,65) = 0.41</td><td align=""center"" colspan=""1"" rowspan=""1"">.524</td><td align=""center"" colspan=""1"" rowspan=""1""><italic>Î·</italic><sub><italic>p</italic></sub><sup><italic>2</italic></sup> = .01</td>", Anxiety , Contractive posture , Expansive posture ,0,
edin,5223,5856907,Cannot tell based on the abstract,, Not wanting to participate again in the future , Control ," ""Question writing"" method ",0,
edin,5223,5856907,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">5. Felt uncomfortable and I did not participate in the future in these programs</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">3.44Â±1.03</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">3.50Â±1.09</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">-0.166</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">0.87</td>,<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">5. Felt uncomfortable and I did not participate in the future in these programs</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">1(3%)</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">6(19%)</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">6(19%)</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">15(47%)</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">4(13%)</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">19(60%)</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">3.47</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">1</td>,verall, the students slightly agreed with creating MCQs. They also mentioned they would not like to take part in similar activity in the future (Table 3).", Not wanting to participate again in the future , Control ," ""Question writing"" method ",0,
edin,5106,3682900,Cannot tell based on the abstract,, Cystatin C after 4 days , Control , N-acetylcysteine ,0,
edin,5106,3682900,No significant difference,"The variations in creatinine and cystatin C concentrations on days 2, 4 and 10 in both groups are reported in FigureÂ 2. The evolution from baseline to day 10 in creatinine and cystatin C levels concentration was not different between the two groups.,<td align=""left"" valign=""bottom"">ââCreatinine<hr></td><td align=""left"" valign=""bottom"">â8.25 Â± 65.62<hr></td><td align=""left"" valign=""bottom"">â8.37 Â± 36.52<hr></td><td align=""left"" valign=""bottom"">0.37<hr></td>", Cystatin C after 4 days , Control , N-acetylcysteine ,0,
edin,5238,4609664,No significant difference,There was no significant difference between RCP and control group (P>0.05)., Cracks , Control , Reciproc system ,0,
edin,5216,2882922,Cannot tell based on the abstract,, Negative events , Control , Late tamoxifen ,0,
edin,5216,2882922,No significant difference,"<td align=""left"">âER-</td><td align=""left"">3</td><td align=""left"">0</td><td align=""left"">p = 0.24</td>", Negative events , Control , Late tamoxifen ,0,
edin,5096,5103135,Significantly increased,"After treatment, peak E, E/A and IVEF were increased by 41%, 44% and 16% respectively, but peak A, LVPWT/mm and IVST/mm were significantly reduced.", IVEF , No treatment , Bisoprolol + trimetazidine ,0,
edin,5176,4831776,Cannot tell based on the abstract,, Insulin AUC , Carbohydrates alone  , Carbohydrates + protein ,0,
edin,5176,4831776,No significant difference,"There was a tendency for a higher insulin concentration at 60 minutes (p = 0.053) after ingestion of CHO+PROT as compared to CHO alone,Area under curve also tended to be higher for insulin after CHO+PROT compared to CHO (p<0.06).", Insulin AUC , Carbohydrates alone  , Carbohydrates + protein ,0,
edin,5225,4815882,No significant difference,"No significant difference was observed between the two groups with respect to OS (median, 15.9 months (simvastatin) vs 19.9 months (placebo), P=0.826).", Overall survival , Placebo , Simvastatine ,0,
edin,5178,4831776,Cannot tell based on the abstract,, Carbohydrate oxidation , Carbohydrates alone  , Carbohydrates + protein ,0,
edin,5178,4831776,No significant difference,"Total carbohydrate oxidation during the exhaustive cycling was 261 Â± 28, 233 Â± 22 and 226 Â± 21 g before the CHO, CHO+PROT and PLA, respectively, and did not differ.,<td align=""left"" colspan=""1"" rowspan=""1""><bold>CHO oxidation (gÂ·min</bold><sup><bold>-1</bold></sup><bold>)</bold></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>,RER and CHO oxidation was significantly higher in CHO compared to PLA (p<0.05), but there was no difference between CHO and CHO+PROT.", Carbohydrate oxidation , Carbohydrates alone  , Carbohydrates + protein ,0,
edin,5090,4423288,Significantly increased,"The gastrotomy creation times for Groups 1, 2, and 3 were 28.0âÂ±â10.1, 4.3âÂ±â1.4, and 20.1âÂ±â10.6 minutes, respectively, with significantly lower time in Group 2 (Pâ<â0.001).", Gastrotomy creation times , Knife + ballon + OTSC , Tunnel + endoclips ,0,
edin,5118,3980039,Cannot tell based on the abstract,, Insulin clearance , Control , Canagliflozin 300 mg ,0,
edin,5118,3980039,Significantly increased,"Insulin clearance was increased by approximately 15% with both doses of canagliflozin compared with placebo (ESM TableÂ 2).Table 5,Insulin clearance was increased with both doses of canagliflozin compared with placebo, although the increase observed with the 100Â mg dose did not reach statistical significance (pâ=â0.07) (ESM TableÂ 2); the increase in insulin clearance observed with the 300Â mg dose compared with placebo was approximately 24% (pâ<â0.0001).", Insulin clearance , Control , Canagliflozin 300 mg ,0,
edin,5071,2949642,Cannot tell based on the abstract,"Tamoxifen-treated patients with estrogen receptor-positive tumors expressing none or low levels of HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival (DRFS) (hazard ratio = 0.38, 95% confidence interval = 0.23 to 0.60, P = 0.000048). However, for patients with a high or intermediate HOXB13 tumor expression, tamoxifen did not prolong the DRFS compared with the untreated patients (hazard ratio = 0.88, 95% confidence interval = 0.47 to 1.65, P = 0.69).", Distant recurrence-free survival , Tamoxifen + low levels of HOXB13 , Tamoxifen + intermediate levels of HOXB13 ,0,
edin,5071,2949642,Significantly decreased,"<td align=""left"" colspan=""7"">ER-positive</td>", Distant recurrence-free survival , Tamoxifen + low levels of HOXB13 , Tamoxifen + intermediate levels of HOXB13 ,0,
edin,5105,3682900,Cannot tell based on the abstract,, Creatitine after 10 days , Control , N-acetylcysteine ,0,
edin,5105,3682900,No significant difference,"The evolution from baseline to day 10 in creatinine and cystatin C levels concentration was not different between the two groups.,<td align=""left"" valign=""bottom""><bold>Day 10</bold><hr></td><td align=""left"" valign=""bottom"">&nbsp;<hr></td><td align=""left"" valign=""bottom"">&nbsp;<hr></td><td align=""left"" valign=""bottom"">&nbsp;<hr></td>", Creatitine after 10 days , Control , N-acetylcysteine ,0,
edin,5168,5091022,No significant difference,"Regarding the hematocrit, there were no differences between groups in measured periods (24, 48, and 72Â h after surgery).", Hematocrit after 72 hrs , 4.8 mm drain , 3.2 mm drain ,0,
edin,5192,3781502,Cannot tell based on the abstract,Responder rate (HbA1c <7.0%) and improvements in fasting plasma glucose were comparable., Goal HbA1c &amp;lt;7.0% , Exenatide , Lixisenatide ,0,
edin,5192,3781502,No significant difference,A similar proportion of patients in each group achieved HbA1c goals of <7.0% at week 24 (48.5% lixisenatide and 49.8% exenatide); t, Goal HbA1c &amp;lt;7.0% , Exenatide , Lixisenatide ,0,
edin,5256,3898240,Significantly increased,"In the â¥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly HDL3, (Î±-carotene, pâ=â0.008; Î²-cryptoxanthin, pâ=â0.042; lutein, pâ=â0.012; lycopene, pâ=â0.016), as did the activities of PON-1 and LCAT in HDL3 (pâ=â0.006 and 0.044, respectively).", Serum Lutein , Fruits and vegetables 1 portion , Fruits and vegetables +6 portions ,0,
edin,5074,3219771,No significant difference,"There were no significant differences in pH, PaCO2, the apparent strong ion difference, the strong ion gap, bicarbonate ion, or lactate between two groups throughout the whole investigation period.", Strong ion difference , Room temperature CO2 , Heated CO2 ,0,
edin,5187,3669111,Cannot tell based on the abstract,, Calcium-phosphorus product , Control , Cinacalcet ,0,
edin,5187,3669111,No significant difference,"Median iPTH (A), mean calcium-phosphorus product (Ca X P) (B), calcium (Ca) (C), and phosphorus (P) (D). iPTH decreased by 42.3% in the cinacalcet group, and by 30.7% in the control group (P = 0.483).", Calcium-phosphorus product , Control , Cinacalcet ,0,
edin,5189,3669111,Cannot tell based on the abstract,, Phosphorus , Control , Cinacalcet ,0,
edin,5189,3669111,No significant difference,"Median iPTH (A), mean calcium-phosphorus product (Ca X P) (B), calcium (Ca) (C), and phosphorus (P) (D). iPTH decreased by 42.3% in the cinacalcet group, and by 30.7% in the control group (P = 0.483).", Phosphorus , Control , Cinacalcet ,0,
edin,5127,5301372,No significant difference,"For the FGF pathwayâamplified subgroup (nâ=â31), the median PFS (95% CI) was 10.9 (3.5â16.5) months vs 5.5 (3.5â16.4) months in the dovitinib vs placebo arms, respectively (HR, 0.64; met the predefined superiority criteria).", Median progression-free survival , Placebo , Dovitinib  ,0,
edin,5119,3980039,Cannot tell based on the abstract,, Plasma glucose , Sitagliptin , Canagliflozin 300 mg ,0,
edin,5119,3980039,Cannot tell based on the abstract,, Plasma glucose , Sitagliptin , Canagliflozin 300 mg ,0,
edin,5119,3980039,Significantly decreased,"Within each study, baseline plasma glucose, insulin and C-peptide profiles, and the corresponding ISRâplasma glucose relationships at baseline were generally similar between the different treatment groups, with the exception of the placebo group in Study 1, which had modestly lower mean plasma glucose concentrations and modestly higher plasma C-peptide concentrations than the two canagliflozin groups, leading to a shift in the mean relationship between baseline ISR and plasma glucose concentration in the placebo compared with the canagliflozin groups (FigsÂ 2, 3, 4).Table 2,In Study 1, both doses of canagliflozin led to an upward shift in the relationship between ISR and plasma glucose, as well as an increased slope (Fig.Â 2jâl), whereas a slight downward shift was observed with placebo.,The effects of canagliflozin on beta cell function observed in Study 2 were generally similar to those seen in Study 1, with both doses of canagliflozin leading to an upward shift and steepening of the curve expressing the relationship between ISR and plasma glucose.,In Study 3, treatment with sitagliptin 100Â mg and canagliflozin 300Â mg produced similar upward shifts in the relationship between ISR and plasma glucose (Fig.Â 4g, h).", Plasma glucose , Sitagliptin , Canagliflozin 300 mg ,0,
edin,5141,4148632,Cannot tell based on the abstract,"Membrane exposure was not observed in any cases. Significant probing depth reduction, attachment-level gain and bone fill were observed for both test and control groups compared to baseline at 3 months after surgery (P<0.05).", Probing pocket depth , Control , Nonchemical membrane ,0,
edin,5141,4148632,No significant difference,"The probing depth reduction for the NC+BM, BC+BM, and BM groups was 5.10Â±1.52, 3.60Â±1.27, and 3.60Â±2.12 mm, respectively,Both collagen membranes (NC and BC) were comparable in terms of pocket depth reduction and gain of CAL.", Probing pocket depth , Control , Nonchemical membrane ,0,
edin,5245,4804082,Cannot tell based on the abstract,, Glutathione  , Control , Vitamin B6 ,0,
edin,5245,4804082,Significantly decreased,"Plasma homocysteine and GSH concentrations, GSH/GSSG ratio, and activity of GR in the vitamin B-6 group significantly decreased by week 12, while total antioxidant capacity (i.e., TEAC level) significantly increased at the end of the intervention period.", Glutathione  , Control , Vitamin B6 ,0,
edin,5107,3682900,No significant difference,Ultra-high dose intravenous N-acetylcysteine did not alter creatinine or cystatin C levels., Cystatin C after 10 days , Control , N-acetylcysteine ,0,
edin,5146,4545550,Cannot tell based on the abstract,, HDL , Control , Yoga ,0,
edin,5146,4545550,No significant difference,"<td>HDL (mmol/L)</td><td>1.3 (0.4)</td><td>1.5 (0.4)</td><td>1.4 (0.4)</td>,<td>HDL (mmol/L) change from baseline</td><td>0.0 (â0.1â0.1)</td><td>0.0 (â0.1â0.1)</td><td>0.0 (â0.1â0.1)</td><td>0.0 (â0.0â0.1)</td><td>0.0 (â0.1â0.1)</td><td>0.0 (â0.1â0.1)</td>", HDL , Control , Yoga ,0,
edin,5160,2713840,Cannot tell based on the abstract,, Success rate , Shoulder type covered stent , Flare type covered stent ,0,
edin,5160,2713840,No significant difference,"The clinical success rate was 80.0% (24/30): 100% for type A, 68.8% for type B, and 83.3% for type C (Table 3); the differences were statistically insignificant (p=0.191).", Success rate , Shoulder type covered stent , Flare type covered stent ,0,
edin,5115,3980039,Cannot tell based on the abstract,"In Study 3, beta cell glucose sensitivity was minimally affected, but the insulin secretion rate at 9Â mmol/l glucose increased to similar degrees from baseline with canagliflozin and sitagliptin [LSM (SEM) changes 38 (8) and 28 (9) pmolÂ minâ1Â mâ2, respectively; pâ<â0.05 for both].", Beta cell glucose sensitivity , Control , Canagliflozin 100 mg ,0,
edin,5115,3980039,Significantly increased,The model-assessed parameters for ISR at 9Â mmol/l glucose and beta cell glucose sensitivity were significantly increased with both doses of canagliflozin (TableÂ 5)., Beta cell glucose sensitivity , Control , Canagliflozin 100 mg ,0,
edin,5070,2949642,No significant difference,"Tamoxifen-treated patients with estrogen receptor-positive tumors expressing none or low levels of HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival (DRFS) (hazard ratio = 0.38, 95% confidence interval = 0.23 to 0.60, P = 0.000048). However, for patients with a high or intermediate HOXB13 tumor expression, tamoxifen did not prolong the DRFS compared with the untreated patients (hazard ratio = 0.88, 95% confidence interval = 0.47 to 1.65, P = 0.69).", Distant recurrence-free survival , Control , Tamoxifen + intermediate levels of HOXB13 ,0,
edin,5072,3219771,No significant difference,"There were no significant differences in pH, PaCO2, the apparent strong ion difference, the strong ion gap, bicarbonate ion, or lactate between two groups throughout the whole investigation period. At T2, pH was decreased whereas PaCO2 was increased in both groups compared with T1 but these changes were not significantly different", pH , Room temperature CO2 , Heated CO2 ,0,
edin,5139,4148632,No significant difference,Membrane exposure was not observed in any cases., Membrane exposure , Bilayer membrane , Nonchemical membrane ,0,
edin,5085,3689826,Cannot tell based on the abstract,, Kessler Psychological Distress Scale , Control ,  E-mail based Self-Help for Depression  ,0,
edin,5085,3689826,No significant difference,"The interaction between group and time on the K10 was significant, F (2, 677.2)â=â3.94, pâ=â.020, but differences between groups in change from pre-intervention to post-intervention were not significant, t (663.9)â=â0.84, pâ=â.399.,The interaction between group and time on the K10 was not significant, F (2, 546.1)â=â2.71, pâ=â.068, and differences between groups in change from pre-intervention to post-intervention were also not significant, t (572.0)â=â0.89, pâ=â.375.", Kessler Psychological Distress Scale , Control ,  E-mail based Self-Help for Depression  ,0,
edin,5230,5215525,Significantly decreased,"After 24 weeks, for dapagliflozin/exenatide versus placebo: the difference in body weight change was â4.13 kg (95% confidence interval â6.44, â1.81; P < .001), which was mostly attributable to adipose tissue reduction without lean tissue change; 36.0% versus 4.2% of participants achieved â¥5% body weight loss, respectively; and prediabetes was less frequent with active treatment (34.8% vs 85.0%, respectively; P < .01).", Body weight , Control , Dapagliflozin + exenatide ,0,
edin,5181,4009088,No significant difference,There was no significant difference between groups for MDF or MPF in VMM and RFM., Median frecuency on Rectus femoris , Control , Glutamine  ,0,
edin,5202,4311411,Significantly increased,"The highest dose (HD) showed consistent evidence of improvement beyond stabilization. CMTNS and ONLS, with a significant improvement of respectively of 8% (0.4% - 16.2%) and 12.1% (2% - 23.2%) in the HD group versus the pool of all other groups, appear to be the most sensitive clinical endpoints to treatment despite their quasi-stability over one year under Placebo", Overall Neuropathy Limitations Scale improvement , Placebo ," High dose (baclofen, naltrexone, sorbitol) ",0,
edin,5196,3570228,Cannot tell based on the abstract,, Mean BP ," Remifentanil 3 ng/ml  and sufentanil 0,3 ng/ml (induction and maintenance)  ", Remifentanil 5 ng/ml (induction) and 4 ng/ml (maintenance) ,0,
edin,5196,3570228,Significantly increased,"In each group, HR and MAP decreased at T1 (P<0.01) and increased at T2 compared with the values at T0. At T2, the MAP in group IV was higher than that in group II, and the HR and MAP of group IV were higher than those in group III (P<0.05). At T8 and T9, the HR and MAP in group IV were higher than those in any other group (P<0.05). At T9, the SpO2 levels in all the groups were lower than those at T0 (P<0.01); the level in group II was lower than that in group IV (P<0.05). The results are summarized in Table I.", Mean BP ," Remifentanil 3 ng/ml  and sufentanil 0,3 ng/ml (induction and maintenance)  ", Remifentanil 5 ng/ml (induction) and 4 ng/ml (maintenance) ,0,
edin,5219,5856907,Cannot tell based on the abstract,, Subjective understanding  , Control ," ""Question writing"" method ",0,
edin,5219,5856907,No significant difference,Achieved a better understanding of the issues	2.56Â±1.15	1.75Â±1.0	2.13	0.042, Subjective understanding  , Control ," ""Question writing"" method ",0,
edin,5248,5339463,Cannot tell based on the abstract,, Child-Turcotte-Pugh score , Granulocyte-colony stimulating factor + peripheral blood monocyte cell , Granulocyte-colony stimulating factor ,0,
edin,5248,5339463,No significant difference,"At baseline, biochemical markers including total bilirubin, albumin, prothrombin time, creatinine, aspartate aminotransferase, alanine aminotransferase, the CTP scores, and the MELD scores were comparable in study groups. PBMC transplantation therapy showed a tendency to improve in median CTP scores at weeks 24 compared to baseline (Fig. 1). However, there were no significant reductions in the median CTP and MELD scores among study groups probably due to small sample size (Fig. 2). In addition, there were no statistical differences in the median CTP and MELD scores among different etiologies of chronic liver diseases.", Child-Turcotte-Pugh score , Granulocyte-colony stimulating factor + peripheral blood monocyte cell , Granulocyte-colony stimulating factor ,0,
edin,5163,3785902,Cannot tell based on the abstract,, Systolic blood pressure during injection , Control , Propofol ,0,
edin,5163,3785902,Significantly decreased,"Significant changes were observed in the SBP, DBP, MBP and HR during injection of drugs (T3) between the two groups (Î± = 0.001, Î± = 0.029, Î± = 0.004, Î± = 0.03 respectively).,<td colspan=""1"" rowspan=""1"" style=""padding-left:25pt"">Î±</td><td colspan=""1"" rowspan=""1"">0.361</td><td colspan=""1"" rowspan=""1"">0.684</td><td colspan=""1"" rowspan=""1"">0.001</td><td colspan=""1"" rowspan=""1"">0.377</td><td colspan=""1"" rowspan=""1"">0.534</td><td colspan=""1"" rowspan=""1"">0.357</td>", Systolic blood pressure during injection , Control , Propofol ,0,
edin,5208,3112403,Cannot tell based on the abstract,, Body weight , Wheat , Flaxseed  ,0,
edin,5208,3112403,No significant difference,"Body weight and BMI were not significantly different compared to the baseline, nor between treatment groups. The average body weight was 96.2 Â± 18.9 vs. 92.2 Â± 20.4 (kg), flaxseed group; 94.7 Â± 20.0 vs. 95.2 Â± 20.3 (kg), wheat bran group at the baseline and end of the study, respectively.,No significant relationships between weight change and glucose, insulin, HOMA-IR, or inflammatory biomarkers were found.", Body weight , Wheat , Flaxseed  ,0,
edin,5157,2713840,Cannot tell based on the abstract,, Patency period  , Shoulder type covered stent , Flare type covered stent ,0,
edin,5157,2713840,No significant difference,"The mean period of patency was 96.25 Â± 105.12 days: 146.25 Â± 112.93 for type-A, 78.82 Â± 112.26 for type-B, and 94.25 Â± 84.21 for type-C; the differences were statistically insignificant (p=0.576) (Table 4).", Patency period  , Shoulder type covered stent , Flare type covered stent ,0,
edin,5080,5617873,No significant difference,"All patients randomized to aripiprazole completed the study, and no serious adverse events were reported.", Serious adverse effects , Placbeo , Aripiprazole ,0,
edin,5065,5610548,Cannot tell based on the abstract,, Lactoferrin , Multiple micronutrient  , LipÃ­d based nutrient suplement ,0,
edin,5065,5610548,No significant difference,"At 6 mo postpartum, there were no significant differences in mean concentrations of total HMOs, sialylated or fucosylated HMOs, lactoferrin, lactalbumin, lysozymes, antitrypsin, IgA, or osteopontin between the 3 intervention groups in either the unadjusted or adjusted models (each P > 0.10) (Table 2).,There were no significant differences in the proportion of women with low concentrations of total HMOs, sialylated HMOs, fucosylated HMOs, lactoferrin, lactalbumin, lysozymes, antitrypsin, or IgA between the 3 intervention groups in either adjusted or unadjusted models (each P > 0.10)", Lactoferrin , Multiple micronutrient  , LipÃ­d based nutrient suplement ,0,
edin,5221,5856907,Cannot tell based on the abstract,, Subjective depth perceived when studying subjects , Control ," ""Question writing"" method ",0,
edin,5221,5856907,Invalid Prompt,, Subjective depth perceived when studying subjects , Control ," ""Question writing"" method ",1, I was not able to find Subjective depth perceived when studying subjects in any part of the article 
edin,5109,4524824,Cannot tell based on the abstract,, Excessive adhesion formation , Colorectal anastomosis with leakage , Colorectal anastomosis without leakage ,0,
edin,5109,4524824,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Adhesions in all</td><td align=""left"" colspan=""1"" rowspan=""1"">9 (90)</td><td align=""left"" colspan=""1"" rowspan=""1"">9 (90)</td>", Excessive adhesion formation , Colorectal anastomosis with leakage , Colorectal anastomosis without leakage ,0,
edin,5177,4831776,Significantly increased,TTE was increased after intake of CHO+PROT compared to CHO (63.5Â±4.4 vs 49.8Â±5.4 min; p<0.05)., Time to exhaustion , Carbohydrates alone  , Carbohydrates + protein ,0,
edin,5117,3980039,Cannot tell based on the abstract,, Insulin clearance , Control , Canagliflozin 100 mg ,0,
edin,5117,3980039,No significant difference,"Insulin clearance was increased by approximately 15% with both doses of canagliflozin compared with placebo (ESM TableÂ 2).Table 5,Insulin clearance was increased with both doses of canagliflozin compared with placebo, although the increase observed with the 100Â mg dose did not reach statistical significance (pâ=â0.07) (ESM TableÂ 2); the increase in insulin clearance observed with the 300Â mg dose compared with placebo was approximately 24% (pâ<â0.0001).", Insulin clearance , Control , Canagliflozin 100 mg ,0,
edin,5220,5856907,Cannot tell based on the abstract,, Subjective learning skills  , Control ," ""Question writing"" method ",0,
edin,5220,5856907,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">2. Developed approaches study and Learning skills</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">2.75Â±1.0</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">2.06Â±0.85</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">2.09</td><td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">0.045</td>", Subjective learning skills  , Control ," ""Question writing"" method ",0,
edin,5156,2713840,Cannot tell based on the abstract,, Patency period  , Shoulder type covered stent , Uncovered nitinol stent ,0,
edin,5156,2713840,No significant difference,"The mean period of patency was 96.25 Â± 105.12 days: 146.25 Â± 112.93 for type-A, 78.82 Â± 112.26 for type-B, and 94.25 Â± 84.21 for type-C; the differences were statistically insignificant (p=0.576) (Table 4).", Patency period  , Shoulder type covered stent , Uncovered nitinol stent ,0,
edin,5172,5091022,Cannot tell based on the abstract,, Blood products used , 4.8 mm drain , 3.2 mm drain ,0,
edin,5172,5091022,No significant difference,The use of blood products was similar in both groups â two units of red blood cells with 300Â mL each unit., Blood products used , 4.8 mm drain , 3.2 mm drain ,0,
edin,5200,3570228,Significantly decreased,"Although group IV had shorter postoperative eye-opening and extubation times compared with the other groups (P<0.05), it also had higher restlessness and pain scores (P<0.01)", Eye opening time ," Remifentanil 3 ng/ml and sufentanil 0,3 ng/ml (induction and maintenance) ", Remifentanil 5 ng/ml (induction) and 4 ng/ml (maintenance) ,0,
edin,5233,5215525,Significantly decreased,"The difference in SBP change for dapagliflozin/exenatide versus placebo was â6.7 mm Hg.,Compared with placebo, dapagliflozin/exenatide dual therapy reduced body weight, frequency of prediabetes and SBP over 24 weeks and was well tolerated in obese adults without diabetes.", Systolic blood pressure , Control , Dapagliflozin + exenatide ,0,
edin,5082,5617873,Cannot tell based on the abstract,, Social withdrawal  , Placbeo , Aripiprazole ,0,
edin,5082,5617873,No significant difference,"here was no significant difference between aripiprazole group and the placebo group in the mean ABC-J stereotypy, inappropriate speech and lethargy/social withdrawal subscale scores, as well as ABC-J response rate, CY-BOCS (compulsion scale) (TableÂ 2).", Social withdrawal  , Placbeo , Aripiprazole ,0,
edin,5232,5215525,Cannot tell based on the abstract,, Pre-diabetes   , Control , Dapagliflozin + exenatide ,0,
edin,5232,5215525,Significantly decreased,"<td align=""left"" colspan=""1"" id=""dom12779-ent-0241"" rowspan=""1"" style=""padding-left:15%"" valign=""top"">Proportion with any IFG or IGT (prediabetes), n/N (%)</td><td align=""char"" char=""("" colspan=""1"" id=""dom12779-ent-0242"" rowspan=""1"" valign=""top"">8/23 (34.8)</td><td align=""char"" char=""("" colspan=""1"" id=""dom12779-ent-0243"" rowspan=""1"" valign=""top"">17/20 (85.0)</td><td align=""char"" colspan=""1"" id=""dom12779-ent-0244"" rowspan=""1"" valign=""top""></td><td align=""char"" char=""."" colspan=""1"" id=""dom12779-ent-0245"" rowspan=""1"" valign=""top"">.002<xref ref-type=""fn"" rid=""dom12779-note-0018"">d</xref>
</td>,Combined, the proportion of participants with prediabetes (any IFG or IGT) significantly decreased from 68.0% to 34.8% (p = .005).,Reduction in prediabetes (any IFG or IGT) from baseline to 24 weeks was significantly greater with dapagliflozin/exenatide than placebo (p = .002).", Pre-diabetes   , Control , Dapagliflozin + exenatide ,0,
edin,5129,5301372,Cannot tell based on the abstract,, Des-continuation due to adverse effects , Placebo , Dovitinib ,0,
edin,5129,5301372,Significantly increased,"The reasons for discontinuation in the dovitinib vs placebo arms were progressive disease (55.3% vs 80.0%), AEs (21.3% vs 2.0%), patient or guardian decision (10.6% vs 0%), termination by sponsor (8.5% vs 16.0%), death (2.1% vs 2.0%), and nonadherence to study treatment (2.1% vs 0%).,More patients discontinued study treatment owing to AEs in the dovitinib arm than in the placebo arm (38.3% vs 8.0%).", Des-continuation due to adverse effects , Placebo , Dovitinib ,0,
edin,5252,5339463,Cannot tell based on the abstract,, Mortality , Control , Granulocyte-colony stimulating factor + peripheral blood monocyte cell ,0,
edin,5252,5339463,No significant difference,"During the 6 months of follow-up, there was no mortality in study groups.", Mortality , Control , Granulocyte-colony stimulating factor + peripheral blood monocyte cell ,0,
edin,5137,5986443,Cannot tell based on the abstract,, Chest press , Placebo then placebo again , Protein then Placebo ,0,
edin,5137,5986443,Significantly increased,"A significant (p < 0.001) time vs. group interaction was observed for SMM, LLLST, CP, KE, and total strength (TS), with both the WP-PLA and PLA-WP presenting greater increases compared with the PLA-PLA, without differences between the timing of protein intake.", Chest press , Placebo then placebo again , Protein then Placebo ,0,
edin,5144,4148632,Cannot tell based on the abstract,, Bone level change , Bilayer membrane , Nonchemical membrane ,0,
edin,5144,4148632,No significant difference,There was no statistically significant difference in bone level change between the test and control groups., Bone level change , Bilayer membrane , Nonchemical membrane ,0,
edin,5229,4815882,No significant difference,The addition of 40âmg simvastatin to the XELIRI/FOLFIRI regimens did not improve PFS in patients with previously treated metastatic colorectal cancer nor did it increase toxicity., Toxicity  , Placebo , Simvastatine ,0,
edin,5241,4609664,Cannot tell based on the abstract,, Cracks , ProTaper system , Mtwo ,0,
edin,5241,4609664,No significant difference,"Based on fracture pattern, all these cracks were exclusively categorized as defected (type I). Regarding crack formation, there was no significant difference between RCP and control samples (P=0.300). Both Mtwo and PTU showed more cracks than RCP (P=0.042) and control (P=0.022). The difference between Mtwo and PTU was not significant (P=1.000).", Cracks , ProTaper system , Mtwo ,0,
edin,5258,3898240,Significantly increased,"In the â¥6- vs. 1-portion post-intervention comparisons, carotenoids increased in serum, HDL2 and particularly HDL3, (Î±-carotene, pâ=â0.008; Î²-cryptoxanthin, pâ=â0.042; lutein, pâ=â0.012; lycopene, pâ=â0.016), as did the activities of PON-1 and LCAT in HDL3 (pâ=â0.006 and 0.044, respectively).", HDL 3 Lecithinâcholesterol acyltransferase , Fruits and vegetables 1 portion , Fruits and vegetables +6 portions ,0,
edin,5227,4815882,Cannot tell based on the abstract,, Response rate , Placebo , Simvastatine ,0,
edin,5227,4815882,No significant difference,"The ORR (overall response rate) was 11.9% in the simvastatin group and 11.8% in the placebo group; the DCR (disease control rate) was 67.2% and 71.1%, respectively. No significant difference in response rate was observed between the two treatment arms (P=1.00 for ORR, P=0.511 for DCR, Table 2).", Response rate , Placebo , Simvastatine ,0,
edin,5087,4423288,Significantly increased,The mean air-leak pressure was statistically higher in Group 3 than in Groups 1 and 2â95.2âÂ±â19.3âmmHg versus 72.5âÂ±â35.2 and 79.0âÂ±â24.5âmmHg (Pâ<â0.05)., Air-leak pressure , Tunnel + endoclips , Tunnel + OTSC ,0,
edin,5218,5856907,Significantly increased,"The differences between pre- and post-test mean scores of the experimental and control groups were 24.53Â±5.74 and 20.63Â±5.58, respectively. The results of independent t-test showed that these differences in the two groups were significant (p=0.009).", Test scores , Control ," ""Question writing"" method ",0,
edin,5108,4524824,No significant difference,None of the animals showed signs of illness 48 hours after the intraperitoneal gastrostomy tube placement., Illness , Colorectal anastomosis with leakage , Colorectal anastomosis without leakage ,0,
edin,5140,4148632,No significant difference,"Membrane exposure was not observed in any cases. Significant probing depth reduction, attachment-level gain and bone fill were observed for both test and control groups compared to baseline at 3 months after surgery (P<0.05). However, there were no statistically significant differences in clinical improvement and radiographic bone fill between treatment protocols (P>0.05).", Probing pocket depth , Bilayer membrane , Nonchemical membrane ,0,
edin,5210,3112403,Cannot tell based on the abstract,, Waist circumference , Wheat , Flaxseed  ,0,
edin,5210,3112403,No significant difference,"The waist circumference did not change significantly. The average waist circumference was 106.9 Â± 13.5 vs. 105.9 Â± 12.7 (cm), flaxseed group; 108.7 Â± 12.2 vs. 106.7 Â± 13.5 (cm), wheat bran group at the baseline and end of the study, respectively.", Waist circumference , Wheat , Flaxseed  ,0,
edin,5150,4545550,Cannot tell based on the abstract,, hs-CRP , Control , Yoga ,0,
edin,5150,4545550,Significantly decreased,"<td>hs-CRP (mg/L)</td><td>5.0 (3.6)</td><td>2.9 (2.2)</td><td>3.6 (3.6)</td>,<td>hs-CRP (mg/L) change from baseline</td><td>â0.8 (â2.2â0.5)</td><td>â0.6 (â2.3â1.1)</td><td>0.2 (â0.6â1.0)</td><td>0.1 (â1.0â1.2)</td><td>0.4 (â1.2â2.1)</td><td>0.5 (â1.4â2.4)</td>", hs-CRP , Control , Yoga ,0,
edin,5102,3682900,No significant difference,Ultra-high dose intravenous N-acetylcysteine did not alter creatinine or cystatin C levels., Cystatin C , Control , N-acetylcysteine ,0,
edin,5161,3785902,No significant difference,"Heart rate and blood pressure in patients receiving propofol were less than the control group (P < 0.05) at the time of injection of propofol, but there were no differences between the two groups at the time of extubation.", Systolic blood pressure after extubation , Control , Propofol ,0,
edin,5123,5865731,Cannot tell based on the abstract,, Happiness  , Contractive posture , Expansive posture ,0,
edin,5123,5865731,Significantly increased,"Pairwise comparisons showed that participants in the expansive condition showed more self-confidence and happiness than participants in the contractive condition (p = .015 and p = .029, respectively)", Happiness  , Contractive posture , Expansive posture ,0,
edin,5158,2713840,Cannot tell based on the abstract,, Success rate , Flare type covered stent , Uncovered nitinol stent ,0,
edin,5158,2713840,No significant difference,"The clinical success rate was 80.0% (24/30): 100% for type A, 68.8% for type B, and 83.3% for type C (Table 3); the differences were statistically insignificant (p=0.191).", Success rate , Flare type covered stent , Uncovered nitinol stent ,0,
edin,5116,3980039,Significantly increased,"In Studies 1 and 2, both canagliflozin doses increased beta cell glucose sensitivity compared with placebo. Placebo-subtracted least squares mean (LSM) (SEM) changes were 23 (9) and 18 (9) pmolÂ minâ1Â mâ2 (mmol/l)â1 with canagliflozin 100 and 300Â mg, respectively (pâ<â0.002, Study 1), and 16 (8) and 10 (9) pmolÂ minâ1Â mâ2 (mmol/l)â1 (pâ<â0.02, Study 2). In Study 3, beta cell glucose sensitivity was minimally affected, but the insulin secretion rate at 9Â mmol/l glucose increased to similar degrees from baseline with canagliflozin and sitagliptin [LSM (SEM) changes 38 (8) and 28 (9) pmolÂ minâ1Â mâ2, respectively; pâ<â0.05 for both].", Beta cell glucose sensitivity , Control , Canagliflozin 300 mg ,0,
edin,5198,3570228,Cannot tell based on the abstract,, Heart rate ," Remifentanil 2 ng/ml  and sufentanil 0,5 ng/ml (induction) and  Remifentanil 3 ng/ml  and sufentanil 0,2 ng/ml (maintenance)  ", Remifentanil 5 ng/ml (induction) and 4 ng/ml (maintenance) ,0,
edin,5198,3570228,Significantly increased,"At T2, the MAP in group IV was higher than that in group II, and the HR and MAP of group IV were higher than those in group III (P<0.05).", Heart rate ," Remifentanil 2 ng/ml  and sufentanil 0,5 ng/ml (induction) and  Remifentanil 3 ng/ml  and sufentanil 0,2 ng/ml (maintenance)  ", Remifentanil 5 ng/ml (induction) and 4 ng/ml (maintenance) ,0,
edin,5234,5215525,Cannot tell based on the abstract,, Diastolic blood pressure , Control , Dapagliflozin + exenatide ,0,
edin,5234,5215525,No significant difference,No significant differences between dapagliflozin/exenatide and placebo were observed for DBP or heart rate (Table 2)., Diastolic blood pressure , Control , Dapagliflozin + exenatide ,0,
edin,5195,3781502,Significantly decreased,"In the lixisenatide group, fewer participants experienced symptomatic hypoglycemia (2.5 vs. 7.9%; P < 0.05), with fewer gastrointestinal events (especially nausea; 24.5 vs. 35.1%; P < 0.05).", Gastrointestinal events , Exenatide , Lixisenatide ,0,
edin,5128,5301372,Cannot tell based on the abstract,, On-treatment deaths , Placebo , Dovitinib  ,0,
edin,5128,5301372,No significant difference,"The reasons for discontinuation in the dovitinib vs placebo arms were progressive disease (55.3% vs 80.0%), AEs (21.3% vs 2.0%), patient or guardian decision (10.6% vs 0%), termination by sponsor (8.5% vs 16.0%), death (2.1% vs 2.0%), and nonadherence to study treatment (2.1% vs 0%).,A total of four on-treatment deaths were reported (two deaths in each treatment arm); of the two on-treatment deaths that occurred in the dovitinib arm, one patient died as a result of breast cancer progression and one patient died because of a pulmonary embolism suspected to be related to study treatment.", On-treatment deaths , Placebo , Dovitinib  ,0,
edin,5142,4148632,No significant difference,"However, there were no statistically significant differences in clinical improvement and radiographic bone fill between treatment protocols (P>0.05).", Clinical improvement , Control , Bilayer membrane ,0,
edin,5170,5091022,Significantly decreased,"The total bleeding measured at the suction drains within 48Â h was higher in Group II, with a statistically significant difference (pÂ =Â 0.005); in the first 24Â h, there was major bleeding in Group II (mean 893Â mL), with a significant difference (pÂ =Â 0.004).", Total blood suctioned after 24 hrs , 4.8 mm drain , 3.2 mm drain ,0,
edin,5067,2949642,Significantly increased,"Tamoxifen-treated patients with estrogen receptor-positive tumors expressing none or low levels of HOXB13 had a clear benefit from tamoxifen in terms of longer distant recurrence-free survival (DRFS) (hazard ratio = 0.38, 95% confidence interval = 0.23 to 0.60, P = 0.000048).", Distant recurrence-free survival , Control , Tamoxifen + low levels of HOXB13 ,0,
edin,5100,5103135,No significant difference,"The differences in the respiratory symptoms, limitation of motion, disease impacts and SGRQ total scores were statistically significant compared with those before treatment (P<0.05) and those of the control group (P<0.05).", Limitation of motion ,  Oxygen + inotropic agents , Bisoprolol + trimetazidine ,0,
edin,5205,4311411,Cannot tell based on the abstract,, Charcot Marie Tooth Neuropathy Score , Placebo ," Low dose (baclofen, naltrexone, sorbitol) ",0,
edin,5205,4311411,No significant difference,"<td>
<bold>CMTNS</bold>
</td><td>2.6 (17.5)</td><td>0.5 (23.2)</td><td>â3.1 (16.0)</td><td>
<bold>7.7 (18.4)</bold>
</td><td>â2.6 (â11.9;7.6)</td><td>0.67</td><td>â3.1 (â11.0;5.4)</td><td>0.74</td><td>5.5 (â3.4;15.2)</td><td>0.16</td><td>0.54</td><td>0.30</td>", Charcot Marie Tooth Neuropathy Score , Placebo ," Low dose (baclofen, naltrexone, sorbitol) ",0,
edin,5206,4311411,Cannot tell based on the abstract,, Charcot Marie Tooth Neuropathy Score , Placebo ," Intermediate dose (baclofen, naltrexone, sorbitol) ",0,
edin,5206,4311411,No significant difference,"<td>
<bold>CMTNS</bold>
</td><td>2.6 (17.5)</td><td>0.5 (23.2)</td><td>â3.1 (16.0)</td><td>
<bold>7.7 (18.4)</bold>
</td><td>â2.6 (â11.9;7.6)</td><td>0.67</td><td>â3.1 (â11.0;5.4)</td><td>0.74</td><td>5.5 (â3.4;15.2)</td><td>0.16</td><td>0.54</td><td>0.30</td>", Charcot Marie Tooth Neuropathy Score , Placebo ," Intermediate dose (baclofen, naltrexone, sorbitol) ",0,
edin,5101,5103135,Cannot tell based on the abstract,, Disease impacts ,  Oxygen + inotropic agents , Bisoprolol + trimetazidine ,0,
edin,5101,5103135,No significant difference,"There were no statistically significant differences in respiratory symptoms, limitation of motion, disease impacts or SGRQ total scores between the treatment group and the control group before treatment (P>0.05).", Disease impacts ,  Oxygen + inotropic agents , Bisoprolol + trimetazidine ,0,
edin,5061,5610548,No significant difference,HMO and bioactive protein concentrations did not differ between groups (P > 0.10 for all comparisons)., Total  Human milk oligosaccharides , Iron and folic acid , LipÃ­d based nutrient suplement ,0,
edin,5088,4423288,Significantly increased,The mean air-leak pressure was statistically higher in Group 3 than in Groups 1 and 2â95.2âÂ±â19.3âmmHg versus 72.5âÂ±â35.2 and 79.0âÂ±â24.5âmmHg (Pâ<â0.05)., Air-leak pressure , Knife + ballon + OTSC , Tunnel + OTSC ,0,
edin,5247,4804082,Cannot tell based on the abstract,, Superoxide dismutase levels , Control , Vitamin B6 ,0,
edin,5247,4804082,No significant difference,"There were no significant changes in blood urea nitrogen, ALT and aspartate aminotransferase, alkaline phosphatase, MDA, activities of SOD, GPx, and GST during the intervention period for both groups.,Vitamin B-6 supplementation had no effect on the changes (Î week 12 â week 0) of MDA, GSH, GSSG, and TEAC levels and the activities of SOD, GPx, GST, and GR (p > 0.05),", Superoxide dismutase levels , Control , Vitamin B6 ,0,
edin,5173,4831776,Cannot tell based on the abstract,, Lactate concentrations  , Carbohydrates alone  , Carbohydrates + protein ,0,
edin,5173,4831776,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1""><bold>Blood lactate (mM)</bold></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1""></td>,Blood lactate concentrations decreased rapidly after exhaustive exercise independent of dietary intervention. Lactate levels declined rapidly and were back at baseline after 30 minutes in all three dietary interventions (Fig 2A).,However, there were no significant differences in substrate selection during the performance test andthe concentrations of plasma lactate and amino acids did not differ between CHO and CHO+PROT.", Lactate concentrations  , Carbohydrates alone  , Carbohydrates + protein ,0,
edin,5443,3685524,Significantly increased,"Central arterial stiffness, measured as augmentation index, augmentation pressure and pulse wave velocity, was higher after wood smoke exposure as compared to filtered air (p < 0.01 for all),", Pulse wave velocity , Control , Wood smoke ,0,
edin,5466,4156403,Significantly decreased,"In PLCO, randomization to cancer screening compared with usual care was associated with a significant decrease in thyroid cancer risk for men (HR â=â0.61; 95% CI: 0.49â0.95) but not women (HR â=â0.91; 95% CI: 0.66â1.26).", PLCO thyroid cancer risk in men , Control , Randomized CT scan ,0,
edin,5449,4478821,Cannot tell based on the abstract,, Laryngeal mask airway insertion score improvement , No atricurium , Atracurium 100% dose  ,0,
edin,5449,4478821,Significantly increased,The LMA insertion score was statistically significant in the four groups (P - 0.001) [Table 3]. The score progressively improved with the increasing dose of the atracurium., Laryngeal mask airway insertion score improvement , No atricurium , Atracurium 100% dose  ,0,
edin,5398,2800022,Cannot tell based on the abstract,, Vitamin D concentration , Breast milk alone , Breast milk + Vit. D ,0,
edin,5398,2800022,Significantly increased,"The 25OHD3 levels of infants in group A, B, and S were 48.8Â±9.74, 33.2Â±7.89 and 42.8Â±9.80 ng/mL, respectively, which was the lowest in group B and showed no differences between group A and S (P<0.001, A=S>B).,At both 6 and 12 months of age, total intake of vitamin D (the sum of vitamin D intake from milk, solid food and vitamin supplementation) were the highest in group A, middle in group S, and lowest in group B (P<0.001, A>S>B).", Vitamin D concentration , Breast milk alone , Breast milk + Vit. D ,0,
edin,5280,5718865,Cannot tell based on the abstract,, Pain after 3 days , Control , Perioneal massage ,0,
edin,5280,5718865,Significantly decreased,"Based on the results, the postpartum perineal pain was different in both groups. Comparison of degrees of pain in the two groups showed that the severity of pain 3 days and 3 months after childbirth was significant (p=0.01, p=0.008, respectively), but the severity of pain in the 10th day did not differ significantly (p=0.78) (Table 3).,The results of this study showed that the two groups were significantly different in terms of perineal pain 3 days, 10 days, and 3 months after childbirth, and the severity of pain 3 days and 3 months after childbirth was significant, but the severity of pain in the 10th day did not significantly differ.,The results showed mean and standard deviation of the participants in the case group (receiving perineal massage) as 25.62Â±4.25 years and those in the control group as 25.31Â±3.86 years.", Pain after 3 days , Control , Perioneal massage ,0,
edin,5431,4399299,No significant difference,Insulin sensitivity during the euglycemic clamp was similar in each group at baseline (3.24 Â± 0.30 vs 3.19 Â± 0.38 mg/kg/min) and did not change (adjusted mean change of 0.26 Â± 0.22 vs 0.32 Â± 0.22 mg/kg/min; P = .86)., Insulin sensitivity , Placebo , Vildagliptin ,0,
edin,5477,3263438,No significant difference,"There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters.", Potassium , Control , Fluticasone furoate + vilanterol ,0,
edin,5460,5501521,Significantly decreased,"n the Lignocaine group, the average mean arterial pressure was 80.3Â mmHg (SD: 4.9) compared to 85.1Â mmHg (SD: 5.4) in the Saline group (95% CI 2.4â7.1, pÂ <Â 0.001).", Mean arterial blood pressure , Control , Lignocaine ,0,
edin,5423,3920467,Significantly decreased,"<td colspan=""1"" rowspan=""1"">Dimetinden</td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td>", Pruritus  , Placebo , Dimetinden ,0,
edin,5368,3117815,Cannot tell based on the abstract,, Emotional aspect of Functional Assessment of Cancer Therapy-Breast , 3-weekly docetaxel , Weekly docetaxel  ,0,
edin,5368,3117815,No significant difference,"<td align=""left"">âEmotional</td><td align=""center"">19.21 (0.51)</td><td align=""center"">19.32 (0.51)</td><td align=""center"">0.024</td><td align=""center"">0.88</td>,Table 2
Primary and secondary outcomes at three weeks after completion of chemotherapy", Emotional aspect of Functional Assessment of Cancer Therapy-Breast , 3-weekly docetaxel , Weekly docetaxel  ,0,
edin,5498,5380326,Significantly decreased,"Our important finding revealed that upon correction of vitamin D insufficiency or deficiency, the serum IP-10 and DPP IV levels were decreased significantly as compare to the placebo group (delta changes; 83.27 vs -133.80; 95% CI [-326.910, -40.758], p = 0.0125, and 271.04 vs -518.69; 95% CI [-1179,15, -59.781], p = 0.0305, respectively.", Interferon gamma-induced protein 10  , Control , Vitamin D supplementation  ,0,
edin,5465,4156403,No significant difference,"In NLST, randomization to lung CT scan was associated with a non-significant increase in thyroid cancer risk (HR â=â1.61; 95% CI: 0.96â2.71).", NLST thyroid cancer risk , Control , Randomized CT scan ,0,
edin,5281,5718865,Cannot tell based on the abstract,, Pain after 10 days , Control , Perioneal massage ,0,
edin,5281,5718865,No significant difference,"Based on the results, the postpartum perineal pain was different in both groups. Comparison of degrees of pain in the two groups showed that the severity of pain 3 days and 3 months after childbirth was significant (p=0.01, p=0.008, respectively), but the severity of pain in the 10th day did not differ significantly (p=0.78) (Table 3).", Pain after 10 days , Control , Perioneal massage ,0,
edin,5476,3263438,Cannot tell based on the abstract,, Plasma glucose , Control , Fluticasone furoate + vilanterol ,0,
edin,5476,3263438,Significantly increased,A small statistically significant increase (0.32âmmol/l; 95% CI 0.10 to 0.53) with FF/VI versus placebo was observed on day 28 (but not on days 1 and 14) for change from baseline in weighted mean plasma glucose FF/VI (figure 3A)., Plasma glucose , Control , Fluticasone furoate + vilanterol ,0,
edin,5386,3894078,Cannot tell based on the abstract,, Collony-forming units , Ultraviolet sanitization , Microwave sanitization   ,0,
edin,5386,3894078,Significantly decreased,"Tukey's post hoc comparisons of the three groups after the sanitization procedure indicated that the microwave group (M = 1.49, 95% CI [1.2729, 1.7071]) gave a significantly lower CFU count than the UV radiation group (M = 3.22, 95% CI [2.93, 3.50], P < 0.001) and the control group (M = 5.88, 95% CI [5.49, 6.26], P < 0.001).", Collony-forming units , Ultraviolet sanitization , Microwave sanitization   ,0,
edin,5263,4731528,No significant difference,"Cytotoxicity of the four materials was not significantly different from that of the control group at 24, 48 and 168 h (P>0.05)", Cytotoxicity  , Control , Biodentine ,0,
edin,5394,4472939,No significant difference,"There was no significant difference in the reduction in CVD by atorvastatin, with above median (HR 0.57) or below median (HR 0.52) change in CRP or change in LDL-cholesterol (HR 0.61 vs 0.50).",  LDL-cholesterol , Control , Atorvastatin ,0,
edin,5393,4472939,No significant difference,"After 1Â year, the atorvastatin arm showed a net CRP lowering of 32% (95% CI â40%, â22%) compared with placebo. The CRP response was highly variable, with 45% of those on atorvastatin having no decrease in CRP (median [interquartile range, IQR] per cent change â9.8% [â57%, 115%]).,There was no significant difference in the reduction in CVD by atorvastatin, with above median (HR 0.57) or below median (HR 0.52) change in CRP or change in LDL-cholesterol (HR 0.61 vs 0.50).",  C-reactive protein , Control , Atorvastatin ,0,
edin,5348,4667406,Cannot tell based on the abstract,, Important adverse effects  , Ischemic pressure  , Anesthetic injections  ,0,
edin,5348,4667406,No significant difference,There were no important harmful or unintended effects., Important adverse effects  , Ischemic pressure  , Anesthetic injections  ,0,
edin,5480,5244020,Cannot tell based on the abstract,, Pain , Control , Lavender  ,0,
edin,5480,5244020,Significantly decreased,"Relative to pretreatment levels, pain magnitude pain magnitude scores after the intervention were reduced 8.22 Â± 4.77% (0.37 Â± 0.21 points) in the control group, 14.39 Â± 4.14% (0.56 Â± 0.16 points) in the lavender group, and 19.65 Â± 4.44% (0.86 Â± 0.19 points) in the linalyl acetate group, with the differences between the lavender (P = 0.002) and linalyl acetate (P < 0.001) groups being significantly more reduced than in the control group (Figure 1(a)).", Pain , Control , Lavender  ,0,
edin,5379,4967427,Cannot tell based on the abstract,, Disability pensions , Standard management  , Intensive case management  ,0,
edin,5379,4967427,No significant difference,"<td align=""left"">&nbsp;&nbsp;Treatment costs (in 1000 CHF)</td><td align=""char"" char=""("">39.8 (1.11)</td><td align=""char"" char=""("">43.5 (1.22)</td><td align=""left"">9.4 [2.3â17.6]</td><td align=""char"" char=""."">0.01</td>,We found no statistically significant differences in allocation of disability pensions between SCM and ICM (TableÂ 2).", Disability pensions , Standard management  , Intensive case management  ,0,
edin,5470,5434591,Significantly decreased,"The primary effect variable, MTPM after 12 months, showed that migration in the denosumab group was statistically significantly less than in the controls. Denosumab MTPM 12 months was reduced by one-third (denosumab: median 0.24âmm, 10% and 90% percentiles: 0.15 and 0.41; placebo: median 0.36âmm, 10% and 90% percentiles: 0.20 and 0.62). The secondary MTPM variables (6 and 24 months) also showed a statistically significant reduction in migration. There was no significant difference in MTPM for the period 12â24 months.", Migration by RSA maximal total point motion after 2 years , Control , Denosumab ,0,
edin,5378,4967427,No significant difference,"Average work incapacity over the 6-year follow-up, including contributions from daily allowances and permanent losses from disability, was slightly but insignificantly higher under ICM than under SCM (21.6 vs. 21.3Â % of pre-accident work capacity).", Average work incapacity  , Standard management  , Intensive case management  ,0,
edin,5274,4713813,Significantly increased,"Following treatment, the silver spike point and acupuncture groups showed significant improvement, based on the Constipation Assessment Scale and the Bowel Function Assessment Form, compared with the control group.", Constipation assessment scale improvement  , Control  , Acupuncture  ,0,
edin,5324,4153077,Cannot tell based on the abstract,, Monocytes and granulocytes engaged in phagocytosis , Control , Galacto-oligosaccharides ,0,
edin,5324,4153077,No significant difference,"The supplementations did not change the percentages of monocytes and granulocytes engaged in phagocytosis compared with maltodextrin (Fig. 2(a) and 2(b)); however, there was a higher percentage of phagocytosing monocytes in the probiotic group compared with the prebiotic (PÂ =Â 0Â·005) group (Fig. 2(a))", Monocytes and granulocytes engaged in phagocytosis , Control , Galacto-oligosaccharides ,0,
edin,5340,5509595,Cannot tell based on the abstract,, VO2max , Half bath , Endurance exercise  ,0,
edin,5340,5509595,Significantly increased,"VO2max (ml/kg/min)	Aerobic exercise	25.12 Â± 1.21	33.07 Â± 2.37	group	7.680*
Half bath	26.18 Â± 1.20	27.07 Â± 1.10	time	8.223*
Control	27.13 Â± 1.01	27.05 Â± 1.00	group*time	9.618**,The results of this study showed a significant improvement of body composition in the exercise and half-bath treatment groups.,In this study, the maximum oxygen uptake, HRmax, and maximum ventilation were also significantly increased after 12 weeks of treatment only in exercise group.", VO2max , Half bath , Endurance exercise  ,0,
edin,5359,3432818,Cannot tell based on the abstract,, Delayed recall  improvement , Control , Astaxanthin-rich Haematococcus pluvialis ,0,
edin,5359,3432818,Significantly increased,"âDelayed recallâ, a measure of accuracy, significantly improved in the high-dosage group at 12 weeks (72.9Â Â±Â 7.5 vs 67.3Â Â±Â 11.8; p<0.05).,However, the changes in response time were as follows: in the high-dosage group, improvement trends were observed for âchoice reactionâ (451.1Â Â±Â 56.7 vs 480.1Â Â±Â 77.5), âdelayed recallâ (818.3Â Â±Â 195.9 vs 880.1Â Â±Â 189.4),", Delayed recall  improvement , Control , Astaxanthin-rich Haematococcus pluvialis ,0,
edin,5331,4183888,Cannot tell based on the abstract,, MucusTM improvement  , Control , Prophylactic professional oral health care ,0,
edin,5331,4183888,No significant difference,"<td>Mucus<sup>TM</sup>
</td><td align=""char"" char=""("">21.4 (3)</td><td align=""char"" char=""("">33.3 (4)</td><td align=""char"" char=""."">0.404</td>,The Saxon test, oral moisture checker test (MucusTM), and electrogustometer test each demonstrated no statistically significant differences between the two treatment groups with regard to changes before and after chemotherapy", MucusTM improvement  , Control , Prophylactic professional oral health care ,0,
edin,5293,4281164,Cannot tell based on the abstract,, Infectious complications , Thymoglobulin four infusions of 1.5 mg/kg  , Thymoglobulin single infusion  ,0,
edin,5293,4281164,Significantly decreased,"In a multivariate regression model of infectious complications, SD rATG induction (P=0.046) and higher 12-month absolute lymphocyte counts (P=0.033) associated with significantly fewer occurrences of severe viral infection (CMV infection or disease, BK nephropathy, and PTLD).", Infectious complications , Thymoglobulin four infusions of 1.5 mg/kg  , Thymoglobulin single infusion  ,0,
edin,5308,3195393,Cannot tell based on the abstract,, Continuous restraint  , Before restraint reduction program , After restraint reduction program ,0,
edin,5308,3195393,Significantly decreased,"there was a significant decrease of continuous restraint after RRC conference (from 85.5% to 63.6%, P = 0.009).", Continuous restraint  , Before restraint reduction program , After restraint reduction program ,0,
edin,5494,4733270,Cannot tell based on the abstract,, Probability of having an injury , Control , Hyperactivity ,0,
edin,5494,4733270,Significantly increased,"After controlling for sociodemographic factors, schizoid behavior problem (ORâ=â2.43, 95Â % CIâ=â1.44-4.11), anxiety/depression (ORâ=â2.76, 95Â % CIâ=â1.50-5.06), and hyperactivity (ORâ=â2.42, 95Â % CIâ=â1.26-4.68) were determined to be the predictors for injury in boys. The results indicate that boys who had scores above the cut-off in schizoid, anxiety/ depression, and hyperactivity behavior were 2.42 to 2.76 times more likely to have an injury than boys with normal scores.,<td></td><td>Hyperactivity</td><td align=""char"" char=""."">0.873</td><td align=""char"" char=""."">0.245</td><td align=""char"" char=""."">12.661</td><td align=""char"" char=""."">2.418</td><td align=""char"" char=""."">1.258</td><td align=""char"" char=""."">4.68</td><td align=""char"" char=""."">0.001</td>", Probability of having an injury , Control , Hyperactivity ,0,
edin,5283,5911298,Significantly decreased,The mean percentage of remaining filling material was 12.96% for PR group and 24.26% for MR group (P=0.0056). T, Remaining filling material , Mani NRT-GPR , Pro Taper universal retreatment  ,0,
edin,5434,4399299,Cannot tell based on the abstract,, Glycated hemoglobin , Placebo , Vildagliptin ,0,
edin,5434,4399299,Significantly decreased,"Mean HbA1c changed by â0.5 Â± 0.1% (P < .0001) from a baseline of 6.5 Â± 0.1% in the vildagliptin group, whereas a small numerical increase (0.2 Â± 0.1% from a baseline of 6.4 Â± 0.1%; P = .14) was seen in the placebo group, resulting in a significant between-group difference of â0.7 Â± 0.1% (P < .001).", Glycated hemoglobin , Placebo , Vildagliptin ,0,
edin,5347,4667406,Significantly increased,"Clinical response rates and pain relief were significantly better at 1, 4, and 12Â weeks for those receiving local anaesthetic injections than ischemic compression via physical therapy. The pain relief of women treated with local anaesthetic injections progressively improved at 1, 4, and 12Â weeks after intervention.", Progressive pain relief  , Ischemic pressure  , Anesthetic injections  ,0,
edin,5313,3944580,No significant difference,"A two-way ANOVA revealed a significant (P < 0.05) interaction effect for leptin and acyl ghrelin. However, changes in obestatin and des-acyl ghrelin concentration were statistically insignificant (P > 0.05).", Des-acyl ghrelin , Control , Motor-driven treadmill exercise  ,0,
edin,5435,3222191,No significant difference,"When controlling for baseline differences, no significant main effect of the learning method was found on computer/Web knowledge, skills, or eHealth literacy efficacy.", Computer knowledge , Control , Collaborative eHealth literacy intervention ,0,
edin,5314,5511285,Cannot tell based on the abstract,, Positional differences improvement (mediolateral) , Traditional measurement  , Genioplasty template system ,0,
edin,5314,5511285,Significantly increased,"The largest angular discrepancy occurred in pitch orientation: RMSD was 2.6Â°, and Bland-Altman lower and upper limits were â5.77Â° and 2.75Â° (TablesÂ 1 and 3). It indicated that the chin segments had an unplanned rotation around the mediolateral (xâ) axis.,<td>Without template</td><td>Mediolateral</td><td>1.45</td><td>Pitch</td><td>7.21</td>,<td>With template</td><td>Mediolateral</td><td>0.62</td><td>Pitch</td><td>2.63</td>,<td>Without template</td><td>Mediolateral</td><td>0.04</td><td>1.47</td><td>â2.84</td><td>(â4.57 to â2.07)</td><td>2.91</td><td>(2.14 to 3.68)</td>,<td>With template</td><td>Mediolateral</td><td>â0.01</td><td>0.62</td><td>â1.23</td><td>(â2.96 to â0.90)</td><td>1.21</td><td>(0.88 to 1.54)</td>,The worse outcomes were found in the control group not using the genioplasty templates.,In all 6 measurements of the chin position and orientation, the result of independent t test showed that there was statistically significant difference between the groups with and without the genioplasty templates.", Positional differences improvement (mediolateral) , Traditional measurement  , Genioplasty template system ,0,
edin,5454,5863632,Significantly decreased,Results indicated that Aussie Optimism with teacher training plus coaching was associated with the best outcomes: a significant increase in student-reported pro-social behavior from pre-test to post-test 1 (maintained at post-test 2) and significantly lower incidence rates from suicidal ideation at post-test 2 and follow-up., Suicidal ideas , Control , Training only ,0,
edin,5478,3263438,Cannot tell based on the abstract,, Vital signs  , Control , Fluticasone furoate + vilanterol ,0,
edin,5478,3263438,No significant difference,"There were no clinically relevant effects on laboratory values, including glucose and potassium, or on vital signs or ECGs/Holters.", Vital signs  , Control , Fluticasone furoate + vilanterol ,0,
edin,5319,4674480,Cannot tell based on the abstract,, Systolic blood pressure , Basal bolus , Insulin degludec and liraglutide ,0,
edin,5319,4674480,Significantly decreased,"Compared with BB or up-titrated basal therapy, estimated improvements in body weight, BMI, and SBP were statistically significantly better with IDegLira.", Systolic blood pressure , Basal bolus , Insulin degludec and liraglutide ,0,
edin,5284,5911298,Significantly increased,The percentage of dentin removal was greater in the PR group (5.02%) than MR group (1.36%) (P=0.0028)., Dentin removed , Mani NRT-GPR , Pro Taper universal retreatment  ,0,
edin,5303,2703617,Significantly decreased,The mean WTs of urgent patients (CTAS 2/3) were also significantly reduced after the FTA was opened (P < 0.001)., Waiting time of urgent patients , Control , Fast track area ,0,
edin,5442,3685524,Significantly increased,"Central arterial stiffness, measured as augmentation index, augmentation pressure and pulse wave velocity, was higher after wood smoke exposure as compared to filtered air (p < 0.01 for all),", Augmentation pressure , Control , Wood smoke ,0,
edin,5415,4899895,Cannot tell based on the abstract,, Respiratory exchange ratio during rest , Placebo , Green tea ,0,
edin,5415,4899895,Significantly decreased,"During the resting period, before exercise, RER was significantly decreased, p < 0.05, after GT ingestion (0.82 Â± 0.08) compared with the placebo (0.86 Â± 0.08).", Respiratory exchange ratio during rest , Placebo , Green tea ,0,
edin,5468,3462792,Cannot tell based on the abstract,, Probability of asking partner about HIV condition , Control , HIV Prevention Digital Media Intervention ,0,
edin,5468,3462792,Significantly decreased,"Contrary to expectations, men in both the webpage and control conditions had significant reductions in asking their partnerâs HIV status at follow-up compared to baseline (OR 0.61, OR 0.60).", Probability of asking partner about HIV condition , Control , HIV Prevention Digital Media Intervention ,0,
edin,5399,2800022,Significantly decreased,"PTH was significantly lower in group S than in group B at 6 months (P=0.001), but did not differ at 12 months.", Intact parathyroid hormone , Breast milk alone , Breast milk + Vit. D ,0,
edin,5367,3117815,Cannot tell based on the abstract,, Physical aspect of Functional Assessment of Cancer Therapy-Breast , 3-weekly docetaxel , Weekly docetaxel  ,0,
edin,5367,3117815,No significant difference,"<td align=""left"">âPhysical</td><td align=""center"">21.20 (0.73)</td><td align=""center"">21.63 (0.74)</td><td align=""center"">0.172</td><td align=""center"">0.68</td>,At the primary endpoint, there were no significant differences in RSCL, physical and psychological scores between groups.", Physical aspect of Functional Assessment of Cancer Therapy-Breast , 3-weekly docetaxel , Weekly docetaxel  ,0,
edin,5428,4399299,Significantly decreased,"Mean fasting liver triglyceride content decreased by 27% with vildagliptin, from 7.3 Â± 1.0% (baseline) to 5.3 Â± 0.9% (endpoint). There was no change in the placebo group.,The between-group difference in change from baseline was significant (P = .013).", Fasting liver triglycerides , Placebo , Vildagliptin ,0,
edin,5341,5509595,Cannot tell based on the abstract,, VO2max , Control , Half bath ,0,
edin,5341,5509595,No significant difference,"VO2max (ml/kg/min)	Aerobic exercise	25.12 Â± 1.21	33.07 Â± 2.37	group	7.680*
Half bath	26.18 Â± 1.20	27.07 Â± 1.10	time	8.223*
Control	27.13 Â± 1.01	27.05 Â± 1.00	group*time	9.618**,In this study, the maximum oxygen uptake, HRmax, and maximum ventilation were also significantly increased after 12 weeks of treatment only in exercise group.", VO2max , Control , Half bath ,0,
edin,5388,4415997,Significantly increased,"Exposure was associated with over twice the odds of using STI services (AOR 2.47; 95%CI 1.78â3.42), 89% greater odds of using perinatal services (AOR 1.89; 95%CI 1.37â2.60) and 56% greater odds of using antenatal services (AOR 1.56; 95%CI 1.10â2.20) among participants in intervention versus comparison communities, after adjustment for baseline differences.", Usage of sexually-transmitted infections services , Control , Sexual and Reproductive Health Intervention ,0,
edin,5312,3944580,No significant difference,"However, changes in obestatin and des-acyl ghrelin concentration were statistically insignificant (P > 0.05).,The data indicated that although acute treadmill exercise resulted in a significant change in acyl ghrelin and leptin levels, it had no effect on plasma obestatin and des-acyl ghrelin levels.", Obestatin , Control , Motor-driven treadmill exercise  ,0,
edin,5492,4733270,Significantly increased,"The significant behavior disorder predictors for unintentional injury in boys were schizoid behavior problem (ORâ=â2.43), anxiety/depression (ORâ=â2.76) and hyperactive (ORâ=â2.42). T", Probability of having an injury , Control , Being schizoid  ,0,
edin,5329,4183888,Cannot tell based on the abstract,, Plaque control record improvement  , Control , Prophylactic professional oral health care ,0,
edin,5329,4183888,Significantly increased,"The PCR showed numerical improvement in 11 patients and deterioration in 1 patient in the POHC group after chemotherapy, as compared with pre-chemotherapy PCR. In the self-care group, six patients showed improvement, while eight patients showed deterioration. Thus, the self-care group showed significantly greater oral health deterioration compared with the POHC group.", Plaque control record improvement  , Control , Prophylactic professional oral health care ,0,
edin,5481,5244020,Cannot tell based on the abstract,"Systolic BP, diastolic BP, heart rate, LUTS, and QoL satisfaction with urinary symptoms were similar in the three groups.", Blood pressure , Control , Linalyl acetate ,0,
edin,5481,5244020,No significant difference,"Aroma inhalation reduced systolic BP, diastolic BP, and HR slightly, but similarly, in the three groups, with no statistically significant differences across the three groups (data unshown).", Blood pressure , Control , Linalyl acetate ,0,
edin,5467,4156403,No significant difference,"In PLCO, randomization to cancer screening compared with usual care was associated with a significant decrease in thyroid cancer risk for men (HR â=â0.61; 95% CI: 0.49â0.95) but not women (HR â=â0.91; 95% CI: 0.66â1.26).", PLCO thyroid cancer risk in women , Control , Randomized CT scan ,0,
edin,5404,2689497,Cannot tell based on the abstract,, Oxygen saturation , IV ovine lipopolysaccharide , Inhaled human activated protein C + IV ovine lipopolysaccharide ,0,
edin,5404,2689497,Significantly increased,"Table 1 displays that oxygen saturation (SaO2) and mixed venous oxygen saturation (SvO2) both improved significantly on inhalation of APC, but without significant intergroup differences compared with LPS alone.", Oxygen saturation , IV ovine lipopolysaccharide , Inhaled human activated protein C + IV ovine lipopolysaccharide ,0,
edin,5488,3417877,No significant difference,The cellulose mask increased moisture levels in the skin significantly more than moist towels (P < 0.05) after a single application. No obvious effects on other skin characteristics were found., Skin texture , Control , Cellulose mask ,0,
edin,5381,4967427,Cannot tell based on the abstract,, Integrity indemnity , Standard management  , Intensive case management  ,0,
edin,5381,4967427,Significantly increased,"As shown in TableÂ 2, the percentage of patients who had received an integrity indemnity until the end of the 6-year follow-up was significantly higher under ICM (37.0Â %) than under SCM (32.0Â %, pÂ <Â 0.001).", Integrity indemnity , Standard management  , Intensive case management  ,0,
edin,5290,4281164,Cannot tell based on the abstract,, Mortality , Thymoglobulin four infusions of 1.5 mg/kg  , Thymoglobulin single infusion  ,0,
edin,5290,4281164,Significantly decreased,"There were significantly fewer deaths among kidney recipients who received SD rATG induction; causes of patient death are presented in Table S3 (SDC, http://links.lww.com/TP/B12)", Mortality , Thymoglobulin four infusions of 1.5 mg/kg  , Thymoglobulin single infusion  ,0,
edin,4918,4260384,Significantly increased,"The envelope type of CAF along with Type I collagen membrane (NEOMEM) was more effective than envelope type of CAF alone, in producing root coverage in multiple gingival recession defects, associated with gain in CAL as also in the width of KT.", the extent of root coverage at 6 months , baseline ," Group A, which were treated with the envelope type of CAF ",0,
edin,4918,4260384,Significantly increased,"The envelope type of CAF along with Type I collagen membrane (NEOMEM) was more effective than envelope type of CAF alone, in producing root coverage in multiple gingival recession defects, associated with gain in CAL as also in the width of KT.", the extent of root coverage at 6 months , baseline ," Group A, which were treated with the envelope type of CAF ",0,
edin,5450,4478821,Significantly increased,The laryngeal mask airway (LMA) insertion score was statistically significant in the four groups (P - 0.001)., Laryngeal mask airway insertion score improvement , No atricurium , Atracurium 50% dose  ,0,
edin,5267,5868223,Cannot tell based on the abstract,, Visiting the ophthalmologist  , Control , Eye health promotion program ,0,
edin,5267,5868223,Significantly increased,"There was statistical difference in the mean change positively in the how frequently children should be taken to an ophthalmologist, believed it was necessary to wear sunglasses on sunny days, knew the symptoms of visual problems in children, had bought their children's sunglasses from an optical store, children spend time outdoors to protect their eye health between the experimental (n = 98) and control (n = 93) groupsâ parents (P < 0.05) [Table 4].", Visiting the ophthalmologist  , Control , Eye health promotion program ,0,
edin,5344,4667406,Cannot tell based on the abstract,, Pain VAS (1 week) , Ischemic pressure  , Anesthetic injections  ,0,
edin,5344,4667406,Cannot tell based on the abstract,, Pain VAS (1 week) , Ischemic pressure  , Anesthetic injections  ,0,
edin,5344,4667406,No significant difference,"<td>P</td><td>.50</td><td>.08</td><td>&lt;.01</td><td>&lt;.01</td><td>---</td>,Although the differences between groups in the various time points were not significant, pain threshold and tolerance improved progressively in the women who received the local anaesthetic injection (TableÂ 4).Table 4", Pain VAS (1 week) , Ischemic pressure  , Anesthetic injections  ,0,
edin,5462,5501521,Significantly decreased,"Systolic blood pressure was also lower in the Lignocaine group: 121.7Â mmHg (SD: 6.1) vs. 128.0Â mmHg (SD: 6.4) in the Saline group; 95% CI 3.5â9.2, pÂ <Â 0.001, as was the mean heart rate [Lignocaine group: 74.9 beats/min (SD: 1.8) vs. 81.5 beats/min (SD: 1.7) in the Saline group, 95% CI 4.1â9.1, pÂ <Â 0.001].", Heart rate , Control , Lignocaine ,0,
edin,5409,2689497,Cannot tell based on the abstract,, PaCO2 level , IV ovine lipopolysaccharide , Inhaled human activated protein C + IV ovine lipopolysaccharide ,0,
edin,5409,2689497,Significantly decreased,"Except for a slight increase in pH (P = 0.002) and a decrease in partial pressure of carbon dioxide in arterial blood (PaCO2; P = 0.013) after inhaled APC, we noticed no changes in acid-base balance.", PaCO2 level , IV ovine lipopolysaccharide , Inhaled human activated protein C + IV ovine lipopolysaccharide ,0,
edin,5485,3417877,Significantly increased,The cellulose mask increased moisture levels in the skin significantly more than moist towels (P < 0.05) after a single application., Facial moisture , Control , Cellulose mask ,0,
edin,5392,4415997,Cannot tell based on the abstract,, Patient service satisfaction , Control , Sexual and Reproductive Health Intervention ,0,
edin,5392,4415997,Significantly increased,"Reported satisfaction increased from 18% to 43% among intervention adolescents versus 17% to 28% among comparison adolescents. Thus, intervention adolescents had 92% higher odds of reporting satisfaction with services than comparison adolescents at endline (OR 1.92, adjusted for baseline satisfaction; 95%CI 1.63â2.26). No gender differences were found in reported service satisfaction.,<td align=""left"" colspan=""1"" rowspan=""1"">Intervention</td><td align=""left"" colspan=""1"" rowspan=""1"">1692</td><td align=""left"" colspan=""1"" rowspan=""1"">304 (18.0)</td><td align=""left"" colspan=""1"" rowspan=""1"">141 (46.4)</td><td align=""left"" colspan=""1"" rowspan=""1"">163 (53.6)</td><td align=""left"" colspan=""1"" rowspan=""1"">1288</td><td align=""left"" colspan=""1"" rowspan=""1"">556 (43.2)</td><td align=""left"" colspan=""1"" rowspan=""1"">250 (45.0)</td><td align=""left"" colspan=""1"" rowspan=""1"">306 (55.0)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">25.2</td>", Patient service satisfaction , Control , Sexual and Reproductive Health Intervention ,0,
edin,5318,4674480,Significantly decreased,"At end of study, differences between IDegLira and BB or up-titrated IGlar, respectively, were as follows: reduction in HbA1c â0.30%, 95% confidence interval (â0.58; â0.01) and â0.65% (â0.83; â0.47); change in body weight â6.89Â kg (â7.92; â5.86) and â4.04Â kg (â4.69; â3.40) all in favor of IDegLira.", Body weight  , Basal bolus , Insulin degludec and liraglutide ,0,
edin,5369,3117815,Cannot tell based on the abstract,, Functional aspect of Functional Assessment of Cancer Therapy-Breast , 3-weekly docetaxel , Weekly docetaxel  ,0,
edin,5369,3117815,No significant difference,"<td align=""left"">âFunctional</td><td align=""center"">19.80 (0.71)</td><td align=""center"">18.48 (0.72)</td><td align=""center"">1.691</td><td align=""center"">0.20</td>,Table 2
Primary and secondary outcomes at three weeks after completion of chemotherapy", Functional aspect of Functional Assessment of Cancer Therapy-Breast , 3-weekly docetaxel , Weekly docetaxel  ,0,
edin,5322,4674480,Significantly decreased,"Confirmed hypoglycemia rate was 122.8 (90.7; 166.1), 1060.8 (680.2; 1654.4), and 286.1 (231.1; 354.1) events/100 patient-years for IDegLira, BB, and up-titrated IGlar, respectively.", Hypoglycemia  , Basal bolus , Insulin degludec and liraglutide  ,0,
edin,5357,3432818,Cannot tell based on the abstract,, Divided attention improvement , Control , Astaxanthin-rich Haematococcus pluvialis ,0,
edin,5357,3432818,Significantly increased,"However, the changes in response time were as follows: in the high-dosage group, improvement trends were observed for âchoice reactionâ (451.1Â Â±Â 56.7 vs 480.1Â Â±Â 77.5), âdelayed recallâ (818.3Â Â±Â 195.9 vs 880.1Â Â±Â 189.4), and âdivided attentionâ (385.3Â Â±Â 72.5 vs 419.4Â Â± 79.6), each p values <0.1 at 12 weeks,", Divided attention improvement , Control , Astaxanthin-rich Haematococcus pluvialis ,0,
edin,5338,5509595,Significantly decreased,The aerobic exercise group showed a significant decrease in body fat than those in the half-bath and control groups., Body fat , Control , Endurance exercise  ,0,
edin,5317,5511285,Cannot tell based on the abstract,, Orientational differences improvement (Pitch) , Traditional measurement  , Genioplasty template system ,0,
edin,5317,5511285,Significantly increased,"Table 3
Bland-Altmanâs Accuracy Estimate of Orientational Differences between the Planned and Postoperative Outcomes (degrees).,<td>Without template</td><td>Pitch</td><td>â4.00</td><td>6.06</td><td>â15.89</td><td>(â17.62 to â12.69)</td><td>7.89</td><td>(4.69 to 11.08)</td>,<td>With template</td><td>Pitch</td><td>â1.51</td><td>2.17</td><td>â5.77</td><td>(â7.50 to â4.63)</td><td>2.75</td><td>(1.61 to 3.90)</td>,The worse outcomes were found in the control group not using the genioplasty templates. In all 6 measurements of the chin position and orientation, the result of independent t test showed that there was statistically significant difference between the groups with and without the genioplasty templates.", Orientational differences improvement (Pitch) , Traditional measurement  , Genioplasty template system ,0,
edin,5389,4415997,Significantly increased,"Exposure was associated with over twice the odds of using STI services (AOR 2.47; 95%CI 1.78â3.42), 89% greater odds of using perinatal services (AOR 1.89; 95%CI 1.37â2.60) and 56% greater odds of using antenatal services (AOR 1.56; 95%CI 1.10â2.20) among participants in intervention versus comparison communities, after adjustment for baseline differences.", Usage of antenatal services  , Control , Sexual and Reproductive Health Intervention ,0,
edin,5426,3920467,Cannot tell based on the abstract,, +25% improvement  , Placebo , Hydroxyzine + chlorpheniramine ,0,
edin,5426,3920467,Significantly increased,"Improvement of more than 25 per cent (50 per cent) of pruritus was seen in 10 (2)/17 dogs with the combination of chlorpheniramine and hydroxyzine, 12 (2)/18 with dimetinden and 2 (1)/19 with placebo. For dogs improving by more than 25 per cent, the difference between placebo and the combination of chlorpheniramine and hydroxyzine and dimetinden, respectively, was significant (P=0.003 and P=0.001, respectively)", +25% improvement  , Placebo , Hydroxyzine + chlorpheniramine ,0,
edin,5295,5530360,Significantly decreased,"At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI <0.5; pâ¤0.001), reductions in fatigue (FACIT-F â¥3.56; pâ¤0.05), improvements in PtGA (pâ¤0.001) and pain (pâ¤0.001) and reductions in duration of MJS (p<0.01).",   Functional Assessment of Chronic Illness Therapy-Fatigue improvement , Placebo , Baricitinib 2 mg ,0,
edin,5302,2703617,Significantly decreased,"Similarly, mean WTs of CTAS 5 patients decreased by 28 min (95% CI 19 min to 37 min, P < 0.001) post FTA.", Waiting time of CTAS 5 , Control , Fast track area ,0,
edin,5486,3417877,No significant difference,"Skin moisture, sebum, elasticity, texture, dullness, and desquamation levels were assessed using a system used for routine skin counseling before applying the trial product and five minutes after its removal.,The cellulose mask increased moisture levels in the skin significantly more than moist towels (P < 0.05) after a single application. No obvious effects on other skin characteristics were found.", Sebum level , Control , Cellulose mask ,0,
edin,5380,4967427,Cannot tell based on the abstract,, Degree of disability , Standard management  , Intensive case management  ,0,
edin,5380,4967427,No significant difference,"<td align=""left"">&nbsp;&nbsp;Average degree (%) of disability for patients receiving a pension</td><td align=""char"" char=""("">34.7 (0.92)</td><td align=""char"" char=""("">34.9 (0.94)</td><td align=""left"">0.4 [â6.0â7.2]</td><td align=""char"" char=""."">0.90</td>,The average degree of disability across these patients was almost identical for both study groups (34.7Â % under SCM vs. 34.9Â % under ICM, pÂ =Â 0.90).", Degree of disability , Standard management  , Intensive case management  ,0,
edin,5345,4667406,Cannot tell based on the abstract,, Pain VAS (4 weeks) , Ischemic pressure  , Anesthetic injections  ,0,
edin,5345,4667406,Significantly decreased,<td>P</td><td>.50</td><td>.08</td><td>&lt;.01</td><td>&lt;.01</td><td>---</td>, Pain VAS (4 weeks) , Ischemic pressure  , Anesthetic injections  ,0,
edin,5352,4676931,Significantly increased,Post hoc analyses showed the statistical superiority of rasagiline versus placebo in the UPDRS Part I depression item (PÂ =Â 0.04) and PDQ-39 mobility (PÂ =Â 0.007) and cognition domains (PÂ =Â 0.026)., Parkinsonâs disease quality of life questionnaire - mobility score improvement , Control , Rasagiline ,0,
edin,5374,5559992,Significantly decreased,"The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).", Anxiety , No treatment , Buprenophine 96 mg ,0,
edin,5361,3883373,No significant difference,"Incidences of UTI - febrile and afebrile - reduced in both groups without any significant differences after two years of prophylaxis. Also, incidence of afebrile UTIs did not significantly differ (0.51Â±1.30 and 0.81Â±1.41 respectively, P =0.3);", Afebrile urianry tract infections , Antibiotics alone  , Probiotics + antibiotics  ,0,
edin,5323,4674480,Significantly decreased,"Confirmed hypoglycemia rate was 122.8 (90.7; 166.1), 1060.8 (680.2; 1654.4), and 286.1 (231.1; 354.1) events/100 patient-years for IDegLira, BB, and up-titrated IGlar, respectively.", Hypoglycemia  , Glucagon-like peptide-1 receptor agonist + basal insulin , Insulin degludec and liraglutide  ,0,
edin,5332,4183888,Cannot tell based on the abstract,, Gustatory measurement improvement  , Control , Prophylactic professional oral health care ,0,
edin,5332,4183888,No significant difference,"Results of the oral environment assessments, including the OAG score, oral mucositis grade assessment, PCR, Saxon test, and tests with the oral moisture checker (MucusTM) and electrogustometer, are presented in TableÂ 4.Table 4

Deterioration rates of oral environment assessment parameters (Ï 2 test),Electrogustometer	21.4 (3)	25.0 (3)	0.596,The assessment parameters consisted of oral cavity photographs, assessment of the oral mucositis grade using the United States National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE) [11], evaluation of the oral environment using Eilersâ Oral Assessment Guide (OAG) [12, 13], evaluation of oral hygiene using plaque control records (PCR) [13, 14], evaluation of dry mouth and oral moisture using the Saxon test [15, 16] and MucusTM [16, 17], and gustatory measurements using an electrogustometer [18â22].", Gustatory measurement improvement  , Control , Prophylactic professional oral health care ,0,
edin,5499,5380326,Significantly decreased,"Our important finding revealed that upon correction of vitamin D insufficiency or deficiency, the serum IP-10 and DPP IV levels were decreased significantly as compare to the placebo group (delta changes; 83.27 vs -133.80; 95% CI [-326.910, -40.758], p = 0.0125, and 271.04 vs -518.69; 95% CI [-1179,15, -59.781], p = 0.0305, respectively.", Dipeptidyl peptidase-4  , Control , Vitamin D supplementation  ,0,
edin,5383,3459660,Cannot tell based on the abstract,, Morning prebronchodilator FEV1 , Control , Tiotropium ,0,
edin,5383,3459660,Significantly increased,"At all time points, tiotropium significantly improved morning prebronchodilator FEV1 compared with control (P < 0.01, Figure 1);", Morning prebronchodilator FEV1 , Control , Tiotropium ,0,
edin,5440,3222191,Cannot tell based on the abstract,, Learning Preferences , Control , Collaborative  eHealth literacy intervention ,0,
edin,5440,3222191,No significant difference,"Multivariate repeated measures analyses found neither an interaction effect among learning preference matching, learning method, and time of measurement (P = .18) nor a significant main effect of the learning preference matching factor (P = .41).", Learning Preferences , Control , Collaborative  eHealth literacy intervention ,0,
edin,5294,4281164,Cannot tell based on the abstract,, Multiple infections , Thymoglobulin four infusions of 1.5 mg/kg  , Thymoglobulin single infusion  ,0,
edin,5294,4281164,Significantly decreased,"Frequencies of multiple infections (two or more infectious origins, e.g., bacterial, viral, fungal) were lower among SD patients (1 vs. 9; P=0.02).", Multiple infections , Thymoglobulin four infusions of 1.5 mg/kg  , Thymoglobulin single infusion  ,0,
edin,5372,5559992,Significantly decreased,"The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).", Anxiety , No treatment , Buprenophine 32 mg ,0,
edin,5337,3996328,Cannot tell based on the abstract,, Body mass index , Traditional exercise  , Eccentric exercise  ,0,
edin,5337,3996328,No significant difference,"Neither the ECC (P = 0.51) nor the TRAD (P = 0.15) group demonstrated a significant change in BMI over time.,Further, the high IMAT group experienced a parallel lowering (P = 0.03) of their elevated pretraining BMI, while the low IMAT group's BMI did not change (P = 0.73).", Body mass index , Traditional exercise  , Eccentric exercise  ,0,
edin,5472,5434591,No significant difference,KOOS sub-variables were similiar between denosumab and placebo after 12 and 24 months., Knee osteoarthritis outcome score after 1 year , Control , Denosumab  ,0,
edin,5279,5718865,Cannot tell based on the abstract,, Second degree lacerations  , Control , Perioneal massage ,0,
edin,5279,5718865,No significant difference,"The results revealed 23.16% of first-degree perineal laceration and 2.11% of second-degree perineal laceration in the case group, and no vestibular laceration or third- and fourth-degree lacerations in the case group. However, there were 5.13% of vestibular laceration, 7.69% of first-degree laceration, 2.56% of second-degree laceration, and 1.05% of third-degree laceration (one woman) in the control group", Second degree lacerations  , Control , Perioneal massage ,0,
edin,5261,4731528,No significant difference,"Cytotoxicity of the four materials was not significantly different from that of the control group at 24, 48 and 168 h (P>0.05).", Cytotoxicity  , Control , Mineral trioxide aggregate  ,0,
edin,5403,2800022,Significantly increased,"Total intake of vitamin D differed among 3 groups (P<0.001, A>S>B), but total intake of Ca and P were higher in group A than in group B and S (P<0.001).", Calcium and phosphorus intake , Breast milk alone , Formula ,0,
edin,5464,5501521,Cannot tell based on the abstract,, Need of ephedrine  , Control , Lignocaine ,0,
edin,5464,5501521,No significant difference,"In the Lignocaine group, twenty-two patients (59%) required either intermittent boluses of either metaraminol or ephedrine compared to fifteen patients (39%) in the Saline group (pÂ =Â 0.1).", Need of ephedrine  , Control , Lignocaine ,0,
edin,5402,2800022,Significantly increased,"Total intake of vitamin D differed among 3 groups (P<0.001, A>S>B), but total intake of Ca and P were higher in group A than in group B and S (P<0.001)", Calcium and phosphorus intake , Breast milk + Vit. D , Formula ,0,
edin,5447,4478821,Significantly decreased,The need of atracurium due to unacceptable surgical conditions based on surgeon satisfaction score was statistically significant when compared among the groups being maximum in Group 0 (P < 0.001), Need of atricurium , No atricurium , Atracurium 25% dose  ,0,
edin,5373,5559992,Significantly decreased,"The results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).", Anxiety , No treatment , Buprenophine 64 mg ,0,
edin,5285,5911298,Cannot tell based on the abstract,, Creation of ledges , Mani NRT-GPR , Pro Taper universal retreatment  ,0,
edin,5285,5911298,No significant difference,"No complications, such as creation of ledges, obstructions, perforations or instrument fractures were registered for the PR or MR instruments, after retreatment procedures.", Creation of ledges , Mani NRT-GPR , Pro Taper universal retreatment  ,0,
edin,5424,3920467,Significantly decreased,"<td colspan=""1"" rowspan=""1"">Dimetinden</td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td><td colspan=""1"" rowspan=""1""></td>", Pruritus  , Placebo , Hydroxyzine + chlorpheniramine ,0,
edin,5343,5509595,Cannot tell based on the abstract,, Pulse wave velocity , Control , Half bath ,0,
edin,5343,5509595,Significantly decreased,"<td align=""left"" colspan=""1"" rowspan=""1"">Control</td><td align=""center"" colspan=""1"" rowspan=""1"">1.64 Â± 0.04</td><td align=""center"" colspan=""1"" rowspan=""1"">1.64 Â± 0.03</td><td align=""center"" colspan=""1"" rowspan=""1"">group*time</td><td align=""center"" colspan=""1"" rowspan=""1"">39.760***</td>,According to those results, body composition, maximal oxygen uptake, heart rate, and arterial pulse wave velocity were significantly different among the groups.", Pulse wave velocity , Control , Half bath ,0,
edin,5420,5316445,Cannot tell based on the abstract,, Rand Short Form 36 score improvement , Control , Wi-Fit exercise program ,0,
edin,5420,5316445,No significant difference,"Adjusting for MMSE and SF-36 Physical and Mental summary scores resulted in between-group differences that were only slightly (<10%) larger, and these covariates were nonsignificant (all p > 0.15, results not shown).", Rand Short Form 36 score improvement , Control , Wi-Fit exercise program ,0,
edin,5339,5509595,Significantly decreased,The aerobic exercise group showed a significant decrease in body fat than those in the half-bath and control groups., Body fat , Half bath , Endurance exercise  ,0,
edin,5371,3117815,Cannot tell based on the abstract,, Depression aspect of the Hospital anxiety and depression scale , 3-weekly docetaxel , Weekly docetaxel  ,0,
edin,5371,3117815,No significant difference,"<td align=""left"">âDepression</td><td align=""center"">4.12 (0.39)</td><td align=""center"">3.14 (0.39)</td><td align=""center"">3.237</td><td align=""center"">0.08</td>,There were also no significant differences between groups in HADS anxiety and depression scores.", Depression aspect of the Hospital anxiety and depression scale , 3-weekly docetaxel , Weekly docetaxel  ,0,
edin,5493,4733270,Significantly increased,"he significant behavior disorder predictors for unintentional injury in boys were schizoid behavior problem (ORâ=â2.43), anxiety/depression (ORâ=â2.76) and hyperactive (ORâ=â2.42).", Probability of having an injury , Control , Anxiety/Depression ,0,
edin,5309,3195393,Cannot tell based on the abstract,, Restraint knowledge , Before restraint reduction program , After restraint reduction program ,0,
edin,5309,3195393,Significantly increased,"When further analysis were conducted, a subsample of nurses (of one unit) were found to have better knowledge after intervention (mean score results: 5.51 versus 6.23, P = 0.04).", Restraint knowledge , Before restraint reduction program , After restraint reduction program ,0,
edin,5354,4676931,Significantly increased,Rasagiline significantly improved UPDRS Parts I (PÂ =Â 0.03) and II (PÂ =Â 0.003) scores versus placebo at week 12., Unified Parkinsonâs Disease Rating Scale Part I score improvement , Control , Rasagiline ,0,
edin,5479,5244020,Significantly decreased,"Significant differences in pain magnitude and urinary residual sense of indwelling catheters were observed among the three groups, with inhalation of linalyl acetate being significantly more effective than inhalation of lavender or vehicle.", Pain , Control , Linalyl acetate ,0,
edin,5501,5380326,Cannot tell based on the abstract,, Tumor necrosis factor alpha , Control , Vitamin D supplementation  ,0,
edin,5501,5380326,Significantly decreased,"<td align=""center"" colspan=""1"" rowspan=""1"">TNF-Î±</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">-14.351</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">-23.407</td><td align=""center"" colspan=""1"" rowspan=""1"">2.515 (38.146)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">0.9476</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">0.08</td>", Tumor necrosis factor alpha , Control , Vitamin D supplementation  ,0,
edin,5487,3417877,No significant difference,"Skin moisture, sebum, elasticity, texture, dullness, and desquamation levels were assessed using a system used for routine skin counseling before applying the trial product and five minutes after its removal.,The cellulose mask increased moisture levels in the skin significantly more than moist towels (P < 0.05) after a single application. No obvious effects on other skin characteristics were found.", Elasticity , Control , Cellulose mask ,0,
edin,4526,5010179,Cannot tell based on the abstract,, Resection rates , Control , Uracil-tegafur and leucovorin ,0,
edin,4526,5010179,No significant difference,The resection rates for the first recurrence were similar between the UFT/LV and surgery alone groups (55.9% vs. 41.0%)., Resection rates , Control , Uracil-tegafur and leucovorin ,0,
edin,5315,5511285,Cannot tell based on the abstract,, Positional differences improvement (anteroposterior) , Traditional measurement  , Genioplasty template system ,0,
edin,5315,5511285,Significantly increased,"Table 2
Bland-Altmanâs Accuracy Estimate of Positional Differences between the Planned and Postoperative Outcomes (mm).,<th colspan=""2"">Lower Limit</th><th colspan=""2"">Upper Limit</th>,The worse outcomes were found in the control group not using the genioplasty templates. In all 6 measurements of the chin position and orientation, the result of independent t test showed that there was statistically significant difference between the groups with and without the genioplasty templates.", Positional differences improvement (anteroposterior) , Traditional measurement  , Genioplasty template system ,0,
edin,5301,2703617,Significantly decreased,"Mean WTs of Canadian Triage Acuity Scale (CTAS) 4 patients decreased by 22 min (95% CI 21 min to 24 min, P < 0.001).", Waiting time of CTAS 4 , Control , Fast track area ,0,
edin,5473,5434591,No significant difference,KOOS sub-variables were similiar between denosumab and placebo after 12 and 24 months., Knee osteoarthritis outcome score after 2 years , Control , Denosumab  ,0,
edin,5410,5427603,No significant difference,"However, the accuracy of these variables in identifying responders in each group was modest (62 and 53%, respectively).", Responders identification accuracy  , Foot orthoses  , Rocker-sole footwear ,0,
edin,5427,3920467,Cannot tell based on the abstract,, +25% improvement  , Placebo , Dimetinden ,0,
edin,5427,3920467,Significantly increased,"mprovement of more than 25 per cent (50 per cent) of pruritus was seen in 10 (2)/17 dogs with the combination of chlorpheniramine and hydroxyzine, 12 (2)/18 with dimetinden and 2 (1)/19 with placebo. For dogs improving by more than 25 per cent, the difference between placebo and the combination of chlorpheniramine and hydroxyzine and dimetinden, respectively, was significant (P=0.003 and P=0.001, respectively).", +25% improvement  , Placebo , Dimetinden ,0,
edin,5475,3263438,No significant difference,The wm heart rate 0â4âh postdose was similar between groups (difference: 0.6âbeats per minute; 95% CI â3.9 to 5.1)., Heart rate , Control , Fluticasone furoate + vilanterol ,0,
edin,5334,4175229,Significantly decreased,"In the experimental group, it was found that pain in the SCM was relived, as the VAS and PPT score decrease significantly and range of motion of temporomandibular joint increase significantly.", Pressure pain threshold improvement  , Control , Kinesio taping  ,0,
edin,5377,5559992,No significant difference,"he results showed a significant reduction in anxiety symptoms within each of the three groups (P = 0.00), but no difference in outcome between the groups (P = 0.605).", Anxiety , Buprenophine 96 mg , Buprenophine 64 mg ,0,
edin,5446,3685524,Cannot tell based on the abstract,, Successive NN interval differences &amp;gt;50 ms , Control , Wood smoke ,0,
edin,5446,3685524,No significant difference,"Data expressed as mean Â± SEM or median with inter quartile range. SDNN standard deviation of successive NN intervals, RMSSD root-mean square of successive NN interval differences; HFn high frequency components expressed as normalised units, LFn low frequency components expressed as normalised units, HF/LF high frequency/low frequency. There were no significant differences in any parameter pre exposure (p>0.05 for all).", Successive NN interval differences &amp;gt;50 ms , Control , Wood smoke ,0,
edin,5297,5530360,Significantly increased,"At week 24, more baricitinib-treated patients versus placebo-treated patients reported normal physical functioning (HAQ-DI <0.5; pâ¤0.001),",  Health Assessment Questionnaire-Disability Index improvement , Placebo , Baricitinib 2 mg ,0,
edin,5726,5858425,Cannot tell based on the abstract,, descriptive improvements post measurement , control group (CG) received lessons as usual , Intervention group (IG) with standing desks and balance pads for 11 weeks ,0,
edin,5726,5858425,No significant difference,"Based on the pre-measurement, descriptive improvements could be found at post measurement for the IG compared to the CG.,The mean changes and their effect sizes were higher in the IG (IG: 0.46â0.48; CG: 0.26) for the digit span task.", descriptive improvements post measurement , control group (CG) received lessons as usual , Intervention group (IG) with standing desks and balance pads for 11 weeks ,0,
edin,5760,5524701,Cannot tell based on the abstract,, post-test scores acute bacterial meningitis scenario , mannequin-based scenarios , SP-based scenarios  ,0,
edin,5760,5524701,No significant difference,The improvement of the SP group scores compared to the mannequin group reached statistical significance in all scenarios except for the acute bacterial meningitis scenario (Table 1)., post-test scores acute bacterial meningitis scenario , mannequin-based scenarios , SP-based scenarios  ,0,
edin,5727,3956097,Significantly decreased,"Our findings showed that there was a statistically significant increase in the mean score of the patientsâ life quality after rehabilitation. Also, the comparison of the scores of the eight aspects of patientsâ life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain", physical pain after rehabilitation , before rehabilitation program , after rehabilitation program ,0,
edin,5532,2876942,No significant difference,"Drug palatability, vomiting, and onset of action of premedication; showed no significant differences between both groups.", Vomiting , Control , Ketamine ,0,
edin,5739,4119719,Cannot tell based on the abstract,, effectiveness after early ischemic stroke , placebo , 4 Channel Functional Electrical Stimulation (FES) ,0,
edin,5739,4119719,Significantly increased,"Four-channel FES and dual-channel FES can both improve motor function, balance, walking ability, and performance in the activities of daily living in subjects with early ischemic stroke.", effectiveness after early ischemic stroke , placebo , 4 Channel Functional Electrical Stimulation (FES) ,0,
edin,5635,5712123,Cannot tell based on the abstract,, time to first rescue analgesic , Duloxetine (D) , duloxetine 60 and etoricoxib 120mg (group D/E) ,0,
edin,5635,5712123,Significantly increased,"The time to first rescue analgesic was significantly prolonged in (D/E)when compared with group D,", time to first rescue analgesic , Duloxetine (D) , duloxetine 60 and etoricoxib 120mg (group D/E) ,0,
edin,5719,3750766,Cannot tell based on the abstract,, pain perception in dorsal anterior cingulate cortex  , placebo , multi-coil rTMS ,0,
edin,5719,3750766,Significantly decreased,"Multi-coil repetitive transcranial magnetic stimulation was successfully used to reliably and safely affect the dorsal anterior cingulate cortex, a deep brain structures that is critical to pain perception, but which cannot be selectively reached with single-coil approaches. Particular configurations and frequencies of field pulses directed toward the dorsal anterior cingulate cortex reduced acute pain in volunteers and chronic pain in fibromyalgia patients.", pain perception in dorsal anterior cingulate cortex  , placebo , multi-coil rTMS ,0,
edin,5541,3952721,No significant difference,"No effect on QTci (individually corrected) was observed at either strength of FF/VI, with mean time-matched treatment differences <5 ms at all time points [upper 90% CIs <10 ms (0â24âh)].", QTc (Fridericia's correction) time , Control , Fluticasone furoate + vilanterol ,0,
edin,5536,2876942,Significantly decreased,Postoperative agitation score and rescue fentanyl consumption were higher in group M than in group KM on admission to the PACU (P < 0.01)., Fentanyl consumption , Control , Ketamine ,0,
edin,5540,3912320,Cannot tell based on the abstract,," Correct response rate for 4,000 Hz frequency ", Control , Occupational noise ,0,
edin,5540,3912320,Significantly increased,"FigureÂ 4 compares the mean correct responses between the control and test groups according to the stimulus frequency. The control group obtained means that were 24%, 21% and 25% higher than those of the test group for the 500, 2,000 and 4,000 Hz frequencies, respectively."," Correct response rate for 4,000 Hz frequency ", Control , Occupational noise ,0,
edin,5749,2364538,No significant difference,"After 6 months use of panty liners the frequencies (and densities) of the selected microorganisms in these two sites had not changed compared to controls, and fatty acid analyses of vaginal secretions gave no evidence of shifts in the microbial flora.", fatty acid analyses of vaginal secretions , control group C (no panty liner wear) , panty liner B (AlwaysÂ® non-deodorant) ,0,
edin,5600,4355974,Cannot tell based on the abstract,, Days patient had to slow down	 , Control , BostonBreathes system ,0,
edin,5600,4355974,No significant difference,<td>Days had to slow down</td><td>2.5</td><td>â1.4</td><td>0.07</td><td>1.1</td><td>â0.4</td><td>0.48</td><td>0.79</td>, Days patient had to slow down	 , Control , BostonBreathes system ,0,
edin,5682,3721088,Cannot tell based on the abstract,, total time taken to complete the test for Object Cancelation test (OC) , computer-based testing , computer-based prism adaptation (PA) ,0,
edin,5682,3721088,Significantly decreased,"The total time taken to complete the test improved significantly after PA for the OC, LC, as well as the LB.", total time taken to complete the test for Object Cancelation test (OC) , computer-based testing , computer-based prism adaptation (PA) ,0,
edin,5642,4307639,Cannot tell based on the abstract,, younger age , no interest group , committed with interest group ,0,
edin,5642,4307639,Significantly decreased,"The committed without interest group were younger (ORâ=â0.79, Pâ=â0.01), and more physically active (ORâ=â1.06, Pâ=â0.005).", younger age , no interest group , committed with interest group ,0,
edin,5543,3952721,Cannot tell based on the abstract,, Adverse effects  , Moxifloxacin , Fluticasone furoate + vilanterol ,0,
edin,5543,3952721,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1""><bold>âAdverse events/serious adverse events</bold></td><td align=""center"" colspan=""1"" rowspan=""1"">0</td><td align=""center"" colspan=""1"" rowspan=""1"">0</td>,here were no serious adverse events or subject withdrawals due to AEs", Adverse effects  , Moxifloxacin , Fluticasone furoate + vilanterol ,0,
edin,5708,5887937,Cannot tell based on the abstract,, efficacy , treatment arms with repeated switches (pooled switched) , continued treatment arms (pooled continued) ,0,
edin,5708,5887937,No significant difference,"Also, no relevant differences were identified in any efficacy parameter when considering the four treatment arms (two continued and two switched) separately during TP2.", efficacy , treatment arms with repeated switches (pooled switched) , continued treatment arms (pooled continued) ,0,
edin,5680,3721088,Cannot tell based on the abstract,, efficacy , computer based testing , computer-based prism adaptation (PA) ,0,
edin,5680,3721088,No significant difference,These patients were not included in the analyses on the efficacy of the digitalized neuropsychological tests (see below). One patient whom had also a small after-effect was not secondly adapted due to emotional factors (see above)., efficacy , computer based testing , computer-based prism adaptation (PA) ,0,
edin,5630,2841147,Cannot tell based on the abstract,, Methacholine reactivity at 24 hrs post allergen challenge , placebo , selective phosphodiesterase 4 inhibitor (GSK256066) ,0,
edin,5630,2841147,No significant difference,"Methacholine reactivity at 24 hrs post allergen challenge was not different after treatment with GSK256066 compared to placebo; the PC20 was 0.31 compared to 0.39 mg/mL respectively, geometric mean (95% CI) doubling dose difference -0.31 (-1.18 to 0.57).", Methacholine reactivity at 24 hrs post allergen challenge , placebo , selective phosphodiesterase 4 inhibitor (GSK256066) ,0,
edin,5593,4737269,Cannot tell based on the abstract,, Ascent vertical toe clearance , Distance single vision lenses , Intermediate progressive addition lenses  ,0,
edin,5593,4737269,No significant difference,"Gait safety parameters were similar between intermediate PALs and distance single vision lenses for all gait safety parameters measured: vertical toe clearance on ascent (Wald Ï2Â =Â 0.4, pÂ =Â 0.54) and its variability (Wald Ï2Â =Â 0.1, pÂ =Â 0.93),", Ascent vertical toe clearance , Distance single vision lenses , Intermediate progressive addition lenses  ,0,
edin,5619,4356062,Cannot tell based on the abstract,Ovarian tissue frozen in CV7 solution showed a higher percentage of morphologically normal follicles or viable follicles than other cryoprotectant solutions Pâ<â0.05., Viable follicles , 10% EG in DPBS + 0.5 M sucroseâ+â20% FBS group , EG plus DMSO in ascending concentrations ,0,
edin,5619,4356062,Significantly increased,"Percentages of viable ovarian follicles derived from non-vitrified and vitrifed ovaries after trypan blue staining is presented in TableÂ 1.Table 1,10% EG in DPBS with 0.5Â M sucroseâ+â20% FBS group CV2,,EG plus DMSO in ascending concentrations or equilibrated in solutions of CV 5 then vitrified in CV 6 group CV7.,<td>CV7</td><td>266</td><td>85</td><td>82 (97)</td><td>3 (3)</td><td>-</td><td>90</td><td>87 (97)</td><td>3 (3)</td><td>-</td><td>91</td><td>89 (98)</td><td>2 (2)</td><td>-</td>,<td>CV2</td><td>275</td><td>84</td><td>79 (94)</td><td>5 (6)</td><td>-</td><td>96</td><td>85 (88)</td><td>11 (12)</td><td>a, b</td><td>95</td><td>81 (85)</td><td>14 (15)</td><td>a, b</td>", Viable follicles , 10% EG in DPBS + 0.5 M sucroseâ+â20% FBS group , EG plus DMSO in ascending concentrations ,0,
edin,5661,2759629,Significantly increased,"Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.", dorsiflexion , conventionally immobilized in palmar flexion and ulnar deviation (PF) , dorsiflexed-immobilized method (DF) ,0,
edin,5506,5707653,Cannot tell based on the abstract,, Formula intakes , Standard formula , Partially Hydrolysed Whey Formula ,0,
edin,5506,5707653,No significant difference,"Secondary outcomes were the frequency of regurgitation episodes, growth rates (weight, length, and head circumference, measured at week 0 and 4), and formula intakes.,Mean formula intakes were also similar in the test (742 mL/day) and the control (738 mL/day) groups", Formula intakes , Standard formula , Partially Hydrolysed Whey Formula ,0,
edin,5523,4144850,Cannot tell based on the abstract,, Open defecation , Control , Total Sanitation Campaign ,0,
edin,5523,4144850,Significantly decreased,"Although on average fewer households in intervention villages were likely to report daily open defecation compared to control villages for adult men (75% intervention versus 84% control; mean difference: 9.5%; p-valueâ=â0.001), adult women (73% intervention versus 83% control; mean difference: 10%; p-value<0.001), and children <5 years (84% intervention versus 89% control; mean difference: 5%; p-valueâ=â0.014), these reductions in reported open defecation behaviors were smaller than the gains in IHL availability.", Open defecation , Control , Total Sanitation Campaign ,0,
edin,5653,3176493,Cannot tell based on the abstract,, maternal immune responses , placebo , praziquantel ,0,
edin,5653,3176493,No significant difference,"Comparing maternal treatment arms, praziquantel during pregnancy had no significant effect on any specific cytokine response in cord blood. That is, the differences between the placebo and praziquantel groups seen among maternal responses were not seen among the cord responses (Figure 2A and 2B).", maternal immune responses , placebo , praziquantel ,0,
edin,5557,5133227,Significantly increased,"In the tube-exchanger group, the success rate of NGT insertion on the first attempt was 92%, which is significantly higher than 68%, the rate in the control group (P = 0.007).", Success rate of NGT insertion , Control , Tube-exchanger ,0,
edin,5607,4030328,Cannot tell based on the abstract,, Saccadic amplitude gain , Ketamine  , Risperidone + saline ,0,
edin,5607,4030328,Significantly decreased,Reduced amplitude gain was observed for risperidone-treated groups compared with the other groups. No other significant main effects or interactions were observed., Saccadic amplitude gain , Ketamine  , Risperidone + saline ,0,
edin,5742,4119719,Cannot tell based on the abstract,, Modified Barthel Index (MBI) after 3 months , placebo , 4 Channel Functional Electrical Stimulation (FES) ,0,
edin,5742,4119719,Significantly increased,"To compare the long-term effects of FES, all of the measurements were reassessed 3 months after the 3-week treatment had ended. A total of 37 came back, with 13 from the four-channel group and 12 each from the placebo and the dual-channel groups. Eight subjects did not come back (3 had moved out of the city, 3 had lost contact, and 2 refused). Almost all of the subjects in all 3 groups demonstrated further improvement since the 3-week treatment had finished, but significant differences were found only between the four-channel and placebo groups in terms of BBS (P = 0.028) and MBI (P = 0.047). At that point 68.8% of those in the four-channel group walked independently compared with 40% of those in the placebo group and 35.7% of the dual-channel group.", Modified Barthel Index (MBI) after 3 months , placebo , 4 Channel Functional Electrical Stimulation (FES) ,0,
edin,5624,4476212,Significantly increased,"Based on the present results, it can be concluded that the 14-day coenzyme Q10 supplementation (5mg.kg-1.day-1) is more effective than the acute supplementation to overcome the exercise-induced adverse responses in some oxidative, inflammatory and biochemical parameters. Therefore, short-term coenzyme Q10 supplementation is recommended to reduce exercise-induced adverse consequences.", overcome the exercise-induced adverse responses , acute supplementation of Q10 , 14-day coenzyme Q10 supplementation (5mg.kg-1.day-1) ,0,
edin,5673,4392433,Significantly decreased,"Vorapaxar also significantly reduced the composite of CV death, MI, stroke, and urgent coronary revascularization (10.1% versus 11.8%, HR, 0.83; 95% CI 0.76 to 0.90; P<0.001),", urgent coronary revascularization , placebo , Vorapaxar ,0,
edin,5694,5019971,Cannot tell based on the abstract,, vWF , unchanged cART regimen , maraviroc intensification ,0,
edin,5694,5019971,No significant difference,"To assess the effect of maraviroc on immune activation and inflammation, we measured T cell activation (defined as either CD38 and HLA-DR double positivity or positivity for CD95) of CD4+ and CD8+ T cells, the inflammation and coagulation markers hsCRP, D-dimer and vWF and the expression of CD40 and CD169 in monocytes (defined by CD14 positivity). No significant differences in change were found between these variables when comparing the intervention to control (data not shown).", vWF , unchanged cART regimen , maraviroc intensification ,0,
edin,5748,2364538,Cannot tell based on the abstract,, better define the labial microflora , control group C (no panty liner wear) , panty liner B (AlwaysÂ® non-deodorant) ,0,
edin,5748,2364538,No significant difference,"After 6 months use of panty liners the frequencies (and densities) of the selected microorganisms in these two sites had not changed compared to controls, and fatty acid analyses of vaginal secretions gave no evidence of shifts in the microbial flora.", better define the labial microflora , control group C (no panty liner wear) , panty liner B (AlwaysÂ® non-deodorant) ,0,
edin,5597,4355974,Cannot tell based on the abstract,, Days limited activity from asthma	 , Control , BostonBreathes system ,0,
edin,5597,4355974,No significant difference,<td>Days limited activity from asthma</td><td>0.6</td><td>â0.2</td><td>0.99</td><td>2.0</td><td>â1.8</td><td>0.13</td><td>0.14</td>, Days limited activity from asthma	 , Control , BostonBreathes system ,0,
edin,5654,3176493,No significant difference,"Despite strong effects on maternal infection intensity and maternal immune responses, praziquantel treatment of infected women during pregnancy had no effect on anti-schistosome immune responses among offspring by age one year.", immune responsiveness of uninfected offspring , placebo , praziquantel ,0,
edin,5528,4608626,Significantly decreased,"In the music therapy group, the time for completion of the Japanese Raven's Colored Progressive Matrices was significantly reduced (p = 0.026), and the results obtained from interviewing the patients' caregivers revealed a significant decrease in the Neuropsychiatric Inventory score (p = 0.042) and a prolongation of the patients' sleep time (p = 0.039).", Neuropsychiatric Inventory score , Control , Singing Training ,0,
edin,5545,4913581,Significantly decreased,"Supplemented cows showed a lower risk for OS, as reflected by a lower OS index (P = .036),", Oxidative stress index , Control , Antioxidant supplementation ,0,
edin,5660,2759629,Cannot tell based on the abstract,, tilt at final check up , conventionally immobilized in palmar flexion and ulnar deviation (PF) , dorsiflexed-immobilized method (DF) ,0,
edin,5660,2759629,Significantly increased,At final follow-up 25 patients (73.52%) of DF group had 13 to 33Â° radial tilt as compared to 14 patients (46.7%) in PF group (P value = 0.002561)., tilt at final check up , conventionally immobilized in palmar flexion and ulnar deviation (PF) , dorsiflexed-immobilized method (DF) ,0,
edin,5534,2876942,No significant difference,Time of eye opening after discontinuation of sevoflurane showed no significant differences between both groups., Eye opening time  , Control , Ketamine ,0,
edin,5616,3487501,No significant difference,There were no significant differences in impeding saliva leakage between the three experimental groups (P>0.05)., Leakage , Guttaflow system  , Lateral compaction ,0,
edin,5744,4060171,No significant difference,"When accounting for missing values with a multiple imputation approach, we found a tendency toward a difference in both the compliance scale and PANSS favoring the system-oriented therapy, although it did not reach statistical significance.", improvement of medical compliance in patients with schizophrenia , reference intervention , system-oriented therapy ,0,
edin,5732,3956097,Significantly increased,"Also, the comparison of the scores of the eight aspects of patientsâ life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain. All differences were statistically significant yet, the difference regarding the aspects of psychological health and general well-being were not significant.", social functioning , before rehabilitation program , after rehabilitation program ,0,
edin,5707,5887937,Cannot tell based on the abstract,, injection site reactions (ISRs) , treatment arms with repeated switches (pooled switched) , continued treatment arms (pooled continued) ,0,
edin,5707,5887937,No significant difference,"The proportion of patients with at least 1 treatmentâemergent AE during TP2 was similar between pooled switched (36.7%) and pooled continued (34.9%) treatment groups. ISRs were treatmentâemergent AEs with the highest incidence in pooled switched and pooled continued treatment groups (4.6% vs 4.3%) followed by pharyngitis (2.6% vs. 3.3%), nasopharyngitis (2.0% vs. 2.7%), headache (2.6% vs. 1.7%) and viral upper respiratory tract infection (2.6% vs. 1.3%, Table 3). The majority of ISRs were mild in severity in both groups (4.1% vs. 4.0%), and none were severe.", injection site reactions (ISRs) , treatment arms with repeated switches (pooled switched) , continued treatment arms (pooled continued) ,0,
edin,5681,3721088,Cannot tell based on the abstract,, feasibility of procedure in sub-acute stroke patients admitted to a rehabilitation center , computer-based testing , computer-based prism adaptation (PA) ,0,
edin,5681,3721088,Significantly increased,"Regarding time for test completion, all tests were performed significantly faster (total time) after PA, see Table 2. Additionally, when addressing the search-times (Table 2) on either the ipsilesional as well as the contralesional side of the stimulus-sheets presented on the tablet, patients performed significantly faster post PA in the OC.", feasibility of procedure in sub-acute stroke patients admitted to a rehabilitation center , computer-based testing , computer-based prism adaptation (PA) ,0,
edin,5514,4994668,Cannot tell based on the abstract,, Colectomy rates , Ciclosporin , Infliximab ,0,
edin,5514,4994668,No significant difference,"urthermore, there was also no significant difference between allocated groups in colectomy rates (in-hospital: 29 [21%] of 135 patients in the infliximab group vs 34 [25%] of 135 patients in the ciclosporin group; at 3 months: 39 [29%] vs 41 [30%]; 12 months: 47 [35%] vs 61 [45%]; overall: 55 [41%] vs 65 [48%]; odds ratio [OR] 1Â·350 [95% CI 0Â·832 to 2Â·188]; p=0Â·223);", Colectomy rates , Ciclosporin , Infliximab ,0,
edin,5596,4355974,No significant difference,Emergency room or acute visits to a physician for asthma did not significantly change in either group., ER visits , Control , BostonBreathes system ,0,
edin,5649,3903148,Cannot tell based on the abstract,, sleep efficiency after 2âweeks , near sea level , high altitude ,0,
edin,5649,3903148,Significantly increased,"<td colspan=""1"" rowspan=""1"">Sleep efficiency (%)</td><td colspan=""1"" rowspan=""1"">86 (5)</td><td colspan=""1"" rowspan=""1"">82 (6)</td><td colspan=""1"" rowspan=""1"">â0.56 â1.21; 0.09</td><td colspan=""1"" rowspan=""1"">1/42/57</td><td colspan=""1"" rowspan=""1"">86 (5)</td><td colspan=""1"" rowspan=""1"">0.03 â0.78; 0.83</td><td colspan=""1"" rowspan=""1"">15/71/13</td><td colspan=""1"" rowspan=""1"">89 (4)</td><td colspan=""1"" rowspan=""1"">0.57 0.04; 1.09</td><td colspan=""1"" rowspan=""1"">59/41/0</td>,hese differences are indicators of poorer sleep at altitude than at near sea level. In contrast, sleep onset latency, stage N1 sleep and wake after sleep onset were possibly lower; and sleep efficiency (figure 2A) was possibly higher after 2âweeks at altitude than on the baseline night (table 2).", sleep efficiency after 2âweeks , near sea level , high altitude ,0,
edin,5511,4994668,Cannot tell based on the abstract,, Crohn's and Ulcerative Colitis Questionnaire scores , Ciclosporin , Infliximab ,0,
edin,5511,4994668,No significant difference,"There was no significant difference in quality-adjusted survival between infliximab and ciclosporin: the observed mean total area under the CUCQ curve was 564Â·0 (SD 241Â·9) in the infliximab group and 587Â·0 (226Â·2) in the ciclosporin group (mean adjusted difference 7Â·9 [95% CI â22Â·0 to 37Â·8]; p=0Â·603).,There was no significant difference between groups in terms of CUCQ scores (mean adjusted difference in AUC/day of survivors 0Â·020 [95% CI â0Â·019 to 0Â·0581]; p=0Â·319", Crohn's and Ulcerative Colitis Questionnaire scores , Ciclosporin , Infliximab ,0,
edin,5508,4731919,Significantly increased,The intervention yielded effects on flossing frequency (pâ<â0.01) and flossing intentions (pâ<â0.01) at follow-up., Dental flossing , Control , Oral health promotion program + free dental treatment ,0,
edin,5567,5440538,Cannot tell based on the abstract,, Calcium levels , Control , Paricalcitol ,0,
edin,5567,5440538,No significant difference,"Overall, of the 29 children for whom data were available, 12 (41.4%) achieved two consecutive reductions of â¥30% from baseline in iPTH levels, and eight (27.6%), 25 (86.2%), and 16 (55.2%) achieved final iPTH, calcium, and phosphorus levels within KDOQI target ranges, respectively.,Changes in laboratory measures, including eGFR, creatinine, calcium, and phosphorus, over the 12-week double-blind period are summarized in Fig.Â 4. There were no statistically significant differences for any of the laboratory assessments between the paricalcitol and placebo groups at any of the time points or overall.Fig 4", Calcium levels , Control , Paricalcitol ,0,
edin,5588,3985324,Cannot tell based on the abstract,, HCV infection , Short-term buprenorphine-naloxone , Long-term buprenorphine-naloxone ,0,
edin,5588,3985324,No significant difference,"Overall, in China, short-term versus long-term B-N treatment was not associated with HCV infection (HR = 0.95; 95% CI, 0.45 to 1.97; P = 0.9) with the Kaplan Meier curve shown in Figure 1 by treatment arm", HCV infection , Short-term buprenorphine-naloxone , Long-term buprenorphine-naloxone ,0,
edin,5658,2759629,Significantly increased,"All fractures united. Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.", radial-ulnar deviation , conventionally immobilized in palmar flexion and ulnar deviation (PF) , dorsiflexed-immobilized method (DF) ,0,
edin,5520,4895420,Cannot tell based on the abstract,, Resolving lesions &amp;gt;27 mm , clarithromycin + rifampin , Gallium maltolate ,0,
edin,5520,4895420,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Resolved lesions &gt;27</td><td align=""char"" char="" "" colspan=""1"" rowspan=""1"">17/25 (68%)</td><td align=""char"" char="" "" colspan=""1"" rowspan=""1"">2/6 (33%)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">.17</td>,mong foals with smaller lesions (<27Â mm), proportions resolving were similar for both groups (TableÂ 2). Although the proportion resolving among the foals with larger lesions (ie, â¥27Â mm) was lower for the GaMâtreated foals than the CLRâtreated foals, this difference was not significant (TableÂ 2).", Resolving lesions &amp;gt;27 mm , clarithromycin + rifampin , Gallium maltolate ,0,
edin,5527,4608626,Significantly decreased,"n the music therapy group, the time for completion of the Japanese Raven's Colored Progressive Matrices was significantly reduced (p = 0.026),", Raven's Colored Progressive Matrice completion time , Control , Singing Training ,0,
edin,5710,3343759,Significantly increased,"Patients with a higher level of education (>12 years) improved more on ANELT by day 21 than those with <12 years of education (3.4 vs. 1.0, respectively).", improvment in ANELT by day 21 , &amp;lt;12 years of education , higher level of education (&amp;gt;12 years) ,0,
edin,5570,3337377,Cannot tell based on the abstract,, Successful epidural space identification , Conventional technique , EpidrumÂ® ,0,
edin,5570,3337377,Significantly increased,"The ED group showed a lower failure rate, fewer cases of more than 2 attempts, a shorter time needed to identify the epidural space, greater ease of the procedure, and better satisfaction scores of the procedure than in the C group, with statistical significance (Table 2).", Successful epidural space identification , Conventional technique , EpidrumÂ® ,0,
edin,5591,4737269,Cannot tell based on the abstract,, Ascent  duration  , Full bifocals  , Intermediate addition multifocals ,0,
edin,5591,4737269,No significant difference,"Gait safety parameters were similar between intermediate PALs and distance single vision lenses for all gait safety parameters measured: vertical toe clearance on ascent (Wald Ï2Â =Â 0.4, pÂ =Â 0.54) and its variability (Wald Ï2Â =Â 0.1, pÂ =Â 0.93), ascent duration (Wald Ï2Â =Â 1.4, pÂ =Â 0.25", Ascent  duration  , Full bifocals  , Intermediate addition multifocals ,0,
edin,5586,4805129,Cannot tell based on the abstract,, Adverse effects , IV iron isomaltoside 1000 (1000 mg) , IV iron isomaltoside 1000 (500 mg) ,0,
edin,5586,4805129,No significant difference,There was no statistical significant difference in the proportion of patients experiencing an adverse event (AE) between Groups A and B [Group A: 95/228 (41.7%); Group B: 53/117 (45.3%)] (Table, Adverse effects , IV iron isomaltoside 1000 (1000 mg) , IV iron isomaltoside 1000 (500 mg) ,0,
edin,5711,3343759,No significant difference,"There was no difference in the degree of aphasia at baseline except for fluency, which was higher in the group responding to treatment.", aphasia types , control , very early speech and language therapy (SLT) ,0,
edin,5577,3003523,Cannot tell based on the abstract,, Short-Form 36-Items improvement , Control , Certolizumab 400 mg ,0,
edin,5577,3003523,Significantly increased,"ignificantly more patients treated with CZP plus MTX than PBO plus MTX also reported improvements in SF-36 MCS equal to or greater than the MCID from weeks 12 to 52 (Table 2; P < 0.05).,Changes from baseline for all SF-36 domains were statistically significant for CZP versus PBO at Weeks 12 and 52; P < 0.05.", Short-Form 36-Items improvement , Control , Certolizumab 400 mg ,0,
edin,5512,4994668,Cannot tell based on the abstract,, Short-Form Six-Dimension scores , Ciclosporin , Infliximab ,0,
edin,5512,4994668,No significant difference,"There was no significant difference between groups in terms of CUCQ scores (mean adjusted difference in AUC/day of survivors 0Â·020 [95% CI â0Â·019 to 0Â·0581]; p=0Â·319; figure 3A), SF-6D scores (mean adjusted difference 0Â·005 [95% CI â0Â·025 to 0Â·035]; p=0Â·737; figure 3B), or EQ-5D scores (QALY mean adjusted difference 0Â·021 [95% CI â0Â·032 to 0Â·096]; p=0Â·350; figure 3C).", Short-Form Six-Dimension scores , Ciclosporin , Infliximab ,0,
edin,5640,4307639,Significantly increased,"Compared with the no interest group, the committed with interest group were more likely to be personal computer users (odds ratio (OR)â=â2.78), physically active (ORâ=â1.03) and had higher levels of loneliness (ORâ=â1.16).", loneliness score , no interest group , committed with interest group ,0,
edin,5628,2147023,Cannot tell based on the abstract,, response rates , study team , directly by the GP ,0,
edin,5628,2147023,Significantly increased,"Two thirds of these (52,948) were sent directly by the GP, and one third (24,872) were sent by the study team, on the GP's behalf. In total, 22,251 questionnaires (28.6%) were returned, with slightly higher response rates achieved by the direct (15,775, or 29.8%) than indirect method (6,470, or 26.0%).", response rates , study team , directly by the GP ,0,
edin,5544,3952721,Cannot tell based on the abstract,, Adverse effects  , Control , Fluticasone furoate + vilanterol ,0,
edin,5544,3952721,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1""><bold>âAdverse events/serious adverse events</bold></td><td align=""center"" colspan=""1"" rowspan=""1"">0</td><td align=""center"" colspan=""1"" rowspan=""1"">0</td>,There were no serious adverse events or subject withdrawals due to AEs. No AEs were severe and all resolved during the study.", Adverse effects  , Control , Fluticasone furoate + vilanterol ,0,
edin,5611,4030328,Cannot tell based on the abstract,, Clinician Administered Dissociative States Scale scores , Placebo , Ketamine   ,0,
edin,5611,4030328,Significantly increased,"CADSS total scores and the subscales of amnesia, and derealisation were significantly higher in the ketamine-treated groups compared with the placebo groups (all P<0.01).", Clinician Administered Dissociative States Scale scores , Placebo , Ketamine   ,0,
edin,5612,3487501,No significant difference,There were no significant differences in impeding saliva leakage between the three experimental groups (P>0.05)., Leakage , Control , Lateral compaction ,0,
edin,5602,5506697,Significantly increased,"OFC-treated patients demonstrated an improvement over placebo at endpoint with respect to mean change from baseline in the patient-rated KINDL-R Self-esteem subscale score (pÂ =Â 0.028), and in the parent KINDL-R ratings of emotional well-being (pÂ =Â 0.020),", Parent rated emotional well being , Control  , Olanzapine + fluoxetine ,0,
edin,5766,5548257,No significant difference,The vitamin D supplementation did not have any significant effect on the exercise capacity (p-value=0.175) or the saturation of oxygen (p-value = 0.635)., exercise capacity , Before vitamin D supplementation in COPD patients , after vitamin D supplementation in COPD patients ,0,
edin,5773,3281341,Significantly increased,The level of plasma Î²-endorphin after the administration of omeprazole was significantly greater than at the start of the study and following the placebo. Responders to omeprazole had an average lower Î²-endorphin plasma concentration than subjects who failed to respond to this therapy. Subjects with symptoms in class III (according to the Canadian Cardiovascular Society classification) after omeprazole administration had a greater Î²-endorphin plasma level than subjects in class II for anginal symptom severity., plasma level of Î²-endorphin after 2-week omeprazole administration , class II anginal symptoms , class III anginal symptoms ,0,
edin,5662,2759629,Significantly increased,"Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.", palmar flexion , conventionally immobilized in palmar flexion and ulnar deviation (PF) , dorsiflexed-immobilized method (DF) ,0,
edin,5771,3281341,Cannot tell based on the abstract,, relationships between the Î²-endorphin plasma level and the course of the treadmill stress test , placebo , double omeprazole dose ,0,
edin,5771,3281341,No significant difference,"We did not find any statistically significant relationships between the Î²-endorphin plasma level and the course of the treadmill stress test, either at the start of the study or after therapy with omeprazole or the placebo.", relationships between the Î²-endorphin plasma level and the course of the treadmill stress test , placebo , double omeprazole dose ,0,
edin,5504,5707653,Cannot tell based on the abstract,, Body weight , Standard formula , Partially Hydrolysed Whey Formula ,0,
edin,5504,5707653,No significant difference,No difference in body weight or in the other anthropometric parameters was seen between the two groups at the end of the trial (Table 2), Body weight , Standard formula , Partially Hydrolysed Whey Formula ,0,
edin,5555,2994546,Cannot tell based on the abstract,, Task analyses usage	 , Control , RSI QuickScan intervention ,0,
edin,5555,2994546,Significantly increased,"<td align=""left"">- Mean costs (SD)</td><td align=""left"">0.75 (6.68)</td><td align=""left"">0.00 (0.00)</td><td></td><td align=""left"">0.75 (0.02; 1.49)</td>,There were significant between-group differences in utilization rates for the ""Education on the Prevention of RSI for Employees"", the training ""RSI and Stress"", the eyesight check, and task analysis (Table 3).", Task analyses usage	 , Control , RSI QuickScan intervention ,0,
edin,5775,5415292,Cannot tell based on the abstract,, scores on pre-tests , noncompleters , completers ,0,
edin,5775,5415292,Significantly increased,"We compared completers and dropouts on baseline sociodemographic characteristics and pre-test scores on knowledge. Using Ï2 and 2-sample t tests, significant association for differences by age or gender was determined between completers and noncompleters. However, those who completed had higher scores on pre-tests compared to dropouts at post-test (P = .03)", scores on pre-tests , noncompleters , completers ,0,
edin,5517,4895420,Cannot tell based on the abstract,, Mortality , clarithromycin + rifampin , Gallium maltolate ,0,
edin,5517,4895420,No significant difference,"our foals died. The cause of death was attributed to infection with R.Â equi in all these foals. One foal (a GaMâtreated foal) was euthanized because it developed colic, underwent celiotomy, and was found to have a septic mesenteric lymphadenitis caused by R.Â equi, and a mesenteric rent with small intestinal entrapment; necropsy revealed chronic, focal granulomatous pneumonia and subacute, multifocal hepatitis attributed to R equi on the basis of microbiologic culture; this foal had been treated for 15Â days. One of the CLR/rifampinâtreated foals was anesthetized for an orthopedic surgical procedure; this foal died during anesthesia, and death was attributed to respiratory failure resulting from bilateral necrotizing granulomatous pneumonia caused by R.Â equi infection; this foal had been treated for 2Â days.", Mortality , clarithromycin + rifampin , Gallium maltolate ,0,
edin,5752,2364538,No significant difference,No increased carriage of medically important species was detected for either site after 6 months of daily (average 7.8 h) panty liner use., increased carriage of medically important species after wearing panty liner , vagina , labia ,0,
edin,5664,2759629,Significantly increased,"All fractures united. Individual movement of dorsiflexion, palmar flexion, supination, pronation and radial-ulnar deviation were all significantly better in the dorsiflexed-immobilized group as compared with the palmar flexed immobilized group.", pronation , conventionally immobilized in palmar flexion and ulnar deviation (PF) , dorsiflexed-immobilized method (DF) ,0,
edin,5751,2364538,No significant difference,"After 6 months use of panty liners the frequencies (and densities) of the selected microorganisms in these two sites had not changed compared to controls, and fatty acid analyses of vaginal secretions gave no evidence of shifts in the microbial flora.", fatty acid analyses of vaginal secretions , control group C (no panty liner wear) , panty liner wear groups A (AlwaysÂ® deodorant) ,0,
edin,5715,3750766,Cannot tell based on the abstract,, safety of multi-coil rTMS affect on the dorsal anterior cingulate cortex , single coil rTMS , multi-coil rTMS ,0,
edin,5715,3750766,Significantly increased,"The results provided here indicate that multi-coil shaped field rTMS directed toward the dACC might provide a safe and effective means of alleviating both acute and chronic pain.,Multi-coil repetitive transcranial magnetic stimulation was successfully used to reliably and safely affect the dorsal anterior cingulate cortex, a deep brain structures that is critical to pain perception, but which cannot be selectively reached with single-coil approaches", safety of multi-coil rTMS affect on the dorsal anterior cingulate cortex , single coil rTMS , multi-coil rTMS ,0,
edin,5636,5712123,Significantly decreased,"Neither Duloxetine nor etoricoxib individually had effect on pain with movement, while their combination revealed a significant reduction in pain scores over the entire postoperative period at rest and on movement. Etoricoxib showed a significant decrease in pain at all times at rest when compared with group P, while it showed significant pain decrease only at 0, 2 and 4Â h when compared with group D.", postoperative pain , placebo , duloxetine 60 and etoricoxib 120mg (group D/E) ,0,
edin,5580,3003523,Significantly decreased,"Patients treated with CZP plus MTX reported significant (P < 0.001), clinically meaningful improvements in HRQoL at the first assessment (week 12); reductions in fatigue, disease activity and pain and improvements in physical function were reported at week 1.,<td align=""left"">MCS</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>", Pain , Control , Certolizumab 400 mg ,0,
edin,5709,5887937,Cannot tell based on the abstract,, safety , two treatment arms with repeated switches (pooled switched) , continued treatment arms (pooled continued) ,0,
edin,5709,5887937,No significant difference,"ISRs were treatmentâemergent AEs with the highest incidence in pooled switched and pooled continued treatment groups (4.6% vs 4.3%) followed by pharyngitis (2.6% vs. 3.3%), nasopharyngitis (2.0% vs. 2.7%), headache (2.6% vs. 1.7%) and viral upper respiratory tract infection (2.6% vs. 1.3%, Table 3),Clinical laboratory parameters, vital signs, physical examination and ECG findings were all comparable for pooled continued and pooled switched groups; no patterns were evident that would suggest a relation to treatment or a potential safety concern.", safety , two treatment arms with repeated switches (pooled switched) , continued treatment arms (pooled continued) ,0,
edin,5631,2841147,Cannot tell based on the abstract,, responses to allergen challenge in mild asthmatics , placebo , selective phosphodiesterase 4 inhibitor (GSK256066) ,0,
edin,5631,2841147,No significant difference,"Methacholine reactivity at 24 hrs post allergen challenge was not different after treatment with GSK256066 compared to placebo; the PC20 was 0.31 compared to 0.39 mg/mL respectively, geometric mean (95% CI) doubling dose difference -0.31 (-1.18 to 0.57).", responses to allergen challenge in mild asthmatics , placebo , selective phosphodiesterase 4 inhibitor (GSK256066) ,0,
edin,5652,3176493,Cannot tell based on the abstract,, IgG4 , placebo , praziquantel ,0,
edin,5652,3176493,Significantly decreased,"For SEA-specific antibodies (Figure 1D), IgE levels were higher in the treated mothers than in the placebo group (p = 0.048) while IgG4 levels were lower in treated mothers compared to the placebo group (p = 0.001).", IgG4 , placebo , praziquantel ,0,
edin,5525,4144850,Cannot tell based on the abstract,, Helminth infections  , Control , Total Sanitation Campaign ,0,
edin,5525,4144850,No significant difference,"In the subsample of 1,150 children with stool collection, 5.7% (66/1150) had helminth infections and the majority (50/66) were Ascaris infections. All remaining infections were tapeworms; no children were infected with T. trichiura or hookworm. We observed no difference in helminth prevalence between intervention and control groups.,<td align=""left"" colspan=""1"" rowspan=""1"">Any helminth present</td><td align=""left"" colspan=""1"" rowspan=""1"">569</td><td align=""left"" colspan=""1"" rowspan=""1"">0.056</td><td align=""left"" colspan=""1"" rowspan=""1"">581</td><td align=""left"" colspan=""1"" rowspan=""1"">0.059</td><td align=""left"" colspan=""1"" rowspan=""1"">0.001 [â0.021 to 0.023]</td><td align=""left"" colspan=""1"" rowspan=""1"">â0.005 [â0.028 to 0.018]</td>", Helminth infections  , Control , Total Sanitation Campaign ,0,
edin,5505,5707653,Cannot tell based on the abstract,, Head circumference , Standard formula , Partially Hydrolysed Whey Formula ,0,
edin,5505,5707653,No significant difference,"Secondary outcomes were the frequency of regurgitation episodes, growth rates (weight, length, and head circumference, measured at week 0 and 4), and formula intakes.,No difference in body weight or in the other anthropometric parameters was seen between the two groups at the end of the trial (Table 2).", Head circumference , Standard formula , Partially Hydrolysed Whey Formula ,0,
edin,5656,3176493,Significantly increased,"Praziquantel treatment during pregnancy showed no effect on cytokine responses or antibodies levels to SWA or SEA either in cord blood or at age one year, except for IgG1 to SWA, which was elevated in infants of treated mothers, reflecting maternal levels.", IgG1 , placebo , praziquantel ,0,
edin,5769,5548257,No significant difference,"The mean FEV1 (p-value = 0.866), FVC (p-value = 0.475) and VC (p-value = 0.425) were not significantly different before and after intervention.", mean forced expiratory volume in one second (FEV1) , Before vitamin D supplementation in COPD patients , after vitamin D supplementation in COPD patients ,0,
edin,5627,4476212,Cannot tell based on the abstract,"Based on the present results, it can be concluded that the 14-day coenzyme Q10 supplementation (5mg.kg-1.day-1) is more effective than the acute supplementation to overcome the exercise-induced adverse responses in some oxidative, inflammatory and biochemical parameters.", inflammatory markers , placebo , coenzyme Q10 supplementation  ,0,
edin,5627,4476212,Significantly decreased,"In other word, compared with the placebo group, inflammatory markers were significantly lower in the group of CoQ10.", inflammatory markers , placebo , coenzyme Q10 supplementation  ,0,
edin,5529,4608626,Significantly increased,"In the music therapy group, the time for completion of the Japanese Raven's Colored Progressive Matrices was significantly reduced (p = 0.026), and the results obtained from interviewing the patients' caregivers revealed a significant decrease in the Neuropsychiatric Inventory score (p = 0.042) and a prolongation of the patients' sleep time (p = 0.039).", Sleep time , Control , Singing Training ,0,
edin,5530,4608626,Cannot tell based on the abstract,, Disability Assessment for Dementia score , Control , Singing Training ,0,
edin,5530,4608626,Significantly decreased,There was also a significant decrease in the DAD score (p = 0.002)., Disability Assessment for Dementia score , Control , Singing Training ,0,
edin,5502,5707653,Significantly decreased,"Compared to controls, the test group showed greater percentage changes in GErate (12.3% vs. 9.1%, p < 0.01).,Compared to a standard formula, a starch-thickened partially hydrolysed whey protein formula supplemented with Lactobacillus reuteri is more effective in decreasing the frequency of regurgitation and improving GErate, and can be of benefit to infants with FR.", Gastric emptying rate , Standard formula , Partially Hydrolysed Whey Formula ,0,
edin,5546,4913581,Cannot tell based on the abstract,, Glucose maximum concentration , Control , Antioxidant supplementation ,0,
edin,5546,4913581,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Glucose</td><td align=""left"" colspan=""1"" rowspan=""1"">mg/dL</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">76.2</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">23.4</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">76.7</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">14.7</td><td align=""center"" colspan=""1"" rowspan=""1"">NS</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">58.7</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">32.2</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">67.9</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">29.3</td><td align=""center"" colspan=""1"" rowspan=""1"">NS</td>,<td align=""left"" colspan=""1"" rowspan=""1"" style=""padding-left:10%"">Glucose (mg/dL)</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">243.6</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">106.8</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">278.4</td><td align=""char"" char=""."" colspan=""1"" rowspan=""1"">200.4</td><td align=""center"" colspan=""1"" rowspan=""1"">NS</td>", Glucose maximum concentration , Control , Antioxidant supplementation ,0,
edin,5765,5548257,No significant difference,Pulmonary function and exercise capacity did not improve with vitamin D supplementation in COPD patients., Pulmonary function , Before vitamin D supplementation in COPD patients , after vitamin D supplementation in COPD patients ,0,
edin,5758,5524701,Significantly increased,"When compared with the mannequin group, the SP simulation group showed a significantly higher average realism score (P=0.002).", realism score , mannequin-based scenarios  , SP-based scenarios ,0,
edin,5606,5506697,Cannot tell based on the abstract,, CDRS' depressed feelings improvement , Control  , Olanzapine + fluoxetine ,0,
edin,5606,5506697,Significantly increased,"Changes in CDRS-R Item scores from baseline to week 8 (mixed-model repeated measures),<td align=""left"">Depressed feelings (11)</td><td align=""char"" char=""("">4.6 (1.1)</td><td align=""char"" char=""("">â2.9 (0.1)</td><td align=""char"" char=""("">4.5 (1.1)</td><td align=""char"" char=""("">â2.4 (0.2)</td><td align=""char"" char=""."">0.005</td>", CDRS' depressed feelings improvement , Control  , Olanzapine + fluoxetine ,0,
edin,5615,3487501,No significant difference,There were no significant differences in impeding saliva leakage between the three experimental groups (P>0.05)., Leakage , Warm vertical compaction  , Lateral compaction ,0,
edin,5700,5019971,Significantly increased,"Twenty-one male patients with suppressed plasma HIV-RNA, on cART, had a known HIV infection for 9.2Â years (IQR 6.9â13.5) with abacavir use for 6.5Â years (2.8â9.3). A significantly increased FMD of 0.73% (IQR â0.25 to 1.70) was seen after maraviroc intensification compared to a decrease of â0.42% (IQR â1.89 to 0.25; pÂ =Â 0.049) in the control period. There was a negative relation between ÎFMD with ÎD-dimer (Î² â22.70, 95% CI â39.27; â6.13, pÂ =Â 0.011) and ÎCD95+ CD4+ T cells (Î² â0.16, 95% CI â0.28; â0.04, pÂ =Â 0.013), adjusted for age and duration of HIV.", D-dimer , unchanged cART regimen , maraviroc intensification ,0,
edin,5728,3956097,Significantly increased,"Our findings showed that there was a statistically significant increase in the mean score of the patientsâ life quality after rehabilitation. Also, the comparison of the scores of the eight aspects of patientsâ life quality before and after rehabilitation revealed that life quality improved in the following directions: physical functioning, limitation of physical health, limitation of psychological health, energy, social functioning, and physical pain. All differences were statistically significant yet, the difference regarding the aspects of psychological health and general well-being were not significant.", improvement in the quality life of heart failure patients , before rehabilitation program , after rehabilitation program ,0,
edin,5716,3750766,Cannot tell based on the abstract,, reduction in acute induced pain , placebo , multi-coil rTMS ,0,
edin,5716,3750766,No significant difference,"Correlating the PET activity ratio with the averaged change in NRS pain ratings during the first 2Â minutes (the time period over which H215O PET is most sensitive due to the rapid decay) yielded a significant correlation coefficient of 0.61.,The 1Â Hz pulse frequency that showed analgesic effect in the acute pain/volunteer study was not effective for the treatment of chronic pain in fibromyalgia patients.,Similarly, despite being effective for acute pain in volunteers, the 4 coil 1Â Hz rTMS configuration did not produce a significant analgesic effect in the chronic pain population, but still generated similar sensory cues.", reduction in acute induced pain , placebo , multi-coil rTMS ,0,
edin,5745,4060171,Cannot tell based on the abstract,, completed follow-up , reference intervention , system-oriented therapy ,0,
edin,5745,4060171,Significantly increased,"There was a significantly greater proportion of the individual compared to the system-oriented group that did not complete follow-up (15/40 versus 4/30, P value 0.017).", completed follow-up , reference intervention , system-oriented therapy ,0,
edin,5537,2876942,Significantly decreased,The time of hospital discharge allowance in group M was longer than in group KM (P < 0.05)., Time for discharge , Control , Ketamine ,0,
edin,5513,4994668,Cannot tell based on the abstract,, EuroQol-5D scores , Ciclosporin , Infliximab ,0,
edin,5513,4994668,No significant difference,"There was no significant difference between groups in terms of CUCQ scores (mean adjusted difference in AUC/day of survivors 0Â·020 [95% CI â0Â·019 to 0Â·0581]; p=0Â·319; figure 3A), SF-6D scores (mean adjusted difference 0Â·005 [95% CI â0Â·025 to 0Â·035]; p=0Â·737; figure 3B), or EQ-5D scores (QALY mean adjusted difference 0Â·021 [95% CI â0Â·032 to 0Â·096]; p=0Â·350; figure 3C).", EuroQol-5D scores , Ciclosporin , Infliximab ,0,
edin,5625,4476212,Significantly decreased,"The acute coenzyme Q10 supplementation attenuated only the exercise-induced increase in response of the plasma CRP. The short-term (14-day) coenzyme Q10 supplementation attenuated the exercise-induced increase in response of the lactate, serum interleukin- 6, tumor necrosis factor-alpha, and CRP in male middle-distance runners.", exercise-induced increase in response of the plasma CRP , placebo , acute coenzyme Q10 supplementation  ,0,
edin,5526,4144850,Cannot tell based on the abstract,, Anemia , Control , Total Sanitation Campaign ,0,
edin,5526,4144850,No significant difference,"However, we found no differences between the randomized groups in anemia prevalence or growth outcomes.", Anemia , Control , Total Sanitation Campaign ,0,
edin,5746,4060171,Cannot tell based on the abstract,, Remission , reference intervention , system-oriented therapy ,0,
edin,5746,4060171,Significantly decreased,"LOCF revealed a significantly lower PANSS score on the remission items in the system-oriented group at follow-up, on average a score of 22 compared to 26 in the individual group, P value 0.036.", Remission , reference intervention , system-oriented therapy ,0,
edin,5757,4488565,Cannot tell based on the abstract,, efficacy of treating patients with chronic functional constipation , placebo , Lax-Asab powder ,0,
edin,5757,4488565,Significantly increased,The mean of weekly defecation times increased in both groups (pÂ =Â 0.001); from 1.8Â Â±Â 0.41 to 4.8Â Â±Â 1.12 times in patients receiving Lax-Asab and from 1.7Â Â±Â 0.44 to 2.2Â Â±Â 0.61 times in patients receiving placebo. A timeâtreatment interaction showed that this increase was significantly higher in the intervention group (pÂ <Â 0.0001). All the other measured outcomes concerning defecation difficulty were significantly improved in patients receiving Lax-Asab compared with placebo. The results are presented in TableÂ 1., efficacy of treating patients with chronic functional constipation , placebo , Lax-Asab powder ,0,
edin,5698,5019971,Cannot tell based on the abstract,, CCR5 expression in CD8+ T cells , unchanged cART regimen , maraviroc intensification ,0,
edin,5698,5019971,Significantly increased,"The study did not include a washout period, as maraviroc has a half-life of 13Â h. To minimize bias, we tested for a carry-over effect of maraviroc. Interestingly, in control period 2 (C2), a significant difference was still found when comparing the percentage of CD8+ CCR5+ expression in T cells between week 16 and baseline (16.3 vs. 8.3; pÂ =Â 0.021), suggesting a carry-over effect to the control period of arm A (C2).,A similar pattern was observed for CCR5 expression in CD8+ T cells (Fig.Â 3d) with a significantly increased expression of 12.5% (IQR 7.6â19.8) and 14.1% (IQR 6.1â17.7) in the intervention of arm A (from 8.3% at week 0; pÂ =Â 0.003) and arm B (from 11.6% at week 8; pÂ =Â 0.008), respectively.", CCR5 expression in CD8+ T cells , unchanged cART regimen , maraviroc intensification ,0,
edin,5538,3912320,Cannot tell based on the abstract,, Correct response rate for 500 Hz frequency , Control , Occupational noise ,0,
edin,5538,3912320,Significantly decreased,"FigureÂ 2 presents the firefighters responses in relation to the frequencies used. Very similar values were observed, and the mean percentages of correct answer for the 500, 2,000 and 4,000 Hz frequencies were 31.9%, 30.4% and 28.07%, respectively.,FigureÂ 4 compares the mean correct responses between the control and test groups according to the stimulus frequency. The control group obtained means that were 24%, 21% and 25% higher than those of the test group for the 500, 2,000 and 4,000 Hz frequencies, respectively.,A comparison of the responses between the groups revealed that the number of correct responses was greater in the control group at all frequencies (p-values were less than 0.01 using the Student's t-test).", Correct response rate for 500 Hz frequency , Control , Occupational noise ,0,
edin,5733,4319300,Cannot tell based on the abstract,, periodontal disease (PD)  , scaling and root planning (SRP) alone (control) , scaling and root planning (SRP) in combination with amoxicillin plus metronidazole ,0,
edin,5733,4319300,No significant difference,Both treatment modalities were successful on PD measurements and CAL over 3 and 6 months compared to the baseline (P < 0.05; respectively). No significant differences were observed between the groups (P > 0.05)., periodontal disease (PD)  , scaling and root planning (SRP) alone (control) , scaling and root planning (SRP) in combination with amoxicillin plus metronidazole ,0,
edin,5690,4329409,Significantly increased,"In active RA patients with an incomplete MTX response, CZP 200 mg every 2 weeks and 400 mg every 4 weeks were comparable and better than placebo for maintaining clinical response to week 4 following a 16-week, open-label run-in phase.", maintaining clinical response to week 4 following a 16-week , placebo + methotrexate , certolizumab pegol (CZP) 200 mg every 2 weeks + methotrexate ,0,
edin,5687,4883261,Significantly increased,The 90% CI of Cmax for HCQ is 103.8â142.3%; the AUC0â60 is 100â114.2% and AUC0ââ 100â115.5%. Both met the criteria according to the SFDAâs guidelines for bioequivalence. The relative bioavailability was 109.5% (according to AUC0â60d) and 110.7% (according to AUC0ââ)., AUC0â60d , reference formulation , single dose of 0.2g hydroxychloroquine sulfate tablets (0.1g/piece) with 250ml water in the test formulation ,0,
edin,5515,4994668,Cannot tell based on the abstract,, Adverse reactions  , Ciclosporin , Infliximab ,0,
edin,5515,4994668,No significant difference,"There was no significant difference between the two drugs in serious adverse reactions, or serious adverse events: 16 serious adverse reactions were noted in 14 participants given infliximab and ten in nine given ciclosporin (event ratio 0Â·938 [95% CI 0Â·590â1Â·493]; p=0Â·788; table 3).", Adverse reactions  , Ciclosporin , Infliximab ,0,
edin,5644,4307639,Significantly increased,"Compared with the no interest group, the committed with interest group were more likely to be personal computer users (odds ratio (OR)â=â2.78), physically active (ORâ=â1.03) and had higher levels of loneliness (ORâ=â1.16).", physically active , no interest group , committed with interest group ,0,
edin,5703,3892103,Cannot tell based on the abstract,, fidelity , self-monitoring of urine glucose (SMUG) , self-monitoring of blood glucose (SMBG)  ,0,
edin,5703,3892103,Invalid Prompt,, fidelity , self-monitoring of urine glucose (SMUG) , self-monitoring of blood glucose (SMBG)  ,1, I wasn't able to find significant data regarding fidelity 
edin,5747,4060171,Cannot tell based on the abstract,, average bed day consumption throughout the 12 months , reference intervention , system-oriented therapy ,0,
edin,5747,4060171,No significant difference,There was no significant difference in the duration of the index hospitalization in the two groups or the average bed day consumption throughout the 12 months., average bed day consumption throughout the 12 months , reference intervention , system-oriented therapy ,0,
edin,5563,5104394,Significantly decreased,"SB was associated with a 44% relative reduction in the planned food intake (p<0.001), a longer consecutive binge refractory period compared to regular binges (median: 48 hours versus 4 hours, p = 0.002) and an average relative reduction by 26% of binge number the day after each SB (p = 0.004).", Binge number , Control , Sequential binge intervention ,0,
edin,5522,4144850,Cannot tell based on the abstract,, Independent household latrines number , Control , Total Sanitation Campaign ,0,
edin,5522,4144850,Significantly increased,The intervention increased the coverage of any type of IHL facility by 20 percentage points (95% CI 13%â27%; p-value<0.001) in intervention villages compared to control villages (44.1% intervention versus 24.2% control). These results indicate that available IHLs were predominantly JMP defined improved sanitation facilities and very few rudimentary latrines or latrines defined as unimproved by the JMP were built., Independent household latrines number , Control , Total Sanitation Campaign ,0,
edin,5618,4356062,Cannot tell based on the abstract,, Viable follicles , 5% EG in DPBS + 0.5&amp;nbsp;M sucroseâ+â20% FBS , EG plus DMSO in ascending concentrations ,0,
edin,5618,4356062,Significantly increased,"5% EG in Dulbeccoâs phosphate- buffered saline (DPBS) with 0.5Â M sucroseâ+â20% FBS group CV1,EG plus DMSO in ascending concentrations or equilibrated in solutions of CV 5 then vitrified in CV 6 group CV7.,<td>CV1</td><td>232</td><td>75</td><td>69 (93)</td><td>6 (7)</td><td>-</td><td>84</td><td>73(86)</td><td>11 (14)</td><td>a, b</td><td>73</td><td>62 (83)</td><td>11 (17)</td><td>a, b</td>,<td>CV7</td><td>266</td><td>85</td><td>82 (97)</td><td>3 (3)</td><td>-</td><td>90</td><td>87 (97)</td><td>3 (3)</td><td>-</td><td>91</td><td>89 (98)</td><td>2 (2)</td><td>-</td>,There was no significant effect of the cryoprotectant type on the viability of primordial follicles Pâ>â0.05. Furthermore, when double cryoprotectant EG plus DMSO was used, primary and secondary follicles had higher viability than that achieved from single cryoprotectant Pâ<â0.05.", Viable follicles , 5% EG in DPBS + 0.5&amp;nbsp;M sucroseâ+â20% FBS , EG plus DMSO in ascending concentrations ,0,
edin,5666,3200258,Cannot tell based on the abstract,, therapeutic targets , HCT in the range 45%â50% , HCT &amp;lt; 45% ,0,
edin,5666,3200258,No significant difference,"At 6-month clinical visit in the standard arm (<45%), 130 (82.3%) patients have been treated with phlebotomy and 83 (52.5%) with HU as cytoreductive therapy and therapeutic targets were broadly respected in the two arms for the majority of patients (Table 2), mean HCT values being 44.4 Â± 2.3 versus 46.5 Â± 2.7. Although the levels of HCT determined by randomization are broadly maintained, there is some difficulty in maintaining HCT levels lower than 44%. Though the HCT levels were significantly different in the two arms, more than 25% of the subjects in each arm were not maintained in the therapeutic range allocated by randomization (Figure 4). At variance with HCT values, the levels of WBC and platelet count were not significantly different between the two treatment arms.", therapeutic targets , HCT in the range 45%â50% , HCT &amp;lt; 45% ,0,
edin,5573,3337377,Significantly increased,"The ED group showed a lower failure rate, fewer cases of more than 2 attempts, a lesser time to identify the epidural space, and better ease and satisfaction scores of procedure than the C group, with statistical significance.", Physician satisfaction  , Conventional technique , EpidrumÂ® ,0,
edin,5699,5019971,Cannot tell based on the abstract,, hsCRP , unchanged cART regimen , maraviroc intensification ,0,
edin,5699,5019971,No significant difference,"To assess the effect of maraviroc on immune activation and inflammation, we measured T cell activation (defined as either CD38 and HLA-DR double positivity or positivity for CD95) of CD4+ and CD8+ T cells, the inflammation and coagulation markers hsCRP, D-dimer and vWF and the expression of CD40 and CD169 in monocytes (defined by CD14 positivity). No significant differences in change were found between these variables when comparing the intervention to control (data not shown).", hsCRP , unchanged cART regimen , maraviroc intensification ,0,
edin,5718,3750766,Significantly decreased,"In fibromyalgia patients, the 20 rTMS sessions also produced a significant pain inhibition (43% reduction in NRS pain over last 24Â hours), but only when operated at 10Â Hz. This degree of pain control was maintained for at least 4Â weeks after the final session.", maintenance of reduction in chronic fibromyalgia pain at 4 weeks , placebo , multi-coil rTMS ,0,
edin,5723,5858425,Cannot tell based on the abstract,, intra-class correlation coefficients , control group (CG) received lessons as usual , Intervention group (IG) with standing desks and balance pads for 11 weeks ,0,
edin,5723,5858425,No significant difference,"Participants noted on average 40.7 (Â±6.5) min of standing time per day on their control sheet (self-report). The external observers recorded 40.4 (Â±4.9) min. The comparison of the two subjective assessments yielded similar results of self-report and external report (t(15) = â0.40, p = 0.70). The intra-class correlation coefficients between both subjective measure were excellent (ICC = 0.94). The Bland-Altman analysis is shown in Figure 2: Comparison between the two subjective measures (self vs. external report) of standing time using Bland-Altman plots. The chart presents the mean difference (intermediate line) and Â±1.96* standard deviation of difference (upper and lower line), showing the limits of agreement.", intra-class correlation coefficients , control group (CG) received lessons as usual , Intervention group (IG) with standing desks and balance pads for 11 weeks ,0,
edin,5604,5506697,Significantly increased,"OFC-treated patients demonstrated an improvement over placebo at endpoint with respect to mean change from baseline in the patient-rated KINDL-R Self-esteem subscale score (pÂ =Â 0.028), and in the parent KINDL-R ratings of emotional well-being (pÂ =Â 0.020), Self-esteem (pÂ =Â 0.030), and Family (pÂ =Â 0.006).", Parent rated self-esteem  , Control  , Olanzapine + fluoxetine ,0,
edin,5669,3585302,Cannot tell based on the abstract,, colicky symptoms , non-responders , responders ,0,
edin,5669,3585302,Invalid Prompt,, colicky symptoms , non-responders , responders ,1, I wasn't able to find results for colicky symptoms
edin,5696,5019971,Significantly increased,A significantly increased FMD of 0.73% (IQR â0.25 to 1.70) was seen after maraviroc intensification compared to a decrease of â0.42% (IQR â1.89 to 0.25; pÂ =Â 0.049) in the control period., flow-mediated dilatation (FMD) , unchanged cART regimen , maraviroc intensification ,0,
edin,5535,2876942,Significantly decreased,Postoperative agitation score and rescue fentanyl consumption were higher in group M than in group KM on admission to the PACU (P < 0.01)., Postoperative agitation , Control , Ketamine ,0,
edin,5768,5548257,No significant difference,The vitamin D supplementation did not have any significant effect on the exercise capacity (p-value=0.175) or the saturation of oxygen (p-value = 0.635)., saturation of oxygen during 6MWT , Before vitamin D supplementation in COPD patients , after vitamin D supplementation in COPD patients ,0,
edin,5576,3003523,Significantly increased,"<td align=""left"">MCS</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td>", Short-Form 36-Items improvement , Control , Certolizumab 200 mg ,0,
edin,5706,5887937,Cannot tell based on the abstract,, biosimilarity , ETN , GP2015 ,0,
edin,5706,5887937,No significant difference,"The EGALITY study confirmed biosimilarity of GP2015 and ETN during the first 12 weeks of treatment.10 The results observed during TP2 are of importance considering that EGALITY is the first study (and the only study to our knowledge), which actually demonstrates that multiple switches between a biosimilar (GP2015) and its originator (ETN) have no impact on efficacy, safety and immunogenicity, across the reported period.", biosimilarity , ETN , GP2015 ,0,
edin,5622,4356062,Cannot tell based on the abstract,, Viable follicles , 5% EGâ+â5% DMSO in DPBS with 0.5 M sucroseâ+â20% FBS group , EG plus DMSO in ascending concentrations ,0,
edin,5622,4356062,Significantly decreased,"<td>CV7</td><td>266</td><td>85</td><td>82 (97)</td><td>3 (3)</td><td>-</td><td>90</td><td>87 (97)</td><td>3 (3)</td><td>-</td><td>91</td><td>89 (98)</td><td>2 (2)</td><td>-</td>,EG plus DMSO in ascending concentrations or equilibrated in solutions of CV 5 then vitrified in CV 6 group CV7.,5% EGâ+â5% DMSO in DPBS with 0.5Â M sucroseâ+â20% FBS group CV5,", Viable follicles , 5% EGâ+â5% DMSO in DPBS with 0.5 M sucroseâ+â20% FBS group , EG plus DMSO in ascending concentrations ,0,
edin,5679,3721088,Cannot tell based on the abstract,, total time taken to complete the test for Line bisection test (LB) , computer-based testing , computer-based prism adaptation (PA) ,0,
edin,5679,3721088,Significantly decreased,"The total time taken to complete the test improved significantly after PA for the OC, LC, as well as the LB.", total time taken to complete the test for Line bisection test (LB) , computer-based testing , computer-based prism adaptation (PA) ,0,
edin,5657,3176493,No significant difference,"Praziquantel treatment during pregnancy showed no effect on cytokine responses or antibodies levels to SWA or SEA either in cord blood or at age one year, except for IgG1 to SWA, which was elevated in infants of treated mothers, reflecting maternal levels.", SWA-specific IgE , placebo , praziquantel ,0,
edin,5674,4392433,Significantly increased,"In patients with prior MI or PAD who have not had a previous stroke or TIA, vorapaxar added to standard therapy is effective for longâterm secondary prevention of thrombotic CV events, while increasing moderate or severe bleeding.", longÃ¢â¬ï¿½term secondary prevention of thrombotic CV events , placebo , Vorapaxar ,0,
edin,5583,4805129,Cannot tell based on the abstract,, Iron concentration , Oral iron  , IV iron isomaltoside 1000 (500 mg) ,0,
edin,5583,4805129,Significantly increased,"There was a statistically significant larger increase in serum iron concentration from baseline to Week 1 and Week 2 in Group A compared with Group B (Week 1: P < 0.001; Week 2: P = 0.003) (TableÂ 4).,Similar results were observed when Group A1 was compared with Group B (Supplementary Table S1) and when Group A2 was compared with Group B at Week 2 (Supplementary Table S2).", Iron concentration , Oral iron  , IV iron isomaltoside 1000 (500 mg) ,0,
edin,5610,4030328,Significantly increased,Ketamine increased saccadic frequency and decreased velocity gain of SPEM (all P<0.01) but had no significant effects on PS or AS (all Pâ©¾0.07)., Smooth pursuit saccadic frequency , Placebo , Ketamine   ,0,
edin,5639,5712123,Significantly decreased,"ConcerningMorphine requirement after 24Â h.; it wassignificantly lower in the D/E group in comparison with groups P, E and D. It should be noted also that there was a significant decrease morphine requirement in both groups E and D.", morphine requirements , P group ," E, D and D/E groups ",0,
edin,5590,4737269,Cannot tell based on the abstract,, Ascent  vertical toe clearance variability  , Full bifocals  , Intermediate addition multifocals ,0,
edin,5590,4737269,No significant difference,"Gait safety parameters were similar between intermediate PALs and distance single vision lenses for all gait safety parameters measured: vertical toe clearance on ascent (Wald Ï2Â =Â 0.4, pÂ =Â 0.54) and its variability (Wald Ï2Â =Â 0.1, pÂ =Â 0.93), ascent duration (Wald Ï2Â =Â 1.4, pÂ =Â 0.25), heel clearance on descent (Wald Ï2Â =Â 0.7, pÂ =Â 0.42) and its variability (Wald Ï2Â =Â 2.4, pÂ =Â 0.12) and descent duration (Wald Ï2Â =Â 1.6, pÂ =Â 0.20).,As the participants were all well adapted PAL wearers, the intermediate bifocals not surprisingly provided gait safety parameters that were poorer than the intermediate PALs and/or distance single vision lenses (TableÂ 1).", Ascent  vertical toe clearance variability  , Full bifocals  , Intermediate addition multifocals ,0,
edin,5689,4329409,Cannot tell based on the abstract,," prior anti-TNF exposure at baseline, ESR ", placebo + methotrexate , certolizumab pegol (CZP) 400 mg every 4 weeks + methotrexate ,0,
edin,5689,4329409,Significantly decreased,"However, more patients who were randomized to the CZP treatment arms had prior anti-TNF exposure at baseline compared to placebo patients; patients with prior anti-TNF use at baseline had longer disease duration and lower ESR than those without (Table1)."," prior anti-TNF exposure at baseline, ESR ", placebo + methotrexate , certolizumab pegol (CZP) 400 mg every 4 weeks + methotrexate ,0,
edin,5916,1859980,Cannot tell based on the abstract,, Dihydrotestosterone concentrations , 50 grams of lipids  , 19 grams of lipids  ,0,
edin,5916,1859980,No significant difference,"<td align=""left"" colspan=""5"" rowspan=""1"">DHT</td>", Dihydrotestosterone concentrations , 50 grams of lipids  , 19 grams of lipids  ,0,
edin,5954,5937795,Significantly increased,"Confinement housed calves shed significantly more oocysts (P = 0.05), had higher plasma cortisol (P = 0.001), and required more supportive care (P = 0.0009) than calves in box stalls.", supportive care , box stalls , confinement housing ,0,
edin,5938,3916855,Significantly increased,"he findings showed that the reduction in serum ferritin level and the increments in haemoglobin, serum iron and transferrin saturation were found to be significant among children allocated to the vitamin A group compared to those allocated to the placebo group (p < 0.01).", haemoglobin , placebo group , vitamin A group ,0,
edin,5831,5228186,Significantly increased,SNP rs11185644 near the RXRA was significantly associated with 25(OH)D dose-response (Pâ=â1.01âÃâ10â4)., Vitamin D level , Calcium  , Vitamin D + Calcium ,0,
edin,5884,4065280,Cannot tell based on the abstract,, Non-inflammatory lesions , Control , Pantothenic acid ,0,
edin,5884,4065280,Significantly decreased,"<td align=""left"">&nbsp;Non-inflammatory</td><td align=""left"">41.2 (16.7)</td><td align=""left"">48.9 (33.7)</td><td align=""char"" char=""."">0.374</td>,Analysis of the number of non-inflammatory blemishes demonstrated a significant mean reduction in lesion count from baseline to week 12 in the study agent versus the placebo group (PÂ =Â 0.0162) (Fig.Â 3).", Non-inflammatory lesions , Control , Pantothenic acid ,0,
edin,5847,4608185,No significant difference,Systolic and diastolic blood pressure did not change significantly over the study for either the ChiRunning or control groups., Systolic blood pressure  , Control , Chi running program ,0,
edin,5869,3348575,Significantly decreased,"On ABPM, the week 14 mean changes from baseline in diastolic and systolic BP were also significantly greater with azilsartan over a 24-h period, and during the daytime, night-time and early morning.,These data demonstrate that once-daily azilsartan provides a more potent 24-h sustained antihypertensive effect than that of candesartan but with equivalent safety.", Systolic blood pressure   , Candesartan , Azilsartan  ,0,
edin,5943,3932017,Significantly increased,"Pulse wave velocity (PWV) and stiffness index (Î²) were remarkably greater (8.388âÂ±â3.254Â m/s vs. 7.269âÂ±â1.332Â m/s; 12.51âÂ±â14.16 vs.9.279âÂ±â2.871), while compliance coefficient (CC) decreased significantly in the diabetes group (0.802âÂ±â0.3094Â mm2/Kpa vs. 0.968âÂ±â0.3992Â mm2/Kpa) (Pâ<â0.05).", Pulse wave velocity (PWV) , control group , diabetes group ,0,
edin,5941,3932017,Cannot tell based on the abstract,, time of rotation peak displacement , control group , diabetes group ,0,
edin,5941,3932017,No significant difference,"In addition, the time difference of radial peak displacement (RD-TD) and the time of rotation peak displacement difference (ROT-DT) in the patient group presented earlier than in the healthy controls. No significant differences were found between the two groups as far as other variables were concerned.", time of rotation peak displacement , control group , diabetes group ,0,
edin,5924,5454908,Cannot tell based on the abstract,, galunisertib plus lomustine , placebo+lomustine , galunisertib plus lomustine ,0,
edin,5924,5454908,Invalid Prompt,, galunisertib plus lomustine , placebo+lomustine , galunisertib plus lomustine ,1, I believe that his question is wrong. You are asking for galunisertib plus lomustine in question stem and it repeats again in provided possibilities 
edin,5911,3327628,Cannot tell based on the abstract,, Medical survey response rate on the south , Control , Offering free continuing medical education ,0,
edin,5911,3327628,Significantly decreased,"<td align=""left"">âSouth</td><td align=""left"">14.1</td><td align=""left"">12.0</td><td align=""left"">16.1</td><td align=""left"">.001</td>,Across all specialties, the response rate among the control group (no offer of CME credit) was 16.6%, while among those offered the CME opportunity, the response rate was actually lower at 12.0% (Table 2).", Medical survey response rate on the south , Control , Offering free continuing medical education ,0,
edin,5912,3327628,Significantly decreased,"A total of 1214 out of 8477 potentially eligible physicians responded to our survey, for an overall response rate of 14.3%. The response rate among the control group (no offer of CME credit) was 16.6%, while among those offered the CME opportunity, the response rate was 12.0% (p < 0.0001).", Overall survey response rate  , Control , Offering free continuing medical education ,0,
edin,5932,3539107,Significantly increased,"Mean operating time and postoperative hospital stay were longer in the diverticulitis group (55.3 Â± 28.8 minutes vs. 41.4 Â± 17.8 minutes, 6.8 Â± 3.4 days vs. 4.9 Â± 1.5 days, P < 0.05).", Mean operating time , appendicitis group , diverticulitis group ,0,
edin,5964,5571924,Significantly increased,"The discrimination performance of the present model for high-risk patients with advanced CRN was better than that of the Asia-Pacific Colorectal Screening score (AUC = 0.678, P < .001) and Schroyâs CAN index (AUC = 0.672, P < .001).,The high-risk group had a 3.7-fold increased risk of advanced CRN compared to the low-risk group (1.1% vs. 4.0%, P < .001).", advanced colorectal neoplasia (CRN) , low-risk group , high-risk group ,0,
edin,5843,3376511,Significantly decreased,"The findings demonstrate that having less user control (ie, a tunneled version of the website) had a negative effect on usersâ perception of efficiency (F1,452 = 97.69, P < .001), but a positive effect on number of pages visited (F1,452 = 171.49, P < .001), time on the website (F1,452 = 6.32, P = .01), and knowledge gained from the website (F1,452 = 134.32, P < .001).", Time spent on the site , Low user control , High user control ,0,
edin,5799,4007144,Significantly increased,"Significant differences were found between men in the intervention and control armsâ reported ability to control their hostility and manage conflict (ARR 1.3, 95% CI 1.06-1.58), and participation in gendered household tasks (ARR 2.47, 95% CI 1.24-4.90).", Participation in household tasks , Control , Intimate partner prevention intervention ,0,
edin,5823,4723179,Cannot tell based on the abstract,, Fusional divergence improvement , Control , Sports Vision Training ,0,
edin,5823,4723179,No significant difference,"To the contrary, no significant difference was found in fusional divergence results (Ï2=2.513, p=0.285).", Fusional divergence improvement , Control , Sports Vision Training ,0,
edin,5950,3751685,Cannot tell based on the abstract,, Between-group differences in frailty at 3 months , usual health care and support services , interdisciplinary multifaceted treatment ,0,
edin,5950,3751685,No significant difference,Between-group differences in frailty were statistically significant at 12 months but not at 3 months., Between-group differences in frailty at 3 months , usual health care and support services , interdisciplinary multifaceted treatment ,0,
edin,5934,3539107,No significant difference,"The site of abdominal pain, fever, signs of localized peritonitis, accompanying gastrointestinal symptoms, and white blood cell count showed no differences between the two groups.", fever , appendicitis group , diverticulitis group ,0,
edin,5965,5571924,Cannot tell based on the abstract,, discrimination performance using AUC (Area under the receiver operating curve) for high risk patients , advanced CRN (ACN) index , final model ,0,
edin,5965,5571924,Significantly increased,"In the validation set, the discrimination performance of the final model was compared with that of the advanced CRN (ACN) index [14] and Asia-Pacific Colorectal Screening score (APCS) [12] using the AUC (Fig 7). The AUC of the final model was 0.716 (95% CI, 0.691â0.741), whereas that of the ACN index was 0.672 (95% CI, 0.645â0.699), and that of the APCS was 0.678 (95% CI, 0.651â0.705). The discrimination performance of the developed model for high-risk patients with advanced CRN was better than that of the ACN index (P < .001) or APCS (P < .001).", discrimination performance using AUC (Area under the receiver operating curve) for high risk patients , advanced CRN (ACN) index , final model ,0,
edin,5921,3411720,Cannot tell based on the abstract,, magnitude of the effect of zinc on rates of respiratory illness , zinc with multi-nutrients , zinc ,0,
edin,5921,3411720,No significant difference,"Upon examination of interaction effects ( Table 4 ), we found no evidence that concurrent supplementation with multi-nutrients influenced the magnitude of the effect of zinc on rates of diarrhea, respiratory illness, fever without localizing signs, or other illness.", magnitude of the effect of zinc on rates of respiratory illness , zinc with multi-nutrients , zinc ,0,
edin,5975,4682219,Cannot tell based on the abstract,, additional CIN lesions , HC2 or COBAS at baseline , both HC2 and COBAS at baseline ,0,
edin,5975,4682219,No significant difference,"<th colspan=""2"" rowspan=""3""></th><th colspan=""9"">COBAS</th>", additional CIN lesions , HC2 or COBAS at baseline , both HC2 and COBAS at baseline ,0,
edin,5963,5844554,Significantly increased,"However in the secure priming condition, WM performance was boosted in the n-back task for individuals who rated higher levels of attachment anxiety. In other words, the subliminal priming of the security led to increased WM capacity of individuals who rated higher levels of attachment anxiety.", WM capacity of individuals who rated higher levels of attachment anxiety , neutral priming conditions , secure conditions ,0,
edin,5968,5549592,Cannot tell based on the abstract,, saliva contamination effect on immediate bond strength , control , simplified conventional system Transbond XTâ¢ Light cure adhesive ,0,
edin,5968,5549592,Significantly decreased,The saliva contamination prior to the application of a hydrophobic simplified conventional adhesive system was responsible for decreasing the immediate bond strength values of brackets cemented on the dental enamel., saliva contamination effect on immediate bond strength , control , simplified conventional system Transbond XTâ¢ Light cure adhesive ,0,
edin,5966,5571924,Significantly increased,"The developed model had good discrimination (AUC = 0.726) and was internally validated (AUC = 0.713). The high-risk group had a 3.7-fold increased risk of advanced CRN compared to the low-risk group (1.1% vs. 4.0%, P < .001). The discrimination performance of the present model for high-risk patients with advanced CRN was better than that of the Asia-Pacific Colorectal Screening score (AUC = 0.678, P < .001) and Schroyâs CAN index (AUC = 0.672, P < .001).", discrimination performance using AUC (Area under the receiver operating curve) for high risk patients , Asia-Pacific Colorectal Screening score (APCS) , final model ,0,
edin,5944,3932017,Significantly increased,"Pulse wave velocity (PWV) and stiffness index (Î²) were remarkably greater (8.388âÂ±â3.254Â m/s vs. 7.269âÂ±â1.332Â m/s; 12.51âÂ±â14.16 vs.9.279âÂ±â2.871), while compliance coefficient (CC) decreased significantly in the diabetes group (0.802âÂ±â0.3094Â mm2/Kpa vs. 0.968âÂ±â0.3992Â mm2/Kpa) (Pâ<â0.05).", stiffness index (Î²) , control group , diabetes group ,0,
edin,5925,5454908,Cannot tell based on the abstract,, Reduction of plasma levels of TGF-Î²1 , galunisertib plus lomustine , galunisertib  ,0,
edin,5925,5454908,No significant difference,"No association was found between tissue pSMAD2 expression and TGF-Î²1 levels in plasma, FOXP3 in blood, or CD4+CD25+CD127â/LOFOXP3+ in plasma, collected at the time of study enrollment (Table S4b).,TGF-Î²1 levels were not changed over time (data not shown).", Reduction of plasma levels of TGF-Î²1 , galunisertib plus lomustine , galunisertib  ,0,
edin,5793,4825255,No significant difference,"The Visual Analogue Scale suggested that in the transitional stages (8-10 cm cervical dilation), the level of pain felt by the experimental group was meaningfully lower than that felt by the control group (p=0.03). However, this was not significantly different between the two groups at 3-4 cm cervical dilation and the second stage of childbirth.", VAS pain during second stage of labor , Control  , Prenatal education ,0,
edin,5891,5011602,Significantly increased,"After the intervention, both groups showed significant improvements in the forced vital capacity, forced expiratory volume in one second, 10-meter walking test, and six-minute walking test over the baseline results.", 10-minute walking test improvement  , Control , Intensive aerobic exercise ,0,
edin,5923,3411720,Significantly decreased,"Zinc supplementation reduced the hazard rate of diarrhea by 24% (4%â40%). By contrast, multi-nutrients seemed to increase this rate (HR; 95% CI: 1.19; 0.94â1.50), particularly in children with asymptomatic Giardia infection at baseline (2.03; 1.24â3.32).,We found no evidence that the efficacy of zinc supplements in reducing diarrhea rates is enhanced by concurrent supplementation with other micronutrients.", rate of diarrhea , multi-nutrients , zinc ,0,
edin,5903,3821116,Significantly decreased,Nausea frequency was also higher in the placebo group than the pregabalin group (P = 0.003)., Nausea  , Placebo , Pregabalin ,0,
edin,5877,4916104,Significantly increased,"12-week study: Lower-limb muscle strength, balancing capacity, and whole body reaction time significantly improved in the exercise group.", Whole body reaction time , Control , Exercise gaming ,0,
edin,5894,4339173,Significantly increased,"All the physical fitness tests were significantly improved after a single session of Thai massage, whereas only the sit and reach, and the sit-ups tests were improved in the control group.", Push-ups , Control , Thai massage  ,0,
edin,5796,4007144,No significant difference,"At follow-up, reported levels of physical and/or sexual IPV in the intervention arm had decreased compared to the control arm (ARR 0.52, 95% CI 0.18-1.51, not significant).", Partner physical violence  , Control , Intimate partner prevention intervention ,0,
edin,5880,4916104,Cannot tell based on the abstract,, Adverse events  , Control , Exercise gaming ,0,
edin,5880,4916104,No significant difference,"We confirmed the presence or absence of adverse events during exercise in each participant at every session.,No adverse events were observed during the 12-week training period.", Adverse events  , Control , Exercise gaming ,0,
edin,5952,5937795,No significant difference,"Calves in confinement had no significant differences in mean log oocysts enumerated per gram of fecal dry matter between CFC and IC samples (P = 0.6), nor were there diurnal variations in oocyst shedding (P = 0.1).", oocysts shedding , box stalls , confinement housing ,0,
edin,5845,3376511,Cannot tell based on the abstract,, Enjoyment , Low user control , High user control ,0,
edin,5845,3376511,No significant difference,"<td colspan=""1"" rowspan=""1""> Enjoyment </td><td colspan=""1"" rowspan=""1""> 1â7 </td><td colspan=""1"" rowspan=""1""> 4.9 (1.5) </td><td colspan=""1"" rowspan=""1""> 5.0 (1.4) </td><td colspan=""1"" rowspan=""1""> 0.72 </td><td colspan=""1"" rowspan=""1""> .40 </td>,Efficiency has a positive effect on website use, but effectiveness and enjoyment do not have a direct effect on website use (only partly confirming Hypothesis 1).", Enjoyment , Low user control , High user control ,0,
edin,5904,3821116,Cannot tell based on the abstract,, Vomiting , Placebo , Pregabalin ,0,
edin,5904,3821116,No significant difference,Vomiting frequency of the pregabalin group was 2.5% (one patient) and in the placebo group the figure was 12.5% (five patients) (P = 0.09)., Vomiting , Placebo , Pregabalin ,0,
edin,5783,4237982,Cannot tell based on the abstract,, Total adipose tissue in women , Control , Intensive lifestyle intervention ,0,
edin,5783,4237982,Significantly decreased,"If TAT loss is partitioned into its component parts, for females, 86% of the reduction was from SAT and 17% from VAT, while IMAT increased 3%. For males, the corresponding values were 70% from SAT, 27% from VAT, and 3% from IMAT. Thus, as a proportion of TAT loss, females have a greater reduction in SAT than males and males have a greater reduction in VAT than females (both P < 0.001). The IMAT difference is not statistically reliable.", Total adipose tissue in women , Control , Intensive lifestyle intervention ,0,
edin,5881,4065280,Significantly decreased,There was a significant mean reduction in total lesion count in the pantothenic acid group versus placebo at week 12 (PÂ =Â 0.0197)., Total lesion count , Control , Pantothenic acid ,0,
edin,5882,4065280,Significantly decreased,Mean reduction in inflammatory lesions was also significantly reduced and DLQI scores were significantly lower at week 12 in the pantothenic acid group versus placebo., Inflammatory lesions , Control , Pantothenic acid ,0,
edin,5906,3821116,Cannot tell based on the abstract,, Sedation , Placebo , Pregabalin ,0,
edin,5906,3821116,No significant difference,"None of the patients complained about other side effects such as: dizziness, sedation, headache or visionary disorder in this study.", Sedation , Placebo , Pregabalin ,0,
edin,5899,2650591,Significantly increased,Whole lung deposition was higher with RespimatÂ® SMI than with pMDI for untrained (37% of delivered dose vs 21% of metered dose) and trained patients (53% of delivered vs 21% of metered dose) (pSign-Test].15; pANOVA < = 0.05)., Lung deposition in trained patients  , Pressurized metered-dose inhalers , RespimatÂ® Soft Mistâ¢ ,0,
edin,5928,3539107,No significant difference,"The site of abdominal pain, fever, signs of localized peritonitis, accompanying gastrointestinal symptoms, and white blood cell count showed no differences between the two groups.", WBC counts , appendicitis group , diverticulitis group ,0,
edin,5788,5852865,Significantly increased,"In this study, we compared the changes in macular pigment over a 24-week supplementation period for two groups of 24 subjects each assigned to either of two supplement formulations, 20âmg/day of lutein or 20âmg equivalent free carotenoids of a combination of diacetate esters of the macular carotenoids. The latter group responded with a larger increase (0.0666âÂ±â0.0481) in macular pigment optical density than the former group (0.0398âÂ±â0.0430), driven largely by the older subjects.", Macular pigment optical density , Lutein , Diacetate esters of macular carotenoids ,0,
edin,5973,4429825,Cannot tell based on the abstract,, difference in the proportions of correct and incorrect trial arm allocations after vignettes standardization for intervention group , phase 1 , phase 2 ,0,
edin,5973,4429825,Cannot tell based on the abstract,, difference in the proportions of correct and incorrect trial arm allocations after vignettes standardization for intervention group , phase 1 , phase 2 ,0,
edin,5973,4429825,No significant difference,"Consequently, intervention arm men were incorrectly assigned to the control arm by reviewers because of the absence of a PSA test (21%) or other study-specific criteria which may have implied the absence of screening (9%), or because men were symptomatic at diagnosis (12%). Correct decisions about the control arm were also based on the absence of either a PSA test result (31%), or prostate cancer diagnosis (8%); or because men were symptomatic or had advanced disease at presentation (13%).Table 1,<td></td><td>b. Symptomatic, high PSA test result, locally advanced/metastatic disease, late presentation</td><td>13</td><td>0</td><td>0</td><td>23</td><td>0</td><td>2</td>", difference in the proportions of correct and incorrect trial arm allocations after vignettes standardization for intervention group , phase 1 , phase 2 ,0,
edin,5918,1859980,Cannot tell based on the abstract,, Dihydrotestosterone concentrations , 5 grams of lipids  , 19 grams of lipids  ,0,
edin,5918,1859980,Significantly increased,"<td align=""left"" colspan=""5"" rowspan=""1"">DHT</td>,<td align=""left"" colspan=""1"" rowspan=""1"">â<italic>C</italic><sub>max</sub> (nmol/l)</td><td align=""char"" char=""Â·"" colspan=""1"" rowspan=""1"">1Â·50 (65Â·8)</td><td align=""char"" char=""Â·"" colspan=""1"" rowspan=""1"">1Â·89 (53Â·7)</td><td align=""char"" char=""Â·"" colspan=""1"" rowspan=""1"">6Â·67 (45Â·7)</td><td align=""char"" char=""Â·"" colspan=""1"" rowspan=""1"">6Â·74 (49Â·3)</td>", Dihydrotestosterone concentrations , 5 grams of lipids  , 19 grams of lipids  ,0,
edin,5852,4608185,No significant difference,"Self-reported running-related injury (i.e. discomfort leading to a decrease in running) was similar between groups (ChiRunning, 4 [1.2 to 8.4] vs. control, 3 [0.7 to 7.1] injuries per 100Â h of running, pâ=â0.72)", Injury incidence  , Standard running program , Chi running program ,0,
edin,5897,4339173,Cannot tell based on the abstract,, Sit and reach , Control , Thai massage  ,0,
edin,5897,4339173,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1"">Sit and reach<sup># </sup>(cm)</td><td align=""center"" colspan=""1"" rowspan=""1"">21.45 Â± 5.50</td><td align=""center"" colspan=""1"" rowspan=""1"">23.06 Â± 5.20<sup>*</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">20.90 Â± 5.41</td><td align=""center"" colspan=""1"" rowspan=""1"">20.57 Â± 6.02</td><td align=""center"" colspan=""1"" rowspan=""1"">18.83 Â± 5.11</td><td align=""center"" colspan=""1"" rowspan=""1"">19.47 Â±4.74<sup>*</sup></td><td align=""center"" colspan=""1"" rowspan=""1"">19.28 Â± 5.04</td><td align=""center"" colspan=""1"" rowspan=""1"">20.80 Â± 5.04<sup>*</sup></td>,Significant improved when compared with the pre-test value (p < 0.05)

), whereas only the sit and reach, and sit-ups tests showed improvements in the control group.,<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">Sit and reach (cm) (n = 17)</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">1.61 Â± 1.65</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top""> 1.51 Â± 1.43</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">â0.1 (â1.17 to 0.98)</td>", Sit and reach , Control , Thai massage  ,0,
edin,5805,4562579,Cannot tell based on the abstract,, Leg blood flow , Control , Resistance exercise ,0,
edin,5805,4562579,No significant difference,"There was no effect of SR or SRÂ +Â RT on femoral artery diameter, leg blood flow, or mean arterial pressure. Heart rate was higher in the fed state as compared to the fasted state (PÂ <Â 0.0001) with no difference between the times when leg blood flow measurements were made on each leg.

Table 3", Leg blood flow , Control , Resistance exercise ,0,
edin,5876,4916104,Significantly increased,"Lower-limb muscle strength, balancing capacity, and whole body reaction time significantly improved in the exercise group.", Balancing capacity , Control , Exercise gaming ,0,
edin,5855,5013640,Significantly decreased,"In the univariable analysis, higher insulin (HRâ=â0.81 [0.67, 0.98] pâ=â0.03) and C-peptide (HRâ=â0.62 [0.39, 1.00]; pâ=â0.05) levels were associated with a longer PFS, while higher Hepatocyte Growth Factor (HGF; HRâ=â1.63 [1.06, 2.51] pâ=â0.03) and Osteopontin (OPN; HRâ=â1.56 [1.13, 2.15]; pâ=â0.01) levels were associated with a shorter PFS.", Progression-free survival , Low hepatocyte growth factor levels , High hepatocyte growth factor levels ,0,
edin,5792,4825255,No significant difference,"The Visual Analogue Scale suggested that in the transitional stages (8-10 cm cervical dilation), the level of pain felt by the experimental group was meaningfully lower than that felt by the control group (p=0.03). However, this was not significantly different between the two groups at 3-4 cm cervical dilation and the second stage of childbirth", VAS pain during 3-4 cm dilatation  , Control  , Prenatal education ,0,
edin,5830,3951509,Cannot tell based on the abstract,, Influenza risk , Control , Home Environment Interventions ,0,
edin,5830,3951509,Significantly decreased,"Compared to children from households not using improved stoves and not in the IHIP trial, children in IHIP intervention households had a relative risk (RR) for influenza-associated illness of 0.35 (95% CI 0.19â0.62), while children living in IHIP control households had a RR of 0.61 (95% CI 0.37â0.98).", Influenza risk , Control , Home Environment Interventions ,0,
edin,5863,3040733,Cannot tell based on the abstract,, Hemorrhages within the fovea. , Climbing profile 2 , Climbing profile 1  ,0,
edin,5863,3040733,No significant difference,No hemorrhages were sighted within the fovea., Hemorrhages within the fovea. , Climbing profile 2 , Climbing profile 1  ,0,
edin,5816,3283075,Significantly decreased,"The numbers of mature oocytes, fertilized oocytes and grade I, II embryos were significantly lower in group 2 than in group 1 or 3.", Fertilized oocytes , GnRH antagonist + oral contraceptive pill , GnRH antagonist   ,0,
edin,5800,4007144,Significantly decreased,"Men participating in the intervention reported decreased intentions to use physical IPV (ARR 0.83, 95% CI 0.66-1.06) and improved attitudes toward sexual IPV (ARR 1.21, 95% CI 0.77-1.91). Significant differences were found between men in the intervention and control armsâ reported ability to control their hostility and manage conflict (ARR 1.3, 95% CI 1.06-1.58), and participation in gendered household tasks (ARR 2.47, 95% CI 1.24-4.90).", Men's intentions to use violence  , Control , Intimate partner prevention intervention ,0,
edin,5837,5584005,Significantly increased,"Improvement in attitudes toward patient safety was statistically significant in the intervention group in six domains: staff, training, and skill (pÂ =Â 0.017); patient counseling (pÂ =Â 0.043); communication about mistakes (pÂ <Â 0.001); response to mistakes (pÂ <Â 0.001); organizational learning â continuous improvement (pÂ <Â 0.001); and overall patient safety perceptions (pÂ =Â 0.033).", Communication about mistakes , Control , Continuous quality improvement program ,0,
edin,5885,4065280,Cannot tell based on the abstract,, Investigators Global Assessment-measured overall efficacy , Control , Pantothenic acid ,0,
edin,5885,4065280,Significantly increased,The overall investigator assessment of improvement at week 12 as measured by a 5-point scale demonstrated that 85.7% of subjects had â¥1 rank improvement in the study agent versus the placebo group (35.7%)., Investigators Global Assessment-measured overall efficacy , Control , Pantothenic acid ,0,
edin,5879,4916104,Cannot tell based on the abstract,, Borgâs scale scores , Control , Exercise gaming ,0,
edin,5879,4916104,Significantly decreased,"The mean score on Borgâs scale was 12Â Â±Â 2 on the first day of the step exercise and 9Â Â±Â 2 on the final day, showing a significant decrease (PÂ <Â 0.001). Therefore, an improvement in exercise tolerance was achieved.", Borgâs scale scores , Control , Exercise gaming ,0,
edin,5809,3506492,No significant difference,"EPO treatment did not significantly modify the difference in uNGAl between 48 hours and randomization compared to placebo [2.5 ng/ml (â17.3; 22.5) vs 0.7 ng/ml (â31.77; 25.15), pâ=â0.77] and the incidence of AKI was similar. I", Acute kidney injury , Control , Erythropoietin ,0,
edin,5892,4339173,Significantly increased,"even physical fitness tests consisting of sit and reach, hand grip strength, 40 yards technical agility, 50-meter sprint, sit-ups, push-ups, and VO2, max were measured before and after Thai massage or rest. [Results] All the physical fitness tests were significantly improved after a single session of Thai massage, whereas only the sit and reach, and the sit-ups tests were improved in the control group.", VO2 Max , Control , Thai massage  ,0,
edin,5927,5454908,Cannot tell based on the abstract,, treatment differences , galunisertib plus lomustine , galunisertib  ,0,
edin,5927,5454908,Significantly increased,"While on treatment, there were significant differences in CD4+, CD4+/CD8+ ratio, eosinophils, and total lymphocyte counts. All these immune cells were reduced in patients treated in both lomustine-containing arms compared to the galunisertib monotherapy arm (overall treatment p < 0.05).", treatment differences , galunisertib plus lomustine , galunisertib  ,0,
edin,5865,4175232,No significant difference,The reaction time showed no statistically significant differences in the interaction involving the time of response and group., Reaction time , Control , Galvanic vestibular stimulation ,0,
edin,5870,3348575,Significantly decreased,"On ABPM, the week 14 mean changes from baseline in diastolic and systolic BP were also significantly greater with azilsartan over a 24-h period, and during the daytime, night-time and early morning.,These data demonstrate that once-daily azilsartan provides a more potent 24-h sustained antihypertensive effect than that of candesartan but with equivalent safety.", Diastolic blood pressure   , Candesartan , Azilsartan  ,0,
edin,5827,4398332,Significantly increased,"THC was detrimental to the recognition of ambiguous faces of 40% intensity. The combination of THC+CBD produced no impairment. Relative to placebo, both THC alone and combined THC+CBD equally increased feelings of being âstonedâ.", Stoned feeling , Control , Tetrahydrocannabinol ,0,
edin,5841,3376511,Significantly increased,"The findings demonstrate that having less user control (ie, a tunneled version of the website) had a negative effect on usersâ perception of efficiency (F1,452 = 97.69, P < .001),", Perception of efficiency , Low user control , High user control ,0,
edin,5873,3348575,Cannot tell based on the abstract,, Controlled patients at week 8 , Candesartan , Azilsartan  ,0,
edin,5873,3348575,Significantly increased,"As shown in Table 2, the proportions of responders at week 16 (LOCF) and week 8 (LOCF) were significantly higher in the azilsartan group (51.8% and 44.1%, respectively) than in the candesartan group (34.3% and 29.4%, respectively) (P<0.0001 and P=0.0001, respectively). Similarly, the proportions of well-controlled patients at week 16 (LOCF) and week 8 (LOCF) were also significantly higher in the azilsartan group (19.3% and 18.0%, respectively) than in the candesartan group (13.3% and 10.0%, respectively) (P=0.0409 and P=0.0041, respectively).", Controlled patients at week 8 , Candesartan , Azilsartan  ,0,
edin,5905,3821116,Cannot tell based on the abstract,, Dizziness , Placebo , Pregabalin ,0,
edin,5905,3821116,No significant difference,"None of the patients complained about other side effects such as: dizziness, sedation, headache or visionary disorder in this study.", Dizziness , Placebo , Pregabalin ,0,
edin,5971,4429825,Cannot tell based on the abstract,, level of uncertainty for the intervention arm men , phase 1 , phase 2 ,0,
edin,5971,4429825,No significant difference,"In phase 2 there was a reduction in the proportion of correct guesses and much greater uncertainty: reviewers were unsure of the trial arm in 45% of all intervention and 48% of control arm assessments.,In phase 1, reviewers were unsure of trial arm allocation in 33% of intervention and 30% of control arm assessments.,<td></td><td>
<bold><italic>(Total for each phaseâ=â100%)</italic></bold>
</td><td>
<bold><italic>21%</italic></bold>
</td><td>
<bold><italic>46%</italic></bold>
</td><td>
<bold><italic>33%</italic></bold>
</td><td>
<bold><italic>9%</italic></bold>
</td><td>
<bold><italic>46%</italic></bold>
</td><td>
<bold><italic>45%</italic></bold>
</td>", level of uncertainty for the intervention arm men , phase 1 , phase 2 ,0,
edin,5859,270049,Cannot tell based on the abstract,, Session duration  , Passive range of motion , Resistance exercise program ,0,
edin,5859,270049,Significantly increased,"<td align=""left"">Duration of session, min. (SD)</td><td></td><td align=""center"">10.0 (0.0)</td><td align=""center"">36.2 (4.8)</td><td align=""center"">&lt;0.001<sup>d</sup></td>,The average duration for an exercise session was 10 minutes for the control group and 36.2 minutes for the exercise group (Table 3).", Session duration  , Passive range of motion , Resistance exercise program ,0,
edin,5933,3539107,No significant difference,"The site of abdominal pain, fever, signs of localized peritonitis, accompanying gastrointestinal symptoms, and white blood cell count showed no differences between the two groups.", accompanying gastrointestinal symptoms , appendicitis group , diverticulitis group ,0,
edin,5961,5844554,Significantly increased,"However in the secure priming condition, WM performance was boosted in the n-back task for individuals who rated higher levels of attachment anxiety. In other words, the subliminal priming of the security led to increased WM capacity of individuals who rated higher levels of attachment anxiety.", attachment anxiety positively predicted performance in n-back tasks in attachment related words , neutral priming conditions , secure conditions ,0,
edin,5931,3539107,Significantly increased,Twenty-five patients (65.8%) of the diverticulitis group and 10 patients (10.2%) of the appendicitis group showed perforation of appendix (P < 0.05)., perforation of appendix , appendicitis group , diverticulitis group ,0,
edin,5794,4825255,Significantly decreased,"The McGill scaleâs results for measuring pain levels, proved a meaningful difference between the experimental group and the control group (p=0.018).", McGill scaleâs pain  , Control  , Prenatal education ,0,
edin,5862,3040733,Cannot tell based on the abstract,, Distance from  optic disc to hemorrhage , Climbing profile 2 , Climbing profile 1  ,0,
edin,5862,3040733,No significant difference,The mean distance from the center of the optic disc to the center of the hemorrhage was 1.5Â±0.8 disc diameters in all climbers; no statistically significant differences were detected between groups and altitudes., Distance from  optic disc to hemorrhage , Climbing profile 2 , Climbing profile 1  ,0,
edin,5946,3751685,Significantly increased,"The score on the Short Physical Performance Battery, in which higher scores indicate better physical status, was stable in the intervention group and had declined in the control group; with the mean difference between groups being 1.44 (95% confidence interval, 0.80, 2.07; P <0.001) at 12 months.", Short Physical Performance Battery at 12 months , interdisciplinary multifaceted treatment , usual health care and support services  ,0,
edin,5782,5532580,Cannot tell based on the abstract,, Depression improvement  , Control , Sexual Assault history ,0,
edin,5782,5532580,Significantly decreased,"The depression symptoms increased monotonically with the number of PA types experienced (p < 0.05) as did all alcohol-related measures, and global functioning decreased (p = 0.006).,For depression, at the 12-month follow-up there was evidence of less improvement in the SA and PA group compared with the No SA and No PA group (5.3, 95% CI 0.1 to 10.5, p < 0.05), and in the SA and PA group versus the SA and No PA group (modelled difference = 7.0, 95% CI 0.6 to 13.4, p < 0.05).", Depression improvement  , Control , Sexual Assault history ,0,
edin,5851,4608185,No significant difference,"Changes in BMI over time were significantly different from zero in the ChiRunning group (pâ=â0.04) but not in the control group (slope for ChiRunning â0.05 [â0.1 to â0.002] vs. control â0.01 [â0.06 to 0.04], between slope difference, pâ=â0.22).", Body mass index , Standard running program , Chi running program ,0,
edin,5795,4825255,Cannot tell based on the abstract,, McGill scaleâs anxiety   , Control  , Prenatal education ,0,
edin,5795,4825255,Significantly decreased,"<td align=""left"" colspan=""1"" rowspan=""1"">Anxiety hospital</td><td align=""center"" colspan=""1"" rowspan=""1"">14.47Â±4.69</td><td align=""center"" colspan=""1"" rowspan=""1"">16.79Â±4.86</td><td align=""center"" colspan=""1"" rowspan=""1"">*p=0.002</td>", McGill scaleâs anxiety   , Control  , Prenatal education ,0,
edin,5857,270049,Cannot tell based on the abstract,"Thirty-nine ill patients, recently admitted to an acute care hospital, who were over age 70 [mean age of 82.0 (SD= 7.3)] and ambulatory prior to admission, were randomized to the resistance exercise group (19) or passive range of motion (ROM) group (20). For the resistance exercise group, participation was 71% (p = 0.004) and adherence was 63% (p = 0.020). Participation and adherence for ROM exercises was 96% and 95%, respectively.", Participation  , Passive range of motion , Resistance exercise program ,0,
edin,5857,270049,Significantly decreased,"In the exercise group, participation was 71% and adherence was 63%. For the control group, participation and adherence were 96% and 95%, respectively (Table 3).,<td align=""left"">Participation, total</td><td></td><td align=""center"">96%</td><td align=""center"">71%</td><td align=""center"">0.004</td>", Participation  , Passive range of motion , Resistance exercise program ,0,
edin,5959,3786468,No significant difference,Green tea suppressed waist-hip ratio of women from a significant increase and suppressed mean arterial pressure of men and women from a significant decrease after week 14. It reduced ALT level in women by 13.0% (P < 0.1) while increasing the antioxidant potential of men and women sera by 2.7% (P < 0.1) and 5.1% (P < 0.1)., antioxidant potential , water , Mauritian green tea ,0,
edin,5820,4723179,Significantly increased,"The phoria screening examination showed that exophoria was the most frequent disorder of binocular vision. Low fusional vergence range was also observed. Following the training period, 3 of the 6 oculomotor variables improved. The greatest effect was observed in near dissociated phoria (Ï2 =14.56, p=0.001 for the right eye; Ï2 =14.757, p=0.001 for the left eye) and fusional convergence (Ï2 =8.522, p=0.014).", Near dissociated phoria improvement of left eye , Control , Sports Vision Training ,0,
edin,5960,5844554,Significantly increased,"WM performance declined in terms of capacity in the n-back task for individuals who rated higher levels of attachment anxiety. However in the secure priming condition, WM performance was boosted in the n-back task for individuals who rated higher levels of attachment anxiety.", WM capacity of individuals who rated higher levels of attachment avoidance , neutral priming conditions , secure conditions ,0,
edin,5589,4737269,Cannot tell based on the abstract,, Ascent vertical toe clearance , Full bifocals  , Intermediate addition multifocals ,0,
edin,5589,4737269,No significant difference,"Gait safety parameters were similar between intermediate PALs and distance single vision lenses for all gait safety parameters measured: vertical toe clearance on ascent (Wald Ï2Â =Â 0.4, pÂ =Â 0.54) and its variability (Wald Ï2Â =Â 0.1, pÂ =Â 0.93), ascent duration (Wald Ï2Â =Â 1.4, pÂ =Â 0.25), heel clearance on descent (Wald Ï2Â =Â 0.7, pÂ =Â 0.42) and its variability (Wald Ï2Â =Â 2.4, pÂ =Â 0.12) and descent duration (Wald Ï2Â =Â 1.6, pÂ =Â 0.20).", Ascent vertical toe clearance , Full bifocals  , Intermediate addition multifocals ,0,
edin,5850,4608185,No significant difference,Systolic and diastolic blood pressure did not change significantly over the study for either the ChiRunning or control groups., Diastolic blood pressure  , Standard running program , Chi running program ,0,
edin,5962,5844554,Cannot tell based on the abstract,, attachment anxiety positively predicted performance in n-back tasks in non-attachment related words , neutral priming conditions , secure conditions ,0,
edin,5962,5844554,Significantly increased,"In secure priming condition, this negative association between attachment anxiety and n-back task performance became reversed (see Fig 4). Specifically, after secure priming, attachment anxiety positively predicted performance in n-back tasks including both attachment related (Î² = .28, p < .05) and non-attachment related words (Î² = .37, p < .05).", attachment anxiety positively predicted performance in n-back tasks in non-attachment related words , neutral priming conditions , secure conditions ,0,
edin,5801,4007144,Cannot tell based on the abstract,, Believing a woman can refuse sex in all circumstances , Control , Intimate partner prevention intervention ,0,
edin,5801,4007144,Significantly increased,"We also found a lower prevalence of menâs reported intention to commit physical IPV (ARR 0.83, 95% CI 0.66 - 1.06) and increased levels of men who believe a woman has the right to refuse sex under all circumstances (ARR 1.21, 95% CI 0.77 - 1.91).", Believing a woman can refuse sex in all circumstances , Control , Intimate partner prevention intervention ,0,
edin,5872,3348575,Cannot tell based on the abstract,, Response at week 16 , Candesartan , Azilsartan  ,0,
edin,5872,3348575,Significantly increased,"As shown in Table 2, the proportions of responders at week 16 (LOCF) and week 8 (LOCF) were significantly higher in the azilsartan group (51.8% and 44.1%, respectively) than in the candesartan group (34.3% and 29.4%, respectively) (P<0.0001 and P=0.0001, respectively).", Response at week 16 , Candesartan , Azilsartan  ,0,
edin,5956,3786468,Significantly increased,Green tea suppressed waist-hip ratio of women from a significant increase and suppressed mean arterial pressure of men and women from a significant decrease after week 14., waist-hip ratio of women , water , Mauritian green tea ,0,
edin,5898,2650591,Significantly increased,"Deposition was measured by gamma scintigraphy. All 13 patients entered (9 males, mean age 62 years; FEV1 46% of predicted) inhaled too fast at screening (peak inspiratory flow rate [IF]: 69â161 L/min). Whole lung deposition was higher with RespimatÂ® SMI than with pMDI for untrained (37% of delivered dose vs 21% of metered dose) and trained patients (53% of delivered vs 21% of metered dose) (pSign-Test].15; pANOVA < = 0.05).", Lung deposition in untrained patients  , Pressurized metered-dose inhalers , RespimatÂ® Soft Mistâ¢ ,0,
edin,5861,3040733,Cannot tell based on the abstract,, Hemorrhages area , Climbing profile 2 , Climbing profile 1  ,0,
edin,5861,3040733,No significant difference,"There was no statistically significant difference in total area and number of hemorrhages between groups at the same altitudes.,egression analysis of drug intake did not yield a significant partial correlation to total number (Betaâ=ââ0.009, pâ=â0.14) or total area of hemorrhages (betaâ=ââ0.08, pâ=â0.19) when corrected for age, time at altitude and AMS-c scores.", Hemorrhages area , Climbing profile 2 , Climbing profile 1  ,0,
edin,5922,3411720,No significant difference,"We found no evidence that concurrent supplementation with multi-nutrients influenced the magnitude of the effect of zinc on rates of diarrhea, respiratory illness, fever without localizing signs, or other illness (guardian-reported illness with symptoms involving skin, ears, eyes and abscesses, but excluding trauma or burns)", magnitude of the effect of zinc on rates of fever without localizing signs , zinc with multi-nutrients , zinc ,0,
edin,5917,1859980,Cannot tell based on the abstract,, Dihydrotestosterone concentrations , 0.6 grams of lipids  , 19 grams of lipids  ,0,
edin,5917,1859980,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"">â<italic>C</italic><sub>max</sub> (nmol/l)</td><td align=""char"" char=""Â·"" colspan=""1"" rowspan=""1"">1Â·50 (65Â·8)</td><td align=""char"" char=""Â·"" colspan=""1"" rowspan=""1"">1Â·89 (53Â·7)</td><td align=""char"" char=""Â·"" colspan=""1"" rowspan=""1"">6Â·67 (45Â·7)</td><td align=""char"" char=""Â·"" colspan=""1"" rowspan=""1"">6Â·74 (49Â·3)</td>,<td align=""left"" colspan=""5"" rowspan=""1"">DHT</td>", Dihydrotestosterone concentrations , 0.6 grams of lipids  , 19 grams of lipids  ,0,
edin,5929,3539107,Significantly increased,"The mean age of patients in the diverticulitis group was significantly older than that of the appendicitis group (49.0 Â± 15.2 years vs. 25.4 Â± 14.2 years, P < 0.05).", mean age of patients , appendicitis group , diverticulitis group ,0,
edin,5802,4562579,Cannot tell based on the abstract,Leg fat-free mass decreased with SR (â124Â Â±Â 61Â g) and increased in the SRÂ +Â RT (+126Â Â±Â 68Â g; PÂ =Â 0.003)., Fat-free leg mass , Control , Resistance exercise ,0,
edin,5802,4562579,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"">âSR&nbsp;+&nbsp;RT</td><td align=""left"" colspan=""1"" rowspan=""1"">9206&nbsp;Â±&nbsp;258</td><td align=""left"" colspan=""1"" rowspan=""1"">9332&nbsp;Â±&nbsp;254<xref ref-type=""table-fn"" rid=""tf2-3"">*</xref><sup>,</sup><xref ref-type=""table-fn"" rid=""tf2-4"">â </xref></td>", Fat-free leg mass , Control , Resistance exercise ,0,
edin,5945,3932017,Significantly decreased,"Pulse wave velocity (PWV) and stiffness index (Î²) were remarkably greater (8.388âÂ±â3.254Â m/s vs. 7.269âÂ±â1.332Â m/s; 12.51âÂ±â14.16 vs.9.279âÂ±â2.871), while compliance coefficient (CC) decreased significantly in the diabetes group (0.802âÂ±â0.3094Â mm2/Kpa vs. 0.968âÂ±â0.3992Â mm2/Kpa) (Pâ<â0.05).", compliance coefficient (CC) , control group , diabetes group ,0,
edin,5815,3283075,Significantly decreased,"The numbers of mature oocytes, fertilized oocytes and grade I, II embryos were significantly lower in group 2 than in group 1 or 3.", Mature oocytes amount  , GnRH agonist luteal low-dose , GnRH antagonist   ,0,
edin,5909,3327628,Cannot tell based on the abstract,, Medical survey response rate on cardiologists  , Control , Offering free continuing medical education ,0,
edin,5909,3327628,Significantly increased,"<td align=""left"">âCardiology</td><td align=""left"">12.7</td><td align=""left"">9.9</td><td align=""left"">15.5</td><td align=""left"">&lt; .0001</td>,Table 2
Response Rates (N = 8477)", Medical survey response rate on cardiologists  , Control , Offering free continuing medical education ,0,
edin,5926,5454908,Cannot tell based on the abstract,, treatment differences , placebo+lomustine , galunisertib  ,0,
edin,5926,5454908,Significantly increased,"While on treatment, there were significant differences in CD4+, CD4+/CD8+ ratio, eosinophils, and total lymphocyte counts. All these immune cells were reduced in patients treated in both lomustine-containing arms compared to the galunisertib monotherapy arm (overall treatment p < 0.05).", treatment differences , placebo+lomustine , galunisertib  ,0,
edin,5784,4237982,Significantly decreased,"Mean ILI changes were different from DSE (P < 0.001 for TAT, SAT, and IMAT and P < 0.01 for VAT in females). Within ILI, SAT and VAT decreased in males and females (P < 0.0001), but IMAT was unchanged (0.00 Â± 0.54 kg; P = 0.99).", Subcutaneous adipose tissue in women , Control , Intensive lifestyle intervention ,0,
